<SEC-DOCUMENT>0001493152-26-012801.txt : 20260326
<SEC-HEADER>0001493152-26-012801.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326073043
ACCESSION NUMBER:		0001493152-26-012801
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38207
		FILM NUMBER:		26794334

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:CELC="http://celcuity.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_CELC_celcuity.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001603454 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001603454</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-12-31" id="xdx2ixbrl0134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0412" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0422" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:NoncashOperatingLeaseExpenseNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2025-12-31" id="xdx2ixbrl0597" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_ConvertibleNotesToCommonStockMember" id="xdx2ixbrl0655" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember" id="xdx2ixbrl0663" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2025-12-31" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="AsOf2024-12-31" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:OtherAccruedLicenseMilestone" contextRef="AsOf2024-12-31" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:OtherAccruedInterest" contextRef="AsOf2024-12-31" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" contextRef="AsOf2025-12-31" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="xdx2ixbrl0999" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="xdx2ixbrl1001" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1396" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1398" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1419" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1431" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1433" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl1467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="celc-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:SeniorNotesDueTwoThousandAndThirtyOneNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:SeniorNotesDueTwoThousandAndThirtyOneNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ConvertibleNotesToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:ConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertibleNotesToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:ConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-18</xbrli:startDate>
        <xbrli:endDate>2023-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-30</xbrli:startDate>
        <xbrli:endDate>2025-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-30</xbrli:startDate>
        <xbrli:endDate>2025-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-302025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-30</xbrli:startDate>
        <xbrli:endDate>2025-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-31</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-08</xbrli:startDate>
        <xbrli:endDate>2024-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-22</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-31_custom_OpenMarketSaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_OpenMarketSaleAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-08-012012-08-31_custom_TwoThousandTwelveEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-08-01</xbrli:startDate>
        <xbrli:endDate>2012-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1427656">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-30</xbrli:startDate>
        <xbrli:endDate>2025-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-012026-02-01_us-gaap_SubsequentEventMember_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-01</xbrli:startDate>
        <xbrli:endDate>2026-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-30</xbrli:startDate>
        <xbrli:endDate>2025-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermETwoLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermETwoLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFTwoLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFTwoLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermGLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermGLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-09</xbrli:startDate>
        <xbrli:endDate>2025-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-28</xbrli:startDate>
        <xbrli:endDate>2025-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-132025-05-13_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-13</xbrli:startDate>
        <xbrli:endDate>2025-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermALoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-30</xbrli:startDate>
        <xbrli:endDate>2024-05-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PfizerLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-08_custom_PfizerLicenseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PfizerLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-08_custom_LicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-08_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-09</xbrli:startDate>
        <xbrli:endDate>2026-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>CELC:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>CELC:Segment</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 0.25in"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 0.25in"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 0.25in"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20250101__20251231_z99cNHpUiWFl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000016" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b><span id="xdx_902_edei--DocumentAnnualReport_c20250101__20251231_zrqmYnuutJl5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_906_edei--DocumentPeriodEndDate_c20250101__20251231_zGJfrwnF5KX"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20250101__20251231_zPCbETAc9whl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000019" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_905_edei--DocumentFiscalYearFocus_c20250101__20251231_zTVbemH9zQX4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b><span id="xdx_902_edei--DocumentTransitionReport_c20250101__20251231_zFTxtqyALup8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000021" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from _______________________ to ___________________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span id="xdx_90B_edei--EntityFileNumber_c20250101__20251231_zCnvGJBxFHd3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000022" name="dei:EntityFileNumber">001-38207</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 0.25in"><b><span id="xdx_90D_edei--EntityRegistrantName_c20250101__20251231_zWnWSfNrbwNe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityRegistrantName">Celcuity
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zjyZLSlAY384"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000024" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20250101__20251231_zX2fmQFU9hTl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityTaxIdentificationNumber">82-2863566</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or Other Jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
    or Organization)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_905_edei--EntityAddressAddressLine1_c20250101__20251231_zuXOiF0d1g9f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressAddressLine1">16305
    36<sup>th</sup></ix:nonNumeric></b></span><b> <span id="xdx_902_edei--EntityAddressAddressLine2_c20250101__20251231_zOkzmmWIfOCb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressAddressLine2">Avenue
    North</ix:nonNumeric></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_909_edei--EntityAddressAddressLine3_c20250101__20251231_zG2Xa6TNIuy3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressAddressLine3">Suite
    100</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    <span id="xdx_90C_edei--EntityAddressCityOrTown_c20250101__20251231_zlyXPKYRXura"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_907_edei--EntityAddressStateOrProvince_c20250101__20251231_zOqw0Ls6LRjk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20250101__20251231_zAA1B10fSEyc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:EntityAddressPostalZipCode">55446</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span id="xdx_907_edei--CityAreaCode_c20250101__20251231_z0f22Bqh3qb1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000032" name="dei:CityAreaCode">(763)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20250101__20251231_zIPwtIWZVrj8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000033" name="dei:LocalPhoneNumber">392-0767</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 18%; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 40%; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20250101__20251231_zz15COlBGqlh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000034" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20250101__20251231_zpSVnyOJ9HI7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000035" name="dei:TradingSymbol">CELC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90B_edei--SecurityExchangeName_c20250101__20251231_zr7kqWuvIQre"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9746; <span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zCX4g1noTVf4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000037" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span> &#9744;&#160;No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744; Yes &#9746;
<span id="xdx_903_edei--EntityVoluntaryFilers_c20250101__20251231_ze6zEIczI1Ue"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746; <span id="xdx_907_edei--EntityCurrentReportingStatus_c20250101__20251231_z63lN3msM2Ll"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746; <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20250101__20251231_zVqxtxPxmvbl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 53%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20250101__20251231_zdhEknnFaa9j"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90A_edei--EntitySmallBusiness_c20250101__20251231_zI4GKmnnFWSk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250101__20251231_z4sB2s3dGPCf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90C_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zLF0PFrM598i"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zLmrb27PEmGl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#9744; Yes <span id="xdx_90A_edei--EntityShellCompany_dbF_c20250101__20251231_zEjOsFH04LDe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span> No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on $13.35, the closing
price of the shares of common stock on June 30, 2025 (the last business day of the registrant&#8217;s most recently completed second
fiscal quarter) as reported by The Nasdaq Capital Market on such date, was approximately $<span id="xdx_90F_edei--EntityPublicFloat_iI_c20250630_zMMhsDOyRaPe"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">457,485,677</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 17, 2026, there were <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_c20260317_zhMfm9U9WdV5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-17" id="Fact000048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,336,675</ix:nonFraction></span> shares of the registrant&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED IN PART BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentsIncorporatedByReferenceTextBlock_c20250101__20251231_zpZJeS4MPydh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000049" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the registrant&#8217;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders are incorporated by reference
into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Annual Report on Form 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_001">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_002">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_003">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_004">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_005">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#sp_006">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_007">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_008">Reserved</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_010">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_011">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_012">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_013">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_014">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_015">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#sp_016">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_017">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span>2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_018">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_019">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_020">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_021">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#sp_022">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_023">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_024">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_025">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Private Securities Litigation Reform Act of 1995 provides a &#8220;safe harbor&#8221; for forward-looking statements. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) contains forward-looking statements regarding us, our business prospects
and our results of operations that are subject to certain risks and uncertainties that could cause our actual business, prospects and
results of operations to differ materially from those that may be anticipated by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to, those described in Part I, Item 1A, &#8220;Risk Factors&#8221;
and elsewhere in this Annual Report. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date of this Annual Report. We expressly disclaim any intent or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. Readers are urged to carefully review and consider the various disclosures
made by us in this Annual Report and in our other reports filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) that
advise interested parties of the risks and uncertainties that may affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements, other than statements of historical facts, contained in this Annual Report, including statements regarding our plans, objectives
and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases,
you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause our results, performance or achievements to
be materially different from the information expressed or implied by the forward-looking statements in this Annual Report. Additionally,
our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures
or investments that we may make. Forward-looking statements may include, among other things, statements relating to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            clinical trial plans and the estimated timelines and costs for such trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans to develop and commercialize our products, and our expectations about the market opportunity
                                            for gedatolisib in the U.S. and internationally, and our ability to serve those markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations with respect to our competitive advantages, including the potential efficacy
                                            of gedatolisib in various patient types alone or in combination with other treatments, and
                                            our interpretation of the data from the <i>PIK3CA</i> WT cohort of the Phase 3 VIKTORIA-1
                                            clinical trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the timeline of patient enrollment and results from clinical trials
                                            for gedatolisib, including our ongoing Phase 3 VIKTORIA-1 clinical trial, ongoing Phase 3
                                            VIKTORIA-2 clinical trial, and ongoing Phase 1b/2 clinical trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding our ability to obtain U.S. Food and Drug Administration (&#8220;FDA&#8221;)
                                            approval, and approvals outside the U.S., to commercialize gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding governmental laws and regulations affecting our operations, including,
                                            without limitation, developments in laws and regulations or their interpretation, including,
                                            among others, changes in tax laws and regulations internationally and in the U.S., and laws
                                            that affect our operations and our laboratory;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations with respect to the development, validation, required approvals, costs, and
                                            development and regulatory timelines, of gedatolisib, including continuity of commercial
                                            supply;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            beliefs related to the potential benefits resulting from Fast Track designation and Breakthrough
                                            Therapy designation as it relates to the development of gedatolisib, and Real-Time Oncology
                                            Review (&#8220;RTOR&#8221;) and Priority Review as relates to the submission to the
                                            FDA, and FDA review of, our New Drug Application (&#8220;NDA&#8221;) for gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans with respect to research and development and related expenses for the foreseeable future;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            beliefs about our ability to capitalize on the exclusive global development and commercialization
                                            rights obtained from our license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) with respect
                                            to gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the future payments that may be owed to Pfizer under our license agreement
                                            with them;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            beliefs with respect to the potential rate and degree of market acceptance and clinical utility
                                            of gedatolisib, both in the U.S. and internationally;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            revenue expectations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding business development activities, including collaborations with pharmaceutical
                                            companies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans with respect to pricing in the U.S. and internationally, and our ability to obtain
                                            reimbursement for gedatolisib, including expectations as to our ability or the amount of
                                            time it will take to achieve successful reimbursement from third-party payors, such as commercial
                                            insurance companies and health maintenance organizations, and from government insurance programs,
                                            such as Medicare and Medicaid;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations as to the use of proceeds from our financing activities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations with respect to availability of capital, including accessing our current debt
                                            facility or any other debt facility or other capital sources in the future, and our assumption
                                            that we will have adequate authorized shares for future equity issuances;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                                                                                                                                                                                                                                            beliefs regarding the adequacy of our cash on hand to fund our clinical trials, anticipated commercial launch expenses, capital
                                                                                                                                                                                                                                                            expenditures, working capital, and other general corporate expenses, as well as the costs associated with being a public
                                                                                                                                                                                                                                                            company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans with respect to potentially raising capital; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding our ability to obtain and maintain intellectual property protection
                                            for gedatolisib, including its formulations and methods of use. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry&#8217;s actual
results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these
forward-looking statements. Certain risks, uncertainties and other factors include, but are not limited to, our limited operating history;
our potential inability to develop, validate, obtain regulatory approval for and commercialize gedatolisib on a timely basis or at all;
the uncertainties and costs associated with clinical studies and with developing and commercializing pharmaceuticals; the complexity
and difficulty of demonstrating the safety and sufficient magnitude of benefit to support regulatory approval of gedatolisib and other
products we may develop; challenges we may face in developing and maintaining relationships with pharmaceutical company partners, including
our current and any future suppliers of our product candidate; the uncertainty and costs associated with clinical trials; the uncertainty
regarding market acceptance by physicians, patients, third-party payors and others in the medical community, and with the size of market
opportunities available to us; <span style="background-color: white">difficulties we may face in managing growth, such as hiring and
retaining a qualified sales force and attracting and retaining key personnel; changes in government regulations; tightening credit markets
and limitations on access to capital; stock market volatility or other factors that may affect our ability to access capital on favorable
terms or at all; and obtaining and maintaining intellectual property protection for gedatolisib and time and expense associated with
enforcing our intellectual property rights against third parties, and defending third-party claims of intellectual property infringement,
investigations or litigation threatened or initiated against us. S</span>ee &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual
Report for additional risks, uncertainties and other factors applicable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of the material factors that make an investment in our common stock speculative or risky. This summary does not address
all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face,
can be found in the &#8220;Risk Factors&#8221; section of Part I, Item 1A of this Annual Report and should be carefully considered, together
with other information in this Annual Report and our other filings with the SEC before making investment decisions regarding our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have not yet commercialized a pharmaceutical product, and we may never generate revenue or profit;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            inability to raise additional capital on acceptable terms in the future may limit our ability
                                            to develop and commercialize our drug candidate, gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
                                            financing activities could dilute the percentage ownership of our stockholders and could
                                            cause our stock price to fall, or could result in operating or other restrictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are dependent on our ability to attract and retain key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            to trade policy, including new or increased tariffs and changing import and export regulations,
                                            could have a material adverse effect on our business, results of operations and financial
                                            condition;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            indebtedness and liabilities could limit the cash flow available for our operations, expose
                                            us to risks that could adversely affect our business, financial condition and results of
                                            operations and impair our ability to satisfy our debt obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            near-term revenue prospects depend on the success of our initial drug product, gedatolisib.
                                            If we are unable to successfully complete clinical development of, obtain regulatory approval
                                            for, or commercialize, gedatolisib, or if we experience delays in doing so, including supply
                                            chain interruptions, our business will be materially and adversely impacted;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            were not involved in the early development of gedatolisib, so we are dependent on third parties
                                            having accurately generated, collected, interpreted and reported data from certain preclinical
                                            and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have not yet successfully completed any registrational clinical trials, and we may
                                            be unable to do so for any drug candidates we may develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            successful development of our products is highly uncertain;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we encounter difficulties enrolling patients in any of our clinical trials, our clinical
                                            development activities could be delayed or otherwise adversely affected;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim,
                                            topline and preliminary data from our clinical studies that we announce or publish from time
                                            to time may change as more data become available and are subject to audit and verification
                                            procedures that could result in material changes in the final data;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face significant competition from other pharmaceutical companies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            a new drug to be approved for marketing, the FDA and other regulatory authorities must determine
                                            that the drug is safe and effective. Because all drugs can have adverse effects, the data
                                            from our Phase 3 clinical study must demonstrate to the satisfaction of the FDA and other
                                            health authorities that the benefits of gedatolisib in combination with fulvestrant and with
                                            or without palbociclib, or gedatolisib in combination with fulvestrant plus a CDK4/6 inhibitor,
                                            outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even if the benefit
                                            is found to be statistically significant, may not support regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            must navigate lengthy, uncertain, and expensive regulatory approval processes to be able
                                            to market our products in the U.S. and other jurisdictions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            depend on intellectual property licensed from Pfizer for our
                                            lead product candidate, gedatolisib, and termination of this license could result in the
                                            loss of significant rights, which would materially and adversely impact our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we fail to comply with our obligations under our patent license with Pfizer, we could lose
                                            certain license rights that are important to our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to obtain and maintain intellectual property protection for our product candidates,
                                            or if the scope of the intellectual property protection obtained is not sufficiently broad,
                                            our competitors could develop and commercialize product candidates similar or identical to
                                            ours, and our ability to successfully commercialize our product candidates may be impaired;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            rely on third parties to conduct certain aspects of our preclinical studies and clinical
                                            trials and to formulate, manufacture and distribute our drug product. If these third parties
                                            do not successfully carry out their contractual duties, meet expected deadlines or comply
                                            with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize,
                                            any potential product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter difficulties in scaling production of, commercializing, marketing and distributing
                                            our products, including in hiring and retaining a qualified sales force.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_002"></span>ITEM
1. Business </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
otherwise provided in this Annual Report, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;
and similar references refer to Celcuity Inc., a Delaware corporation. We own various unregistered trademarks and service marks, including
our corporate logo. Solely for convenience, the trademarks, trade names and service marks in this Annual Report, including those owned
by third parties, may be referred to without the <sup>&#174;</sup>,<sup>TM</sup> or <sup>SM</sup> symbols, but such references should
not be construed as any indicator that the owner of such trademarks, trade names and service marks will not assert, to the fullest extent
under applicable law, their rights thereto. We do not intend the use or display of other companies&#8217; trademarks, trade names and
service marks to imply an endorsement or sponsorship of us by any other companies.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid
tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the phosphatidylinositol 3-kinase
(&#8220;PI3K&#8221;), serine/threonine-protein kinase protein kinase B (&#8220;AKT&#8221;), mechanistic target of rapamycin
(&#8220;mTOR&#8221;) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all
class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PI3K/AKT/mTOR (&#8220;PAM&#8221;) pathway.
Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational
therapies that target PI3K&#945;, AKT, or mTORC1 alone or together. Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib
in combination with fulvestrant, with or without palbociclib, in patients with hormone receptor-positive (HR+), human epidermal
growth factor receptor 2-negative (HER2-) (&#8220;HR+/HER2-&#8221;) advanced breast cancer (&#8220;ABC&#8221;) has completed
enrollment and reported detailed results for cohort 1, patients with <i>PIK3CA</i> wild-type (&#8220;WT&#8221;) tumors, and has
completed enrollment of cohort 2, patients with <i>PIK3CA</i> mutant-type (&#8220;MT&#8221;) tumors. Our Phase 3 clinical trial,
VIKTORIA-2, evaluating gedatolisib in combination with a cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitor and fulvestrant
as first-line treatment for patients with endocrine treatment resistant HR+/HER2- ABC is ongoing. A Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer
(&#8220;mCRPC&#8221;), is ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, gedatolisib was granted Fast Track designation for the treatment of patients with HR+/HER2- ABC after progression on CDK4/6
therapy. Fast Track designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening
diseases or conditions and which demonstrate the potential to address an unmet medical need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, gedatolisib was granted Breakthrough Therapy designation for HR+/HER2- ABC after progression on CDK4/6 therapy. Breakthrough
Therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended
to treat a serious or life-threatening condition. The criteria for Breakthrough Therapy designation requires preliminary clinical evidence
that demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we dosed the first patient in our Phase 3, open-label, randomized, two-part clinical trial, VIKTORIA-1. This trial is evaluating
the efficacy and safety of gedatolisib in combination with fulvestrant, with and without palbociclib, in adults with HR+/HER2- ABC who
have received prior treatment with a CDK4/6 inhibitor in combination with an aromatase inhibitor. Two studies based on <i>PIK3CA</i>
mutation status are included in the trial. According to confirmed <i>PIK3CA</i> mutation status, patients were manually assigned either
to a cohort evaluating patients who have <i>PIK3CA</i> WT tumors or to a cohort evaluating patients who have <i>PIK3CA</i> MT tumors.
The two cohorts were randomized separately. The cohort evaluating <i>PIK3CA</i> WT patients reported detailed study results in the third
and fourth quarters of 2025. The cohort evaluating patients with <i>PIK3CA</i> MT tumors has completed enrollment, and topline data is
expected to be available in the second quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we dosed our first patient in our Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with
darolutamide in patients with mCRPC. Initial preliminary data for the Phase 1 portion of the trial were reported in the fourth
quarter of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the third quarter of 2024, we commenced site selection and activation activities to support a Phase 3, open-label, randomized
clinical trial, VIKTORIA-2, designed to evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as
first-line treatment for patients with HR+/HER2- endocrine treatment resistant ABC. The first patient was dosed in July 2025. For
the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib. This multi-center, international trial enrolled 35
evaluable subjects in the safety run-in portion of the study to evaluate the safety of gedatolisib when combined with ribociclib and
fulvestrant. The safety run-in was completed in the first quarter of 2026. In the Phase 3 portion of the study, approximately 638
subjects are expected to be randomized and assigned to Cohort 1 (<i>PIK3CA</i> WT) or Cohort 2 (<i>PIK3CA</i> MT) based on their <i>PIK3CA</i>
status. Subjects in each cohort are expected to be randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and
ribociclib or palbociclib) or Arm B (fulvestrant and ribociclib or palbociclib). We intend to provide an update on our final Phase 3 study design in the second quarter of 2026. It is expected that approximately 200
clinical sites across North America, Europe, and Asia-Pacific will participate, including many sites included in the VIKTORIA-1
clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2025, the FDA granted our request to submit our NDA for gedatolisib under the FDA&#8217;s Real-Time Oncology Review (&#8220;RTOR&#8221;)
program based on data from the <i>PIK3CA</i> WT cohort of the Phase 3 VIKTORIA-1 clinical trial. We made our first NDA pre-submission
in September 2025 and completed our submission of the NDA in November 2025. The FDA accepted our NDA on January 16, 2026, designating
it for Priority Review, with a target user fee goal date of July 17, 2026, pursuant to the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;)
VII.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
PI3K/AKT/mTOR (PAM) Pathway</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dysregulation
of the PAM signaling pathway is observed in many types of cancer, including breast and prostate cancer. The important role the PAM pathway
plays in cancer has led to significant investment in the development of many different PI3K and mTOR inhibitors for solid tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activities
associated with PI3K involve complex essential cell regulatory mechanisms, including feedforward and feedback signaling loops.
Overactivation of the pathway is frequently present in human malignancies and plays a key role in cancer progression. Four catalytic
isoforms of class I PI3K preferentially mediate signal transduction and tumor cell survival based on the type of malignancy and the
genetic or epigenetic alterations an individual patient harbors. Due to the multiple subcellular locations, activities, and
importance of the different PI3K complexes in regulating many types of cancer cell proliferation, control of PI3K activity is an
important target in cancer therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mTOR
is a critical effector in cell-signaling pathways commonly dysregulated in human cancers. The mTOR signaling pathway integrates both
intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation, and survival. mTOR
is a serine/threonine protein kinase, a downstream effector of PI3K, and regulated by hormones, growth factors, and nutrients, that are
contained in two functionally distinct protein assemblies &#8211; mTORC1 and mTORC2. In cancer, dysfunctional signaling leads to various
constitutive activities of the mTOR complexes, making mTOR a good therapeutic target.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
efficacious and well-tolerated therapies that target this pathway has been challenging. This reflects the inherent adaptability and complexity
of the PAM pathway, where numerous feedforward and feedback loops, crosstalk with other pathways, and compensatory pathways enable resistance
to PAM pathway inhibition. Another major hurdle for the development of PAM pathway inhibitors has been the inability to achieve optimal
drug-target blockade in tumors while avoiding undue toxicities in patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gedatolisib</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
inhibiting multiple components of the PAM pathway, gedatolisib can overcome adaptive resistance mechanisms that inhibitors of single
PI3K/AKT/mTOR components do not address. As a result, we believe gedatolisib offers distinct advantages over currently approved and investigational
therapies that target PI3K&#945;, AKT or mTORC1 alone or together.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overcomes
    limitations of therapies that only inhibit a single class I PI3K isoform, AKT, or one mTOR kinase complex.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a pan-class I isoform PI3K inhibitor with low nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and p110&#948;
isoforms and the mTORC1 and mTORC2 complexes. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive
inhibition of the PAM pathway. Each PI3K isoform and mTOR complex is known to preferentially affect different signal transduction
events that involve tumor cell survival, depending upon the aberrations associated with the linked pathway. When a therapy only
inhibits a single class I PI3K isoform (e.g., alpelisib, a PI3K&#945; inhibitor), AKT (e.g., capivasertib, an AKT inhibitor) or
only one mTOR kinase complex (e.g., everolimus, an mTORC1 inhibitor), numerous feedforward and feedback loops between the PI3K
isoforms and mTOR complexes cross-activate the uninhibited sub-units. This, in turn, induces compensatory resistance that reduces
the efficacy of isoform specific PI3K&#945;, AKT, or mTORC1 kinase inhibitors. Inhibiting all four PI3K isoforms and both the
mTORC1 and mTORC2 complexes, as getatolisib does, thus prevents the confounding effect of isoform interaction that may occur with
isoform-specific PI3K inhibitors and the confounding interaction between PI3K isoforms, AKT, and mTOR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
compare the functional effect of inhibiting single versus multiple PAM pathway components, we evaluated gedatolisib, and component-selective
inhibitors for PI3K&#945; (alpelisib), AKT (capivasertib) and mTORC1 (everolimus) in a panel of breast cancer cell lines using a live
cell proliferation rate dose response analysis. The results of this analysis are presented in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Breast
Cancer Cell Line Proliferation Rate Dose Response Analysis </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Average
values for 14 PIK3CA MT and 14 PIK3CA WT breast cancer cell lines</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note:
Growth rate (&#8220;GR&#8221;) was assessed using 28 cell lines by measuring live cells reducing potential with Real Time-Glo MT luciferase
assay before and after 72-hour drug treatment. GR50 (concentration required to inhibit growth rate by 50%) is a measure of potency. Max
cell growth inhibition (GR at highest drug concentration tested) is a measure of efficacy.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Source:
Rossetti S. et.al., npj Breast Cancer, 2024</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
average, gedatolisib was at least 300-fold more potent on average than the single component PAM inhibitors analyzed and only gedatolisib
induced a significant cytotoxic effect. In addition, gedatolisib&#8217;s potency and efficacy was comparable in cell lines with and without
<i>PIK3CA</i> mutations, in contrast to the single component PAM inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Better
    tolerated by patients than oral PI3K and mTOR drugs.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is administered intravenously (&#8220;IV&#8221;) on a four-week cycle of once a week for three weeks, then one week off, in contrast to the orally
administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors
have repeatably been found to induce significant side effects that were not well tolerated by patients. This typically leads to a high
proportion of patients requiring dose reductions or treatment discontinuation. The challenging toxicity profile of these drug candidates ultimately played a significant role in the decisions to halt their development,
despite showing promising efficacy. By contrast, gedatolisib&#8217;s comprehensive inhibition of the PAM pathway at low nanomolar potency,
IV route of administration, and pharmacokinetic properties enables it to achieve optimal anti-proliferative effects on tumor cells without
inducing the levels of hyperglycemia, rash, and diarrhea typically associated with oral single-component inhibitors of the PAM pathway.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isoform-specific
PI3K or mTORC1 inhibitors administered orally were developed to reduce toxicities in patients. While the range of toxicities
associated with single-component PAM inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on
a continuous basis still leads to challenging toxicities. The experience with the FDA approved oral PI3K&#945; inhibitor,
alpelisib, and mTORC1 inhibitor, everolimus, illustrates the challenge. In their Phase 3 pivotal trials, alpelisib and everolimus
were found to induce hyperglycemia in 79% and 69% of patients evaluated, respectively. In addition, 26% and 24% of patients
discontinued alpelisib and everolimus, respectively, due to treatment related adverse events. By contrast, in the 103-patient dose
expansion portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and
less than 9% discontinued treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, 1,127 patients and healthy volunteers have received gedatolisib in 12 completed or ongoing clinical trials.
Of these, 123 patients with solid tumors were treated with gedatolisib as a single agent in two clinical trials, 36 healthy volunteers
were treated in two clinical trials, and the remaining 968 patients received gedatolisib in combination with other anti-cancer agents
in eight clinical trials. Additional patients received gedatolisib in combination with other anti-cancer agents in 10 investigator sponsored
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breast
Cancer Program</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast
cancer is the most prevalent cancer in women, accounting for 30% of all female cancers and 7% of cancer-related deaths in the United
States. The National Cancer Institute estimated that approximately 316,950 new cases of breast cancer would be diagnosed in the United
States in 2025, and approximately 42,170 breast cancer patients would die of the disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
different breast cancer subtypes are currently identified using molecular tests that determine the level of HR and HER2 expression. The
most common subtype of ABC is HR+/HER2-. Approximately 70% of all breast cancer tumors express the estrogen receptor (&#8220;ER&#8221;),
which, upon activation, regulates the expression of various genes involved in tumor proliferation. Despite progress in treatment strategies,
HR+/HER2- advanced or metastatic breast cancer remains an incurable disease, with a median overall survival (OS) of three years and a
five-year survival rate of 34%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
different classes of targeted therapies are currently used to treat HR+/HER2- tumors: endocrine-based therapies, CDK4/6 inhibitors, and
PAM inhibitors. Each of the CDK4/6 inhibitors and PAM inhibitors are generally used to respond to the related mechanisms of resistance
to endocrine therapy, namely, activation of the CDK4/6 and PAM pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nearly
80% of breast cancers have direct or indirect activation of the PAM pathway. The upregulation of the PAM pathway promotes hormone-dependent
and independent ER transcriptional activity, which contributes to endocrine resistance, leading to tumor cell growth, survival, motility,
and metabolism. Clinical studies have demonstrated that PAM inhibition can restore sensitivity to endocrine therapy (ET).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the PAM pathway, like other mitogenic pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative cell cycling.
The available evidence indicates that resistance to CDK4/6 inhibition in patients with HR+/HER2- ABC is a transient adaptive mechanism,
most likely involving the PAM pathway. This data indicates that CDK4/6 signaling may be restored in CDK4/6 resistant tumors when PAM
inhibitors are applied. Thus, continuing CDK4/6 inhibitor treatment in combination with a PAM inhibitor in patients who progressed on
their prior CDK4/6 inhibitor, would both blockade the potentially reactivated CDK4/6 pathway and prevent adaptive activation of the PAM
pathway. This suggests the limited efficacy induced by current standard-of-care (SOC) therapies in patients who have progressed on a
CDK4/6 therapy reflects the mechanistic inadequacy of relying on partial PAM inhibition (e.g., alpelisib or everolimus) and no CDK4/6
inhibition to address this complex disease mechanism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the complex connection between the PAM and CDK4/6 pathways can potentially enable gedatolisib to adaptively reactivate CDK4/6
signaling that reportedly occurs in CDK4/6 resistant tumors when the PAM pathway is comprehensively inhibited. By re-activating CDK4/6
signaling, we believe gedatolisib can restore the therapeutic effect of CDK4/6 inhibition when it is combined with a CDK4/6 inhibitor.
The contributory effect of a CDK4/6 inhibitor when combined with gedatolisib would thus largely reflect the interaction between the two
therapies that gedatolisib initiates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
of gedatolisib&#8217;s anti-tumor activity in breast cancer cells was provided in a study evaluating the MCF7 xenograft model (ER+/HER2-/PIK3CA
mutant), where the combination of gedatolisib with palbociclib and fulvestrant caused 90% tumor regression with no tumor regrowth observed
for more than 60 days after the final dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Source:
Layman SABCS 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Experience with Gedatolisib in Breast Cancer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
favorability of preliminary results from a Phase 1b clinical trial (B2151009, further described below) which evaluated 138 patients
with HR+/HER2- ABC led us to focus our initial clinical development program on ABC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2022, gedatolisib was granted Fast Track designation for the treatment of patients with HR+/HER2- ABC after progression on
CDK4/6 therapy. Fast Track designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening
diseases or conditions and which demonstrate the potential to address an unmet medical need. The designation offers the opportunity for
frequent interactions with the FDA to discuss the drug&#8217;s development plan and to ensure collection of appropriate data needed to
support drug approval, as well as eligibility for rolling submission of an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2022, gedatolisib was granted Breakthrough Therapy designation for HR+/HER2- ABC after progression on CDK4/6 therapy. Breakthrough
Therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended
to treat a serious or life-threatening condition. The criteria for Breakthrough Therapy designation require preliminary clinical evidence
that demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapies.
The benefits of Breakthrough Therapy designation include more intensive guidance from the FDA on an efficient development program, access
to a scientific liaison to help accelerate review time, and potential eligibility for Priority Review if relevant criteria are met. Our
breakthrough application was supported by data from a Phase 1b clinical trial that assessed the safety, tolerability and clinical activity
of gedatolisib in combination with palbociclib and fulvestrant in patients with HR+/HER2- ABC whose disease progressed during treatment
with a CDK4/6 therapy and an aromatase inhibitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Phase
3 HR+/HER2- ABC Clinical Trial (VIKTORIA-1) </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, we initiated VIKTORIA-1, a Phase 3, open-label, randomized clinical trial to evaluate the efficacy and safety of gedatolisib in
combination with fulvestrant with or without palbociclib in adults with HR+/HER2- ABC whose disease has progressed after prior CDK4/6
therapy in combination with an aromatase inhibitor. This multi-center, international trial has completed enrollment of 754 subjects at
nearly 200 clinical sites across North America, Europe, Latin America, and Asia-Pacific. The first patient was dosed in December 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial is separately evaluating subjects according to their <i>PIK3CA</i> status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subjects
    who meet eligibility criteria and do not have confirmed <i>PIK3CA</i> mutations (i.e., WT) were randomly assigned (1:1:1) to receive
    a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant (Arm C).
    During the fourth quarter of 2024, we achieved our enrollment goal of 351 subjects who are <i>PIK3CA</i> WT. We reported topline
    data and detailed results for this group in the third and fourth quarters of 2025, as described below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subjects
    who meet eligibility criteria and have <i>PIK3CA</i> mutations (i.e., MT) were randomly assigned (3:3:1) to receive a regimen of
    either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and fulvestrant (Arm
    F). Enrollment of up to 350 subjects who are PIK3CA MT is ongoing. We expect topline data for this group to be available in the second
    quarter of 2026.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial primary endpoints are progression free survival (&#8220;PFS&#8221;)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,</span> per RECIST 1.1 criteria, as assessed by blinded independent central review (&#8220;BICR&#8221;).
Two primary endpoints will be evaluated in subjects who are <i>PI3KCA</i> WT, and one primary endpoint will be evaluated in subjects
who are <i>PI3KCA</i> MT. In subjects who are <i>PI3KCA</i> WT, the PFS of gedatolisib in combination with palbociclib and fulvestrant
(Arm A) will be compared to fulvestrant monotherapy (Arm C), and the PFS in gedatolisib in combination with fulvestrant (Arm B) will
be compared to fulvestrant monotherapy (Arm C). In subjects who are <i>PI3KCA</i> MT, the PFS of gedatolisib in combination with palbociclib
and fulvestrant (Arm D) will be compared to alpelisib combined with fulvestrant (Arm E).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
subjects will receive treatment according to the assigned study arm until objective progressive disease, unacceptable toxicity, death,
or withdrawal of consent, whichever occurs first. Subjects in Arm C will have the option to receive the treatment regimen provided in
Arm A or Arm B upon radiographically confirmed disease progression. Subjects will be followed for adverse events, safety laboratory testing,
tumor assessment by RECIST v1.1, quality of life, and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, we announced topline data from the <i>PIK3CA </i>WT cohort of the VIKTORIA-1 clinical trial and on October 18, 2025, at
the European Society of Medical Oncology (&#8220;ESMO&#8221;) congress, additional efficacy and safety results from this cohort were
presented. The key efficacy and safety data from the <i>PIK3CA</i> WT cohort showed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib triplet (gedatolisib, fulvestrant and palbociclib) demonstrated a statistically significant and clinically meaningful
    improvement in PFS among patients, reducing the risk of disease progression or death by 76% compared to fulvestrant (based on a hazard
    ratio [HR] of 0.24, 95% confidence interval [CI] 0.17-0.35; p&lt;0.0001). The median PFS, as assessed by BICR, was 9.3 months with
    the gedatolisib triplet versus 2.0 months with fulvestrant, an incremental improvement of 7.3 months. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib doublet (gedatolisib and fulvestrant) also demonstrated a statistically significant and clinically meaningful improvement
    in PFS among patients, reducing the risk of disease progression or death by 67% compared to fulvestrant (HR of 0.33, 95% CI 0.24-0.48;
    p&lt;0.0001). The median PFS, as assessed by BICR, was 7.4 months with the gedatolisib doublet versus 2.0 months with fulvestrant,
    an incremental improvement of 5.4 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    objective response rate (&#8220;ORR&#8221;) of the gedatolisib triplet was 31% compared to 1% with fulvestrant and the median duration
    of response (&#8220;DOR&#8221;) was 17.5 months. The ORR of the gedatolisib doublet was 28.3% and the median DOR was 12.0 months.
    The median DOR was not determinable for fulvestrant because there was only one objective response.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib triplet and doublet were generally well tolerated in the trial with mostly low-grade treatment-related adverse events
    (&#8220;TRAEs&#8221;). The most common Grade 3 TRAEs for the gedatolisib triplet, gedatolisib doublet, and fulvestrant groups included
    neutropenia (52.3%, 0%, and 0.8% of patients, respectively); stomatitis (19.2%, 12.3%, and 0% of patients, respectively) rash (4.6%,
    5.4%, and 0% of patients, respectively); and hyperglycemia (2.3%, 2.3%, and 0% of patients, respectively). The primary Grade 4 TRAEs
    for the gedatolisib triplet and gedatolisib doublet groups were neutropenia (10.0% and 0.8%, respectively), leukopenia (0.8% in the
    gedatolisib triplet group) and pneumonitis (0.8% in gedatolisib doublet group). TRAEs led to the discontinuation of study treatment
    in 2.3% of patients in the gedatolisib triplet group, 3.1% in the gedatolisib doublet group, and 0% in the fulvestrant group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
detailed results from cohort 1, <i>PIK3CA</i> WT cohort, established several new milestones in the history of drug development for HR+/HER2-
ABC:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    hazard ratios for the gedatolisib triplet and doublet are more favorable than have ever been reported by any Phase 3 trial for patients
    with HR+/HER2- ABC.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    7.3- and 5.4-months incremental improvements in median PFS for the gedatolisib triplet and gedatolisib doublet over fulvestrant,
    respectively, are higher than have ever been reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving at least their
    second line of therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
    is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/<i>PIK3CA</i>
    WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    median DOR and incremental ORR improvement relative to control for the gedatolisib triplet and doublet are the highest reported for
    an endocrine therapy-based regimen in 2L HR+/HER2- ABC.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2025, updated efficacy and safety results from the Phase 3 VIKTORIA-1 PIK3CA WT cohort were presented at the 2025 San Antonio
Breast Cancer Symposium including patient sub-group analyses, safety analyses and patient reported outcomes for well-being measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For patients enrolled in the U.S., Canada, Western Europe,
and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7.1 months with the gedatolisib doublet versus 1.9 months
for fulvestrant (HR=0.14; 95% CI: 0.08-0.28; p&lt;0.0001).</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both gedatolisib regimens delayed time to definitive deterioration
versus fulvestrant according to patient reported outcomes for well-being measures that included mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression (the EQ-5D-5L score). The median time to definitive deterioration was 23.7 months (HR=0.39; 95%
CI: 0.25-0.67; p = 0.0003) for patients treated with the gedatolisib triplet and not reached for the gedatolisib doublet (HR=0.37; 95%
CI: 0.24-0.66; p = 0.0003) versus 4.0 months for fulvestrant. Additionally, for the first eight cycles of treatment, the patients&#8217; assessment of their well-being remained
stable relative to their assessment prior to starting treatment with gedatolisib.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
median PFS benefit of the gedatolisib triplet and doublet compared to fulvestrant was consistent across subgroups with the gedatolisib
triplet showing higher clinical benefit in nearly all subgroups compared to the gedatolisib doublet, particularly for patients who were
pre/perimenopausal, endocrine therapy resistant, or had visceral metastases. For patients enrolled in the United States and Canada, median
PFS was 19.3 months (HR=0.13; 90% CI: 0.07-0.29) for the gedatolisib triplet and 14.9 months (HR=0.35; 90% CI: 0.17-0.76) for the gedatolisib
doublet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
these results, the gedatolisib regimens represent a potential new standard of care for patients with HR+/HER2-, <i>PIK3CA</i> WT ABC
whose disease progressed on or after treatment with a CDK4/6 inhibitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
from cohort 2 of the VIKTORIA-1 Phase 3 clinical trial, the <i>PIK3CA</i> MT cohort, are expected to be available in the second quarter
of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="text-decoration: underline">B2151009 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1b HR+/HER2- ABC Clinical Trial </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1b dose-finding trial with an expansion portion for safety and efficacy evaluated gedatolisib when added to either the standard
doses of palbociclib plus letrozole or palbociclib plus fulvestrant in patients with HR+/HER2- ABC. PI3K mutation status was not used
as an eligibility criterion. Patient enrollment for the trial is complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 138 patients with HR+/HER2- ABC were dosed in the clinical trial. Four patients from this study continue
to receive study treatment, as of December 31, 2025, each of whom has received study treatment for more than six years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35
    patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the maximum tolerable dose
    (&#8220;MTD&#8221;) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies. The MTD
    was determined to be 180 mg administered intravenously once weekly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103
    patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus palbociclib
    and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical
    control data of the doublet combination (palbociclib plus endocrine therapy). All patients received gedatolisib in combination with
    standard doses of palbociclib and endocrine therapy (either letrozole or fulvestrant). In Arms A, B, and C, patients received an
    intravenous dose of 180 mg of gedatolisib once weekly. In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on
    a four-week cycle of three-weeks-on, one-week-off. Objective response was determined using Response Evaluation Criteria in Solid
    Tumors v1.0, or RECIST v1.0.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm
    A</b>: ABC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting. First-line
    endocrine-based therapy for advanced disease (CDK4/6 treatment naive).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm
    B</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting, with no prior therapy
    with any CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm
    C</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior
    therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arm
    D</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior
    therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, the ORR in aggregate among patients with evaluable
    tumors was 63%.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Best
    responses, as measured by RECIST v1.0, are shown in the following chart for Arm A (1<sup>st</sup> line patients) and Arm D
    (2<sup>nd</sup>/3<sup>rd</sup> line patients who received the VIKTORIA-1 Phase 3 trial dosing regimen). The dotted line represents
    the cutoff for partial response (PR), defined as a 30% reduction from the baseline tumor assessment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Source:
Layman SABCS 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    analysis:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event. The Grade 3 and
    4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (63%), stomatitis (27%) and rash (20%).
    Neutropenia is a known class effect of CDK4/6 inhibitors. Stomatitis was reversible in most patients with a steroidal mouth rinse.
    All grades of treatment-related adverse events related to hyperglycemia were reported in 22% of patients; Grade 3 or 4 hyperglycemia
    was reported in 7% of patients. Gedatolisib was discontinued in less than 9% of patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the patients in Arm D, who received the Phase 3 dosing schedule, Grade 3 and 4 treatment-emergent adverse events occurring in at
    least 20% of patients were neutropenia (67%), leukopenia (22%), and stomatitis (22%). All grades of treatment-related adverse events
    related to hyperglycemia were reported in 26% of patients; Grade 3 or 4 hyperglycemia were reported in 7% of patients. Gedatolisib
    was discontinued in 4% of patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Best
    overall response data for each arm is presented in the table below:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 92%; margin-left: 0.25in">
  <tr>
    <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><b>Total Expansion Arms (N=103)</b></td></tr>
  <tr>
    <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Arm A</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Arm B</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Arm C</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Arm D</b></span></td></tr>
  <tr style="text-align: left; background-color: rgb(204,238,255); vertical-align: middle">
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt"><b>Prior Therapy</b></span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">CDKi-naive</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2L+</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">CDKi-naive</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">CDKi-pretreated</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">CDKi-pretreated</p></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>n (Full, response evaluable)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">31, 27</span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">13,13</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">32, 28</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">27, 27</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Study Treatment</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + L + G</span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Gedatolisib schedule</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">3 wks on/1 wk off</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>ORR <sup>(1) </sup>(evaluable)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">85%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">77%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">63%</span></td></tr>
  <tr style="text-align: left; background-color: White; vertical-align: middle">
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt"><b>mPFS <sup>(2)</sup>, mos (range)</b></span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">48.4</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(16.9, NR)</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(7.6, 38.3)</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5.1</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(3.3, 7.5)</p></td>
    <td style="text-align: center; vertical-align: middle">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: middle">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(7.4, 16.7)</p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>PFS % at 12 mos <sup>(2)</sup></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">72.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">54.5%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">23.6%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">53.2%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>WT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>MT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>WT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>MT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>WT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>MT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>WT</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>MT</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-size: 10pt"><b>PIK3CA status</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">81%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">16%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">69%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">31%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">75%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">25%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">56%</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-size: 10pt">41%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>ORR (evaluable)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">81%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">78%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">25%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">63%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">60%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">73%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>PFS at 12 months</b></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">74%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">60%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">50%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">67%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">22%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">29%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">49%</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">60%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
ORR represents PR, except in Arm A, which had 1 CR = Complete response. Responses per RECIST 1.1; (2) Includes 2 unconfirmed PR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abbreviations:
1L = first line, 2L = second line; mos = months; NR = not reached; ORR = objective response rate; PFS = progression free
survival</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
Layman R. et. al, Lancet Oncol., 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
results from the Phase 1b portion of the clinical trial were presented at the ESMO congress in October 2025. The analyses reported efficacy
data from patients who were treated with the same drug regimen being evaluated in the VIKTORIA-1 study, gedatolisib combined with fulvestrant
and palbociclib. This included patients from Escalation Arm B and Expansion Arms B, C and D of the Phase 1b study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described above, patients in Escalation Arm B and Expansion Arms B and C received a 180 mg dose of gedatolisib once weekly (&#8220;weekly
dose&#8221;). Patients in Expansion Arm D received a 180 mg dose of gedatolisib on days 1, 8, and 15 of a four-week cycle (&#8220;intermittent
dose&#8221;), which is the same dose regimen patients in the VIKTORIA-1 study receive. The proportion of patients who received the intermittent
dose of gedatolisib was 37% for those with <i>PIK3CA</i> MT tumors and 25% for those with <i>PIK3CA</i> WT tumors. The proportion of
patients who received prior treatment with a CDK4/6 inhibitor was 73% for those with <i>PIK3CA</i> WT tumors, and 71% for those with
<i>PIK3CA</i> MT tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
PFS and the ORR were assessed in sub-groups of patients according to their <i>PIK3CA</i> status (Table 1). For all analyzed patients
with <i>PIK3CA</i> MT tumors (n=30), median PFS was 14.6 months and the ORR in response evaluable patients was 48%. Median PFS was 19.7
months and the ORR was 64% in patients with <i>PIK3CA</i> MT tumors who received the intermittent dose of gedatolisib used in the VIKTORIA-1
study. For patients with <i>PIK3CA</i> WT tumors (n=60), median PFS was 9.0 months and the ORR in response evaluable patients was 41%.
Median PFS was 9.1 months and the ORR was 53% in patients with <i>PIK3CA</i> WT tumors who received the intermittent dose of gedatolisib
used in the VIKTORIA-1 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
1: Efficacy Analysis of Phase 1b Patients Treated with Gedatolisib Plus Palbociclib Plus Fulvestrant</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 72%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center">PIK3CA MT</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center">PIK3CA WT</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intermittent Dose</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intermittent dose</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">N</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Median PFS (months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ORR</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Phase
3 HR+/HER2- ABC Clinical Trial (VIKTORIA-2) </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, we dosed the first patient in VIKTORIA-2, a Phase 3, multi-center, open-label, randomized, clinical trial designed to
evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with
HR+/HER2- endocrine treatment resistant ABC. For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib.
This multi-center, international trial enrolled 35 evaluable subjects in the safety run-in portion of the study to evaluate the
safety of gedatolisib when combined with ribociclib and fulvestrant. The safety run-in was completed in the first quarter of 2026.
In the Phase 3 portion of the study, approximately 638 subjects are expected to be randomized and assigned to Cohort 1
(<i>PIK3CA</i> WT) or Cohort 2 (<i>PIK3CA</i> MT) based on their <i>PIK3CA</i> status. Subjects in each cohort are expected to be
randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib) or Arm B (fulvestrant and
ribociclib or palbociclib). We intend to provide an update on our final Phase 3 study design in the second quarter of 2026. It is expected that approximately 200 clinical sites across North America, Europe, and
Asia-Pacific will participate, including many sites included in the VIKTORIA-1 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prostate
Cancer Program </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, prostate cancer is the second leading cause of cancer death in men. Current estimates predict that one in eight men
will be diagnosed with prostate cancer in his lifetime. The National Cancer Institute estimated that in 2025 there would be over 313,780
new cases of prostate cancer in the United States and approximately 35,770 deaths from the disease. Although approximately 69% of patients
are diagnosed with localized prostate cancer, about 8% of patients present with metastatic disease with a 5-year survival rate of 38%.
Androgen deprivation therapy (&#8220;ADT&#8221;) via medical or surgical castration has been the mainstay treatment for metastatic prostate
cancer. However, prostate cancer cells develop resistance to ADT and progress to castration resistance, leading to poor prognosis and
a median overall survival of about three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Men
with mCRPC have a poor prognosis and a predicted survival rate of fewer than two years from the initial time of progression. Treatment
options for prostate cancer depend on many different factors, including the stage of the cancer. Castration-resistant prostate cancer
is defined by disease progression despite ADT and is often indicated by rising levels of PSA. Current standard of care for men with castration-resistant
prostate cancer provides that patients should initially receive a combination of ADT and either abiraterone, which works by decreasing
androgen levels, or enzalutamide, which works by blocking androgen binding to androgen receptors (&#8220;AR&#8221;). If the disease progresses
despite these second-generation hormonal therapies, chemotherapy is considered the next treatment option. Treatment with chemotherapy
is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea,
decreased mental capacity and increased risk of infections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies have demonstrated a potential association between the PAM pathway and AR signaling in prostate cancer cells developing resistance
to ADT. In these studies, the AR and PAM pathways were shown to cross-regulate each other. This is similar to the relationship demonstrated
in breast cancer with the estrogen receptor pathway and the PAM pathway. Additionally, 70% - 100% of mCRPC tumors have PAM related pathway
alterations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
clinical studies have shown promising results by inhibiting the PAM pathway in combination with an AR inhibitor. In separate Phase 2
and Phase 3 trials, the AKT inhibitor, ipatasertib, showed improvement in radiographic PFS (&#8220;rPFS&#8221;) in patients with mCRPC
and tumors with phosphatase and tensin homolog (&#8220;PTEN&#8221;) loss when ipatasertib was combined with the AR inhibitor, abiraterone,
versus abiraterone alone. In a Phase 2 trial, the pan-PI3K inhibitor, samotolisib, reported median rPFS of 10.2 when combined with enzalutamide
versus 5.5 months for enzalutamide alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
of gedatolisib&#8217;s in vivo activity in prostate cancer was provided in a study evaluating the 22RV-1, PC3, and enzalutamide sensitive
model (&#8220;C4-2&#8221;) prostate cancer xenograft models. As seen in the figures below, gedatolisib induced greater than 80% tumor
growth inhibition, regardless of the xenograft model&#8217;s sensitivity to the AR inhibitor, enzalutamide and the cell lines&#8217;
PTEN or AR status. In addition, gedatolisib combined with enzalutamide induced significantly greater tumor growth inhibition than enzalutamide
alone in the C4-2.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_004.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>S</i>ource:
Sen, ASCO-GU, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Phase
1b/2 mCRPC Clinical Trial (CELC-G-201) </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received approval from the FDA in mid-2023 to proceed with the clinical development of gedatolisib in combination with Nubeqa<sup>&#174;</sup>
(darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with mCRPC. We have since initiated a Phase 1b/2
clinical trial (CELC-G-201) that will enroll up to 54 participants with mCRPC who progressed after treatment with an AR inhibitor. We
dosed our first patient in this trial in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary objectives of the Phase 1b portion of the trial include assessment of the safety and tolerability of gedatolisib in combination
with darolutamide and determination of the recommended Phase 2 dose (&#8220;RP2D&#8221;) of gedatolisib. The primary objective of the
Phase 2 portion of the trial is to assess the radiographic PFS at six months of patients who received the RP2D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Phase 1b portion of the clinical trial, we enrolled 38 participants randomly assigned to receive 600 mg of darolutamide twice
daily combined with either 120 mg of gedatolisib in Arm 1 or 180 mg of gedatolisib in Arm 2. In both arms, gedatolisib was
administered once weekly for three weeks, then one week off. Additionally, all patients received prophylactic treatment for
stomatitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2025, we announced preliminary data for the CELC-G-201 Phase 1b trial, utilizing a May 30, 2025 data cut-off. Based on these
data, we amended the clinical trial protocol to enable exploration of additional doses in the Phase 1b portion of this clinical trial
to determine the RP2D. Once RP2D is determined, an additional 12 participants will then be enrolled in the Phase 2 portion of the study
at the RP2D level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On October 18,
2025, at the ESMO congress, we presented updated clinical results for the CELC-G-201 Phase 1b trial based on an August 15, 2025 data
cut-off. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among the 38 patients enrolled, 61% had received
one line of prior systemic therapy and 39% had received at least two or more lines of prior therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Updated
clinical results from the Phase 1 portion of the clinical trial were presented at the ESMO congress in October 2025. The Phase 1 data
set utilized an August 15, 2025 data cut-off. Median duration of follow-up was 9.0 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
six-month rPFS rate and median rPFS for patients from both arms combined was 67% and 9.1 months, respectively. For patients treated with
120 mg gedatolisib, the six-month rPFS rate was 74% and median rPFS was 9.5 months. For patients treated with 180 mg gedatolisib, the
six-month rPFS rate was 61% and the median rPFS was 7.4 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combination of gedatolisib and darolutamide was generally well tolerated in the trial with mostly low-grade TRAEs. No dose limiting toxicities
were observed in either arm. The only Grade 3 TRAEs for patients from both arms combined included rash (5.3%), stomatitis (2.6%), and
pruritus (2.6%); no Grade 3 hyperglycemia was reported. Additionally, no Grade 4 or 5 TRAEs were observed, and no patients discontinued
study treatment due to a TRAE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the amended Phase 1/1b portion of the clinical trial, up to six patients are planned to be enrolled in each of three arms and treated
with different doses. Upon completion of Phase 1, up to an additional 40 patients will be randomly assigned to up to four Phase 1b cohorts
to determine the RP2D. Dose levels will be selected based on the results from the Phase 1 clinical
trial. In the Phase 2 dose expansion study, which will include subjects from the Phase 1/1b clinical trial, up to 18 additional subjects
will be enrolled to achieve a total of approximately 30 subjects treated with the RP2D. All patients will also receive standard doses
of darolutamide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investigator-Sponsored
Trials</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an investigator-sponsored Phase 2 clinical trial, 44 patients with HER2+/<i>PIK3CA</i> mutated metastatic breast cancer were treated
with gedatolisib plus standard doses of trastuzumab-pkrb. No prophylaxis for stomatitis was administered. The median number of prior
anti-HER2 therapies enrolled patients received in the metastatic setting was four or more; 86% of patients had received at least three
prior anti-HER2 therapies. The data cut-off was February 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
efficacy and safety results, as presented at the American Society of Clinical Oncology meeting in June 2025, showed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ORR among all patients enrolled was 43%.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    PFS was 6.0 months (95% CI, 5.0-7.7).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    overall survival was 24.7 months (95% CI; 17.3-NA).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    patients discontinued gedatolisib due to a treatment-related AE.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    (2.3%) patient experienced Grade 3 hyperglycemia.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investigator sponsored trial has been initiated in collaboration with the Dana-Farber Cancer Institute and Massachusetts General Hospital
to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pfizer
Gedatolisib License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, we entered into a license agreement (the &#8220;Gedatolisib License Agreement&#8221;) with Pfizer pursuant to which we acquired
exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture, and commercialize gedatolisib for
the treatment, diagnosis and prevention of all diseases. Pursuant to the Gedatolisib License Agreement, we are obligated to use commercially
reasonable efforts to develop and seek regulatory approval for at least one product in the U.S. and if regulatory approval is obtained,
to commercialize such product in the U.S. and at least one international major market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid Pfizer a $5.0 million upfront fee upon execution of the Gedatolisib License Agreement and issued 349,406 shares of our common
stock to Pfizer pursuant to an Equity Grant Agreement. We are also required to make milestone payments to Pfizer upon achievement of
certain development and commercial milestone events, including a $5.0 million milestone payment we made in January 2026 following
FDA acceptance of our NDA submission, up to an aggregate of $335.0 million. We will pay Pfizer tiered royalties on sales of
gedatolisib at percentages ranging from the low to mid-teens, that may be subject to deductions for expiration of valid claims,
amounts due under third-party licenses and generic competition. Unless earlier terminated, the Gedatolisib License Agreement will
expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later
of (a) 12 years following the date of First Commercial Sale of such Product in such country, (b) the expiration of all regulatory or
data exclusivity in such country for such Product, or (c) the date upon which the manufacture, use, sale, offer for sale or
importation of such Product in such country would no longer infringe, but for the license granted herein, a Valid Claim of a
Licensed Patent Right. Capitalized terms in this paragraph have the meanings set forth in the Gedatolisib License
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the right to terminate the Gedatolisib License Agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not
terminate the agreement for convenience. Either we or Pfizer may terminate the Gedatolisib License Agreement if the other party is in
material breach and such breach is not cured within the specified cure period. In addition, either we or Pfizer may terminate the Gedatolisib
License Agreement in the event of specified insolvency events involving the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Formulation,
Manufacturing and Distribution </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties to formulate, manufacture and distribute gedatolisib. We have entered into agreements with contract manufacturing
organizations (&#8220;CMOs&#8221;) to produce the drug substance gedatolisib and formulate, produce and package finished drug product
for clinical use and, if approved, commercial supply. We have entered into agreements with distributors and a third-party logistics provider
(&#8220;3PL&#8221;) to distribute finished product for clinical use and, if approved, commercial supply. We require all of our CMOs,
distributors, and our 3PL to conduct manufacturing and distribution activities in compliance with applicable laws, including current
good manufacturing practice (&#8220;cGMP&#8221;) and current good distribution practice, requirements. We anticipate that these CMOs,
distributors, and 3PL will have the capacity to support both clinical- and commercial-scale production and distribution. We may also
elect to enter into agreements with other CMOs to formulate and manufacture supplies of drug substance and finished drug product.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
and Marketing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, we intend to market and commercialize them in the U.S. and select international markets,
either alone or in partnership with others. Cancer patients are primarily treated by medical, surgical, or radiation oncologists, and
we believe these physicians, and the multi-disciplinary teams surrounding them, including nurses, advanced practitioners, and pharmacists,
can be reached with a targeted sales force.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Competition
for Gedatolisib</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is characterized by rapid evolution of technologies and intense competition. We face competition from major pharmaceutical
and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.
Any product candidates that we successfully develop and commercialize will compete with approved treatment options, including off-label
therapies, and new therapies that may become available in the future. Key considerations that would impact our ability to effectively
compete with other therapies include the efficacy, safety, method of administration, cost, level of promotional activity, and intellectual
property protection of our products. Many of the companies against which we may compete have significantly greater financial resources
and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory
approvals and marketing approved products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several PI3K, AKT, and mTOR inhibitors approved by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca
plc, ITOVEBI from F. Hoffmann-La Roche Ltd, COPIKTRA from Verastem, Inc., and ZYDELIG from Gilead Sciences, Inc. We are aware that other
companies are, or may be, developing products for this indication, including BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics
Limited, Relay Therapeutics, Inc., Revolution Medicines Inc., and Takeda Pharmaceutical Company Limited. There may be additional companies
with programs suitable for addressing these patient populations that could be competitive with our efforts but that have not yet disclosed
specific clinical development plans. Smaller or early-stage companies, including oncology-focused therapeutics companies, may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies
may also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites,
enrolling patients in clinical trials and acquiring technologies complementary to, or necessary for, our programs. The availability of
reimbursement from government and private payors will also significantly impact the pricing and competitiveness of our products. Our
competitors may obtain FDA or other regulatory approvals for their products more rapidly than we may obtain approvals for our product
candidates, which could result in our competitors establishing a strong market position before we are able to commercialize our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Market Opportunity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Based on our analysis of published epidemiological data, we estimate that approximately 37,000 patients in the U.S.
have HR+/HER2- ABC who have progressed after a CDK4/6 inhibitor.&#160;If gedatolisib ultimately receives FDA approval for the treatment
of both <span style="font-weight: normal"><i>PIK3CA </i></span>WT and <span style="font-weight: normal"><i>PIK3CA </i></span>MT populations,
using internal duration of treatment estimates and pricing assumptions consistent with currently available novel therapeutics for breast
cancer, we estimate the total addressable market for gedatolisib in the second-line setting is more than $5.0 billion.&#160;Given the
significant penetration our research is suggesting we can achieve, we believe it is reasonable to estimate that a second-line indication
for gedatolisib could potentially generate peak revenue of up to $2.5 billion annually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, to operate without
infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. We plan to protect our
proprietary positions using a variety of methods, which include obtaining U.S. and foreign patents related to our inventions and
improvements, and prosecuting additional U.S. and foreign patents that we determine are important to the development and
implementation of our business. For example, we, directly and via our licensors, currently have, or are
pursuing, patents covering the composition of matter, formulation, and methods of using our drug product candidates and we plan to
pursue additional patent protection as appropriate. We also rely on trade secrets, trademarks, know-how, continuing technological
innovation and potential in-licensing opportunities to develop and maintain our proprietary position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gedatolisib
Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into the Gedatolisib License Agreement with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under
Pfizer patents and know-how to develop, manufacture and commercialize gedatolisib. We have an exclusive license under the Gedatolisib
License Agreement to patent rights in the U.S. and numerous foreign jurisdictions relating to gedatolisib, in addition to our own patents.
The patent rights we own or which we have in-licensed under the Gedatolisib License Agreement include 13 granted patents in the U.S.
and more than 297 patents granted in numerous foreign jurisdictions. A U.S. patent covering gedatolisib as a composition of matter has
a statutory expiration date in December 2029 (including 209 days of Patent Term Adjustment), a U.S. patent that covers the cyclodextrin
formulation of gedatolisib that is currently used in our clinical trials expires in January 2041 (including 578 days of Patent Term Adjustment),
and a U.S. patent that covers the method of using gedatolisib in breast cancer expires in August 2042 (including 37 days of Patent Term
Adjustment), not including any Patent Term Extension that may be awarded by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;),
and relevant foreign counterparts. Issued patents will, as appropriate, be listed in the FDA&#8217;s Approved Drug Products with Therapeutic
Equivalence Evaluations (&#8220;Orange Book&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Trademark</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied for trademark protection for our preferred commercial product tradename, and the USPTO has allowed the tradename for
registration. The FDA has conditionally approved the use of this tradename subject to the FDA&#8217;s approval of our NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
Secrets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade
secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We
protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees,
consultants, scientific advisors, contractors and partners. These agreements generally provide that all confidential information developed
or made known during the course of an individual or entity&#8217;s relationship with us must be kept confidential during and after the
relationship. These agreements also generally provide that all inventions resulting from work performed for us or relating to our business
and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition,
we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our
proprietary information by third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Approval
of Gedatolisib and Other Drug Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in the U.S. at the federal, state and local level and in other countries and jurisdictions, including the EU, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage,
record-keeping, promotion, advertising, marketing, distribution, post-approval monitoring and reporting, and export and import of drug
products, such as gedatolisib and other drugs that may be used in combination with, or compete with, gedatolisib. Generally, before a
new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format
specific for each regulatory authority and submitted for review and approved by the regulatory authority. The regulatory approval process
is time-consuming and requires significant capital expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Approval Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Overview
of FDA Approval Process</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, and other
federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of
pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or
judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total
or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. The process required
by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of nonclinical laboratory tests, animal studies and formulation studies according to good laboratory practices (&#8220;GLPs&#8221;),
    or other applicable regulations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an application for an investigational new drug application (&#8220;IND&#8221;), which must become effective before
    human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as current good
    clinical practices (&#8220;cGCPs&#8221;), to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA for a new drug;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection (&#8220;PAI&#8221;) of the manufacturing facility or facilities where the drug is produced
    to assess compliance with the FDA cGMPs, to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s
    identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">FDA Bioresearch Monitoring (&#8220;BIMO&#8221;) inspections
of the nonclinical and clinical trial sites that generated the data in support of the NDA; and</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    acceptance, review and approval of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources and approvals are inherently uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preclinical
and Clinical Stages</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements,
including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including
information about product chemistry, manufacturing and controls and a proposed clinical trial protocol. Long term preclinical tests,
such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after
the submission of an IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor
questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or disease-affected patients
under the supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance
with cGCPs. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing
procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each
protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of an IND. Furthermore, each clinical trial
must be reviewed and approved by an Institutional Review Board (&#8220;IRB&#8221;), for each institution at which the clinical trial
will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also monitors the clinical trial until completed. Human clinical trials are typically conducted in three
sequential phases, which may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, side effect tolerability and safety of the drug.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At
    the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety
    risks are identified, and a preliminary evaluation of efficacy is conducted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3 clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
registrational trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#8217;s
efficacy and safety such that it can be used to justify the approval of the drug. Generally, registrational trials are Phase 3 trials
but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there
is an unmet medical need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow
up.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse
events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on
various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can
suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with
the requirements of the IRB or if the drug has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information
about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information
related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial
is made public as part of the registration of the clinical trial. Sponsors are also obligated to discuss the results of their clinical
trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of
completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development
programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">FDA
Review and Approval Process</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. Prior to granting approval of the NDA, which
is required before marketing of the product may begin in the U.S., the FDA must determine whether to accept the submission and, thereafter,
conduct an in-depth review. This process may take a year or more. The NDA must include the results of all preclinical, clinical and other
testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls. The cost of preparing
and submitting an NDA is substantial. The submission of an NDA to the FDA, absent an applicable application user fee waiver, is subject
to a substantial application user fee, currently $4,682,003 for Fiscal Year 2026, and the manufacturer and/or sponsor under an approved
NDA are also subject to annual program fees for eligible products, which are currently $442,213 for Fiscal Year 2026. As a company with
fewer than 500 employees submitting its first NDA, we have qualified for the application fee waiver.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an advisory committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation and a recommendation
as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations. Before approving an NDA, the FDA will typically conduct a BIMO inspection, including inspecting one or
more clinical sites to assure compliance with cGCPs. Additionally, the FDA will conduct a PAI of the facility or the facilities at which
the finished drug is manufactured to assure compliance with cGMP. The FDA will not approve the product unless compliance with cGMP is
satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter (&#8220;CRL&#8221;).
A CRL generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order
for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission
of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two to six months depending
on the type of information included.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), to help ensure that the benefits
of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements
to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing
or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for
a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval
testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance
with regulatory standards is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling or manufacturing processes
or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement
for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures
and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">U.S.
Marketing Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
NDA approval of a new chemical entity (&#8220;NCE&#8221;), which is a drug (i.e., gedatolisib) that contains no active moiety that has
been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot accept
any Abbreviated New Drug Application (&#8220;ANDA&#8221;), seeking approval of a generic version of that drug. Certain changes to a drug,
such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the
FDA cannot approve an ANDA for a generic drug that includes the change. An ANDA may be submitted one year before NCE exclusivity expires
if a Paragraph IV certification is filed with the ANDA. If there is no listed patent in the Orange Book, no ANDA may be filed before
the expiration of the exclusivity period. If approved, we expect to receive five-year NCE exclusivity for gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent
Term Extension</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
NDA approval, owners of relevant drug patents may apply to the USPTO for up to a five-year patent term extension (&#8220;PTE&#8221;)
for one patent. The allowable PTE is calculated as half of the drug&#8217;s testing phase&#8212;the time between IND and NDA submission&#8212;and
all of the review phase&#8212;the time between NDA submission and approval, up to a maximum of five years. The time can be shortened
if the USPTO, in coordination with the FDA, determines that the applicant did not pursue approval with due diligence. The total patent
term after the extension may not exceed 14 years from NDA approval. We intend to seek five-year PTE should the FDA approve our NDA for
gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension
increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for
which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been
submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fast
Track Designation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or
life-threatening disease or condition for which there is no effective treatment, and which demonstrate the potential to address unmet
medical needs for the condition. Under the Fast Track program, the sponsor of a new drug candidate may request that the FDA designate
the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate.
The FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#8217;s request.
Gedatolisib has received Fast Track designation from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Fast Track program and the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening
illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably
likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account
the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for
a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly
than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including
the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required
post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the
market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to
prior review by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with the FDA, the
FDA may initiate review of sections of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available
if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable
user fees if not waived. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section
of the NDA is submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation
is no longer supported by data emerging in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Breakthrough
Therapy Designation</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breakthrough
Therapy designation by the FDA provides more extensive development consultation opportunities with FDA senior staff, allows for the rolling
review of the drug&#8217;s application for approval and indicates that the product could be eligible for Priority Review if supported
by clinical data at the time of application submission for drugs that are intended to treat a serious or life-threatening disease or
condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints. Under the Breakthrough Therapy program, the sponsor of a new drug candidate may request
that the FDA designate the drug candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the filing of
the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Breakthrough Therapy designation within 60
days of receipt of the sponsor&#8217;s request. Gedatolisib received Breakthrough Therapy
designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Real-Time
Oncology Review (&#8220;RTOR&#8221;)&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RTOR
is an FDA review program within the Oncology Center of Excellence that allows sponsors to submit key sections of an oncology NDA on a
rolling basis. The intent of RTOR is to start FDA review earlier, improve efficiency, and potentially shorten overall NDA review times.
On August 27, 2025, the FDA granted our request to submit our NDA on a rolling basis via the RTOR program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Priority
Review&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
Priority Review is a designation by the FDA that shortens the review timeline for certain marketing applications, including NDAs. Priority
Review reduces the FDA&#8217;s PDUFA goal review time from the standard 10 months to six months. The FDA grants Priority Review if the
NDA is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness
over available therapies. On January 16, 2026, the FDA accepted our NDA and awarded Priority Review, with a PDUFA goal date
of July 17, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disclosure
of Clinical Trial Information</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the
clinical trial is then made public as part of the registration at www.clinicaltrials.gov. Sponsors are also obligated to discuss the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to
two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding
the progress of development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union Approval Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Overview</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, our product candidates may also be subject to extensive regulatory requirements. As in the U.S., medicinal products can be marketed
only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the U.S., the various phases of
preclinical and clinical research in the EU are subject to significant regulatory controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Clinical Trials Regulation (EU) No 536/2014 came into effect in 2022. The Clinical Trials Regulation is directly applicable in all the
EU Member States, and repealed the Clinical Trials Directive 2001/20/EC. The Clinical Trials Regulation aims to simplify and streamline
the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via
a single-entry point, the Clinical Trial Information System; a single set of documents to be prepared and submitted for the application
as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications
for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which
an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by
each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the
relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State.
However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain a marketing authorization of a drug in the EU, we may submit Marketing Authorisation Applications (&#8220;MAA&#8221;), either
under the so-called centralized or national authorization procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Centralized
Procedure</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines
Agency (the &#8220;EMA&#8221;), that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway. The centralized
procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products,
advanced therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active
substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune
diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant
therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized
procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written
or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human
Use (the &#8220;CHMP&#8221;). Accelerated assessment might be granted by the CHMP in exceptional cases when a medicinal product is expected
to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation
of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">National
Authorization Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal
products that fall outside the scope of the centralized procedure:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decentralized
    procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of
    medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized
    procedure.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual
    recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance
    with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries
    in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above-described procedures, before granting an MAA, the EMA or the competent authorities of the Member States of the European Economic
Area (the &#8220;EEA&#8221;), assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality,
safety and efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">EU
Regulatory Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic applicants from relying on
the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization
in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity
period prevents a successful generic applicant from commercializing its product in the EU until ten years have elapsed from the initial
authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years
if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new
therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical
benefit in comparison with existing therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drug
Approval-Related Regulations &#8211; Rest of the World</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
other countries outside of the EU and the U.S., such as countries in Eastern Europe, Latin America or Asia, the requirements governing
the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the
clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles
that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be
subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pricing
and Reimbursement of our Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any products we sell or may sell. Sales of our drug products will depend,
in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs
such as VA, Tricare, Medicare and Medicaid, commercial health insurers, and other managed care organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain coverage and reimbursement for our drug product, we will conduct extensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of our product. Whether or not we conduct such studies, our products may not be considered
medically necessary or cost-effective. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an
adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure
that other payors will also provide coverage, and adequate reimbursement, for the product. Third-party reimbursement may not be sufficient
to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a
focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products, examining the medical
necessity and reviewing the cost-effectiveness of drug products and questioning product safety and efficacy. If these third-party payors
do not consider our product to be cost-effective compared to other available products, they may not cover our product or, if they do,
the level of reimbursement may not be sufficient to allow us to realize a profit on the use of our product. The U.S. government, state
legislatures and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of
government-paid healthcare costs, including price controls and restrictions on reimbursement. Adoption of such controls and measures,
and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our product and
could adversely affect our net revenue and results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Inflation Reduction Act (the &#8220;IRA&#8221;) was signed into law, which, among other things, requires manufacturers
of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount program with a new discounting
program. Gedatolisib, if approved, will be subject to these provisions of the IRA, and we have taken these provisions into account when developing our business strategy, operations, and our projected financial condition and results. In addition, changes to the Medicaid
program or the federal 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications
sold to certain health care facilities, could have a material impact on our business following commercialization. We expect to see continued
focus by Congress and the Trump Administration on regulating drug pricing, which could result in legislative and regulatory changes designed
to control costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and reimbursement schemes vary widely from country to country. Some countries may require the completion of additional studies that compare
the cost-effectiveness of a particular drug product to currently available drugs. The downward pressure on healthcare costs in general,
particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new drug
products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing
within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement
and pricing arrangements for our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coverage
policies, third-party reimbursement rates and pricing regulation may change at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in
the U.S. in addition to the FDA, including CMS, the HHS Office of Inspector General and HHS Office for Civil Rights, other divisions
of the HHS, the Department of Justice, and state regulatory bodies including Boards of Pharmacy and Price Transparency Boards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
systems, physicians, pharmacists, and third-party payors will play a primary role in the recommendation and prescription of any products
for which we obtain marketing approval. Our current and future arrangements with third-party payors, healthcare systems, physicians and
pharmacists may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business
or financial arrangements and relationships through which we market, sell and distribute our drug product. In the U.S., these laws include,
without limitation, state and federal anti-kickback, false claims, physician payment transparency, and patient data privacy and security
laws and regulations, including but not limited to those described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Anti-Kickback Statute (the &#8220;AKS&#8221;) prohibits, among other things, any person or entity from knowingly and willfully
offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return
for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service
reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221;
has been broadly interpreted to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical
and medical device manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other hand.
A person does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation
of the AKS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals
or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including
Medicare and Medicaid) claims for items or services that are false or fraudulent, claims for items or services not provided as claimed,
or claims for medically unnecessary items or services. This could apply even if we are not submitting claims directly to payors as would
be the case with sales of drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under a federal law directed at &#8220;self-referral,&#8221; commonly known as the &#8220;Stark Law,&#8221; there are prohibitions,
with certain exceptions, on referrals for certain designated health services, including laboratory services, that are covered by the
Medicare and Medicaid programs by physicians who personally, or through a family member, have an investment or ownership interest in,
or a compensation arrangement with, an entity performing the tests. The prohibition also extends to payment for any testing referred
in violation of the Stark Law. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and there may be
significant penalties for violations. Many states have comparable laws that are not limited to Medicare and Medicaid referrals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
regulations present compliance and litigation risks for our business and others in our industry. We incur compliance-related expenses
and expect to incur additional expenses if and when our products are commercialized. We may be subject to penalties or limitations on
government program participation if we are found to have violated these regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes
that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by
means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody
of, any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare
benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for healthcare benefits, items or services. Similar to the AKS, a person or entity does not need to have actual knowledge
of the statute or specific intent to violate it in order to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare
providers, and their ownership and investment interests. The Affordable Care Act, imposed, among other things, annual reporting requirements
through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#8220;transfers of value&#8221; to these
providers. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership
or investment interests may result in civil monetary penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and
their respective implementing regulations, impose specified requirements relating to the privacy, security and transmission of
individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made
HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or
agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a
service for or on behalf of a covered entity. Although we are not a &#8220;covered entity&#8221; and we would not be considered a
&#8220;business associate&#8221; in the normal course of our business and therefore not regulated by HIPAA, our business frequently interacts with covered entities and business associates
who are subject to HIPAA. In addition, state laws govern the privacy and security of
health information in certain circumstances, many of which differ from each other in significant ways and may not have the same
requirements, thus complicating compliance efforts. See &#8220;International Data Collection&#8221; below for a discussion of data
privacy and security enactments of the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, the California Consumer Privacy Act, as amended and expanded by the California Privacy Rights Act (collectively,
the &#8220;CCPA&#8221;), imposes data protection obligations on certain businesses. Although we are not currently regulated by any comprehensive state privacy law, we expect we will be regulated by
such laws in the future as our business develops. While there are certain limited exceptions under
the CCPA for clinical trial data and other health data that would apply to us, these regulations exemplify the vulnerability of our
business to the evolving regulatory environment related to personal data and protected health information, which causes us to incur
compliance costs. Privacy legislation similar to the CCPA has been adopted in many other U.S. states, and regulation of the collection, use, and disclosure of personal information remains a common focus of state legislation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">States
and foreign jurisdictions also have fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services. Some state laws also require pharmaceutical
companies to comply with the brand pharmaceutical industry&#8217;s voluntary compliance guidelines (i.e., the PhRMA Code) and the
relevant federal government compliance guidances, and require drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to sell products, we will need to comply with state laws, including those that require the registration of manufacturers and wholesale
distributors of drug and biological products. Several states have enacted legislation requiring pharmaceutical and biotechnology companies
to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,
pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other
healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales
and marketing, and to prohibit certain other sales and marketing practices. If and when we commercialize our products, all of our activities
are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment, especially in light
of the lack of applicable precedent and regulations. If our operations are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, exclusion of drugs
from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our business strategy
operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other
agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business
and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found
to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including
exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well
as responding to possible investigations by government authorities, can be time- and resource consuming and can divert a company&#8217;s
attention from the business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>International
Data Collection</i>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract research organizations (&#8220;CROs&#8221;) and clinical investigators involved in our clinical trials may collect,
receive, store, process, use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share
(collectively, &#8220;process&#8221;) personal data as defined in data protection laws, from individuals residing outside the U.S.
Accordingly, we are subject to numerous foreign privacy and security laws regulating the collection, use, safeguarding, transfer and
other processing of personal data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Globally,
virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must
comply. For example, in the EU/EEA, we are subject to the EU General Data Protection Regulation (the &#8220;EU GDPR&#8221;), and
associated Data Protection Legislation, which govern the collection and use of personal data as it pertains to individuals residing
in the EU/EEA. This legislation imposes several requirements, including, but not limited to: providing information to individuals
regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data,
processing personal data only under one of the six lawful bases for processing, <span style="background-color: white">managing
contractual relationships with vendors and other third parties, </span>and notifying the appointment of a data protection officer to
the relevant EU/EEA competent national data protection authorities. The EU GDPR also imposes strict rules on the transfer of
personal data outside of the EU/EEA. Personal data transferred to a jurisdiction outside the EU/EEA that does not provide adequate
protection for personal data (an &#8220;adequate jurisdiction&#8221;) must be protected by standard contractual clauses (a standard
form of contract approved by the European Commission). Currently, the U.S. is only an adequate jurisdiction for companies that
certify to the EU-U.S. Data Privacy Framework. As we are not certified to the EU-U.S. Data Privacy Framework, we must rely on
standard contractual clauses and other Article 45 protections when transferring personal data from the EU/EEA to the U.S. Companies
that must comply with the EU GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of
data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenue of
the noncompliant company, whichever is greater. The EU GDPR also confers a private right of action in some circumstances on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation
for damages resulting from violations of the EU GDPR. We have incurred, and expect to continue to incur, compliance expenses in
connection with the EU GDPR. If we are found to be in violation of the EU GDPR, our product development timeline may be affected,
which would potentially affect our ability to generate revenue and might impact our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
following the withdrawal of the United Kingdom from the EU, we have to comply with the GDPR as implemented in the United Kingdom (the
&#8220;UK GDPR&#8221;). The UK GDPR penalty structure mirrors the EU GDPR and has the ability to fine up to the greater of &#8364;20 million/&#163;17
million or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data
transfers from European Union member states to the United Kingdom without additional safeguards. However, the framework for transfer
of personal data from the UK to jurisdictions outside the UK, EU, or EEA is different from the EU GDPR. The UK has implemented its own
standard contractual clauses to protect UK personal data transferred to countries that are not adequate jurisdictions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
and Future Legislation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. and other jurisdictions, continued healthcare reform measures may result in more rigorous coverage criteria and additional downward
pressure on the price that we, or any collaborators, may receive. Individual states in the U.S. have also been increasingly passing legislation
and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some
cases, designed to encourage importation from other countries and bulk purchasing. Regulations may also prevent or delay marketing approval
of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Regulatory Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations use small amounts of hazardous materials in research and development and generate regulated medical waste in the normal course
of performing our laboratory tests. This subjects us to a variety of federal, state and local environmental and safety laws and regulations.
Some of the regulations under the current regulatory structure provide for strict liability, holding a party potentially liable without
regard to fault or negligence. We could be held liable for damages and fines as a result of our, or others&#8217;, business operations
should contamination of the environment or individual exposure to hazardous substances occur. We cannot predict how changes in laws or
development of new regulations will affect our business operations or the cost of compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were organized as a Minnesota limited liability company in 2011 and commenced operations in 2012. On September 15, 2017, we converted
from a Minnesota limited liability company into a Delaware corporation and changed our name from Celcuity LLC to Celcuity Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees
and Labor Relations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had 155 full-time employees, most of which were engaged in research and development activities, though hiring
employees in preparation for anticipated commercial launch has begun. None of our employees are currently represented by a labor union
or covered by a collective bargaining agreement and we believe that our relations with our employees are good. During 2025, our voluntary
turnover rate was approximately 4%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
About Our Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning our executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    G. Laing, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Science Officer, Vice President, Secretary and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
    Hahne</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Brian
F. Sullivan</i> is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in
2012. Mr. Sullivan has over 30 years of experience founding and building successful, high-growth technology companies. He was Chairman
and CEO of SterilMed, a medical device reprocessing company, from 2003, when he led an investment group to acquire a majority interest,
until its sale to Ethicon Endo-Surgery Inc., a Johnson &amp; Johnson company, for $330 million in 2011. Previously, he was co-founder
and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter &amp;
Gamble for $265 million in 1999. Mr. Sullivan previously served on the board of directors of two publicly-held companies, Entegris, Inc.
and Virtual Radiologic Inc. Mr. Sullivan has received nine U.S. patents and has several patents pending. He graduated <i>magna cum laude</i>
with distinction from Harvard College with an A.B. in economics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lance
G. Laing, Ph.D.</i> is our co-Founder and has served as Chief Science Officer, Vice President, Secretary and a director since we
commenced operations in 2012. Dr. Laing&#8217;s career spans more than 20 years in drug discovery research and technology
development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National
Institutes of Health post-doctoral fellowship at Washington University Medical School in biophysics. He has received 27 U.S. patents
and has several U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased
by Novartis), where he worked under Professor Peter Kim. He also was Director of Chemistry and Bioapplications and Director of
Detection Product Development for two companies that each developed instruments similar to those used by Celcuity. His work at these
two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these
instruments. Most recently, he served as an executive director for an international drug discovery and development
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vicky
Hahne</i> joined as our Chief Financial Officer in July 2017. She has more than 25 years of financial leadership experience, including
the most recent 20 years in the healthcare industry. Prior to joining Celcuity, Ms. Hahne served as Controller of Respiratory Technologies
Inc., a medical device manufacturer, from 2015 to 2017. While at Respiratory Technologies, she played a key role in the due diligence
process to sell the company to Koninklijke Philips. In 2014, she served as Controller for Ability Network Inc., a healthcare information
technology company. From 2007 to 2012, Ms. Hahne served as Controller of SterilMed Inc., a medical device reprocessing company, where
she was significantly involved in the sale of the company to Johnson &amp; Johnson. Prior to these roles, Ms. Hahne held several senior
financial positions at SimonDelivers Inc., including Chief Financial Officer. Ms. Hahne has extensive experience in early stage, high
growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions, building
infrastructure and systems. She received a B.S. degree in Finance and Accounting from Northern State University and received her CPA
certificate in 1990.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_003"></span>ITEM
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
factors that could cause actual results to differ from our expectations and that could negatively impact our financial condition and
results of operations are discussed below and elsewhere in this Annual Report. Additional risks and uncertainties not presently known
to us or that are currently not believed to be significant to our business may also affect our actual results and could harm our business,
financial condition and results of operations. If any of the risks or uncertainties described below or any additional risks and uncertainties
actually occur, our business, results of operations and financial condition could be materially and adversely affected. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not yet commercialized a pharmaceutical product, and we may never generate revenue or profit.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company that commenced activities in January 2012. We have not yet commercialized a
pharmaceutical product, and our commercial business plan has not been tested. Since inception, we have had no revenue and have
incurred significant operating losses. We have financed our operations primarily through private placements and registered offerings
of our equity securities, unsecured convertible notes, and borrowings under loan agreements. To generate revenue and become and
remain profitable, we need to successfully complete our existing clinical trials and develop, obtain regulatory approval for, and
commercialize gedatolisib pursuant to our license agreement with Pfizer. We must also build operational and financial infrastructure
to support commercial operations, train and manage employees, and market and sell our anticipated drug product, if
approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability.
We expect to continue to incur significant expenses and operating losses for the foreseeable future, and the net losses we incur may
fluctuate significantly from quarter to quarter. Our failure to become and remain profitable would decrease our value and could impair
our ability to raise capital, maintain or expand our research and development efforts, expand our business, or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our drug candidate,
gedatolisib.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may require additional capital to finance operating expenses and capital expenditures in the future as we prepare to launch, and if we
launch, gedatolisib, and expand our infrastructure, commercial operations and research and development activities. If we are not able
to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development
programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or market
development programs, which could lower the economic value of those programs to our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
financing activities could dilute the percentage ownership of our stockholders and could cause our stock price to fall or could result
in operating or other restrictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional
funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, it will result in
dilution to current stockholders. Any equity securities issued may also provide for rights, preferences or privileges senior to those
of holders of our existing securities. The incurrence of additional indebtedness or the issuance of certain equity securities could result
in increased fixed payment obligations and could also include restrictive covenants, such as limitations on our ability to incur additional
debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions
that could adversely affect our ability to conduct our business. In the event that we enter into collaborations or licensing arrangements
to raise capital, we may be required to accept unfavorable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on our ability to attract and retain key personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are materially dependent upon the services of our officers and key employees, including Brian F. Sullivan, our Chief Executive
Officer, and Dr. Lance G. Laing, our Chief Science Officer. Successful implementation of our business plan will also require the services
of other consultants and additional personnel. We cannot assure you that we will be able to attract and retain such persons as employees,
independent contractors, consultants or otherwise. If we are not able to attract individuals with the skills required for our business,
or if we lose the services of either Mr. Sullivan or Dr. Laing, we may be unable to successfully implement our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability claims may damage our reputation and, if insurance proves inadequate, these claims may harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be exposed to the risk of product liability claims that is inherent in the pharmaceutical industry. A product liability claim may
damage our reputation by raising questions about our product&#8217;s safety and could limit our ability to sell our product. In addition,
product liability insurance for the pharmaceutical industry is generally expensive to the extent it is available at all. There can be
no assurance that we will be able to obtain or maintain such insurance on acceptable terms for any product we bring to market. Further,
our product liability insurance coverage may not provide coverage or may be insufficient to reimburse us for any or all expenses or losses
we may suffer. A successful claim against us with respect to uninsured liabilities or in excess of insurance coverage could have a material
adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result,
we may encounter difficulties in managing our growth, which could disrupt our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug
development, regulatory affairs and, in anticipation of our product candidate potentially receiving marketing approval, sales, marketing
and distribution. To manage this growth, we must continue to implement and improve our managerial, operational and financial systems,
and continue to recruit and train additional qualified personnel. Due to finite financial and human resources, we may not be able to
effectively manage the expansion of our operations or recruit and train sufficient numbers of additional qualified personnel. The expansion
of our operations is costly and may divert our management and business development resources. Any inability to manage growth could delay
the execution of our business plans or disrupt our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to trade policy, including new or increased tariffs and changing import and export regulations, could have a material adverse effect
on our business, results of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, results of operations, and financial condition could be adversely affected by uncertainty and changes in U.S. or international
trade policies, including tariffs, quotas, trade agreements, or other trade restrictions imposed by the U.S. or other governments. For
example, the U.S. has instituted certain changes, and has proposed additional changes, in trade policies that include the negotiation
or termination of trade agreements, the imposition of higher tariffs on imports into the U.S., and other government regulations affecting
trade between the U.S. and other countries. New tariffs and other changes in U.S. trade policy have triggered, and may in the future
trigger, retaliatory actions by affected countries, and foreign governments may institute or may consider imposing trade sanctions on
U.S. goods. Several recent tariff announcements have been followed by announcements of limited exemptions, revisions, and temporary pauses,
resulting in significant uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
increasing uncertainty related to trade policies, on February 20, 2026, the U.S. Supreme Court ruled against the U.S. presidential
administration&#8217;s use of tariffs under the International Emergency Economic Powers Act (the &#8220;IEEPA&#8221;). However, the
decision creates uncertainty related to various aspects of the tariffs previously collected under the IEEPA, and not all tariffs
announced throughout 2025 were impacted by this U.S. Supreme Court decision. Additionally, in response to the U.S. Supreme Court
ruling, the U.S. presidential administration imposed a new worldwide tariff effective for 150 days from February 24, 2026. The
imposition of these new, worldwide tariffs, as well as the potential for further tariff actions by the U.S. presidential
administration or others, represents a significant source of uncertainty. The imposition of tariffs and other trade restrictions, as
well as the escalation of trade disputes and any downturns in the global economy resulting therefrom, could materially and adversely
affect our business, financial condition and results of operations. The extent and duration of the tariffs and other trade
restrictions and the resulting impact on general economic conditions and on our business are uncertain and depend on various
factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or
exclusions that may be granted, and availability and cost of alternative sources of supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
imposition of, or increase in, tariffs or other restrictions on imports of active pharmaceutical ingredient (&#8220;API&#8221;), finished
drug product or other materials (or the components of these materials) could increase the cost for such API, finished drug product or
other materials and also increase the prices for such materials available domestically or locally, if any, which in turn could increase
our costs for API and our finished drug product. Such cost increases could materially and adversely affect our results of operations
and financial condition. Tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial
and economic conditions and commodity markets, declining consumer confidence, significant inflation, and diminished expectations for
the economy. Such conditions could have a material adverse impact on our business, results of operations and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our
business, financial condition and results of operations and impair our ability to satisfy our debt obligations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had $338.8 million aggregate principal amount of indebtedness for borrowed money, of which $130.0 million was
secured indebtedness consisting of the Term Loans (as defined in Note 10 to our financial statements included elsewhere in this Annual
Report). Included in the aggregate principal amount is $201.3 million principal amount of additional indebtedness as a result of the
offering of the Company&#8217;s 2.750% Senior Notes due 2031 (the &#8220;Notes&#8221;). We may incur additional indebtedness to meet
future financing needs. For example, we have an additional $220.0 million in incremental Term Loans that can be drawn under the A&amp;R
Loan Agreement (as defined in Note 10 to our financial statements included elsewhere in this Annual Report) upon the achievement of certain
regulatory milestones and product revenue thresholds. Our indebtedness could have significant negative consequences for our security
holders and our business, results of operations and financial condition by, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increasing
                                            our vulnerability to adverse economic and industry conditions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            our ability to obtain additional financing on acceptable terms or at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
                                            the dedication of a substantial portion of our cash flow from operations to service our indebtedness,
                                            which will reduce the amount of cash available for other purposes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            our flexibility to plan for, or react to, changes in our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting
                                            the interests of our existing stockholders as a result of issuing shares of our common stock
                                            upon conversion of the Notes; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">placing
                                            us at a possible competitive disadvantage with competitors that are less leveraged than us
                                            or have better access to capital.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under
our indebtedness, and our cash needs may increase in the future. In addition, the A&amp;R Loan Agreement contains, and any future indebtedness
that we may incur in the future may contain, financial and other restrictive covenants that limit our ability to operate our business,
raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our
indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness
becoming immediately due and payable in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay any cash amounts
due upon maturity, and our other indebtedness may limit our ability to repurchase the Notes or to pay any cash amounts due upon their
maturity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noteholders
may, subject to a limited exception, require us to repurchase their Notes following a fundamental change at a cash repurchase price generally
equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental
change repurchase date. Upon maturity of the Notes, we must pay their principal amount and accrued and unpaid interest in cash, unless
they have been previously converted, redeemed or repurchased. We may not have enough available cash or be able to obtain financing at
the time we are required to repurchase the Notes or pay any cash amounts due upon their maturity. In addition, applicable law, regulatory
authorities and the agreements governing our other indebtedness may restrict our ability to repurchase the Notes or to pay any cash amounts
due upon their maturity. Our failure to repurchase Notes or to pay any cash amounts due upon their maturity when required will constitute
a default under the indenture, dated as of August 1, 2025, between the Company and U.S. Bank Trust Company, National Association, as
trustee (the &#8220;Base Indenture&#8221;), as supplemented by the first supplemental indenture (the &#8220;Supplemental Indenture,&#8221;
and the Base Indenture, as supplemented by the Supplemental Indenture, the &#8220;Indenture&#8221;). A default under the Indenture or
the fundamental change itself could also lead to a default under agreements governing our other indebtedness, which may result in that
other indebtedness becoming immediately payable in full after any applicable notice or grace periods. We may not have sufficient funds
to satisfy all amounts due under our indebtedness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in the Indenture could delay or prevent an otherwise beneficial takeover of us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions in the Notes and the Indenture could make a third-party attempt to acquire us more difficult or expensive. For example, if
a takeover constitutes a fundamental change, then, subject to limited exceptions, Noteholders will have the right to require us to repurchase
their Notes for cash. In addition, if a takeover constitutes a make-whole fundamental change, then we may be required to temporarily
increase the conversion rate of the Notes. In either case, and in other cases, our obligations under the Notes and the Indenture could
increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including
in a transaction that holders of our common stock may view as favorable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Product Strategy </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
near-term revenue prospects depend on the success of our initial drug product, gedatolisib. If we are unable to successfully complete
clinical development of, obtain regulatory approval for, or commercialize, gedatolisib, or if we experience delays in doing so, including
supply chain interruptions, our business will be materially and adversely impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success and ability to generate revenue, if ever, is dependent on our ability to successfully develop, obtain regulatory approval
for and commercialize gedatolisib for one or more intended uses. We may not have the financial resources to continue development of,
or to modify existing or enter into new collaborations for, our current or future product candidates if we experience any issues that
delay or prevent regulatory approval of, or our ability to commercialize, gedatolisib, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
                                            authorities that gedatolisib is safe and effective;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
                                            or inconclusive results from our clinical trials or the clinical trials of others for drug
                                            products similar to ours, leading to a decision or requirement to conduct additional preclinical
                                            studies or clinical trials or abandon a program;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related
                                            adverse events experienced by subjects in our clinical trials or by individuals using drugs
                                            or therapies similar to gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
                                            effectiveness of gedatolisib or companion therapeutics during clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">better
                                            than expected performance of control arms, such as placebo groups, which could lead to negative
                                            or inconclusive results from our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
                                            drop-out rates of subjects from clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate
                                            supply or quality of drug products or other materials necessary for the conduct of our clinical
                                            trials or to support commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
                                            than anticipated clinical trial or manufacturing costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
                                            FDA or comparable regulatory authority inspection and review of a clinical trial site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            of our third-party contractors or investigators to comply with regulatory requirements or
                                            otherwise meet their contractual obligations in a timely manner, or at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            and changes in regulatory requirements, policy and guidelines, including the imposition of
                                            additional regulatory oversight around clinical testing generally or with respect to our
                                            therapies in particular;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruptions
                                            to our supply of API, finished drug product or other materials; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
                                            interpretations of our clinical data by the FDA and comparable foreign regulatory authorities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
were not involved in the early development of gedatolisib; therefore, we are dependent on third parties having accurately generated,
collected, interpreted and reported data from certain preclinical and clinical trials of gedatolisib.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no involvement with or control over the initial preclinical and clinical development of gedatolisib. We are dependent on third parties
having conducted their research and development in accordance with the applicable protocols and legal, regulatory and scientific standards;
having accurately reported the results of all preclinical studies and clinical trials conducted with respect to such drug product; and
having correctly collected and interpreted the data from these trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not yet successfully completed any registrational clinical trials, and we may be unable to do so for any drug candidates we may
develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to successfully achieve primary clinical endpoints in registrational clinical trials, in order to obtain and maintain the approval
of the FDA or comparable foreign regulatory authorities to market our drug product. Carrying out clinical trials, including later-stage
registrational clinical trials, is a complicated process. As an organization, we have not previously completed any registrational clinical
trials. In order to do so, we continue to build and expand our clinical development and regulatory capabilities, and there is risk that
we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our clinical
trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory
requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates. Consequently, we may be unable
to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission, approval, and maintaining
approval of our drug product. We may require more time and incur greater costs than our competitors and may not succeed in obtaining
regulatory approval of any drug products that we develop. Failure to commence or complete, or delays in, our planned clinical trials,
could prevent us from or delay us in commercializing our drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful development of our products is highly uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the successful development of our pharmaceutical products, which is highly uncertain and is dependent on numerous
factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to
reach the market for several reasons including, among other things, that clinical trial results may show the product candidates to be
less effective than expected or to have unacceptable side effects or toxicities; we may fail to receive the necessary regulatory approvals
or there may be a delay in receiving such approvals; or the proprietary rights of others and their competing products and technologies
may prevent our product candidates from being commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory
authority varies significantly from one drug product to the next and from one country to the next and may be difficult to predict. We
will incur significant research and development expenses before knowing whether our products are commercially viable, and may abandon
development of a specific trial, or a product candidate, at any time for a variety of reasons. If we expend resources on products that
are ultimately not commercially viable, our timing for becoming profitable and our ability to invest in other products in our pipeline
would be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if <span style="background-color: white">gedatolisib</span> receives marketing approval for the intended uses that we are pursuing,
we will continue to be subject to significant post-approval regulatory obligations. Compliance with these requirements is costly, and
any failure to comply or other issues with our drug products post-approval could adversely affect our business, financial condition and
results of operations. In addition, there is always the risk that we, a regulatory authority, or a third party might identify previously
unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical
trials for a variety of reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patient eligibility and exclusion criteria defined in the protocol;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            size of the patient population required for analysis of the clinical trial&#8217;s primary
                                            endpoints;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proximity of patients to clinical trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the clinical trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience,
                                            and the ability of these investigators to identify and enroll suitable patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perception
                                            of the safety profile of our drug products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient consents; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion
of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data become available
and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary or interim data from our clinical studies, which is based on a preliminary analysis
of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review
of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary or
interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify
such results once additional data have been received and fully evaluated. Preliminary or interim data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, preliminary or interim data should be viewed with caution until the final data are available. Adverse differences between
preliminary or interim data and final data could significantly harm our reputation and marketing efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including healthcare providers or payors, may not accept or agree with our assumptions, estimates, calculations, conclusions
or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the
approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information
we choose to publicly disclose regarding a particular study is based on what is typically extensive information, you or others may not
agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we
determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise
regarding our business. If the preliminary or interim data that we report differ from actual results, or if others, including healthcare
providers or payors, disagree with the conclusions reached, our ability to commercialize our product candidate may be harmed, which could
harm our business, operating results, prospects or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to commercialize any drug product, we must demonstrate through extensive preclinical studies
and clinical trials that such drug product is safe and effective in humans. Clinical testing is expensive and can take many years to
complete, and its outcome is inherently uncertain. We may be unable to establish clinical endpoints that applicable regulatory authorities
would consider clinically meaningful, and a clinical trial can fail at any stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Differences
in trial design between early-stage clinical trials and later-stage clinical trials, which involve a greater number of patients and take
years to complete, make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical
data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed
satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. Additionally, we are conducting
and plan to conduct some open-label clinical trials, where both the patient and investigator know whether the patient is receiving the
investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only
the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various
limitations that may exaggerate any therapeutic effect as patients in those trials are aware when they are receiving treatment. Open-label
clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to
their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator
bias&#8221; where those assessing and reviewing the outcomes of the clinical trials are aware of which patients have received treatment
and may interpret the information of the treated group more favorably given this knowledge. Where a randomized, placebo-controlled clinical
trial is designed to allow enrolled subjects to cross-over to the treatment arm, there may be a risk of inadvertent unblinding of subjects
prior to cross-over, which may limit the clinical meaningfulness of those data and may require the conduct of additional clinical trials.
As such, the results from an open-label clinical trial may not be predictive of future clinical trial results with any of our product
candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
completion of clinical trials, or achievement of a predefined primary endpoint, is a prerequisite to submitting an NDA, or NDA supplement,
to the FDA, and similar marketing applications to comparable foreign regulatory authorities, for each drug product and, consequently,
the ultimate approval and commercial marketing of any drug products. We may experience delays in initiating or completing clinical trials,
or achieving event thresholds, including if it takes longer than expected to activate the targeted number of clinical sites, if the enrollment
of patients is slower than anticipated or negatively affected by staffing shortages at clinical sites, or by other unanticipated factors,
or if the FDA or other regulatory authorities require us to pause one or more of our clinical trials due to unexpected safety issues.
We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could
delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether our clinical trials will
begin or continue as planned, will need to be reassigned or will be completed on schedule, or at all. Significant clinical trial delays
also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our
competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates
and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial
condition and results of operations significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition, and our operating results will suffer if we fail to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs
that are able to achieve similar or better results than our lead product candidate, gedatolisib. Our potential competitors include major
multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, and universities and
other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger
research and development staff and experienced marketing and manufacturing organizations and well-established sales forces.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease
indications that gedatolisib is also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate
discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop
obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated
in our competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for
investment in these industries. Our competitors, either alone or with collaboration partners, may succeed in developing, acquiring or
licensing on an exclusive basis products that are more effective, safer, more easily commercialized or less costly than our product candidates
or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.
We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy,
safety, tolerability, reliability, convenience of use, price, and reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval of drug products, the availability and price of our competitors&#8217; products could limit the demand
and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of
our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment
to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates
for use in limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical
trial delays; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational
harm; and other adverse consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyberattacks,
malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and
availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. We rely
on contract research organizations, contract manufacturing organizations, distributors, supply chain resources, and other third-party
service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including,
without limitation, on-site systems and cloud-based data centers, systems handling human resources, financial reporting and controls,
customer relationship management, regulatory compliance, and other infrastructure operations. We also communicate sensitive data, including
patient data, electronically, and through relationships with multiple third-party vendors and their subcontractors. These applications
and data encompass a wide variety of sensitive information, including research and development information, patient data, commercial
information, and business and financial information. Our ability to monitor these third parties&#8217; security practices is limited,
and these third parties may not have adequate security measures in place. If we or any of our third-party service providers experience
a security incident or other interruption, we could experience adverse consequences. We cannot guarantee that third parties and infrastructure
in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable
defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology
systems that support us and our services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
threats are becoming increasingly difficult to detect, and come from a variety of sources, including without limitation, nation-state
actors and activists that create disruption for geopolitical reasons and in conjunction with military conflicts and defense activities.
This risk is heightened as a result of global wars and other major conflicts. In addition, we and the third parties upon which we rely
face an evolving cybersecurity threat landscape, which includes social-engineering attacks (including through deep fakes, which may be
increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including
as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel
misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, attacks enhanced or facilitated by
artificial intelligence (&#8220;AI&#8221;), software or hardware failures, loss of data or other information technology assets, adware,
telecommunications failures, natural disasters, terrorism, and other similar threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our employees and contractors work remotely. Remote work involves risks to our information technology systems and data, as
individuals utilize network connections, computers and devices outside our premises or network, including working at home, while in transit
and in public locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ransomware
attacks also continue to increase in prevalence and severity and can lead to significant interruptions in our operations, ability to
provide our services, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative
impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations
prohibiting such payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we take steps designed to identify, prevent, assess and mitigate vulnerabilities in our information systems and to mitigate related third-party
risks, there can be no assurance that we will be able to detect and remediate all such vulnerabilities, including on a timely basis.
The threats and techniques used to exploit vulnerabilities change frequently and are often sophisticated in nature. Therefore, we (or
third parties on whom we rely) may be unable to detect a vulnerability until after a security incident has occurred. Further, we or third
parties on which we rely may face downtime as a result of adopting new information technology systems that are designed to enhance compliance
or reduce vulnerabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction,
loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of
the third parties upon whom we rely. This could disrupt our clinical trials, damage our reputation, and negatively affect our ability
to conduct our business in the ordinary course, including our ability to collect, process, and prepare company financial information,
provide information and educational materials through our website, and manage the administrative aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against
security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain certain measures
to protect our information technology systems and sensitive information and to notify relevant stakeholders, including affected individuals,
regulatory authorities and our stockholders, of certain security incidents. The disclosure decisions are complex, may take time to determine,
and may be subject to change as an investigation progresses. Providing disclosure may be costly, and the failure to comply with such
requirements could also lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are
perceived to have experienced a security incident, we may face government enforcement actions (for example, investigations, fines, penalties,
audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including
personal information); litigation (including class claims) and mass arbitration; indemnification obligations; negative publicity; reputational
harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.
Accordingly, security incidents and attendant consequences may damage our financial position and negatively impact our ability to grow
and operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if the information technology systems of the third parties upon which we rely become subject to security incidents, we may have insufficient
recourse against such third parties, and we may have to expend significant resources to mitigate the impact of such an event, and to
develop and implement protections to prevent future events of this nature from occurring. There can be no assurance that limitations
of liability in our third-party contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy
and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate
liabilities arising out of our data privacy and security practices. Additionally, we cannot be sure that such coverage will continue
to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public
sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine
our competitive advantage or market position. Additionally, our sensitive information could be leaked, disclosed, or revealed as a result
of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Artificial
intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information,
proprietary information and personal data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issues
in the use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability
or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks
and challenges that could impact our business. Our vendors may incorporate generative artificial intelligence tools into their offerings
without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly
evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability
to maintain an adequate level of service and experience. If any of our vendors experiences an actual or perceived breach or privacy or
security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential
information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad
actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities
involving the theft and misuse of personal information, confidential information and intellectual property. Any of these outcomes could
damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
health matters may materially and adversely impact our business, including ongoing clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of COVID-19 and government measures taken in response demonstrated that public health matters have a significant impact on the
global economy, with healthcare systems particularly affected. Future outbreaks or variants of COVID-19, or the emergence of other pandemics
or public health disruptions, could materially and adversely impact our clinical trials, business, financial condition and results of
operations. Potential disruptions include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in enrolling patients in clinical trials and obtaining the results of completed
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
                                            rates of patients withdrawing from clinical trials following enrollment as a result of quarantine
                                            or public health concerns;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
                                            of healthcare resources away from the conduct of clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in prospective clinical trial collaborations with pharmaceutical companies and sponsors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            or delays in the operations of the FDA or other regulatory authorities, which may impact
                                            review and approval timelines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on our ability to recruit and hire key personnel due to our inability to meet with candidates
                                            because of travel restrictions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on employee resources that would otherwise be focused on the conduct of clinical trials and
                                            research as a result of focus on health matters and loss of productivity from remote work.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Product Development and Product Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain approval from the FDA or comparable foreign regulatory authorities to market our products for their intended
use, we will not be able to generate revenue. For a new drug to be approved for marketing, the FDA and other regulatory authorities must
determine that the drug is safe and effective. Because all drugs can have adverse effects, the data from our Phase 3 clinical study must
demonstrate to the satisfaction of the FDA and other health authorities that the benefits of gedatolisib in combination with fulvestrant,
and with or without palbociclib, or gedatolisib in combination with fulvestrant plus a CDK4/6 inhibitor, outweigh its risks. Failure
to demonstrate sufficient magnitude of benefit, even if the benefit is found to be statistically significant, may not support regulatory
approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of our products, particularly gedatolisib, depends on securing approval from the FDA and equivalent foreign regulatory
bodies. This requires rigorous pre-clinical and clinical studies, including Phase 3 clinical trials for each intended use, that the benefits
of the therapy outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even if the benefit is found to be statistically
significant, may not support regulatory approval. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years
and requires substantial resources for research, development and testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
a drug meets its primary efficacy endpoint objective in a Phase 3 clinical trial, and the drug sponsor has additional nonclinical and
clinical data required by the FDA or other regulatory authorities, the drug sponsor may submit an NDA seeking marketing approval. Upon
submission of an NDA, these health authorities perform a benefit-risk assessment that considers the strength and quality of evidence
available and takes remaining uncertainties into account. These considerations include an assessment of the strengths and limitations
of clinical trials, including design, and potential implications for assessing drug efficacy, the magnitude of benefit and interpretation
of clinical importance, the benefit attributed to the drug when studied in combination with other therapies, and the clinical relevance
of the study endpoints. We are currently conducting a Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with
fulvestrant with or without palbociclib, in patients with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR+/HER2-
ABC after progression on CDK4/6 therapy<span style="background-color: white">, </span>conducting a Phase 3 clinical
trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant
as first-line treatment for patients with endocrine treatment resistant HR+/HER2- ABC, <span style="background-color: white">and conducting a Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer.
In November 2025, we completed our NDA submission to the FDA for gedatolisib in </span>HR+/HER2- ABC <span style="background-color: white">based
on clinical data from the <i>PIK3CA</i> WT cohort of the Phase 3 VIKTORIA-1 clinical trial. On January 16, 2026, the FDA accepted our
NDA, designated it for Priority Review, and identified July 17, 2026 as our PDUFA target goal date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have sought feedback from the FDA and other regulatory authorities on the design of gedatolisib clinical trials, with the goal of addressing
these considerations in the clinical trials&#8217; design. However, due to the complexity of clinical trials, the uncertainty of outcomes,
and the uncertainty of how the FDA and other regulatory authorities may balance benefits and risks in their review of an NDA, it may
not be practical or possible to address all benefit-risk assessment considerations in a clinical trial so that sufficient evidence is
generated to support a marketing approval, even if the primary endpoint objective is achieved in the Phase 3 stage of the trial. The
FDA or other regulatory authorities may require us to redesign or conduct additional unplanned clinical trials before granting any approval
and we may not get approval at all. Regulatory approval </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur
during our regulatory review. We cannot predict whether our research and clinical approaches will result in a drug that the FDA considers
safe for humans and effective for indicated uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
regulatory approvals are delayed or not obtained, especially with respect to gedatolisib, it will negatively impact our ability to commercialize
our products and generate revenue and may </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminish any
competitive advantages that we may otherwise enjoy<span style="background-color: white">. If we are required to conduct additional clinical
trials or other testing of gedatolisib beyond those that we currently contemplate, if we are unable to successfully complete clinical
trials or other testing of gedatolisib, or if the results of these trials or tests are not positive or are only modestly positive or
if there are safety concerns, we may:</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            delayed in obtaining marketing approval, supplemental marketing approval, or
                                            not obtain marketing approval at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval with labeling that includes significant use or distribution restrictions or safety
                                            warnings, including boxed warnings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            subject to changes in the way our products are administered;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            required to perform additional clinical trials to support approval or be subject to additional
                                            post-marketing testing requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions
                                            on its distribution in the form of the FDA&#8217;s REMS program or through modification to an existing REMS;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            sued; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
                                            damage to our reputation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the size of the FDA group dedicated to reviewing oncology-related submissions is reduced, further delays of our regulatory
submissions may be encountered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Breakthrough
Therapy Designation, Fast Track Designation, NDA submission via RTOR, and being awarded Priority Review from the FDA may not actually
lead to a faster development or regulatory review or approval process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address
unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation. The designation offers the opportunity
for frequent interactions with the FDA to discuss the drug&#8217;s development plan and to ensure collection of appropriate data needed
to support drug approval, as well as eligibility for submission of an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a drug may receive Breakthrough Therapy Designation if it is intended, alone or in combination with one or more other products,
to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. The benefits of Breakthrough Therapy Designation include more intensive guidance from the FDA
on an efficient development program, access to a scientific liaison to help accelerate review time, and potential eligibility for Priority
Review if relevant criteria are met. This designation can expedite the development and regulatory review of an investigational medicine
that is intended to treat a serious or life-threatening condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track and Breakthrough Therapy Designations, as well as seeking to submit our NDA on a rolling basis pursuant to the FDA&#8217;s RTOR
program, and receiving Priority Review, are within the discretion of the FDA. The FDA has granted both designations to our lead drug
candidate, gedatolisib, and has accepted our NDA which was filed via RTOR and designated it for Priority Review. However, such designations
and programs may not result in a faster development process, review or approval compared to products considered for approval under conventional
FDA review procedures, and none of these designations and awards assures ultimate approval by the FDA. In addition, the FDA may later
decide that the product no longer meets the qualification conditions and may rescind such designations or programs, or the FDA may not
approve our NDA by the Priority Review PDUFA target goal date of July 17, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining FDA approval of our product candidates in the U.S. does not mean that we will be successful in obtaining regulatory approval
of our product candidates in other jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining FDA approval of our product candidates in the U.S. does not guarantee that we will be able to obtain or maintain regulatory
approval in any other jurisdiction, while a failure or delay in obtaining FDA approval in the U.S. may have a negative effect on the
regulatory approval process in other jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, a
comparable foreign regulatory authority must also approve the manufacturing, marketing and promotion of the product candidate in those
countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may
not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be
approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge
for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and
costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory
requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability
to realize the full market potential of our product candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive initial regulatory approvals, we will be subject to ongoing regulatory obligations and continued regulatory review, which
may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or
experience unanticipated problems with our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, distribution, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety and
other post-marketing information, including both federal and state requirements in the U.S. and requirements of comparable foreign regulatory
authorities. In addition, we will be subject to continued compliance with requirements for any clinical trials that we conduct post-approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements.
Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production and quality control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which
the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data
we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint
data such as patient-reported outcome measures. The FDA may impose consent decrees or withdraw approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously
unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information, imposition of post-marketing studies or clinical trials to assess new safety risks or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of our products, withdrawal of the product from the market
                                            or voluntary or mandatory product recalls;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning letters or holds on clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            by the FDA to approve pending applications or supplements to approved applications filed
                                            by us or suspension or revocation of license approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention or refusal to permit the import or export of our product candidates;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the approved label. If we are slow or unable to adapt to changes
in existing requirements or adopt new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose
any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercializing Our Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our products achieve requisite approvals, they may fail to achieve the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any product we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients,
third-party payors and others in the medical community. For example, existing drug therapies may be viewed as more reliable or more easily
administered than gedatolisib. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate
significant product revenues and we may not become profitable. The degree of market acceptance of any product candidate, if approved
for commercial sale, will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
                                            and potential advantages compared to alternatives;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to offer our products, if approved, for sale at acceptable prices;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
                                            and ease of administration compared to other treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of the target patient population to try new therapies and of physicians to prescribe
                                            or initiate these therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            strength of marketing and distribution support;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to obtain sufficient third-party coverage, market access and adequate reimbursement;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our products do not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not become
profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we commercialize any product candidates, we will be subject to U.S. and foreign governmental regulations as well as private payor policies
that mandate price controls or limitations on patient access to our products or establish prices paid by government entities or programs
for our products. Our business and our future results could be adversely affected by changes in such regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we or our partners are successful in obtaining marketing approval, commercial success of any approved products will also depend in
large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors
such as the VA, Medicare and Medicaid programs, 340B, and managed care organizations in the U.S. or country specific governmental organizations
in foreign countries. Government and private payors routinely seek to manage utilization and control costs, and there is considerable
public and government scrutiny of pharmaceutical pricing. Efforts by states and the federal government to regulate prices or payment
for pharmaceutical products, including proposed actions to facilitate drug importation, limit reimbursement to lower international (i.e.,
most favored nation) reference prices, require deep discounts, and require manufacturers to report and make public price increases and
sometimes provide a written justification for such price increases, could adversely affect our business if and as implemented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability
of reimbursement may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare, including
the Inflation Reduction Act, which requires manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount
program with a new discounting program. Some states have implemented, and others are considering implementing, patient access constraints
or cost cutting under the Medicaid program, and some are considering measures that would apply to broader segments of their populations
that are not Medicaid-eligible. State legislatures also have continued to focus on addressing drug costs, generally by increasing price
transparency or limiting drug price increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors also could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product
and appropriateness for specific patient populations, to qualify for reimbursement, which could be costly and divert our resources. If
government and other healthcare payors do not provide coverage and adequate reimbursement for our products once approved, market acceptance
and commercial success would be reduced. Even if coverage is provided, the approved reimbursement amount may not be high enough to support
pricing that results in a sufficient return on our research and development investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect pricing pressures will continue globally. U.S. and foreign governmental regulations that mandate price controls or limitations
on patient access to our products or establish prices paid by government entities or programs for our products could impact our business,
and our future results could be adversely affected by changes in such regulations or policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties in scaling production of, commercializing, marketing and distributing our products, including in hiring and
retaining a qualified sales force.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to commercialize any of our products in the U.S. and other jurisdictions, we must build production, marketing, sales, managerial
and other non-technical capabilities, or make arrangements with third parties to perform these services, and we may not be successful
in doing so. These activities will be expensive and time-consuming and will require significant attention of our executive officers to
manage. There are risks and material costs involved in establishing our own sales and marketing capabilities, as well as with entering
into arrangements with third parties to perform these services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, there is intense competition for qualified sales personnel and our inability to hire or retain an adequate number of sales
representatives could limit our ability to maintain or expand our business and increase sales. Furthermore, there is no guarantee that
the market opportunity for gedatolisib will be as significant as we expect or exist at all. If we are unable to successfully commercialize
our products in the U.S. or other jurisdictions, or if we are delayed in doing so, including if we are unable to develop our marketing
and sales networks or if our sales personnel do not perform as expected, we may never generate any revenue and our business may fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, operational and financial goals may not be attainable if the market opportunities for our products are smaller than we expect.
Our internal research and third-party estimates may not accurately reflect the market opportunities for gedatolisib today or in the future.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total market opportunities that we believe exist are based on a variety of assumptions and estimates, including the size of the addressable
patient population in applicable jurisdictions, other available drugs in these markets, payor coverage, anticipated reimbursement, and
the price we will be able to charge for our products. In addition, we have relied on third-party publications, research, surveys and
studies for information related to determining market opportunities, including without limitation, information on the number of addressable
cancer patients and those receiving various forms of treatment, the cost of drug therapy, the amount of revenue generated from various
types of drug therapy, the objective response rates of drug therapies, the number of deaths caused by cancer and the expected growth
in cancer drug therapy. Our internal research and estimates on market opportunities have been verified by independent sources, but any
or all of our assumptions and/or estimates may prove to be incorrect for several reasons, such as inaccurate reports or information that
we have relied on, potential patients or providers not being amenable to using our products or such patients becoming difficult to identify
and access, limited reimbursement for our products, pricing pressure due to availability of alternative drugs or an inability to obtain
the necessary regulatory approvals for new indications. If any or all of our assumptions and estimates prove inaccurate, we may not attain
our business, operational and financial goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on intellectual property licensed from Pfizer for our lead product candidate, and termination of
this license could result in the loss of significant rights, which would materially and adversely impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on patents and know-how, both our own and licensed from Pfizer. Key patents covering gedatolisib
and any combination therapies using our product candidates are licensed from Pfizer pursuant to the Gedatolisib License Agreement. Any
termination of the product license could result in the loss of significant rights and would cause material adverse harm to our ability
to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may also arise between us and Pfizer regarding intellectual property subject to the Gedatolisib License Agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            and the extent to which our product candidates and processes infringe on intellectual property
                                            of the licensor that is not subject to the license agreement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            right to sublicense patent and other rights to third parties under collaborative development
                                            relationships;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            diligence obligations with respect to the use of licensed assets in relation to our development
                                            and commercialization of our product candidates and what activities satisfy those diligence
                                            obligations; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ownership of inventions and know-how resulting from the joint creation or use of intellectual
                                            property by our licensors and us and our partners.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are generally also subject to all of the same risks with respect to protection of intellectual property that we own, as we are for intellectual
property that we license. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize
products could materially suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under our patent license with Pfizer, we could lose license rights that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to a license agreement with Pfizer pursuant to which we in-license key patents for gedatolisib. This license imposes various
diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, Pfizer may
have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed
intellectual property. Further, we cannot be certain that the activities conducted by Pfizer, or its predecessors, were performed in
compliance with applicable laws and regulations or will result in additional valid and enforceable patents and other intellectual property
rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials and other programs currently, and may in the future, involve additional product candidates that require the use of, or
reliance on, proprietary rights held by third parties. Accordingly, the growth of our business depends in part on our ability to acquire,
in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or
other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations.
We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which could harm our business. We
may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to
develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development
delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may
be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to
expend significant time and resources to develop or license replacement technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established
or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that
we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive
advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be
no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property
surrounding the additional product candidates that we may seek to acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our products could be significantly
diminished.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to
obtain or enforce. We may not be able to protect our trade secrets adequately. We have a policy of requiring our consultants, advisors
and strategic partners to enter into confidentiality agreements and our employees to enter into invention, non-disclosure and restrictive
covenant agreements. However, no assurance can be given that we have entered into appropriate agreements with all parties that have had
access to our trade secrets, know-how or other proprietary information. There is also no assurance that such agreements will provide
meaningful protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure
of information. Furthermore, we cannot provide assurance that any of our employees, consultants, contract personnel, or strategic partners,
either accidentally or through willful misconduct, will not cause serious damage to our programs and/or our strategy, for example by
disclosing important trade secrets, know-how or proprietary information to our competitors. It is also possible that our trade secrets,
know-how or other proprietary information could be obtained by third parties as a result of breaches of our physical or electronic security
systems. Any disclosure of confidential data into the public domain or to third parties could allow our competitors to learn our trade
secrets and use the information in competition against us. In addition, others may independently discover our trade secrets and proprietary
information. Any action to enforce our rights is likely to be time consuming and expensive, and may ultimately be unsuccessful, or may
result in a remedy that is not commercially valuable. These risks are accentuated in foreign countries where laws or law enforcement
practices may not protect proprietary rights as fully as in the United States. Any unauthorized disclosure of our trade secrets or proprietary
information could harm our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims by employees claiming ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact
develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached,
and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of
what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims,
litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain intellectual property protection for our product candidates, or if the scope of the intellectual
property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or
identical to ours, and our ability to successfully commercialize our product candidates may be impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied for patents that protect our product candidates, and our patent portfolio for our drug candidate, gedatolisib, includes
13 issued patents in the U.S. and more than 297 patents granted in numerous foreign jurisdictions. We cannot ensure that our intellectual
property position will not be challenged or that all patents for which we have applied will be granted. We cannot know with certainty
whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we
were the first to file for patent protection of such inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all
necessary or desirable patent applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to
seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the
laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. Additionally, the
laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future. There also may be patent reforms in foreign jurisdictions that could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents in those jurisdictions. It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical
development output before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in
part, or which effectively prevent others from commercializing competitive product candidates. Moreover, given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our owned patent portfolio may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our products depends upon our ability to manufacture, market and sell our products without infringing the proprietary
rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We
may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our products. Additionally, because current and future employees may have been previously employed at universities or other biotechnology,
diagnostic technology or pharmaceutical companies, including our competitors or potential competitors and strategic partners, third parties
may assert infringement claims against us based on existing patents or patents that may be granted in the future, or they may allege
that our employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
litigation could result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, which could limit our ability to stop others from using or commercializing similar product candidates, or limit
the duration of the patent protection of our products. If we are found to infringe a third party&#8217;s intellectual property rights,
we could be required to obtain additional licenses from such third party to continue developing and marketing our applicable products.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain
a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced,
including by court order, to cease commercializing the infringing technology or product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully
infringed a patent. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business
operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets
of third parties could have a similar negative impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly
and time consuming and could be unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or
other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be
expensive and time consuming, and could distract our technical and management personnel from their normal responsibilities. Any claims
we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their
patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole
or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our
patents at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent
infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other
fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for, or commercialize, any potential product candidates.</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend upon third parties to execute certain aspects of our operational plans and to conduct certain aspects of our preclinical studies.
Additionally, we depend on third parties, including independent investigators, to conduct our clinical trials, under agreements with
universities, medical institutions, CROs, strategic partners and others. Our reliance on third parties may affect our development timelines
and increase our costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited control over third-party clinical investigators and limited visibility into their day-to-day activities, including with
respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our clinical
trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. We and these
third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign
regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through
periodic inspections of clinical trial sponsors, clinical investigators and clinical trial sites. If we or any of these third parties
fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the
FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical
studies or clinical trials before approving our marketing applications. Moreover, our business may be adversely affected if any of these
third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
third parties conducting aspects of our preclinical studies or our clinical trials will not be our employees and, except for remedies
that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time
and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial
entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which
could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain
is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines,
including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain
regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects
for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or precluded
entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties to formulate, manufacture and distribute our drug product exposes us to risks that may delay the
development, regulatory approval and commercialization of our drug product or result in higher product and operational
costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not directly formulate, manufacture or distribute our drug product candidate and do not intend to establish our own formulation,
manufacturing or distribution facilities. We have contracted with third-party contract manufacturers to formulate, manufacture and
supply our drug product, and we use other third parties to package, store and distribute drug product for our clinical trials. If
our drug product receives FDA approval, we will rely on one or more third-party contract manufacturers to manufacture and package
our commercial drug product, and we will use a 3PL to distribute our commercial drug product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on a limited number of third-party manufacturers, including one primary manufacturer of the active ingredient gedatolisib, exposes
us to risks that, among other things, we may be unable to identify manufacturers on acceptable terms or at all because the number of
potential manufacturers is limited and the FDA must approve any replacement or additional manufacturer; our third-party manufacturers
might be unable to manufacture our drugs in the volume and of the quality required to meet our clinical and/or commercial needs, if any;
our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to
supply our clinical trials, or to successfully produce, store and distribute our products commercially; and our contract manufacturers
may fail to comply with good manufacturing practice and other government regulations and corresponding foreign standards. Each of these
risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA, or the commercialization of our product
candidates or result in higher costs or deprive us of potential product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
issues or price increases by our shipping carriers could adversely affect our business, results of operations and financial condition,
and harm our reputation and ability to provide our products on a timely basis.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expedited,
reliable shipping is essential to our operations. Should our shipping carriers encounter delivery performance issues such as loss, damage
or destruction of our API or product, such occurrences may damage our reputation and adversely affect our business. In addition, any
significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe
weather, natural disasters or other service interruptions by delivery services we use would adversely affect our ability to receive and
process product orders on a timely basis. There are only a few providers of overnight nationwide transport services, and there can be
no assurance that we will be able to maintain arrangements with providers on acceptable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Risks Related to Government Regulation for Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with applicable U.S. data security and privacy regulations may increase our operational costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we are not a covered entity under HIPAA, and our clinical operations are exempt from most state and federal data protection
regulations. The personal data of clinical trial subjects collected by our CROs&#8217; U.S. clinical sites is considered protected
health information, or PHI, subject to the U.S. sites&#8217; compliance with HIPAA. We will incur significant costs to establish and maintain data privacy
safeguards and, if we are required to comply with HIPAA or U.S. state regulations in the future, our costs could increase
further, which would negatively affect our operating results. Furthermore, we cannot guarantee that such safeguards have been and
will continue to be adequate under applicable laws. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we receive FDA approval and launch gedatolisib in the U.S., we expect to be subject to comprehensive state privacy laws. For
example, the CCPA applies to personal information of
consumers, business representatives, and employees, and requires covered businesses to provide specific disclosures related to a
business&#8217;s processing of personal data, new operational practices, and requirements to respond to certain requests from
California residents related to their personal data. New regulations and enforcement actions related to the CCPA and similar state
comprehensive privacy laws continue to impact how companies think about and establish compliance mechanisms across the U.S. U.S.
privacy compliance is further complicated by inconsistent state laws that require complex operational frameworks for full
compliance. Accordingly, the CCPA and other similar state laws may impact our business activities and increase our compliance costs,
as well as our legal risks. The regulatory framework for the collection, use, safeguarding, transfer and other processing of
information is rapidly evolving and is likely to remain uncertain for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evolving
U.S. data privacy regulations may interrupt or delay our development, regulatory and commercialization activities and increase our cost
of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us
and could have a material adverse effect on our business, financial condition or results of operations. Even if we are not determined
to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and
generate negative publicity, which could harm our reputation and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect
and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which
may have a material adverse effect on our business, financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs and clinical investigators involved in our clinical trials may collect, receive, store, process, use, generate, transfer, disclose,
make accessible, protect, secure, dispose of, transmit and share (collectively, &#8220;process&#8221;) personal data as defined in data protection
laws outside the U.S. Accordingly, we are subject to numerous foreign privacy and security laws regulating the collection, use, safeguarding,
transfer and other processing of personal data.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Globally, virtually every jurisdiction in which we operate has established
its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other
processing of personal data regarding individuals in the UK, the EU, and the EEA, is subject to the UK GDPR and EU GDPR (together, &#8220;UK/EU
GDPR&#8221;), which is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements
relating to the processing of health and other sensitive data, obtaining consent of the individuals to whom the personal data relates,
providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. In addition,
the UK/EU GDPR also imposes strict rules on the transfer of personal data to countries outside the UK/EU/EEA, including the U.S., and,
as a result, increases the scrutiny that clinical trial sites located in the UK/EU/EEA should apply to transfers of personal data from
such sites to countries that are considered to lack an adequate level of data protection, such as the U.S. The UK/EU GDPR also permits
data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines
for violations of the UK/EU GDPR, which can be up to 4% of global revenue or &#163;17 million/&#8364;20 million, whichever is greater,
and it also confers a private right of action on data subjects and consumer associates to lodge complaints with supervisory authorities,
seek judicial remedies, and obtain compensation for damages resulting from violations of the UK/EU GDPR. In addition, the UK/EU GDPR provides
that UK/EU/EEA member states may make their own further laws and regulations limiting the processing of personal data, including genetic,
biometric or health data. Given the breadth and depth of changes in data protection obligations, preparing for and complying with these
requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices,
as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data
collected in the UK/EU/EEA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evolving
data privacy regulations may interrupt or delay our development, regulatory and commercialization activities and increase our cost of
doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and
could have a material adverse effect on our business, financial condition or results of operations. Even if we are not determined to
have violated these laws, government investigations into these issues typically require the expenditure of significant resources and
generate negative publicity, which could harm our reputation and our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will also need to expend a considerable amount of resources complying with other federal, state and foreign laws and regulations. If
we are unable to comply or have not complied with such laws, we could face substantial penalties or other adverse actions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject, directly or indirectly, to other federal, state and foreign laws and regulations that are complex and their application
to our specific products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate.
Compliance with laws and regulations will require us to expend considerable resources implementing internal policies and procedures for
compliance and ongoing monitoring and will require significant attention of our management team. This will be challenging as an early-stage
company with limited financial resources and human capital. These laws include, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
                                            XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute,
                                            which prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration,
                                            directly or indirectly, in cash or in kind, in return for or to reward the referral of patients
                                            or arranging for the referral of patients, or in return for the recommendation, arrangement,
                                            purchase, lease or order of items or services that are covered, in whole or in part, by a
                                            federal healthcare program such as Medicare or Medicaid;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            civil False Claims Act, which forbids the knowing submission or &#8220;causing the submission&#8221;
                                            of false or fraudulent information or the failure to disclose information in connection with
                                            the submission and payment of claims for reimbursement to Medicare, Medicaid, federal healthcare
                                            programs or private health plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians
                                            from referring Medicare or Medicaid patients to providers of&#8201;&#8221;designated health
                                            services&#8221; with whom the physician or a member of the physician&#8217;s immediate family
                                            has an ownership interest or compensation arrangement, unless a statutory or regulatory exception
                                            applies, and similar state equivalents that may apply regardless of payor; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery
                                            statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and the USA PATRIOT Act,
                                            which among other things, prohibit companies and their employees, agents, third-party intermediaries,
                                            joint venture partners and collaborators from authorizing, promising, offering, or providing,
                                            directly or indirectly, improper payments or benefits to recipients in the public or private
                                            sector.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states and foreign governments have adopted similar laws and regulations. Violations of law could subject us to civil or criminal penalties,
monetary fines, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings
and curtailment of our operations. We could also be required to change or terminate some portions of operations or business or could
be disqualified from providing services to healthcare providers doing business with government programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at the FDA and other government agencies from funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns
and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop
and secure approval of our product candidates in a timely manner, which would negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA, play an important role in the development of our product
candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including NDAs, INDs,
requests for special designations and marketing applications. If these oversight and review activities are disrupted, then correspondingly
our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the loss of FDA leadership and personnel and new leadership at the U.S. Department of Health &amp; Human Services, the FDA and
the Center for Drug Evaluation and Research could lead to disruptions and delays in FDA guidance and review and approval of our product
candidate. Further, while the FDA&#8217;s review of marketing applications and other activities for new drugs is largely funded through
the user fee program established under PDUFA, it remains unclear how the administration&#8217;s recent reduction in force and budget
cuts will impact this program and the ability of the FDA to provide guidance and review our product candidate in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also substantial uncertainty as to how regulatory reform measures being implemented by the Trump Administration across the government
will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office, the President
has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and
engages in regulatory and oversight activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development
programs or delay the agency&#8217;s review of our regulatory submissions, including the NDA we submitted in November 2025 that was accepted
by the FDA in January 2026, our business would be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control
of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock,
thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing
the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our
current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these
provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
                                            the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            the manner in which stockholders can remove directors from our board of directors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            advance notice requirements for stockholder proposals that can be acted on at stockholder
                                            meetings and nominations to our board of directors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            that stockholder actions must be effected at a duly called stockholder meeting and prohibit
                                            actions by our stockholders by written consent;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            who may call stockholder meetings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
                                            our board of directors to issue preferred stock without stockholder approval, which could
                                            be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership
                                            of a potential hostile acquirer, effectively preventing acquisitions that have not been approved
                                            by our board of directors; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            the approval of the holders of at least two-thirds of the votes that all our stockholders
                                            would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation
                                            or bylaws.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess
of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction
in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed
manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our
common stock or could subject us to securities litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price may be extremely volatile. The stock market in general and the market for smaller medical technology companies in particular
have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of
this volatility, investors may not be able to sell our common stock at or above the price they paid for such stock. The market price
for our common stock may be influenced by many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competitive products or technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
                                            of existing or future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            or legal developments in the United States and other countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            recruitment or departure of key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            level of expenses related to any of our products or clinical development programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated changes in estimates as to financial results, development timelines or recommendations
                                            by securities analysts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                            results that fail to meet expectations of securities analysts that cover our company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
                                            in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the structure of healthcare payment systems;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            conditions in the pharmaceutical, biotechnology and medical technology sectors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our stock by us, our insiders and our other stockholders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic and market conditions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
companies that have experienced volatility in the market price of their stock have been subject to an increased incidence of securities
class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result
in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of shares of our common stock, including by us and significant stockholders, could negatively affect our stock price. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public market could occur at any time. Since December 2023, we have issued
6,478,782 shares of common stock pursuant to equity financing arrangements, including pursuant to our Open Market Sale Agreement<sup>SM</sup>
with Jefferies LLC (&#8220;Jefferies&#8221;), as agent, pursuant to which we may currently offer and sell, from time to time, through
Jefferies, shares of our common stock having an aggregate offering price of up to $400.0 million, all of which remains available for
sale. In addition, in August 2025, we issued and sold in a public offering $201.3 million aggregate principal amount of Notes, which
would result in the issuance of 3,923,002 shares if the Notes were converted in full as of December 31, 2025. We may enter into additional
equity or convertible debt financing arrangements in the future. The shares of common stock that we have issued pursuant to equity financings,
or may issue in the future pursuant to equity or convertible debt financings, may be resold at any time in the discretion of the investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our A&amp;R Loan Agreement, as amended by the First Amendment to the A&amp;R Loan Agreement, the Second Amendment to A&amp;R Loan Agreement
and the Third Amendment to the A&amp;R Loan Agreement, Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;),
has the right, at its election and until May 9, 2026, to convert up to 20% of the outstanding principal of the Term A Loan into shares
of the Company&#8217;s common stock at a price per share of $10.00. In addition, Innovatus continues to have the right to exercise a
previously disclosed warrant to purchase 26,042 shares of common stock at an exercise price of $14.40 per share, and Innovatus and Oxford
Finance LLC, a Delaware limited liability company, and certain of its affiliates, continue to have the right to exercise previously disclosed
warrants to purchase 154,413 shares of common stock at an exercise price of $14.84 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of substantial amounts of shares of our common stock or other securities by these investors or our other stockholders or by us under
the Open Market Sale Agreement<sup>SM</sup>, or the perception in the market that the holders of a large number of shares of our common
stock intend to sell their shares, could reduce the trading price of our common stock, make it more difficult for you to sell your shares
at a price that you desire and impair our ability to raise capital through the sale of equity or equity-related securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_001"></span>ITEM
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98E_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-KMTV_zh1qtXs1qFDa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000052-01" escape="true" id="Fact000052" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_002"></span>ITEM
1C. Cybersecurity</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span id="xdx_C04_gBFCRMPFAIAMT-KMTV_z9LjSslapxIi"><ix:continuation continuedAt="ConU000052-02" id="ConU000052-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C04_gBFCRMPFAIAMT-KMTV_zd6I5KVDj5Sa"><ix:continuation id="ConU000052-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management &amp; Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management process is a component of our overall approach to managing material risks that could impact our operations,
including cybersecurity threats. In general, we seek to manage material internal and third-party cybersecurity risks through an approach
that focuses on: (i) protecting information systems and the information residing therein; (ii) identifying, preventing, and mitigating
cybersecurity threats; and (iii) assessing and responding to cybersecurity incidents when they occur. Maintaining, monitoring, and updating
our information security program&#8212;in an effort to ensure that it remains reasonable and appropriate in light of changes in the security
threat landscape, available technology, and applicable legal and contractual requirements&#8212;is an ongoing effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</div><!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zPE2J48wJxKe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">We
have implemented and maintain various processes, procedures, and measures to support our overall risk management strategy and to manage
and mitigate the material risks posed by cybersecurity threats to our systems and data.</ix:nonNumeric></span> With respect to cybersecurity, these measures
include conducting risk assessments of our operations and using a risk register to assess identified risks; developing business continuity,
disaster recovery and incident response plans; implementing technical safeguards and tools; conducting ongoing cybersecurity awareness
training; and using contractual protections where appropriate. Our incident response plan outlines the procedures for reporting, investigating,
and remediating cybersecurity incidents, including a framework to facilitate the escalation to our management team and board of cybersecurity
incidents, so that our management team is alerted in a timely manner to material information that would be required to be disclosed or
reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IT department maintains policies and procedures regarding network security, data protection and incident response. Pursuant to those
policies, IT engages with the Chief Financial Officer, General Counsel and other experts when assessing cybersecurity threats, incident
response, and making disclosure determinations following a data or network breach. The Vice President, IT is accountable at the management
level for our overall IT risk management program. Additionally, our Chief Executive Officer and Audit Committee receive regular updates
from the Chief Financial Officer, General Counsel and the Vice President, IT about significant threats and incidents involving cybersecurity
and data protection, as well as security enhancements made to our IT infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use <span id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zipBTX3fdTAb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> service providers for a variety of services throughout our business, ranging from infrastructure support and maintenance,
cybersecurity incident response, data protection and privacy compliance. In addition, we engage with contract research organizations,
contract manufacturing organizations, distributors, and other supply chain resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the use of external service providers improves our operational capabilities, and we have implemented a vendor qualification
and management program that applies to our service providers, including those that handle health information, personal information,
or other information subject to protection under applicable privacy and data protection regulations. This program is designed to identify,
address and seek to mitigate potential cybersecurity and data protection risks that arise from our use of external service providers.
While we do not have full visibility into the cybersecurity risk management processes of our vendors, we require new service providers
to complete a vendor questionnaire that identifies the vendor&#8217;s network and user protections, such as the use of multi-factor authentication,
and other cybersecurity risk management processes. Vendors that store or access our confidential information are required to certify
that their information systems comply with applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on
our third-party service providers to provide notification of, and remediate, significant cybersecurity threats and cybersecurity incidents
that jeopardize the confidentiality, integrity, or availability of our information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically evaluate, test, and update our policies, standards, and processes to mitigate cybersecurity threats and manage incidents
effectively. These efforts include risk assessments, vulnerability assessments and remediations, phishing tests and employee education,
and external scans. Additionally, to enhance our capabilities, we periodically engage third-party service providers, including cybersecurity
consultants, to incorporate threat intelligence into our processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Form 10-K, we are <span id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zZdq1dpZU2wi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000055" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span>t aware of any risks from cybersecurity threats, including those resulting from any previous
cybersecurity incidents experienced by us or, to our knowledge, by any of our third-party service providers, that have materially affected,
or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. For further discussion
of cybersecurity and data privacy risks that may materially affect the Company and how they may do so, see &#8220;Risk Factors&#8212;If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical
trial delays; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational
harm; and other adverse consequences,&#8221; included in Item 1A of this Annual Report on Form 10-K.</span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>


</ix:continuation></div><!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98C_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_gBFCRBODOTB-ZSTB_zSvgPpOABpr4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000059-01" escape="true" id="Fact000059" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRBODOTB-ZSTB_zoPCi9AWYTQc"><ix:continuation continuedAt="ConU000059-02" id="ConU000059-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C09_gBFCRBODOTB-ZSTB_zFQopWAME70l"><ix:continuation continuedAt="ConU000059-03" id="ConU000059-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zyNLlmbEho35" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
Audit Committee oversees Celcuity&#8217;s management of risks arising from cybersecurity threats. <span id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zPSgImT98hWj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000061" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations</ix:nonNumeric></span>. Additionally, we have
processes to promptly notify the Audit Committee and Board of a significant cybersecurity incident and to inform the Audit Committee
and Board of remediation progress, as appropriate</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Vice President, IT has overall responsibility for our information security program, with support from our management team and specialized
partners in cybersecurity incident response and privacy. <span id="xdx_902_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zbgtjC9IF8O3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000062" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">The process includes managing our incident response strategy. If a cybersecurity
incident meets certain criteria, however, our CEO, CFO and General Counsel will become involved with the response strategy, including
decisions about public disclosure and reporting. Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine
strategic cybersecurity priorities and to establish compliance procedures</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our business leaders have the appropriate expertise, background and depth of experience to manage risks arising from cybersecurity
threats. Our Vice President, IT has served in various roles in information technology and information security for over three decades,
which includes experience in the biotech, pharmaceutical and healthcare industries and experience in cybersecurity risk management and
data privacy compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we, and the third parties upon which we rely, collect, process, receive, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, share and store  proprietary,
confidential, and sensitive information, including health information, personal information, credit card and other financial
information, or other sensitive information owned or controlled by ourselves or our customers, payors, and other parties.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0B_gBFCRBODOTB-ZSTB_zhNU3FgbITJg"><ix:continuation id="ConU000059-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_003"></span>ITEM
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently lease and occupy approximately 16,000 square feet in Minneapolis, Minnesota, which includes our clinical laboratory and offices.
On March 13, 2023, we signed the fourth amendment to our lease agreement, which expires April 30, 2026. The lease provides for monthly
rent, real estate taxes and operating expenses. We believe that this leased space is adequate to meet current requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 5, 2025, we signed a lease agreement for new clinical laboratory and office space in Minneapolis, Minnesota for approximately
19,594 square feet. The lease term will commence on April 1, 2026. The lease provides for monthly rent, real estate taxes and operating
expenses. The lease term is 62 months with two options to extend the lease term for five years each.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_004"></span>ITEM
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party
to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_005"></span>ITEM
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_006"></span><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_007"></span>ITEM
5. Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Price Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has been listed on The Nasdaq Capital Market under the symbol &#8220;CELC&#8221; since September 20, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 17, 2026, there were approximately 101 holders of record of our common stock. The actual number of holders of common stock
is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street
name by brokers and nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by
other entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance
the operation and expansion of our business. We do not expect to pay cash dividends on our common stock in the foreseeable future. Payment
of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including
our financial condition, operating results, current and anticipated cash needs, outstanding indebtedness and plans for expansion and
restrictions imposed by lenders, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Unregistered Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2025, we issued 1,496 shares of common stock upon the exercise of previously issued warrants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,089 shares were issued to the placement agent from private
placements that closed on April 28, 2017 and May 17, 2017 pursuant to the exercise of warrants at an exercise price of $8.42 per share,
resulting in cash proceeds of less than $0.1 million; and</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">407 shares were issued to the placement agent from private
placements that closed on January 21, 2016 and May 2, 2016 pursuant to the exercise of warrants at an exercise price of $7.56 per share,
resulting in cash proceeds of less than $0.1 million.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_008"></span>ITEM
6. Reserved</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_009"></span>ITEM
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our
financial statements and the related notes included elsewhere in this Annual Report. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business
and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk
Factors&#8221; discussed in Item 1A of Part I of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a kinase inhibitor of the phosphatidylinositol 3-kinase (&#8220;PI3K&#8221;),
serine/threonine-protein kinase protein kinase B (&#8220;AKT&#8221;), mechanistic target of rapamycin (&#8220;mTOR&#8221;) pathway that
binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib
induces comprehensive inhibition of the PI3K/AKT/mTOR (&#8220;PAM&#8221;) pathway. Its mechanism of action and pharmacokinetic properties
are differentiated from other currently approved and investigational therapies that target PI3K&#945;, AKT, or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients
with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (&#8220;HR+/HER2-&#8221;) advanced breast
cancer (&#8220;ABC&#8221;) has completed enrollment and reported detailed results for cohort 1, patients with <i>PIK3CA</i> wild-type
(&#8220;WT&#8221;) tumors, and has completed enrollment of cohort 2, patients with <i>PIK3CA</i> mutant-type (&#8220;MT&#8221;) tumors.
Our Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitor and fulvestrant
as first-line treatment for patients with endocrine treatment resistant HR+/HER2- ABC is ongoing. A Phase 1b/2
clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant
prostate cancer (&#8220;mCRPC&#8221;), is ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, we obtained exclusive global development and commercialization rights to gedatolisib under a license agreement with Pfizer.
We believe gedatolisib&#8217;s unique mechanism of action, differentiated chemical structure, favorable pharmacokinetic properties, and
intravenous route of administration offer distinct advantages over currently approved and investigational therapies that target PI3K&#945;,
AKT, or mTORC1 alone or together.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overcomes
    limitations of therapies that only inhibit a single class I PI3K isoform, AKT, or one mTOR kinase complex.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a pan-class I isoform PI3K inhibitor with low nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and p110&#948; isoforms
and the mTORC1 and mTORC2 complexes. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition
of the PAM pathway. Each PI3K isoform and mTOR complex is known to preferentially affect different signal transduction events that involve
tumor cell survival, depending upon the aberrations associated with the linked pathway. When a therapy only inhibits a single class I
PI3K isoform (e.g., alpelisib, a PI3K&#945; inhibitor), AKT (e.g., capivasertib, an AKT inhibitor) or only one mTOR kinase complex (e.g.,
everolimus, an mTORC1 inhibitor), numerous feedforward and feedback loops between the PI3K isoforms and mTOR complexes cross-activate
the uninhibited sub-units. This, in turn, induces compensatory resistance that reduces the efficacy of isoform specific PI3K&#945;,
AKT, or mTORC1 kinase inhibitors. Inhibiting all four PI3K isoforms and both mTOR complexes, as gedatolisib does, thus prevents the confounding
effect of isoform interaction that may occur with isoform-specific PI3K inhibitors and the confounding interaction between PI3K isoforms,
AKT, and mTOR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Better
    tolerated by patients than oral PI3K and mTOR drugs.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is administered intravenously on a four-week cycle of three weeks-on, one week-off, in contrast to the orally administered pan-PI3K or
dual PI3K/mTOR inhibitors that are no longer being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been found
to induce significant side effects that were not well tolerated by patients. This typically leads to a high proportion of patients requiring
dose reductions or treatment discontinuation. The challenging toxicity profile of these drug candidates ultimately played a significant
role in the decisions to halt their development, despite showing promising efficacy. By contrast, gedatolisib&#8217;s comprehensive inhibition
of the PAM pathway at low nanomolar potency, IV route of administration, and pharmacokinetic properties enables it to achieve optimal
anti-proliferative effects on tumor cells without inducing the levels of hyperglycemia, rash, and diarrhea typically associated with
oral single-component inhibitors of the PAM pathway.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isoform-specific
PI3K or mTORC1 inhibitors administered orally were developed to reduce toxicities in patients. While the range of toxicities
associated with single-component PAM inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a
continuous basis can still lead to challenging toxicities. The experience with an FDA-approved oral p110-&#945; specific inhibitor,
PIQRAY, illustrates the challenge. In its Phase 3 pivotal trial, PIQRAY was found to induce a Grade 3 or 4 adverse event
(&#8220;AE&#8221;) related to hyperglycemia in 39% of patients evaluated. In addition, 26% of patients discontinued alpelisib due to
treatment related AEs. By contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial with gedatolisib, only
7% of patients experienced Grade 3 or 4 hyperglycemia and less than 9% discontinued treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, 1,127 patients and healthy volunteers have received gedatolisib in 12 completed or ongoing clinical trials. Of
these, 123 patients with solid tumors were treated with gedatolisib as a single agent in two clinical trials, 36 healthy volunteers
were treated in two clinical trials, and the remaining 968 patients received gedatolisib in combination with other anti-cancer
agents in eight clinical trials. Additional patients received gedatolisib in combination with other anti-cancer agents in 10
investigator sponsored clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>B2151009
Phase 1b Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">A Phase 1b dose-finding trial with
an expansion portion for safety and efficacy evaluated gedatolisib when added to either the standard doses of palbociclib plus letrozole
or palbociclib plus fulvestrant in patients with HR+/HER2- ABC. PI3K mutation status was not used as an eligibility criterion. Patient
enrollment for the trial is complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">A total of 138 patients with HR+/HER2-
ABC were dosed in the clinical trial. Four patients from this study continue to receive study treatment, as of December
31, 2025, each of whom has received study treatment for more than six years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">35 patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the maximum tolerable dose (&#8220;MTD&#8221;) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies. The MTD was determined to be 180 mg administered intravenously once weekly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">103 patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus palbociclib and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical control data of the doublet combination (palbociclib plus endocrine therapy). All patients received gedatolisib in combination with standard doses of palbociclib and endocrine therapy (either letrozole or fulvestrant). In Arms A, B, and C, patients received an intravenous dose of 180 mg of gedatolisib once weekly. In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on a four-week cycle of three-weeks-on, one-week-off. Objective response was determined using Response Evaluation Criteria in Solid Tumors v1.0, or RECIST v1.0.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.65in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Arm A</b>: ABC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting. First-line endocrine-based therapy for advanced disease (CDK4/6 treatment naive).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Arm B</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting, with no prior therapy with any CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Arm C</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.65in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Arm D</b>: ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for advanced disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: -0.25in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, the ORR in aggregate among patients with evaluable tumors was 63%.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Best responses, as measured by RECIST v1.0, are shown in the following chart for Arm A (1<sup>st</sup> line patients) and Arm D (2<sup>nd</sup>/3<sup>rd</sup> line patients who received the VIKTORIA-1 Phase 3 trial dosing regimen). The dotted line represents the cutoff for partial response (PR), defined as a 30% reduction from the baseline tumor assessment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_006.jpg" alt=""/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><i>Source: Laym<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an

SABCS 2021</span></i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    analysis:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For all arms in aggregate,
    all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event. The Grade 3 and 4 treatment-emergent adverse
    events occurring in at least 20% of patients were neutropenia (63%), stomatitis (27%) and rash (20%). Neutropenia is a known class
    effect of CDK4/6 inhibitors. Stomatitis was reversible in most patients with a steroidal mouth rinse. All grades of treatment-related
    adverse events related to hyperglycemia were reported in 22% of patients; Grade 3 or 4 hyperglycemia was reported in 7% of patients.
    Gedatolisib was discontinued in less than 9% of patients.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the patients in Arm
    D, who received the Phase 3 dosing schedule, Grade 3 and 4 treatment-emergent adverse events occurring in at least 20% of patients
    were neutropenia (67%), leukopenia (22%), and stomatitis (22%). All grades of treatment-related adverse events related to hyperglycemia
    were reported in 26% of patients; Grade 3 or 4 hyperglycemia were reported in 7% of patients. Gedatolisib was discontinued in 4%
    of patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Best overall response data
    for each arm is presented in the table below:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Total Expansion Arms</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(N=103)</b></p></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 44%">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt"><b>Arm A</b></span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt"><b>Arm B</b></span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt"><b>Arm C</b></span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; text-align: center; width: 12%"><span style="font-size: 10pt"><b>Arm D</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Prior Therapy</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-naive</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L+</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-naive</p></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-pretreated</p></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2L/3L</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CDKi-pretreated</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>n (Full, response evaluable)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">31, 27</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">13,13</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">32, 28</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">27, 27</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Study Treatment</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + L + G</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">P + F + G</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Gedatolisib schedule</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">weekly</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">3 wks on/1 wk off</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>ORR <sup>(1) </sup>(evaluable)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">85%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">77%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">63%</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>mPFS <sup>(2)</sup>, mos (range)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">48.4</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(16.9, NR)</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(7.6, 38.3)</p></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">5.1</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(3.3, 7.5)</p></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">12.9</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(7.4, 16.7)</p></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>PFS % at 12 mos <sup>(2)</sup></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">72.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">54.5%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">23.6%</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">53.2%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">WT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">MT</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">PIK3CA status</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">81</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">16</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">69</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">31</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">75</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">25</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">56</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">41</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">ORR (evaluable)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">PFS at 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
ORR represents PR, except in Arm A, which had 1 CR = Complete response. Responses per RECIST 1.1; (2) Includes 2 unconfirmed PR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abbreviations:
1L = first line; 2L = second line; mos = months; NR = not reached; ORR = objective response rate; PFS = progression free survival</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
Layman R. et. al, Lancet Oncol., 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
results from the Phase 1b portion of the clinical trial were presented at the ESMO congress in October 2025. The analyses reported efficacy
data from patients who were treated with the same drug regimen being evaluated in the VIKTORIA-1 study, gedatolisib combined with fulvestrant
and palbociclib. This included patients from Escalation Arm B and Expansion Arms B, C and D of the Phase 1b study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described above, patients in Escalation Arm B and Expansion Arms B and C received a 180 mg dose of gedatolisib once weekly (&#8220;weekly
dose&#8221;). Patients in Expansion Arm D received a 180 mg dose of gedatolisib on days 1, 8, and 15 of a four-week cycle (&#8220;intermittent
dose&#8221;), which is the same dose regimen patients in the VIKTORIA-1 study receive. The proportion of patients who received the intermittent
dose of gedatolisib was 37% for those with <i>PIK3CA</i> MT tumors and 25% for those with <i>PIK3CA</i> WT tumors. The proportion of
patients who received prior treatment with a CDK4/6 inhibitor was 73% for those with <i>PIK3CA</i> WT tumors, and 71% for those with
<i>PIK3CA</i> MT tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
PFS and the ORR were assessed in sub-groups of patients according to their <i>PIK3CA</i> status (Table 1). For all analyzed patients
with <i>PIK3CA</i> MT tumors (n=30), median PFS was 14.6 months and the ORR in response evaluable patients was 48%. Median PFS was 19.7
months and the ORR was 64% in patients with <i>PIK3CA</i> MT tumors who received the intermittent dose of gedatolisib used in the VIKTORIA-1
study. For patients with <i>PIK3CA</i> WT tumors (n=60), median PFS was 9.0 months and the ORR in response evaluable patients was 41%.
Median PFS was 9.1 months and the ORR was 53% in patients with <i>PIK3CA</i> WT tumors who received the intermittent dose of gedatolisib
used in the VIKTORIA-1 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
1: Efficacy Analysis of Phase 1b Patients Treated with Gedatolisib Plus Palbociclib Plus Fulvestrant</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center">PIK3CA MT</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center">PIK3CA WT</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intermittent Dose</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intermittent dose</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-weight: bold">N</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Median PFS (months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ORR</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VIKTORIA-1
Phase 3 Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed enrollment of our Phase 3, open-label, randomized clinical trial, VIKTORIA-1, to evaluate the efficacy and safety of
gedatolisib treatment regimens in adults with HR+/HER2- ABC whose disease has progressed after prior CDK4/6 therapy in combination
with an aromatase inhibitor. Over 200 clinical sites in North America, Europe, Latin America, and Asia-Pacific are participating in
the study. The first patient was dosed in this trial in December 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
VIKTORA-1 Phase 3 clinical trial involves two study cohorts that enable separate evaluation of subjects according to their <i>PIK3CA</i>
status. Subjects who met eligibility criteria and had <i>PIK3CA</i> WT tumors (cohort 1) were randomly assigned (1:1:1) to receive a
regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant (Arm C). During
the fourth quarter of 2024, we achieved our enrollment goal of 351 subjects for the <i>PIK3CA</i> WT cohort. The primary completion date
for this cohort was achieved in May 2025 and the database cut-off date for this cohort was May 30, 2025. Subjects who met eligibility
criteria and had <i>PIK3CA</i> MT tumors (cohort 2) were randomly assigned (3:3:1) to receive a regimen of either gedatolisib, palbociclib,
and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and fulvestrant (Arm F). Enrollment of approximately 350 subjects
who have <i>PIK3CA</i> MT tumors is complete. We expect topline data for cohort 2 to be available in the second quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, we announced topline data from the <i>PIK3CA </i>WT cohort of the VIKTORIA-1 clinical trial and on October 18, 2025, at
the ESMO congress, additional efficacy and safety results from this cohort were presented. The key efficacy and safety data from the
<i>PIK3CA</i> WT cohort showed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib triplet (gedatolisib, fulvestrant and palbociclib) demonstrated a statistically significant and clinically meaningful
    improvement in PFS among patients, reducing the risk of disease progression or death by 76% compared to fulvestrant (based on a hazard
    ratio [HR] of 0.24, 95% confidence interval [CI] 0.17-0.35; p&lt;0.0001). The median PFS, as assessed by blinded independent central
    review (&#8220;BICR&#8221;), was 9.3 months with the gedatolisib triplet versus 2.0 months with fulvestrant, an incremental improvement
    of 7.3 months. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib doublet (gedatolisib and fulvestrant) also demonstrated a statistically significant and clinically meaningful improvement
    in PFS among patients, reducing the risk of disease progression or death by 67% compared to fulvestrant (HR of 0.33, 95% CI 0.24-0.48;
    p&lt;0.0001). The median PFS, as assessed by BICR, was 7.4 months with the gedatolisib doublet versus 2.0 months with fulvestrant,
    an incremental improvement of 5.4 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ORR of the gedatolisib triplet was 31% compared to 1% with fulvestrant and the median DOR
    was 17.5 months. The ORR of the gedatolisib doublet was 28.3% and the median DOR was 12.0 months. The median DOR was not determinable
    for fulvestrant because there was only one objective response.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    gedatolisib triplet and doublet were generally well tolerated in the trial with mostly low-grade TRAEs. The most common Grade 3 TRAEs for the gedatolisib triplet, gedatolisib doublet, and fulvestrant groups included
    neutropenia (52.3%, 0%, and 0.8% of patients, respectively); stomatitis (19.2%, 12.3%, and 0% of patients, respectively) rash (4.6%,
    5.4%, and 0% of patients, respectively); and hyperglycemia (2.3%, 2.3%, and 0% of patients, respectively). The primary Grade 4 TRAEs
    for the gedatolisib triplet and gedatolisib doublet groups were neutropenia (10.0% and 0.8%, respectively), leukopenia (0.8% in the
    gedatolisib triplet group) and pneumonitis (0.8% in gedatolisib doublet group). TRAEs led to the discontinuation of study treatment
    in 2.3% of patients in the gedatolisib triplet group, 3.1% in the gedatolisib doublet group, and 0% in the fulvestrant group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
detailed results from cohort 1, <i>PIK3CA</i> WT cohort, established several new milestones in the history of drug development for HR+/HER2-
ABC:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    hazard ratios for the gedatolisib triplet and doublet are more favorable than have ever been reported by any Phase 3 trial for patients
    with HR+/HER2- ABC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    7.3- and 5.4-months incremental improvements in median PFS for the gedatolisib triplet and gedatolisib doublet over fulvestrant,
    respectively, are higher than have ever been reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving at least their
    second line of therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
    is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/<i>PIK3CA</i>
    WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    median DOR and incremental ORR improvement relative to control for the gedatolisib triplet and doublet are the highest reported for
    an endocrine therapy-based regimen in 2L HR+/HER2- ABC.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
median PFS benefit of the gedatolisib triplet and doublet compared to fulvestrant was consistent across subgroups with the gedatolisib
triplet showing higher clinical benefit in nearly all subgroups compared to the gedatolisib doublet, particularly for patients who were
pre/perimenopausal, endocrine therapy resistant, or had visceral metastases. For patients enrolled in the United States and Canada, median
PFS was 19.3 months (HR=0.13; 90% CI: 0.07-0.29) for the gedatolisib triplet and 14.9 months (HR=0.35; 90% CI: 0.17-0.76) for the gedatolisib
doublet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2025, updated efficacy and safety results from the Phase 3 VIKTORIA-1 PIK3CA WT cohort were presented at the 2025 San Antonio
Breast Cancer Symposium including patient sub-group analyses, safety analyses and patient reported outcomes for well-being measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For patients enrolled in the U.S., Canada, Western Europe,
and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7.1 months with the gedatolisib doublet versus 1.9 months
for fulvestrant (HR=0.14; 95% CI: 0.08-0.28; p&lt;0.0001).</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both gedatolisib regimens delayed time to definitive deterioration
versus fulvestrant according to patient reported outcomes for well-being measures that included mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression (the EQ-5D-5L score). The median time to definitive deterioration was 23.7 months (HR=0.39; 95%
CI: 0.25-0.67; p = 0.0003) for patients treated with the gedatolisib triplet and not reached for the gedatolisib doublet (HR=0.37; 95%
CI: 0.24-0.66; p = 0.0003) versus 4.0 months for fulvestrant. Additionally, for the first eight cycles of treatment, the patients&#8217; assessment of their well-being remained
stable relative to their assessment prior to starting treatment with gedatolisib.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
these results, the gedatolisib regimens represent a new potential standard of care for patients with HR+/HER2-, <i>PIK3CA</i> WT ABC
whose disease progressed on or after treatment with a CDK4/6 inhibitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
from cohort 2 of the VIKTORIA-1 Phase 3 clinical trial, the <i>PIK3CA</i> MT cohort, are expected to be available in the second quarter
of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VIKTORIA-2
Phase 3 Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, we dosed the first patient in VIKTORIA-2, a Phase 3, multi-center, open-label, randomized, clinical trial designed to
evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with
HR+/HER2- endocrine treatment resistant ABC. For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib.
This multi-center, international trial enrolled <span>35</span> evaluable subjects in the safety run-in portion of the study to
evaluate the safety of gedatolisib when combined with ribociclib and fulvestrant. The safety run-in was completed in the first
quarter of 2026. In the Phase 3 portion of the study, approximately 638 subjects are expected to be randomized and assigned to
Cohort 1 (<i>PIK3CA</i> WT) or Cohort 2 (<i>PIK3CA</i> MT) based on their <i>PIK3CA</i> status. Subjects in each cohort are expected
to be randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib) or Arm B (fulvestrant
and ribociclib or palbociclib). We intend to provide an update on our final Phase 3 study design in the second quarter of 2026. It is expected that approximately 200 clinical sites across North America, Europe, and
Asia-Pacific will participate, including many sites included in the VIKTORIA-1 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CELC-G-201
Phase 1b/2 Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received approval from the FDA in mid-2023 to proceed with the clinical development of gedatolisib in combination with Nubeqa<sup>&#174;</sup>
(darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with mCRPC. We have since initiated a Phase 1b/2
clinical trial, CELC-G-201, that will enroll up to 54 participants with mCRPC who progressed after treatment with an androgen receptor
inhibitor. The first patient was dosed in this trial in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of the Phase 1b portion of the trial include assessment of the safety and tolerability of gedatolisib in combination
with darolutamide and determination of the recommended Phase 2 dose (&#8220;RP2D&#8221;) of gedatolisib. The primary objective of the
Phase 2 portion of the trial is to assess the radiographic PFS at six months of patients who received the RP2D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Phase 1b portion of the clinical trial, 38 patients with mCRPC were randomly assigned to receive 600 mg of darolutamide twice daily
combined with either 120 mg of gedatolisib in Arm 1 or 180 mg of gedatolisib in Arm 2. In both arms, gedatolisib was administered once
weekly for three weeks, then one week off. Additionally, all patients received prophylactic treatment for stomatitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, we announced preliminary data for the CELC-G-201 Phase 1b trial, utilizing a May 30, 2025 data cut-off. Based on these
data, we amended the clinical trial protocol to enable exploration of additional doses in the Phase 1b portion of this clinical trial
to determine the RP2D. Once RP2D is determined, an additional 12 participants will then be enrolled in the Phase 2 portion of the study
at the RP2D level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2025, at the ESMO congress, we presented updated clinical results for the CELC-G-201 Phase 1b trial based on an August 15,
2025 data cut-off. Among the 38 patients enrolled, 61% had received one line of prior systemic therapy and 39% had received at least
two or more lines of prior therapy. Median duration of follow-up was 9.0 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
six-month radiographic progression-free survival (&#8220;rPFS&#8221;) rate and median rPFS for patients from both arms combined was 67
% and 9.1 months, respectively. For patients treated with 120 mg gedatolisib, the six-month rPFS rate was 74% and median rPFS was 9.5
months. For patients treated with 180 mg gedatolisib, the six-month rPFS rate was 61% and the median rPFS was 7.4 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combination of gedatolisib and darolutamide was generally well tolerated in the trial with mostly low-grade TRAEs. No dose limiting toxicities
were observed in either arm. The only Grade 3 TRAEs for patients from both arms combined included rash (5.3%), stomatitis (2.6%), and
pruritus (2.6%); no Grade 3 hyperglycemia was reported. Additionally, no Grade 4 or 5 TRAEs were observed, and no patients discontinued
study treatment due to a TRAE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the amended Phase 1/1b portion of the clinical trial, up to six patients are planned to be enrolled in each of three arms and treated
with different doses. Upon completion of Phase 1, up to an additional 40 patients will be randomly assigned to up to four Phase 1b cohorts
to determine the RP2D. Dose levels will be selected based on the results from the Phase 1 clinical trial. In the Phase 2 dose expansion
study, which will include subjects from the Phase 1/1b clinical trial, up to 18 additional subjects will be enrolled to achieve a total
of approximately 30 subjects treated with the RP2D. All patients will also receive standard doses of darolutamide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investigator-Sponsored
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an investigator-sponsored Phase 2 clinical trial, 44 patients with HER2+/<i>PIK3CA</i> mutated metastatic breast cancer were treated
with gedatolisib plus standard doses of trastuzumab-pkrb. No prophylaxis for stomatitis was administered. The median number of prior
anti-HER2 therapies enrolled patients received in the metastatic setting was four or more; 86% of patients had received at least three
prior anti-HER2 therapies. The data cut-off was February 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
efficacy and safety results, as presented at the American Society of Clinical Oncology meeting in June 2025, showed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ORR among all patients enrolled was 43%.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    PFS was 6.0 months (95% CI, 5.0-7.7).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    overall survival was 24.7 months (95% CI; 17.3-NA).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    patients discontinued gedatolisib due to a treatment-related AE.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    (2.3%) patient experienced Grade 3 hyperglycemia.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investigator sponsored trial has been initiated in collaboration with the Dana-Farber Cancer Institute and Massachusetts General Hospital
to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
                                                                                                                                      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January 2026, the FDA accepted for filing our NDA for gedatolisib in HR+/HER2- PIK3CA WT ABC. The FDA granted Priority Review and assigned
a PDUFA goal date of July 17, 2026.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In March 2026, efficacy and safety results from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib were published
in the Journal of Clinical Oncology. The cohort consisted of patients with HR+/HER2-/PIK3CA WT ABC whose disease progressed while on or
after treatment with a CDK4/6 inhibitor and an aromatase inhibitor.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue from product sales or other sources to date, and we continue to incur significant research and development
and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses
in each period since our inception in 2012. For the years ended December 31, 2025 and 2024, we reported a net loss of $177.0 million
and $111.8 million, respectively. As of December 31, 2025, we had an accumulated deficit of&#8201;$448.9 million. As of December 31,
2025, we had $441.5 million in cash, cash equivalents and short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Components
of Operating Results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue. Upon the execution of the Pfizer license agreement in April 2021, we acquired exclusive world-wide
licensing rights to develop and commercialize gedatolisib. In 2022, we initiated VIKTORIA-1, a Phase 3 clinical trial, to support potential
regulatory approval to market gedatolisib. Our Phase 3 clinical trial, VIKTORIA-2, and Phase 1b/2 clinical trial, CELC-G-201,
are ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the FDA&#8217;s RTOR program, in September 2025 we made the first pre-submission of our NDA to the FDA and completed the final NDA
submission to the FDA on November 17, 2025. The FDA formally accepted our NDA submission on January 16, 2026, designated it for Priority
Review, and has assigned a PDUFA target goal date of July 17, 2026. If we obtain regulatory approvals to market gedatolisib, we expect
to generate revenue from sales of the drug commencing in the second half of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have primarily focused on research and development of gedatolisib, a PI3K/mTOR targeted therapy. Research and development
expenses primarily include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses related to our research and development activities, including salaries, benefits, recruiting, travel and stock-based compensation
    expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laboratory
    supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    fees paid to third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">validation
    costs for gedatolisib; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
    expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, benefits and stock-based compensation related to our executive, finance and
support functions. Other general and administrative expenses include professional fees for auditing, tax, and legal services associated
with being a public company, director and officer insurance, software costs, investor relations and travel expenses for our general and
administrative personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
and Marketing </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
and costs related to marketing, supply chain, distribution, market access and other commercial operations related activities are being
incurred in anticipation of the commercialization of gedatolisib. These expenses consist primarily of employee-related expenses, professional
and consulting fees related to these functions and operations, software costs, and the acquisition of data required to support our market
analysis for gedatolisib. We expect sales and marketing expenses to increase as we get closer to a potential FDA approval date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense to date is primarily related to the A&amp;R Loan Agreement and the Notes (each as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income consists of interest income earned on our cash, cash equivalents, and investment balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years Ended December 31, 2025 and 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statements of operations data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">144,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">104,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">40,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">39</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,197</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,133</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">172,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113,267</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">58,925</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(172,192</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(113,267</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58,925</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,148</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,280</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,868</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,768</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other (expense) income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,850</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,488</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,338</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(426</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(177,042</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(111,779</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(65,263</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(177,042</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(111,779</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(65,263</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">58</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, our research and development expenses were $145.0 million, representing an increase of $40.8 million,
or 39%, compared to 2024. The increase was primarily due to a $26.7 million increase in employee-related and consulting expenses, of
which $13.1 million related to commercial headcount additions and other launch activities. The remaining increase was primarily due to
a $6.0 million increase in activities supporting our ongoing clinical trials, a $5.0 million development milestone payment under the
license agreement with Pfizer, and a $3.1 million increase in other costs primarily related to commercial launch activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
research and development is central to our business model. We plan to continue to increase our research and development expenses for
the foreseeable future as we seek to continue to develop gedatolisib, including conducting the VIKTORIA-1 and VIKTORIA-2 Phase 3 clinical
trials, and the CELC-G-201 Phase 1b/2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, our general and administrative expenses were $27.2 million, representing an increase of $18.1 million,
or 200%, compared to 2024. The increase was primarily due to a $14.9 million increase in employee-related and consulting expenses, of
which $10.4 million related to non-cash stock-based compensation. The remaining $3.2 million increase was primarily due to an increase
in professional fees, expanding infrastructure costs and other administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will continue to increase in future periods, reflecting both increased costs
in connection with the potential future commercialization of gedatolisib, an expanding infrastructure, and increased professional fees
associated with public company regulatory developments and requirements, and other compliance matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense during the year ended December 31, 2025, was $17.1 million and represents an increase of $6.9 million, or 67%, compared to 2024.
Interest expense in 2025 is attributable to the Notes and the A&amp;R Loan Agreement, and in 2024 is attributable to the A&amp;R Loan
Agreement. The increase is primarily due to the incremental $61.7 million funding of the Term Loan C in May 2024, the issuance of $201.3
million aggregate principal amount of Notes in July 2025 and the $30.0 million distribution of the Term Loan D in September 2025. The
$17.1 million of interest expense includes $4.2 million of non-cash interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income during the year ended December 31, 2025 was $12.3 million and represents an increase of $0.5 million, or 5%, compared to 2024.
The increase was primarily the result of a higher invested cash balance, partially offset by lower market interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred losses and cumulative negative cash flows from operations. Through December 31, 2025, we have funded
our operations primarily through private placements, registered offerings of our equity securities, convertible notes, and borrowings
under loan agreements. From inception through December 31, 2025, we raised an aggregate of $506.8 million of net proceeds through sales
of our securities, $194.9 million of net proceeds through the issuance of the Notes, and $130.0 million of gross proceeds through borrowings
under loan agreements, not including payable-in-kind interest. As of December 31, 2025, our cash and cash equivalents and short-term investments were $165.7 million
and $275.8 million, respectively, and we had an accumulated deficit of $448.9 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Capital
Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
help meet our liquidity requirements, we have entered into various equity and financing arrangements. As of December 31, 2025, our material
cash requirements for the operations of our business consisted primarily of the current and long-term liabilities noted on our balance
sheets, as well as other commitments, including the following notable items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, we issued and sold 2,172,368 Shares and Pre-Funded Warrants to purchase up to
                                            400,000 shares of common stock pursuant to the Equity Underwriting Agreement with the Representatives
                                            of the Underwriters, resulting in net proceeds of $91.6 million (see Note 8. Stockholders&#8217;
                                            Equity).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            August 2025, we issued $201.3 million aggregate principal amount of convertible notes, resulting
                                            in net proceeds of $194.9 million (see Note 10. Debt).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2025 and 2024, investors exercised 5,282,375 and 1,827,357 warrants, net of shares withheld
                                            for exercise price, respectively, which generated $42.1 million and $14.7 million in cash,
                                            respectively (see Note 8. Stockholders&#8217; Equity).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            February 2022, we entered into an Open Market Sale Agreement with Jefferies, as agent, pursuant
                                            to which we may offer and sell, from time to time, through Jefferies, shares of our common
                                            stock having an aggregate offering price of up to $50.0 million, which amount was subsequently
                                            increased to $400.0 million on January 9, 2026. In May 2024 and April 2024, we sold 149,700
                                            and 285,714 shares of common stock, respectively, at an average selling price of $17.55 per
                                            share, generating net proceeds of $7.3 million after deducting commissions and other offering
                                            expenses of $0.3 million (see Note 8. Stockholders&#8217; Equity and Note 13. Subsequent
                                            Events).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            May 2024, we issued and sold 3,871,000 shares of common stock pursuant to an underwriting
                                            agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company,
                                            Incorporated, resulting in net proceeds of $56.3 million (see Note 8. Stockholders&#8217;
                                            Equity).</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify">In <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
  2025, we entered into the Third Amendment (the &#8220;Third Amendment&#8221;) to the Amended and Restated Loan and Security
  Agreement (the &#8220;A&amp;R Loan Agreement&#8221;); in July 2025, we entered into the Second Amendment to the A&amp;R Loan
  Agreement; and in May 2025, we entered into the First Amendment to the A&amp;R Loan Agreement. In May 2024, we entered into the
  A&amp;R Loan Agreement, which amended and restated, in its entirety, the Loan and Security Agreement, dated April 8, 2021, as
  amended, between us and Innovatus, as collateral agent, and the Lenders named therein (the &#8220;Prior Loan
  Agreement&#8221;).</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, we received funding of the $30.0 million Term D Loan (as defined in the Amended A&amp;R Loan Agreement) upon achievement
of the Term D Milestone (as defined in the Amended A&amp;R Loan Agreement), resulting in net proceeds of $27.7 million. In connection
with the funding of the Term D Loan, we issued warrants with an exercise price of $14.84 per share to purchase an aggregate of 50,537
shares of our common stock to Innovatus, Oxford, and certain of its affiliates. Subsequent to the Third Amendment, we may draw (i) up
to $100.0 million under Term E Loan (as defined in the Amended A&amp;R Loan Agreement) upon FDA approval of gedatolisib in second line
wild-type ABC patients post CDK4/6 inhibitor therapy; (ii) up to three $40.0 million Term F Loans (as defined in the
Amended A&amp;R Loan Agreement), for a total of $120.0 million, upon achievement of certain trailing three months&#8217; product revenue
thresholds; and (iii) up to $150.0 million Term G Loan (as defined in the Amended A&amp;R Loan Agreement), which continues to be available
only in the Lenders&#8217; sole discretion upon our request. The term loans include financial covenants related to liquidity and other
financial measures and have a maturity date of November 1, 2029.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: -13.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we received funding of the first $100 million under the A&amp;R Loan Agreement, including tranche payments of $16.8 million
(the &#8220;Term A Loan&#8221;) and $21.5 million (the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans
under the Prior Loan Agreement plus accrued payment-in-kind interest, in addition to $61.7 million of new borrowings (the &#8220;Term
C Loan&#8221;), resulting in net proceeds of $59.2 million. In connection with the funding of the Term C Loan, we issued warrants
with an exercise price of $14.84 per share to purchase an aggregate of 103,876 shares of our common stock to Innovatus and Oxford (see
Note 10. Debt).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: -13.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and capital resource requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development and general and administrative expenses will increase as we continue to develop gedatolisib,
conduct the VIKTORIA-1 Phase 3 clinical trial, the CELC-G-201 Phase 1b/2 trial, and the VIKTORIA-2 Phase 3 clinical trial, conduct other
studies and clinical trials, and pursue other business development activities. We would also expect to scale sales and marketing expenses
as we prepare for commercial launch and then commercialize gedatolisib. We expect to use cash on hand, together with the funds received
or to be received under the debt and equity financings described above, to fund our research and development expenses, clinical trial
costs, capital expenditures, working capital, sales and marketing expenses, and general corporate expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current business plan, we believe that our current cash, cash equivalents and short-term investments, together with available
borrowings under the Amended A&amp;R Loan Agreement, will provide sufficient cash to finance our operations through 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expectations as to how long our current capital resources will be sufficient to fund our operations are based on assumptions that may
not be accurate, and we could use our current capital resources sooner than we currently expect. In addition, we may seek to raise additional
capital to finance capital expenditures and operating expenses over the next several years as we seek to obtain approval for and launch
gedatolisib; expand our infrastructure, commercial operations and research and development activities; and take advantage of financing
or other opportunities that we believe to be in the best interests of the Company and our stockholders. Additional capital may be raised
through the sale of common or preferred equity or convertible debt securities, entry into debt facilities or other third-party funding
arrangements. The sale of equity and convertible debt securities may result in dilution to our stockholders and those securities may
have rights senior to those of our common stock. Agreements entered into in connection with such capital raising activities could contain
covenants that would restrict our operations or require us to relinquish certain rights. Additional capital may not be available on reasonable
terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the primary sources and uses of cash and cash equivalents (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash and cash equivalents (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 10pt">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(153,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(83,467</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64,084</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,069</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">360,552</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">138,388</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,188</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,148</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $153.3 million during the year ended December 31, 2025, and consisted of a net loss of $177.0 million
and working capital changes of $2.7 million, partially offset by non-cash expenses of $26.4 million. The $2.7 million decrease in working
capital consisted of a $15.4 million increase in accrued expenses, partially offset by a $15.1 million increase in prepaid expenses and
other current and non-current assets and a $3.0 million decrease in accounts payable. The $26.4 million of non-cash expenses consisted
of $21.4 million of stock-based compensation expense, net non-cash interest income and expense of $4.8 million, and depreciation expense
of $0.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $83.5 million during the year ended December 31, 2024, and consisted of a net loss of&#8201;$111.8
million, partially offset by working capital changes of $18.3 million and non-cash expenses of $10.0 million. The $18.3 million increase
in working capital consisted of a $13.2 million increase in accrued expenses, a $4.3 million increase in accounts payable, and a $0.8
million decrease in prepaid expenses and other current and non-current assets. The $10.0 million of non-cash expenses consisted of $7.0
million of stock-based compensation expense, net non-cash interest income and expense of $2.9 million, and depreciation expense of $0.1
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $64.1 million during the year ended December 31, 2025, and consisted of $63.9 million of net purchases
of short-term investments in U.S. treasury securities and $0.2 million in purchases of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $63.1 million during the year ended December 31, 2024, and consisted of $62.8 million of net purchases
of short-term investments in U.S. treasury securities and $0.3 million in purchases of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $360.6 million during the year ended December 31, 2025, and consisted primarily of net proceeds
of $195.0 million from the Note Offering, $91.6 million from the Equity Offering, and $27.7 million from the Term D Loan. In addition,
cash provided by financing activities consisted of proceeds of $42.1 million from the exercise of common stock warrants and $4.2 million
from the exercise of employee stock options and employee stock purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $138.4 million during the year ended December 31, 2024, and consisted primarily of net proceeds
of $59.2 million from the Term C Loan incremental funding, $56.3 million from an equity offering, and $7.3 million from the at-the-market
offering. In addition, cash provided by financing activities consisted of proceeds of $14.7 million from the exercise of common stock
warrants and $1.1 million from the exercise of employee stock options and employee stock purchases, partially offset by $0.2 million
of secondary registration statement costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and
adopted by us as of the specified effective date. Unless otherwise discussed in Note 2 to our financial statements included elsewhere
in this Annual Report, we believe that the impact of recently issued standards that are not yet effective will not have a material impact
on our financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CRITICAL
ACCOUNTING POLICIES AND USE OF ESTIMATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States, or Generally Accepted Accounted
Principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that
affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial
statements, as well as the reported expenses during the reporting periods. These items are monitored and analyzed by us for changes in
facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience
and on various other factors that we believe are reasonable under the circumstances; the results of which form the basis for making judgments
about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected
in reported results for the period in which they become known. Actual results may differ materially from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in Note 2 to our financial statements included elsewhere in this Annual Report.
Of our significant accounting policies, we believe that the following reflect the critical accounting estimates used in the preparation
of our financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of
the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of option grants using the Black-Scholes option-pricing model and the fair value of awards with market-based
vesting conditions using the Monte Carlo simulation model. Estimating the fair value of equity awards using these valuation models is
affected by assumptions regarding a number of variables, including the expected stock price volatility, the expected term of the award,
the risk-free interest rate, expected dividends, and the price per share of our common stock on the grant date. Changes in these assumptions
can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective
and generally require significant analysis and judgment to develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record prepaid or accrued clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials.
These costs can be a significant component of our research and development expenses. We use progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, our estimated expenses in future periods and actual services performed may vary from these
estimates, and these estimates may become more significant. Changes in these estimates that result in material changes to our prepaid
or accrued clinical trial costs could materially affect our results of operations and financial position.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 16.55pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_010"></span>ITEM
7A. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are not required to provide disclosure pursuant to this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_011"></span>ITEM
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_026"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Celcuity Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_988_edei--AuditorOpinionTextBlock_c20250101__20251231_zIMxkys9mQL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000063" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2025 and 2024, and the related statements
of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31,
2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally
accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--AuditorName_c20250101__20251231_zXKcj1fKdEal" style="display: none"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000064" name="dei:AuditorName">Boulay LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--AuditorLocation_c20250101__20251231_zUor7mPyGt9e"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000065" name="dei:AuditorLocation">Minneapolis,
Minnesota</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID: <span id="xdx_90C_edei--AuditorFirmId_c20250101__20251231_zH3H1EI0s2R1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000066" name="dei:AuditorFirmId">542</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sp_027"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Celcuity
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands, except share and par value amounts)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_pn3n3_zkMDkUtMkc85" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20251231_zT8KY4uOX165" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_za5b8gN6cAbe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z5aK69SG8Lo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zsMyTlfaRcbb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCz7ZR_zfHQS0gm2QXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165,703</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,515</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermInvestments_i02I_maCz7ZR_zm4dp4PmUI9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2025-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maCz7ZR_zrgib8sdbH68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid clinical trial costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherAssetsCurrent_i02I_maCz7ZR_zOCIW9UBqIRc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,266</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,698</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtCz7ZR_maCz2Wh_zEq5ZllP7htf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">465,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCz2Wh_zo0CSVKgu1V1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCz2Wh_zcXEcgBWgyP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i01I_maCz2Wh_zIdmeHZBH2Tl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_mtCz2Wh_zRByqhjK3y46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">466,558</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">245,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zvQARDv5UKNg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_zy6DeFJnfzli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maLCzsIm_zMQe5vHfnplf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccruedClinicalTrialCosts_i02I_maLCzsIm_zcRvpBijhaj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued clinical trial costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:AccruedClinicalTrialCosts" contextRef="AsOf2025-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:AccruedClinicalTrialCosts" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzsIm_zsDBKubba832" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzsIm_zivQ0y1d3rt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">172</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzsIm_maLz6Ib_z7AiGSsilMng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLz6Ib_zdAE2O4ccTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0122">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebtNoncurrent_i01I_maLz6Ib_zKuEskditAq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2025-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0126">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_i01I_maLz6Ib_znkh0IQ9K7L1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Note payable, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">126,527</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_maLASEzBIU_mtLz6Ib_zF4qR1Tbm0Wl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">366,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129,504</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzBIU_zGSFXNvpPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies (Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0134">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zg0g8A5H17sc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maSEzYW0_zRIxSi5SFSla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20251231_zUeeAh1bMEQ5" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zLCifeBti9Q3" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zM4Xskap8FAf" title="Preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zfGBA5cdPIM6" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized as of December 31, 2025 and 2024; <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20251231_znOht0eyies8" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231_zCoO9xIEf7jh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231_z0XOkaEzCZc" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231_zNZk3ayjpsfk" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2025 and 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0140">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_maSEzYW0_zs6aZRzwICIc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251231_zLWnU8aA8xy5" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zlFsH2ynaKoe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zpAIGzYB86X7" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_ztkcTGO1ujv9" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized as of December 31, 2025 and 2024; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_zLeGryLk0xM2" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_z8tHXXBQF0Th" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,244,960</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_z7unt8TbuNdk" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zmCtGeSCuADe" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2025 and 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_i02I_maSEzYW0_znOLjaefoM32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">549,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzYW0_zOmrtxiVL733" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">448,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">271,855</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_mtSEzYW0_maLASEzBIU_zrbNGNuQRQN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,619</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzBIU_zDzvlMxPKKUb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">466,558</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">245,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_028"></span>Celcuity
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands, except share and per share amounts)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_pn3n3_zFVjjg8Lhui7" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20251231_zyGheL8mN7cd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_zNdZsfhsIHQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zt0TEGfWE0vb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzRup_z3Jhsgn4IzSc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 10pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzRup_z5ha0ODd4Ejg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzRup_msCzvE6_zGnfgzHgl0R9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">172,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113,267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_mtCzvE6_maCzj6U_zjXtNDrL2hZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">172,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113,267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zYcN7s19WUth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestExpenseNonoperating_i01N_di_msCz7wH_zLi6V6Es3D6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,148</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,280</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InvestmentIncomeInterest_i01_maCz7wH_zyDhKIlLOu4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-012024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,768</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_i01T_mtCz7wH_maCzj6U_zeymELjIf8Aa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other (expense) income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,850</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzj6U_maCzn5E_zzjvBQjxhAXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">177,042</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111,779</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_msCzn5E_zElxb6CL0CIj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0221">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzn5E_zXZBJGUzvhFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">177,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111,779</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20250101__20251231_zzEOKHo3GM03" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20251231_zpnCz2wMNd85" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.79</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_ztTFP1pNvdh8" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zlfcctvul7Hf" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20251231_zCFCARPaGTx2" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20251231_zakgLFDdDHJg" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,757,691</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_za19QvI5usZe" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zNIaw6EH2vvc" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,449,393</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_029"></span><b>Celcuity
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands, except share amounts)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_pn3n3_zZxXWKXjNoy5" summary="xdx: Statement - Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQ2KX308t6c4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z89WY8T2a4V9" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zf5wUpDRHH6d" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Capital</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zc6OXKRjB2tf" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_ziRQ8x8vjkvd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Total <br/> Stockholders&#8217;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zBfhytrVadta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 37%; font-weight: bold">Balance as of December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z058TWIIJhz7" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,506,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zowPM2pOn2Q1" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">854,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299,818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">160,076</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139,769</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z4zBe1zNYnab" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z64TdvNe4gI4" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_zZnEnfGrHAig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2FyZ9xJil59" title="Conversion of preferred stock to common stock, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,365,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zH6vzv4fFTFc" title="Conversion of preferred stock to common stock, shares" style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">536,557</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zJL8XWFTcFNj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcfij6eTsO9b" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2024-01-012024-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z8hcf6vp2w52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6lnYTsaEXli" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueStockWarrantsExercised_zMJyO6XyCBi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of common stock warrants, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhxHwxIq9SC8" title="Exercise of common stock warrants, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,827,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-01-012024-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,736</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zUaMX1Ig0Lo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in an ATM offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxwSgAMPvqc" title="Issuance of common stock in an ATM offering, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">435,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_zuzJQ4Omarvh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGGzQCXEv3Ke" title="Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,871,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2024-01-012024-12-31" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zF01NkYaEgQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock warrants, note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,229</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z8NPuNZt2R5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111,779</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111,779</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20250101__20251231_eus-gaap--StockholdersEquity_iS_zPBbaqUScoAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqAI5k8lLWjg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1SxfSpKqW8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">271,855</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,619</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20250101__20251231_eus-gaap--StockholdersEquity_iS_zcWhvofgAjBh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zENvfFLqSuY4" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,143,242</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRj0J1b10jVl" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,437</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">271,855</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,619</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zuFtacs1UgZh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzFnkZWW8Sie" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2025-01-01to2025-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_zsSDk4pwSvH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuHBEu0p3F5d" title="Conversion of preferred stock to common stock, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd2G7c8y2Z89" title="Conversion of preferred stock to common stock, shares" style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="Fact000358" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">317,577</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ztbWKofg00H8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrYGeffQtMg9" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2025-01-01to2025-12-31" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">711</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zloI6TxeaIp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSeNEdnDPyG7" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">393,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-01-01to2025-12-31" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueStockWarrantsExercised_z2QvyUsuxdfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of common stock warrants, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjdGaoKxs3Sk" title="Exercise of common stock warrants, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,282,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-01to2025-12-31" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,061</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_zM8LWNuK0H0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock warrants in connection with note agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,786</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" contextRef="From2025-01-01to2025-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,786</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_zviC2EcBxtI9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM9ozFufZ8lc" title="Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,172,368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zKAjKJa0v417" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">177,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">177,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zDFEierGrPZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zexOfnx8xVLh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,244,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbHEOKcX1iDg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">549,404</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000407" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">448,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,555</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zzcxwUICZxYg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozOda6QnB23" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,244,960</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJbzLxxd38i" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">549,404</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">448,897</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,555</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_030"></span><b>Celcuity
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pn3n3_zOdMYMsl8RP5" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20251231_zTCEjIakgei4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zbQ5oaBPsGW5" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zU9MYpNTEAN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maNCPBUzA3U_zKt1gvU97Lgl" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">177,042</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111,779</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zu2FS4xgyzCd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash and cash equivalents used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_maNCPBUzA3U_ziShme79CS6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000434" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_maNCPBUzA3U_zCP7B8J65xN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzA3U_zT1c8s9Qld45" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Amortization of debt issuance costs and discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2025-01-01to2025-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-012024-12-31" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaidInKindInterest_i02_maNCPBUzA3U_zOnD8kNRDXAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Payment-in-kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-012024-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NoncashOperatingLeaseExpenseNet_i02_maNCPBUzA3U_zbBKgHshFwzb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Non-cash operating lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:NoncashOperatingLeaseExpenseNet" contextRef="From2025-01-01to2025-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInAccruedInterestIncome_i02N_di_msNCPBUzA3U_znB1jpSRr56a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Change in accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ChangeInAccruedInterestIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ChangeInAccruedInterestIncome" contextRef="From2024-01-012024-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zaTUuC1NIiW9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzA3U_zFWqANKad8hd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Prepaid clinical trial costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,127</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,994</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msNCPBUzA3U_zCqAsHboHs4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Other current and non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,991</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2024-01-012024-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzA3U_zMLyL4cRkcUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,040</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInAccruedClinicalTrialCosts_i03_maNCPBUzA3U_zPkfEGCJ4BF1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Accrued clinical trial costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:IncreaseDecreaseInAccruedClinicalTrialCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:IncreaseDecreaseInAccruedClinicalTrialCosts" contextRef="From2024-01-012024-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i03_maNCPBUzA3U_zxGdO9BbX8Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,013</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzA3U_maCCERCzxA5_zXIAOBicHB0c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">153,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">83,467</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zKL9Favf5F4d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleAndMaturityOfOtherInvestments_i01_maNCPBUztw7_zjCYvyBaDqt1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from maturities of investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332,507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="From2024-01-012024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">642,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireInvestments_i01N_di_msNCPBUztw7_z5Rdz1Wudgak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchases of investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">396,342</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-01-012024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705,165</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUztw7_zyQSvHaHrGCi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">249</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUztw7_maCCERCzxA5_zHa3bSn7lEql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64,084</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zjesNZl1FZUb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockPlans_i01_maNCPBUzW8h_zZt5Vei8XVW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2025-01-01to2025-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" contextRef="From2024-01-012024-12-31" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzW8h_zamFeLIzg2hi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from exercise of common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2025-01-01to2025-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-012024-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzW8h_zD55BCHXZzaj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,736</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzW8h_zusAz4DeuR88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from convertible debt, net of debt issuance costs of $<span id="xdx_903_eus-gaap--DeferredFinanceCostsCurrentNet_iI_pn3n3_c20251231_zbYTZSttw8yi" title="Proceeds from convertible note payable, net of debt issuance cost and discount"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2025-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,246</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DeferredFinanceCostsCurrentNet_iI_pn3n3_c20241231_z5IdCQRCVvyd" title="Proceeds from convertible note payable, net of debt issuance cost and discount"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2024-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> during the years ended December 31, 2025 and 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_i01_maNCPBUzW8h_zpPqkzS8i9p1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from note payable, net of debt issuance costs of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_c20251231_zml7DdaTCgLk" title="Debt issuance costs and discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2025-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,255</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_c20241231_zPs3Yu0DQjLa" title="Debt issuance costs and discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,438</ix:nonFraction></span> during the years ended December 31, 2025 and 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,226</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromOtherEquity_i01_maNCPBUzW8h_zjrX0wXgXzjc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from equity offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2025-01-01to2025-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-01-012024-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsFromAtmOfferingNetOfIssuanceCosts_i01_maNCPBUzW8h_zirSJigbLr55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from an ATM offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaymentsForSecondaryRegistrationStatementCosts_i01N_di_msNCPBUzW8h_zp7OnUoAN32g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Payments for secondary registration statement costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CELC:PaymentsForSecondaryRegistrationStatementCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CELC:PaymentsForSecondaryRegistrationStatementCosts" contextRef="From2024-01-012024-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzW8h_maCCERCzxA5_zltSoEsmBtL1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360,552</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138,388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzxA5_zC5k52YZPuSh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,148</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAbstract_iB_zKOpid5Efb5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zFFskyNGy7T6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,663</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zSz8S3PBCtOg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">End of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165,703</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,515</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z4tvZjYzU1z9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestPaidNet_i01_zz4g7wQ3YcIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,586</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CashPaidForOperatingLeases_i01_z73yZJF5pkrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for operating leases</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CashPaidForOperatingLeases" contextRef="From2025-01-01to2025-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CashPaidForOperatingLeases" contextRef="From2024-01-012024-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zfbiSsmbZf51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosures of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockWarrantsIssuedWithNotePayableTransaction_i01_zGt1joWPaa69" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Common stock warrants issued with the note payable transaction</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CommonStockWarrantsIssuedWithNotePayableTransaction" contextRef="From2025-01-01to2025-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,786</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:CommonStockWarrantsIssuedWithNotePayableTransaction" contextRef="From2024-01-012024-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,229</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PropertyAndEquipmentIncludedInAccountsPayable_i01_z4ZQqJ0Uial1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment included in accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_i01_zwOzhDuhVuIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred financing, offering and registration statement costs included in accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sp_031"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELCUITY
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000558" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zcuHu0fZI2Cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_822_zYNqMeQ8y7j3">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on the development of targeted
therapies for the treatment of multiple solid tumor indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a kinase
inhibitor of the phosphatidylinositol 3-kinase (&#8220;PI3K&#8221;), serine/threonine-protein kinase protein kinase B (&#8220;AKT&#8221;),
mechanistic target of rapamycin (&#8220;mTOR&#8221;) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and
mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PI3K/AKT/mTOR (&#8220;PAM&#8221;)
pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational
therapies that target PI3K&#945;, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in
combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor
receptor 2-negative (HER2-) (&#8220;HR+/HER2-&#8221;) advanced breast cancer (&#8220;ABC&#8221;) has completed enrollment and reported
detailed results for cohort 1, patients with <i>PIK3CA</i> wild-type (&#8220;WT&#8221;) tumors, and has completed enrollment of cohort
2, patients with <i>PIK3CA</i> mutant-type (&#8220;MT&#8221;) tumors. Our Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib
in combination with a cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitor and fulvestrant as first-line treatment for patients
with endocrine treatment resistant HR+/HER2- ABC is ongoing. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib
in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. The Company was co-founded
in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenue to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has not generated any revenue from product sales or other sources and has incurred operating losses and negative
cash flows from operations. The Company&#8217;s primary uses of cash, cash equivalents, and investments to date have been funding clinical
trials and research and development activities, the scaling of commercial launch related activities such as marketing, supply chain,
distribution, market access and other commercial operations, business planning, establishing and maintaining the Company&#8217;s intellectual
property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and
administrative support for these operations. As of December 31, 2025, the Company had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zlytoKkGzHY4" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">448.9</ix:nonFraction></span> million. To date,
the Company has funded operations primarily through private placements, registered offerings of its equity securities, convertible notes,
and borrowings under loan agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had $<span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zcJP1Uc9YhH4" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">441.5</ix:nonFraction></span> million in cash, cash equivalents and short-term investments. The Company believes its existing
cash, cash equivalents and short-term investments will be sufficient to fund planned operations for at least one year from the issuance
of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, the clinical and commercial success
of its initial drug product, gedatolisib, the regulatory approval of gedatolisib, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000564" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_za1GI9lDVlY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_821_zMV7gxTrM3X">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000566" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZyqntnbGC3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zSEcArUGpUL7">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
Operating results during the year ended December 31, 2025, are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000568" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_z4wX2KuNTQh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zq0Rkpzqv5Hd">Accounting
Estimates</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such
estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000570" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyuqO5zJgMfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_zX3Kco5Tshj5">Cash
and Cash Equivalents</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its accounts at two financial institutions. As of December 31, 2025 and 2024, the Company had $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_z9RHZLhNlC2g" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">165.7</ix:nonFraction></span> million and $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zzkYYFbsgxCl" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000574" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">22.5</ix:nonFraction></span>
million, respectively, in business checking accounts and money market funds that are considered cash equivalents. Cash and cash equivalents
are classified as Level 1 assets under the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000576" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_841_eus-gaap--InvestmentPolicyTextBlock_zHhi3kTKMJhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zNunFUOvHYNb">Investments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its investments in U.S. treasury securities and has classified them as held-to-maturity at the time of purchase. Held-to-maturity
purchases are those investments which the Company has the ability and intent to hold until maturity. Held-to-maturity investments are
recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity investment using the straight-line method. The difference between the carrying
value, which is based on cost, and the aggregate fair value of the held-to-maturity investments, was immaterial as of December 31, 2025.
As of December 31, 2025 and 2024, the Company had $<span id="xdx_907_eus-gaap--ShortTermInvestments_iI_pn5n6_c20251231_zZD871QV3Pu1" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2025-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">275.8</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_ziLL23bT0Wa9" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">212.6</ix:nonFraction></span> million, respectively, of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000582" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zW2gzexcYwa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zmywVMpiYPyj">Fair
Value of Financial Instruments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The accounting guidance establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Unobservable inputs that are significant to the fair value measurement and supported by little or no market activity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
level in the fair value hierarchy within which a fair value measurement in its entirety falls, is based on the lowest level input that
is significant to the fair value measurement in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash equivalents, accounts payable, accrued expenses and other financial working capital items approximate fair value
as of each of December 31, 2025 and 2024, due to the short maturity nature of these items. Refer to Note 10 for disclosures around the
Company&#8217;s <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z13StAFalI86" title="Accrue interest payable rate"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z2cFbGR9qQUa" title="Accrue interest payable rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-01-012024-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2025-01-012025-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.750</ix:nonFraction></ix:nonFraction></span></span>% Senior Notes due 2031 (the &#8220;Notes&#8221;) and note payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000588" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZKo6AbqVvxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zT1PkDBaxKtc">Concentration
of Credit Risk</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents, and
investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company
has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000590" name="CELC:AllowanceForCreditLossesPolicyTextBlock"><p id="xdx_849_ecustom--AllowanceForCreditLossesPolicyTextBlock_zPDb6xwx063k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86A_zCVZbl4QFzhc">Allowance
for Credit Losses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
investments in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that
it will be required to sell, the investment before recovery of its amortized cost basis. If either of the criteria regarding intent or
requirement to sell is met, the investment&#8217;s amortized cost basis is written down to fair value through earnings. For investments
that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses
or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes
in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates
that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost
basis of the investment. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit
loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost
basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000592" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQGdqKZJAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_zaLp4t9hew6c">Property
and Equipment</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and
repairs are expensed as incurred; major improvements and betterments are capitalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000594" name="CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
useful lives of property and equipment are as follows for the major classes of assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_ztk6McHWACA7" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify">Asset description</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center">Estimated useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000596" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"><span style="-sec-ix-hidden: xdx2ixbrl0597">Shorter of remaining lease term or estimated useful life</span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zi5mSi50J9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000599" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zx6fJWTV2tY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_z8XMZLoRvvog">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies
leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use
asset and current and non-current lease liabilities, as applicable, on the balance sheets. The Company has elected not to recognize on
the balance sheets leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease
term. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s leases may include options to extend or terminate the leases. Periods covered by an option to extend the lease are included
in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate
the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. The Company monitors
its plans to renew or terminate its material leases each reporting period. If a lease includes provisions for leasehold improvements
for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets.
If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding
right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease
term. The present value of future lease payments is discounted using the interest rate implicit in the lease contracts if that rate
is readily determinable; otherwise, the Company utilizes information available at the commencement of the lease to calculate the incremental
borrowing rate, which reflects the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar
term and in a similar economic environment. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the
period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities,
real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company.
The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000601" name="us-gaap:CapitalizationAndAmortizationOfFuelCostsPolicy"><p id="xdx_84B_eus-gaap--CapitalizationAndAmortizationOfFuelCostsPolicy_zZyNUMrJAi27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zX4lzNpaEKzi">Capitalized
Software Development Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company capitalizes qualifying costs incurred during the application development stage related to software developed for internal use.
Capitalized software development costs are classified as other non-current assets on the balance sheets. As of December 31, 2025 and
2024, the Company had $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn5n6_c20251231_zM6b5cWY6VC" title="Capitalized software development costs"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2025-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and <span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0_do_c20241231_zlMEzTHKCPo1" title="Capitalized software development costs"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2024-12-31" id="Fact000605" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> capitalized software development costs, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software,
beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general
and administrative expenses. The Company did not record any amortization expense during the years ended December 31, 2025 and 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000607" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlOi0Upf1PA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zhM3A0omLsCd">Long-Lived
Assets</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment,
the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000609" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_847_eus-gaap--DeferredChargesPolicyTextBlock_zD1nPD22SC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_zqNNtcbHJsu7">Deferred
Transaction Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
transaction costs primarily consist of legal fees that are capitalized as incurred and will be offset against the proceeds from future
equity financing arrangements. The deferred transaction costs will be reviewed periodically to assess the probability that future securities
will be offered. In the event that no future offering will occur, any deferred transaction costs will be expensed. Total costs incurred,
but not accounted for as a reduction in equity, were $<span id="xdx_904_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20251231_z8r3RBeFpgX6" title="Deferred transaction costs"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2025-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20241231_zUpNBA8nvcm2" title="Deferred transaction costs"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2024-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million as of December 31, 2025 and 2024, respectively. D<span style="background-color: white">eferred
transaction costs are classified as other assets on the balance sheets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000615" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_84A_eus-gaap--DebtPolicyTextBlock_zcAx6RA6yAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zgV1CyFnZHhk">Debt
Issuance Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes debt issuance costs as deferred costs, which are capitalized and amortized over the term of the related debt
using the effective interest method. These costs primarily consist of fees, commissions, and legal and other costs directly
attributable to securing debt financing. Debt issuance costs are reported as a direct reduction of the carrying amount of the
related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements of operations over
the life of the debt instrument. In the event of early extinguishment of debt, any related unamortized debt issuance costs are
written off and recognized as a component of the gain or loss on extinguishment of debt in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000617" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zV1w1M8nL3P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86F_zCXXW4tYrEEk">Comprehensive
Loss</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other
than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000619" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zviD542vWEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zp6BOAhm9hV1">Commitments
and Contingencies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other
amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount,
the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000621" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z1nUe2xca6V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zMG8KiOHKv49">Stock-Based
Compensation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation consists of stock options, restricted stock awards and restricted stock units issued
to certain employees and non-employees of the Company under the 2017 Amended and Restated Stock Incentive Plan, and shares issued under
the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense based on the estimated grant date fair value using the Black-Scholes
option-pricing model and the expense is recognized on a straight-line basis over the requisite service period. Compensation expense
for awards with performance-based conditions is recognized when the achievement of the performance condition is deemed
probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Monte Carlo simulation model for awards with market-based vesting conditions. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inputs for the Black-Scholes valuation model and the Monte Carlo simulation model require management&#8217;s significant assumptions,
including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected
dividends. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available
in combination with the Company&#8217;s calculated volatility since being publicly traded. The expected term of the award is based on
the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free interest rate is based on the
rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected term of the award at the
grant date. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay
any dividends on its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with such agreements would also be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Restricted
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records compensation expense based on the quoted fair value of the shares on the grant date over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ESPP</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense for ESPP rights is recorded in line with each respective offering period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000623" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIunJ3n2ufXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_z0eJafjg7AM5">Research
and Development</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs were $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn6n6_c20250101__20251231_z12fj9fPToT6" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">145.0</ix:nonFraction></span> million and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_z3gNzyhfz9ni" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">104.2</ix:nonFraction></span> million during the years
ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000629" name="us-gaap:InProcessResearchAndDevelopmentPolicy"><p id="xdx_840_eus-gaap--InProcessResearchAndDevelopmentPolicy_zvxAfo7Fc65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_z4e7z51IdGNc">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party service providers to conduct certain aspects of clinical studies and to formulate and manufacture its drug
product. While there are alternative vendors that can perform these functions, any disruption or delay by the Company&#8217;s current
third-party service providers in carrying out their contractual duties could delay its clinical trials and/or the commercial launch of
 gedatolisib, if approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company records prepaid or accrued
clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials. These costs can be a
significant component of the Company&#8217;s research and development expenses. The Company uses progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, the Company&#8217;s estimated expenses in future periods and actual services performed
may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes
to the Company&#8217;s prepaid or accrued clinical trial costs could materially affect the Company&#8217;s results of operations and
financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000631" name="CELC:LicensesPolicyTextBlock"><p id="xdx_840_ecustom--LicensesPolicyTextBlock_zc84EiKOSzja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zdYLlh0qBtz4">Licenses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upfront
payments and other consideration under license agreements are expensed as research and development expense upon receipt of the license,
and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
license agreements include milestone payments which are recognized when it becomes probable that the achievement of those milestones
will be met. The Company records this expense as research and development expense in its statements of operations. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000633" name="CELC:PatentCostsPolicyTextBlock"><p id="xdx_84B_ecustom--PatentCostsPolicyTextBlock_zawpsPqfjNCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_z3zaSHAgoOal">Patent
Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000635" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zMp5hH9dGpD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zJiPQCUlSyMg">Income
Taxes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss
and tax credit carryforwards. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized
in results of operations in the period that includes the enactment date. The effects of any future changes in tax laws or rates have
not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that
the deferred tax assets will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the impact of an uncertain tax position in its financial statements if, in management&#8217;s judgment, the position
is more-likely-than-not sustainable upon audit based on the position&#8217;s technical merits. This involves the identification of potential
uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position
is necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000637" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgrcRyEGF68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zxYl1G2LUNR6">Segment
Data</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has <span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20251231_zyV0gJPysRfb" title="Number of operating segment"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zBXIOtyInZfa" title="Number of reportable segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2025-01-01to2025-12-31" id="Fact000639" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-12-31" id="Fact000641" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></ix:nonFraction></span></span> reportable operating segment, which is the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#8217;s chief operating decision makers (&#8220;CODMs&#8221;) are its chief executive officer, chief science
officer and chief financial officer, who, together manage the Company&#8217;s operations as one operating segment for the purpose of
evaluating financial performance and allocating resources. The CODMs assess the performance and allocate resources for the reportable
segment based on net loss and total assets, which are the same amounts in all material respects as those reported in the statements of
operations and balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000643" name="CELC:RecentAccountingPrononcementAdoptedPolicyTextBlock"><p id="xdx_84C_ecustom--RecentAccountingPrononcementAdoptedPolicyTextBlock_zykMCmeNJmPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_z9oy2onAva6a">Recently Adopted
Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09,
<i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the annual income
tax disclosures for the effective tax rate reconciliation, income taxes paid, and continuing operations. ASU 2023-09 also eliminates
certain disclosure requirements related to unrecognized tax benefits. ASU 2023-09 is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 on January 1, 2025 on a retrospective basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000645" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zI0ml4PUQfTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_864_zw21V0E5gg1h">Recent
Accounting Pronouncements Not Yet Adopted</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03<i>, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), which requires public entities to provide
disaggregated disclosure of income statement expense. In January 2025, the FASB issued ASU 2025-01, <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i>, to clarify the effective
date of ASU 2024-03. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025<i>, </i>the FASB issued ASU 2025-05<i>, Measurement of Credit Losses for Accounts Receivable and Contract Assets</i> (&#8220;ASU
2025-05&#8221;), which provides certain entities with an additional practical expedient for estimating expected credit losses on current
accounts receivable and current contract assets arising from revenue transactions under Accounting Standards Codification (&#8220;ASC&#8221;)
606. ASU 2025-05 is effective for all entities for annual and interim periods in fiscal years beginning after December 15, 2025. Early
adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2025-05 on its financial statements and
related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software </i>(&#8220;ASU 2025-06&#8221;), which modernizes the accounting for
internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs
when management has committed to the software project, and it is probable the software will be completed and perform to its intended
use. In evaluating whether it is probable the project will be completed, management is required to consider whether there is significant
uncertainty associated with the development activities of the software. ASU 2025-06 is effective for annual and interim periods beginning
after December 15, 2027. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective
basis. The Company is currently evaluating the timing, method of its adoption, and effect of ASU 2025-06 on its financial statements
and related disclosures.</span></p>

</ix:nonNumeric><p id="xdx_852_zCWzM4W03Ghd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000647" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zRMsbBidY5v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span><span id="xdx_82C_zRnbgNmfQRfk">Net Loss Per Common Share</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options, convertible note, warrants,
restricted stock and preferred stock have been excluded from the calculation because their effect would be anti-dilutive.
Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000649" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zORYutVOwcoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the potentially-dilutive shares that have been excluded from the calculation of diluted weighted-average shares
outstanding because their inclusion would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z5QGd34saOD3" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zmiwONDliCC2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_ziB8ERXgONb3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zMZiJmSvch96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_OptionsToPurchaseCommonStockMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,842,485</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember" id="Fact000652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,306,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesToCommonStockMember_zCYOYBvJ442f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note as-if-converted-to-common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_ConvertibleNotesToCommonStockMember" id="Fact000654" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,296,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z0n4IUGxwnmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">274,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember" id="Fact000658" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,521,152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zSts8C0b8t1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zhapCbcSARVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Preferred stock as-if-converted-to-common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember" id="Fact000664" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zXTfV9N7vzj2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,440,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,004,978</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zpfn2jNhLOWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of shares of common stock issuable upon conversion of the Notes is <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zZwOhTZ0Xqdf" title="Debt conversion, number of shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2025-01-012025-12-31_srt_MaximumMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,296,053</ix:nonFraction></span>. As of December 31, 2025, the number of shares
issuable based on the Company&#8217;s closing common stock price would be <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231_zsPa8XWSvsY9" title="Debt conversion, number of shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2025-01-01to2025-12-31" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,923,002</ix:nonFraction></span> if the Notes were converted in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, pre-funded warrant shares of <span id="xdx_90A_ecustom--PrefundedWarrantShares_iI_c20251231_zYYCzTTEV7g1" title="Pre-funded warrant shares"><ix:nonFraction name="CELC:PrefundedWarrantShares" contextRef="AsOf2025-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,147,787</ix:nonFraction></span> and <span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20241231_zckerqX3QTgl" title="Pre-funded warrant shares"><ix:nonFraction name="CELC:PrefundedWarrantShares" contextRef="AsOf2024-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></span>, respectively, were included in the
computation of basic and diluted net loss per share, as the pre-funded warrants are exercisable for nominal consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000677" name="us-gaap:InvestmentTextBlock"><p id="xdx_80E_eus-gaap--InvestmentTextBlock_zaEzdAeDtini" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82A_zZTKmvcocLb8">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
investments for which the Company has the positive intent and ability to hold to maturity are classified as held-to-maturity and reported
at historical cost adjusted for amortization of premiums and accretion of discounts. Expected credit losses, if any, are recorded through
the establishment of an allowance for credit losses. All of the Company&#8217;s held-to-maturity investments are U.S. treasury securities
that are guaranteed or otherwise supported by the United States government and have no history of credit losses. Accordingly, the Company
does not expect to incur any credit losses on held-to-maturity investments and has no allowance for credit losses recorded for these
investments. As of December 31, 2025, all of the Company&#8217;s held-to-maturity investments had maturities of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000679" name="us-gaap:InvestmentTableTextBlock"><p id="xdx_897_eus-gaap--InvestmentTableTextBlock_zIw6y3x3FzVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s held-to-maturity investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z9VkKqNddUAc" style="display: none">Schedule of Investment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zS2HjqxEFScd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zdHHY3oytKqk">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zw5EFQuv06ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_zMPPl2Q5vWpl">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_480_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zhlS1jzeWiT8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zIHFZOjFXl3l">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_zOZiMPCK5oF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zYTQN66rSKi1">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_418_20251231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zyZAFzIPQay2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275,794</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">225</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276,019</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20251231_z9wbGKXfl9vi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2025-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275,794</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2025-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2025-12-31" id="Fact000691" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276,019</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zDJAenC5wlUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zWQvLHjoRvda">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zJ8u1D7HdVg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_z5SmvX2XEiy6">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zzXxS7N8w3Li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zbYZEkUByjd9">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_z8NLpWxhuCX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zBwpQIjZEqnk">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41B_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQJNT1vkE24g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,589</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000697" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,671</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_418_20241231_zfqjcTaUByIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecurities" contextRef="AsOf2024-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="AsOf2024-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2024-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zP75axjGoJB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. treasury securities are classified as Level 2 investments within the fair value hierarchy. These assets have been
valued based on quoted prices in active markets for similar assets or other inputs that are observable or can be corroborated by observable
market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in valuation techniques or transfers within the fair value hierarchy during the years presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000705" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z1IzjeLSsmm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_825_zc93a7nIJAsl">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000707" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxBgPwA6mhB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zHgvA72Kgd55" style="display: none">Summary of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zyTdLKSsDgNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zIuzqQovFCHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOVBm9dvY31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,354</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhWT1ENzaIH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">304</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zvOutspI9J44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt">Total property and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,658</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zP8QBER7Dw9c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,159</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,992</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zdsQLanmJtpf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 10pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">499</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">336</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zNh4YhIfYeKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_900_eus-gaap--Depreciation_pn5n6_c20250101__20251231_zIYKdD9wMTPd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--Depreciation_pn5n6_c20240101__20241231_zXUT31eu0ygb" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million during the years ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000728" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zLvZ8fMuJURf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82D_z06hjorMYkc8">Other Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000730" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZbWWTgPirOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued expenses consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zj2tIjtimwig" style="display: none">Schedule
of Other Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_z52ERfs6jbuc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zyb99emckFoh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maOALCzJtq_z9f7AjR0Usy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Employee compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,338</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2024-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherAccruedLicenseMilestone_iI_maOALCzJtq_zu2RMw5Kvkhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:OtherAccruedLicenseMilestone" contextRef="AsOf2025-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccruedInterest_iI_maOALCzJtq_zLzTDb4eKmr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:OtherAccruedInterest" contextRef="AsOf2025-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzJtq_zXrs85If1x79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2025-12-31" id="Fact000741" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maOALCzJtq_zl5AKWtjUVw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,813</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">874</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzJtq_zZpg8DjEfTd3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,865</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zdpC3meloNO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, and 2024, accounts payable included $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20251231_zUkwZTmiRyB6" title="Accounts payable included accrued interest"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zaC7jz3tevm1" title="Accounts payable included accrued interest"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">820</ix:nonFraction></span> of accrued interest, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000754" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zn6L9igRsxCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_820_z65XpHziTd96">Commitments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: left; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Operating
and Finance Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its corporate space in Minneapolis, Minnesota, with an operating lease in place through April 30, 2026 (the &#8220;Existing
Lease&#8221;). The Existing Lease provides for monthly rent, real estate taxes, and operating expenses. Rent expense is recorded on a
straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company entered into a lease for clinical laboratory and office space in Minnesota for <span id="xdx_905_eus-gaap--AreaOfLand_iI_usqft_c20251130_zpCiYYXsrGC6" title="Square feet"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2025-11-30" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">19,594</ix:nonFraction></span> square feet. <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20251101__20251130_zCdOoCCDTyM" title="Lease option to extend"><ix:nonNumeric contextRef="From2025-11-012025-11-30" id="Fact000758" name="us-gaap:LesseeOperatingLeaseOptionToExtend">The lease
term will commence on April 1, 2026 and is 62 months with two options to extend the lease term for five years each. The Company also
has a one-time option to terminate the lease at the end of the third year, provided certain conditions are met.</ix:nonNumeric> </span>To exercise this option,
the Company must pay a termination fee equal to eight months&#8217; rent plus the landlord&#8217;s unamortized transaction costs, which
include abated rent, tenant improvement allowances and broker fees. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20251101__20251130_z2XeypAftfRh" title="Lease description"><ix:nonNumeric contextRef="From2025-11-012025-11-30" id="Fact000760" name="us-gaap:LesseeOperatingLeaseDescription">The initial annual lease payment is $<span id="xdx_903_eus-gaap--OperatingLeasePayments_pn5n6_c20251101__20251130_zXrdOaQbJ496" title="Initial annual lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-11-012025-11-30" id="Fact000762" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million and increases by
3.5% on an annual basis, resulting in total undiscounted future minimum lease payments of $<span id="xdx_901_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn5n6_c20251130_z99u4GodQlVl" title="Undiscounted future minimum lease"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-11-30" id="Fact000764" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million over the initial <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20251130_zYh1W81o6era" title="Lease term"><ix:nonNumeric contextRef="AsOf2025-11-30" format="ixt-sec:durmonth" id="Fact000766" name="us-gaap:LesseeOperatingLeaseTermOfContract">62</ix:nonNumeric></span>-month term.</ix:nonNumeric>
</span>As of December 31, 2025, the lease has not commenced and is therefore excluded from the tables below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000768" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5OAgmDvZCz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under the Company&#8217;s Existing Lease consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zFNpIZgwWV3j" style="display: none">Schedule
of Minimum Lease Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zd68EMBIexzj" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zUJ1rqmQQXC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; text-indent: 9pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_iI_maLOLLPzXrd_zrTeJp5gO3S3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zfuLN0O1hiyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNAOuArXgvM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zPYqHNQA0Eo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zpbBBzqH2pJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: operating lease liabilities, current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxd97nAkHF13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and discount rate under the Company&#8217;s Existing Lease were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zkpNCPmDa5ze" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact000784" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.3</ix:nonNumeric></span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zdzuwqCIGnn4" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000786" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.3</ix:nonNumeric></span>
years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Weighted-average discount rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFzrBzzk5Oac" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zCm9fm80LA4b" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zukE4zy9Kwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000792" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_ze1GqYxJdhzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents components of lease costs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zR5QI8yk12aj" style="display: none">Schedule of Lease Costs</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20250101__20251231_zGGU5Xhnmcgg" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20240101__20241231_zlqgEUsFD1D4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zCqkWBzh8CP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--VariableLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zrB0DEKtwVbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_pn3n3_mtLCzphc_z2BpqhRDFbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-012024-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">324</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zFs5wNnq9OL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Clinical
Research Studies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third-party
service providers that include, among others, arrangements with vendors, consultants, contract manufacturing organizations, and contract
research organizations. Contracts related to the Company&#8217;s ongoing clinical trials are generally cancelable with advance notice
and the Company&#8217;s obligations under these contracts are primarily based on services performed through termination dates plus certain
cancelation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be
subject to amendments as a result of any change orders executed. As of December 31, 2025, the Company had $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20251231_zWDYx32IGm87" title="Non-cancelable contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2025-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction> </span>million of non-cancelable
purchase commitments with respect to these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Registration
Rights Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a securities purchase agreement with certain investors pursuant to which the Company agreed to sell to the investors
in a private placement pre-funded warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdLgI1OmU4Yc" title="Pre-funded warrants sold to investors"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></span> shares of the Company&#8217;s common stock in October 2023 (the &#8220;Securities Purchase Agreement&#8221;),
the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the investors. Under
the Registration Rights Agreement, the Company agreed to file a registration statement and to use commercially reasonable efforts to cause such registration statement to become effective and to keep such
registration statement effective until such time as there are no longer registrable securities held by the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company fails to meet the specified filing deadlines, effectiveness deadlines, or maintain the effectiveness of the registration
statement, <span id="xdx_906_eus-gaap--RegistrationPaymentArrangementTerm_c20250101__20251231_zcNLKNPkrlXk" title="Registration rights"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000807" name="us-gaap:RegistrationPaymentArrangementTerm">the
Company is required to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0% of the aggregate
amount paid pursuant to the Securities Purchase Agreement by such investor&#160;for each 30-day period or pro rata for any portion
thereof during which such event continues, provided that the maximum liquidated damages shall not exceed 6.0% of the aggregate
amount invested by each such holder in the registrable securities.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for these arrangements in accordance with ASC 825-20, <i>Registration Payment Arrangements</i>. As of December 31,
2025, the required registration statement has been timely filed and declared effective by the SEC, and the Company remains in
compliance with the maintenance requirements. Management has determined that it is not probable that the Company will be obligated
to pay any liquidated damages; accordingly, no liability has been recorded for these arrangements.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000809" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTf2Ux3D7zNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_z98N5HmjSZs4">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Capital
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company&#8217;s authorized capital stock consisted of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zJjYdsfUBFIg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></span> shares of common stock, of which <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zcP87RyHEJz3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,244,960</ix:nonFraction></span>
shares were outstanding, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zCkkfZr0wOF3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares of preferred stock, including <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zX8m2jQ78vI7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850,000</ix:nonFraction></span> shares designated as Series A Preferred Stock,
of which <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20251231_z2QTmNQHBmb4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000819" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></span> were outstanding. As of December 31, 2025, no dividends have been declared on the Company&#8217;s capital stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">July
2025 Equity Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2025, the Company entered into an underwriting agreement (the &#8220;Equity Underwriting Agreement&#8221;) with Jefferies
LLC (&#8220;Jefferies&#8221;), TD Securities (USA) LLC, and Leerink Partners LLC as representatives (the
&#8220;Representatives&#8221;) of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;) agreeing,
subject to customary conditions, to issue and sell in a public offering (i) <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zOwi6t22itnl" title="Number of share sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,836,842</ix:nonFraction></span>
shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, at a price to the public of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z0PXs6UPLt8l" title="Sale of stock perice per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.00</ix:nonFraction></span>
per Share and (ii) in lieu of Shares to certain investors, pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z1DuOVzIo6W9" title="Prefunded warrant shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span>
shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), at a price to the public of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zell8W0EWesj" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.999</ix:nonFraction></span>
per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zuS9JyWijuC5" title="Exercise price per warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share exercise price for each such Pre-Funded Warrant (the &#8220;Equity Offering&#8221;). In addition, pursuant to the Equity
Underwriting Agreement, the Company granted the Underwriters an option to purchase up to an additional <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zcrlcf88qlEc" title="The number of additional common stock shares the Underwriters can purchase"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,526</ix:nonFraction></span>
shares of common stock (the &#8220;Option Shares&#8221;), less underwriting discounts and commissions. The Underwriters exercised
their option to purchase the Option Shares in full on July 30, 2025. The Equity Offering was completed on July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds from the Equity Offering, after deducting underwriting discounts and commissions and offering expenses, were $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_ziW0um8Cddp3" title="The cash inflow associated with the amount received from entity's offering of stock to the public"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000833" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">91.6</ix:nonFraction></span> million,
including the proceeds from the Underwriters&#8217; exercise of their option in full to purchase the Option Shares. The Company may also
receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zNeqmJXLgNVa" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, or alternatively, at the election
of each holder, shares of common stock may be issued through a cashless exercise, with the net number of shares of common stock determined
according to the formula set forth in each Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at any time after the date of
issuance until all of the Pre-Funded Warrants are exercised. <span id="xdx_904_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250730__20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zp7XYY1Vzzhg" title="Pre-funded warrant exercisable description"><ix:nonNumeric contextRef="From2025-07-302025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember" id="Fact000837" name="us-gaap:SaleOfStockDescriptionOfTransaction">A holder (together with its &#8220;attribution parties,&#8221; as defined
in the Pre-Funded Warrant) may not exercise any portion of the Pre-Funded Warrants if immediately after exercise, the holder (together
with its attribution parties), would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise. However, a holder may increase or decrease such percentage to any other percentage not in excess
of 19.99%, which increase or decrease shall not become effective until 61 days after notice from the holder to the Company.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sale
and Issuance of Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus
&amp; Company, Incorporated as representatives of the several underwriters relating to the issuance and sale of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zPV5ZuHbjmpf" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,871,000</ix:nonFraction></span> shares of common
stock, at a price to the public of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zYsnbmQKlUw4" title="Issuance of public offering price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.50</ix:nonFraction></span> per share, generating gross proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zE486h3Wy01k" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">60.0</ix:nonFraction></span> million. The offering closed on May 31, 2024
and resulted in net proceeds to the Company of $<span id="xdx_903_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zzWgaqRf9m09" title="Net proceeds from public offering"><ix:nonFraction name="CELC:ProceedsFromIssuanceOfCommonStockNet" contextRef="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember" id="Fact000845" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">56.3</ix:nonFraction></span> million after deducting underwriting discounts and other offering expenses payable
by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zg8Xyijxdon4" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,700</ix:nonFraction></span> shares of common stock
in a single transaction at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5mE2J82qjF1" title="Issuance of public offering price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.65</ix:nonFraction></span> per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zNDCQgTXQCwi" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z2jzKsB4saOb" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">285,714</ix:nonFraction></span> shares of common stock
in a single transaction at a price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z6ckh86vykJa" title="Share price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.50</ix:nonFraction></span> per share, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zY9EdIUhP4h5" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" id="Fact000857" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions
and other offering expenses related to the Open Market Sale Agreement transactions in May and April 2024 were $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_z1RjZoIh99ab" title="Commissions and other offering expenses"><span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zgwXXxxewzT4" title="Commissions and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-05-012024-05-31_custom_OpenMarketSaleAgreementMember" id="Fact000859" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-04-012024-04-30_custom_OpenMarketSaleAgreementMember" id="Fact000861" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></ix:nonFraction></span></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000863" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuWHMhzGo9Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had the following common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zY1ytPWLNUyc" style="display: none">Schedule
of Common Stock Warrants</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/> Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_znF7acZVjZ4" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantOneMember" format="ixt:datemonthdayyear" id="Fact000865" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">1/21/2016</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zhnZppxtvQ45" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantOneMember" format="ixt:datemonthdayyear" id="Fact000867" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">1/14/2026</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zk2Mw9EYW8H3" title="Number of Warrants Outstanding" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantOneMember" id="Fact000869" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">28,716</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zHyXpIYLRYi" title="Exercise Price" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantOneMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 46%; text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zI8hpZN5OdBc" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantOneMember" id="Fact000873" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Private placement offering &#8211; issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zWoep6ko0o6h" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantTwoMember" format="ixt:datemonthdayyear" id="Fact000875" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/2/2016</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zkl24SZw7vEh" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantTwoMember" format="ixt:datemonthdayyear" id="Fact000877" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/2/2026</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zKwhd0DvrB12" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantTwoMember" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">18,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zFAO4x8AVNQ9" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantTwoMember" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zS7k8CSa0a3j" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantTwoMember" id="Fact000883" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Private placement offering &#8211; issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zAFRJnIXM30b" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantThreeMember" format="ixt:datemonthdayyear" id="Fact000885" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">4/28/2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zRKSHCpIQnwa" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantThreeMember" format="ixt:datemonthdayyear" id="Fact000887" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/28/2027</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zcDmLPUyp4Td" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantThreeMember" id="Fact000889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">32,458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zReh2tr8pRm4" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantThreeMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zuNGbngV4fBj" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantThreeMember" id="Fact000893" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Private placement offering &#8211; issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zclugJRqklN7" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantFourMember" format="ixt:datemonthdayyear" id="Fact000895" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/17/2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zxiXJsqAg9i8" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantFourMember" format="ixt:datemonthdayyear" id="Fact000897" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/17/2027</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEziq4xBRE57" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantFourMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_znoRCtWmvgCd" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantFourMember" id="Fact000901" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_z9xKaE7Arcq7" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantFourMember" id="Fact000903" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Private placement offering &#8211; issued to placement agent</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z7MA7HnPVIpj" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantFiveMember" format="ixt:datemonthdayyear" id="Fact000905" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">4/8/2021</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBOiBldDJvNf" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantFiveMember" format="ixt:datemonthdayyear" id="Fact000907" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">4/8/2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_znqkO7Jpk9Bk" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantFiveMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">26,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zqMM6I1aTAfj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantFiveMember" id="Fact000911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zAZdpAqgLUl1" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantFiveMember" id="Fact000913" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zEFvxS7ie88g" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantSixMember" format="ixt:datemonthdayyear" id="Fact000915" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/30/2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zy1eUogQej5g" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantSixMember" format="ixt:datemonthdayyear" id="Fact000917" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/30/2034</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdrW9Y4jmDmk" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantSixMember" id="Fact000919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">84,227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zWim2INAWGub" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantSixMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdm4KenlCym1" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantSixMember" id="Fact000923" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zq1Rclq2cx44" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantSevenMember" format="ixt:datemonthdayyear" id="Fact000925" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">5/30/2024</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z3WLQeqny3Ff" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantSevenMember" format="ixt:datemonthdayyear" id="Fact000927" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">5/30/2034</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_za2mYVkOjUc1" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantSevenMember" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">19,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zgKKOcOQfO69" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantSevenMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zMnEPRfw0b0e" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantSevenMember" id="Fact000933" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zHdsHyxT9PQ6" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantEightMember" format="ixt:datemonthdayyear" id="Fact000935" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">9/9/2025</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zjCg9xYcyDT2" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantEightMember" format="ixt:datemonthdayyear" id="Fact000937" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">9/9/2035</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zLLSV398LSSk" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantEightMember" id="Fact000939" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">25,269</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zSFbo8yOcaUf" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantEightMember" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zfYJFO2roqVg" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantEightMember" id="Fact000943" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_z6sgr6CaXIYd" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantNineMember" format="ixt:datemonthdayyear" id="Fact000945" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">9/9/2025</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zSnWlrTdJqsl" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantNineMember" format="ixt:datemonthdayyear" id="Fact000947" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">9/9/2035</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zn6CZLd8Raq6" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantNineMember" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">25,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zQHkfNELAb9b" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantNineMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zuuO2eabQgW6" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantNineMember" id="Fact000953" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Debt financing &#8211; issued to lender</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zdHCDyqWLa44" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantTenMember" format="ixt:datemonthdayyear" id="Fact000955" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">10/18/2023</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zNiCWbmI4cC8" title="Number of Warrants Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantTenMember" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,747,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z4SdBJHrOnq8" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantTenMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zzANf3ZPrRMk" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantTenMember" id="Fact000961" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Private placement offering &#8211; issued to investors</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_z7PfKVLsdvxj" title="Issue Date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantElevenMember" format="ixt:datemonthdayyear" id="Fact000963" name="CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">7/31/2025</ix:nonNumeric></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">N/A</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zcGfIow7zqk8" title="Number of Warrants Outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_WarrantElevenMember" id="Fact000965" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">400,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zjLdLiLLDsK9" title="Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantElevenMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zUiYBUZj5gQ7" title="Offering"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantElevenMember" id="Fact000969" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Equity offering &#8211; issued to underwriters</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total warrants outstanding</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_z6Yy2e5tTo0k" title="Number of Warrants Outstanding" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31" id="Fact000971" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,422,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td title="Exercise Price" style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zCWBFAhATkal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Funded
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded
warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRwbdsTUGT5k" title="Pre-funded warrants sold to investors"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,747,787</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAmCPPU4Z3Zb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. Each warrant to purchase
one share had a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV8BpTWG9ife" title="Warrant purchase price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.699</ix:nonFraction></span> per share, and an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsXVpykm0fA3" title="Exercise price of common stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share for the common stock issuable upon exercise
of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant is immediately exercisable and will not expire. Under the terms of the warrants, the Company may not effect the exercise of any
such warrant, and a holder will not be entitled to exercise any portion of any warrant, if, upon giving effect to such exercise, the
aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who
could be deemed to be acting as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose
beneficial ownership of common stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates for
purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) would exceed
4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#8220;Maximum Percentage&#8221;).
A holder may reset the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the
Company, or a lower percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only
to that holder and not to any other holder of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company, other obligations of the parties and termination provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000981" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zKyuRQPGnTud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHKDaQ9sDNLe" style="display: none">Schedule
of Common Stock Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdZ94uhfSK5f" title="Common stock warrants, outstanding shares" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,268,939</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbbqAq7Di5ck" title="Weighted- average exercise price per share, outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.04</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zr3btbfI5lV1" title="Common stock warrants, issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdOFkWbiJAm3" title="Weighted- average exercise price per share, issued" style="text-align: right"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKlIT7Yuuu7" title="Common stock warrants, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,282,375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zf8zruGCcwn4" title="Weighted- average exercise price per share, exercised" style="text-align: right"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Surrendered upon cashless exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z5YU7llqoyJ4" title="Common stock warrants, surrendered upon cashless exercise" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,541</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zLYOpxidlSx6" title="Weighted- average exercise price per share, surrendered upon cashless exercise" style="text-align: right"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMizbNcfmHx5" title="Common stock warrants, expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zJd6gzxtBn0k" title="Weighted- average exercise price per share, expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zY4JevYww3J1" title="Common stock warrants, outstanding shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-12-31_custom_PrefundedWarrantsMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,422,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z59zeD648rui" title="Weighted- average exercise price per share, outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_custom_PrefundedWarrantsMember" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zFC0BNDh0IQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, several of the Company&#8217;s investors exercised <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znxFSsD9p9wk" title="Additional warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,827,357</ix:nonFraction></span>
common stock warrants, net of shares withheld for the exercise price, at exercise prices ranging between $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zN7fSoNfBU3e" title="Class of warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_srt_MinimumMember_custom_PrefundedWarrantsMember" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.05</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zEClnvNV3hh4" title="Class of warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_srt_MaximumMember_custom_PrefundedWarrantsMember" id="Fact001011" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.50</ix:nonFraction></span>
per share, which generated $<span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zHF5cxuCjVg3" title="Proceeds from warant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember" id="Fact001013" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.7</ix:nonFraction></span>
million in cash. During the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z3MvDscA8A62" title="Common stock warrants expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,544</ix:nonFraction></span>
common stock warrants expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A preferred stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PreferredStockVotingRights_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHbB9vIAvTy2" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001017" name="us-gaap:PreferredStockVotingRights">The
Series A preferred stock is non-voting, and each share is convertible at the option of the holder, subject to certain limitations, into
10 shares of common stock. Holders of Series A preferred stock are entitled to receive dividends, on an as-if-converted-to-common stock
basis, when, as and if, and in the same form as, dividends are actually paid on the common stock. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as defined in the Certificate of
Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders of Series A preferred stock
are entitled to be paid from assets of the Company available for distribution to its stockholders, before any payment is made to the
holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the original issue price
(<span id="xdx_908_eus-gaap--CommonStockConversionBasis_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKsgAAOuvQx6" title="Common stock converted basis"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001019" name="us-gaap:CommonStockConversionBasis">$5.75 on an as-converted-to-common stock basis</ix:nonNumeric></span>), plus all accrued and unpaid dividends and (ii) the amount that the holder would have
been entitled to receive at such time if the Series A preferred stock were converted into common stock. The Company may not, without
the consent of holders of a majority of the outstanding shares of Series A preferred stock, amend its charter in a manner that adversely
affects the powers, preferences or rights of the Series A preferred stock or issue or obligate itself to issue shares of any additional
class or series of capital stock unless the same ranks junior to the Series A preferred stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company and the payment of dividends.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0vPzVwClfH4" title="Conversion of preferred to common stock, shares"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,577</ix:nonFraction></span> shares of Series A preferred stock were converted into <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QZQQZKgs7i" title="Conversion of preferred to common stock, shares"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,770</ix:nonFraction></span> shares of common stock. As
of December 31, 2025, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5i1gdO0ybFd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001025" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares of Series A preferred stock were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001027" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLuItsdnxrU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_823_zeXtXG7mKgqh">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2012
Equity Incentive Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2012, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20120801__20120831__us-gaap--PlanNameAxis__custom--TwoThousandTwelveEquityIncentivePlanMember_zM6gtsJD1vKf" title="Stock based compensation description"><ix:nonNumeric contextRef="From2012-08-012012-08-31_custom_TwoThousandTwelveEquityIncentivePlanMember" id="Fact001029" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Company adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provided for options, restricted
stock awards, performance stock awards and stock bonuses. The exercise price of each option granted under the 2012 Plan is not less than
100% of the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Plan is
ten years. The Company&#8217;s board of directors administers the 2012 Plan and determines the provisions of incentive awards, including
eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. In September 2017, the 2012 Plan was frozen and no further awards may be
made under the 2012 Plan.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2017
Amended and Restated Stock Incentive Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_z0n5vRNzsOMc" title="Stock based compensation description"><ix:nonNumeric contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" id="Fact001031" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Company adopted the 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan provides
for the grant of options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock bonuses.
The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on the date
of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered by
the compensation committee of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other
determinations necessary for the administration of the 2017 Plan.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zZ5bHPexIIrf" title="Number of shares reserved for issuance description"><ix:nonNumeric contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenPlanMember" id="Fact001033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1 of each year from 2026 to 2027 by
the number of shares equal to 1.0% of the aggregate number of outstanding shares of common stock as of the immediately preceding December
31.</ix:nonNumeric></span> However, the Company&#8217;s board of directors may reduce the amount of the increase in any particular year. The number of shares
reserved for issuance under the 2017 Plan was automatically increased by <span id="xdx_909_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zu1vQ7ho5Bi9" title="Number of shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2025-01-01_custom_TwoThousandSeventeenPlanMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">371,432</ix:nonFraction></span> and <span id="xdx_901_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zpnVLhuVPXL9" title="Number of shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2024-01-01_custom_TwoThousandSeventeenPlanMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">255,060</ix:nonFraction></span> shares on January 1, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the board of directors and the stockholders approved additional increases of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z6nNPwSBcZyi" title="Number of shares reserved for issuance, additional increases"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="From2025-01-012025-12-31_custom_TwoThousandSeventeenPlanMember" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> and
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z9FyvHfjAABg" title="Number of shares reserved for issuance, additional increases"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="From2024-01-012024-12-31_custom_TwoThousandSeventeenPlanMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span>, respectively, to the number of shares reserved for issuance under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the number of shares available for issuance under the 2017 Plan is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z7kIUC3NquR8" title="Number of shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-12-31_custom_TwoThousandSeventeenPlanMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,591,634</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Stock
Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2017 Plan are exercisable at various dates as determined upon grant and will expire no more than 10 years from their
date of grant. The exercise price of each option shall be determined by the board of directors based on the estimated fair value of the
Company&#8217;s common stock on the grant date. The exercise price shall not be less than 100% of the fair market value of the Company&#8217;s
common stock on the grant date. Most option grants generally vest <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9dTr5QzcwU9" title="Option vested percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on the first anniversary of the original vesting commencement date,
with the balance vesting monthly over the remaining <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSJ1D3SGXX3c" title="Option vested period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" format="ixt-sec:durwordsen" id="Fact001047" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">three years</ix:nonNumeric></span>. The 2017 Plan is generally administered by the compensation committee
of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other determinations necessary
for the administration of the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001049" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTcIIS7MgWOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zlfIIvSxZYSd" style="display: none">Schedule of Stock Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average remaining contractual term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Options outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCkkFqEa3hA7" title="Options outstanding at beginning of year" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_StockOptionMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,306,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMrXPEQNQhsk" title="Options outstanding, weighted average exercise price at beginning of year" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_StockOptionMember" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z827ybDJ6FT8" title="Options outstanding, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001055" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfVKMidhnWxf" title="Options outstanding, aggregate intrinsic value" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_us-gaap_StockOptionMember" id="Fact001057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,914</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvNkbSZkP4f" title="Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,186,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx8BY35J20T3" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBgTugSTIG62" title="Shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">393,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJRL0p6hVJzi" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBGFofiqjod7" title="Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">257,784</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFvDeYHk0Gxd" title="Weighted Average Exercise, Forfeited" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.29</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPMAvV2Ci8Ae" title="Options outstanding at end of year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,842,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJUeAh6Ohkm1" title="Options outstanding, weighted average exercise price at end of year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.62</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRpxRljttXc" title="Options outstanding, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001075" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRoCp1nQzBl" title="Options outstanding, aggregate intrinsic value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">468,191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z22A603GPpa1" title="Shares, options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,740,854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUxQ8RT8mgid" title="Weighted Average Exercise Price, Options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.61</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zafuMNCGgrKd" title="Options exercisable, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001083" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.6</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgWXNQtrKRHk" title="Options exercisable, aggregate intrinsic value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-12-31_us-gaap_StockOptionMember" id="Fact001085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zRmzYZgIWFY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company modified previously granted stock option awards to 44 employees by reducing the exercise price of these options
to the Company&#8217;s closing common stock price on the modification date. During the year ended December 31, 2025, the incremental
compensation expense recognized as a result of these modifications was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEbOxAGEBFGf" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001087" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. The effect of these modifications on stock-based
compensation over the remaining service periods will be $<span id="xdx_90A_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHyW3d1nUdie" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001089" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, the market conditions associated with options previously granted to an employee were satisfied following
the achievement of the specified stock price threshold. As a result, the options vested and the Company recognized $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsghp4TFUmGc" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001091" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.4</ix:nonFraction></span> million in stock-based
compensation expense related to these awards during the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the weighted-average grant date fair value of options granted was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQyUcCSuSM28" title="Weighted-average grant date fair value of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.01</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKLtiLHbux2l" title="Weighted-average grant date fair value of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.22</ix:nonFraction></span> per share,
respectively. The total intrinsic value of options exercised during the years ended December 31, 2025 and 2024, was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zK2IC7BfVC3b" title="Total intrinsic value of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001097" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.7</ix:nonFraction></span> million and
$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zS9xHGJyemp2" title="Total intrinsic value of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact001099" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million, respectively. Upon the exercise of stock options, the Company will issue new shares of its common stock. As of December
31, 2025, the unrecognized compensation cost related to outstanding employee and non-employee options was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHBwHWyZ9IKi" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact001101" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">52.7</ix:nonFraction></span> million and is expected
to be recognized as expense over a weighted-average period of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkbUGsQ1ZG5" title="Weighted-average period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001103" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.7</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001105" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z3FcRz9Z6IZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used in the Black-Scholes option pricing model and Monte Carlo simulation model to determine the fair value of the employee
and non-employee stock option grants issued, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHooiLxHocnc" style="display: none">Schedule of Assumptions for Fair Value of Employee
And Non-Employee Stock Option</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zftQrWlbl5I1" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2025-01-01to2025-12-31" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction></span>% &#8722; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zEwoFc6JrAyd" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2025-01-01to2025-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.7</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zRFq2DnHJSQ" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-012024-12-31" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.5</ix:nonFraction></span>% &#8722; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjePQYYY2x43" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-012024-12-31" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.7</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_z6dJPR4OaN51" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2025-01-01to2025-12-31" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.4</ix:nonFraction></span>% &#8722; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zuWx75cDXpV5" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2025-01-01to2025-12-31" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.1</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zFtSAyO9ecTi" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-012024-12-31" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">71.2</ix:nonFraction></span>% &#8722; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zK42ZgMSlxQj" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-012024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76.2</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_zoqo3A5HeYL1" title="Expected life (years)"><ix:nonNumeric contextRef="From2025-01-012025-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span> &#8722; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0dMAcFxpFdb" title="Expected life (years)"><ix:nonNumeric contextRef="From2025-01-012025-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10.0</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zj9pmRcLPN8a" title="Expected life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.3</ix:nonNumeric> </span>&#8722; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zf3CXz8mmseb" title="Expected life (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10.0</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_z034pBWCJwz8" title="Expected dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-01to2025-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zBjl1WuZGpo8" title="Expected dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zqcRHHL9OmT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for stock options of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrexFWYFtkaj" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001135" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million
and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX4wc6vHjIMg" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001137" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.6</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Restricted
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001139" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zpkKKu1o9ZB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award and restricted stock unit activity during the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVDyisgCqHH4" style="display: none">Schedule of Restricted Stock Award And Restricted Stock Unit Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average grant date fair value per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR764yhxFZ0i" title="Outstanding shares" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2IAvpjTNKMh" title="Weighted-average grant date fair value per share, outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkTXxhRztcic" title="Granted shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQAA84K3GOj" title="Weighted-average grant date fair value per share, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">89.43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxngmZhrjeBi" title="Vested shares" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcxsEPykwxok" title="Weighted-average grant date fair value per share, vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.83</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 9pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvp5duBIU3uj" title="Forfeited shares" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zre61j4B5Omk" title="Weighted-average grant date fair value per share, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">98.49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg7btdZuLY7i" title="Outstanding shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOZtNknRa617" title="Weighted-average grant date fair value per share, outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember" id="Fact001159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">87.25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zr7g9kI8in6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the unrecognized compensation cost related to outstanding restricted stock was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD73JRzblUKj" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001161" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million and is expected to
be recognized over a weighted-average period of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgRlh61bIB7h" title="Weighted-average period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" format="ixt-sec:duryear" id="Fact001163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.9</ix:nonNumeric></span> years. The total fair value of restricted stock vested during the year ended December
31, 2025 was less than $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFrzVNnCDBg6" title="Total fair value of restricted stock vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001165" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span>million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for restricted stock of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkXhTy2tOvI6" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001167" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million
and less than $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJuhnagOZbd" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1427656" id="Fact001169" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2017
Employee Stock Purchase Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, <span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zNL7eWWSrptc" title="Employee stock purchase plan description"><ix:nonNumeric contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001171" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription">the Company adopted the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides participating employees
with an opportunity to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions. The ESPP is available
to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value
of the Company&#8217;s common stock. The ESPP is administered using overlapping 24 month offering periods (the &#8220;Offering Periods&#8221;).
Each Offering Period has four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and
November 1 of each year. Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of
the fair market value of a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase
date has a lower price, the employee will automatically be placed in the Offering Period beginning immediately after the purchase date.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z6YMVZmEWkWg" title="Number of shares reserved for issuance description"><ix:nonNumeric contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001173" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
number of shares reserved for issuance under the ESPP automatically increases on January 1 of each year from 2023 to 2027 by the number
of shares equal to 0.5% of the aggregate number of outstanding shares of common stock as of the immediately preceding December 31.</ix:nonNumeric></span> However,
the Company&#8217;s board of directors may reduce the amount of the increase in any particular year. The number of shares reserved for
issuance under the ESPP was automatically increased by <span id="xdx_90C_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_ztkc3zKI8Ibc" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2025-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,716</ix:nonFraction></span> and <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zMuviZlBUBC" title="Change in common stock, shares reserved for issuance"><ix:nonFraction name="CELC:ChangeInCommonStockSharesReservedForIssuance" contextRef="AsOf2024-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,530</ix:nonFraction></span> shares on January 1, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the number of shares available for issuance under the ESPP is <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z9uPhR5KjFYk" title="Number of shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">469,576</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense related to the ESPP of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zjwrZ56LwCk8" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001181" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million
and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zVbGnKbKX70l" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember" id="Fact001183" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Stock-based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001185" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziI9tdsa1ugl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the following stock-based compensation expense in its statements of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zwdJtQjabLL6" style="display: none">Schedule
of Stock-based Compensation Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231_zQtol8iQV0Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zXTRHnhdGiub" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zckkQtDacQ07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,409</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,405</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zoucFZd5Trn4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_z2oJyb8fyoXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,383</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zMXa4m9dn6C9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact001196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,383</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A8_za1T61RK1uU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001199" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zNJ9iwbJZHJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_827_zqTVI7TqyZG4">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">July
2025 Convertible Notes Offering</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2025, the Company entered into an underwriting agreement (the &#8220;Note Underwriting Agreement&#8221;) with the Underwriters,
subject to customary conditions, to issue and sell in a public offering $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zjW3xipiuuTd" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001201" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">175.0</ix:nonFraction></span> million aggregate principal amount of the Notes to the
Underwriters (the &#8220;Note Offering&#8221;). In addition, pursuant to the Note Underwriting Agreement, the Company granted the Underwriters
an option to purchase up to an additional $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zo5THxCavrV7" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember" id="Fact001203" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.3</ix:nonFraction></span> million aggregate principal amount of Notes solely to cover over-allotments. On July
30, 2025, the Underwriters exercised such option to purchase an additional $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJojX9ASBFD3" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember" id="Fact001205" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.3</ix:nonFraction></span> million aggregate principal amount of the Notes. The
issuance of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250801__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z1rc3wJthAt9" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-08-01_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001207" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">201.3</ix:nonFraction></span> million aggregate principal amount of the Notes was completed on August 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes were issued pursuant to, and are governed by, an indenture (the &#8220;Base Indenture&#8221;), dated as of August 1, 2025, between
the Company and U.S. Bank Trust Company, National Association, as trustee (the &#8220;Trustee&#8221;), as supplemented by a first supplemental
indenture (the &#8220;Supplemental Indenture,&#8221; and the Base Indenture, as supplemented by the Supplemental Indenture, the &#8220;Indenture&#8221;),
dated as of August 1, 2025, between the Company and the Trustee. The net proceeds from the Note Offering, after deducting underwriting
discounts and commissions and offering expenses, were $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBy8QJ7EBD1i" title="Net proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember" id="Fact001209" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">194.9</ix:nonFraction></span> million, including the proceeds from the Underwriters&#8217; exercise of
their over-allotment option in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes are general, unsecured, senior obligations of the Company. The Notes will accrue interest payable semi-annually in arrears on February
1 and August 1 of each year, beginning on February 1, 2026, at a rate equal to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260201__20260201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5bZi4EXSiBl" title="Accrue interest payable rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2026-02-012026-02-01_us-gaap_SubsequentEventMember_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.750</ix:nonFraction></span>% per year. In addition, special interest will accrue
on the Notes upon the occurrence of certain events relating to the Company&#8217;s failure to file certain reports with the SEC as provided
in the Indenture and as described below. The Notes also have customary provisions relating to the occurrence of &#8220;Events of Default&#8221;
(as defined in the Indenture) with certain interest penalty provisions. The Notes will mature on August 1, 2031, unless earlier converted,
redeemed or repurchased by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noteholders
may convert their Notes at their option at any time prior to the close of business on the scheduled trading day immediately preceding
the maturity date based on an initial conversion rate of <span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionRatio1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zBfkY00FdAh8" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">19.4932</ix:nonFraction></span> shares of common stock, per $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zEV3IefxYaF6" title="Principal amount"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> principal amount of the Notes, which
is equivalent to an initial conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5JxhvZoeKp" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span> per share of common stock. The conversion rate is subject to customary adjustments
upon the occurrence of certain events as described in the Indenture. In addition, if certain corporate events that constitute a &#8220;Make-Whole
Fundamental Change&#8221; (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased
for a specified period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DebtInstrumentRedemptionDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zQKzqYDaaDDe" title="Redemption description"><ix:nonNumeric contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001219" name="us-gaap:DebtInstrumentRedemptionDescription">The
Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company&#8217;s option at any
time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately
before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid
interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds
130% of the conversion price on (i) each of at least <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zMDQkhaajZ09" title="Trading days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">20</ix:nonFraction></span> trading days, whether or not consecutive, during the <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zfiS8p3T0LJg" title="Consecutive trading days"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">30</ix:nonFraction></span> consecutive trading days
ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading
day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes
unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company
sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with
respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances
if it is converted after it is called for redemption.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a &#8220;Fundamental Change&#8221; (as defined in the Indenture) occurs, then, subject to certain conditions and except as set forth
in the Indenture, noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount
of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The definition in the Indenture of a Fundamental Change includes certain business combination transactions involving the Company and
certain de-listing events with respect to the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
the Notes contain a beneficial ownership limitation, and as a result of such limitation, noteholders do not have the right to convert
all or any portion of the Notes held by such noteholder, to the extent that immediately prior to, or immediately after giving effect
to such conversion by such noteholder, together with its affiliates and any other persons acting as a group together with such noteholder
or any of such noteholder&#8217;s affiliates, would <span id="xdx_905_eus-gaap--DebtInstrumentDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zlp8C3osLE0c" title="Beneficial ownership description"><ix:nonNumeric contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001225" name="us-gaap:DebtInstrumentDescription">beneficially own in excess of 4.99% of the number of shares of the Company&#8217;s
common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes;
provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that
such limitation in no event can exceed 19.99%.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Notes, which differs from their carrying value, is influenced by interest rates, stock price and stock price volatility
and is determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an
active market and therefore the fair value is determined using Level 2 inputs. As of December 31, 2025, the carrying value and fair value
of the Notes was $<span id="xdx_909_eus-gaap--ConvertibleDebtNoncurrent_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z3dJUdAbK471" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001227" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">195.3</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--NotesReceivableFairValueDisclosure_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z4RYwsXowP81" title="Fair value of the Notes"><ix:nonFraction name="us-gaap:NotesReceivableFairValueDisclosure" contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001229" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">436.5</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance costs attributed to the Notes amounted to $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zXdRWHalttef" title="Discount amount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001231" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span>
million and were discounted from the Notes. The issuance cost discount is being amortized to interest expense over the term of the
Notes based on the effective interest rate method. As of December 31, 2025, the effective interest rate was <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zhYseCXMpbf" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.3</ix:nonFraction></span>%.
During the year ended December 31, 2025, interest expense related to the Notes was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zeSe91SKnsrk" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001235" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span>
million, including $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zepFXfvQYXib" title="Discount amount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" id="Fact001237" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million related to discount amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Amended
and Restated Loan and Security Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Third
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2025, the Company entered into the Third Amendment (the &#8220;Third Amendment&#8221;) to the Amended and Restated Loan
and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;) with Oxford Finance LLC, a Delaware limited liability company
(&#8220;Oxford&#8221;), as collateral agent and a lender, Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership
(&#8220;Innovatus&#8221;), as a lender, and the other lenders party thereto (together with Oxford and Innovatus, the
&#8220;Lenders&#8221;), pursuant to which the A&amp;R Loan Agreement was amended to (i) replace Innovatus with Oxford as collateral
agent; (ii) recognize the achievement of the Term D Milestone (as defined in the A&amp;R Loan Agreement, as amended by the Third
Amendment (the &#8220;Amended A&amp;R Loan Agreement&#8221;)) and provide for the immediate disbursement of the $<span id="xdx_905_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zziupAojIKz1" title="Disbursement loan amount"><ix:nonFraction name="CELC:DisbursementLoanAmount" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001239" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span>
million Term D Loan (as defined in the Amended A&amp;R Loan Agreement); (iii) increase the size of the Term E Loan (as defined in
the Amended A&amp;R Loan Agreement) from $<span id="xdx_90E_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zZSyeJnlayA2" title="Contingent loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember" id="Fact001241" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">50.0</ix:nonFraction></span>
million to up to $<span id="xdx_901_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermETwoLoanMember_zP3U8a74fA2e" title="Contingent loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermETwoLoanMember" id="Fact001243" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">100.0</ix:nonFraction></span>
million, which Term E Loan may only be drawn upon FDA approval of gedatolisib in second line wild-type ABC
patients post CDK4/6 inhibitor therapy; (iv) add three new up to $<span id="xdx_909_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zthlCpxtehdg" title="Contingent loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember" id="Fact001245" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">40.0</ix:nonFraction></span>
million Term F Loans (as defined in the Amended A&amp;R Loan Agreement), for a total of $<span id="xdx_908_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzUAsh4rGZsj" title="Contingent loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001247" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">120.0</ix:nonFraction></span>
million, which may only be drawn upon achievement of certain trailing three months&#8217; product revenue thresholds; (v) replace
the prior $<span id="xdx_904_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFTwoLoanMember_zOE6xVw3try4" title="Contingent loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFTwoLoanMember" id="Fact001249" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">45.0</ix:nonFraction></span>
million Term F Loan (as defined in the A&amp;R Loan Agreement) with a new $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermGLoanMember_zSQItI5irxzd" title="Contingent loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermGLoanMember" id="Fact001251" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">150.0</ix:nonFraction></span>
million Term G Loan (as defined in the Amended A&amp;R Loan Agreement), which continues to be available only in the Lenders&#8217;
sole discretion upon the Company&#8217;s request; (vi) require an amendment fee payable by the Company to the Lenders in the amount
of $<span id="xdx_904_ecustom--AmendmentFee_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZZSPj30VzZ2" title="Amendment fee payable"><ix:nonFraction name="CELC:AmendmentFee" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001253" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million, which was paid at the closing of the Third Amendment; (vii) make certain revisions to the non-utilization fee for the Term
E Loan, and add a new non-utilization fee for the Term F Loans, in each case equal to 3.0% of the applicable unfunded commitment,
after taking into consideration any reductions to the applicable term loan commitment that the Company may make by notice to the
collateral agent before the date that is eight weeks after the achievement of any applicable milestones; and (viii) extend the
maturity date of the term loans to November 1, 2029. The Term E Loan and each Term F Loan also are subject to other customary
conditions and limits on when the Company can request funding. With the disbursement of the $<span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwIEMMMhyagk" title="Disbursement loan amount"><ix:nonFraction name="CELC:DisbursementLoanAmount" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001255" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span>
million Term D Loan, the Company received net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z5LnX8pzav5g" title="Net proceeds from loan"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001257" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.7</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the A&amp;R Loan Agreement, a Final Fee equal to <span id="xdx_901_ecustom--DebtFinalFeePercentage_iI_pid_dp_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zPjQPZxOgoNl" title="Debt final fee percentage"><ix:nonFraction name="CELC:DebtFinalFeePercentage" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></span>% of the $<span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zZi3lmIKEKve" title="Disbursement loan amount"><ix:nonFraction name="CELC:DisbursementLoanAmount" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001261" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million Term D Loan was recognized and an additional
$<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zYAEUtwe9nwa" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" id="Fact001263" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million was added to debt principal and a corresponding debt discount to be amortized over the life of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Third Amendment, the Company issued warrants with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdeJxjkvrBD4" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></span> per share to purchase an aggregate
of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3KOKwpAUOq8" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,537</ix:nonFraction></span> shares of the Company&#8217;s common stock to Innovatus, Oxford, and certain of its affiliates (the &#8220;Third Amendment
Warrants&#8221;). The Third Amendment Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the funding date of the Term D Loan. The number of shares of common stock for which each Third Amendment Warrant is exercisable and
the associated exercise price are subject to certain proportional adjustments as set forth in such Third Amendment Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
portion of the proceeds from the Term D Loan in the amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zXIo47y5aDge"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember" id="Fact001268" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was allocated to the Third Amendment Warrants based
on their relative fair value to the underlying Term D Loan. The proceeds allocated to the Third Amendment Warrants were recorded as additional
paid in capital in the accompanying balance sheets and were discounted from the Term D Loan. The relative fair value of the Third Amendment
Warrants was based on the Black-Scholes model with the following assumptions: risk-free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zUk5W1e8peA9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.1</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%;
expected volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwGubhApG6Lh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.4</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%;
expected life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zIyGBJcFhRsl"><ix:nonNumeric contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember" format="ixt-sec:duryear" id="Fact001271" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10.0</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years; and expected dividend yield of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z9GaAKrUnQU8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The underlying stock price used in the analysis was the traded market price. The discount related to the Third Amendment Warrants is
being amortized to interest expense ratably over the term of the Term D Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Second
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, the Company entered into the Second Amendment (the &#8220;Second Amendment&#8221;) to the A&amp;R Loan Agreement with
Innovatus, as collateral agent, and the Lenders including Innovatus in its capacity as a Lender and Oxford, pursuant to which Innovatus
and Oxford, as Lenders, have agreed to make certain term loans (&#8220;Term Loans&#8221;) to the Company in the aggregate principal amount
of up to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zGVu2FjAhbz1" title="Debt instrument principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact001274" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">180</ix:nonFraction></span> million. The A&amp;R Loan Agreement was amended to (i) subject to certain terms and conditions, permit the issuance of
the Notes discussed above and certain transactions in connection therewith, including the conversion thereof settled solely in common
stock (together with cash in lieu of the issuance of any fractional share of common stock), (ii) permit capped call transactions in connection
with the pricing of the Notes, (iii) require an amendment fee payable by the Company to Oxford in the amount of less than $<span id="xdx_905_ecustom--AmendmentFee_iI_pn5n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_z0IuHxQczcg1" title="Amendment fee payable"><ix:nonFraction name="CELC:AmendmentFee" contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact001276" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million,
which was paid upon execution of the Second Amendment, and (iv) extend to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zrAGHknOGxb6" title="Maturity date"><ix:nonNumeric contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" format="ixt:datemonthdayyearen" id="Fact001278" name="us-gaap:DebtInstrumentMaturityDate">May 9, 2026</ix:nonNumeric></span> the expiration date of Innovatus&#8217; right to
convert up to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_ze5dx5i4Shk2" title="Conversion percentage"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact001280" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of the outstanding principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share
of $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zL1coVu8wIsf" title="Common stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in connection with the release of the topline data from the wild-type cohort of the VIKTORIA-1 Phase 3 clinical trial, the Company achieved
the Term D Milestone (as defined in the A&amp;R Loan Agreement) and therefore became eligible to draw an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zeNtBvfcXrtc" title="Amount of indebtedness eligible to incur under Term D Loan"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" id="Fact001284" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million of
indebtedness under the Term D Loan (as defined in the A&amp;R Loan Agreement). As described above, the Term D Loan was disbursed to the
Company in connection with the Third Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">First
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2025, the Company entered into the First Amendment (the &#8220;First Amendment&#8221;) to the A&amp;R Loan Agreement, pursuant
to which the Company agreed to <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zDgzxSboZEbf" title="First Amendment description"><ix:nonNumeric contextRef="From2025-05-132025-05-13_custom_LoanAgreementMember" id="Fact001286" name="us-gaap:DebtInstrumentDescription">(i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment,
(ii) extend to March 9, 2026 the expiration date of Innovatus&#8217; right to convert up to 20% of the outstanding principal of the Term
A Loan into shares of the Company&#8217;s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D
Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&amp;R Loan Agreement),
(iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company
had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the
Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders
from any and all claims arising out of or related to the A&amp;R Loan Agreement, the First Amendment and related documentation.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">May
30, 2024 Amendment and Restatement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2024, the Company entered into the A&amp;R Loan Agreement. The A&amp;R Loan Agreement amended and restated, in its entirety,
that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and Innovatus, as collateral agent, and
the Lenders named therein (the &#8220;Prior Loan Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
of the first $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zVNBS9WrKuT6" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001288" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million under the A&amp;R Loan Agreement occurred on May 30, 2024, including tranche payments of $<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zIt9owQwRmm2" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001290" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.8</ix:nonFraction></span> million (the
&#8220;Term A Loan&#8221;) and $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zBywFpf9mrre" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember" id="Fact001292" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">21.5</ix:nonFraction></span> million (the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans under
the Prior Loan Agreement plus accrued payment-in-kind interest, in addition to $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zabCoOTcteag" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember" id="Fact001294" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">61.7</ix:nonFraction></span> million of new borrowings (the &#8220;Term C Loan&#8221;).
As described above, the Term D Loan was disbursed to the Company in connection with the Third Amendment. Prior to the Third Amendment,
the Company also would have become eligible to draw on a fifth tranche of $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z18iOBq3PGUh" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember" id="Fact001296" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50.0</ix:nonFraction></span> million (the &#8220;Term E Loan&#8221;), upon achievement
of certain clinical trial milestones and satisfaction of certain financial covenants. The Lenders also could have, in their sole discretion
upon the Company&#8217;s request, made additional term loans to the Company of $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zXOQ5LL7ndtg" title="Funded loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember" id="Fact001298" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">45.0</ix:nonFraction></span> million (the &#8220;Term F Loan&#8221;). Funding
of these additional tranches was also subject to other customary conditions and limits on when the Company could have requested funding
for such tranches. Costs associated with the new borrowings were approximately $<span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0cR5GxuVLN8" title="Costs associated with new borrowings"><ix:nonFraction name="us-gaap:OtherBorrowings" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001300" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the A&amp;R Loan Agreement, <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zxCLtgbyFY4d" title="Debt instrument interest rate description"><ix:nonNumeric contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember" id="Fact001302" name="us-gaap:DebtInstrumentInterestRateTerms">the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months
if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</ix:nonNumeric></span> The A&amp;R Loan Agreement is secured by all assets of the Company. Proceeds are being used for working capital purposes and
to fund the Company&#8217;s general business requirements, including the ongoing Phase 3 VIKTORIA-1 clinical trial, the Phase 1b/2 CELC-G-201
clinical trial, and the Phase 3 VIKTORIA-2 clinical trial. The A&amp;R Loan Agreement contains customary representations and warranties
and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity and other financial measures. Prior
to the Second Amendment, Innovatus also had the right, at its election and until August 9, 2025, to convert up to <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zRT2FgyccyCl" title="Loan % convertible to stock"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zfYOuhCUf0i" title="Common stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>. Innovatus will continue
to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zrrvM0TXY429" title="Common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,042</ix:nonFraction></span> shares of
common stock at a price per share of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_znOYr6IsZgq9" title="Common stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction></span> through April 8, 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A&amp;R Loan Agreement contains a Final Fee, which is equal to <span id="xdx_902_ecustom--FinalFeePercentage_pid_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTi3OiqpyoHa" title="Final fee percentage"><ix:nonFraction name="CELC:FinalFeePercentage" contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></span>% of the initial funding of the agreement and is due on the earliest
to occur of (a) the Maturity Date, (b) the acceleration of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent
non-utilization fee for the Term E Loans. Following the disbursement of the Term D Loan in connection with the Third Amendment, the non-utilization
provisions related to the Term D Loan are no longer operative. The Term D Loan shall become due and payable on the earliest of (i) the
termination of the Term D Draw Period, (ii) the Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole
of the Term Loans. If the Company achieves the Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term
E Draw Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#8217;s achievement
of the Term E Milestone, of the Company&#8217;s intent not to draw the full amount of the Term E Loan, a non-utilization fee with respect
to the Term E Loan shall become due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date,
(iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective
Date, the Company shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;R
Loan Agreement, provided the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least
seven business days prior to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance
with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid
interest thereon through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that
are due and payable, including, without limitation, Lenders&#8217; Expenses and interest at the Default Rate with respect to any past
due amounts. At May 30, 2024, the Company recognized the Final Fee of $<span id="xdx_902_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEokQVdWVgg" title="Final fee"><ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001314" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million as additional debt principal and a corresponding debt
discount to be amortized over the life of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the funding of each of the Term C Loan and the Term D Loans, the Company agreed to issue to Innovatus and Oxford
warrants to purchase that number of shares of the Company&#8217;s common stock equal to <span id="xdx_90E_ecustom--WarrantOrRightToPurchasePercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z9QKeCu0Rqj5" title="Warrant or right, reason for issuance, description"><ix:nonFraction name="CELC:WarrantOrRightToPurchasePercentage" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% of the principal amount of the applicable
Term Loan divided by the exercise price, which was, with respect to the Term C Loan, equal to the lower of (i) the volume weighted average
closing price of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding
the execution of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of
the A&amp;R Loan Agreement. Accordingly, on May 30, 2024, the Company issued <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYJwbrXD19a" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,876</ix:nonFraction></span> warrants with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLKOP0uhNOqd" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.84</ix:nonFraction></span> per share.
The relative fair value of the warrants was approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z34miiz2AUQd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember" id="Fact001322" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million. For the Term D Loans, the exercise price was based on the lower
of (i) the exercise price for the warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the Term D Loan funding.
Prior to the Third Amendment, the Company also was required to issue warrants to Innovatus and Oxford in connection with the funding
of the Term E Loan and the Term F Loan. The warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the applicable funding date. The number of shares of common stock for which each warrant is exercisable and the associated exercise
price are subject to certain proportional adjustments as set forth in such warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the change of terms under ASC 470-50, <i>Debt &#8211; Modification and Extinguishment</i> with respect to the Third
Amendment, the Second Amendment, the First Amendment and the A&amp;R Loan Agreement and concluded the change in terms did not result
in significant and consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not
an extinguishment of the debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001324" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zRG7JCSbpWeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable, non-current consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z2DbeMGS5Xk4" style="display: none">Schedule of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zovM67dRbgB8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0n0LvfZYN2g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_maLTNPzDBl_z9vpQiPRdoU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-12-31" id="Fact001326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinalFee_iI_pn3n3_maLTNPzDBl_z9QoO55Wjuah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2025-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:FinalFee" contextRef="AsOf2024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentInKindInterestDebt_iI_pn3n3_maLTNPzDBl_zOKlikdS4cy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PaymentInKindInterestDebt" contextRef="AsOf2025-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PaymentInKindInterestDebt" contextRef="AsOf2024-12-31" id="Fact001333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">593</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTNPzDBl_zQ8GVUbVYhH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2025-12-31" id="Fact001335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,619</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,614</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msLTNPzDBl_zWisoCvbjpP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2025-12-31" id="Fact001338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,401</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,752</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermNotesPayable_iTI_pn3n3_mtLTNPzDBl_zhySW4epDuT4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2025-12-31" id="Fact001341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">126,527</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97,727</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zy0Ns2H2k1Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the fair value of the note payable, which differs from its carrying value, is determined using the Company&#8217;s estimated discount rate, volatility and risk-free rate, which are
considered Level 3 inputs. As of December 31, 2025, the fair value of the note payable was $<span id="xdx_907_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20251231_zObChx03k3lj" title="Fair value of note payable"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="AsOf2025-12-31" id="Fact001344" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">160.2</ix:nonFraction></span> million. As of December 31, 2024,
the carrying value of the note payable approximates the fair value (Level 3 inputs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt issuance costs and discount will be amortized to interest expense over the term of the Notes based on the effective interest rate
method. As of December 31, 2025 and 2024, the effective interest rate was <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231_z5NK4KBMyZF1" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-12-31" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.7</ix:nonFraction></span>% and <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231_zoLlJxpyCHTe" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.3</ix:nonFraction></span>%, respectively. During the year ended December
31, 2025, interest expense related to the note payable was $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zHG7f7XZ4Bz1" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2025-01-01to2025-12-31" id="Fact001350" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.4</ix:nonFraction></span> million, including $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231_zVPTkV0YThQl" title="Discount amount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-12-31" id="Fact001352" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million related to discount amortization. During
the year ended December 31, 2024, interest expense related to the note payable was $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zF3j1K1oiFRa" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31" id="Fact001354" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.3</ix:nonFraction></span> million, including $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231_zYqUrMtQBuN4" title="Discount amount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31" id="Fact001356" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million related to discount
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001358" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgSteUrovpbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, future principal payments, including the incurred PIK interest and Final Fee, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zJ98d1GXjbx8" style="display: none">Schedule of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_z38QyhHt3cta" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz4sG_zhGh6N4oAla4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%; text-align: left">2028</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2025-12-31" id="Fact001360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,899</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz4sG_zRWKrlbGtgT2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2025-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz4sG_zw5BHz5Etjnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2025-12-31" id="Fact001364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137,547</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zQ0kF1vKCqJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company was in full compliance with all financial covenants of the Amended A&amp;R Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001366" name="CELC:LicenseAgreementTestBlock"><p id="xdx_80F_ecustom--LicenseAgreementTestBlock_zjuBp8wM44Rh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82E_zgNWyvHu0vg6">License Agreement</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) to research, develop, manufacture
and commercialize gedatolisib. During 2021, the Company paid $<span id="xdx_909_eus-gaap--PaymentsForFees_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember_zbc509plt2Q9" title="Payment for upfront fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember" id="Fact001368" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million in upfront fees and
issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqYm3BxcJfIc" title="Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-04-08_custom_PfizerLicenseAgreementMember_us-gaap_CommonStockMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">349,406</ix:nonFraction></span> shares of the Company&#8217;s common stock to Pfizer pursuant to an Equity Grant Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $<span id="xdx_907_ecustom--AggregateValueOfMilestoneEvents_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z0tKV2Vzsji1" title="Aggregate value of milestone events"><ix:nonFraction name="CELC:AggregateValueOfMilestoneEvents" contextRef="From2021-04-082021-04-08_custom_LicenseAgreementMember_srt_MaximumMember" id="Fact001372" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">335.0</ix:nonFraction></span> million. One of these milestone events requires a $<span id="xdx_90D_ecustom--PaymentOnMilestoneEventOne_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zflpqQkHfooa" title="Payment on milestone event one"><ix:nonFraction name="CELC:PaymentOnMilestoneEventOne" contextRef="From2021-04-082021-04-08_custom_LicenseAgreementMember" id="Fact001374" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million payment within 60 days following the FDA
regulatory filing of a New Drug Application (&#8220;NDA&#8221;) for gedatolisib. The FDA granted the Company&#8217;s request to submit
its NDA via the FDA&#8217;s Real-Time Oncology Review (&#8220;RTOR&#8221;) program, and the Company completed its final NDA submission
to the FDA in November 2025. The Company recorded the $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseMilestone_pn5n6_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0l1FXNmv5Sf" title="Research and development expense"><ix:nonFraction name="CELC:ResearchAndDevelopmentExpenseMilestone" contextRef="From2025-06-012025-06-30_custom_LicenseAgreementMember" id="Fact001376" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million NDA filing milestone as research and development expense in June 2025.
As of December 31, 2025, this amount was included in other accrued expenses on the Company&#8217;s balance sheets. Additionally, the
Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject
to deductions for expiration of valid patent claims, amounts due under third-party licenses and generic competition. Unless earlier terminated,
the license agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country
basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration
of all regulatory or data exclusivity in such country for such product, or (c) the date upon which the manufacture, use, sale, offer
for sale or importation of such product in such country would no longer infringe, but for the license granted in the license agreement,
a valid claim of a licensed patent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the license agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001378" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zB4ycJKhnbT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_82D_zaFnGuP0iiS1">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20250101__20251231_ztRlKSeyVz8i" title="Income tax benefit::XDX::-"><span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20240101__20241231_zKRqlBujv4eh" title="Income tax benefit::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1380"><span style="-sec-ix-hidden: xdx2ixbrl1382">No</span></span></span></span>
income tax benefit was recorded during the years ended December 31, 2025 and 2024, due to net losses and recognition of a valuation allowance.
The following table, which reflects the Company&#8217;s retrospective adoption of ASU 2023-09, presents a reconciliation of the
U.S. federal statutory rate to the Company&#8217;s effective tax rate, including the amount (in thousands):</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001384" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB3xO0XQqI93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zXKuzL1MbR" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zUwDHxk8jng3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zoWNkiNcVURl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_ziebyqsOJc92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001386" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37,179</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20250101__20251231_zL63fZk0dl26" title="Tax benefit at statutory rate, percentage" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001387" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,474</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20240101__20241231_z6cRILfVTY7" title="Tax benefit at statutory rate, percentage" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_zgqX4NFo0xvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20250101__20251231_zDpqV0uM4qG" title="State income tax benefit, net of federal tax effect, percentage" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001394" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20240101__20241231_zVzAFXxTxCve" title="State income tax benefit, net of federal tax effect, percentage" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1398">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zhml9Ekrhf68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001400" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20250101__20251231_zOmMd2nRCly4" title="Federal change in valuation allowance on deferred tax assets, percentage" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20240101__20241231_zdb0sY3vq3m6" title="Federal change in valuation allowance on deferred tax assets, percentage" style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21.3</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zax8rep7fNze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Federal research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2025-01-01to2025-12-31" id="Fact001407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,358</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20250101__20251231_zH4mnEAzRpyc" title="Federal research and development credits, percentage" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2025-01-01to2025-12-31" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2024-01-012024-12-31" id="Fact001408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">982</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20240101__20241231_zTw96vKP64D2" title="Federal research and development credits, percentage" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2024-01-012024-12-31" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzqmi_zrZMhgxG5O75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior year adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001414" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">343</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20250101__20251231_znonAdPmj3L8" title="Prior year adjustments, percentage" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20240101__20241231_zsnyNadTXYgi" title="Prior year adjustments, percentage" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzqmi_zwRyp2LG002a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-deductible items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">645</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20250101__20251231_zpePl9cUOEnf" title="Non-deductible items, percentage" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2024-01-012024-12-31" id="Fact001422" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20240101__20241231_zl13fGkZpJ7j" title="Non-deductible items, percentage" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2024-01-012024-12-31" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zojvmUBQFXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20250101__20251231_zK8BpRcZ8NZc" title="Income tax expense (benefit), percentage" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20240101__20241231_zfOpLpICZWM" title="Income tax expense (benefit), percentage" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zj8MHAkAjtU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted, introducing a series of corporate tax changes in the
U.S., including 100% bonus depreciation on qualified property and full expensing of domestic research and development expenditures.
The impacts of OBBBA are reflected in our results of operations during the year ended December 31, 2025. OBBBA did not have a
material impact on the Company&#8217;s effective income tax rate and its net deferred tax assets as the Company maintains a full
valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets (liabilities) reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to
its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, <i>Income Taxes</i>, the
Company recorded a valuation allowance to fully offset the net deferred tax assets as of December 31, 2025 and 2024, because it is more
likely than not that the Company will not realize future benefits associated with these deferred tax assets. The tax effects of temporary
differences and carryforwards that give rise to significant portions of the deferred tax assets (liabilities) were (in thousands):</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001435" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUFrOLm4Vzyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zre4SKsiI4lb" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zcIYmg432i63" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zkrhoV03I3be" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gross deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzhJd_zln8t7ZgwkH3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-left: 9pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2025-12-31" id="Fact001437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">253</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact001438" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhJd_zoB2sDFjTEq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-12-31" id="Fact001440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,861</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhJd_ze93AiysZFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact001443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzhJd_zIUU6WviV2zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:DeferredTaxAssetsRightofuseAssets" contextRef="AsOf2025-12-31" id="Fact001446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:DeferredTaxAssetsRightofuseAssets" contextRef="AsOf2024-12-31" id="Fact001447" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsLeaseLiability_iNI_di_msDTAGzhJd_zHeeNCWYlM17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001449" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001450" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_maDTAGzhJd_zzn3WiI5NEjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Section 174 expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" contextRef="AsOf2025-12-31" id="Fact001452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" contextRef="AsOf2024-12-31" id="Fact001453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_maDTAGzhJd_zhY8OqeXuK6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" contextRef="AsOf2025-12-31" id="Fact001455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" contextRef="AsOf2024-12-31" id="Fact001456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzhJd_zEFoI7g1VCQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Net operating losses and tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001458" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,483</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhJd_maDTALNzwuF_zYguL3PnOq6d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact001461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001462" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzwuF_zgvG9dZHx7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact001464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,281</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,214</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzwuF_zSgkTYACRlLb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zw4nMVGVelI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had federal and state net operating loss carryforwards of $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_z5bfEfY9SMh2" title="Federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2025-12-31" id="Fact001470" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">83.3</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zbDIeqydPvd6" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2025-12-31" id="Fact001472" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million, respectively.
The federal and state net operating loss carryforwards for 2017 will begin to expire during the year ending December 31, 2037. The federal
net operating loss carryforwards starting in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance
as of December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had federal and state research and development tax credit carryforwards resulting in deferred tax assets
of $<span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwvpU8Y4FgWg" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember" id="Fact001474" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zpHnSKFDCzx4" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001476" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million, respectively. The federal and state credit carryforwards will begin to expire during the years ending
December 31, 2038 and December 31, 2033, respectively. These deferred tax assets were subject to a full valuation allowance as of December
31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of Section 382 of the Internal Revenue Code of 1986, certain substantial changes in the Company&#8217;s ownership, including
a sale of the Company, or significant changes in ownership due to sales of equity, may limit in the future the amount of net operating
loss carryforwards available to offset future taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes uncertain tax positions in accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that
the tax positions will be sustained upon examination by tax authorities. For those tax positions that meet the more-likely-than not recognition
threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate
settlement. As of December 31, 2025 and 2024, the Company had <span id="xdx_90A_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20251231_zddnx6RfG1X4" title="Uncertain tax positions"><span id="xdx_902_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20241231_zwwzxLDpgCZd" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="AsOf2025-12-31" id="Fact001478" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="AsOf2024-12-31" id="Fact001480" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> significant uncertain tax positions. There are <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_zE7mnCpCYX09" title="Unrecognized tax benefits"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20241231_ztnBIQiKME3j" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2025-12-31" id="Fact001482" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact001484" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized tax benefits
included on the balance sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be
a significant change in unrecognized tax benefits within the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is no longer subject to U.S. federal income
tax examinations for years before 2022, although carryforward attributes that were generated before 2022 may still be adjusted upon examination
if used in a future period. State income tax statutes vary by jurisdiction. In most states in which the Company operates, the statute
of limitations remains open for four years, and accordingly, the Company is generally no longer subject to state income tax examinations
for years before 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax
positions as a component of general and administrative expenses. As of December 31, 2025, the Company had <span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20251231_zWrCQwo0An2f" title="Accrued interest or penalties"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="AsOf2025-12-31" id="Fact001486" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> accrued interest or penalties
and no amounts were recognized in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company made state tax payments which were deemed immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001488" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zXsOXkjyedj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_824_zCWQNwrnbswh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2026, the Company filed a new registration statement and accompanying prospectus supplement, which increased the aggregate
offering amount under the Open Market Sale Agreement to $<span id="xdx_903_ecustom--AggregateOfferingAmount_pn5n6_c20260109__20260109__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRP6AY2JAHV" title="Aggregate offering amount"><ix:nonFraction name="CELC:AggregateOfferingAmount" contextRef="From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember" id="Fact001490" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">400.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_81F_zba4AhKzu4Ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_012"></span>ITEM
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_013"></span>ITEM
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures as of December 31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures
of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and
forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required
disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the evaluation of our disclosure controls and procedures as of December 31, 2025, our Chief Executive Officer and Chief Financial
Officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management
Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934. Management has assessed the effectiveness of our internal control over financial
reporting as of December 31, 2025 based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(&#8220;COSO &#8211; 2013&#8221;) in Internal Control-Integrated Framework. Based on this assessment, our Chief Executive Officer and
Chief Financial Officer concluded that our system of internal control over financial reporting was effective as of such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to our designation
as a small reporting company or SRC and Non-Accelerated filer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes to our system of internal control over financial reporting during the three months ended December 31, 2025 that have
materially affected, or are reasonably likely to materially affect, our system of internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_014"></span>ITEM
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eecd--MtrlTermsOfTrdArrTextBlock_c20251001__20251231_zKqV8JsiJigf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" escape="true" id="Fact001491" name="ecd:MtrlTermsOfTrdArrTextBlock">On
<span><span id="xdx_904_eecd--TrdArrAdoptionDate_c20251001__20251231_zDiVZPjSgOVk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" id="Fact001492" name="ecd:TrdArrAdoptionDate">December 8, 2025</ix:nonNumeric></span></span>, Oncology Diagnostic &amp; Drug Development Consulting LLC, an entity controlled by <span id="xdx_901_eecd--TrdArrIndName_c20251001__20251231_zszfvE2Zlq3i" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" id="Fact001493" name="ecd:TrdArrIndName">Richard E. Buller</ix:nonNumeric></span>, <span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbT_c20251001__20251231_zIJLl0FNZMma" title="Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleantrue" id="Fact001495" name="ecd:Rule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></span> a 10b5-1
plan for the sale of up to <span id="xdx_901_eecd--TrdArrSecuritiesAggAvailAmt_iI_c20251231_zr5hNgUfzYic" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonFraction name="ecd:TrdArrSecuritiesAggAvailAmt" contextRef="AsOf2025-12-31" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000</ix:nonFraction></span> shares of Celcuity Inc. common stock beginning March 18, 2026 through <span id="xdx_902_eecd--TrdArrExpirationDate_c20251001__20251231_zdPLoHFgwEAk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" id="Fact001497" name="ecd:TrdArrExpirationDate">December 23, 2026</ix:nonNumeric></span>.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2025, none of our other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) <span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbT_c20251001__20251231_zlnQJXf3ME9h" title="Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleantrue" id="Fact001499" name="ecd:Rule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></span></span>
or <span id="xdx_903_eecd--Rule10b51ArrTrmntdFlag_dbF_c20251001__20251231_zg7l4eGSQkWd" title="Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90C_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20251001__20251231_zFm8IEuebln7" title="Rule 10b51 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001501" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001503" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined
in Item 408 of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_015"></span>ITEM
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_016"></span><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_017"></span>ITEM
10. Directors, Executive Officers and Corporate Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding our executive officers is included in Part I, Item 1 of this Annual Report under the caption &#8220;Information About Our Executive
Officers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a Code of Ethical Business Conduct that applies to our directors, officers and employees. In addition,
our CEO, CFO and other senior financial officers of the company are subject to a Code of Ethical Business Conduct for Senior Financial
Officers. These codes are available on the corporate governance section of our website (which is a subsection of the investor relations
section of our website) at the following address: www.celcuity.com. We intend to disclose on our website any amendments or waivers to
these codes that are required to be disclosed by SEC or Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information required by this Item 10 will be contained in our definitive proxy statement for our 2026 Annual Meeting of Stockholders
(the &#8220;Definitive Proxy Statement&#8221;) under the captions &#8220;Corporate Governance&#8221; and &#8220;Meetings and Committees
of the Board of Directors&#8221; and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_018"></span>ITEM
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 11 will be contained in the Definitive Proxy Statement under the captions &#8220;Corporate Governance,&#8221;
&#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_019"></span>ITEM
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 12 will be contained in the Definitive Proxy Statement under the captions &#8220;Beneficial Ownership
of Common Stock&#8221; and &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; and is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_020"></span>ITEM
13. Certain Relationships and Related Transactions, and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 13 will be contained in the Definitive Proxy Statement under the captions &#8220;Corporate Governance&#8221;
and &#8220;Certain Relationships and Related Transactions&#8221; and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_021"></span>ITEM
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 14 will be contained in the Definitive Proxy Statement under the caption &#8220;Proposal No. 2, Ratification
of Appointment of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_022"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_023"></span>ITEM
15. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_026">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_027">Balance Sheets &#8211; December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_028">Statements of Operations &#8211; Years ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_029">Statements of Changes in Stockholders&#8217; Equity &#8211; Years ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_030">Statements of Cash Flows &#8211; Years ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_031">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Exhibit Index immediately following the signature page hereto, which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_024"></span>ITEM
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_025"></span><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 26, 2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CELCUITY
    INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian F. Sullivan</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below constitutes and appoints Brian F. Sullivan and Vicky Hahne as the undersigned&#8217;s true and lawful
attorneys-in fact and agents, each acting alone, with full power of substitution and resubstitution, for the undersigned and in the undersigned&#8217;s
name, place and stead, in any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto,
and other documents in connection therewith, with the Securities and Exchange Commission, granted unto said attorneys-in-fact and agents,
each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and
about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming
all said attorneys-in-fact and agents, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done
by virtue thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 28%"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 51%"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 17%; vertical-align: bottom"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian F. Sullivan</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vicky Hahne</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
    Hahne</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance G. Laing</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Science Officer, Vice President and Secretary, and </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    G. Laing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard E. Buller</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    E. Buller</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dave F. Dalvey</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
    F. Dalvey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Leo T. Furcht</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leo
    T. Furcht</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Polly A. Murphy</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polly
    A. Murphy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard J. Nigon</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    J. Nigon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Charles R. Romp</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles
    R. Romp</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELCUITY
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex2-1.htm" style="-sec-extract: exhibit">Form of Plan of Conversion (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224040594/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Incorporation of the Company, as amended, including the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 9, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex3-2.htm" style="-sec-extract: exhibit">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm" style="-sec-extract: exhibit">Specimen Certificate representing shares of common stock of Celcuity Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registered Securities.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-9.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Units of Membership Interest issued by Celcuity LLC to Cedar Point Capital, LLC, as placement agent of membership units and unsecured convertible promissory notes of Celcuity LLC (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex42.htm" style="-sec-extract: exhibit">Form of Warrant issued by Celcuity Inc. to Innovatus Life Sciences Lending Fund I, LP in connection with the Loan and Security Agreement dated April 8, 2021 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex41.htm" style="-sec-extract: exhibit">Equity Grant Agreement, dated April 7, 2021, between the Company and Pfizer Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant to Purchase Common Stock issued by Celcuity Inc. in connection with the Securities Purchase Agreement, dated October 18, 2023 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex4-3.htm" style="-sec-extract: exhibit">Form of Amendment to Placement Agent&#8217;s Warrants, dated February 13, 2024 (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex4-5.htm" style="-sec-extract: exhibit">Form of Amendment to Warrants to Purchase Shares of Common Stock, dated February 13, 2024 (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Stock issued by Celcuity Inc. in connection with the Amended and Restated Loan Agreement, dated May 30, 2024 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 30, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225021739/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 31, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225021894/ex4-1.htm" style="-sec-extract: exhibit">Indenture, dated as of August 1, 2025, between Celcuity Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225021894/ex4-2.htm" style="-sec-extract: exhibit">First Supplemental Indenture, dated as of August 1, 2025, between Celcuity Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225021894/ex4-2.htm" style="-sec-extract: exhibit">Form of Certificate Representing the 2.750% Convertible Senior Notes due 2031 (included as Exhibit A in Exhibit 4.12 above).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Stock issued by Celcuity Inc. in connection with the Third Amendment to Amended and Restated Loan and Security Agreement, dated September 9, 2025 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 10, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-1.htm" style="-sec-extract: exhibit">Celcuity Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225011273/ex10-1.htm" style="-sec-extract: exhibit">Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 16, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223016627/ex10-1.htm" style="-sec-extract: exhibit">Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 12, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-3.htm" style="-sec-extract: exhibit">Form of Stock Option Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-4.htm" style="-sec-extract: exhibit">Form of Restricted Stock Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-5.htm" style="-sec-extract: exhibit">Form of Restricted Stock Unit Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-6.htm" style="-sec-extract: exhibit">Form of Stock Appreciation Rights Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-7.htm" style="-sec-extract: exhibit">Celcuity LLC 2012 Equity Incentive Plan, adopted August 10, 2012, as amended by First Amendment to the Celcuity LLC 2012 Equity Incentive Plan, adopted November 12, 2015 (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-8.htm" style="-sec-extract: exhibit">Form of Unit Option Agreement pursuant to the Celcuity LLC 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-size: 10pt">10.10</span></td>
    <td style="width: 0.1in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex10-11.htm" style="-sec-extract: exhibit">Commercial Lease, dated September 28, 2017, between West Glen Development I, LLC and Celcuity, LLC (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495420008729/celc_ex103.htm" style="-sec-extract: exhibit">Commercial Lease, First Amendment to Lease, dated July 28, 2020, between West Glen Development I, LLC and the Company (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex104.htm" style="-sec-extract: exhibit">Commercial Lease, Second Amendment to Lease, dated July 19, 2021, between West Glen Development I, LLC and the Company (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222020778/ex10-1.htm" style="-sec-extract: exhibit">Commercial Lease, Third Amendment to Lease, dated July 27, 2022, by and between West Glen Development I, LLC and the Company (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2022).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223007785/ex10-1.htm" style="-sec-extract: exhibit">Commercial Lease, Fourth Amendment to Lease, dated March 13, 2023, by and between West Glen Development I, LLC and the Company (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on March 15, 2023).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-13.htm" style="-sec-extract: exhibit">Clinical Trial Agreement, dated May 8, 2017, by and between NSABP Foundation, Inc. and Celcuity LLC (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421001743/celc_ex1015.htm" style="-sec-extract: exhibit">Amendment No. 1, Clinical Trial Agreement for FB-12 Phase II Study, by and between NSABP Foundation, Inc and the Company, dated October 15, 2020 (incorporated by reference Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 16, 2021).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.17+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-14.htm" style="-sec-extract: exhibit">Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Brian F. Sullivan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.18+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-15.htm" style="-sec-extract: exhibit">Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Lance G. Laing (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.19+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-16.htm" style="-sec-extract: exhibit">Confidentiality, Non-Compete, and Proprietary Rights Agreement, dated May 17, 2017, between Celcuity LLC and Vicky Hahne (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.20</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex10-17.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement between the Company and each of its officers and directors (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.21&#8224;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex103.htm" style="-sec-extract: exhibit">License Agreement, dated April 8, 2021, by and between the Company and Pfizer Inc. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.22&#8224;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex105.htm" style="-sec-extract: exhibit">Amendment No. 1 to License Agreement, dated May 6, 2021, by and between the Company and Pfizer Inc. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.23</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222003285/ex1-1.htm" style="-sec-extract: exhibit">Open Market Sale Agreement<sup>SM</sup>, dated February 4, 2022, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on February 4, 2022).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.24</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated May 15, 2022, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-size: 10pt">10.25</span></td>
    <td style="width: 0.1in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated May 15, 2022, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.26</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex102.htm" style="-sec-extract: exhibit">Loan and Security Agreement, dated as of April 8, 2021, by and between the Company and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.27</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Loan and Security Agreement, dated August 9, 2022, by and among the Company and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 11, 2022).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.28</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.29</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315223038005/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2023).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.30</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/ex10-1.htm" style="-sec-extract: exhibit">Second Amendment to Loan and Security Agreement, dated March 29, 2024, by and among the Company and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on March 29, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.31+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224018943/ex10-1.htm" style="-sec-extract: exhibit">Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 13, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.32+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex10-1.htm" style="-sec-extract: exhibit">Amendment to Form of Stock Option Agreement pursuant to Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.33+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224019974/ex10-2.htm" style="-sec-extract: exhibit">Form of Non-Qualified Stock Option Transfer Agreement pursuant to Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.34&#8224;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Loan and Security Agreement, dated May 30, 2024, by and among the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, and the Lenders named therein (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 30, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.35+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225001826/ex10-35.htm">Celcuity Inc. Change in Control and Severance Plan and Summary Plan Description (incorporated by reference to Exhibit 10.35 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 31, 2025).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.36+</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225011053/ex10-2.htm" style="-sec-extract: exhibit">Form of Stock Option Agreement (Performance-Based) pursuant to Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.37</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225011053/ex10-3.htm" style="-sec-extract: exhibit">First Amendment to Amended and Restated Loan and Security Agreement, dated May 13, 2025, by and among the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, the Lenders named therein and Oxford Finance LLC (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225021274/ex10-1.htm" style="-sec-extract: exhibit">Second Amendment to Amended and Restated Loan and Security Agreement, dated July 28, 2025, by and among the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, the Lenders named therein and Oxford Finance LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2025).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-size: 10pt">10.39&#8224;</span></td>
    <td style="width: 0.1in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/ex10-1.htm" style="-sec-extract: exhibit">Third Amendment to Amended and Restated Loan and Security Agreement, dated September 9, 2025, by and among the Company, Oxford Finance LLC, as collateral agent, the Lenders named therein and Innovatus Life Sciences Lending Fund I, LP (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 10, 2025).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.40+*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ex10-40.htm"><span style="font-size: 10pt">Form of Restricted Stock Unit Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">19*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex19.htm">Celcuity Inc. Policy to Prohibit Insider Trading.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">23.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex23-1.htm">Consent of Boulay PLLP.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">24.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="#sp_025">Power of Attorney (included on the signature page).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">31.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex31-1.htm">Certification of principal executive officer required by Rule 13a-14(a).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">31.2*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex31-2.htm">Certification of principal financial officer required by Rule 13a-14(a).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">32.1**</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of principal executive officer.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">32.2**</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex32-2.htm">Section 1350 Certification of principal financial officer.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">97</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315224011549/ex97.htm" style="-sec-extract: exhibit">Celcuity Inc. Policy for the Recoupment of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 27, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">101</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The following information from the Annual Report on Form 10-K of the Company for the year ended December 31, 2025, formatted, in Inline XBRL: (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Changes in Stockholders&#8217; Equity, (iv) the Statements of Cash Flows, (v) the Notes to Financial Statements, and (vi) the information under Part II, Item 9B &#8220;Other Information.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">+</span></td>
    <td><span style="font-size: 10pt">Management contract or compensatory plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#8224;</span></td>
    <td><span style="font-size: 10pt">Certain portions have been omitted from this exhibit.</span></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 98; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 54.7pt; text-align: justify; text-indent: -27.35pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: right"></p>





























































<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJwdjsEKwjAQRO+C/7DkrE3RW28FRQSRQr8gbbdpMM3WTWLUr9f0Nsy8GUbUw2CCIacs3FSH1oudmEJYKilTSsW7Y1sQa3koy6NksihfyB15XGmx3Yjo91qppWoD9Y+r9xGHU2TjdINsaGgnxejvmNYoz2ehXI9AI/Q0z+TA5y74FYVA0IzmiwxL5IyGbCkH52c04QMXzlatGXFGF/4ffjrLRoY= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Registrant&rsquo;s Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Pursuant to Section 12 of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934, as amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the terms of our capital stock is subject to and qualified in its entirety by reference to our certificate of incorporation,
as amended, and bylaws, copies of which are on file with the SEC as exhibits to previous SEC filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, Celcuity Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and the &ldquo;Company&rdquo;) had one class
of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;): common
stock, par value $0.001 per share. In addition, we have certain equity interests outstanding that are convertible into common stock,
which are described in more detail below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we were authorized to issue 95,000,000 shares of common stock and 2,500,000 shares of preferred stock, $0.001 par
value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fully
Paid and Nonassessable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding shares of our common stock are fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available
for that purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
and Preferences</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Right
to Liquidation Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction
of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent and Registrar</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company. The transfer agent and registrar&rsquo;s
address is One State Street Plaza, 30th Floor, New York, NY 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Nasdaq Capital Market</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on The Nasdaq Capital Market under the symbol &ldquo;CELC&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is authorized, without action by the stockholders, to designate and issue up to an aggregate of 2,500,000 shares of
preferred stock in one or more series. Our board of directors is authorized to designate the rights, preferences and privileges of the
shares of each series and any of its qualifications, limitations or restrictions. Our board of directors is able to authorize the issuance
of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common
stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and
other corporate purposes, could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting
the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change
in control of the Company, which might harm the market price of our common stock. See also &ldquo;Anti-Takeover Effect of Delaware Law
and Certain Charter and Bylaw Provisions&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2022, in connection with a Securities Purchase Agreement, dated May 15, 2022, by and among the Company and the Investors named
therein (the &ldquo;2022 Investors,&rdquo; and such Securities Purchase Agreement, the &ldquo;2022 Securities Purchase Agreement&rdquo;),
the Company filed a Certificate of Designations (the &ldquo;Certificate of Designations&rdquo;) with the Secretary of State of the State
of Delaware, designating 1,850,000 shares out of the authorized but unissued shares of its preferred stock as Series A Convertible Preferred
Stock (&ldquo;Series A Preferred Stock&rdquo;). No shares of Series A Preferred Stock remained outstanding as of December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2025
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Third Amendment, dated September 9, 2025 (the &ldquo;Third Amendment&rdquo;) to the Amended and Restated Loan and Security Agreement
(the &ldquo;A&amp;R Loan Agreement&rdquo;), by and among the Company, Oxford Finance LLC (&ldquo;Oxford&rdquo;), as collateral agent,
and the Lenders named therein, including Oxford in its capacity as a Lender and Innovatus Life Sciences Lending Fund I, LP (&ldquo;Innovatus&rdquo;),
pursuant to which Oxford and Innovatus, as Lenders, have made or agreed to make certain term loans, including the Term D Loan (as such
term is defined in the A&amp;R Loan Agreement, as amended by the Third Amendment (the &ldquo;Amended A&amp;R Loan Agreement&rdquo;))
to the Company, the Company issued to Oxford and Innovatus warrants (the &ldquo;2025 Warrants&rdquo;) to purchase an aggregate of 50,537
shares of common stock <FONT STYLE="background-color: white">with an exercise price of $14.84 per share. The 2025 Warrants may be exercised
on a cashless basis and are exercisable through the tenth anniversary of the funding date of the Term D Loan. The number of shares of
common stock for which each 2025 Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments
as set forth in such 2025 Warrant.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2025
Pre-Funded Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Underwriting Agreement, dated July 30, 2025, by and among the Company, and Jefferies LLC, TD Securities (USA) LLC, and Leerink Partners
LLC as representatives (the &ldquo;Underwriting Agreement&rdquo;), the Company issued pre-funded warrants (the &ldquo;2025 Pre-Funded
Warrants&rdquo;) to purchase up to 400,000 shares of common stock. Each 2025 Pre-Funded Warrant to purchase one share was sold for a
purchase price of $37.999 per 2025 Pre-Funded Warrant and has an exercise price of $0.001 per share (for aggregate consideration equating
to $38.00 per share of common stock issuable upon exercise of the 2025 Pre-Funded Warrants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2025 Pre-Funded Warrant may be exercised on a cashless basis and is immediately exercisable and will not expire. Under the terms of the
2025 Pre-Funded Warrants, the Company may not effect the exercise of any such 2025 Pre-Funded Warrant, and a holder will not be entitled
to exercise any portion of any 2025 Pre-Funded Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common
stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group
together with the holder or any of the holder&rsquo;s affiliates, and any other persons whose beneficial ownership of common stock would
or could be aggregated with the holder&rsquo;s or any of the holder&rsquo;s affiliates for purposes of Section 13(d) or Section 16 of
the Exchange Act) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the
Securities and Exchange Commission (the &ldquo;Maximum Percentage&rdquo;). A holder may reset the Maximum Percentage to a higher or lower
percentage (not to exceed 19.99%), effective 61 days after written notice to the Company. Any such increase or decrease will apply only
to that holder and not to any other holder of 2025 Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2024
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the A&amp;R Loan Agreement, pursuant to which Innovatus and Oxford, as Lenders, have agreed to make certain term loans, including the
Term C Loan, the Term D Loan, the Term E Loan, and the Term F Loan (as such terms are defined in the A&amp;R Loan Agreement and, each,
a &ldquo;Term Loan&rdquo;) to the Company, the Company issued to Innovatus and Oxford warrants (the &ldquo;2024 Warrants&rdquo;) to purchase
that number of shares of common stock equal to <FONT STYLE="background-color: white">2.5% of the principal amount of the applicable Term
Loan divided by the exercise price, which was, with respect to the Term C Loan, equal to the lower of (i) the volume weighted average
closing price of the Company&rsquo;s common stock for the five-trading day period ending on the last trading day immediately preceding
the execution of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of
the A&amp;R Loan Agreement. Accordingly, on May 30, 2024, the Company issued 103,876 2024 Warrants with an exercise price of $14.84 per
share. The 2024 Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary of the applicable funding
date. The number of shares of common stock for which each 2024 Warrant is exercisable and the associated exercise price are subject to
certain proportional adjustments as set forth in such 2024 Warrant.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2023
Pre-Funded Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Securities Purchase Agreement, dated October 18, 2023, by and among the Company and the Investors named therein (the &ldquo;2023
Investors,&rdquo; and such Securities Purchase Agreement, the &ldquo;2023 Securities Purchase Agreement&rdquo;), the Company issued pre-funded
warrants (the &ldquo;2023 Warrants&rdquo;) to purchase 5,747,787 shares of common stock. Each 2023 Warrant to purchase one share was
sold for a purchase price of $8.699 per Warrant and has an exercise price of $0.001 per share (for aggregate consideration equating to
$8.70 per share of common stock issuable upon exercise of the 2023 Warrants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2023 Warrant is immediately exercisable and will not expire. Under the terms of the 2023 Warrants, the Company may not effect the exercise
of any such 2023 Warrant, and a holder will not be entitled to exercise any portion of any 2023 Warrant, if, upon giving effect to such
exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons
acting or who could be deemed to be acting as a group together with the holder or any of the holder&rsquo;s affiliates, and any other
persons whose beneficial ownership of common stock would or could be aggregated with the holder&rsquo;s or any of the holder&rsquo;s
affiliates for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed the Maximum Percentage. A holder may reset the
Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company, or a lower percentage,
effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and not to any
other holder of 2023 Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2023
Registration Rights Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2023 Securities Purchase Agreement, the Company entered into a Registration Rights Agreement (the &ldquo;2023 Registration
Rights Agreement&rdquo;) with the 2023 Investors, pursuant to which the Company agreed to register for resale the Registrable Securities
(the &ldquo;2023 Registrable Securities&rdquo;), which include: (i) the shares of common stock then issued or issuable upon exercise
of the 2023 Warrants (assuming the 2023 Warrants are exercisable in full without regard to any exercise limitation therein) (the &ldquo;2023
Warrant Shares&rdquo;), and (ii) any other securities issued or issuable with respect to, in exchange for or in replacement of, the 2023
Warrant Shares issued and sold pursuant to the 2023 Securities Purchase Agreement. Under the 2023 Registration Rights Agreement, the
Company agreed to file a registration statement covering the resale by the 2023 Investors of the 2023 Registrable Securities no later
than 30 days following the Closing Date (as defined in the 2023 Registration Rights Agreement). The Company agreed to use commercially
reasonable efforts to cause the registration statement to become effective and to keep such registration statement effective until such
time as there are no longer 2023 Registrable Securities held by the 2023 Investors. The Company agreed to be responsible for all fees
and expenses incurred in connection with the registration of the 2023 Registrable Securities. The Company filed a registration statement
on Form S-3 registering for resale the 2023 Registrable Securities, which was declared effective on November 28, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the 2023 Investors customary indemnification rights in connection with the registration statement, including for liabilities
arising under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The 2023 Investors also granted the Company
customary indemnification rights in connection with the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2022
Registration Rights Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2022 Securities Purchase Agreement, the Company entered into a Registration Rights Agreement (the &ldquo;2022 Registration
Rights Agreement&rdquo;) with the 2022 Investors, pursuant to which the Company agreed to register for resale the Registrable Securities
(the &ldquo;2022 Registrable Securities&rdquo;), which include: (i) the common stock, (ii) the shares of common stock then issued or
issuable upon conversion of the Series A Preferred Stock (assuming on such date the shares of Series A Preferred Stock are convertible
in full without regard to any conversion limitations in the Certificate of Designations), and (iii) the common stock then issued or issuable
upon exercise of the 2022 Warrants (assuming the 2022 Warrants are exercisable in full without regard to any exercise limitations therein).
Under the 2022 Registration Rights Agreement, the Company agreed to file a registration statement covering the resale by the 2022 Investors
of the 2022 Registrable Securities no later than 30 days following (i) the Closing Date (as defined in the 2022 Registration Rights Agreement)
and (ii) the date the Company obtained the necessary stockholder approval to increase the aggregate authorized number of shares of capital
stock and the number of shares of common stock such that the Company had available, and had reserved, such number of its duly authorized
but unissued shares of common stock as shall be sufficient to effect the conversion of all shares of Series A Preferred Stock then outstanding
or available for issuance upon the exercise of the 2022 Warrants. The Company agreed to use commercially reasonable efforts to cause
the registration statement to become effective and to keep such registration statement effective until such time as there are no longer
2022 Registrable Securities held by the 2022 Investors. The Company agreed to be responsible for all fees and expenses incurred in connection
with the registration of the 2022 Registrable Securities. The Company filed a registration statement on Form S-3 registering for resale
the 2022 Registrable Securities, which was declared effective on January 11, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted the 2022 Investors customary indemnification rights in connection with the registration statement, including for liabilities
arising under the Securities Act. The 2022 Investors also granted the Company customary indemnification rights in connection with the
registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in each of the 2025 Warrants, the 2025 Pre-Funded Warrants, the 2024 Warrants, the
2023 Warrants, the Third Amendment, the A&amp;R Loan Agreement, the Underwriting Agreement, the 2023 Securities Purchase Agreement, the
2022 Securities Purchase Agreement, the 2023 Registration Rights Agreement and the 2022 Registration Rights Agreement were made solely
for the benefit of the parties thereto and may be subject to limitations agreed upon by the contracting parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effect of Delaware Law and Certain Charter and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, as amended, and bylaws contain provisions that could have the effect of discouraging potential acquisition
proposals or tender offers or delaying or preventing a change of control of our Company. A summary of these provisions is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
    of directors vacancies. </I></B>Our bylaws authorize only our board of directors to fill vacant directorships, including newly created
    seats. In addition, the number of directors constituting our board of directors will be permitted to be set only by a resolution
    adopted by our board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors
    and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult
    to change the composition of our board of directors but promotes continuity of management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
    notice requirements for stockholder proposals and director nominations.</I></B> Our bylaws provide advance notice procedures for
    stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors
    at our annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s
    notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from
    making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. These provisions
    may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate
    of directors or otherwise attempting to obtain control of the Company.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
    cumulative voting.</I></B> The Delaware General Corporation Law, or DGCL, provides that stockholders are not entitled to the right
    to cumulate votes in the election of directors unless a corporation&rsquo;s certificate of incorporation provides otherwise. Our
    certificate of incorporation, as amended, does not provide for cumulative voting.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
    action; special meetings of stockholders.</I></B> Our certificate of incorporation, as amended, provides that our stockholders may
    not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder
    controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of
    our stockholders called in accordance with our bylaws. Further, our bylaws provide that special meetings of our stockholders may
    be called only by a majority of our board of directors, the chairperson of our board of directors, or our Chief Executive Officer,
    thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
    consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
    of directors.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issuance
    of undesignated preferred stock.</I></B> We have 650,000 shares of undesignated preferred stock. Our board of directors has the authority,
    without further action by the stockholders, to issue this preferred stock with rights and preferences, including voting rights, designated
    from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our
    board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer,
    proxy contest or other means.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
    of charter and bylaw provisions.</I></B> The affirmative vote of stockholders representing at least two-thirds of the voting power
    of all then-outstanding capital stock is required to amend, alter or repeal certain provisions of our certificate of incorporation,
    as amended, including the provision noted above regarding stockholders not being able to act by written consent. A majority of our
    board of directors has authority to adopt, amend or repeal provisions of our bylaws. Stockholders also have the authority to adopt,
    amend or repeal provisions of our bylaws, but only with the affirmative vote of stockholders representing at least two-thirds of
    the voting power of all then-outstanding capital stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware
corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three
years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rdquo; includes a merger, asset sale or other transaction
resulting in a financial benefit to the interested stockholder, and an &ldquo;interested stockholder&rdquo; is a person who owns 15%
or more of the voting stock of a corporation, or any affiliate or associate of a corporation who, within three years prior, did own 15%
or more of the voting stock of that corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>3
<FILENAME>ex10-40.htm
<DESCRIPTION>EX-10.40
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0cm">Exhibit 10.40</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CELCUITY
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017
STOCK INCENTIVE PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESTRICTED
STOCK UNIT AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
RESTRICTED STOCK UNIT AGREEMENT (&ldquo;<U>Agreement</U>&rdquo;) is entered into as of the &ldquo;<U>Grant Date</U>&rdquo; set forth
below, by and between Celcuity Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;) and the person named below (the &ldquo;<U>Participant</U>&rdquo;).
The Award granted hereby is granted under the Celcuity Inc. 2017 Stock Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). Unless otherwise
defined herein, terms used in this Agreement that are defined in the Plan will have the meanings given to them in the Plan.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">1. <U>Grant of Award</U>.
The Company hereby grants to the Participant a restricted stock unit award (the &ldquo;<U>Award</U>&rdquo;) for the number of restricted
stock units (the &ldquo;<U>Units</U>&rdquo;) set forth below, on the terms and conditions set forth herein, and subject to the terms
and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of
the Plan and the terms and conditions of this Agreement, the terms and conditions of the Plan will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
Number:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU-______________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
    Commencement Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Number of Restricted Stock Units Subject to the Award:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________
    Units</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Unit represents the right to receive one share of the Company&rsquo;s Common Stock (&ldquo;<U>Shares</U>&rdquo;). The Units granted to
the Participant will be credited to an account in the Participant&rsquo;s name maintained by the Company. This account shall be unfunded
and maintained for book-keeping purposes only, with the Units simply representing an unfunded and unsecured obligation of the Company.
The Units subject to this Award will be subject to the restrictions set forth in Section 2 of this Agreement and will be subject to forfeiture
for the period and on the terms and conditions set forth in Section 3 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">2. <U>Non-Transferability</U>. Neither
this Award nor the Units subject to this Award may be sold, transferred, assigned, pledged or otherwise encumbered or disposed of other
than by will or by the laws of descent or distribution. The Units and the Participant&rsquo;s right to receive Shares in Settlement of
the Units will be subject to forfeiture as provided in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">3. <U>Vesting of Restricted Stock Units</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt">(a) <U>Vesting</U>.
The Units will remain subject to forfeiture until vested as provided herein. The Units will vest, and the risk of forfeiture will lapse,
<I>[insert vesting schedule]</I>; <I>provided</I>, <I>however</I>, that if the Participant ceases to provide services to the Company
before this Award has become vested with respect to all of the Units, no additional Units will vest after the termination of such services.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt">(b) <U>Treatment Upon
a Change in Control</U>. In the event of a Change in Control of the Company, the Committee administering the Plan may take any of the
actions described in Section 14 of the Plan with respect to this Award.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt">(c) <U>Accelerated
Vesting upon Death or Disability</U>. If the Participant ceases to provide services to the Company by reason of the Participant&rsquo;s
death or Disability before this Award has become vested with respect to all of the Units, all unvested Units will vest as of such termination
date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 72pt">(d) <U>Termination
of Service Relationship</U>. If the Participant ceases to provide services to the Company for any reason other than death or disability
before this Award has become vested with respect to all of the Units, the Participant will immediately forfeit all unvested Units without
any payment therefor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt">4. <U>Settlement of
Units</U>. After any Units vest pursuant to Section 3, the Company will, as soon as practicable, and no later than the March 15 of the
year following the year that such Units vest, cause to be issued and delivered to the Participant, or to the Participant&rsquo;s designated
beneficiary or estate in the event of the Participant&rsquo;s death, one Share in payment and settlement of each vested Unit. Delivery
of the Shares will be effected by issuance of one or more stock certificates issued in the Participant&rsquo;s name, by a book-entry
in the Participant&rsquo;s name with the Company&rsquo;s transfer agent, or by the electronic delivery of the Shares to a brokerage account
designated by the Participant, and shall be subject to the tax withholding provisions of Section 5 and shall be in complete satisfaction
and settlement of such vested Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">5. <U>Tax Consequences and Withholding</U>.
No Shares will be delivered to the Participant in settlement of vested Units unless the Participant has made arrangements acceptable
to the Company for payment of any federal, state, local or foreign withholding taxes that may be due as a result of the delivery of the
Shares (&ldquo;<U>Withholding Taxes</U>&rdquo;). Specifically, pursuant to the Grant Notice and this Section 5, Participant hereby agrees
to a &ldquo;same day sale&rdquo; commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &ldquo;<U>FINRA
Dealer</U>&rdquo;) as Participant&rsquo;s agent (the &ldquo;<U>Agent</U>&rdquo;) whereby the Agent is irrevocably authorized to sell
a portion of the Shares to be issued on a vesting date necessary to satisfy the Withholding Taxes and whereby the FINRA Dealer will forward
the proceeds necessary to satisfy the Withholding Taxes directly to the Company. If, for any reason, such &ldquo;same day sale&rdquo;
commitment pursuant to this Section 5 does not result in sufficient proceeds to satisfy the Withholding Taxes or would be prohibited
by applicable law at the applicable time, Participant authorizes the Company to satisfy the obligations with regard to all Withholding
Taxes by one or a combination of the following: (a) withholding from any compensation otherwise payable to Participant by the Company;
(b) causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted
by the Company); or (c) withholding a number of whole Shares having a fair market value, as determined by the Company as of the date
on which the Withholding Taxes obligations arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">6. <U>Section 409A</U>. This Award is intended
to be exempt from Section 409A of the Code under the short-term deferral exception specified in Treas. Reg. &sect;1.409A-l(b)(4), and
to the maximum extent permitted this Agreement will be interpreted and administered in accordance with this intent. Each amount to be
paid or benefit to be provided under this Agreement shall be construed as a separate and distinct payment for purposes of Section 409A.</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">7. <U>No Shareholder Rights</U>. The Units
subject to this Award do not entitle the Participant to any rights of a shareholder of the Company&rsquo;s Common Stock. The Participant
will not have any of the rights of a shareholder of the Company in connection with the grant of Units subject to this Agreement unless
and until Shares are issued to the Participant upon settlement of the Units as provided in Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">8. <U>NO GUARANTEE
OF CONTINUED SERVICE</U>. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF UNITS PURSUANT TO THE VESTING SCHEDULE IN THIS
AGREEMENT IS EARNED ONLY BY CONTINUING AS AN EMPLOYEE, DIRECTOR, OR CONSULTANT AT THE WILL OF THE COMPANY (AND NOT THROUGH THE ACT OF
BEING HIRED OR BEING GRANTED AN AWARD). THE PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED
HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS AN EMPLOYEE,
DIRECTOR, OR CONSULTANT FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE WITH THE PARTICIPANT&rsquo;S RIGHT
OR THE COMPANY&rsquo;S RIGHT TO TERMINATE THE PARTICIPANT&rsquo;S RELATIONSHIP (A) AS AN EMPLOYEE AT ANY TIME, WITH OR WITHOUT CAUSE;
(B) AS A CONSULTANT PURSUANT TO THE TERMS OF THE PARTICIPANT&rsquo;S AGREEMENT WITH THE COMPANY OR AN AFFILIATE; OR (C) AS A DIRECTOR
PURSUANT TO THE BYLAWS OF THE COMPANY AND ANY APPLICABLE PROVISIONS OF THE CORPORATE LAW OF THE STATE OR OTHER JURISDICTION IN WHICH
THE COMPANY IS DOMICILED, AS THE CASE MAY BE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt">9. <U>Entire Agreement;
Governing Law</U>. The Plan is incorporated herein by reference. The Plan and this Agreement constitute the entire agreement of the parties
regarding the acquisition of stock in the Company and supersede in their entirety all prior oral and written undertakings and agreements
of the Company and the Participant on that subject, with the exception of any other Awards previously granted and delivered to the Participant
under the Plan or any similar plan maintained by the Company or its Affiliates. This Agreement may not be modified adversely to the Participant&rsquo;s
interest except by means of a writing signed by the Company and the Participant. This Agreement is governed by the internal substantive
laws but not the choice of law rules of the State of Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
page to Restricted Stock Unit Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
the Participant&rsquo;s signature and the signature of the Company&rsquo;s representative below, the Participant and the Company agree
that this Award is granted under and governed by the terms and conditions of the Plan and this Agreement. The Participant has reviewed
the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement
and fully understands all provisions of the Plan and Agreement. The Participant hereby agrees to accept as binding, conclusive and final
all decisions or interpretations of the Board of Directors (or any Committee to whom the Board has delegated administration of the Plan)
upon any questions relating to the Plan and this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
a condition to acceptance of this Award, to the fullest extent permitted under the Plan, Section 5 of this Agreement and applicable law,
Participant acknowledges that Withholding Taxes will be satisfied through the sale of a number of Shares issued on the settlement of
vested Units and the remittance of the cash proceeds to the Company. The Company is authorized and directed by the Participant, to make
payment from the cash proceeds of this sale directly to the appropriate taxing authorities in an amount equal to the taxes required to
be withheld. The mandatory sale of Shares to cover Withholding Taxes is imposed by the Company on the Participant in connection with
the receipt of this Award, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be
interpreted to meet the requirements of Rule 10b5-1(c). </B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Participant further agrees to notify the Company of any change in the Participant&rsquo;s residence address indicated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Signature)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
    Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16305
    36th Avenue N., Suite 100</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
    MN 55446</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLICY
TO PROHIBIT INSIDER TRADING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Amended &amp; Restated February 12, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy to Prohibit Insider Trading (the &ldquo;<B>Insider Trading Policy</B>&rdquo; or the &ldquo;<B>Policy</B>&rdquo;) provides guidelines
for directors, officers, employees, or other representatives of Celcuity Inc. (&ldquo;<B>Celcuity</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;)
who may have access to material non-public information about the Company or its customers, suppliers and other business partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal securities laws and Company policy prohibit transactions in Company Securities at a time when you may be in possession of material
information about the Company that has not been publicly disclosed. &ldquo;<B>Company Securities</B>&rdquo; means the Company&rsquo;s
common stock, options to purchase common stock, or any other type of securities that the Company may issue, including (but not limited
to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as
exchange-traded put or call options or swaps relating to the Company&rsquo;s Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are similarly prohibited from buying or selling securities of Company customers, suppliers or other business partners when you have received,
through your employment or other relationship with the Company, material non-public information about such customers, suppliers or business
partners. These prohibitions also apply to members of your household as well as all others whose transactions may be attributable to
you. Anyone who violates these prohibitions can face severe civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Material
information</B>&rdquo; is any information that a reasonably prudent investor would consider to be important in making a decision to buy
or sell a security. It specifically includes any information that would affect the public market price for the Company&rsquo;s common
stock. Either positive or negative information may be material. Once a public announcement has been made of the material information,
you should wait at least 24 hours following the announcement before engaging in any market trade of Company stock (e.g., announcement
at 10:00 a.m. on Monday, trade after 10:00 a.m. on Tuesday; announcement at 2:00 p.m. on Friday, trade after 2:00 p.m. on Monday), assuming
at the time of the transaction you do not have other material information that has not been made public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
laws and Company policy also prohibit disclosure of material non-public information except on a need-to-know basis. Even if you are not
engaging in any stock trading activity, you must not disclose material information to others, especially to those outside the Company.
This information is owned by the Company and must be protected as such. <B>Any questions from brokers, securities analysts or the media
regarding the Company should be directed to the Chief Executive Officer, the Chief Financial Officer, or the General Counsel.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is only a summary. Please refer to the entire Insider Trading Policy set forth below for additional restrictions and requirements. If
you have any questions about this Policy or your ability to share information or engage in a transaction involving Company Securities,
please contact our General Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Insider
Trading Policy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Need for an Insider Trading Policy</B>: The Company&rsquo;s stock is publicly-traded; therefore, the Company is required to take active
steps to prevent violations of insider trading laws by Company personnel, and members of the Board of Directors (each, a &ldquo;<B>Director</B>&rdquo;).
Although insider trading has long been illegal, over the years Congress has expanded the enforcement authority of the Securities and
Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) and the Justice Department, increased substantially the penalties for insider trading,
and created potential liability for companies and other &ldquo;controlling persons,&rdquo; such as directors and managers, for violations
by anyone under their supervision, influence or control. We are adopting this Insider Trading Policy to protect the Company and its Directors
and personnel from liability and reputational harm, and to avoid even the appearance of improper conduct on the part of anyone employed
by or associated with Celcuity (because anyone with material non-public information could be considered an &ldquo;insider&rdquo;). We
cannot afford to have our reputation for integrity and ethical conduct damaged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Consequences</B>: The consequences of insider trading violations can be severe. For individuals who trade on inside information (or tip
information to others), the consequences can include a civil penalty of up to three times the profit gained or loss avoided, a criminal
penalty (no matter how small the profit) of up to $5 million, and a prison sentence of up to 20 years. For a company (as well as possibly
any supervisory person) that fails to take appropriate steps to prevent illegal trading, the consequences can include a civil penalty
of the greater of $1 million or three times the profit gained or loss avoided as a result of the individual&rsquo;s violation, and a
criminal penalty of up to $25 million. In addition, any employee or consultant who violates this Policy faces discipline or even termination
of employment for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the above consequences, even an SEC investigation that does not result in prosecution, can tarnish one&rsquo;s reputation and irreparably
damage a career. Regulators use sophisticated surveillance techniques to identify transactions that may appear illegal, so you should
assume that any suspicious trading activity, even if it is through foreign accounts or family members or friends or relates to only a
small number of shares, will be detected and vigorously prosecuted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration
of the Policy</B>: Our General Counsel will administer the Policy, provided that with respect to the General Counsel, the Chief Financial
Officer will administer the Policy. All determinations by such individuals will be final and not subject to further review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Policy</B>: It is the policy of the Company that no Director, employee or other Company personnel (including contractors) who is aware
of material non-public information relating to the Company (so-called &ldquo;inside&rdquo; information of a nature which could affect
the Company&rsquo;s stock price or affect an investor&rsquo;s decision to buy or sell the Company Securities) may, directly or indirectly
through family members or other persons or entities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engage
                                            in any transaction in Company Securities (including sales, purchases and bona fide gifts),
                                            unless this Policy provides a specific exception;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommend
                                            that others engage in transactions in Company Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclose
                                            material non-public information to persons within the Company whose jobs do not require them
                                            to have that information, or outside of the Company to anyone; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engage
                                            in any other action to take advantage of material non-public information, including assisting
                                            anyone engaged in the above activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small
transactions, and transactions that may be necessary or justifiable for independent reasons (such as the need to sell Company stock to
raise money for an emergency expenditure), are no exception. The securities laws do not recognize any mitigating circumstances, and even
the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
                                            Information</U>. Material information is any information that a reasonable investor would
                                            consider important in a decision to buy, hold or sell securities. In short, any information
                                            that could reasonably affect a company&#8217;s stock is deemed to be &#8220;material.&#8221;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Examples</U>.
                                            Common examples of information that will frequently be regarded as material are: projections
                                            of future earnings or losses; changes in projections which have been made public, news of
                                            a pending or proposed merger, acquisition, or tender offer; news of a significant product
                                            development or clinical trial results; changes in dividend policies, the declaration of a
                                            stock split or the offering of additional securities; changes in management; impending bankruptcy
                                            or financial liquidity problems; significant licensing or collaboration agreements; significant
                                            cybersecurity incidents or other significant disruptions in our business, reputation or assets;
                                            and the gain or loss of a substantial customer, supplier or other business partner. This
                                            is not an exhaustive list. Either positive or negative information may be material.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&#8220;Non-public&#8221;
                                            Information</U>. As you can appreciate, it is also improper for Company personnel to enter
                                            a trade immediately after Celcuity has made a public announcement of material information,
                                            including earnings releases. Because Company stockholders and the investing public should
                                            be afforded the time to receive the information and act upon it, as a general rule you should
                                            not engage in any transactions until at least 24 hours after the information has been released.
                                            Thus, if an announcement is made at 10:00 a.m. on Monday, after 10:00 a.m. on Tuesday generally
                                            would be the first time you should trade, assuming you do not have other material information
                                            that has not been made public. If an announcement is made at 2:00 p.m. on Friday, the first
                                            time trading would be permitted would generally be after 2:00 p.m. on the following Monday.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>20/20
                                            Hindsight</U>. Remember, if your securities transactions become the subject of scrutiny,
                                            they will be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
                                            in any securities transaction, you should carefully consider how regulators and others might
                                            view your transaction in hindsight.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
                                            by Dependents &amp; Household Members</U>. This Policy also applies to anyone living in your
                                            household (other than an unrelated person who the applicable Administrator of this Policy
                                            determines should not be covered by this Policy) and anyone financially dependent upon you
                                            or whose transactions in Company Securities are directed by you or are subject to your influence
                                            or control, even if they do not live in your household (such as parents, siblings or adult
                                            children who consult with you before they trade in Company Securities). Company personnel
                                            are expected to be responsible for compliance by their dependents and personal household,
                                            and you should treat all transactions by such persons as if the transactions were for your
                                            own account.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy does not, however, apply to personal securities transactions of family members, financial dependents, or household members where
the purchase or sale decision is made by a third party not controlled by, influenced by, or related to you or your family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
                                            by Entities That You Influence or Control.</U> This Policy applies to any entities that you
                                            influence or control, including any corporations, partnerships or trusts (collectively referred
                                            to as &#8220;<B>Controlled Entities</B>&#8221;), and transactions by these Controlled Entities
                                            should be treated for the purposes of this Policy and applicable securities laws as if they
                                            were for your own account. However, nothing in this Policy is intended to limit the ability
                                            of a venture capital partnership or other similar entity with which a director is affiliated
                                            to distribute Company Securities to its partners, members or other similar persons. It is
                                            the responsibility of each affected Director and the affiliated entity, in consultation with
                                            their own counsel (as appropriate), to determine the timing of any distributions, based on
                                            all relevant facts and circumstances and applicable securities laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosing
                                            Information to Others</U>. Whether the information is proprietary information about the Company
                                            or one of its customers, suppliers or other business partners, or information that could
                                            have an impact on the market price of the Company&#8217;s or its customer&#8217;s, supplier&#8217;s
                                            or other business partner&#8217;s stock, Company personnel must not pass the information
                                            on to others. The above penalties apply whether or not you derive any benefit from another&#8217;s
                                            actions. In order to prevent unintentional disclosure, all inquiries and requests for information
                                            regarding the Company or the Company&#8217;s customers, suppliers or other business partners
                                            (e.g., from the media, stockbrokers or securities analysts) should be referred to our General
                                            Counsel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy also applies to information relating to any other organization, including our customers, suppliers, and other business partners,
and organizations that are involved in a potential transaction or business relationship with the Company, obtained in the course of your
employment or other relationship with Celcuity. For example, you must keep information about that other company confidential and cannot
engage in transactions in that other company&rsquo;s securities if you are aware of non-public information that is material to that company.
Note that what constitutes &ldquo;material non-public information&rdquo; differs by company. Information that is not material to Celcuity
may be material to another company. Please consult with our General Counsel if you have any questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exceptions</B>:
This Policy does not apply to the following transactions, except as specifically noted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            exercise of stock options, except this Policy <B>does apply</B> to both the cashless exercise
                                            of such options and open market sales of shares acquired through the exercise of any options.
                                            Furthermore, stock option exercises are subject to the terms of the Company&#8217;s governing
                                            stock option plans and any agreements entered into between the Company and the holders of
                                            such options.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            purchase of Company Securities under the Company&#8217;s employee stock purchase plan resulting
                                            from the periodic contribution of money to the plan pursuant to a payroll deduction election,
                                            including any decision to terminate contributions made during any pay period, except that
                                            this Policy <B>does apply</B> to the sale of Company Securities purchased pursuant to the
                                            employee stock purchase plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            initial election to participate in the employee stock purchase plan for any enrollment period
                                            or any modifications following such initial election (i.e., to increase or decrease the contributions
                                            made during any pay period), if such election or modification was made at a time when the
                                            Covered Person does not possess material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            purchase of Company Securities in the Company&#8217;s 401(k) plan resulting from the periodic
                                            contribution of money to the plan pursuant to a payroll deduction election. This Policy <B>does
                                            apply</B>, however, to certain elections you may make under the 401(k) plan, including: (a)
                                            an election to increase or decrease the percentage of your periodic contributions that will
                                            be allocated to the Company Securities fund; (b) an election to make an intra-plan transfer
                                            of an existing account balance into or out of the Company Securities fund; (c) an election
                                            to borrow money against your 401(k) plan account if the loan will result in a liquidation
                                            of some or all of your Company Securities fund balance; and (d) an election to pre-pay a
                                            plan loan if the pre-payment will result in the allocation of loan proceeds to the Company
                                            stock fund. It should be noted that sales of Company Securities from a 401(k) account are
                                            also subject to Rule 144, and therefore &#8220;affiliates&#8221; of the Company (typically
                                            officers and Directors) should ensure that a Form 144 is filed when required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            other purchase of Company Securities from the Company or sales of Company Securities to the
                                            Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Prohibited Transactions: </B>Celcuity prohibits Company personnel from engaging in any of the following activities with respect to Company
Securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
                                            in Company Securities on a short-term basis</U>. Any Company stock purchased in the open
                                            market must be held for a minimum of six months. Subject to the terms of the applicable awards,
                                            stock received from the Company as a compensatory equity award that is registered with the
                                            SEC on a Form S-8 need not be held for six months and can be sold at any time, assuming you
                                            do not have any material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Margin
                                            accounts and pledged securities</U>. This Policy prohibits holding Company Securities in
                                            a margin account or otherwise pledging Company Securities as collateral for a loan. Securities
                                            held in a margin account as collateral for a margin loan may be sold by the broker without
                                            the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities
                                            pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower
                                            defaults on the loan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hedging
                                            Transactions.</U> This Policy prohibits engaging in any hedging transactions with respect
                                            to Company Securities. Hedging transactions include transactions for which the value of the
                                            trade is tied to the value of Company Securities. Examples are put options, call options,
                                            and other derivative and financial instruments such as prepaid variable forwards, equity
                                            swaps, collars and exchange funds. Such transactions may permit a director, officer or employee
                                            to continue to own Company Securities obtained through employee benefit plans or otherwise,
                                            but without the full risks and rewards of ownership. When that occurs, the director, officer
                                            or employee may no longer have the same objectives as the Company&#8217;s other shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short
                                            Sales.</U> This Policy prohibits short sales of Company Securities. Short sales (i.e., the
                                            sale of a security that the seller does not own) may evidence an expectation on the part
                                            of the seller that the securities will decline in value, and therefore have the potential
                                            to signal to the market that the seller lacks confidence in the Company&#8217;s prospects.
                                            In addition, short sales may reduce a seller&#8217;s incentive to seek to improve the Company&#8217;s
                                            performance. Section 16(c) of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange
                                            Act</B>&#8221;), also prohibits officers and directors from engaging in short sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standing
                                            and Limit Orders.</U> Standing and limit orders (except standing and limit orders under approved
                                            Rule 10b5-1 Plans, as described below) create heightened risks for insider trading violations
                                            similar to the use of margin accounts. There is no control over the timing of purchases or
                                            sales that result from standing instructions to a broker, and as a result the broker could
                                            execute a transaction when a director, officer or other employee is in possession of material
                                            non-public information. The Company therefore discourages placing standing or limit orders
                                            on Company Securities. If a person subject to this Policy determines that they must use a
                                            standing order or limit order, the order should be limited to short duration and should otherwise
                                            comply with the restrictions and procedures outlined below under the heading &#8220;Trading
                                            Windows and Advance Notice Procedure for Directors, Executive Officers and Certain Other
                                            Key Employees.&#8221; In addition, if you are a Covered Person under this Policy, you should
                                            inform any broker with whom you place a standing or limit order of that designation at the
                                            time the order is placed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Windows and Advance Notice Procedure for Directors, Executive Officers and Certain Other Key Employees</B>: Because the Company&rsquo;s
directors, executive officers and certain other key employees listed below (the &ldquo;<B>Covered Persons</B>&rdquo;) have regular access
to material non-public information, this Policy requires that such persons comply with the trading window and advance notice procedures
described below for all transactions in Company Securities. A &ldquo;<B>Covered Person</B>&rdquo; is any of the following persons subject
to this Policy: (a) all executive officers and Directors of Celcuity Inc., (b) all administrative assistants supporting executive officers,
(c) all members of the senior management team of Celcuity, (d) those persons within Celcuity identified by the Company&rsquo;s General
Counsel as a Covered Person for purposes of this Insider Trading Policy, and (e) if they are otherwise subject to this Policy, the household
members, dependents and Controlled Entities of the individuals identified in (a), (b), (c), or (d) of this sentence. The Company may
amend the list from time to time as it deems necessary to add or subtract from the list of Covered Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading window and advance notice procedures are not applicable to employees other than the Covered Persons. However, even if you are
not subject to these additional restrictions, you should exercise caution when engaging in transactions outside of the trading window
because of the heightened risk that those transactions will attract regulatory scrutiny and may expose you to accusations of improper
behavior.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
Window</U>: Transactions in Company Securities by Covered Persons will be restricted to certain window periods following the end of each
quarter. The window during which trades generally will be permitted, provided such trades comply with advance notice procedures (see
below) and provided you possess no material non-public information, will begin 24 hours (not including weekends and other non-business
days) after the public release of all material information with respect to the financial results of the most recently completed quarter
and will end at the close of market on the 15th day of the third month following the end of the most recent fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Event-Specific
Restricted Periods</U>: From time to time, there may be a material event that is known only to certain Covered Persons. In such instances,
to avoid the appearance of impropriety, the General Counsel, together with the Chief Financial Officer, may not allow any Covered Persons
to engage in transactions in Company Securities, regardless of whether the trading window is open. The General Counsel also has discretion
to close the trading window early in any particular quarter. In either of these situations, the General Counsel may notify Covered Persons
that they should not trade in Company Securities, without disclosing the reason for the restriction. The existence of an event-specific
restricted period or shortening of the trading window will not be announced to the Company as a whole and should not be communicated
to any other person. Even if the General Counsel has not designated you as a person who should not trade due to an event-specific restriction,
you should not trade while aware of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pre-Clearance
of Transactions</U>: To provide assistance in avoiding even the appearance of an improper transaction (which could result, for example,
where a person engages in a trade while unaware of a pending major development), all transactions in Company Securities by &ldquo;Covered
Persons&rdquo; (as defined above) must notify the General Counsel of the proposed transaction by submitting the Transaction Pre-Clearance
Form set forth in <U>Attachment 1</U>, as updated from time to time by the Company, and await pre-clearance from the General Counsel.
The pre-clearance request should be submitted at least two business days in advance of the proposed transaction and must be effected
within five business days of receipt of pre-clearance, unless an exception is granted. Covered Persons should also notify the General
Counsel once the pre-cleared transaction is completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-clearance will serve only to confirm the status of the trading window. Even if you receive pre-clearance of an open trading window
from the General Counsel, you are still prohibited under this Policy from effecting the transaction if you possess material non-public
information or it would violate any other provision of this Policy or any applicable securities law or regulation. Pre-clearance is not
a defense to a claim of insider trading and does not excuse you from otherwise complying with securities laws or this Policy. You may
want to consult outside counsel regarding the proposed transaction. Transactions by the General Counsel must receive pre-clearance by
the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rule
10b5-1 Plans and Exceptions</U>: The trading window restrictions and pre-clearance procedures set forth above do not apply to the transactions
to which this Policy does not apply, as described under the heading &ldquo;Exceptions.&rdquo; Further, the trading window restrictions,
event-specific restricted periods, and pre-clearance procedures do not apply to transactions conducted pursuant to a binding contract,
written plan or specific instruction that is adopted and operated in compliance with Rule 10b5-1(c) of the Exchange Act and is adopted
at a time when such Covered Person does not possess material non-public information, so long as the underlying contract, instruction
or plan also complies with the Company&rsquo;s Rule 10b5-1 Plan Guidelines set forth in <U>Attachment 2</U> (&ldquo;<B>Rule 10b5-1 Plan
Guidelines</B>&rdquo;). Any adoption, modification or termination of a Rule 10b5-1 Plan must be submitted to the General Counsel for
approval, at least five business days prior to entering into, modifying or terminating the Rule 10b5-1 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Covered Persons who enter into any written contract, plan, instruction or arrangement, including holders of certain Company
equity awards, such as restricted stock units, where the plan or instruction authorizes an agent to sell only such shares as are necessary
to satisfy the Company&rsquo;s tax withholding obligations arising exclusively from the vesting of the equity award, at a time that such
Covered Person is not aware of material non-public, which (i) specifies the amount of Company Securities to be purchased or sold and
the price at which and the date on which they are to be purchased or sold, or (ii) includes a written formula or algorithm to determine
those transactions, or (iii) does not permit the Covered Person to exercise any subsequent influence over the transactions, must also
(x) submit a request for approval at least five business days prior to entering into, modifying or terminating the contract, plan, instruction
or arrangement, even if it does not meet the specific criteria of Rule 10b5-1(c) or the Company&rsquo;s Rule 10b5-1 Plan Guidelines,
or (y) with respect to certain Company equity awards, otherwise comply with the process established by the Company&rsquo;s equity plan
administrator for such plan or instruction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Termination
Transactions:</B> This Policy continues to apply to transactions in Company Securities even after termination of service to the Company.
If an individual is in possession of material non-public information when his or her service terminates, that individual may not engage
in transactions in Company Securities until that information has become public or is no longer material. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification:
</B>Company personnel may be required from time to time to re-certify their understanding of and intent to comply with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Assistance: </B>Any person who has any general questions about this Policy or questions about specific transactions should contact the
General Counsel. Remember, however, the ultimate responsibility for adhering to this Policy and avoiding improper transactions rests
with <U>you</U>. In this regard, it is imperative that you use your best judgment and consult with your legal and financial advisors,
as needed. We advise you to seek assistance if you have any questions at all. The rules relating to insider trading can be complex, and
a violation can carry severe consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSACTION
PRE-CLEARANCE FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Covered Person: ________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Notice: ________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
Date of Transaction: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
describe the proposed transaction, including the type of transaction (purchase, sale, option exercise, gift, etc.), the number of shares,
and any third parties involved in the transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
list any transactions in the securities of Celcuity Inc. (&ldquo;Celcuity&rdquo;) in which you have engaged during the six months prior
to the date of this notice, including, but not limited to, purchases or sales in the open market, exercises of options or warrants, gifts,
or receipt of grants of restricted stock or other equity, <U>OR</U> if you have not had any such transactions in the preceding six months,
please so indicate by checking this box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of Transaction</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
check the following box to indicate that you are not in possession of material non-public information regarding Celcuity. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1pt; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
of Covered Person</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NOTICE:
This Form relates only to certain aspects of Celcuity&rsquo;s Policy to Prohibit Insider Trading. Pre-clearance by the Company only indicates
that a trading window is open. It does not indicate whether the transaction is allowable under applicable securities laws or Celcuity
policies. YOU are responsible for compliance with all applicable securities laws and Celcuity policies. You are encouraged to consult
outside counsel before engaging in the proposed transaction. Failure to receive pre-clearance at all or on a timely basis shall not give
rise to any claims against the General Counsel, Chief Financial Officer, Chief Executive Officer or Celcuity.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be completed by the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-cleared
    this ____ day of ______________, 20___.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt"></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
  </FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
  Counsel</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Attachment
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Celcuity
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Rule
10b5-1 Plan Guidelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), provides a defense from insider
trading liability if transactions occur pursuant to a plan that complies with the conditions set forth in Rule 10b5-1(c) of the Exchange
Act (a &ldquo;<B>Rule 10b5-1 Plan</B>&rdquo;). If the plan meets the requirements of Rule 10b5-1, transactions in Company Securities
may occur without regard to certain insider trading restrictions. In order to avoid a violation of securities laws and to comply with
the Celcuity Inc. Policy to Prohibit Insider Trading (the &ldquo;<B>Policy</B>&rdquo;), any person subject to the Policy that intends
to use a Rule 10b5-1 Plan must comply with these Rule 10b5-1 Guidelines. Please note that brokers may apply additional procedures, which
may be more stringent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is not aware of material non-public
information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price
at which they are to be traded or the date of the trade. The Rule 10b5-1 Plan must either specify the amount, pricing and timing of transactions
in advance or delegate discretion on these matters to an independent third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
specified in the Policy, a Rule 10b5-1 Plan must be approved by the General Counsel and meet the requirements of Rule 10b5-1 and these
Guidelines. Any Rule 10b5-1 Plan must be submitted for approval five business days prior to entering into, modifying or terminating the
Rule 10b5-1 Plan. Following approval of entry into the Rule 10b5-1 Plan, no further pre-approval of transactions conducted under the
Rule 10b5-1 Plan will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following guidelines apply to all Rule 10b5-1 Plans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            may enter into, modify or terminate a Rule 10b5-1 Plan only during a trading window. In addition,
                                            you may not enter into, modify or terminate a Rule 10b5-1 Plan during an event-specific restricted
                                            period or otherwise while you are aware of material non-public information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            otherwise determined by the General Counsel, all Rule 10b5-1 Plans must have a duration of
                                            at least 6 months and no more than 2 years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            officers and directors, no transaction may take place under a Rule 10b5-1 Plan until the
                                            later of (a) 90 days after adoption or modification (as specified in Rule 10b5-1) of the
                                            Rule 10b5-1 Plan or (b) two business days following the disclosure of the Company&#8217;s
                                            financial results in a Form 10-Q or Form 10-K for the fiscal quarter (the Company&#8217;s
                                            fourth fiscal quarter in the case of a Form 10-K) in which the Rule 10b5-1 Plan was adopted
                                            or modified (as specified in Rule 10b5-1). In any event, the cooling-off period is subject
                                            to a maximum of 120 days after adoption of the plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            persons other than officers and directors, no transaction may take place under a Rule 10b5-1
                                            Plan until 30 days following the adoption or modification (as specified in Rule 10b5-1) of
                                            a Rule 10b5-1 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to certain limited exceptions specified in Rule 10b5-1, you may not enter into more than
                                            one Rule 10b5-1 Plan at the same time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to certain limited exceptions specified in Rule 10b5-1, you are limited to only one &ldquo;single
                                            trade&rdquo; Rule 10b5-1 Plan during any 12-month period (i.e., a Rule 10b5-1 Plan designed
                                            to effect an open market purchase or sale of the total amount of securities subject to the
                                            Rule 10b5-1 Plan as a single transaction).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            must act in good faith with respect to a Rule 10b5-1 Plan. A Rule 10b5-1 Plan cannot be entered
                                            into as part of a plan or scheme to evade the prohibition of Rule 10b-5. Therefore, although
                                            modifications to an existing Rule 10b5-1 Plan are not prohibited, a Rule 10b5-1 Plan should
                                            be adopted with the intention that it will not be amended or terminated prior to its expiration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
                                            and directors must include a representation in the Rule 10b5-1 Plan at the time of its adoption
                                            or modification that (i) the person is not aware of material non-public information about
                                            the Company or Company Securities and (ii) the person is adopting the plan in good faith
                                            and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Company&rsquo;s officers and directors must make certain disclosures in SEC filings concerning Rule 10b5-1 Plans. Officers
and directors of the Company must undertake to provide any information requested by the Company regarding Rule 10b5-1 Plans for the purpose
of providing the required disclosures or any other disclosures that the Company deems to be appropriate under the circumstances. Each
director, officer and other Section 16 insider understands that the approval or adoption of a pre-planned selling program in no way reduces
or eliminates such person&rsquo;s obligations under Section 16 of the Exchange Act, including such person&rsquo;s disclosure and short-swing
trading liabilities thereunder. If any questions arise, such person should consult with their own counsel in implementing a Rule 10b5-1
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[For
use outside of Veeva.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby certifies that they have read and understand, and agree to comply with, Celcuity Inc.&rsquo;s Policy to Prohibit Insider
Trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 49%"></TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
  (please print)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued our report dated March 26, 2026, with respect to the financial statements included in the Annual Report of Celcuity Inc.
on Form 10-K for the year ended December 31, 2025. We hereby consent to the incorporation by reference in the Registration Statements
of Celcuity Inc. on Form S-8 (Reg. Nos. 333-287766, 333-279556, 333-271976, 333-270238, 333-265328, 333-256500, 333-253940, 333-238787,
and 333-221117) and on Form S-3 (Reg. No. 333-292646, 333-281887 and 333-275551).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><IMG SRC="ex23-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
Minnesota</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 26, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Brian F. Sullivan, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Celcuity Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 26, 2026</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian F. Sullivan</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: right; text-indent: -22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: right; text-indent: -22pt"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify; text-indent: -22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Vicky Hahne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Celcuity Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54.7pt; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 26, 2026</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Vicky Hahne</I></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky Hahne</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the filing of the Annual Report
on Form 10-K for the year ended December 31, 2025 (the &ldquo;Report&rdquo;) by Celcuity Inc. (the &ldquo;Registrant&rdquo;), I, Brian
F. Sullivan, the Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 26, 2026</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Brian F. Sullivan</I></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian F. Sullivan</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the filing of the Annual Report
on Form 10-K for the year ended December 31, 2025 (the &ldquo;Report&rdquo;) by Celcuity Inc. (the &ldquo;Registrant&rdquo;), I, Vicky
Hahne, the Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section
1350, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 26, 2026</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Vicky Hahne</I></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky Hahne</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "U D # 2(  A$! Q$!_\0
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M!\L,'">]6EI8;DD?1@Z4M,A_U2YY.*?3*"BBB@ HHHH **** "BBB@ HHHH
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ML_!&[ Q#J6.W_+H];&H?L@_M)ZCG=X9\&1@^FMN?_:==M^RY^R5\8_AU\?\
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M)&JJ_D8[\C'>B*3?*B[M*[/M?PYH.G^%=%L](TJRAT[3;.(0V]K;IMCB0#
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MX]S^9KZO_8:'_$M\9]\7%MC/./W;5\H9KZP_8:'_ !+?&GO<6W_HMJ5P.O\
MBU^T_#\)_&<OAV3PU-JS1V\5Q]I2\6('?NPNTJ>FT]ZX[_AN:V_Z$BX_\&*?
M_$5YS^U[_P EMN_^P=:_^U*\7I@?5W_#<UM_T)%Q_P"#%/\ XBD_X;HML_\
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M FI>(I8?M,EN8XK>WS@37$CJD2$]E+,,GTS7Z++!8:"YI(_G]8G$2GRIG/\
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M8R6M'FA2NMMW_F6O!?P G\9Z;->)K\5DL4QAV&U9\C&<YW<=:Z#_ (92N?\
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MW+HS>88BV,#.,9JT/?@UTWPT_P"1NM_^N4O_ *#55,KPBBVD*GC\2Y)-B?\
M#/UQ_P!#!#_X"M_\52'X 7"_\Q^'_P !'_\ BJ]CYH RP'0$@$XZ#/\ G\:\
M1X6@M;'K+$57I<\</[/]P&P=?AR.O^B-_P#%4Z+X!W-O()$\1(LB$$.MLP*L
M#P1\W:O-K7]H3Q;X?U[Q<VMW:R2:?::M>V^GO$GV"[BMVQ ;*5>793Q*&.<@
MUK6/Q=\;RZ'XGTZUDN=6U.PAT:^:^@M ]Q;VMZH:Y,<:CYVB7<47!./7%9^Q
MPSZ&KG76ESO-2^">K:O,)=0\6/>S !!+<PO(X7J!EG/TJI_PS]<?]#!#_P"
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M>C49/+TE0&N0,>;C/WJX36+/6M<U6\U&YTYUN+N5II1!#L3<3DD+VYK]%/\
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MN3-'";9C;RM$)8"03%(!]Y"0#CVJ#_A4>GGQ;%XB+:W]NB*&.W&HR"T0(NU
M(!\N%'0?C7Z0_P#"LO"O_0!LO^_0H_X5EX5_Z %E_P!^A6<LXDW=TE?YFT<N
MC%6YG8_/N\\*1:D]XUW9O<K=VQM)8Y,E?)/WD [ ]3ZD#TJKX5\!6O@NPEM-
M,M;D1RR&:22XD,LDC8VC+'T   [ 5^AW_"LO"O\ T ;+_OU1_P *S\*_] &R
M_P"_57_;53F34$9?V7"W+SL^"_L5SG_4/^5=#X!4Z?XG@GN<00B*3+R$ #(X
MK[3_ .%9>%?^@#9?]^A2'X8>$S_S +'_ +]"E+.JLH\O(@CE=.,N;F9\]_V]
MIW_/];_]_!3EU_3E((OH,C_IH*^@O^%8^%/^@!8_]^J/^%8>$_\ H 6/_?JN
M)YA-Z.*.SZG'NSX[TSX2?#G2]1%V@-W'%#=6]K8WM[YMI8QW+%KA8(ND8<L<
M\GKQBMWP3X:\*> $NQI%ZYGN]@ENKR\\^=D1=L<>\_P(O"KVKZG_ .%7^$_^
M@!8_]^A1_P *P\*?] "Q_P"_0K/Z[)7Y8H;PJ>\F?(_B?X=>!?&&BZ=I>IR&
M2"P=WAFBO-DY+@B7?)U829._^]D]*["UU72+*VAMX+JVA@A18XXU<810,!1[
M "OH@?#'PG_T +'_ +]"C_A6/A3_ * %C_WZK19A--M16HOJD7NSY\&O:;WO
M[?\ [^"O5O@?>V]];ZP8)TG59(P2A!P<&NM_X5AX4_Z %C_WZ%:>B^%])\.+
M,NF6$%B)B#((5QN(Z9K&MBY5H.#2-(8:-.7,C4W#(&>32U\]_&?]IN\^%7CN
M7P_!X?AU%([:&X\][@H3OW<8 [;:XG_AN34_^A2MO_ MO_B:X#K/KJBOD3_A
MN34\@?\ ")6V3_T]M_\ $TO_  W)J>?^12MO_ MO_B: /KJBOD3_ (;DU/\
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M^_Z%FV&?^GEO\*KZ[A_Y@_U1SFU_9?C'_,^GO-7^\*!,A'#BOF'_ (:XOO\
MH6;?_P "6_PKM_A7\;KGXA7>I)-I,5D+5(W&R4MG<2,=/:M*>)HU9J$'JSBQ
MG#V9X"C+$8BG:*W=U^C/:0ZD=12[AZUS*^)F _X]Q_WU2_\ "4,/^7<?]]&N
M[V4UK8^:YEL=+N'K2;AZUS@\3MG_ (]U/T:D/BEL9^SJ1ZALTO93[!SQ9TNX
M>M&X>M<V?%#8'^CKSQ]Z@>)V(S]G4#_>I^RF+VD3I-P]:3</6N<_X2A_^?=?
M^^J/^$H?_GW7_OJCV4^P>TB=)N'K1N'K7-_\).__ #[K_P!]4'Q0X'_'NO\
MWW1[*?8/:1.DW#UHW#UKFQXI8Y_T<<?[5 \4-G'V<<_[5'LI![1'1[AGK2Y'
MJ*YH^*R.MNHX!Y;IFE/BAE.#;#/^]2]E/H/G1TFX>M&X>M<V/%#'_EW7_OJC
M_A*'_P"?=?\ OJG[*?87M(G2;AZT;AZUS8\4,?\ E@H]RU)_PE#$X^S GTW<
MT>RGV#GB=+D'O2;QZUS9\4G('D*#Z;J/^$H89_T=>.OS4>RD'M(G2[AZT;AZ
MUS?_  E#?\\%_P"^J/\ A*'_ .?=?^^J/93#VD3I P/0TM8^DZTVH7)C,03"
MYR#FMBLVG%V9:::NAI=0>H!I!(IQS7&_%;QG+\/O"=UKD-LMZ\+QIY#OM4[F
MQDD>E>(_\-<ZA@Y\-VQX_P"?EO\ "N2KB:5%VFSW<!D>89G2=;"T[Q3MNCZ@
M\U?44>8,]17S#_PUS?'C_A&+?.,X^TMT_*FM^US?#@>&[9/?[4<?RK+Z]A^D
MCTO]4LX6]'\5_F?4(8>HI#(H."17R^/VO+Y1_P BW;M]+EO\*7_AKJ^<\>&+
M?TYNCQ^E+Z_A[VYA_P"J6<_\^?Q7^9]/^8I[BD,J^HKYA_X:WOCDGPQ;X_Z^
M6_PI#^UO?JOR^&;;_P "6_PJOKV'_F#_ %2SB]O8Z^L?\SZ@$JG^(4N\>M>3
M_#+XP3^/=*N;Z32H[-H)S!M24L#P#GI[UV7_  E;_P#/NO\ WU75&I"<5*/4
M^?KX#$X>I*E4C:2T9TQD4=6%'F+_ 'A7,'Q2Y_Y=ES_O4?\ "4DD8MU_[ZHY
MS#ZM5['4;A1D5S0\5OC_ (]EX_VJ0^+6Z?9U!';=TI\Z']6J]CIMP]12;P.I
M%<U_PE<F?^/8?]]4+XFD=P/LZ@GCEJ:DF[(3P]5*[1TNX=<TN17SW<?M.7L-
MQ-&- @(21D!^T'G!(STIO_#4%\!_R+\'_@2?\*]%9?B6KJ)Y4L91B[2D?0V:
M,U\]/^U!?+G/A^#CK_I#<?I2']J"^''_  C\&?3[2?\ "J_L[%?R"^NT']H^
MA2P'4T>8OK7SS_PU!>L2/[ @XZC[01_2C_AI^]/3P_ ?^WAO\*I99BWM#\4/
MZY0[GT,'!Z&EW#.,U\\?\-/WP_Y@$ _[>#_A72?#[XZ7/C;Q7;Z1)I,=JLL<
MDGG"8L1M&<8Q6<\#B*<7*4=$..+I2ERIGL>:6JWVK_8IKWNP$[>V:X+,Z[EN
MDR*JB_!SA<XH^V\9"Y'J*$F,M9%&:J_;,D@+GKS3OM7^Q3LQ7+&12U5-U_L_
MK4L,WF \8Q19C/A;]KW_ )+==_\ 8.M?_:E>+U[[^U5X3US6_C'<W.G:/>WL
M!T^V7SH(2Z[AO^7/XUY%_P *[\5_]"WJ?_@,U(#"MY/+N86,<<H$BYCF7<A^
MH[BO</%O@#PW>ZIX/U_2=,M[/09[@6&JV$!(C^T+(@* 9XW[@=N1P#7F%OX"
M\66UQ',OAK4&:-@P5[0LI([$=Q[5TPO?B:'.W1KQ8C>)J!METT>2;A5PLFSI
MD=?KS3=K:;@EK=['8'1O#L?[1\_@L^$M$?13J*6^UK=MZ1^4&P#NP"6.<]:\
MG\>WMI+XAO+.STC3]*2SGF@7^SXRGG*'X++N(R .O%=4;[XFGQBWBO\ L2Y_
MM\CF[_LM>N,;MN,;L#&[K7/ZSX0\9Z]J=SJ%YX;O_M-P^^3R;(QJ6]=HX!J7
M>ZL/2S3.2_6E3)=?J.?QKH#\.O%6/^1;U/\ \!FI4^'?BH,O_%.ZERP S;MC
M.:4M4[%0=FGZ&L""2?4TN16I)X1UV&22(Z/>,R,5;$1."#R,TW_A%-=_Z U[
M_P!^37P\J4^9Z']6QQF&<5^\7WHRPWS 8Y_2O-O#NMZM)\8_&6AMJ5U<V%MI
MUK<VT%VPD6WDD+ D# ..!QFO7O\ A%-=# _V+>],_P"I-<S:?!.2S\2WNO1:
M#K*ZK?0^1<2F:0AX^0%"]!C)QCI6M*/)S<T>AP8RO"JZ;I5%HTW[R6FM^OH<
MS\/K7Q)9:SXFM]8UR7Q!I$<Z#3[NZC5)B^W]^!M &P-@#CM7<#'I6=X/^!P\
M"O=/HWA[58GN0!(;B66<X!)XWD[<DDG'6NE_X137?^@->_\ ?DTZT)2=DMAX
M&O1I4>2I42=W]I,S#BO9_P!F@YU#Q%QTA@_]">O*O^$5UW_H"WO_ 'Y->O\
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MQLW!R5V@\\U[WIO[,W@S0++0;#23J%EI^D7LM^(VUF:66X>2/RRLDC2$NNW
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M(_\ K5(;>0'[AQ]1UIC+M)4N@(./OK_C5W70EZ;M##D D 9[9]?PY_+FO(_
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M2PC?L0KN7.!DA<_4VG_#;POI5CJ<-O<7"W6HQ"*YU1M2=KYT#$A1.6W* 2<
M8 K9\-^'M!\(:>;+2%@LH&<RN1,&DED/5W<DLS'U)IW;TL+F7<^>]-_:*U?X
M?>#/!3_$;[>VL1B9-2BTV*,W%U)$'<B0,RJ/)M_+DFVG/F-M4'I7TSINHP:M
MI]K?6CB6UNHDGAD'1D8!E/X@BN(\4?"'P+XR\.:9H>K6<-SI^FR&2V NBLB%
ML^8"X.XA\G>"?FR<UVEO)8VEO%!!-;Q0Q((T1)%"JH&  ,] *$]/^ )M=&BY
M4]L<!N,\BJ O+;_GZA_[^+_C5NTGC=7*2)(%Z[&#?RH>VH1?F?$/[7<CI\;;
ML+(Z#^SK4X5B!_RTKQ@SS?\ /:7_ +^'_&O9?VO?^2W7?_8-M?\ VI7BYJ#0
MLV4-]JE[#9V8GN;J=@D<,;L69CT &16^_P .?&<(O#+H.K)]B4R7.Z-AY*8S
MEQGY?7Z5RV64JR$JZD,"IP1CO7TII_Q \+ZCXE\.:C?7,!_X2_1VT?Q C8Q
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MX?;C[Z^@KZQHHKRL15G6J<]1W9[&%A&%.T59'D?[2-^;7P,D(0,+F[CB8D]
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M%7] ^'4?B/6]/TS[<]N;N;R_.\L/LX)SC(ST]:**EXNNDVILM8>D[>ZCTO\
MX9%3_H:W_P#!>/\ XY2?\,C)_P!#6_\ X+Q_\<HHKC698S_GXS3ZI0_D0I_9
M&4C'_"628]/L _\ CE!_9&0]?%DA_P"W ?\ QRBBC^T\9_S\8_JE#^1!_P ,
MCJ.GBR0?]N _^.4G_#(J?]#6_P#X+Q_\<HHH_M/&?\_&+ZI0_D0?\,C1C_F:
MG_\   ?_ !RO4?@E\)D^%L>L1C4VU,WLD;EF@$6S:",?>.>M%%95<97K0<:D
+VT:4J%*$[QC8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #G D # 2(  A$! Q$!_\0
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M7/T7N/$VCVEC+>SZK90V<+F*2XDN$6-'!P5+$X!!['FIEUO3FCM7%_;%+O\
MX]V$RXFXS\AS\W'I7Q'\'?"D7C/X,^.K>+PUX:\7ZO!\1]?FL=-\671AM6/G
M,'< !MS 'ICC.<CK7C?AC5=6MO@?\!H/ J/J'B[1_%^M6<%KJ4@^SB_2&1O*
MB920T*E@$YYQ26OX?B5;]3]*==^)'A;PS<6UOJ>O6-G<7,YM88GF!=Y0 2@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 5F>);S4+#0;^XTJ"VN-0BA:2&*\E:.%F SAF56('N%/TK3JEK7_('OO\
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M?="M+9;B16:#=%#))!(DHCFE+B*$X/WB8V![*<9ZTAGIS_<;Z54T7_D#V/\
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M;-.54<J@C7[A95 !)!((->K:MXM\,^&]0L=-U37-*TN^NB$M+2\NHH9)B2%
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M-@,C'>.-P7KE>O&/>/@S\6O"FI?#S2_[,LKBT6VC6VGAM;!F5944!CF-2"2
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M*4J?NN]M;:JW:]UKUT.HU72;JTC\[Q-XX73X3U5)$M4/MDD?I7.PWWPY$_\
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MM[H,8)XY@N,F-PV,@$=/8@_C4U !1110 4444 %%%% !1110 4444 %%%(2
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M.M'U3_EYR^7ZF?LZ/.FUK;S/3O\ A";7_H(:M_X,)?\ &C_A";7_ *"&K?\
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MN(;:UEM?)ABN(Q(5(D@DW"-QM)QGRVX/(Q[UU.*>O46AF?VW_P!0^^_[\_\
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M:W<21-/&&*D'(P?3VZ5)X?\ #.F^%K-K72[86L#/O9=[.6; &26))P%4#G@
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M]BT*WEMX[R;SY5EN'E^;&.-Y.T#/0<44460.M5DG%R=GOKN=51113,0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #$ D # 2(  A$! Q$!_\0
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M_P"$-T#_ * >G?\ @)'_ (5^2_\ P\W^.?\ S_>'_P#P4C_XNC_AYO\ '/\
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MU?\ 8&8;<Z^]_P"1BU36Z7W'ZF?\(;H'_0#T[_P$C_PH_P"$-T#_ * >G?\
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MVD^&=7O;<J+BVLYIHRPR RH2,CZBA3FW;F8_91[+[B#_ (0W0/\ H!Z=_P"
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M\=,X-[H(^ND?_9TEDF.>JFOO?^0O[-EV1^L__"&Z!_T ]._\!8_\*/\ A#=
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M.3@=ZZB\_9ZAT<^)[:[^(UE;RZ#IJ:D(5L;C;/:R*KQC.0(V=F5?+;G<:SM
M^+'Q%TR^\.IJFFS^)M+L M_9:)JFGC[/,D:D))\J!F5.N<D9 S65XR^*NH^(
M;;Q'#_8-GH,/B>:UO[KR#*2_E;]I5I&)*N7+')QE1CI7+;%2GNK>5N_GKM<X
M9S74X0W]Y.,2W5P^>N^5F]_7UKJ['XJ>)K'P?=>&8;]$TJZ5TF_<(9Y$9@SH
M9<;BK%02,]JYR/1[X[\65R=D0G?]TWRQDX#GCA22,'IS6E?>"O$&DF$7VA:E
M9^>&,7GVKIY@5=S;<CG"\GT%>FXTI)*=NZV/-G4?0S&NKB:2.22XFDDC ".S
MDE0.@!SQCVJR^I7DUPMQ)>7,EPHPLKS,7 ] <YK3MO 7B6YN?LT/AW59;GRE
MG\E+.0OY;?=?&,[3V-9UWIMUITPBO+::UE(R$F0H2,D9P?<$?@:WCR2>ECSY
MS8Z/4;Q6+"[N Q.[(E;.0, ]>N.*1WDG<O*[2.>K.23^9IB)4R)6RBD>=4J
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MI\MU>)P-X4E"P/:OI(?\$N_A$#_Q^^(O_ \?_$4X?\$OOA&.EYXC_P# \?\
MQ->;/,<LJ3<Y.6]]O7_/K?ML<,IJ3/FGQE^U#X2UW1-2T^U78MG=:7. 4DG7
M6H(8E#Q!)MT<,B/DYV!7 Y]Y/ O[37@7^WM3OI+>3PM&Z6P\J6RB594C=VD*
M"U1!YV&&S>"O7-?28_X)A?"0?\OGB+_P/'_Q-.'_  3$^$@/_'WXA_\  X?_
M !-2L=E/+R^]_5O\C"3?0^4-1^/VA6/P_P#!B:'J-L_B72I8;>UAEMKA([2#
MYQ.;L%RDA)8,#& >OTKB/C;KO@SQ?H.GZIHVJ33Z_'<&T-F49(UM@92TNW:
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M-;TLWRRE)2BY77DO/M;O^1S3PV(FK:?>?F*B5*JXK]-Q_P $V?A6/^7S7_\
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MN79+\CFG2KRV/F/7_C/I6B^+=)O]-^(EUXCMM%T>]>TNRMQ'<7FHO\R?:"0
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M"F1#!D_WJ )*Q)_^1PLO^O"?_P!&15MUB3_\CA9?]>$__HR*KCN_0B?00_\
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M'H,\K_;?\Z/*_P!M_P Z?FC.*Y#J&>5_MO\ G1Y7^V_YT_(HS0 SRO\ ;?\
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MUCPSJ7B*_O= AGU%8]/EDS$H3.P 8SQ]:Y3]C7_DZ[Q1_P!<[[_T=3OV=_\
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MHL^JQAF<E\;6&<^OO2?#^Q2V_P""@-];K)*ZQ:M=@-(Y9CB-NI[TJU_:UO\
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M+ZYT47QMCYY$HW$?+A"I [DTI=/0(]?4^AO"EBNF>&=*LT2U1+>UCB5;+/D
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MO[!<?F?\+.^9EQI7\)Q_?JW_ ,$\8M_BCQYEF7%BGW3C_EH:K?L#_P#-3_\
ML%?_ !=7?^"=_P#R,_CW_KQ3_P!&-3S3X<Q_[A?DC/+-\M_[B_J5/^"?4>_X
MU>-1N88TZ3H<?\O25;_88B#_ +1'Q !9AMM+@Y!Q_P O:U6_X)[?\EK\;?\
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MU\Q_^@U[!#UD_P!ZOPS+=ZW^-G[WF?PT/\"):Q)O^1PLO^O"?_T9%6W6)/\
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M7OCA_P GY:#_ -A#3/YK51_WBE_V#F<_X%7_ +"3]"16-XR_Y%+7/^O&;_T
MULUC>,O^12US_KQF_P#0#7Y/3^./R/U^I\#$\'#/A'1QZV40_P#'!7->!/@A
MX7^'UU<76GP75U>S7;WGVO4;I[B9&8$%5=CD)@GY>E=-X-_Y%+1O^O.'_P!!
M%;5%3XWZL*?P1]$%8/C7P]=^*/#UWIMGJ<FE23Q/&94B60,&0KM8,.G/;!XZ
MUO4UY%C*[F"[CM&3C)]!4&AX)\//V;M0\$ZSH]R^J6,UO9W2W1Q [3PA5=1#
M%(3]Q_,+/D<E5]*]HGB,NOJ [1XM3RIQ_&*LP:O973Q)#>6\KRAC&L<JL7"G
M#8P><'@XZ5$?^1A'_7J?_0Z )_L3?\_$W_?5'V)O^?B;_OJI?.8LP5,[3C.:
M/,D_YY?^/4 1?8F_Y^)O^^J/L3?\_$W_ 'U4OF2?\\O_ !ZCS)/^>7_CU $7
MV)O^?B;_ +ZH^Q-_S\3?]]5+YDG_ #R_\>H\R3_GE_X]0!%]B;_GXF_[ZH^Q
M-_S\3?\ ?52^9)_SR_\ 'J/,D_YY_P#CU $7V)O^?B;_ +ZH^Q-_S\3?]]5+
MYLG_ #S_ /'J/-D_YY_^/4 1?8F_Y^)O^^J/L3?\_$W_ 'U4OFR?\\__ !ZC
MS9/^>?\ X]0!%]B;_GXF_P"^J/L3?\_$W_?52^;)_P \_P#QZCS9/^>?_CU
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MI:&/_M&.,K<O+^ZM:]]CYC$9?_9LL%1YN;][?:V]AOP'C)_;OUQ=[#%UJGS
M\_=:CP3&3_P4'U1=[#_B;WGS \_ZLT_X"_\ )^6N?]?>J_\ H+4G@D_\;"]4
M_P"PO>?^BS7JUOXM;_L&7ZGD4/X5#_L)?Z#/"\9/_!0B^3>V?[7N?FSS_JS2
MZ_'C_@H;9KN8_P#$V@^8GG_4BE\+L!_P4,OO^PO<_P#HLTOB _\ &Q&S_P"P
MO!_Z)%5_R^_[EA+^#_W,GU!?Q$?&*%-['_28_F)Y^[7L5LGEAUW%L-U8\UY!
MJ!_XO-%_U\Q_^@U[#%]Z3_>K\,RW>M_C9^]YG\-#_ B2L2;_ )'"R_Z\)_\
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M%6KC<'.G%M1DVWVVW/-/V85!_;9\4CL+C5__ $>:7X4J/^&^]5';^T;_ /\
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M31&7Q N':/\ T4\K_OBKD.I6EPT8BNH9#(&*!) =X!PQ&#S@]?2JY_Y&$?\
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M0M/^_P"O^-%GV"Z+'V?W'_?(H^S^X_[Y%5_[=TW_ *"%I_W_ %_QH_MW3?\
MH(6G_?\ 7_&BS[!=%C[/[C_OD4?9_<?]\BJ_]NZ;_P!!"T_[_K_C1_;NF_\
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M_P!_U_QHL^P719$++T?'T IVQ_\ GH?R%5/[=TW_ *"%I_W_ %_QH_MW3?\
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M'4-DEC=76CWL<UQ<QWELP>1)9H7B9QY@8# <D#&,@<5T7]NZ;_T$+3_O^O\
MC1_;NF_]!"T_[_K_ (U-GV-+HX#PC\#;7PGJVDWPUW4+]K#,C1SI"BW,^QXQ
M/(40$OLD8$@@$X)R:]+:&-V#,@+ 8SCG%4_[=TW_ *"%I_W_ %_QH_MW3?\
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M_H(6G_?]?\:+/L%T7/)3^Z*3R(_[@JI_;NF_]!"T_P"_Z_XT?V[IO_00M/\
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M@=:?]^$_PH_L#3/^@=:?]^$_PHHHYGW#ECV#^P-,_P"@=:?]^$_PH_L#3/\
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FY8]@_L#3/^@=:?\ ?A/\*/[ TS_H'6A_[8)_A111S/N'+'L?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "C D # 2(  A$! Q$!_\0
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M,?$>I:)JFFQ6"*Z2AVDC*9+X(  _,].?PK*TKQAK-U?:=#(T4J22;25BV_:
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M;9Y$PO.,\@X_$#'XUE:9X9QXDOM;O(U/F3)/9Q[S^Z/E",[EQC=@'UZUU5%
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M@:3$8C'I]LIBD,L9$8&USU8>]9TO_)1K;_L%2_\ HU*(/&NCW#PHCS;I9/+
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MSJ$WLLO^MUA%']VU@S^IS3L4H2>R.AS@9-96H>(=.TV>"&>4M),=JB,;CGW
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M.9]PB"R []O7'KBD)F!H^FV.E^.]3AL+."UC:P@9DAC" G?)S@=ZZRN=M?\
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M% &*7(^:_,[=M/\ (/:3[LY--7B3[NG01?[T#_\ Q-6%U\]/M%I%_P!L9/\
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M;5$;4+B5&LH27O;DR,#N?(!/L1Q[UM7/BO2+<E5NA/(!]R$;JS$TRSN?B#J
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M/]:JW'B?3;>XBA,C.TO0HA('UI2Q-**O*2^\F51O=FS16?\ VO W^KAN9/\
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M^"__ .SH_L[Q9_T,%C_X+_\ [.NCHH&<Y_9WBS_H8+'_ ,%__P!G1_9WBO\
MZ&"Q_P#!?_\ 9UT=9'B6ZOK'0;NZT[ROM,2;@902 ._ ZG% &'HA\7ZMI,-[
M)K%E;O)NS$=/.5PQ'=_;-:']G>+/^A@L?_!?_P#9U#HFM7][XDO+.?;Y$<>X
M($P8R-N,GON#$_A74T"3N<Y_9WBS_H8+'_P7_P#V=']G>+/^A@L?_!?_ /9U
MT=% SG/[.\6?]#!8_P#@O_\ LZSM:/B_2K 7,>L64[&:./8-//1F"D\/VSFN
MTKC_ !3XAO=,UJWL[">-Y6MWF>W>/^$ _-N]<XPH]#28%W^SO%?_ $,%C_X+
M_P#[.C^SO%G_ $,%C_X+_P#[.K7AF_N=1T:.XN765R[J)57:)%#$!L>XK9I@
M<Y_9WBS_ *&"Q_\ !?\ _9T?V=XL_P"A@L?_  7_ /V=='10!SG]G>+/^A@L
M?_!?_P#9TFF3Z[;^)_[.U.[@N[=[-IUDBMC%M<.%P3N.>"3725YUJ'BS5K>^
MNH;>YBFB2X 240?[)/E'WR,>OYT@/1:*:F< D8)'2G4P"BBB@# \7-?C1&^P
M&X#^:F\V_P#K F>=OZ5S7B"/Q)*?#OFPZ6^;F)?WQ?>7*$L' &,9':O1*Y;Q
M;J]_I<^G+9HA$CG.Z/=YC J @]"02<^U*PA3;>*6ZV?AP_C+_A55=&\0)=/<
M#3_#OFN,$EIL?EC%=B*6H=*G+>*^X+'*?8?$W_/AX;_\B_\ Q-12Z1XAGDC>
M33_#A:,Y4AIAC\A7844.E3:LXK[@LCEQ;>*A_P N?AW\Y?\ XFLZS?Q$^N:A
M;1:;X?CN(%C,DNZ7Y]X)]/:NW?.P[0"V.,UP,'B37!J.GPSK 'FNY891'"<2
MA9M@ )Y&U3G-#A"^R!V-S;XO'2#P_P#]]2_X4QX/%CNKO:^'F9?NDF7(_2NF
M'2EJN5/=#.=W>,O^>>@_]]S?X4F?&7_/+0?^^YO\*Z.BJ YJ67QC%"\ABT(A
M%+8#S=OPJMI6I>+]5TJUOX[?0XTN(Q($:27(SV/%7?&.KRZ-HRSV]RL,\DJQ
M1!HPPD8]%.> /4]@#5;PMK%_J-]J$%X(MD&-JQIM$9W,-N>_"AOQI 6-WC/_
M )YZ#_WW-_A1N\9_\\]!_P"^YO\ "NBHI@<[N\9_\\]!_P"^YO\ "C=XS_YY
MZ#_WW-_A714&@#E+C5O$NFWFG#4+?27MKJ[2V8V[R;UW9Y&1CM75UQ7B?7K[
M3M7\BUGBD7R&9HC#N,!&"),]QC/MQBNB\/WD]_H=K=7.#+(I)(7 ;D@'';(Y
M_&E<#3HHHI@%%%% !1110 4W8-V[OZTZB@ HHHH *:^=I .">_I3J0@$8(R*
M /.=&\>7XCM)=16*XAN;>YF=HE"&$Q2[!GG&&SW[UKV/CB.^6%X-,G(N+9KF
M/##,@1BK@>X('UR*Z5-*T^.)XDL;98W&&01+@\YY&/7FFQ:7:PW#2I& I38L
M6!L0=]H[9SSZTA&+<^,K>'1=/U..W:6*]E,2J&VE& 8G.?\ <(JG_P +&L'#
M&*RNW'E>8,+R?D5SQUX#CGV-=!J&@V.I+9I-'B.TG$\:)@+NP1R.X^8U;^PV
MA8L;6'<5"D^6,D#M]* U,#3_ !A#>W.HJT0$-NT:P,A+&7=$).<#@<]:S[/X
MAI)IAO+G3G58[%+V=HI P1&9E QU)RM=E':V\+,T4$:,X 8JH!(' S]*B33K
M&,.$L[=0Z>6P$8 *^A]N>E,9RMW\0;:W80-82_:&M9+@1LPQ\J,^#]0IYJK-
M\2K:T4^?ILA=(5D=HI%(_P!4)"!GG@$_E79C2]/5E86-L&5=H(B7(&,8Z=,$
MBFMH^F-G=I]J<\<PKZ8]/3BD!S5U\0K6!;EH;"XF6WN5MBV0H+G''/U%7O#O
MBM?$.HW$,5MY4$=K;W",SY9O-4MC'MTK9;3+!]VZRMSO(+9B'S$="?7%206=
MK;',%O%$=H3*(!\HZ#CM3$3T444#$(!ZBD"@9P ,^E.HH **** "BBB@!-HS
MGOZTM%% !1110!P\WC2^M-<N;:6""2VBU6+3P(P?,P\8?=[X[CTJW#X\T^[
M\JUN&0W)M"Q"X$FT,H//\0.![UT"Z1IR74ERME )Y&W/)L&2<8S]<<5"F@Z?
M#)$;>WC@CC<2&*- %9@,*3QU&.*0C-D\7V,6E:GJ/D38TY_+N(L 2 YQTS[Y
M'M4">/\ 2VGC@,=PLID,;J4'[MM^P9YYRWI6OJF@66J:5>:>Z>3'=@"5H@ Q
MQCO^%3QZ/IT:P@6<!,/W&\L9!/)/Y\T 8%IX\L;O4880ABMFMGGDFE(!C*N$
MVE>H.31!XYAFOVM!83NS7<UM$8V4[A&JLS')&!AJZ.+3;*"=9XK2%)5# .J
M, 3D\^]-&E6"W8NELX1.'9_,"#.XC!.?4@4QG/#X@:8UK:W/DW(ANIA%$Y0
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MIPRAV;8?;#8_ 593Q@DL0EBM T?DK(3YP!#,<*A&.IY_#ZU3B\9.AN+AH3+
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MBMP\1$2@19**HP%)[X]:L 8HHH K:=*\VEVDLC;G>%&8^I*C-6:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ +L# 2(  A$! Q$!_\0
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M\&_V.]#U%;SP-\*=7^#-EXPTF&*:2YN?C-^TIXUO_!WA>SM]@*7;:1\-M/\
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MNHM3TWPUX8M+#PMX:\/V,=Q86EIHT"Z?9VR[T0*Y=+WWZ'QGXBU3XM_\$_\
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MJ.6X59(XY)Q))4I75DK?\ _F9^#_ .QA_P %,/V"OAQ\7_AG\$OBK^RMX/\
MV;(?$/Q"^*M]\:]7\-Z[JWQ(T;P39Z-I;R+IFBPM!HFG:]IGA/PII]O:7&I1
M76GZ7J]K>7EAMB996]__ .""_P 'Y=0_9T\6_MR>/[V\\5_&?]LGQQXC\77_
M (_\1"2X\9W7PP\+ZU_PC7@K3=2OHV#WD_B$^')O%5S):/\ 9;NPU#0X'25K
M!5'B/_!7?_@IN-9\"_'C]D']F71K_P 3^(;Z;P!\"OBK\<%U1-+^'O@KQ/\
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MMIME9VD4,5A9VT$%M'!9HBK#%# F (T"Z8  P  .> ,#DY/ ]3R?>E
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MD.2Y8@%BDP,@X&0" <<@'J >N#@9^E+10 4444 %(0#U /U /\Z6B@!" >"
M1Z$ TA56!4JI!!4@@$%3U4@C!![@\'O3J* $*JP*E05(P5(!!!&""#P01Q@]
MJ  ,D  DY) QDX R?4X &3V '0"EHH **** "BBB@ HHHH **** "BBB@ P,
MYP,\<]^,D?D22/3)II1"'4HI63.\%00^0%.\8PV5 4YSD  \444 +M7(;:-P
M! ; R <9 /4 X&?7 ]*%55&%4*,LV%  W,Q9C@8&68EF/4L23DDT44 +1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ D # 2(  A$! Q$!_\0
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M7_/G!_WZ%']G67_/G!_W[%>"#XO^+?\ GK9?^ __ ->E_P"%O>+?^>ME_P"
M_P#]>G]0KDN43WK^SK'_ )\X/^_:T?V=9?\ /G!_W[6O!_\ A;OBS_GM9?\
M@/\ _7KIO 7Q!U_Q#XKAT[4'MC;O$[$1P[3D#CG-3/!UH1<GT$IP;L>I?V?9
M?\^<'_?L4?V=9?\ /G!_W[%6J*X;ON:<J*O]G67_ #YP?]^Q1_9UC_SYP?\
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M/"7B'2M!L7BNX)YI+N;;<^6<!8-I&/\ :Y;./]D5M6?AO3KOPKI\RZ;'#,3
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MM-"8A_Y"@_ZX_P!:\Y^*,D%MJ>GR^<XN9(]B11WJP,^UMP/S*1@>I(KT8_\
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M 'Q_*ND'4_6OFZ#;<K]SZBNDE&W8=55O^0I%_P!<7_FM6:K-_P A2+_KB_\
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MC:K_ -NBH?\ +K_MXC^%0_XJK5.3_J&_]&"I/AH,^-=8Y/$3_P#HP5'\*?\
MD:M4_P"N#?\ H8J7X9_\CMK/_7)__1@J:^]7TB50VI>K*_P^'_%P[\<_=F_]
M"I?"8_XNU=CG_67']:/A[_R42_\ ]V;_ -"H\)_\E;O/^NEQ_6JJ_%4_PHBG
M\-/_ !,/"Z_\7?NAS_K+C^1I-,'_ !>B?D_\?,O_ *":=X7_ .2P77_76X_D
M:33/^2T3_P#7S+_Z":)?%+_ ./PQ_P 86(_XO1*.?^/E_P#T&B['_%ZHQS_Q
M\I_Z#18_\EIE_P"OE_\ T&EN_P#DM<?_ %\I_P"@T=?^W!?9_P"WSO)A_P 5
M.HR?OC^5=(@P".>O>N<F_P"1H'_70?RKI%[_ %KY:AO+U/K<1M'T%JLW_(3B
M_P"N+_S6K/>JS?\ (3B_ZXO_ #6NM'(Q#_R%!_UQ_K7!?$ORH)H)IHFFCFMS
M;NCVK3I]\,"H5A\^1TYSQ7>G_D*#_KC_ %KA/B7:SLUM<VV@P7LD,3;;MW+/
M!D\A8PRD\9.>:&".XTB(0:-8PKYI6.!%'G+M?A1]X=C3K^Q%_"(FN+B$9Y,$
MFTGVI=-"+I=J(Y#(@B7:[+M+#'7':K$DBQQL[L%11DL3P!2&<WI/A)=)N;1H
M[QI(H"6"N@W$X91\WIANE= 1F^'_ %S_ *U!!JVGW,D4<%Y#(\J[XU5QEE]1
M4_\ R_#_ *Y_UH FP/\ )HP/\FEHH 3 _P FC _R:6B@!,#_ ":,#_)I:* $
MP/\ )HP/\FEHH 3 _P FC _R:6B@#.O;6ZEO+1[9[=8DD)N!)'N9UQP%/8YI
M;O1M.OIUFNK*&:5!A7= 2*OT4U)K8EQ3W1FZCH.EZNT;:A917#1\(9!G%4/$
M7A#3_$D-K#=-+&EMD1B)L<$ ?TKH:*J-2<6FGL3*E"2::W.3\4>&M,N_#T$=
MZ;LV^GQY46XR[  #IWZ54\2^$YM8\*Z=INELJK;E6'V@D';M[\=>:[>C%7&O
M4BTT]C.>'IR336YY_J?A74Q\-;?0XHTGO8G4L$;@_,3U-0?\([JL?PJET@VA
M-^7R(@P)^^#_ "KT>BM%BII6\[_,S>$@W?RM\CR^#2[W2?A%J5K?6[0S[F;8
M3DX+#TJIX(!'PZ\29!'R2=?^N5>LLBNNUE# ]0163XCBCB\*:L(XU4&TEX5<
M?P&M%BG).+6[N92PBBU-/96///AKSX6\1?[O_LAH^%/_ ![:W_US7^34OPU!
M'A;Q%D$?+W_W#2?"G_CVUO\ ZYK_ ":N^KJJWJOT//I;TO1C?A!_R%-5_P"N
M*?S-1?#K_DH&H_[DO_H8J7X0?\A/5?\ KBG_ *$U1?#K_DH&H_[DO_H8IUOB
MK>B%2^&CZL3P9_R5:_\ ]^Y_]#I=#'_%X[C_ *[S?^@FD\&?\E7U#_?N?_0Z
M70_^2R7'_7>;^1IS^*?^ 4/AA_C()1_Q>C_M]'_H(J;Q-_R5^T_Z[0?TJ&7_
M )+1_P!OH_\ 014WB;_DK]I_UV@_I1]J/^ 3^"7^,]C%5M1_Y!UU_P!<G_E5
MD56U'_D'77_7)_Y5X*W/HGL)I_\ R#+;_KDO\JX3PS:"W\5)J+&V-MJ)D%H$
MGG8KLR'P&^7YNOX<5WFG_P#(-MO^N2_RKEM/30;3Q;##86EY+.RR,K;F:&U)
M/S#:3\A/L*'N$=D=G5'5-.&J6$MHUQ- LBLI:)L'D$?UJ]2$X%(HY73/"+:?
M=02FZB*)()&18L8*@A0I))"_,2<YYKHV7=>#YB/W?;ZTY+F"0J$FC8ODKA@=
MV.N*3_E]_P"V?]: '^5_TTD_.CRO^FDGYU)10!'Y7_323\Z/*_Z:2?G4E% $
M?E?]-)/SH\K_ *:2?G4E% $?E?\ 323\Z/*_Z:2?G4E% $?E?]-)/SI/)XP7
M<_C4M% $7D#IN;'IFHYK*&X@>"8%XG&&1NC"K-%%V*R.?O\ P[;1^'M0L=)M
MHH'N(BH5?E!;'>N=\*>$]4T;PSK%E=H@GN5(B5),@_(1S7H/2BMXUYJ+CWU.
M>6'A*2EVT/,_"/AK5/#_ (=\0#4H1"9H,IMD#9 1L]/K6=\+5SI&O\D?NDZ?
M[K5Z=K>?["U #K]FD_\ 037F?PM1ETCQ!N5E_=)U&/X6KNA5=6E4E+=M'!.B
MJ56G&.R3*_PO&1KG)'^C]OQJ7X3KF_U;DC]T.A]ZC^%W_,=_Z]_\:E^$O_(0
MU;_KD/YFNJOM6_[=.6AO2^9'\*AGQ5JG7_4-T_ZZ"I/AH,^-M8&3_JW_ /1@
MJ/X4_P#(U:I_UP;_ -#%2_#3_D=M9_ZY/_Z,%3B-ZOI$JAM2]65OA\,_$._&
M3]V;_P!"I?"@_P"+M78R?]9<<_G2_#W_ )*)?_[LW_H5'A/_ )*W>?\ 72X_
MK55?BJ?X413^&G_B8>&!_P 7?NAD_P"LN.?P-)IH_P"+SSC)_P"/F7_T&G>%
M_P#DL%U_UUN/Y&DTS_DM$_\ U\R_^@FB7Q2_P#C\,?\ &)8C/QHE&3_Q\O\
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MD\O8 "^&7/J!ACQ6X1F^'_7/^M5K?7-,NIHH;>]BDDE4LBJW+ =?Y'\JM?\
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M/ XK7(!OAG_GG_6JMMKNF7=Q'!!=H\L@)5.<\9R/8\'CVJW_ ,OP_P"N?]:
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M^QP>?G/F^6-V?7-*^F6,EP+B2TA><8(D:,%@1TYJWFC-%WW#ECV # JMJ/\
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?(O\ O@444 'V2W_YX1?]\"C[);_\\(O^^!110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ ,,# 2(  A$! Q$!_\0
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MI(4KHC9]S_;/_;$UGQS_ ,%$?V+_ -JC1O@%\;?BA\&?A[\*OB+)^RWX!O\
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MFWL]=UR*XADM[+7;%!;2R^=A/%/^"77P+M=0_P""CO[='QC^)OQ4\5?&6?\
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)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>celc-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6I2bP9z5Z86ekhvWB/bVl6Ty0sT0VDaijO5JkGUZkE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:CELC="http://celcuity.com/20251231" elementFormDefault="qualified" targetNamespace="http://celcuity.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://celcuity.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OrganizationAndLiquidity" id="OrganizationAndLiquidity">
          <link:definition>999015 - Disclosure - Organization and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
          <link:definition>999017 - Disclosure - Net Loss Per Common Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Investments" id="Investments">
          <link:definition>999018 - Disclosure - Investments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999019 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OtherAccruedExpenses" id="OtherAccruedExpenses">
          <link:definition>999020 - Disclosure - Other Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Commitments" id="Commitments">
          <link:definition>999021 - Disclosure - Commitments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999022 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999023 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Debt" id="Debt">
          <link:definition>999024 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/LicenseAgreement" id="LicenseAgreement">
          <link:definition>999025 - Disclosure - License Agreement</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999026 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999027 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
          <link:definition>999030 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/InvestmentsTables" id="InvestmentsTables">
          <link:definition>999031 - Disclosure - Investments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999032 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OtherAccruedExpensesTables" id="OtherAccruedExpensesTables">
          <link:definition>999033 - Disclosure - Other Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/CommitmentsTables" id="CommitmentsTables">
          <link:definition>999034 - Disclosure - Commitments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999035 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999036 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/DebtTables" id="DebtTables">
          <link:definition>999037 - Disclosure - Debt (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999038 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" id="OrganizationAndLiquidityDetailsNarrative">
          <link:definition>999039 - Disclosure - Organization and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:definition>999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" id="ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails">
          <link:definition>999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
          <link:definition>999043 - Disclosure - Net Loss Per Common Share (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" id="ScheduleOfInvestmentDetails">
          <link:definition>999044 - Disclosure - Schedule of Investment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" id="SummaryOfPropertyAndEquipmentDetails">
          <link:definition>999045 - Disclosure - Summary of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999046 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" id="ScheduleOfOtherAccruedExpensesDetails">
          <link:definition>999047 - Disclosure - Schedule of Other Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" id="OtherAccruedExpensesDetailsNarrative">
          <link:definition>999048 - Disclosure - Other Accrued Expenses (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" id="ScheduleOfMinimumLeasePaymentsDetails">
          <link:definition>999049 - Disclosure - Schedule of Minimum Lease Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" id="ScheduleOfLeaseCostsDetails">
          <link:definition>999050 - Disclosure - Schedule of Lease Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
          <link:definition>999051 - Disclosure - Commitments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" id="ScheduleOfCommonStockWarrantsDetails">
          <link:definition>999052 - Disclosure - Schedule of Common Stock Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" id="ScheduleOfCommonStockWarrantsOutstandingDetails">
          <link:definition>999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999054 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" id="ScheduleOfStockOptionsActivityDetails">
          <link:definition>999055 - Disclosure - Schedule of Stock Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" id="ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails">
          <link:definition>999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" id="ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails">
          <link:definition>999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" id="ScheduleOfStock-basedCompensationExpensesDetails">
          <link:definition>999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999059 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" id="ScheduleOfLong-termDebtDetails">
          <link:definition>999060 - Disclosure - Schedule of Long-term Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" id="ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails">
          <link:definition>999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999062 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" id="LicenseAgreementDetailsNarrative">
          <link:definition>999063 - Disclosure - License Agreement (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999066 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999067 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <element id="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" name="SeniorNotesDueTwoThousandAndThirtyOneNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ConvertibleNotesToCommonStockMember" name="ConvertibleNotesToCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" name="PreferredStockOnAnAsIfConvertedToCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" name="JulyTwoThousandAndTwentyFiveEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LeerinkPartnersLLCMember" name="LeerinkPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantFourMember" name="WarrantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantFiveMember" name="WarrantFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantSixMember" name="WarrantSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantSevenMember" name="WarrantSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantEightMember" name="WarrantEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantNineMember" name="WarrantNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantTenMember" name="WarrantTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantElevenMember" name="WarrantElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandTwelveEquityIncentivePlanMember" name="TwoThousandTwelveEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" name="TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ResearchAndDevelopmentExpensesMember" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NoteUnderwritingAgreementMember" name="NoteUnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" name="JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AmendedAndRestatedLoanAgreementMember" name="AmendedAndRestatedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InnovatusLifeSciencesMember" name="InnovatusLifeSciencesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermDLoanMember" name="TermDLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermELoanMember" name="TermELoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermETwoLoanMember" name="TermETwoLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermFLoanMember" name="TermFLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermFTwoLoanMember" name="TermFTwoLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermGLoanMember" name="TermGLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" name="ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" name="SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermALoanMember" name="TermALoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermBLoanMember" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermCLoanMember" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PriorLoanAgreementMember" name="PriorLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PfizerLicenseAgreementMember" name="PfizerLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" name="StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" name="StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NoncashOperatingLeaseExpenseNet" name="NoncashOperatingLeaseExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ChangeInAccruedInterestIncome" name="ChangeInAccruedInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" name="IncreaseDecreaseInAccruedClinicalTrialCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" name="ProceedsFromAtmOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentsForSecondaryRegistrationStatementCosts" name="PaymentsForSecondaryRegistrationStatementCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CashPaidForOperatingLeases" name="CashPaidForOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" name="CommonStockWarrantsIssuedWithNotePayableTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PropertyAndEquipmentIncludedInAccountsPayable" name="PropertyAndEquipmentIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" name="DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DisclosureLicenseAgreementAbstract" name="DisclosureLicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementTestBlock" name="LicenseAgreementTestBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AllowanceForCreditLossesPolicyTextBlock" name="AllowanceForCreditLossesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicensesPolicyTextBlock" name="LicensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" name="RecentAccountingPrononcementAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PrefundedWarrantShares" name="PrefundedWarrantShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OtherAccruedLicenseMilestone" name="OtherAccruedLicenseMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OtherAccruedInterest" name="OtherAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" name="StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockBasedCompensationExpensesAbstract" name="StockBasedCompensationExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockBasedCompensationExpensesTable" name="StockBasedCompensationExpensesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CELC_StockBasedCompensationExpensesLineItem" name="StockBasedCompensationExpensesLineItem" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StatementOfIncomeLocationBalanceAxis" name="StatementOfIncomeLocationBalanceAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="CELC_StatementOfIncomeLocationBalanceDomain" name="StatementOfIncomeLocationBalanceDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ChangeInCommonStockSharesReservedForIssuance" name="ChangeInCommonStockSharesReservedForIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" name="RemainingStockBasedCompensationExpenseRelatedToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinalFee" name="FinalFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentInKindInterestDebt" name="PaymentInKindInterestDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DisbursementLoanAmount" name="DisbursementLoanAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AmendmentFee" name="AmendmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DebtFinalFeePercentage" name="DebtFinalFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinalFeePercentage" name="FinalFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_WarrantOrRightToPurchasePercentage" name="WarrantOrRightToPurchasePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementAbstract" name="LicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementTable" name="LicenseAgreementTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CELC_AggregateValueOfMilestoneEvents" name="AggregateValueOfMilestoneEvents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentOnMilestoneEventOne" name="PaymentOnMilestoneEventOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ResearchAndDevelopmentExpenseMilestone" name="ResearchAndDevelopmentExpenseMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsRightofuseAssets" name="DeferredTaxAssetsRightofuseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AggregateOfferingAmount" name="AggregateOfferingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>celc-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Cover" roleURI="http://celcuity.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheets" roleURI="http://celcuity.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfOperations" roleURI="http://celcuity.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlows" roleURI="http://celcuity.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidity" roleURI="http://celcuity.com/role/OrganizationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShare" roleURI="http://celcuity.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Investments" roleURI="http://celcuity.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipment" roleURI="http://celcuity.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpenses" roleURI="http://celcuity.com/role/OtherAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Commitments" roleURI="http://celcuity.com/role/Commitments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquity" roleURI="http://celcuity.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensation" roleURI="http://celcuity.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Debt" roleURI="http://celcuity.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreement" roleURI="http://celcuity.com/role/LicenseAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxes" roleURI="http://celcuity.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEvents" roleURI="http://celcuity.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareTables" roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#InvestmentsTables" roleURI="http://celcuity.com/role/InvestmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesTables" roleURI="http://celcuity.com/role/OtherAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsTables" roleURI="http://celcuity.com/role/CommitmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityTables" roleURI="http://celcuity.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationTables" roleURI="http://celcuity.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtTables" roleURI="http://celcuity.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesTables" roleURI="http://celcuity.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidityDetailsNarrative" roleURI="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareDetailsNarrative" roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfInvestmentDetails" roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SummaryOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfOtherAccruedExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesDetailsNarrative" roleURI="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfMinimumLeasePaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLeaseCostsDetails" roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsDetailsNarrative" roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtDetailsNarrative" roleURI="http://celcuity.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreementDetailsNarrative" roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AccruedClinicalTrialCosts" xlink:label="loc_CELCAccruedClinicalTrialCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_CELCAccruedClinicalTrialCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="loc_CELCNoncashOperatingLeaseExpenseNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCNoncashOperatingLeaseExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="loc_CELCChangeInAccruedInterestIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCChangeInAccruedInterestIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:label="loc_CELCIncreaseDecreaseInAccruedClinicalTrialCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCIncreaseDecreaseInAccruedClinicalTrialCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidity" xlink:title="999015 - Disclosure - Organization and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999017 - Disclosure - Net Loss Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999018 - Disclosure - Investments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999019 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpenses" xlink:title="999020 - Disclosure - Other Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999021 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999022 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999024 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="999025 - Disclosure - License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999030 - Disclosure - Net Loss Per Common Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999031 - Disclosure - Investments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesTables" xlink:title="999033 - Disclosure - Other Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999034 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999036 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999037 - Disclosure - Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="999039 - Disclosure - Organization and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999043 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999044 - Disclosure - Schedule of Investment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999045 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999046 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" xlink:title="999047 - Disclosure - Schedule of Other Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedLicenseMilestone" xlink:label="loc_CELCOtherAccruedLicenseMilestone" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_CELCOtherAccruedLicenseMilestone" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedInterest" xlink:label="loc_CELCOtherAccruedInterest" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_CELCOtherAccruedInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" xlink:title="999048 - Disclosure - Other Accrued Expenses (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" xlink:title="999049 - Disclosure - Schedule of Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:label="loc_CELCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_CELCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999050 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999051 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" xlink:title="999052 - Disclosure - Schedule of Common Stock Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" xlink:title="999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999054 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999055 - Disclosure - Schedule of Stock Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" xlink:title="999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" xlink:title="999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999060 - Disclosure - Schedule of Long-term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_CELCFinalFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="loc_CELCPaymentInKindInterestDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_CELCPaymentInKindInterestDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermNotesPayable" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999062 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="999063 - Disclosure - License Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="loc_CELCDeferredTaxAssetsRightofuseAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELCDeferredTaxAssetsRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="loc_CELCDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELCDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>celc-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Cover" roleURI="http://celcuity.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheets" roleURI="http://celcuity.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfOperations" roleURI="http://celcuity.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlows" roleURI="http://celcuity.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidity" roleURI="http://celcuity.com/role/OrganizationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShare" roleURI="http://celcuity.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Investments" roleURI="http://celcuity.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipment" roleURI="http://celcuity.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpenses" roleURI="http://celcuity.com/role/OtherAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Commitments" roleURI="http://celcuity.com/role/Commitments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquity" roleURI="http://celcuity.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensation" roleURI="http://celcuity.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Debt" roleURI="http://celcuity.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreement" roleURI="http://celcuity.com/role/LicenseAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxes" roleURI="http://celcuity.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEvents" roleURI="http://celcuity.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareTables" roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#InvestmentsTables" roleURI="http://celcuity.com/role/InvestmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesTables" roleURI="http://celcuity.com/role/OtherAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsTables" roleURI="http://celcuity.com/role/CommitmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityTables" roleURI="http://celcuity.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationTables" roleURI="http://celcuity.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtTables" roleURI="http://celcuity.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesTables" roleURI="http://celcuity.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidityDetailsNarrative" roleURI="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareDetailsNarrative" roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfInvestmentDetails" roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SummaryOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfOtherAccruedExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesDetailsNarrative" roleURI="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfMinimumLeasePaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLeaseCostsDetails" roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsDetailsNarrative" roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtDetailsNarrative" roleURI="http://celcuity.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreementDetailsNarrative" roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidity" xlink:title="999015 - Disclosure - Organization and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999017 - Disclosure - Net Loss Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999018 - Disclosure - Investments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999019 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpenses" xlink:title="999020 - Disclosure - Other Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999021 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999022 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999024 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="999025 - Disclosure - License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999030 - Disclosure - Net Loss Per Common Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999031 - Disclosure - Investments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesTables" xlink:title="999033 - Disclosure - Other Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999034 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999036 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999037 - Disclosure - Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="999039 - Disclosure - Organization and Liquidity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:label="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShortTermInvestments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="loc_CELCOptionsToPurchaseCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCOptionsToPurchaseCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ConvertibleNotesToCommonStockMember" xlink:label="loc_CELCConvertibleNotesToCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCConvertibleNotesToCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CELCWarrantsToPurchaseCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCWarrantsToPurchaseCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999043 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantShares" xlink:label="loc_CELCPrefundedWarrantShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCPrefundedWarrantShares_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999044 - Disclosure - Schedule of Investment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999045 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999046 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" xlink:title="999047 - Disclosure - Schedule of Other Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" xlink:title="999048 - Disclosure - Other Accrued Expenses (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" xlink:title="999049 - Disclosure - Schedule of Minimum Lease Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999050 - Disclosure - Schedule of Lease Costs (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999051 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="loc_us-gaapRegistrationPaymentArrangementTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementTerm_60" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" xlink:title="999052 - Disclosure - Schedule of Common Stock Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOneMember" xlink:label="loc_CELCWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTwoMember" xlink:label="loc_CELCWarrantTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantThreeMember" xlink:label="loc_CELCWarrantThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFourMember" xlink:label="loc_CELCWarrantFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFiveMember" xlink:label="loc_CELCWarrantFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSixMember" xlink:label="loc_CELCWarrantSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSevenMember" xlink:label="loc_CELCWarrantSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantEightMember" xlink:label="loc_CELCWarrantEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantNineMember" xlink:label="loc_CELCWarrantNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTenMember" xlink:label="loc_CELCWarrantTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantElevenMember" xlink:label="loc_CELCWarrantElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_240" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" xlink:title="999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPrefundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999054 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_UnderwritingAgreementMember" xlink:label="loc_CELCUnderwritingAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCUnderwritingAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCPrefundedWarrantsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="loc_CELCLeerinkPartnersLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCLeerinkPartnersLLCMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPrefundedWarrantsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_270" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_270" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_270" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_270" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_270" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_CELCProceedsFromIssuanceOfCommonStockNet_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCProceedsFromIssuanceOfCommonStockNet_270" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_270" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_270" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_270" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_270" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_270" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_270" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_270" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis_270" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_270" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999055 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" xlink:title="999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" xlink:title="999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesLineItem" xlink:label="loc_CELCStockBasedCompensationExpensesLineItem" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesTable" xlink:label="loc_CELCStockBasedCompensationExpensesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CELCStockBasedCompensationExpensesLineItem" xlink:to="loc_CELCStockBasedCompensationExpensesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_CELCStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CELCStockBasedCompensationExpensesTable" xlink:to="loc_CELCStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CELCStatementOfIncomeLocationBalanceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_CELCStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CELCStatementOfIncomeLocationBalanceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CELCStatementOfIncomeLocationBalanceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_CELCStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CELCStatementOfIncomeLocationBalanceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpensesMember" xlink:label="loc_CELCResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CELCStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CELCResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_GeneralAndAdministrativeExpensesMember" xlink:label="loc_CELCGeneralAndAdministrativeExpensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CELCStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CELCGeneralAndAdministrativeExpensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CELCStockBasedCompensationExpensesLineItem" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="loc_CELCTwoThousandTwelveEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandTwelveEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:label="loc_CELCTwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_CELCTwoThousandSeventeenEmployeeStockPurchasePlanMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenEmployeeStockPurchasePlanMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="loc_CELCChangeInCommonStockSharesReservedForIssuance_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCChangeInCommonStockSharesReservedForIssuance_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription_210" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999060 - Disclosure - Schedule of Long-term Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999062 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoteUnderwritingAgreementMember" xlink:label="loc_CELCNoteUnderwritingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCNoteUnderwritingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_CELCThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_CELCSecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLoanAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PriorLoanAgreementMember" xlink:label="loc_CELCPriorLoanAgreementMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCPriorLoanAgreementMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermETwoLoanMember" xlink:label="loc_CELCTermETwoLoanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermETwoLoanMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFLoanMember" xlink:label="loc_CELCTermFLoanMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFLoanMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFTwoLoanMember" xlink:label="loc_CELCTermFTwoLoanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFTwoLoanMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermGLoanMember" xlink:label="loc_CELCTermGLoanMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermGLoanMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermALoanMember" xlink:label="loc_CELCTermALoanMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermALoanMember_240" xlink:type="arc" order="243" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember_250" xlink:type="arc" order="253" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember_260" xlink:type="arc" order="263" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtNoncurrent_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure" xlink:label="loc_us-gaapNotesReceivableFairValueDisclosure_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesReceivableFairValueDisclosure_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DisbursementLoanAmount" xlink:label="loc_CELCDisbursementLoanAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCDisbursementLoanAmount_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendmentFee" xlink:label="loc_CELCAmendmentFee_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCAmendmentFee_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DebtFinalFeePercentage" xlink:label="loc_CELCDebtFinalFeePercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCDebtFinalFeePercentage_400" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_400" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_400" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_400" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_400" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_400" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_400" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_400" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_400" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_400" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice_400" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_400" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherBorrowings_400" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_400" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_400" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFeePercentage" xlink:label="loc_CELCFinalFeePercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFeePercentage_400" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFee_400" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="loc_CELCWarrantOrRightToPurchasePercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCWarrantOrRightToPurchasePercentage_400" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_400" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure_400" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="999063 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementTable" xlink:label="loc_CELCLicenseAgreementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCLicenseAgreementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PfizerLicenseAgreementMember" xlink:label="loc_CELCPfizerLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCPfizerLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementMember" xlink:label="loc_CELCLicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLicenseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateValueOfMilestoneEvents" xlink:label="loc_CELCAggregateValueOfMilestoneEvents_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAggregateValueOfMilestoneEvents_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentOnMilestoneEventOne" xlink:label="loc_CELCPaymentOnMilestoneEventOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCPaymentOnMilestoneEventOne_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpenseMilestone" xlink:label="loc_CELCResearchAndDevelopmentExpenseMilestone_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCResearchAndDevelopmentExpenseMilestone_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateOfferingAmount" xlink:label="loc_CELCAggregateOfferingAmount_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CELCAggregateOfferingAmount_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="loc_us-gaapUsefulLifeDescriptionOfTermDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUsefulLifeDescriptionOfTermDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" order="1000" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:label="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>celc-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:label="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:to="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember_lbl" xml:lang="en-US">Senior Notes Due 2031 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="CELC_OptionsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OptionsToPurchaseCommonStockMember" xlink:to="CELC_OptionsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ConvertibleNotesToCommonStockMember" xlink:label="CELC_ConvertibleNotesToCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ConvertibleNotesToCommonStockMember" xlink:to="CELC_ConvertibleNotesToCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ConvertibleNotesToCommonStockMember_lbl" xml:lang="en-US">Convertible notes to common stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="CELC_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantsToPurchaseCommonStockMember" xlink:to="CELC_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:to="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_lbl" xml:lang="en-US">Preferred Stock On An As If Converted To Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="CELC_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_UnderwritingAgreementMember" xlink:label="CELC_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwritingAgreementMember" xlink:to="CELC_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:label="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:to="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember_lbl" xml:lang="en-US">July 2025 Equity Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="CELC_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantsMember" xlink:to="CELC_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="CELC_LeerinkPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LeerinkPartnersLLCMember" xlink:to="CELC_LeerinkPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LeerinkPartnersLLCMember_lbl" xml:lang="en-US">Leerink Partners LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="CELC_OpenMarketSaleAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OpenMarketSaleAgreementMember_lbl" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JefferiesLLCMember" xlink:label="CELC_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOneMember" xlink:label="CELC_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOneMember" xlink:to="CELC_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTwoMember" xlink:label="CELC_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTwoMember" xlink:to="CELC_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantThreeMember" xlink:label="CELC_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantThreeMember" xlink:to="CELC_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFourMember" xlink:label="CELC_WarrantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFourMember" xlink:to="CELC_WarrantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantFourMember_lbl" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFiveMember" xlink:label="CELC_WarrantFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFiveMember" xlink:to="CELC_WarrantFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantFiveMember_lbl" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSixMember" xlink:label="CELC_WarrantSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSixMember" xlink:to="CELC_WarrantSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantSixMember_lbl" xml:lang="en-US">Warrant Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSevenMember" xlink:label="CELC_WarrantSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSevenMember" xlink:to="CELC_WarrantSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantSevenMember_lbl" xml:lang="en-US">Warrant Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantEightMember" xlink:label="CELC_WarrantEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantEightMember" xlink:to="CELC_WarrantEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantEightMember_lbl" xml:lang="en-US">Warrant Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantNineMember" xlink:label="CELC_WarrantNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantNineMember" xlink:to="CELC_WarrantNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantNineMember_lbl" xml:lang="en-US">Warrant Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTenMember" xlink:label="CELC_WarrantTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTenMember" xlink:to="CELC_WarrantTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantTenMember_lbl" xml:lang="en-US">Warrant Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantElevenMember" xlink:label="CELC_WarrantElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantElevenMember" xlink:to="CELC_WarrantElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantElevenMember_lbl" xml:lang="en-US">Warrant Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="CELC_TwoThousandTwelveEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="CELC_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US">2012 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:label="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:to="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_lbl" xml:lang="en-US">2017 Amended And Restated Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="CELC_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2017 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceAxis" xlink:label="CELC_StatementOfIncomeLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StatementOfIncomeLocationBalanceAxis" xlink:to="CELC_StatementOfIncomeLocationBalanceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StatementOfIncomeLocationBalanceAxis_lbl" xml:lang="en-US">Statement of Income Location Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpensesMember" xlink:label="CELC_ResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ResearchAndDevelopmentExpensesMember" xlink:to="CELC_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_GeneralAndAdministrativeExpensesMember" xlink:label="CELC_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GeneralAndAdministrativeExpensesMember" xlink:to="CELC_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_GeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoteUnderwritingAgreementMember" xlink:label="CELC_NoteUnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoteUnderwritingAgreementMember" xlink:to="CELC_NoteUnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NoteUnderwritingAgreementMember_lbl" xml:lang="en-US">Note Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:label="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:to="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_lbl" xml:lang="en-US">July 2025 Convertible Notes Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedAndRestatedLoanAgreementMember" xlink:to="CELC_AmendedAndRestatedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember_lbl" xml:lang="en-US">Amended and Restated Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="CELC_InnovatusLifeSciencesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InnovatusLifeSciencesMember_lbl" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermDLoanMember" xlink:label="CELC_TermDLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermDLoanMember_lbl" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermELoanMember" xlink:label="CELC_TermELoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermELoanMember_lbl" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermETwoLoanMember" xlink:label="CELC_TermETwoLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermETwoLoanMember" xlink:to="CELC_TermETwoLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermETwoLoanMember_lbl" xml:lang="en-US">Term E Two Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFLoanMember" xlink:label="CELC_TermFLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFLoanMember" xlink:to="CELC_TermFLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermFLoanMember_lbl" xml:lang="en-US">Term F Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFTwoLoanMember" xlink:label="CELC_TermFTwoLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFTwoLoanMember" xlink:to="CELC_TermFTwoLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermFTwoLoanMember_lbl" xml:lang="en-US">Term F Two Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermGLoanMember" xlink:label="CELC_TermGLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermGLoanMember" xlink:to="CELC_TermGLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermGLoanMember_lbl" xml:lang="en-US">Term G Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Third Amendment to Amended and Restated Loan and Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Second Amendment To Amended And Restated Loan And Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LoanAgreementMember" xlink:label="CELC_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanAgreementMember" xlink:to="CELC_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermALoanMember" xlink:label="CELC_TermALoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermALoanMember" xlink:to="CELC_TermALoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermALoanMember_lbl" xml:lang="en-US">Term A Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermBLoanMember" xlink:label="CELC_TermBLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermBLoanMember_lbl" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermCLoanMember" xlink:label="CELC_TermCLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermCLoanMember_lbl" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PriorLoanAgreementMember" xlink:label="CELC_PriorLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PriorLoanAgreementMember" xlink:to="CELC_PriorLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PriorLoanAgreementMember_lbl" xml:lang="en-US">Prior Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PfizerLicenseAgreementMember" xlink:label="CELC_PfizerLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PfizerLicenseAgreementMember" xlink:to="CELC_PfizerLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PfizerLicenseAgreementMember_lbl" xml:lang="en-US">Pfizer License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementMember" xlink:label="CELC_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementMember" xlink:to="CELC_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AccruedClinicalTrialCosts" xlink:label="CELC_AccruedClinicalTrialCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AccruedClinicalTrialCosts" xlink:to="CELC_AccruedClinicalTrialCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AccruedClinicalTrialCosts_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of preferred stock to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Employee stock purchases, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an ATM offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an ATM offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of common stock warrants, note payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_lbl" xml:lang="en-US">Issuance of common stock warrants in connection with note agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash and cash equivalents used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Payment-in-kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="CELC_NoncashOperatingLeaseExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoncashOperatingLeaseExpenseNet" xlink:to="CELC_NoncashOperatingLeaseExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NoncashOperatingLeaseExpenseNet_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="CELC_ChangeInAccruedInterestIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_ChangeInAccruedInterestIncome_lbl" xml:lang="en-US">Change in accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current and non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:label="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:to="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xml:lang="en-US">Proceeds from maturities of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchases of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from equity offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:to="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from an ATM offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_lbl" xml:lang="en-US">Payments for secondary registration statement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_CashPaidForOperatingLeases" xlink:label="CELC_CashPaidForOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingLeases" xlink:to="CELC_CashPaidForOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CashPaidForOperatingLeases_lbl" xml:lang="en-US">Cash paid for operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:to="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_lbl" xml:lang="en-US">Common stock warrants issued with the note payable transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Deferred financing, offering and registration statement costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Proceeds from convertible note payable, net of debt issuance cost and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b51 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b51 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b51 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Other Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DisclosureLicenseAgreementAbstract" xlink:label="CELC_DisclosureLicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DisclosureLicenseAgreementAbstract" xlink:to="CELC_DisclosureLicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DisclosureLicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementTestBlock" xlink:label="CELC_LicenseAgreementTestBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementTestBlock" xlink:to="CELC_LicenseAgreementTestBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_LicenseAgreementTestBlock_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AllowanceForCreditLossesPolicyTextBlock" xlink:label="CELC_AllowanceForCreditLossesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AllowanceForCreditLossesPolicyTextBlock" xlink:to="CELC_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AllowanceForCreditLossesPolicyTextBlock_lbl" xml:lang="en-US">Allowance for Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy" xlink:label="us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy" xlink:to="us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy_lbl" xml:lang="en-US">Capitalized Software Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Transaction Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">Clinical Trial Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicensesPolicyTextBlock" xlink:label="CELC_LicensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicensesPolicyTextBlock" xlink:to="CELC_LicensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicensesPolicyTextBlock_lbl" xml:lang="en-US">Licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PatentCostsPolicyTextBlock" xlink:label="CELC_PatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PatentCostsPolicyTextBlock" xlink:to="CELC_PatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Data</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" xlink:label="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" xlink:to="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Award And Restricted Stock Unit Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Long Term Debt Future Principal Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_2_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Accrue interest payable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Capitalized software development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantShares" xlink:label="CELC_PrefundedWarrantShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantShares" xlink:to="CELC_PrefundedWarrantShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PrefundedWarrantShares_lbl" xml:lang="en-US">Pre-funded warrant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xml:lang="en-US">Amortized Cost, as Adjusted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xml:lang="en-US">Gross Unrealized Holding Gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xml:lang="en-US">Gross Unrealized Holding Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xml:lang="en-US">Estimated Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedLicenseMilestone" xlink:label="CELC_OtherAccruedLicenseMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OtherAccruedLicenseMilestone" xlink:to="CELC_OtherAccruedLicenseMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OtherAccruedLicenseMilestone_lbl" xml:lang="en-US">License milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedInterest" xlink:label="CELC_OtherAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OtherAccruedInterest" xlink:to="CELC_OtherAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OtherAccruedInterest_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Consulting and professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable included accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:label="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:to="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: operating lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Square feet</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease option to extend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Initial annual lease payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Undiscounted future minimum lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Non-cancelable contractual commitment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="us-gaap_RegistrationPaymentArrangementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementTerm" xlink:to="us-gaap_RegistrationPaymentArrangementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementTerm_lbl" xml:lang="en-US">Registration rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:to="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Common stock warrants, outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted- average exercise price per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Common stock warrants, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted- average exercise price per share, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Common stock warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_lbl" xml:lang="en-US">Weighted- average exercise price per share, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl" xml:lang="en-US">Common stock warrants, surrendered upon cashless exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_lbl" xml:lang="en-US">Weighted- average exercise price per share, surrendered upon cashless exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Common stock warrants, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_lbl" xml:lang="en-US">Weighted- average exercise price per share, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Common stock warrants, outstanding shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted- average exercise price per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Prefunded warrant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Warrant purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">The number of additional common stock shares the Underwriters can purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">The cash inflow associated with the amount received from entity's offering of stock to the public</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Pre-funded warrant exercisable description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:to="CELC_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US">Net proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Commissions and other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Pre-funded warrants sold to investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Additional warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warant exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Common stock warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xml:lang="en-US">Common stock converted basis</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_lbl" xml:lang="en-US">Conversion of preferred to common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding at end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price at end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Outstanding shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant date fair value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesTable" xlink:label="CELC_StockBasedCompensationExpensesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockBasedCompensationExpensesTable" xlink:to="CELC_StockBasedCompensationExpensesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockBasedCompensationExpensesTable_lbl" xml:lang="en-US">StockBasedCompensationExpensesTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesLineItem" xlink:label="CELC_StockBasedCompensationExpensesLineItem" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockBasedCompensationExpensesLineItem" xlink:to="CELC_StockBasedCompensationExpensesLineItem_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockBasedCompensationExpensesLineItem_lbl" xml:lang="en-US">StockBasedCompensationExpensesLineItem [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Number of shares reserved for issuance description</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:to="CELC_ChangeInCommonStockSharesReservedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance_lbl" xml:lang="en-US">Change in common stock, shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xml:lang="en-US">Number of shares reserved for issuance, additional increases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Option vested percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Option vested period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xml:lang="en-US">Remaining stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Total fair value of restricted stock vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xml:lang="en-US">Employee stock purchase plan description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFee" xlink:label="CELC_FinalFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinalFee_lbl" xml:lang="en-US">Add: Final fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="CELC_PaymentInKindInterestDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentInKindInterestDebt_lbl" xml:lang="en-US">Add: PIK interest (added to principal)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: unamortized debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermNotesPayable_2_lbl" xml:lang="en-US">Total long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Net proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Redemption description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Consecutive trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">First Amendment description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure" xlink:label="us-gaap_NotesReceivableFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableFairValueDisclosure" xlink:to="us-gaap_NotesReceivableFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableFairValueDisclosure_lbl" xml:lang="en-US">Fair value of the Notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Discount amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Discount amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DisbursementLoanAmount" xlink:label="CELC_DisbursementLoanAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DisbursementLoanAmount" xlink:to="CELC_DisbursementLoanAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DisbursementLoanAmount_lbl" xml:lang="en-US">Disbursement loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Contingent loan</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendmentFee" xlink:label="CELC_AmendmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendmentFee" xlink:to="CELC_AmendmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AmendmentFee_lbl" xml:lang="en-US">Amendment fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Net proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DebtFinalFeePercentage" xlink:label="CELC_DebtFinalFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DebtFinalFeePercentage" xlink:to="CELC_DebtFinalFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DebtFinalFeePercentage_lbl" xml:lang="en-US">Debt final fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Funded loan amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Conversion percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Amount of indebtedness eligible to incur under Term D Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherBorrowings" xlink:label="us-gaap_OtherBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherBorrowings" xlink:to="us-gaap_OtherBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherBorrowings_lbl" xml:lang="en-US">Costs associated with new borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Debt instrument interest rate description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFeePercentage" xlink:label="CELC_FinalFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePercentage" xlink:to="CELC_FinalFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinalFeePercentage_lbl" xml:lang="en-US">Final fee percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_FinalFee_2_lbl" xml:lang="en-US">Final fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="CELC_WarrantOrRightToPurchasePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOrRightToPurchasePercentage" xlink:to="CELC_WarrantOrRightToPurchasePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_WarrantOrRightToPurchasePercentage_lbl" xml:lang="en-US">Warrant or right, reason for issuance, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Fair value of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementTable" xlink:label="CELC_LicenseAgreementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementTable" xlink:to="CELC_LicenseAgreementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicenseAgreementTable_lbl" xml:lang="en-US">LicenseAgreementTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for upfront fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateValueOfMilestoneEvents" xlink:label="CELC_AggregateValueOfMilestoneEvents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AggregateValueOfMilestoneEvents" xlink:to="CELC_AggregateValueOfMilestoneEvents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AggregateValueOfMilestoneEvents_lbl" xml:lang="en-US">Aggregate value of milestone events</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentOnMilestoneEventOne" xlink:label="CELC_PaymentOnMilestoneEventOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentOnMilestoneEventOne" xlink:to="CELC_PaymentOnMilestoneEventOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentOnMilestoneEventOne_lbl" xml:lang="en-US">Payment on milestone event one</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpenseMilestone" xlink:label="CELC_ResearchAndDevelopmentExpenseMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ResearchAndDevelopmentExpenseMilestone" xlink:to="CELC_ResearchAndDevelopmentExpenseMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ResearchAndDevelopmentExpenseMilestone_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit at statutory rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Federal change in valuation allowance on deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Federal change in valuation allowance on deferred tax assets, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Federal research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Federal research and development credits, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year adjustments, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible items, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax expense (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax expense (benefit), percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsRightofuseAssets" xlink:to="CELC_DeferredTaxAssetsRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="CELC_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_lbl" xml:lang="en-US">Section 174 expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_lbl" xml:lang="en-US">Start-up expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses and tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Accrued interest or penalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateOfferingAmount" xlink:label="CELC_AggregateOfferingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AggregateOfferingAmount" xlink:to="CELC_AggregateOfferingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AggregateOfferingAmount_lbl" xml:lang="en-US">Aggregate offering amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_doc" xml:lang="en-US">Conversion of preferred to common stock, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">Exercise of common stock warrants, net of shares withheld for exercise price, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xml:lang="en-US">Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xml:lang="en-US">Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement_doc" xml:lang="en-US">Stock issued during period value issuance of common stock warrants in connection with note agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoncashOperatingLeaseExpenseNet" xlink:to="CELC_NoncashOperatingLeaseExpenseNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NoncashOperatingLeaseExpenseNet_doc" xml:lang="en-US">Noncash operating lease expense net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ChangeInAccruedInterestIncome_doc" xml:lang="en-US">Change in accrued interest income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:to="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_doc" xml:lang="en-US">Increase decrease in accrued clinical trial costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_doc" xml:lang="en-US">Payments for secondary registration statement costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:to="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds from atm offering net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xml:lang="en-US">Deferred financing costs and offering and registration statement costs included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xml:lang="en-US">Property and equipment included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:to="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_CommonStockWarrantsIssuedWithNotePayableTransaction_doc" xml:lang="en-US">Common stock warrants issued with note payable transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AccruedClinicalTrialCosts" xlink:to="CELC_AccruedClinicalTrialCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AccruedClinicalTrialCosts_doc" xml:lang="en-US">Accrued clinical trial costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CashPaidForOperatingLeases" xlink:to="CELC_CashPaidForOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_CashPaidForOperatingLeases_doc" xml:lang="en-US">Cash paid for operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AllowanceForCreditLossesPolicyTextBlock" xlink:to="CELC_AllowanceForCreditLossesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AllowanceForCreditLossesPolicyTextBlock_doc" xml:lang="en-US">Allowance For Credit Losses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicensesPolicyTextBlock" xlink:to="CELC_LicensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LicensesPolicyTextBlock_doc" xml:lang="en-US">Licenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PatentCostsPolicyTextBlock" xlink:to="CELC_PatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PatentCostsPolicyTextBlock_doc" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" xlink:to="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recent Accounting Prononcement Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantShares" xlink:to="CELC_PrefundedWarrantShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PrefundedWarrantShares_doc" xml:lang="en-US">Prefunded warrant, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OtherAccruedLicenseMilestone" xlink:to="CELC_OtherAccruedLicenseMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OtherAccruedLicenseMilestone_doc" xml:lang="en-US">Other accrued license milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OtherAccruedInterest" xlink:to="CELC_OtherAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OtherAccruedInterest_doc" xml:lang="en-US">Other accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:to="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_doc" xml:lang="en-US">Lessee operating lease liability payments due after year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwritingAgreementMember" xlink:to="CELC_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:to="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember_doc" xml:lang="en-US">July 2025 Equity Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrefundedWarrantsMember" xlink:to="CELC_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PrefundedWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LeerinkPartnersLLCMember" xlink:to="CELC_LeerinkPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LeerinkPartnersLLCMember_doc" xml:lang="en-US">Leerink Partners LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:to="CELC_ProceedsFromIssuanceOfCommonStockNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromIssuanceOfCommonStockNet_doc" xml:lang="en-US">Proceeds from issuance of common stock net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OpenMarketSaleAgreementMember_doc" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:to="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_doc" xml:lang="en-US">Class of warrant or righst date from which warrants or rights issue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOneMember" xlink:to="CELC_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTwoMember" xlink:to="CELC_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantThreeMember" xlink:to="CELC_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFourMember" xlink:to="CELC_WarrantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantFourMember_doc" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantFiveMember" xlink:to="CELC_WarrantFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantFiveMember_doc" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSixMember" xlink:to="CELC_WarrantSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantSixMember_doc" xml:lang="en-US">Warrant Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantSevenMember" xlink:to="CELC_WarrantSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantSevenMember_doc" xml:lang="en-US">Warrant Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantEightMember" xlink:to="CELC_WarrantEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantEightMember_doc" xml:lang="en-US">Warrant Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantNineMember" xlink:to="CELC_WarrantNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantNineMember_doc" xml:lang="en-US">Warrant Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantTenMember" xlink:to="CELC_WarrantTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantTenMember_doc" xml:lang="en-US">Warrant Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantElevenMember" xlink:to="CELC_WarrantElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantElevenMember_doc" xml:lang="en-US">Warrant Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:to="CELC_ChangeInCommonStockSharesReservedForIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ChangeInCommonStockSharesReservedForIssuance_doc" xml:lang="en-US">Change in common stock, shares reserved for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xml:lang="en-US">Remaining stock based compensation expense related to modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NoteUnderwritingAgreementMember" xlink:to="CELC_NoteUnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NoteUnderwritingAgreementMember_doc" xml:lang="en-US">Note Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:to="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_doc" xml:lang="en-US">July 2025 Convertible Notes Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DisbursementLoanAmount" xlink:to="CELC_DisbursementLoanAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DisbursementLoanAmount_doc" xml:lang="en-US">Disbursement loan amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedAndRestatedLoanAgreementMember" xlink:to="CELC_AmendedAndRestatedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AmendedAndRestatedLoanAgreementMember_doc" xml:lang="en-US">Amended and Restated Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InnovatusLifeSciencesMember_doc" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermDLoanMember_doc" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermELoanMember_doc" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermETwoLoanMember" xlink:to="CELC_TermETwoLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermETwoLoanMember_doc" xml:lang="en-US">Term E Two Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFLoanMember" xlink:to="CELC_TermFLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermFLoanMember_doc" xml:lang="en-US">Term F Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermFTwoLoanMember" xlink:to="CELC_TermFTwoLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermFTwoLoanMember_doc" xml:lang="en-US">Term F Two Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermGLoanMember" xlink:to="CELC_TermGLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermGLoanMember_doc" xml:lang="en-US">Term G Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendmentFee" xlink:to="CELC_AmendmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AmendmentFee_doc" xml:lang="en-US">Amendment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DebtFinalFeePercentage" xlink:to="CELC_DebtFinalFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DebtFinalFeePercentage_doc" xml:lang="en-US">Debt final fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xml:lang="en-US">Third Amendment to Amended and Restated Loan and Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_doc" xml:lang="en-US">Second Amendment To Amended And Restated Loan And Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanAgreementMember" xlink:to="CELC_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermALoanMember" xlink:to="CELC_TermALoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermALoanMember_doc" xml:lang="en-US">Term A Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermBLoanMember_doc" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermCLoanMember_doc" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PriorLoanAgreementMember" xlink:to="CELC_PriorLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PriorLoanAgreementMember_doc" xml:lang="en-US">Prior Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePercentage" xlink:to="CELC_FinalFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinalFeePercentage_doc" xml:lang="en-US">Final fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFee" xlink:to="CELC_FinalFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinalFee_doc" xml:lang="en-US">Final fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantOrRightToPurchasePercentage" xlink:to="CELC_WarrantOrRightToPurchasePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantOrRightToPurchasePercentage_doc" xml:lang="en-US">Warrant or right, reason for issuance, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentInKindInterestDebt_doc" xml:lang="en-US">Payment in kind interest debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementTestBlock" xlink:to="CELC_LicenseAgreementTestBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LicenseAgreementTestBlock_doc" xml:lang="en-US">License Agreement [Test Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PfizerLicenseAgreementMember" xlink:to="CELC_PfizerLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PfizerLicenseAgreementMember_doc" xml:lang="en-US">Pfizer License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AggregateValueOfMilestoneEvents" xlink:to="CELC_AggregateValueOfMilestoneEvents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AggregateValueOfMilestoneEvents_doc" xml:lang="en-US">Aggregate value of milestone events</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementMember" xlink:to="CELC_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentOnMilestoneEventOne" xlink:to="CELC_PaymentOnMilestoneEventOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentOnMilestoneEventOne_doc" xml:lang="en-US">Payment on milestone event one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember_doc" xml:lang="en-US">2017 Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsRightofuseAssets" xlink:to="CELC_DeferredTaxAssetsRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsRightofuseAssets_doc" xml:lang="en-US">Deferred tax assets right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_doc" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:to="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_doc" xml:lang="en-US">Start-up expenditures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="CELC_TwoThousandTwelveEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandTwelveEquityIncentivePlanMember_doc" xml:lang="en-US">2012 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:to="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_doc" xml:lang="en-US">2017 Amended And Restated Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted- average exercise price per share, outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted- average exercise price per share, issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_doc" xml:lang="en-US">Weighted- average exercise price per share, exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_doc" xml:lang="en-US">Weighted- average exercise price per share, surrendered upon cashless exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_doc" xml:lang="en-US">Weighted- average exercise price per share, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AggregateOfferingAmount" xlink:to="CELC_AggregateOfferingAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AggregateOfferingAmount_doc" xml:lang="en-US">Aggregate offering amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OptionsToPurchaseCommonStockMember" xlink:to="CELC_OptionsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OptionsToPurchaseCommonStockMember_doc" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ConvertibleNotesToCommonStockMember" xlink:to="CELC_ConvertibleNotesToCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ConvertibleNotesToCommonStockMember_doc" xml:lang="en-US">Convertible Notes to Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_WarrantsToPurchaseCommonStockMember" xlink:to="CELC_WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:to="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember_doc" xml:lang="en-US">Preferred Stock On An As If Converted To Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:to="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of preferred stock to common stock value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:to="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares_doc" xml:lang="en-US">Conversion of preferred stock to common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:to="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember_doc" xml:lang="en-US">Senior Notes Due 2031 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StatementOfIncomeLocationBalanceAxis" xlink:to="CELC_StatementOfIncomeLocationBalanceAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StatementOfIncomeLocationBalanceAxis_doc" xml:lang="en-US">Statement of Income Location Balance [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ResearchAndDevelopmentExpensesMember" xlink:to="CELC_ResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">Research and Development Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GeneralAndAdministrativeExpensesMember" xlink:to="CELC_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ResearchAndDevelopmentExpenseMilestone" xlink:to="CELC_ResearchAndDevelopmentExpenseMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ResearchAndDevelopmentExpenseMilestone_doc" xml:lang="en-US">Research and development expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ChangeInAccruedInterestIncome" xlink:to="CELC_ChangeInAccruedInterestIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ChangeInAccruedInterestIncome_3_lbl" xml:lang="en-US">ChangeInAccruedInterestIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:to="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IncreaseDecreaseInAccruedClinicalTrialCosts_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedClinicalTrialCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:to="CELC_PaymentsForSecondaryRegistrationStatementCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentsForSecondaryRegistrationStatementCosts_3_lbl" xml:lang="en-US">PaymentsForSecondaryRegistrationStatementCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_2_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_2_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_2_lbl" xml:lang="en-US">Investment [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementTestBlock" xlink:to="CELC_LicenseAgreementTestBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicenseAgreementTestBlock_3_lbl" xml:lang="en-US">License Agreement [Test Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_2_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:to="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredTaxAssetsLeaseLiability" xlink:to="CELC_DeferredTaxAssetsLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredTaxAssetsLeaseLiability_3_lbl" xml:lang="en-US">DeferredTaxAssetsLeaseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>celc-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Cover" roleURI="http://celcuity.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheets" roleURI="http://celcuity.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfOperations" roleURI="http://celcuity.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlows" roleURI="http://celcuity.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StatementsOfCashFlowsParenthetical" roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidity" roleURI="http://celcuity.com/role/OrganizationAndLiquidity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShare" roleURI="http://celcuity.com/role/NetLossPerCommonShare" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Investments" roleURI="http://celcuity.com/role/Investments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipment" roleURI="http://celcuity.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpenses" roleURI="http://celcuity.com/role/OtherAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Commitments" roleURI="http://celcuity.com/role/Commitments" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquity" roleURI="http://celcuity.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensation" roleURI="http://celcuity.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Debt" roleURI="http://celcuity.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreement" roleURI="http://celcuity.com/role/LicenseAgreement" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxes" roleURI="http://celcuity.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEvents" roleURI="http://celcuity.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareTables" roleURI="http://celcuity.com/role/NetLossPerCommonShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#InvestmentsTables" roleURI="http://celcuity.com/role/InvestmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://celcuity.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesTables" roleURI="http://celcuity.com/role/OtherAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsTables" roleURI="http://celcuity.com/role/CommitmentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityTables" roleURI="http://celcuity.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationTables" roleURI="http://celcuity.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtTables" roleURI="http://celcuity.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesTables" roleURI="http://celcuity.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OrganizationAndLiquidityDetailsNarrative" roleURI="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#NetLossPerCommonShareDetailsNarrative" roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfInvestmentDetails" roleURI="http://celcuity.com/role/ScheduleOfInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SummaryOfPropertyAndEquipmentDetails" roleURI="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfOtherAccruedExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#OtherAccruedExpensesDetailsNarrative" roleURI="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfMinimumLeasePaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLeaseCostsDetails" roleURI="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#CommitmentsDetailsNarrative" roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfCommonStockWarrantsOutstandingDetails" roleURI="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#StockholdersEquityDetailsNarrative" roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" roleURI="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfStock-basedCompensationExpensesDetails" roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLong-termDebtDetails" roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#DebtDetailsNarrative" roleURI="http://celcuity.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#LicenseAgreementDetailsNarrative" roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://celcuity.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="celc-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AccruedClinicalTrialCosts" xlink:label="loc_CELCAccruedClinicalTrialCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_CELCAccruedClinicalTrialCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoncashOperatingLeaseExpenseNet" xlink:label="loc_CELCNoncashOperatingLeaseExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCNoncashOperatingLeaseExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInAccruedInterestIncome" xlink:label="loc_CELCChangeInAccruedInterestIncome" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCChangeInAccruedInterestIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_IncreaseDecreaseInAccruedClinicalTrialCosts" xlink:label="loc_CELCIncreaseDecreaseInAccruedClinicalTrialCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_CELCIncreaseDecreaseInAccruedClinicalTrialCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaapProceedsFromStockPlans" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:label="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCProceedsFromAtmOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentsForSecondaryRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCPaymentsForSecondaryRegistrationStatementCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_CashPaidForOperatingLeases" xlink:label="loc_CELCCashPaidForOperatingLeases" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CELCCashPaidForOperatingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_CommonStockWarrantsIssuedWithNotePayableTransaction" xlink:label="loc_CELCCommonStockWarrantsIssuedWithNotePayableTransaction" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCCommonStockWarrantsIssuedWithNotePayableTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidity" xlink:title="999015 - Disclosure - Organization and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="999017 - Disclosure - Net Loss Per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Investments" xlink:title="999018 - Disclosure - Investments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaapInvestmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipment" xlink:title="999019 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpenses" xlink:title="999020 - Disclosure - Other Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="999021 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="999022 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="999024 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="999025 - Disclosure - License Agreement">
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DisclosureLicenseAgreementAbstract" xlink:label="loc_CELCDisclosureLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementTestBlock" xlink:label="loc_CELCLicenseAgreementTestBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCDisclosureLicenseAgreementAbstract" xlink:to="loc_CELCLicenseAgreementTestBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AllowanceForCreditLossesPolicyTextBlock" xlink:label="loc_CELCAllowanceForCreditLossesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCAllowanceForCreditLossesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy" xlink:label="loc_us-gaapCapitalizationAndAmortizationOfFuelCostsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCapitalizationAndAmortizationOfFuelCostsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicensesPolicyTextBlock" xlink:label="loc_CELCLicensesPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCLicensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PatentCostsPolicyTextBlock" xlink:label="loc_CELCPatentCostsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock" xlink:label="loc_CELCRecentAccountingPrononcementAdoptedPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCRecentAccountingPrononcementAdoptedPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_CELCScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareTables" xlink:title="999030 - Disclosure - Net Loss Per Common Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/InvestmentsTables" xlink:title="999031 - Disclosure - Investments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentTables" xlink:title="999032 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesTables" xlink:title="999033 - Disclosure - Other Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="999034 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="999036 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="999037 - Disclosure - Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="999039 - Disclosure - Organization and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:label="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCSeniorNotesDueTwoThousandAndThirtyOneNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails" xlink:title="999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OptionsToPurchaseCommonStockMember" xlink:label="loc_CELCOptionsToPurchaseCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCOptionsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ConvertibleNotesToCommonStockMember" xlink:label="loc_CELCConvertibleNotesToCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCConvertibleNotesToCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CELCWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CELCWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:label="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPreferredStockOnAnAsIfConvertedToCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="999043 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantShares" xlink:label="loc_CELCPrefundedWarrantShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCPrefundedWarrantShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfInvestmentDetails" xlink:title="999044 - Disclosure - Schedule of Investment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails" xlink:title="999045 - Disclosure - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999046 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails" xlink:title="999047 - Disclosure - Schedule of Other Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedLicenseMilestone" xlink:label="loc_CELCOtherAccruedLicenseMilestone" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELCOtherAccruedLicenseMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OtherAccruedInterest" xlink:label="loc_CELCOtherAccruedInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELCOtherAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative" xlink:title="999048 - Disclosure - Other Accrued Expenses (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails" xlink:title="999049 - Disclosure - Schedule of Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:label="loc_CELCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CELCLesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999050 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="999051 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="loc_us-gaapRegistrationPaymentArrangementTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails" xlink:title="999052 - Disclosure - Schedule of Common Stock Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOneMember" xlink:label="loc_CELCWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTwoMember" xlink:label="loc_CELCWarrantTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantThreeMember" xlink:label="loc_CELCWarrantThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFourMember" xlink:label="loc_CELCWarrantFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantFiveMember" xlink:label="loc_CELCWarrantFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSixMember" xlink:label="loc_CELCWarrantSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantSevenMember" xlink:label="loc_CELCWarrantSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantEightMember" xlink:label="loc_CELCWarrantEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantNineMember" xlink:label="loc_CELCWarrantNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantTenMember" xlink:label="loc_CELCWarrantTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantElevenMember" xlink:label="loc_CELCWarrantElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCWarrantElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:label="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELCClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails" xlink:title="999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue" xlink:label="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CELCShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="999054 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_UnderwritingAgreementMember" xlink:label="loc_CELCUnderwritingAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELCPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LeerinkPartnersLLCMember" xlink:label="loc_CELCLeerinkPartnersLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCLeerinkPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PrefundedWarrantsMember" xlink:label="loc_CELCPrefundedWarrantsMember_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELCPrefundedWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_CELCProceedsFromIssuanceOfCommonStockNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCProceedsFromIssuanceOfCommonStockNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:label="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999055 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails" xlink:title="999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails" xlink:title="999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails" xlink:title="999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesAbstract" xlink:label="loc_CELCStockBasedCompensationExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesTable" xlink:label="loc_CELCStockBasedCompensationExpensesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStockBasedCompensationExpensesAbstract" xlink:to="loc_CELCStockBasedCompensationExpensesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StockBasedCompensationExpensesLineItem" xlink:label="loc_CELCStockBasedCompensationExpensesLineItem" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStockBasedCompensationExpensesTable" xlink:to="loc_CELCStockBasedCompensationExpensesLineItem" order="200" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_CELCStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStockBasedCompensationExpensesTable" xlink:to="loc_CELCStatementOfIncomeLocationBalanceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CELCStatementOfIncomeLocationBalanceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CELCStatementOfIncomeLocationBalanceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpensesMember" xlink:label="loc_CELCResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CELCResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_GeneralAndAdministrativeExpensesMember" xlink:label="loc_CELCGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CELCGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCStockBasedCompensationExpensesLineItem" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="loc_CELCTwoThousandTwelveEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandTwelveEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:label="loc_CELCTwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:label="loc_CELCTwoThousandSeventeenEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ChangeInCommonStockSharesReservedForIssuance" xlink:label="loc_CELCChangeInCommonStockSharesReservedForIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCChangeInCommonStockSharesReservedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999060 - Disclosure - Schedule of Long-term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCFinalFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentInKindInterestDebt" xlink:label="loc_CELCPaymentInKindInterestDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCPaymentInKindInterestDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="999062 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_NoteUnderwritingAgreementMember" xlink:label="loc_CELCNoteUnderwritingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCNoteUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_CELCThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="loc_CELCSecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:label="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCJulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendedAndRestatedLoanAgreementMember" xlink:label="loc_CELCAmendedAndRestatedLoanAgreementMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedAndRestatedLoanAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PriorLoanAgreementMember" xlink:label="loc_CELCPriorLoanAgreementMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCPriorLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermETwoLoanMember" xlink:label="loc_CELCTermETwoLoanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermETwoLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFLoanMember" xlink:label="loc_CELCTermFLoanMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermFTwoLoanMember" xlink:label="loc_CELCTermFTwoLoanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermFTwoLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermGLoanMember" xlink:label="loc_CELCTermGLoanMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermGLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermALoanMember" xlink:label="loc_CELCTermALoanMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermALoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure" xlink:label="loc_us-gaapNotesReceivableFairValueDisclosure" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesReceivableFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DisbursementLoanAmount" xlink:label="loc_CELCDisbursementLoanAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCDisbursementLoanAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AmendmentFee" xlink:label="loc_CELCAmendmentFee" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCAmendmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DebtFinalFeePercentage" xlink:label="loc_CELCDebtFinalFeePercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCDebtFinalFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherBorrowings" xlink:label="loc_us-gaapOtherBorrowings" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFeePercentage" xlink:label="loc_CELCFinalFeePercentage" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_FinalFee" xlink:label="loc_CELCFinalFee" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_WarrantOrRightToPurchasePercentage" xlink:label="loc_CELCWarrantOrRightToPurchasePercentage" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCWarrantOrRightToPurchasePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="999063 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementAbstract" xlink:label="loc_CELCLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementTable" xlink:label="loc_CELCLicenseAgreementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCLicenseAgreementAbstract" xlink:to="loc_CELCLicenseAgreementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PfizerLicenseAgreementMember" xlink:label="loc_CELCPfizerLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCPfizerLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_LicenseAgreementMember" xlink:label="loc_CELCLicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCLicenseAgreementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateValueOfMilestoneEvents" xlink:label="loc_CELCAggregateValueOfMilestoneEvents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCAggregateValueOfMilestoneEvents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_PaymentOnMilestoneEventOne" xlink:label="loc_CELCPaymentOnMilestoneEventOne" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCPaymentOnMilestoneEventOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_ResearchAndDevelopmentExpenseMilestone" xlink:label="loc_CELCResearchAndDevelopmentExpenseMilestone" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCResearchAndDevelopmentExpenseMilestone" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsRightofuseAssets" xlink:label="loc_CELCDeferredTaxAssetsRightofuseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsLeaseLiability" xlink:label="loc_CELCDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:label="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELCDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20251231.xsd#CELC_AggregateOfferingAmount" xlink:label="loc_CELCAggregateOfferingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CELCAggregateOfferingAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 17, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celcuity
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001603454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2863566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16305
    36th<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Avenue
    North<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite
    100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-0767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457,485,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,336,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions
of the registrant&#8217;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders are incorporated by reference
into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2025 and 2024, and the related statements
of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31,
2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally
accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Boulay LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis,
Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 165,703<span></span>
</td>
<td class="nump">$ 22,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">275,794<span></span>
</td>
<td class="nump">212,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid clinical trial costs</a></td>
<td class="nump">18,896<span></span>
</td>
<td class="nump">6,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">2,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">465,659<span></span>
</td>
<td class="nump">244,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">349<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">466,558<span></span>
</td>
<td class="nump">245,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,407<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">16,826<span></span>
</td>
<td class="nump">16,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">20,865<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,152<span></span>
</td>
<td class="nump">31,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="nump">195,324<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">126,527<span></span>
</td>
<td class="nump">97,727<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">366,003<span></span>
</td>
<td class="nump">129,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">549,404<span></span>
</td>
<td class="nump">387,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(448,897)<span></span>
</td>
<td class="num">(271,855)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">100,555<span></span>
</td>
<td class="nump">115,619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 466,558<span></span>
</td>
<td class="nump">$ 245,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">48,244,960<span></span>
</td>
<td class="nump">37,143,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,244,960<span></span>
</td>
<td class="nump">37,143,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 144,995<span></span>
</td>
<td class="nump">$ 104,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,197<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">172,192<span></span>
</td>
<td class="nump">113,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(172,192)<span></span>
</td>
<td class="num">(113,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(17,148)<span></span>
</td>
<td class="num">(10,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">12,298<span></span>
</td>
<td class="nump">11,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(4,850)<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(177,042)<span></span>
</td>
<td class="num">(111,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (177,042)<span></span>
</td>
<td class="num">$ (111,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.79)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.79)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">46,757,691<span></span>
</td>
<td class="nump">39,449,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">46,757,691<span></span>
</td>
<td class="nump">39,449,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 299,818<span></span>
</td>
<td class="num">$ (160,076)<span></span>
</td>
<td class="nump">$ 139,769<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">25,506,012<span></span>
</td>
<td class="nump">854,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, shares</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares', window );">Conversion of preferred stock to common stock, shares</a></td>
<td class="nump">5,365,570<span></span>
</td>
<td class="num">(536,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">33,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">103,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,734<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,827,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in an ATM offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an ATM offering, net of issuance costs, shares</a></td>
<td class="nump">435,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,248<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="nump">3,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants, note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,229<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(111,779)<span></span>
</td>
<td class="num">(111,779)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">387,437<span></span>
</td>
<td class="num">(271,855)<span></span>
</td>
<td class="nump">115,619<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">37,143,242<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,383<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, shares</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares', window );">Conversion of preferred stock to common stock, shares</a></td>
<td class="nump">3,175,770<span></span>
</td>
<td class="num">(317,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">77,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,485<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">393,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,055<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of common stock warrants, net of shares withheld for exercise price, shares</a></td>
<td class="nump">5,282,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,550<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="nump">2,172,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(177,042)<span></span>
</td>
<td class="num">(177,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement', window );">Issuance of common stock warrants in connection with note agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 549,404<span></span>
</td>
<td class="num">$ (448,897)<span></span>
</td>
<td class="nump">$ 100,555<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="nump">48,244,960<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants, net of shares withheld for exercise price, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock warrants in connection with note agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of common stock warrants, net of shares withheld for exercise price, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (177,042)<span></span>
</td>
<td class="num">$ (111,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and cash equivalents used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">21,383<span></span>
</td>
<td class="nump">6,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payment-in-kind interest</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NoncashOperatingLeaseExpenseNet', window );">Non-cash operating lease expense</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInAccruedInterestIncome', window );">Change in accrued interest income</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid clinical trial costs</a></td>
<td class="num">(12,127)<span></span>
</td>
<td class="num">(1,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current and non-current assets</a></td>
<td class="num">(2,991)<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,040)<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IncreaseDecreaseInAccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">10,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">15,388<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(153,280)<span></span>
</td>
<td class="num">(83,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">332,507<span></span>
</td>
<td class="nump">642,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(396,342)<span></span>
</td>
<td class="num">(705,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(64,084)<span></span>
</td>
<td class="num">(63,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchases</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">3,485<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">42,061<span></span>
</td>
<td class="nump">14,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively</a></td>
<td class="nump">195,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively</a></td>
<td class="nump">27,745<span></span>
</td>
<td class="nump">59,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from equity offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">91,592<span></span>
</td>
<td class="nump">56,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts', window );">Proceeds from an ATM offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentsForSecondaryRegistrationStatementCosts', window );">Payments for secondary registration statement costs</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">360,552<span></span>
</td>
<td class="nump">138,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">143,188<span></span>
</td>
<td class="num">(8,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">22,515<span></span>
</td>
<td class="nump">30,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">165,703<span></span>
</td>
<td class="nump">22,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">10,348<span></span>
</td>
<td class="nump">7,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CashPaidForOperatingLeases', window );">Cash paid for operating leases</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CommonStockWarrantsIssuedWithNotePayableTransaction', window );">Common stock warrants issued with the note payable transaction</a></td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable', window );">Deferred financing, offering and registration statement costs included in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CashPaidForOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CashPaidForOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ChangeInAccruedInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in accrued interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ChangeInAccruedInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CommonStockWarrantsIssuedWithNotePayableTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants issued with note payable transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CommonStockWarrantsIssuedWithNotePayableTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs and offering and registration statement costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IncreaseDecreaseInAccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IncreaseDecreaseInAccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_NoncashOperatingLeaseExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash operating lease expense net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_NoncashOperatingLeaseExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentsForSecondaryRegistrationStatementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for secondary registration statement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentsForSecondaryRegistrationStatementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from atm offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PropertyAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Proceeds from convertible note payable, net of debt issuance cost and discount</a></td>
<td class="nump">$ 6,246<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt issuance costs and discount</a></td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 2,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (177,042)<span></span>
</td>
<td class="num">$ (111,779)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">On
<span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_904_eecd--TrdArrAdoptionDate_c20251001__20251231_zDiVZPjSgOVk">December 8, 2025</span></span>, Oncology Diagnostic &amp; Drug Development Consulting LLC, an entity controlled by <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_901_eecd--TrdArrIndName_c20251001__20251231_zszfvE2Zlq3i">Richard E. Buller</span>, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbT_c20251001__20251231_zIJLl0FNZMma" title="Rule 10b51 Arrangement Adopted">adopted</span> a 10b5-1
plan for the sale of up to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_901_eecd--TrdArrSecuritiesAggAvailAmt_iI_c20251231_zr5hNgUfzYic">12,000</span> shares of Celcuity Inc. common stock beginning March 18, 2026 through <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_902_eecd--TrdArrExpirationDate_c20251001__20251231_zdPLoHFgwEAk">December 23, 2026</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard E. Buller<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b51 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 8, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b51 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Rule 10b51 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 23, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_002"></span>ITEM
1C. Cybersecurity</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management &amp; Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management process is a component of our overall approach to managing material risks that could impact our operations,
including cybersecurity threats. In general, we seek to manage material internal and third-party cybersecurity risks through an approach
that focuses on: (i) protecting information systems and the information residing therein; (ii) identifying, preventing, and mitigating
cybersecurity threats; and (iii) assessing and responding to cybersecurity incidents when they occur. Maintaining, monitoring, and updating
our information security program&#8212;in an effort to ensure that it remains reasonable and appropriate in light of changes in the security
threat landscape, available technology, and applicable legal and contractual requirements&#8212;is an ongoing effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</div>
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">51</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zPE2J48wJxKe">We
have implemented and maintain various processes, procedures, and measures to support our overall risk management strategy and to manage
and mitigate the material risks posed by cybersecurity threats to our systems and data.</span> With respect to cybersecurity, these measures
include conducting risk assessments of our operations and using a risk register to assess identified risks; developing business continuity,
disaster recovery and incident response plans; implementing technical safeguards and tools; conducting ongoing cybersecurity awareness
training; and using contractual protections where appropriate. Our incident response plan outlines the procedures for reporting, investigating,
and remediating cybersecurity incidents, including a framework to facilitate the escalation to our management team and board of cybersecurity
incidents, so that our management team is alerted in a timely manner to material information that would be required to be disclosed or
reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IT department maintains policies and procedures regarding network security, data protection and incident response. Pursuant to those
policies, IT engages with the Chief Financial Officer, General Counsel and other experts when assessing cybersecurity threats, incident
response, and making disclosure determinations following a data or network breach. The Vice President, IT is accountable at the management
level for our overall IT risk management program. Additionally, our Chief Executive Officer and Audit Committee receive regular updates
from the Chief Financial Officer, General Counsel and the Vice President, IT about significant threats and incidents involving cybersecurity
and data protection, as well as security enhancements made to our IT infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zipBTX3fdTAb">third-party</span> service providers for a variety of services throughout our business, ranging from infrastructure support and maintenance,
cybersecurity incident response, data protection and privacy compliance. In addition, we engage with contract research organizations,
contract manufacturing organizations, distributors, and other supply chain resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the use of external service providers improves our operational capabilities, and we have implemented a vendor qualification
and management program that applies to our service providers, including those that handle health information, personal information,
or other information subject to protection under applicable privacy and data protection regulations. This program is designed to identify,
address and seek to mitigate potential cybersecurity and data protection risks that arise from our use of external service providers.
While we do not have full visibility into the cybersecurity risk management processes of our vendors, we require new service providers
to complete a vendor questionnaire that identifies the vendor&#8217;s network and user protections, such as the use of multi-factor authentication,
and other cybersecurity risk management processes. Vendors that store or access our confidential information are required to certify
that their information systems comply with applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on
our third-party service providers to provide notification of, and remediate, significant cybersecurity threats and cybersecurity incidents
that jeopardize the confidentiality, integrity, or availability of our information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically evaluate, test, and update our policies, standards, and processes to mitigate cybersecurity threats and manage incidents
effectively. These efforts include risk assessments, vulnerability assessments and remediations, phishing tests and employee education,
and external scans. Additionally, to enhance our capabilities, we periodically engage third-party service providers, including cybersecurity
consultants, to incorporate threat intelligence into our processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Form 10-K, we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zZdq1dpZU2wi">no</span>t aware of any risks from cybersecurity threats, including those resulting from any previous
cybersecurity incidents experienced by us or, to our knowledge, by any of our third-party service providers, that have materially affected,
or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. For further discussion
of cybersecurity and data privacy risks that may materially affect the Company and how they may do so, see &#8220;Risk Factors&#8212;If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical
trial delays; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational
harm; and other adverse consequences,&#8221; included in Item 1A of this Annual Report on Form 10-K.</span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#160;</span></span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zyNLlmbEho35">Our
Audit Committee oversees Celcuity&#8217;s management of risks arising from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zPSgImT98hWj">Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations</span>. Additionally, we have
processes to promptly notify the Audit Committee and Board of a significant cybersecurity incident and to inform the Audit Committee
and Board of remediation progress, as appropriate</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Vice President, IT has overall responsibility for our information security program, with support from our management team and specialized
partners in cybersecurity incident response and privacy. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zbgtjC9IF8O3">The process includes managing our incident response strategy. If a cybersecurity
incident meets certain criteria, however, our CEO, CFO and General Counsel will become involved with the response strategy, including
decisions about public disclosure and reporting. Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine
strategic cybersecurity priorities and to establish compliance procedures</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our business leaders have the appropriate expertise, background and depth of experience to manage risks arising from cybersecurity
threats. Our Vice President, IT has served in various roles in information technology and information security for over three decades,
which includes experience in the biotech, pharmaceutical and healthcare industries and experience in cybersecurity risk management and
data privacy compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we, and the third parties upon which we rely, collect, process, receive, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, share and store  proprietary,
confidential, and sensitive information, including health information, personal information, credit card and other financial
information, or other sensitive information owned or controlled by ourselves or our customers, payors, and other parties.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
Audit Committee oversees Celcuity&#8217;s management of risks arising from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zPSgImT98hWj">Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations</span>. Additionally, we have
processes to promptly notify the Audit Committee and Board of a significant cybersecurity incident and to inform the Audit Committee
and Board of remediation progress, as appropriate<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The process includes managing our incident response strategy. If a cybersecurity
incident meets certain criteria, however, our CEO, CFO and General Counsel will become involved with the response strategy, including
decisions about public disclosure and reporting. Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine
strategic cybersecurity priorities and to establish compliance procedures<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Liquidity</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zcuHu0fZI2Cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_822_zYNqMeQ8y7j3">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on the development of targeted
therapies for the treatment of multiple solid tumor indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a kinase
inhibitor of the phosphatidylinositol 3-kinase (&#8220;PI3K&#8221;), serine/threonine-protein kinase protein kinase B (&#8220;AKT&#8221;),
mechanistic target of rapamycin (&#8220;mTOR&#8221;) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and
mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PI3K/AKT/mTOR (&#8220;PAM&#8221;)
pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational
therapies that target PI3K&#945;, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in
combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor
receptor 2-negative (HER2-) (&#8220;HR+/HER2-&#8221;) advanced breast cancer (&#8220;ABC&#8221;) has completed enrollment and reported
detailed results for cohort 1, patients with <i>PIK3CA</i> wild-type (&#8220;WT&#8221;) tumors, and has completed enrollment of cohort
2, patients with <i>PIK3CA</i> mutant-type (&#8220;MT&#8221;) tumors. Our Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib
in combination with a cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitor and fulvestrant as first-line treatment for patients
with endocrine treatment resistant HR+/HER2- ABC is ongoing. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib
in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. The Company was co-founded
in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenue to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has not generated any revenue from product sales or other sources and has incurred operating losses and negative
cash flows from operations. The Company&#8217;s primary uses of cash, cash equivalents, and investments to date have been funding clinical
trials and research and development activities, the scaling of commercial launch related activities such as marketing, supply chain,
distribution, market access and other commercial operations, business planning, establishing and maintaining the Company&#8217;s intellectual
property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and
administrative support for these operations. As of December 31, 2025, the Company had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zlytoKkGzHY4" title="Accumulated deficit">448.9</span> million. To date,
the Company has funded operations primarily through private placements, registered offerings of its equity securities, convertible notes,
and borrowings under loan agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had $<span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zcJP1Uc9YhH4" title="Cash and cash equivalents">441.5</span> million in cash, cash equivalents and short-term investments. The Company believes its existing
cash, cash equivalents and short-term investments will be sufficient to fund planned operations for at least one year from the issuance
of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, the clinical and commercial success
of its initial drug product, gedatolisib, the regulatory approval of gedatolisib, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_za1GI9lDVlY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_821_zMV7gxTrM3X">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZyqntnbGC3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zSEcArUGpUL7">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
Operating results during the year ended December 31, 2025, are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_z4wX2KuNTQh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zq0Rkpzqv5Hd">Accounting
Estimates</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such
estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyuqO5zJgMfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_zX3Kco5Tshj5">Cash
and Cash Equivalents</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its accounts at two financial institutions. As of December 31, 2025 and 2024, the Company had $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_z9RHZLhNlC2g" title="Cash and cash equivalents">165.7</span> million and $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zzkYYFbsgxCl" title="Cash and cash equivalents">22.5</span>
million, respectively, in business checking accounts and money market funds that are considered cash equivalents. Cash and cash equivalents
are classified as Level 1 assets under the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_841_eus-gaap--InvestmentPolicyTextBlock_zHhi3kTKMJhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zNunFUOvHYNb">Investments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its investments in U.S. treasury securities and has classified them as held-to-maturity at the time of purchase. Held-to-maturity
purchases are those investments which the Company has the ability and intent to hold until maturity. Held-to-maturity investments are
recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity investment using the straight-line method. The difference between the carrying
value, which is based on cost, and the aggregate fair value of the held-to-maturity investments, was immaterial as of December 31, 2025.
As of December 31, 2025 and 2024, the Company had $<span id="xdx_907_eus-gaap--ShortTermInvestments_iI_pn5n6_c20251231_zZD871QV3Pu1" title="Short-term investments">275.8</span> million and $<span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_ziLL23bT0Wa9" title="Short-term investments">212.6</span> million, respectively, of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zW2gzexcYwa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zmywVMpiYPyj">Fair
Value of Financial Instruments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The accounting guidance establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Unobservable inputs that are significant to the fair value measurement and supported by little or no market activity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
level in the fair value hierarchy within which a fair value measurement in its entirety falls, is based on the lowest level input that
is significant to the fair value measurement in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash equivalents, accounts payable, accrued expenses and other financial working capital items approximate fair value
as of each of December 31, 2025 and 2024, due to the short maturity nature of these items. Refer to Note 10 for disclosures around the
Company&#8217;s <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z13StAFalI86" title="Accrue interest payable rate"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z2cFbGR9qQUa" title="Accrue interest payable rate">2.750</span></span>% Senior Notes due 2031 (the &#8220;Notes&#8221;) and note payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZKo6AbqVvxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zT1PkDBaxKtc">Concentration
of Credit Risk</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents, and
investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company
has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--AllowanceForCreditLossesPolicyTextBlock_zPDb6xwx063k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86A_zCVZbl4QFzhc">Allowance
for Credit Losses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
investments in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that
it will be required to sell, the investment before recovery of its amortized cost basis. If either of the criteria regarding intent or
requirement to sell is met, the investment&#8217;s amortized cost basis is written down to fair value through earnings. For investments
that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses
or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes
in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates
that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost
basis of the investment. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit
loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost
basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQGdqKZJAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_zaLp4t9hew6c">Property
and Equipment</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and
repairs are expensed as incurred; major improvements and betterments are capitalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
useful lives of property and equipment are as follows for the major classes of assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_ztk6McHWACA7" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify">Asset description</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center">Estimated useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives">4</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"><span style="-sec-ix-hidden: xdx2ixbrl0597">Shorter of remaining lease term or estimated useful life</span></span></td></tr>
  </table>

<p id="xdx_8A9_zi5mSi50J9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zx6fJWTV2tY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_z8XMZLoRvvog">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies
leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use
asset and current and non-current lease liabilities, as applicable, on the balance sheets. The Company has elected not to recognize on
the balance sheets leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease
term. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s leases may include options to extend or terminate the leases. Periods covered by an option to extend the lease are included
in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate
the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. The Company monitors
its plans to renew or terminate its material leases each reporting period. If a lease includes provisions for leasehold improvements
for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets.
If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding
right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease
term. The present value of future lease payments is discounted using the interest rate implicit in the lease contracts if that rate
is readily determinable; otherwise, the Company utilizes information available at the commencement of the lease to calculate the incremental
borrowing rate, which reflects the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar
term and in a similar economic environment. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the
period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities,
real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company.
The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CapitalizationAndAmortizationOfFuelCostsPolicy_zZyNUMrJAi27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zX4lzNpaEKzi">Capitalized
Software Development Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company capitalizes qualifying costs incurred during the application development stage related to software developed for internal use.
Capitalized software development costs are classified as other non-current assets on the balance sheets. As of December 31, 2025 and
2024, the Company had $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn5n6_c20251231_zM6b5cWY6VC" title="Capitalized software development costs">0.1</span> million and <span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0_do_c20241231_zlMEzTHKCPo1" title="Capitalized software development costs">no</span> capitalized software development costs, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software,
beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general
and administrative expenses. The Company did not record any amortization expense during the years ended December 31, 2025 and 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlOi0Upf1PA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zhM3A0omLsCd">Long-Lived
Assets</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment,
the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--DeferredChargesPolicyTextBlock_zD1nPD22SC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_zqNNtcbHJsu7">Deferred
Transaction Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
transaction costs primarily consist of legal fees that are capitalized as incurred and will be offset against the proceeds from future
equity financing arrangements. The deferred transaction costs will be reviewed periodically to assess the probability that future securities
will be offered. In the event that no future offering will occur, any deferred transaction costs will be expensed. Total costs incurred,
but not accounted for as a reduction in equity, were $<span id="xdx_904_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20251231_z8r3RBeFpgX6" title="Deferred transaction costs">0.2</span> million and $<span id="xdx_905_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20241231_zUpNBA8nvcm2" title="Deferred transaction costs">0.2</span> million as of December 31, 2025 and 2024, respectively. D<span style="background-color: white">eferred
transaction costs are classified as other assets on the balance sheets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--DebtPolicyTextBlock_zcAx6RA6yAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zgV1CyFnZHhk">Debt
Issuance Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes debt issuance costs as deferred costs, which are capitalized and amortized over the term of the related debt
using the effective interest method. These costs primarily consist of fees, commissions, and legal and other costs directly
attributable to securing debt financing. Debt issuance costs are reported as a direct reduction of the carrying amount of the
related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements of operations over
the life of the debt instrument. In the event of early extinguishment of debt, any related unamortized debt issuance costs are
written off and recognized as a component of the gain or loss on extinguishment of debt in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zV1w1M8nL3P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86F_zCXXW4tYrEEk">Comprehensive
Loss</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other
than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zviD542vWEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zp6BOAhm9hV1">Commitments
and Contingencies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other
amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount,
the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z1nUe2xca6V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zMG8KiOHKv49">Stock-Based
Compensation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation consists of stock options, restricted stock awards and restricted stock units issued
to certain employees and non-employees of the Company under the 2017 Amended and Restated Stock Incentive Plan, and shares issued under
the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense based on the estimated grant date fair value using the Black-Scholes
option-pricing model and the expense is recognized on a straight-line basis over the requisite service period. Compensation expense
for awards with performance-based conditions is recognized when the achievement of the performance condition is deemed
probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Monte Carlo simulation model for awards with market-based vesting conditions. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inputs for the Black-Scholes valuation model and the Monte Carlo simulation model require management&#8217;s significant assumptions,
including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected
dividends. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available
in combination with the Company&#8217;s calculated volatility since being publicly traded. The expected term of the award is based on
the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free interest rate is based on the
rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected term of the award at the
grant date. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay
any dividends on its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with such agreements would also be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Restricted
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records compensation expense based on the quoted fair value of the shares on the grant date over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ESPP</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense for ESPP rights is recorded in line with each respective offering period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIunJ3n2ufXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_z0eJafjg7AM5">Research
and Development</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs were $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn6n6_c20250101__20251231_z12fj9fPToT6" title="Research and development expense">145.0</span> million and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_z3gNzyhfz9ni" title="Research and development expense">104.2</span> million during the years
ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--InProcessResearchAndDevelopmentPolicy_zvxAfo7Fc65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_z4e7z51IdGNc">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party service providers to conduct certain aspects of clinical studies and to formulate and manufacture its drug
product. While there are alternative vendors that can perform these functions, any disruption or delay by the Company&#8217;s current
third-party service providers in carrying out their contractual duties could delay its clinical trials and/or the commercial launch of
 gedatolisib, if approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company records prepaid or accrued
clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials. These costs can be a
significant component of the Company&#8217;s research and development expenses. The Company uses progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, the Company&#8217;s estimated expenses in future periods and actual services performed
may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes
to the Company&#8217;s prepaid or accrued clinical trial costs could materially affect the Company&#8217;s results of operations and
financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--LicensesPolicyTextBlock_zc84EiKOSzja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zdYLlh0qBtz4">Licenses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upfront
payments and other consideration under license agreements are expensed as research and development expense upon receipt of the license,
and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
license agreements include milestone payments which are recognized when it becomes probable that the achievement of those milestones
will be met. The Company records this expense as research and development expense in its statements of operations. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--PatentCostsPolicyTextBlock_zawpsPqfjNCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_z3zaSHAgoOal">Patent
Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zMp5hH9dGpD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zJiPQCUlSyMg">Income
Taxes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss
and tax credit carryforwards. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized
in results of operations in the period that includes the enactment date. The effects of any future changes in tax laws or rates have
not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that
the deferred tax assets will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the impact of an uncertain tax position in its financial statements if, in management&#8217;s judgment, the position
is more-likely-than-not sustainable upon audit based on the position&#8217;s technical merits. This involves the identification of potential
uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position
is necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgrcRyEGF68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zxYl1G2LUNR6">Segment
Data</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has <span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20251231_zyV0gJPysRfb" title="Number of operating segment"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zBXIOtyInZfa" title="Number of reportable segment">one</span></span> reportable operating segment, which is the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#8217;s chief operating decision makers (&#8220;CODMs&#8221;) are its chief executive officer, chief science
officer and chief financial officer, who, together manage the Company&#8217;s operations as one operating segment for the purpose of
evaluating financial performance and allocating resources. The CODMs assess the performance and allocate resources for the reportable
segment based on net loss and total assets, which are the same amounts in all material respects as those reported in the statements of
operations and balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--RecentAccountingPrononcementAdoptedPolicyTextBlock_zykMCmeNJmPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_z9oy2onAva6a">Recently Adopted
Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09,
<i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the annual income
tax disclosures for the effective tax rate reconciliation, income taxes paid, and continuing operations. ASU 2023-09 also eliminates
certain disclosure requirements related to unrecognized tax benefits. ASU 2023-09 is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 on January 1, 2025 on a retrospective basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zI0ml4PUQfTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_864_zw21V0E5gg1h">Recent
Accounting Pronouncements Not Yet Adopted</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03<i>, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), which requires public entities to provide
disaggregated disclosure of income statement expense. In January 2025, the FASB issued ASU 2025-01, <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i>, to clarify the effective
date of ASU 2024-03. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025<i>, </i>the FASB issued ASU 2025-05<i>, Measurement of Credit Losses for Accounts Receivable and Contract Assets</i> (&#8220;ASU
2025-05&#8221;), which provides certain entities with an additional practical expedient for estimating expected credit losses on current
accounts receivable and current contract assets arising from revenue transactions under Accounting Standards Codification (&#8220;ASC&#8221;)
606. ASU 2025-05 is effective for all entities for annual and interim periods in fiscal years beginning after December 15, 2025. Early
adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2025-05 on its financial statements and
related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software </i>(&#8220;ASU 2025-06&#8221;), which modernizes the accounting for
internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs
when management has committed to the software project, and it is probable the software will be completed and perform to its intended
use. In evaluating whether it is probable the project will be completed, management is required to consider whether there is significant
uncertainty associated with the development activities of the software. ASU 2025-06 is effective for annual and interim periods beginning
after December 15, 2027. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective
basis. The Company is currently evaluating the timing, method of its adoption, and effect of ASU 2025-06 on its financial statements
and related disclosures.</span></p>

<p id="xdx_852_zCWzM4W03Ghd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zRMsbBidY5v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span><span id="xdx_82C_zRnbgNmfQRfk">Net Loss Per Common Share</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options, convertible note, warrants,
restricted stock and preferred stock have been excluded from the calculation because their effect would be anti-dilutive.
Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zORYutVOwcoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the potentially-dilutive shares that have been excluded from the calculation of diluted weighted-average shares
outstanding because their inclusion would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z5QGd34saOD3" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zmiwONDliCC2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_ziB8ERXgONb3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zMZiJmSvch96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,842,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesToCommonStockMember_zCYOYBvJ442f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note as-if-converted-to-common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,296,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z0n4IUGxwnmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">274,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,521,152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zSts8C0b8t1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zhapCbcSARVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Preferred stock as-if-converted-to-common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,175,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zXTfV9N7vzj2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,440,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zpfn2jNhLOWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of shares of common stock issuable upon conversion of the Notes is <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zZwOhTZ0Xqdf" title="Debt conversion, number of shares issued">5,296,053</span>. As of December 31, 2025, the number of shares
issuable based on the Company&#8217;s closing common stock price would be <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231_zsPa8XWSvsY9" title="Debt conversion, number of shares issued">3,923,002</span> if the Notes were converted in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, pre-funded warrant shares of <span id="xdx_90A_ecustom--PrefundedWarrantShares_iI_c20251231_zYYCzTTEV7g1" title="Pre-funded warrant shares">6,147,787</span> and <span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20241231_zckerqX3QTgl" title="Pre-funded warrant shares">5,747,787</span>, respectively, were included in the
computation of basic and diluted net loss per share, as the pre-funded warrants are exercisable for nominal consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InvestmentTextBlock_zaEzdAeDtini" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82A_zZTKmvcocLb8">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
investments for which the Company has the positive intent and ability to hold to maturity are classified as held-to-maturity and reported
at historical cost adjusted for amortization of premiums and accretion of discounts. Expected credit losses, if any, are recorded through
the establishment of an allowance for credit losses. All of the Company&#8217;s held-to-maturity investments are U.S. treasury securities
that are guaranteed or otherwise supported by the United States government and have no history of credit losses. Accordingly, the Company
does not expect to incur any credit losses on held-to-maturity investments and has no allowance for credit losses recorded for these
investments. As of December 31, 2025, all of the Company&#8217;s held-to-maturity investments had maturities of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--InvestmentTableTextBlock_zIw6y3x3FzVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s held-to-maturity investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z9VkKqNddUAc" style="display: none">Schedule of Investment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zS2HjqxEFScd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zdHHY3oytKqk">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zw5EFQuv06ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_zMPPl2Q5vWpl">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_480_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zhlS1jzeWiT8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zIHFZOjFXl3l">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_zOZiMPCK5oF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zYTQN66rSKi1">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_418_20251231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zyZAFzIPQay2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">275,794</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">276,019</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20251231_z9wbGKXfl9vi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">275,794</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,019</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zDJAenC5wlUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zWQvLHjoRvda">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zJ8u1D7HdVg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_z5SmvX2XEiy6">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zzXxS7N8w3Li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zbYZEkUByjd9">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_z8NLpWxhuCX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zBwpQIjZEqnk">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41B_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQJNT1vkE24g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">212,589</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">82</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">212,671</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_418_20241231_zfqjcTaUByIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zP75axjGoJB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. treasury securities are classified as Level 2 investments within the fair value hierarchy. These assets have been
valued based on quoted prices in active markets for similar assets or other inputs that are observable or can be corroborated by observable
market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in valuation techniques or transfers within the fair value hierarchy during the years presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z1IzjeLSsmm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_825_zc93a7nIJAsl">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxBgPwA6mhB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zHgvA72Kgd55" style="display: none">Summary of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zyTdLKSsDgNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zIuzqQovFCHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOVBm9dvY31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhWT1ENzaIH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">304</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zvOutspI9J44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt">Total property and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,658</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,328</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zP8QBER7Dw9c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,159</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,992</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zdsQLanmJtpf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 10pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">336</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zNh4YhIfYeKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_900_eus-gaap--Depreciation_pn5n6_c20250101__20251231_zIYKdD9wMTPd" title="Depreciation expense">0.2</span> million and $<span id="xdx_906_eus-gaap--Depreciation_pn5n6_c20240101__20241231_zXUT31eu0ygb" title="Depreciation expense">0.1</span> million during the years ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Accrued Expenses</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zLvZ8fMuJURf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82D_z06hjorMYkc8">Other Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZbWWTgPirOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued expenses consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zj2tIjtimwig" style="display: none">Schedule
of Other Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_z52ERfs6jbuc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zyb99emckFoh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maOALCzJtq_z9f7AjR0Usy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Employee compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,338</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,092</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherAccruedLicenseMilestone_iI_maOALCzJtq_zu2RMw5Kvkhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccruedInterest_iI_maOALCzJtq_zLzTDb4eKmr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzJtq_zXrs85If1x79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maOALCzJtq_zl5AKWtjUVw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">874</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzJtq_zZpg8DjEfTd3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zdpC3meloNO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, and 2024, accounts payable included $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20251231_zUkwZTmiRyB6" title="Accounts payable included accrued interest">0</span> and $<span id="xdx_90E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zaC7jz3tevm1" title="Accounts payable included accrued interest">820</span> of accrued interest, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zn6L9igRsxCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_820_z65XpHziTd96">Commitments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: left; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Operating
and Finance Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its corporate space in Minneapolis, Minnesota, with an operating lease in place through April 30, 2026 (the &#8220;Existing
Lease&#8221;). The Existing Lease provides for monthly rent, real estate taxes, and operating expenses. Rent expense is recorded on a
straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company entered into a lease for clinical laboratory and office space in Minnesota for <span id="xdx_905_eus-gaap--AreaOfLand_iI_usqft_c20251130_zpCiYYXsrGC6" title="Square feet">19,594</span> square feet. <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20251101__20251130_zCdOoCCDTyM" title="Lease option to extend">The lease
term will commence on April 1, 2026 and is 62 months with two options to extend the lease term for five years each. The Company also
has a one-time option to terminate the lease at the end of the third year, provided certain conditions are met. </span>To exercise this option,
the Company must pay a termination fee equal to eight months&#8217; rent plus the landlord&#8217;s unamortized transaction costs, which
include abated rent, tenant improvement allowances and broker fees. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20251101__20251130_z2XeypAftfRh" title="Lease description">The initial annual lease payment is $<span id="xdx_903_eus-gaap--OperatingLeasePayments_pn5n6_c20251101__20251130_zXrdOaQbJ496" title="Initial annual lease payment">0.3</span> million and increases by
3.5% on an annual basis, resulting in total undiscounted future minimum lease payments of $<span id="xdx_901_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn5n6_c20251130_z99u4GodQlVl" title="Undiscounted future minimum lease">1.5</span> million over the initial <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20251130_zYh1W81o6era" title="Lease term">62</span>-month term.
</span>As of December 31, 2025, the lease has not commenced and is therefore excluded from the tables below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5OAgmDvZCz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under the Company&#8217;s Existing Lease consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zFNpIZgwWV3j" style="display: none">Schedule
of Minimum Lease Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zd68EMBIexzj" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zUJ1rqmQQXC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; text-indent: 9pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_iI_maLOLLPzXrd_zrTeJp5gO3S3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zfuLN0O1hiyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNAOuArXgvM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zPYqHNQA0Eo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zpbBBzqH2pJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: operating lease liabilities, current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxd97nAkHF13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and discount rate under the Company&#8217;s Existing Lease were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zkpNCPmDa5ze" title="Weighted-average remaining lease term">0.3</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zdzuwqCIGnn4" title="Weighted-average remaining lease term">1.3</span>
years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Weighted-average discount rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFzrBzzk5Oac" title="Weighted-average discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zCm9fm80LA4b" title="Weighted-average discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zukE4zy9Kwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_ze1GqYxJdhzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents components of lease costs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zR5QI8yk12aj" style="display: none">Schedule of Lease Costs</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20250101__20251231_zGGU5Xhnmcgg" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20240101__20241231_zlqgEUsFD1D4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zCqkWBzh8CP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--VariableLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zrB0DEKtwVbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">110</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_pn3n3_mtLCzphc_z2BpqhRDFbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zFs5wNnq9OL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Clinical
Research Studies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third-party
service providers that include, among others, arrangements with vendors, consultants, contract manufacturing organizations, and contract
research organizations. Contracts related to the Company&#8217;s ongoing clinical trials are generally cancelable with advance notice
and the Company&#8217;s obligations under these contracts are primarily based on services performed through termination dates plus certain
cancelation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be
subject to amendments as a result of any change orders executed. As of December 31, 2025, the Company had $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20251231_zWDYx32IGm87" title="Non-cancelable contractual commitment">5.5 </span>million of non-cancelable
purchase commitments with respect to these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Registration
Rights Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a securities purchase agreement with certain investors pursuant to which the Company agreed to sell to the investors
in a private placement pre-funded warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdLgI1OmU4Yc" title="Pre-funded warrants sold to investors">5,747,787</span> shares of the Company&#8217;s common stock in October 2023 (the &#8220;Securities Purchase Agreement&#8221;),
the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the investors. Under
the Registration Rights Agreement, the Company agreed to file a registration statement and to use commercially reasonable efforts to cause such registration statement to become effective and to keep such
registration statement effective until such time as there are no longer registrable securities held by the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company fails to meet the specified filing deadlines, effectiveness deadlines, or maintain the effectiveness of the registration
statement, <span id="xdx_906_eus-gaap--RegistrationPaymentArrangementTerm_c20250101__20251231_zcNLKNPkrlXk" title="Registration rights">the
Company is required to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0% of the aggregate
amount paid pursuant to the Securities Purchase Agreement by such investor&#160;for each 30-day period or pro rata for any portion
thereof during which such event continues, provided that the maximum liquidated damages shall not exceed 6.0% of the aggregate
amount invested by each such holder in the registrable securities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for these arrangements in accordance with ASC 825-20, <i>Registration Payment Arrangements</i>. As of December 31,
2025, the required registration statement has been timely filed and declared effective by the SEC, and the Company remains in
compliance with the maintenance requirements. Management has determined that it is not probable that the Company will be obligated
to pay any liquidated damages; accordingly, no liability has been recorded for these arrangements.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTf2Ux3D7zNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_z98N5HmjSZs4">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Capital
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company&#8217;s authorized capital stock consisted of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zJjYdsfUBFIg" title="Common stock, shares authorized">95,000,000</span> shares of common stock, of which <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zcP87RyHEJz3" title="Common stock, shares outstanding">48,244,960</span>
shares were outstanding, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zCkkfZr0wOF3" title="Preferred stock, shares authorized">2,500,000</span> shares of preferred stock, including <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zX8m2jQ78vI7" title="Preferred stock, shares authorized">1,850,000</span> shares designated as Series A Preferred Stock,
of which <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20251231_z2QTmNQHBmb4" title="Preferred stock, shares outstanding">none</span> were outstanding. As of December 31, 2025, no dividends have been declared on the Company&#8217;s capital stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">July
2025 Equity Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2025, the Company entered into an underwriting agreement (the &#8220;Equity Underwriting Agreement&#8221;) with Jefferies
LLC (&#8220;Jefferies&#8221;), TD Securities (USA) LLC, and Leerink Partners LLC as representatives (the
&#8220;Representatives&#8221;) of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;) agreeing,
subject to customary conditions, to issue and sell in a public offering (i) <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zOwi6t22itnl" title="Number of share sold">1,836,842</span>
shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, at a price to the public of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z0PXs6UPLt8l" title="Sale of stock perice per share">38.00</span>
per Share and (ii) in lieu of Shares to certain investors, pre-funded warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z1DuOVzIo6W9" title="Prefunded warrant shares">400,000</span>
shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), at a price to the public of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zell8W0EWesj" title="Share price">37.999</span>
per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zuS9JyWijuC5" title="Exercise price per warrants">0.001</span>
per share exercise price for each such Pre-Funded Warrant (the &#8220;Equity Offering&#8221;). In addition, pursuant to the Equity
Underwriting Agreement, the Company granted the Underwriters an option to purchase up to an additional <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zcrlcf88qlEc" title="The number of additional common stock shares the Underwriters can purchase">335,526</span>
shares of common stock (the &#8220;Option Shares&#8221;), less underwriting discounts and commissions. The Underwriters exercised
their option to purchase the Option Shares in full on July 30, 2025. The Equity Offering was completed on July 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds from the Equity Offering, after deducting underwriting discounts and commissions and offering expenses, were $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_ziW0um8Cddp3" title="The cash inflow associated with the amount received from entity's offering of stock to the public">91.6</span> million,
including the proceeds from the Underwriters&#8217; exercise of their option in full to purchase the Option Shares. The Company may also
receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zNeqmJXLgNVa" title="Warrant exercise price">0.001</span> per share, or alternatively, at the election
of each holder, shares of common stock may be issued through a cashless exercise, with the net number of shares of common stock determined
according to the formula set forth in each Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at any time after the date of
issuance until all of the Pre-Funded Warrants are exercised. <span id="xdx_904_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250730__20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zp7XYY1Vzzhg" title="Pre-funded warrant exercisable description">A holder (together with its &#8220;attribution parties,&#8221; as defined
in the Pre-Funded Warrant) may not exercise any portion of the Pre-Funded Warrants if immediately after exercise, the holder (together
with its attribution parties), would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise. However, a holder may increase or decrease such percentage to any other percentage not in excess
of 19.99%, which increase or decrease shall not become effective until 61 days after notice from the holder to the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sale
and Issuance of Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus
&amp; Company, Incorporated as representatives of the several underwriters relating to the issuance and sale of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zPV5ZuHbjmpf" title="Sale of stock number of shares issued in transaction">3,871,000</span> shares of common
stock, at a price to the public of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zYsnbmQKlUw4" title="Issuance of public offering price per share">15.50</span> per share, generating gross proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zE486h3Wy01k" title="Gross proceeds from public offering">60.0</span> million. The offering closed on May 31, 2024
and resulted in net proceeds to the Company of $<span id="xdx_903_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zzWgaqRf9m09" title="Net proceeds from public offering">56.3</span> million after deducting underwriting discounts and other offering expenses payable
by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zg8Xyijxdon4" title="Sale of stock number of shares issued in transaction">149,700</span> shares of common stock
in a single transaction at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5mE2J82qjF1" title="Issuance of public offering price per share">17.65</span> per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zNDCQgTXQCwi" title="Gross proceeds from public offering">2.6</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z2jzKsB4saOb" title="Sale of stock">285,714</span> shares of common stock
in a single transaction at a price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z6ckh86vykJa" title="Share price">17.50</span> per share, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zY9EdIUhP4h5" title="Gross proceeds">5.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions
and other offering expenses related to the Open Market Sale Agreement transactions in May and April 2024 were $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_z1RjZoIh99ab" title="Commissions and other offering expenses"><span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zgwXXxxewzT4" title="Commissions and other offering expenses">0.3</span></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuWHMhzGo9Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had the following common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zY1ytPWLNUyc" style="display: none">Schedule
of Common Stock Warrants</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/> Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_znF7acZVjZ4" title="Issue Date">1/21/2016</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zhnZppxtvQ45" title="Expiration Date">1/14/2026</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zk2Mw9EYW8H3" style="width: 11%; text-align: right" title="Number of Warrants Outstanding">28,716</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zHyXpIYLRYi" style="width: 9%; text-align: right" title="Exercise Price">7.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 46%; text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zI8hpZN5OdBc" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zWoep6ko0o6h" title="Issue Date">5/2/2016</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zkl24SZw7vEh" title="Expiration Date">5/2/2026</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zKwhd0DvrB12" style="text-align: right" title="Number of Warrants Outstanding">18,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zFAO4x8AVNQ9" style="text-align: right" title="Exercise Price">7.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zS7k8CSa0a3j" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zAFRJnIXM30b" title="Issue Date">4/28/2017</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zRKSHCpIQnwa" title="Expiration Date">4/28/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zcDmLPUyp4Td" style="text-align: right" title="Number of Warrants Outstanding">32,458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zReh2tr8pRm4" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zuNGbngV4fBj" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zclugJRqklN7" title="Issue Date">5/17/2017</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zxiXJsqAg9i8" title="Expiration Date">5/17/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEziq4xBRE57" style="text-align: right" title="Number of Warrants Outstanding">14,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_znoRCtWmvgCd" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_z9xKaE7Arcq7" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z7MA7HnPVIpj" title="Issue Date">4/8/2021</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBOiBldDJvNf" title="Expiration Date">4/8/2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_znqkO7Jpk9Bk" style="text-align: right" title="Number of Warrants Outstanding">26,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zqMM6I1aTAfj" style="text-align: right" title="Exercise Price">14.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zAZdpAqgLUl1" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zEFvxS7ie88g" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zy1eUogQej5g" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdrW9Y4jmDmk" style="text-align: right" title="Number of Warrants Outstanding">84,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zWim2INAWGub" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdm4KenlCym1" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zq1Rclq2cx44" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z3WLQeqny3Ff" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_za2mYVkOjUc1" style="text-align: right" title="Number of Warrants Outstanding">19,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zgKKOcOQfO69" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zMnEPRfw0b0e" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zHdsHyxT9PQ6" title="Issue Date">9/9/2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zjCg9xYcyDT2" title="Expiration Date">9/9/2035</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zLLSV398LSSk" style="text-align: right" title="Number of Warrants Outstanding">25,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zSFbo8yOcaUf" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zfYJFO2roqVg" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_z6sgr6CaXIYd" title="Issue Date">9/9/2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zSnWlrTdJqsl" title="Expiration Date">9/9/2035</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zn6CZLd8Raq6" style="text-align: right" title="Number of Warrants Outstanding">25,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zQHkfNELAb9b" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zuuO2eabQgW6" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zdHCDyqWLa44" title="Issue Date">10/18/2023</span></td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zNiCWbmI4cC8" style="text-align: right" title="Number of Warrants Outstanding">5,747,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z4SdBJHrOnq8" style="text-align: right" title="Exercise Price">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zzANf3ZPrRMk" title="Offering">Private placement offering &#8211; issued to investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_z7PfKVLsdvxj" title="Issue Date">7/31/2025</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">N/A</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zcGfIow7zqk8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding">400,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zjLdLiLLDsK9" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zUiYBUZj5gQ7" title="Offering">Equity offering &#8211; issued to underwriters</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total warrants outstanding</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_z6Yy2e5tTo0k" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Warrants Outstanding">6,422,560</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zCWBFAhATkal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Funded
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain
investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded
warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRwbdsTUGT5k" title="Pre-funded warrants sold to investors">5,747,787</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAmCPPU4Z3Zb" title="Common stock, par value">0.001</span> per share. Each warrant to purchase
one share had a purchase price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV8BpTWG9ife" title="Warrant purchase price">8.699</span> per share, and an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsXVpykm0fA3" title="Exercise price of common stock warrants">0.001</span> per share for the common stock issuable upon exercise
of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant is immediately exercisable and will not expire. Under the terms of the warrants, the Company may not effect the exercise of any
such warrant, and a holder will not be entitled to exercise any portion of any warrant, if, upon giving effect to such exercise, the
aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who
could be deemed to be acting as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose
beneficial ownership of common stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates for
purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) would exceed
4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#8220;Maximum Percentage&#8221;).
A holder may reset the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the
Company, or a lower percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only
to that holder and not to any other holder of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company, other obligations of the parties and termination provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zKyuRQPGnTud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHKDaQ9sDNLe" style="display: none">Schedule
of Common Stock Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdZ94uhfSK5f" style="width: 16%; text-align: right" title="Common stock warrants, outstanding shares">11,268,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbbqAq7Di5ck" style="width: 16%; text-align: right" title="Weighted- average exercise price per share, outstanding">4.04</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zr3btbfI5lV1" style="text-align: right" title="Common stock warrants, issued">450,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdOFkWbiJAm3" style="text-align: right" title="Weighted- average exercise price per share, issued">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKlIT7Yuuu7" style="text-align: right" title="Common stock warrants, exercised">(5,282,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zf8zruGCcwn4" style="text-align: right" title="Weighted- average exercise price per share, exercised">8.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Surrendered upon cashless exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z5YU7llqoyJ4" style="text-align: right" title="Common stock warrants, surrendered upon cashless exercise">(14,541</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zLYOpxidlSx6" style="text-align: right" title="Weighted- average exercise price per share, surrendered upon cashless exercise">10.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMizbNcfmHx5" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zJd6gzxtBn0k" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- average exercise price per share, expired"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zY4JevYww3J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock warrants, outstanding shares">6,422,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z59zeD648rui" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- average exercise price per share, outstanding">0.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zFC0BNDh0IQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, several of the Company&#8217;s investors exercised <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znxFSsD9p9wk" title="Additional warrants exercised">1,827,357</span>
common stock warrants, net of shares withheld for the exercise price, at exercise prices ranging between $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zN7fSoNfBU3e" title="Class of warrant exercise price">8.05</span>
and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zEClnvNV3hh4" title="Class of warrant exercise price">9.50</span>
per share, which generated $<span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zHF5cxuCjVg3" title="Proceeds from warant exercise">14.7</span>
million in cash. During the year ended December 31, 2024, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z3MvDscA8A62" title="Common stock warrants expired">3,544</span>
common stock warrants expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A preferred stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--PreferredStockVotingRights_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHbB9vIAvTy2" title="Preferred stock voting rights">The
Series A preferred stock is non-voting, and each share is convertible at the option of the holder, subject to certain limitations, into
10 shares of common stock. Holders of Series A preferred stock are entitled to receive dividends, on an as-if-converted-to-common stock
basis, when, as and if, and in the same form as, dividends are actually paid on the common stock. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as defined in the Certificate of
Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders of Series A preferred stock
are entitled to be paid from assets of the Company available for distribution to its stockholders, before any payment is made to the
holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the original issue price
(<span id="xdx_908_eus-gaap--CommonStockConversionBasis_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKsgAAOuvQx6" title="Common stock converted basis">$5.75 on an as-converted-to-common stock basis</span>), plus all accrued and unpaid dividends and (ii) the amount that the holder would have
been entitled to receive at such time if the Series A preferred stock were converted into common stock. The Company may not, without
the consent of holders of a majority of the outstanding shares of Series A preferred stock, amend its charter in a manner that adversely
affects the powers, preferences or rights of the Series A preferred stock or issue or obligate itself to issue shares of any additional
class or series of capital stock unless the same ranks junior to the Series A preferred stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company and the payment of dividends.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0vPzVwClfH4" title="Conversion of preferred to common stock, shares">317,577</span> shares of Series A preferred stock were converted into <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QZQQZKgs7i" title="Conversion of preferred to common stock, shares">3,175,770</span> shares of common stock. As
of December 31, 2025, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5i1gdO0ybFd" title="Preferred stock, shares outstanding">no</span> shares of Series A preferred stock were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLuItsdnxrU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_823_zeXtXG7mKgqh">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2012
Equity Incentive Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2012, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20120801__20120831__us-gaap--PlanNameAxis__custom--TwoThousandTwelveEquityIncentivePlanMember_zM6gtsJD1vKf" title="Stock based compensation description">the Company adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provided for options, restricted
stock awards, performance stock awards and stock bonuses. The exercise price of each option granted under the 2012 Plan is not less than
100% of the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Plan is
ten years. The Company&#8217;s board of directors administers the 2012 Plan and determines the provisions of incentive awards, including
eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. In September 2017, the 2012 Plan was frozen and no further awards may be
made under the 2012 Plan.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2017
Amended and Restated Stock Incentive Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_z0n5vRNzsOMc" title="Stock based compensation description">the Company adopted the 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan provides
for the grant of options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock bonuses.
The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on the date
of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered by
the compensation committee of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other
determinations necessary for the administration of the 2017 Plan.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zZ5bHPexIIrf" title="Number of shares reserved for issuance description">The
number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1 of each year from 2026 to 2027 by
the number of shares equal to 1.0% of the aggregate number of outstanding shares of common stock as of the immediately preceding December
31.</span> However, the Company&#8217;s board of directors may reduce the amount of the increase in any particular year. The number of shares
reserved for issuance under the 2017 Plan was automatically increased by <span id="xdx_909_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zu1vQ7ho5Bi9" title="Number of shares reserved for issuance">371,432</span> and <span id="xdx_901_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zpnVLhuVPXL9" title="Number of shares reserved for issuance">255,060</span> shares on January 1, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the board of directors and the stockholders approved additional increases of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z6nNPwSBcZyi" title="Number of shares reserved for issuance, additional increases">3,000,000</span> and
<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z9FyvHfjAABg" title="Number of shares reserved for issuance, additional increases">1,500,000</span>, respectively, to the number of shares reserved for issuance under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the number of shares available for issuance under the 2017 Plan is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z7kIUC3NquR8" title="Number of shares available for issuance">2,591,634</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Stock
Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2017 Plan are exercisable at various dates as determined upon grant and will expire no more than 10 years from their
date of grant. The exercise price of each option shall be determined by the board of directors based on the estimated fair value of the
Company&#8217;s common stock on the grant date. The exercise price shall not be less than 100% of the fair market value of the Company&#8217;s
common stock on the grant date. Most option grants generally vest <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9dTr5QzcwU9" title="Option vested percentage">25</span>% on the first anniversary of the original vesting commencement date,
with the balance vesting monthly over the remaining <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSJ1D3SGXX3c" title="Option vested period">three years</span>. The 2017 Plan is generally administered by the compensation committee
of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other determinations necessary
for the administration of the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTcIIS7MgWOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zlfIIvSxZYSd" style="display: none">Schedule of Stock Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average remaining contractual term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Options outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCkkFqEa3hA7" style="width: 11%; text-align: right" title="Options outstanding at beginning of year">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMrXPEQNQhsk" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z827ybDJ6FT8" title="Options outstanding, weighted average remaining contractual term">8.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfVKMidhnWxf" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value">13,914</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvNkbSZkP4f" style="text-align: right" title="Shares, Granted">2,186,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx8BY35J20T3" style="text-align: right" title="Weighted Average Exercise Price, Granted">35.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBgTugSTIG62" style="text-align: right" title="Shares, Exercised">(393,301</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJRL0p6hVJzi" style="text-align: right" title="Weighted Average Exercise Price, Exercised">8.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBGFofiqjod7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(257,784</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFvDeYHk0Gxd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise, Forfeited">14.29</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPMAvV2Ci8Ae" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at end of year">5,842,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJUeAh6Ohkm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, weighted average exercise price at end of year">19.62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRpxRljttXc" title="Options outstanding, weighted average remaining contractual term">7.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRoCp1nQzBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value">468,191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z22A603GPpa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">2,740,854</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUxQ8RT8mgid" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options exercisable">11.61</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zafuMNCGgrKd" title="Options exercisable, weighted average remaining contractual term">6.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgWXNQtrKRHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value">241,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zRmzYZgIWFY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company modified previously granted stock option awards to 44 employees by reducing the exercise price of these options
to the Company&#8217;s closing common stock price on the modification date. During the year ended December 31, 2025, the incremental
compensation expense recognized as a result of these modifications was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEbOxAGEBFGf" title="Stock based compensation expense related to modification">0.2</span> million. The effect of these modifications on stock-based
compensation over the remaining service periods will be $<span id="xdx_90A_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHyW3d1nUdie" title="Remaining stock based compensation expense related to modification">0.3</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, the market conditions associated with options previously granted to an employee were satisfied following
the achievement of the specified stock price threshold. As a result, the options vested and the Company recognized $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsghp4TFUmGc" title="Stock-based compensation expense">8.4</span> million in stock-based
compensation expense related to these awards during the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the weighted-average grant date fair value of options granted was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQyUcCSuSM28" title="Weighted-average grant date fair value of options granted">25.01</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKLtiLHbux2l" title="Weighted-average grant date fair value of options granted">11.22</span> per share,
respectively. The total intrinsic value of options exercised during the years ended December 31, 2025 and 2024, was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zK2IC7BfVC3b" title="Total intrinsic value of options exercised">35.7</span> million and
$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zS9xHGJyemp2" title="Total intrinsic value of options exercised">0.6</span> million, respectively. Upon the exercise of stock options, the Company will issue new shares of its common stock. As of December
31, 2025, the unrecognized compensation cost related to outstanding employee and non-employee options was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHBwHWyZ9IKi" title="Unrecognized compensation cost">52.7</span> million and is expected
to be recognized as expense over a weighted-average period of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkbUGsQ1ZG5" title="Weighted-average period">1.7</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z3FcRz9Z6IZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used in the Black-Scholes option pricing model and Monte Carlo simulation model to determine the fair value of the employee
and non-employee stock option grants issued, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHooiLxHocnc" style="display: none">Schedule of Assumptions for Fair Value of Employee
And Non-Employee Stock Option</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zftQrWlbl5I1" title="Risk-free interest rate, minimum">3.6</span>% &#8722; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zEwoFc6JrAyd" title="Risk-free interest rate, maximum">4.7</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zRFq2DnHJSQ" title="Risk-free interest rate, minimum">3.5</span>% &#8722; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjePQYYY2x43" title="Risk-free interest rate, maximum">4.7</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_z6dJPR4OaN51" title="Expected volatility, minimum">74.4</span>% &#8722; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zuWx75cDXpV5" title="Expected volatility, maximum">82.1</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zFtSAyO9ecTi" title="Expected volatility, minimum">71.2</span>% &#8722; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zK42ZgMSlxQj" title="Expected volatility, maximum">76.2</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_zoqo3A5HeYL1" title="Expected life (years)">5.0</span> &#8722; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0dMAcFxpFdb" title="Expected life (years)">10.0</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zj9pmRcLPN8a" title="Expected life (years)">5.3 </span>&#8722; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zf3CXz8mmseb" title="Expected life (years)">10.0</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_z034pBWCJwz8" style="width: 16%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zBjl1WuZGpo8" style="width: 16%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_zqcRHHL9OmT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for stock options of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrexFWYFtkaj" title="Stock-based compensation expense">20.0</span> million
and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX4wc6vHjIMg" title="Stock-based compensation expense">6.6</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Restricted
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zpkKKu1o9ZB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award and restricted stock unit activity during the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVDyisgCqHH4" style="display: none">Schedule of Restricted Stock Award And Restricted Stock Unit Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average grant date fair value per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR764yhxFZ0i" style="width: 16%; text-align: right" title="Outstanding shares">1,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2IAvpjTNKMh" style="width: 16%; text-align: right" title="Weighted-average grant date fair value per share, outstanding">14.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkTXxhRztcic" style="text-align: right" title="Granted shares">34,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQAA84K3GOj" style="text-align: right" title="Weighted-average grant date fair value per share, granted">89.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxngmZhrjeBi" style="text-align: right" title="Vested shares">(1,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcxsEPykwxok" style="text-align: right" title="Weighted-average grant date fair value per share, vested">14.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 9pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvp5duBIU3uj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited shares">(6,600</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zre61j4B5Omk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, forfeited">98.49</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg7btdZuLY7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares">27,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOZtNknRa617" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value per share, outstanding">87.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zr7g9kI8in6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the unrecognized compensation cost related to outstanding restricted stock was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD73JRzblUKj" title="Unrecognized compensation cost">2.3</span> million and is expected to
be recognized over a weighted-average period of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgRlh61bIB7h" title="Weighted-average period">1.9</span> years. The total fair value of restricted stock vested during the year ended December
31, 2025 was less than $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFrzVNnCDBg6" title="Total fair value of restricted stock vested">0.1 </span>million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for restricted stock of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkXhTy2tOvI6" title="Stock-based compensation expense">0.1</span> million
and less than $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJuhnagOZbd" title="Stock-based compensation expense">0.1</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2017
Employee Stock Purchase Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, <span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zNL7eWWSrptc" title="Employee stock purchase plan description">the Company adopted the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides participating employees
with an opportunity to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions. The ESPP is available
to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value
of the Company&#8217;s common stock. The ESPP is administered using overlapping 24 month offering periods (the &#8220;Offering Periods&#8221;).
Each Offering Period has four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and
November 1 of each year. Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of
the fair market value of a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase
date has a lower price, the employee will automatically be placed in the Offering Period beginning immediately after the purchase date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z6YMVZmEWkWg" title="Number of shares reserved for issuance description">The
number of shares reserved for issuance under the ESPP automatically increases on January 1 of each year from 2023 to 2027 by the number
of shares equal to 0.5% of the aggregate number of outstanding shares of common stock as of the immediately preceding December 31.</span> However,
the Company&#8217;s board of directors may reduce the amount of the increase in any particular year. The number of shares reserved for
issuance under the ESPP was automatically increased by <span id="xdx_90C_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_ztkc3zKI8Ibc" title="Change in common stock, shares reserved for issuance">185,716</span> and <span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zMuviZlBUBC" title="Change in common stock, shares reserved for issuance">127,530</span> shares on January 1, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the number of shares available for issuance under the ESPP is <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z9uPhR5KjFYk" title="Number of shares available for issuance">469,576</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense related to the ESPP of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zjwrZ56LwCk8" title="Stock-based compensation expense">1.3</span> million
and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zVbGnKbKX70l" title="Stock-based compensation expense">0.3</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Stock-based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziI9tdsa1ugl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the following stock-based compensation expense in its statements of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zwdJtQjabLL6" style="display: none">Schedule
of Stock-based Compensation Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231_zQtol8iQV0Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zXTRHnhdGiub" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zckkQtDacQ07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,409</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,405</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zoucFZd5Trn4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,583</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_z2oJyb8fyoXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,383</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zMXa4m9dn6C9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,383</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8A8_za1T61RK1uU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zNJ9iwbJZHJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_827_zqTVI7TqyZG4">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">July
2025 Convertible Notes Offering</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2025, the Company entered into an underwriting agreement (the &#8220;Note Underwriting Agreement&#8221;) with the Underwriters,
subject to customary conditions, to issue and sell in a public offering $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zjW3xipiuuTd" title="Principal amount">175.0</span> million aggregate principal amount of the Notes to the
Underwriters (the &#8220;Note Offering&#8221;). In addition, pursuant to the Note Underwriting Agreement, the Company granted the Underwriters
an option to purchase up to an additional $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zo5THxCavrV7" title="Principal amount">26.3</span> million aggregate principal amount of Notes solely to cover over-allotments. On July
30, 2025, the Underwriters exercised such option to purchase an additional $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJojX9ASBFD3" title="Principal amount">26.3</span> million aggregate principal amount of the Notes. The
issuance of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250801__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z1rc3wJthAt9" title="Principal amount">201.3</span> million aggregate principal amount of the Notes was completed on August 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes were issued pursuant to, and are governed by, an indenture (the &#8220;Base Indenture&#8221;), dated as of August 1, 2025, between
the Company and U.S. Bank Trust Company, National Association, as trustee (the &#8220;Trustee&#8221;), as supplemented by a first supplemental
indenture (the &#8220;Supplemental Indenture,&#8221; and the Base Indenture, as supplemented by the Supplemental Indenture, the &#8220;Indenture&#8221;),
dated as of August 1, 2025, between the Company and the Trustee. The net proceeds from the Note Offering, after deducting underwriting
discounts and commissions and offering expenses, were $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBy8QJ7EBD1i" title="Net proceeds from offering">194.9</span> million, including the proceeds from the Underwriters&#8217; exercise of
their over-allotment option in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes are general, unsecured, senior obligations of the Company. The Notes will accrue interest payable semi-annually in arrears on February
1 and August 1 of each year, beginning on February 1, 2026, at a rate equal to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260201__20260201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5bZi4EXSiBl" title="Accrue interest payable rate">2.750</span>% per year. In addition, special interest will accrue
on the Notes upon the occurrence of certain events relating to the Company&#8217;s failure to file certain reports with the SEC as provided
in the Indenture and as described below. The Notes also have customary provisions relating to the occurrence of &#8220;Events of Default&#8221;
(as defined in the Indenture) with certain interest penalty provisions. The Notes will mature on August 1, 2031, unless earlier converted,
redeemed or repurchased by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noteholders
may convert their Notes at their option at any time prior to the close of business on the scheduled trading day immediately preceding
the maturity date based on an initial conversion rate of <span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionRatio1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zBfkY00FdAh8" title="Conversion rate">19.4932</span> shares of common stock, per $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zEV3IefxYaF6" title="Principal amount">1,000</span> principal amount of the Notes, which
is equivalent to an initial conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5JxhvZoeKp" title="Conversion price">51.30</span> per share of common stock. The conversion rate is subject to customary adjustments
upon the occurrence of certain events as described in the Indenture. In addition, if certain corporate events that constitute a &#8220;Make-Whole
Fundamental Change&#8221; (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased
for a specified period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--DebtInstrumentRedemptionDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zQKzqYDaaDDe" title="Redemption description">The
Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company&#8217;s option at any
time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately
before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid
interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds
130% of the conversion price on (i) each of at least <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zMDQkhaajZ09" title="Trading days">20</span> trading days, whether or not consecutive, during the <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zfiS8p3T0LJg" title="Consecutive trading days">30</span> consecutive trading days
ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading
day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes
unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company
sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with
respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances
if it is converted after it is called for redemption.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a &#8220;Fundamental Change&#8221; (as defined in the Indenture) occurs, then, subject to certain conditions and except as set forth
in the Indenture, noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount
of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The definition in the Indenture of a Fundamental Change includes certain business combination transactions involving the Company and
certain de-listing events with respect to the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
the Notes contain a beneficial ownership limitation, and as a result of such limitation, noteholders do not have the right to convert
all or any portion of the Notes held by such noteholder, to the extent that immediately prior to, or immediately after giving effect
to such conversion by such noteholder, together with its affiliates and any other persons acting as a group together with such noteholder
or any of such noteholder&#8217;s affiliates, would <span id="xdx_905_eus-gaap--DebtInstrumentDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zlp8C3osLE0c" title="Beneficial ownership description">beneficially own in excess of 4.99% of the number of shares of the Company&#8217;s
common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes;
provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that
such limitation in no event can exceed 19.99%.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Notes, which differs from their carrying value, is influenced by interest rates, stock price and stock price volatility
and is determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an
active market and therefore the fair value is determined using Level 2 inputs. As of December 31, 2025, the carrying value and fair value
of the Notes was $<span id="xdx_909_eus-gaap--ConvertibleDebtNoncurrent_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z3dJUdAbK471" title="Convertible debt">195.3</span> million and $<span id="xdx_904_eus-gaap--NotesReceivableFairValueDisclosure_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z4RYwsXowP81" title="Fair value of the Notes">436.5</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance costs attributed to the Notes amounted to $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zXdRWHalttef" title="Discount amount">6.4</span>
million and were discounted from the Notes. The issuance cost discount is being amortized to interest expense over the term of the
Notes based on the effective interest rate method. As of December 31, 2025, the effective interest rate was <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zhYseCXMpbf" title="Interest rate">3.3</span>%.
During the year ended December 31, 2025, interest expense related to the Notes was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zeSe91SKnsrk" title="Interest expense">2.7</span>
million, including $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zepFXfvQYXib" title="Discount amount">0.4</span>
million related to discount amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Amended
and Restated Loan and Security Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Third
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2025, the Company entered into the Third Amendment (the &#8220;Third Amendment&#8221;) to the Amended and Restated Loan
and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;) with Oxford Finance LLC, a Delaware limited liability company
(&#8220;Oxford&#8221;), as collateral agent and a lender, Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership
(&#8220;Innovatus&#8221;), as a lender, and the other lenders party thereto (together with Oxford and Innovatus, the
&#8220;Lenders&#8221;), pursuant to which the A&amp;R Loan Agreement was amended to (i) replace Innovatus with Oxford as collateral
agent; (ii) recognize the achievement of the Term D Milestone (as defined in the A&amp;R Loan Agreement, as amended by the Third
Amendment (the &#8220;Amended A&amp;R Loan Agreement&#8221;)) and provide for the immediate disbursement of the $<span id="xdx_905_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zziupAojIKz1" title="Disbursement loan amount">30.0</span>
million Term D Loan (as defined in the Amended A&amp;R Loan Agreement); (iii) increase the size of the Term E Loan (as defined in
the Amended A&amp;R Loan Agreement) from $<span id="xdx_90E_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zZSyeJnlayA2" title="Contingent loans">50.0</span>
million to up to $<span id="xdx_901_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermETwoLoanMember_zP3U8a74fA2e" title="Contingent loans">100.0</span>
million, which Term E Loan may only be drawn upon FDA approval of gedatolisib in second line wild-type ABC
patients post CDK4/6 inhibitor therapy; (iv) add three new up to $<span id="xdx_909_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zthlCpxtehdg" title="Contingent loan">40.0</span>
million Term F Loans (as defined in the Amended A&amp;R Loan Agreement), for a total of $<span id="xdx_908_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzUAsh4rGZsj" title="Contingent loan">120.0</span>
million, which may only be drawn upon achievement of certain trailing three months&#8217; product revenue thresholds; (v) replace
the prior $<span id="xdx_904_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFTwoLoanMember_zOE6xVw3try4" title="Contingent loan">45.0</span>
million Term F Loan (as defined in the A&amp;R Loan Agreement) with a new $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermGLoanMember_zSQItI5irxzd" title="Contingent loan">150.0</span>
million Term G Loan (as defined in the Amended A&amp;R Loan Agreement), which continues to be available only in the Lenders&#8217;
sole discretion upon the Company&#8217;s request; (vi) require an amendment fee payable by the Company to the Lenders in the amount
of $<span id="xdx_904_ecustom--AmendmentFee_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZZSPj30VzZ2" title="Amendment fee payable">0.1</span>
million, which was paid at the closing of the Third Amendment; (vii) make certain revisions to the non-utilization fee for the Term
E Loan, and add a new non-utilization fee for the Term F Loans, in each case equal to 3.0% of the applicable unfunded commitment,
after taking into consideration any reductions to the applicable term loan commitment that the Company may make by notice to the
collateral agent before the date that is eight weeks after the achievement of any applicable milestones; and (viii) extend the
maturity date of the term loans to November 1, 2029. The Term E Loan and each Term F Loan also are subject to other customary
conditions and limits on when the Company can request funding. With the disbursement of the $<span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwIEMMMhyagk" title="Disbursement loan amount">30.0</span>
million Term D Loan, the Company received net proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z5LnX8pzav5g" title="Net proceeds from loan">27.7</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the A&amp;R Loan Agreement, a Final Fee equal to <span id="xdx_901_ecustom--DebtFinalFeePercentage_iI_pid_dp_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zPjQPZxOgoNl" title="Debt final fee percentage">4.5</span>% of the $<span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zZi3lmIKEKve" title="Disbursement loan amount">30.0</span> million Term D Loan was recognized and an additional
$<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zYAEUtwe9nwa" title="Funded loan amount">1.4</span> million was added to debt principal and a corresponding debt discount to be amortized over the life of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Third Amendment, the Company issued warrants with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdeJxjkvrBD4" title="Warrants exercise price per share">14.84</span> per share to purchase an aggregate
of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3KOKwpAUOq8" title="Warrants issued">50,537</span> shares of the Company&#8217;s common stock to Innovatus, Oxford, and certain of its affiliates (the &#8220;Third Amendment
Warrants&#8221;). The Third Amendment Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the funding date of the Term D Loan. The number of shares of common stock for which each Third Amendment Warrant is exercisable and
the associated exercise price are subject to certain proportional adjustments as set forth in such Third Amendment Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
portion of the proceeds from the Term D Loan in the amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zXIo47y5aDge">2.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was allocated to the Third Amendment Warrants based
on their relative fair value to the underlying Term D Loan. The proceeds allocated to the Third Amendment Warrants were recorded as additional
paid in capital in the accompanying balance sheets and were discounted from the Term D Loan. The relative fair value of the Third Amendment
Warrants was based on the Black-Scholes model with the following assumptions: risk-free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zUk5W1e8peA9">4.1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%;
expected volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwGubhApG6Lh">74.4</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%;
expected life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zIyGBJcFhRsl">10.0</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years; and expected dividend yield of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z9GaAKrUnQU8">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The underlying stock price used in the analysis was the traded market price. The discount related to the Third Amendment Warrants is
being amortized to interest expense ratably over the term of the Term D Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Second
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2025, the Company entered into the Second Amendment (the &#8220;Second Amendment&#8221;) to the A&amp;R Loan Agreement with
Innovatus, as collateral agent, and the Lenders including Innovatus in its capacity as a Lender and Oxford, pursuant to which Innovatus
and Oxford, as Lenders, have agreed to make certain term loans (&#8220;Term Loans&#8221;) to the Company in the aggregate principal amount
of up to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zGVu2FjAhbz1" title="Debt instrument principal amount">180</span> million. The A&amp;R Loan Agreement was amended to (i) subject to certain terms and conditions, permit the issuance of
the Notes discussed above and certain transactions in connection therewith, including the conversion thereof settled solely in common
stock (together with cash in lieu of the issuance of any fractional share of common stock), (ii) permit capped call transactions in connection
with the pricing of the Notes, (iii) require an amendment fee payable by the Company to Oxford in the amount of less than $<span id="xdx_905_ecustom--AmendmentFee_iI_pn5n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_z0IuHxQczcg1" title="Amendment fee payable">0.1</span> million,
which was paid upon execution of the Second Amendment, and (iv) extend to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zrAGHknOGxb6" title="Maturity date">May 9, 2026</span> the expiration date of Innovatus&#8217; right to
convert up to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_ze5dx5i4Shk2" title="Conversion percentage">20</span>% of the outstanding principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share
of $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zL1coVu8wIsf" title="Common stock price per share">10.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in connection with the release of the topline data from the wild-type cohort of the VIKTORIA-1 Phase 3 clinical trial, the Company achieved
the Term D Milestone (as defined in the A&amp;R Loan Agreement) and therefore became eligible to draw an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zeNtBvfcXrtc" title="Amount of indebtedness eligible to incur under Term D Loan">30.0</span> million of
indebtedness under the Term D Loan (as defined in the A&amp;R Loan Agreement). As described above, the Term D Loan was disbursed to the
Company in connection with the Third Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">First
Amendment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2025, the Company entered into the First Amendment (the &#8220;First Amendment&#8221;) to the A&amp;R Loan Agreement, pursuant
to which the Company agreed to <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zDgzxSboZEbf" title="First Amendment description">(i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment,
(ii) extend to March 9, 2026 the expiration date of Innovatus&#8217; right to convert up to 20% of the outstanding principal of the Term
A Loan into shares of the Company&#8217;s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D
Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&amp;R Loan Agreement),
(iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company
had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the
Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders
from any and all claims arising out of or related to the A&amp;R Loan Agreement, the First Amendment and related documentation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">May
30, 2024 Amendment and Restatement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2024, the Company entered into the A&amp;R Loan Agreement. The A&amp;R Loan Agreement amended and restated, in its entirety,
that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and Innovatus, as collateral agent, and
the Lenders named therein (the &#8220;Prior Loan Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
of the first $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zVNBS9WrKuT6" title="Funded loan amount">100</span> million under the A&amp;R Loan Agreement occurred on May 30, 2024, including tranche payments of $<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zIt9owQwRmm2" title="Funded loan amount">16.8</span> million (the
&#8220;Term A Loan&#8221;) and $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zBywFpf9mrre" title="Funded loan amount">21.5</span> million (the &#8220;Term B Loan&#8221;) reflecting repayment of the principal amount of loans under
the Prior Loan Agreement plus accrued payment-in-kind interest, in addition to $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zabCoOTcteag" title="Funded loan amount">61.7</span> million of new borrowings (the &#8220;Term C Loan&#8221;).
As described above, the Term D Loan was disbursed to the Company in connection with the Third Amendment. Prior to the Third Amendment,
the Company also would have become eligible to draw on a fifth tranche of $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z18iOBq3PGUh" title="Funded loan amount">50.0</span> million (the &#8220;Term E Loan&#8221;), upon achievement
of certain clinical trial milestones and satisfaction of certain financial covenants. The Lenders also could have, in their sole discretion
upon the Company&#8217;s request, made additional term loans to the Company of $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zXOQ5LL7ndtg" title="Funded loan amount">45.0</span> million (the &#8220;Term F Loan&#8221;). Funding
of these additional tranches was also subject to other customary conditions and limits on when the Company could have requested funding
for such tranches. Costs associated with the new borrowings were approximately $<span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0cR5GxuVLN8" title="Costs associated with new borrowings">2.4</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the A&amp;R Loan Agreement, <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zxCLtgbyFY4d" title="Debt instrument interest rate description">the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months
if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</span> The A&amp;R Loan Agreement is secured by all assets of the Company. Proceeds are being used for working capital purposes and
to fund the Company&#8217;s general business requirements, including the ongoing Phase 3 VIKTORIA-1 clinical trial, the Phase 1b/2 CELC-G-201
clinical trial, and the Phase 3 VIKTORIA-2 clinical trial. The A&amp;R Loan Agreement contains customary representations and warranties
and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity and other financial measures. Prior
to the Second Amendment, Innovatus also had the right, at its election and until August 9, 2025, to convert up to <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zRT2FgyccyCl" title="Loan % convertible to stock">20</span>% of the outstanding
principal of the Term A Loan into shares of the Company&#8217;s common stock at a price per share of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zfYOuhCUf0i" title="Common stock price per share">10.00</span>. Innovatus will continue
to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zrrvM0TXY429" title="Common stock issued">26,042</span> shares of
common stock at a price per share of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_znOYr6IsZgq9" title="Common stock price per share">14.40</span> through April 8, 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A&amp;R Loan Agreement contains a Final Fee, which is equal to <span id="xdx_902_ecustom--FinalFeePercentage_pid_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTi3OiqpyoHa" title="Final fee percentage">4.5</span>% of the initial funding of the agreement and is due on the earliest
to occur of (a) the Maturity Date, (b) the acceleration of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent
non-utilization fee for the Term E Loans. Following the disbursement of the Term D Loan in connection with the Third Amendment, the non-utilization
provisions related to the Term D Loan are no longer operative. The Term D Loan shall become due and payable on the earliest of (i) the
termination of the Term D Draw Period, (ii) the Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole
of the Term Loans. If the Company achieves the Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term
E Draw Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#8217;s achievement
of the Term E Milestone, of the Company&#8217;s intent not to draw the full amount of the Term E Loan, a non-utilization fee with respect
to the Term E Loan shall become due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date,
(iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective
Date, the Company shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;R
Loan Agreement, provided the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least
seven business days prior to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance
with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid
interest thereon through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that
are due and payable, including, without limitation, Lenders&#8217; Expenses and interest at the Default Rate with respect to any past
due amounts. At May 30, 2024, the Company recognized the Final Fee of $<span id="xdx_902_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEokQVdWVgg" title="Final fee">4.5</span> million as additional debt principal and a corresponding debt
discount to be amortized over the life of the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the funding of each of the Term C Loan and the Term D Loans, the Company agreed to issue to Innovatus and Oxford
warrants to purchase that number of shares of the Company&#8217;s common stock equal to <span id="xdx_90E_ecustom--WarrantOrRightToPurchasePercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z9QKeCu0Rqj5" title="Warrant or right, reason for issuance, description">2.5</span>% of the principal amount of the applicable
Term Loan divided by the exercise price, which was, with respect to the Term C Loan, equal to the lower of (i) the volume weighted average
closing price of the Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding
the execution of the A&amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of
the A&amp;R Loan Agreement. Accordingly, on May 30, 2024, the Company issued <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYJwbrXD19a" title="Warrants issued">103,876</span> warrants with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLKOP0uhNOqd" title="Warrants exercise price per share">14.84</span> per share.
The relative fair value of the warrants was approximately $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z34miiz2AUQd" title="Fair value of warrants">1.2</span> million. For the Term D Loans, the exercise price was based on the lower
of (i) the exercise price for the warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#8217;s common stock for the five-trading day period ending on the last trading day immediately preceding the Term D Loan funding.
Prior to the Third Amendment, the Company also was required to issue warrants to Innovatus and Oxford in connection with the funding
of the Term E Loan and the Term F Loan. The warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the applicable funding date. The number of shares of common stock for which each warrant is exercisable and the associated exercise
price are subject to certain proportional adjustments as set forth in such warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the change of terms under ASC 470-50, <i>Debt &#8211; Modification and Extinguishment</i> with respect to the Third
Amendment, the Second Amendment, the First Amendment and the A&amp;R Loan Agreement and concluded the change in terms did not result
in significant and consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not
an extinguishment of the debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zRG7JCSbpWeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable, non-current consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z2DbeMGS5Xk4" style="display: none">Schedule of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zovM67dRbgB8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0n0LvfZYN2g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_maLTNPzDBl_z9vpQiPRdoU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">130,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinalFee_iI_pn3n3_maLTNPzDBl_z9QoO55Wjuah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentInKindInterestDebt_iI_pn3n3_maLTNPzDBl_zOKlikdS4cy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTNPzDBl_zQ8GVUbVYhH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,619</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,614</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msLTNPzDBl_zWisoCvbjpP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,401</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,752</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermNotesPayable_iTI_pn3n3_mtLTNPzDBl_zhySW4epDuT4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,527</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,727</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zy0Ns2H2k1Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the fair value of the note payable, which differs from its carrying value, is determined using the Company&#8217;s estimated discount rate, volatility and risk-free rate, which are
considered Level 3 inputs. As of December 31, 2025, the fair value of the note payable was $<span id="xdx_907_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20251231_zObChx03k3lj" title="Fair value of note payable">160.2</span> million. As of December 31, 2024,
the carrying value of the note payable approximates the fair value (Level 3 inputs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt issuance costs and discount will be amortized to interest expense over the term of the Notes based on the effective interest rate
method. As of December 31, 2025 and 2024, the effective interest rate was <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231_z5NK4KBMyZF1" title="Interest rate">12.7</span>% and <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231_zoLlJxpyCHTe" title="Interest rate">12.3</span>%, respectively. During the year ended December
31, 2025, interest expense related to the note payable was $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zHG7f7XZ4Bz1" title="Interest expense">14.4</span> million, including $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231_zVPTkV0YThQl" title="Discount amount">2.7</span> million related to discount amortization. During
the year ended December 31, 2024, interest expense related to the note payable was $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zF3j1K1oiFRa" title="Interest expense">10.3</span> million, including $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231_zYqUrMtQBuN4" title="Discount amount">1.3</span> million related to discount
amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgSteUrovpbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, future principal payments, including the incurred PIK interest and Final Fee, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zJ98d1GXjbx8" style="display: none">Schedule of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_z38QyhHt3cta" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz4sG_zhGh6N4oAla4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%; text-align: left">2028</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">43,899</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz4sG_zRWKrlbGtgT2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz4sG_zw5BHz5Etjnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,547</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zQ0kF1vKCqJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company was in full compliance with all financial covenants of the Amended A&amp;R Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DisclosureLicenseAgreementAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_LicenseAgreementTestBlock', window );">License Agreement</a></td>
<td class="text"><p id="xdx_80F_ecustom--LicenseAgreementTestBlock_zjuBp8wM44Rh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82E_zgNWyvHu0vg6">License Agreement</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) to research, develop, manufacture
and commercialize gedatolisib. During 2021, the Company paid $<span id="xdx_909_eus-gaap--PaymentsForFees_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember_zbc509plt2Q9" title="Payment for upfront fees">5.0</span> million in upfront fees and
issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqYm3BxcJfIc" title="Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement">349,406</span> shares of the Company&#8217;s common stock to Pfizer pursuant to an Equity Grant Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $<span id="xdx_907_ecustom--AggregateValueOfMilestoneEvents_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z0tKV2Vzsji1" title="Aggregate value of milestone events">335.0</span> million. One of these milestone events requires a $<span id="xdx_90D_ecustom--PaymentOnMilestoneEventOne_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zflpqQkHfooa" title="Payment on milestone event one">5.0</span> million payment within 60 days following the FDA
regulatory filing of a New Drug Application (&#8220;NDA&#8221;) for gedatolisib. The FDA granted the Company&#8217;s request to submit
its NDA via the FDA&#8217;s Real-Time Oncology Review (&#8220;RTOR&#8221;) program, and the Company completed its final NDA submission
to the FDA in November 2025. The Company recorded the $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseMilestone_pn5n6_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0l1FXNmv5Sf" title="Research and development expense">5.0</span> million NDA filing milestone as research and development expense in June 2025.
As of December 31, 2025, this amount was included in other accrued expenses on the Company&#8217;s balance sheets. Additionally, the
Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject
to deductions for expiration of valid patent claims, amounts due under third-party licenses and generic competition. Unless earlier terminated,
the license agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country
basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration
of all regulatory or data exclusivity in such country for such product, or (c) the date upon which the manufacture, use, sale, offer
for sale or importation of such product in such country would no longer infringe, but for the license granted in the license agreement,
a valid claim of a licensed patent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the license agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DisclosureLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DisclosureLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_LicenseAgreementTestBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Test Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_LicenseAgreementTestBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zB4ycJKhnbT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_82D_zaFnGuP0iiS1">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20250101__20251231_ztRlKSeyVz8i" title="Income tax benefit::XDX::-"><span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20240101__20241231_zKRqlBujv4eh" title="Income tax benefit::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1380"><span style="-sec-ix-hidden: xdx2ixbrl1382">No</span></span></span></span>
income tax benefit was recorded during the years ended December 31, 2025 and 2024, due to net losses and recognition of a valuation allowance.
The following table, which reflects the Company&#8217;s retrospective adoption of ASU 2023-09, presents a reconciliation of the
U.S. federal statutory rate to the Company&#8217;s effective tax rate, including the amount (in thousands):</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB3xO0XQqI93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zXKuzL1MbR" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zUwDHxk8jng3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zoWNkiNcVURl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_ziebyqsOJc92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(37,179</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20250101__20251231_zL63fZk0dl26" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(23,474</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20240101__20241231_z6cRILfVTY7" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_zgqX4NFo0xvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20250101__20251231_zDpqV0uM4qG" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20240101__20241231_zVzAFXxTxCve" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1398">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zhml9Ekrhf68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20250101__20251231_zOmMd2nRCly4" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage">(21.6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20240101__20241231_zdb0sY3vq3m6" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage">(21.3</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zax8rep7fNze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Federal research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,358</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20250101__20251231_zH4mnEAzRpyc" style="text-align: right" title="Federal research and development credits, percentage">0.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20240101__20241231_zTw96vKP64D2" style="text-align: right" title="Federal research and development credits, percentage">0.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzqmi_zrZMhgxG5O75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior year adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20250101__20251231_znonAdPmj3L8" style="text-align: right" title="Prior year adjustments, percentage">0.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20240101__20241231_zsnyNadTXYgi" style="text-align: right" title="Prior year adjustments, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzqmi_zwRyp2LG002a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-deductible items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">645</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20250101__20251231_zpePl9cUOEnf" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage">(0.4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20240101__20241231_zl13fGkZpJ7j" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage">(0.6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zojvmUBQFXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20250101__20251231_zK8BpRcZ8NZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"><span style="-sec-ix-hidden: xdx2ixbrl1431">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20240101__20241231_zfOpLpICZWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A8_zj8MHAkAjtU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted, introducing a series of corporate tax changes in the
U.S., including 100% bonus depreciation on qualified property and full expensing of domestic research and development expenditures.
The impacts of OBBBA are reflected in our results of operations during the year ended December 31, 2025. OBBBA did not have a
material impact on the Company&#8217;s effective income tax rate and its net deferred tax assets as the Company maintains a full
valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets (liabilities) reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to
its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, <i>Income Taxes</i>, the
Company recorded a valuation allowance to fully offset the net deferred tax assets as of December 31, 2025 and 2024, because it is more
likely than not that the Company will not realize future benefits associated with these deferred tax assets. The tax effects of temporary
differences and carryforwards that give rise to significant portions of the deferred tax assets (liabilities) were (in thousands):</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUFrOLm4Vzyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zre4SKsiI4lb" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zcIYmg432i63" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zkrhoV03I3be" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gross deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzhJd_zln8t7ZgwkH3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-left: 9pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">459</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhJd_zoB2sDFjTEq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,861</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhJd_ze93AiysZFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzhJd_zIUU6WviV2zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsLeaseLiability_iNI_di_msDTAGzhJd_zHeeNCWYlM17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_maDTAGzhJd_zzn3WiI5NEjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Section 174 expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_maDTAGzhJd_zhY8OqeXuK6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,998</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzhJd_zEFoI7g1VCQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Net operating losses and tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,483</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,340</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhJd_maDTALNzwuF_zYguL3PnOq6d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzwuF_zgvG9dZHx7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(100,281</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,214</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzwuF_zSgkTYACRlLb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zw4nMVGVelI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had federal and state net operating loss carryforwards of $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_z5bfEfY9SMh2" title="Federal net operating loss carryforwards">83.3</span> million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zbDIeqydPvd6" title="State net operating loss carryforwards">4.8</span> million, respectively.
The federal and state net operating loss carryforwards for 2017 will begin to expire during the year ending December 31, 2037. The federal
net operating loss carryforwards starting in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance
as of December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had federal and state research and development tax credit carryforwards resulting in deferred tax assets
of $<span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwvpU8Y4FgWg" title="Tax credit carryforwards">4.3</span> million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zpHnSKFDCzx4" title="Tax credit carryforwards">2.0</span> million, respectively. The federal and state credit carryforwards will begin to expire during the years ending
December 31, 2038 and December 31, 2033, respectively. These deferred tax assets were subject to a full valuation allowance as of December
31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of Section 382 of the Internal Revenue Code of 1986, certain substantial changes in the Company&#8217;s ownership, including
a sale of the Company, or significant changes in ownership due to sales of equity, may limit in the future the amount of net operating
loss carryforwards available to offset future taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes uncertain tax positions in accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that
the tax positions will be sustained upon examination by tax authorities. For those tax positions that meet the more-likely-than not recognition
threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate
settlement. As of December 31, 2025 and 2024, the Company had <span id="xdx_90A_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20251231_zddnx6RfG1X4" title="Uncertain tax positions"><span id="xdx_902_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20241231_zwwzxLDpgCZd" title="Uncertain tax positions">no</span></span> significant uncertain tax positions. There are <span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_zE7mnCpCYX09" title="Unrecognized tax benefits"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20241231_ztnBIQiKME3j" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits
included on the balance sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be
a significant change in unrecognized tax benefits within the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is no longer subject to U.S. federal income
tax examinations for years before 2022, although carryforward attributes that were generated before 2022 may still be adjusted upon examination
if used in a future period. State income tax statutes vary by jurisdiction. In most states in which the Company operates, the statute
of limitations remains open for four years, and accordingly, the Company is generally no longer subject to state income tax examinations
for years before 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax
positions as a component of general and administrative expenses. As of December 31, 2025, the Company had <span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20251231_zWrCQwo0An2f" title="Accrued interest or penalties">no</span> accrued interest or penalties
and no amounts were recognized in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2025 and 2024, the Company made state tax payments which were deemed immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zXsOXkjyedj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_824_zCWQNwrnbswh">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2026, the Company filed a new registration statement and accompanying prospectus supplement, which increased the aggregate
offering amount under the Open Market Sale Agreement to $<span id="xdx_903_ecustom--AggregateOfferingAmount_pn5n6_c20260109__20260109__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRP6AY2JAHV" title="Aggregate offering amount">400.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZyqntnbGC3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zSEcArUGpUL7">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).
Operating results during the year ended December 31, 2025, are not necessarily indicative of results to be expected for any future year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_z4wX2KuNTQh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zq0Rkpzqv5Hd">Accounting
Estimates</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such
estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyuqO5zJgMfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_zX3Kco5Tshj5">Cash
and Cash Equivalents</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its accounts at two financial institutions. As of December 31, 2025 and 2024, the Company had $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_z9RHZLhNlC2g" title="Cash and cash equivalents">165.7</span> million and $<span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zzkYYFbsgxCl" title="Cash and cash equivalents">22.5</span>
million, respectively, in business checking accounts and money market funds that are considered cash equivalents. Cash and cash equivalents
are classified as Level 1 assets under the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_841_eus-gaap--InvestmentPolicyTextBlock_zHhi3kTKMJhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zNunFUOvHYNb">Investments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its investments in U.S. treasury securities and has classified them as held-to-maturity at the time of purchase. Held-to-maturity
purchases are those investments which the Company has the ability and intent to hold until maturity. Held-to-maturity investments are
recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity investment using the straight-line method. The difference between the carrying
value, which is based on cost, and the aggregate fair value of the held-to-maturity investments, was immaterial as of December 31, 2025.
As of December 31, 2025 and 2024, the Company had $<span id="xdx_907_eus-gaap--ShortTermInvestments_iI_pn5n6_c20251231_zZD871QV3Pu1" title="Short-term investments">275.8</span> million and $<span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_ziLL23bT0Wa9" title="Short-term investments">212.6</span> million, respectively, of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zW2gzexcYwa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zmywVMpiYPyj">Fair
Value of Financial Instruments</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The accounting guidance establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Unobservable inputs that are significant to the fair value measurement and supported by little or no market activity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
level in the fair value hierarchy within which a fair value measurement in its entirety falls, is based on the lowest level input that
is significant to the fair value measurement in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of cash equivalents, accounts payable, accrued expenses and other financial working capital items approximate fair value
as of each of December 31, 2025 and 2024, due to the short maturity nature of these items. Refer to Note 10 for disclosures around the
Company&#8217;s <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z13StAFalI86" title="Accrue interest payable rate"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z2cFbGR9qQUa" title="Accrue interest payable rate">2.750</span></span>% Senior Notes due 2031 (the &#8220;Notes&#8221;) and note payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZKo6AbqVvxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zT1PkDBaxKtc">Concentration
of Credit Risk</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial
instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents, and
investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company
has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AllowanceForCreditLossesPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><p id="xdx_849_ecustom--AllowanceForCreditLossesPolicyTextBlock_zPDb6xwx063k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86A_zCVZbl4QFzhc">Allowance
for Credit Losses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
investments in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that
it will be required to sell, the investment before recovery of its amortized cost basis. If either of the criteria regarding intent or
requirement to sell is met, the investment&#8217;s amortized cost basis is written down to fair value through earnings. For investments
that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses
or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes
in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates
that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost
basis of the investment. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit
loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost
basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQGdqKZJAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_zaLp4t9hew6c">Property
and Equipment</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and
repairs are expensed as incurred; major improvements and betterments are capitalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
useful lives of property and equipment are as follows for the major classes of assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_ztk6McHWACA7" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify">Asset description</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center">Estimated useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives">4</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"><span style="-sec-ix-hidden: xdx2ixbrl0597">Shorter of remaining lease term or estimated useful life</span></span></td></tr>
  </table>

<p id="xdx_8A9_zi5mSi50J9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zx6fJWTV2tY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_z8XMZLoRvvog">Leases</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies
leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use
asset and current and non-current lease liabilities, as applicable, on the balance sheets. The Company has elected not to recognize on
the balance sheets leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease
term. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s leases may include options to extend or terminate the leases. Periods covered by an option to extend the lease are included
in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate
the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. The Company monitors
its plans to renew or terminate its material leases each reporting period. If a lease includes provisions for leasehold improvements
for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets.
If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding
right-of-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease
term. The present value of future lease payments is discounted using the interest rate implicit in the lease contracts if that rate
is readily determinable; otherwise, the Company utilizes information available at the commencement of the lease to calculate the incremental
borrowing rate, which reflects the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar
term and in a similar economic environment. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lease
cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the
period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities,
real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company.
The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy', window );">Capitalized Software Development Costs</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CapitalizationAndAmortizationOfFuelCostsPolicy_zZyNUMrJAi27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zX4lzNpaEKzi">Capitalized
Software Development Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company capitalizes qualifying costs incurred during the application development stage related to software developed for internal use.
Capitalized software development costs are classified as other non-current assets on the balance sheets. As of December 31, 2025 and
2024, the Company had $<span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn5n6_c20251231_zM6b5cWY6VC" title="Capitalized software development costs">0.1</span> million and <span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0_do_c20241231_zlMEzTHKCPo1" title="Capitalized software development costs">no</span> capitalized software development costs, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software,
beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general
and administrative expenses. The Company did not record any amortization expense during the years ended December 31, 2025 and 2024. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlOi0Upf1PA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zhM3A0omLsCd">Long-Lived
Assets</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment,
the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Transaction Costs</a></td>
<td class="text"><p id="xdx_847_eus-gaap--DeferredChargesPolicyTextBlock_zD1nPD22SC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_zqNNtcbHJsu7">Deferred
Transaction Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
transaction costs primarily consist of legal fees that are capitalized as incurred and will be offset against the proceeds from future
equity financing arrangements. The deferred transaction costs will be reviewed periodically to assess the probability that future securities
will be offered. In the event that no future offering will occur, any deferred transaction costs will be expensed. Total costs incurred,
but not accounted for as a reduction in equity, were $<span id="xdx_904_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20251231_z8r3RBeFpgX6" title="Deferred transaction costs">0.2</span> million and $<span id="xdx_905_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20241231_zUpNBA8nvcm2" title="Deferred transaction costs">0.2</span> million as of December 31, 2025 and 2024, respectively. D<span style="background-color: white">eferred
transaction costs are classified as other assets on the balance sheets.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--DebtPolicyTextBlock_zcAx6RA6yAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zgV1CyFnZHhk">Debt
Issuance Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes debt issuance costs as deferred costs, which are capitalized and amortized over the term of the related debt
using the effective interest method. These costs primarily consist of fees, commissions, and legal and other costs directly
attributable to securing debt financing. Debt issuance costs are reported as a direct reduction of the carrying amount of the
related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements of operations over
the life of the debt instrument. In the event of early extinguishment of debt, any related unamortized debt issuance costs are
written off and recognized as a component of the gain or loss on extinguishment of debt in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zV1w1M8nL3P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86F_zCXXW4tYrEEk">Comprehensive
Loss</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other
than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zviD542vWEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zp6BOAhm9hV1">Commitments
and Contingencies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other
amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount,
the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z1nUe2xca6V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zMG8KiOHKv49">Stock-Based
Compensation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation consists of stock options, restricted stock awards and restricted stock units issued
to certain employees and non-employees of the Company under the 2017 Amended and Restated Stock Incentive Plan, and shares issued under
the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to account for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock-based compensation expense based on the estimated grant date fair value using the Black-Scholes
option-pricing model and the expense is recognized on a straight-line basis over the requisite service period. Compensation expense
for awards with performance-based conditions is recognized when the achievement of the performance condition is deemed
probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Monte Carlo simulation model for awards with market-based vesting conditions. If the factors change and different
assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inputs for the Black-Scholes valuation model and the Monte Carlo simulation model require management&#8217;s significant assumptions,
including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected
dividends. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available
in combination with the Company&#8217;s calculated volatility since being publicly traded. The expected term of the award is based on
the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free interest rate is based on the
rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected term of the award at the
grant date. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay
any dividends on its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with such agreements would also be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Restricted
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records compensation expense based on the quoted fair value of the shares on the grant date over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ESPP</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense for ESPP rights is recorded in line with each respective offering period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIunJ3n2ufXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_z0eJafjg7AM5">Research
and Development</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development costs were $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn6n6_c20250101__20251231_z12fj9fPToT6" title="Research and development expense">145.0</span> million and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_z3gNzyhfz9ni" title="Research and development expense">104.2</span> million during the years
ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Clinical Trial Costs</a></td>
<td class="text"><p id="xdx_840_eus-gaap--InProcessResearchAndDevelopmentPolicy_zvxAfo7Fc65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_z4e7z51IdGNc">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on third-party service providers to conduct certain aspects of clinical studies and to formulate and manufacture its drug
product. While there are alternative vendors that can perform these functions, any disruption or delay by the Company&#8217;s current
third-party service providers in carrying out their contractual duties could delay its clinical trials and/or the commercial launch of
 gedatolisib, if approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company records prepaid or accrued
clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials. These costs can be a
significant component of the Company&#8217;s research and development expenses. The Company uses progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, the Company&#8217;s estimated expenses in future periods and actual services performed
may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes
to the Company&#8217;s prepaid or accrued clinical trial costs could materially affect the Company&#8217;s results of operations and
financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_LicensesPolicyTextBlock', window );">Licenses</a></td>
<td class="text"><p id="xdx_840_ecustom--LicensesPolicyTextBlock_zc84EiKOSzja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zdYLlh0qBtz4">Licenses</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upfront
payments and other consideration under license agreements are expensed as research and development expense upon receipt of the license,
and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
license agreements include milestone payments which are recognized when it becomes probable that the achievement of those milestones
will be met. The Company records this expense as research and development expense in its statements of operations. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_84B_ecustom--PatentCostsPolicyTextBlock_zawpsPqfjNCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_z3zaSHAgoOal">Patent
Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zMp5hH9dGpD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zJiPQCUlSyMg">Income
Taxes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss
and tax credit carryforwards. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized
in results of operations in the period that includes the enactment date. The effects of any future changes in tax laws or rates have
not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that
the deferred tax assets will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the impact of an uncertain tax position in its financial statements if, in management&#8217;s judgment, the position
is more-likely-than-not sustainable upon audit based on the position&#8217;s technical merits. This involves the identification of potential
uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position
is necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Data</a></td>
<td class="text"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgrcRyEGF68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_zxYl1G2LUNR6">Segment
Data</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has <span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20251231_zyV0gJPysRfb" title="Number of operating segment"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zBXIOtyInZfa" title="Number of reportable segment">one</span></span> reportable operating segment, which is the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#8217;s chief operating decision makers (&#8220;CODMs&#8221;) are its chief executive officer, chief science
officer and chief financial officer, who, together manage the Company&#8217;s operations as one operating segment for the purpose of
evaluating financial performance and allocating resources. The CODMs assess the performance and allocate resources for the reportable
segment based on net loss and total assets, which are the same amounts in all material respects as those reported in the statements of
operations and balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84C_ecustom--RecentAccountingPrononcementAdoptedPolicyTextBlock_zykMCmeNJmPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_z9oy2onAva6a">Recently Adopted
Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09,
<i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the annual income
tax disclosures for the effective tax rate reconciliation, income taxes paid, and continuing operations. ASU 2023-09 also eliminates
certain disclosure requirements related to unrecognized tax benefits. ASU 2023-09 is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 on January 1, 2025 on a retrospective basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zI0ml4PUQfTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_864_zw21V0E5gg1h">Recent
Accounting Pronouncements Not Yet Adopted</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03<i>, Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses</i> (&#8220;ASU 2024-03&#8221;), which requires public entities to provide
disaggregated disclosure of income statement expense. In January 2025, the FASB issued ASU 2025-01, <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i>, to clarify the effective
date of ASU 2024-03. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025<i>, </i>the FASB issued ASU 2025-05<i>, Measurement of Credit Losses for Accounts Receivable and Contract Assets</i> (&#8220;ASU
2025-05&#8221;), which provides certain entities with an additional practical expedient for estimating expected credit losses on current
accounts receivable and current contract assets arising from revenue transactions under Accounting Standards Codification (&#8220;ASC&#8221;)
606. ASU 2025-05 is effective for all entities for annual and interim periods in fiscal years beginning after December 15, 2025. Early
adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2025-05 on its financial statements and
related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software </i>(&#8220;ASU 2025-06&#8221;), which modernizes the accounting for
internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs
when management has committed to the software project, and it is probable the software will be completed and perform to its intended
use. In evaluating whether it is probable the project will be completed, management is required to consider whether there is significant
uncertainty associated with the development activities of the software. ASU 2025-06 is effective for annual and interim periods beginning
after December 15, 2027. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective
basis. The Company is currently evaluating the timing, method of its adoption, and effect of ASU 2025-06 on its financial statements
and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AllowanceForCreditLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance For Credit Losses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AllowanceForCreditLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_LicensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_LicensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Prononcement Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fuel costs amortized and recorded and recovered through rates, such as under a fuel adjustment clause or other tracking arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478742/980-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
useful lives of property and equipment are as follows for the major classes of assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_ztk6McHWACA7" style="display: none">Schedule of Estimated Useful Lives of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify">Asset description</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center">Estimated useful life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives">4</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"><span style="-sec-ix-hidden: xdx2ixbrl0597">Shorter of remaining lease term or estimated useful life</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zORYutVOwcoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the potentially-dilutive shares that have been excluded from the calculation of diluted weighted-average shares
outstanding because their inclusion would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z5QGd34saOD3" style="display: none">Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zmiwONDliCC2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_ziB8ERXgONb3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zMZiJmSvch96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,842,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesToCommonStockMember_zCYOYBvJ442f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note as-if-converted-to-common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,296,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z0n4IUGxwnmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">274,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,521,152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zSts8C0b8t1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zhapCbcSARVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Preferred stock as-if-converted-to-common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,175,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zXTfV9N7vzj2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,440,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,004,978</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><p id="xdx_897_eus-gaap--InvestmentTableTextBlock_zIw6y3x3FzVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s held-to-maturity investments (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z9VkKqNddUAc" style="display: none">Schedule of Investment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zS2HjqxEFScd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zdHHY3oytKqk">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zw5EFQuv06ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_zMPPl2Q5vWpl">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_480_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zhlS1jzeWiT8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zIHFZOjFXl3l">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_zOZiMPCK5oF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zYTQN66rSKi1">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_418_20251231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zyZAFzIPQay2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">275,794</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">276,019</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20251231_z9wbGKXfl9vi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">275,794</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,019</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zDJAenC5wlUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zWQvLHjoRvda">Amortized Cost, as Adjusted</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zJ8u1D7HdVg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_z5SmvX2XEiy6">Gross Unrealized Holding Gains</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zzXxS7N8w3Li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zbYZEkUByjd9">Gross Unrealized Holding Losses</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_z8NLpWxhuCX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zBwpQIjZEqnk">Estimated Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amortized Cost, as Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Unrealized Holding Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41B_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQJNT1vkE24g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. treasury securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">212,589</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">82</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">212,671</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_418_20241231_zfqjcTaUByIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxBgPwA6mhB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zHgvA72Kgd55" style="display: none">Summary of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zyTdLKSsDgNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zIuzqQovFCHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOVBm9dvY31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,025</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhWT1ENzaIH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">304</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zvOutspI9J44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt">Total property and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,658</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,328</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zP8QBER7Dw9c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,159</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,992</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zdsQLanmJtpf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 10pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">336</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Expenses</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZbWWTgPirOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued expenses consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zj2tIjtimwig" style="display: none">Schedule
of Other Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_z52ERfs6jbuc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zyb99emckFoh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maOALCzJtq_z9f7AjR0Usy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Employee compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,338</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,092</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherAccruedLicenseMilestone_iI_maOALCzJtq_zu2RMw5Kvkhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccruedInterest_iI_maOALCzJtq_zLzTDb4eKmr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzJtq_zXrs85If1x79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Consulting and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maOALCzJtq_zl5AKWtjUVw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">874</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzJtq_zZpg8DjEfTd3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Lease Payments</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5OAgmDvZCz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under the Company&#8217;s Existing Lease consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zFNpIZgwWV3j" style="display: none">Schedule
of Minimum Lease Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zd68EMBIexzj" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zUJ1rqmQQXC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; text-indent: 9pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_iI_maLOLLPzXrd_zrTeJp5gO3S3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zfuLN0O1hiyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNAOuArXgvM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: Amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zPYqHNQA0Eo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zpbBBzqH2pJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less: operating lease liabilities, current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxd97nAkHF13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and discount rate under the Company&#8217;s Existing Lease were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zkpNCPmDa5ze" title="Weighted-average remaining lease term">0.3</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zdzuwqCIGnn4" title="Weighted-average remaining lease term">1.3</span>
years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Weighted-average discount rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFzrBzzk5Oac" title="Weighted-average discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zCm9fm80LA4b" title="Weighted-average discount rate">10.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_ze1GqYxJdhzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents components of lease costs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zR5QI8yk12aj" style="display: none">Schedule of Lease Costs</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_491_20250101__20251231_zGGU5Xhnmcgg" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_498_20240101__20241231_zlqgEUsFD1D4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zCqkWBzh8CP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--VariableLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zrB0DEKtwVbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">110</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_pn3n3_mtLCzphc_z2BpqhRDFbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">324</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuWHMhzGo9Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the Company had the following common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zY1ytPWLNUyc" style="display: none">Schedule
of Common Stock Warrants</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration <br/> Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Offering</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_znF7acZVjZ4" title="Issue Date">1/21/2016</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zhnZppxtvQ45" title="Expiration Date">1/14/2026</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zk2Mw9EYW8H3" style="width: 11%; text-align: right" title="Number of Warrants Outstanding">28,716</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zHyXpIYLRYi" style="width: 9%; text-align: right" title="Exercise Price">7.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 46%; text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zI8hpZN5OdBc" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zWoep6ko0o6h" title="Issue Date">5/2/2016</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zkl24SZw7vEh" title="Expiration Date">5/2/2026</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zKwhd0DvrB12" style="text-align: right" title="Number of Warrants Outstanding">18,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zFAO4x8AVNQ9" style="text-align: right" title="Exercise Price">7.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zS7k8CSa0a3j" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zAFRJnIXM30b" title="Issue Date">4/28/2017</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zRKSHCpIQnwa" title="Expiration Date">4/28/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zcDmLPUyp4Td" style="text-align: right" title="Number of Warrants Outstanding">32,458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zReh2tr8pRm4" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zuNGbngV4fBj" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zclugJRqklN7" title="Issue Date">5/17/2017</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zxiXJsqAg9i8" title="Expiration Date">5/17/2027</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEziq4xBRE57" style="text-align: right" title="Number of Warrants Outstanding">14,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_znoRCtWmvgCd" style="text-align: right" title="Exercise Price">8.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_z9xKaE7Arcq7" title="Offering">Private placement offering &#8211; issued to placement agent</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z7MA7HnPVIpj" title="Issue Date">4/8/2021</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBOiBldDJvNf" title="Expiration Date">4/8/2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_znqkO7Jpk9Bk" style="text-align: right" title="Number of Warrants Outstanding">26,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zqMM6I1aTAfj" style="text-align: right" title="Exercise Price">14.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zAZdpAqgLUl1" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zEFvxS7ie88g" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zy1eUogQej5g" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdrW9Y4jmDmk" style="text-align: right" title="Number of Warrants Outstanding">84,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zWim2INAWGub" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdm4KenlCym1" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zq1Rclq2cx44" title="Issue Date">5/30/2024</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z3WLQeqny3Ff" title="Expiration Date">5/30/2034</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_za2mYVkOjUc1" style="text-align: right" title="Number of Warrants Outstanding">19,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zgKKOcOQfO69" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zMnEPRfw0b0e" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zHdsHyxT9PQ6" title="Issue Date">9/9/2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zjCg9xYcyDT2" title="Expiration Date">9/9/2035</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zLLSV398LSSk" style="text-align: right" title="Number of Warrants Outstanding">25,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zSFbo8yOcaUf" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zfYJFO2roqVg" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_z6sgr6CaXIYd" title="Issue Date">9/9/2025</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zSnWlrTdJqsl" title="Expiration Date">9/9/2035</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zn6CZLd8Raq6" style="text-align: right" title="Number of Warrants Outstanding">25,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zQHkfNELAb9b" style="text-align: right" title="Exercise Price">14.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zuuO2eabQgW6" title="Offering">Debt financing &#8211; issued to lender</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zdHCDyqWLa44" title="Issue Date">10/18/2023</span></td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zNiCWbmI4cC8" style="text-align: right" title="Number of Warrants Outstanding">5,747,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z4SdBJHrOnq8" style="text-align: right" title="Exercise Price">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zzANf3ZPrRMk" title="Offering">Private placement offering &#8211; issued to investors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_z7PfKVLsdvxj" title="Issue Date">7/31/2025</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">N/A</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zcGfIow7zqk8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding">400,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zjLdLiLLDsK9" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">0.001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zUiYBUZj5gQ7" title="Offering">Equity offering &#8211; issued to underwriters</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="3" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total warrants outstanding</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_z6Yy2e5tTo0k" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Warrants Outstanding">6,422,560</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zKyuRQPGnTud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all common stock warrants outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHKDaQ9sDNLe" style="display: none">Schedule
of Common Stock Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdZ94uhfSK5f" style="width: 16%; text-align: right" title="Common stock warrants, outstanding shares">11,268,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbbqAq7Di5ck" style="width: 16%; text-align: right" title="Weighted- average exercise price per share, outstanding">4.04</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zr3btbfI5lV1" style="text-align: right" title="Common stock warrants, issued">450,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdOFkWbiJAm3" style="text-align: right" title="Weighted- average exercise price per share, issued">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKlIT7Yuuu7" style="text-align: right" title="Common stock warrants, exercised">(5,282,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zf8zruGCcwn4" style="text-align: right" title="Weighted- average exercise price per share, exercised">8.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Surrendered upon cashless exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z5YU7llqoyJ4" style="text-align: right" title="Common stock warrants, surrendered upon cashless exercise">(14,541</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zLYOpxidlSx6" style="text-align: right" title="Weighted- average exercise price per share, surrendered upon cashless exercise">10.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMizbNcfmHx5" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zJd6gzxtBn0k" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- average exercise price per share, expired"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zY4JevYww3J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock warrants, outstanding shares">6,422,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z59zeD648rui" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- average exercise price per share, outstanding">0.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTcIIS7MgWOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zlfIIvSxZYSd" style="display: none">Schedule of Stock Options Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average remaining contractual term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Options outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCkkFqEa3hA7" style="width: 11%; text-align: right" title="Options outstanding at beginning of year">4,306,977</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMrXPEQNQhsk" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year">11.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z827ybDJ6FT8" title="Options outstanding, weighted average remaining contractual term">8.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfVKMidhnWxf" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value">13,914</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvNkbSZkP4f" style="text-align: right" title="Shares, Granted">2,186,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx8BY35J20T3" style="text-align: right" title="Weighted Average Exercise Price, Granted">35.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBgTugSTIG62" style="text-align: right" title="Shares, Exercised">(393,301</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJRL0p6hVJzi" style="text-align: right" title="Weighted Average Exercise Price, Exercised">8.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBGFofiqjod7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited">(257,784</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFvDeYHk0Gxd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise, Forfeited">14.29</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPMAvV2Ci8Ae" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at end of year">5,842,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJUeAh6Ohkm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, weighted average exercise price at end of year">19.62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRpxRljttXc" title="Options outstanding, weighted average remaining contractual term">7.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRoCp1nQzBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value">468,191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z22A603GPpa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable">2,740,854</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUxQ8RT8mgid" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options exercisable">11.61</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zafuMNCGgrKd" title="Options exercisable, weighted average remaining contractual term">6.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgWXNQtrKRHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value">241,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z3FcRz9Z6IZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used in the Black-Scholes option pricing model and Monte Carlo simulation model to determine the fair value of the employee
and non-employee stock option grants issued, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHooiLxHocnc" style="display: none">Schedule of Assumptions for Fair Value of Employee
And Non-Employee Stock Option</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zftQrWlbl5I1" title="Risk-free interest rate, minimum">3.6</span>% &#8722; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zEwoFc6JrAyd" title="Risk-free interest rate, maximum">4.7</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zRFq2DnHJSQ" title="Risk-free interest rate, minimum">3.5</span>% &#8722; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjePQYYY2x43" title="Risk-free interest rate, maximum">4.7</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_z6dJPR4OaN51" title="Expected volatility, minimum">74.4</span>% &#8722; <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zuWx75cDXpV5" title="Expected volatility, maximum">82.1</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zFtSAyO9ecTi" title="Expected volatility, minimum">71.2</span>% &#8722; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zK42ZgMSlxQj" title="Expected volatility, maximum">76.2</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_zoqo3A5HeYL1" title="Expected life (years)">5.0</span> &#8722; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0dMAcFxpFdb" title="Expected life (years)">10.0</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zj9pmRcLPN8a" title="Expected life (years)">5.3 </span>&#8722; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zf3CXz8mmseb" title="Expected life (years)">10.0</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_z034pBWCJwz8" style="width: 16%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zBjl1WuZGpo8" style="width: 16%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Award And Restricted Stock Unit Activity</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zpkKKu1o9ZB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock award and restricted stock unit activity during the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVDyisgCqHH4" style="display: none">Schedule of Restricted Stock Award And Restricted Stock Unit Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average grant date fair value per share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Outstanding as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR764yhxFZ0i" style="width: 16%; text-align: right" title="Outstanding shares">1,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2IAvpjTNKMh" style="width: 16%; text-align: right" title="Weighted-average grant date fair value per share, outstanding">14.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkTXxhRztcic" style="text-align: right" title="Granted shares">34,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQAA84K3GOj" style="text-align: right" title="Weighted-average grant date fair value per share, granted">89.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxngmZhrjeBi" style="text-align: right" title="Vested shares">(1,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcxsEPykwxok" style="text-align: right" title="Weighted-average grant date fair value per share, vested">14.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 9pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvp5duBIU3uj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited shares">(6,600</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zre61j4B5Omk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, forfeited">98.49</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg7btdZuLY7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares">27,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOZtNknRa617" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value per share, outstanding">87.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expenses</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziI9tdsa1ugl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the following stock-based compensation expense in its statements of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zwdJtQjabLL6" style="display: none">Schedule
of Stock-based Compensation Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231_zQtol8iQV0Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zXTRHnhdGiub" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zckkQtDacQ07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,409</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,405</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zoucFZd5Trn4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,583</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_z2oJyb8fyoXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,383</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zMXa4m9dn6C9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,383</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,988</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zRG7JCSbpWeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable, non-current consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z2DbeMGS5Xk4" style="display: none">Schedule of Long-term Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zovM67dRbgB8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0n0LvfZYN2g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_maLTNPzDBl_z9vpQiPRdoU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">130,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinalFee_iI_pn3n3_maLTNPzDBl_z9QoO55Wjuah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Add: Final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentInKindInterestDebt_iI_pn3n3_maLTNPzDBl_zOKlikdS4cy5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Add: PIK interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTNPzDBl_zQ8GVUbVYhH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: 10pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,619</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,614</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msLTNPzDBl_zWisoCvbjpP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,401</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,752</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermNotesPayable_iTI_pn3n3_mtLTNPzDBl_zhySW4epDuT4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,527</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,727</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Long Term Debt Future Principal Payments</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgSteUrovpbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, future principal payments, including the incurred PIK interest and Final Fee, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zJ98d1GXjbx8" style="display: none">Schedule of Long Term Debt Future Principal Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_z38QyhHt3cta" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz4sG_zhGh6N4oAla4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%; text-align: left">2028</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">43,899</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz4sG_zRWKrlbGtgT2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz4sG_zw5BHz5Etjnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,547</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB3xO0XQqI93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zXKuzL1MbR" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zUwDHxk8jng3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zoWNkiNcVURl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">%</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_ziebyqsOJc92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(37,179</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20250101__20251231_zL63fZk0dl26" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(23,474</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20240101__20241231_z6cRILfVTY7" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_zgqX4NFo0xvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20250101__20251231_zDpqV0uM4qG" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1396">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20240101__20241231_zVzAFXxTxCve" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1398">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zhml9Ekrhf68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal change in valuation allowance on deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20250101__20251231_zOmMd2nRCly4" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage">(21.6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20240101__20241231_zdb0sY3vq3m6" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage">(21.3</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zax8rep7fNze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Federal research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,358</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20250101__20251231_zH4mnEAzRpyc" style="text-align: right" title="Federal research and development credits, percentage">0.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20240101__20241231_zTw96vKP64D2" style="text-align: right" title="Federal research and development credits, percentage">0.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzqmi_zrZMhgxG5O75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior year adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20250101__20251231_znonAdPmj3L8" style="text-align: right" title="Prior year adjustments, percentage">0.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20240101__20241231_zsnyNadTXYgi" style="text-align: right" title="Prior year adjustments, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzqmi_zwRyp2LG002a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Non-deductible items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">645</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20250101__20251231_zpePl9cUOEnf" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage">(0.4</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20240101__20241231_zl13fGkZpJ7j" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage">(0.6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zojvmUBQFXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20250101__20251231_zK8BpRcZ8NZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"><span style="-sec-ix-hidden: xdx2ixbrl1431">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20240101__20241231_zfOpLpICZWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"><span style="-sec-ix-hidden: xdx2ixbrl1433">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUFrOLm4Vzyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zre4SKsiI4lb" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zcIYmg432i63" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zkrhoV03I3be" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gross deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzhJd_zln8t7ZgwkH3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-left: 9pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">459</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhJd_zoB2sDFjTEq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,861</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhJd_ze93AiysZFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzhJd_zIUU6WviV2zl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsLeaseLiability_iNI_di_msDTAGzhJd_zHeeNCWYlM17" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_maDTAGzhJd_zzn3WiI5NEjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Section 174 expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_maDTAGzhJd_zhY8OqeXuK6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Start-up expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,998</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzhJd_zEFoI7g1VCQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Net operating losses and tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,483</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,340</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhJd_maDTALNzwuF_zYguL3PnOq6d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzwuF_zgvG9dZHx7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(100,281</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,214</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzwuF_zSgkTYACRlLb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Liquidity (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 448,897<span></span>
</td>
<td class="nump">$ 271,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 441,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Leasehold Improvements [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 165,703,000<span></span>
</td>
<td class="nump">$ 22,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">275,794,000<span></span>
</td>
<td class="nump">212,589,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized software development costs</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 144,995,000<span></span>
</td>
<td class="nump">$ 104,203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember', window );">Senior Notes Due 2031 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Accrue interest payable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">11,440,750<span></span>
</td>
<td class="nump">13,004,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember', window );">Preferred Stock On An As If Converted To Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,175,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,842,485<span></span>
</td>
<td class="nump">4,306,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_ConvertibleNotesToCommonStockMember', window );">Convertible notes to common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,296,053<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">274,773<span></span>
</td>
<td class="nump">5,521,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">27,439<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_ConvertibleNotesToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_ConvertibleNotesToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CELC_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, number of shares issued</a></td>
<td class="nump">3,923,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PrefundedWarrantShares', window );">Pre-funded warrant shares</a></td>
<td class="nump">6,147,787<span></span>
</td>
<td class="nump">5,747,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, number of shares issued</a></td>
<td class="nump">5,296,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PrefundedWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrant, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PrefundedWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost, as Adjusted</a></td>
<td class="nump">$ 275,794<span></span>
</td>
<td class="nump">$ 212,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Holding Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">276,019<span></span>
</td>
<td class="nump">212,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost, as Adjusted</a></td>
<td class="nump">275,794<span></span>
</td>
<td class="nump">212,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Holding Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 276,019<span></span>
</td>
<td class="nump">$ 212,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 2,658<span></span>
</td>
<td class="nump">$ 2,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(2,159)<span></span>
</td>
<td class="num">(1,992)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 8,338<span></span>
</td>
<td class="nump">$ 4,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_OtherAccruedLicenseMilestone', window );">License milestone</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_OtherAccruedInterest', window );">Interest</a></td>
<td class="nump">3,379<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional fees</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 20,865<span></span>
</td>
<td class="nump">$ 5,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_OtherAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_OtherAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_OtherAccruedLicenseMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accrued license milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_OtherAccruedLicenseMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Expenses (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable included accrued interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">$ (1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liabilities, current</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease
term will commence on April 1, 2026 and is 62 months with two options to extend the lease term for five years each. The Company also
has a one-time option to terminate the lease at the end of the third year, provided certain conditions are met.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial annual lease payment is $0.3 million and increases by
3.5% on an annual basis, resulting in total undiscounted future minimum lease payments of $1.5 million over the initial 62-month term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Initial annual lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted future minimum lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">62 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Non-cancelable contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementTerm', window );">Registration rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Company is required to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0% of the aggregate
amount paid pursuant to the Securities Purchase Agreement by such investor&#160;for each 30-day period or pro rata for any portion
thereof during which such event continues, provided that the maximum liquidated damages shall not exceed 6.0% of the aggregate
amount invested by each such holder in the registrable securities.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement | shares</a></td>
<td class="nump">5,747,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the term of the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482804/825-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Common Stock Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">6,422,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Jan. 21,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Jan. 14,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">28,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Private placement offering &#8211; issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May  02,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May  02,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">18,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Private placement offering &#8211; issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Apr. 28,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Apr. 28,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">32,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Private placement offering &#8211; issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 17,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 17,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">14,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Private placement offering &#8211; issued to placement agent<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember', window );">Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Apr.  08,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Apr.  08,  2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">26,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember', window );">Warrant Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 30,  2034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">84,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember', window );">Warrant Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">May 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">May 30,  2034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">19,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember', window );">Warrant Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Sep.  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Sep.  09,  2035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">25,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember', window );">Warrant Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Sep.  09,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Sep.  09,  2035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">25,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Debt financing &#8211; issued to lender<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember', window );">Warrant Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Oct. 18,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">5,747,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Private placement offering &#8211; issued to investors<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantElevenMember', window );">Warrant Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue', window );">Issue Date</a></td>
<td class="text">Jul. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Offering</a></td>
<td class="text">Equity offering &#8211; issued to underwriters<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst date from which warrants or rights issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_WarrantElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Common Stock Warrants Outstanding (Details) - Pre-Funded Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Common stock warrants, outstanding shares</a></td>
<td class="nump">11,268,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue', window );">Weighted- average exercise price per share, outstanding</a></td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Common stock warrants, issued</a></td>
<td class="nump">450,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted- average exercise price per share, issued</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Common stock warrants, exercised</a></td>
<td class="num">(5,282,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue', window );">Weighted- average exercise price per share, exercised</a></td>
<td class="nump">$ 8.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther', window );">Common stock warrants, surrendered upon cashless exercise</a></td>
<td class="num">(14,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue', window );">Weighted- average exercise price per share, surrendered upon cashless exercise</a></td>
<td class="nump">$ 10.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Common stock warrants, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue', window );">Weighted- average exercise price per share, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Common stock warrants, outstanding shares</a></td>
<td class="nump">6,422,560<span></span>
</td>
<td class="nump">11,268,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue', window );">Weighted- average exercise price per share, outstanding</a></td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="nump">$ 4.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average exercise price per share, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average exercise price per share, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average exercise price per share, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average exercise price per share, surrendered upon cashless exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average exercise price per share, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2025</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>May 08, 2024</div></th>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,244,960<span></span>
</td>
<td class="nump">37,143,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Prefunded warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,422,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,061<span></span>
</td>
<td class="nump">$ 14,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Common stock warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Pre-funded warrants sold to investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,175,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember', window );">July 2025 Equity Offering [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Pre-funded warrant exercisable description</a></td>
<td class="text">A holder (together with its &#8220;attribution parties,&#8221; as defined
in the Pre-Funded Warrant) may not exercise any portion of the Pre-Funded Warrants if immediately after exercise, the holder (together
with its attribution parties), would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise. However, a holder may increase or decrease such percentage to any other percentage not in excess
of 19.99%, which increase or decrease shall not become effective until 61 days after notice from the holder to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Leerink Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | July 2025 Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="nump">1,836,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price</a></td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">The number of additional common stock shares the Underwriters can purchase</a></td>
<td class="nump">335,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | July 2025 Equity Offering [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Prefunded warrant shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Warrant purchase price</a></td>
<td class="nump">$ 37.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">The cash inflow associated with the amount received from entity's offering of stock to the public</a></td>
<td class="nump">$ 91,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,700<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.65<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Pre-funded warrants sold to investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,747,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Series A preferred stock is non-voting, and each share is convertible at the option of the holder, subject to certain limitations, into
10 shares of common stock. Holders of Series A preferred stock are entitled to receive dividends, on an as-if-converted-to-common stock
basis, when, as and if, and in the same form as, dividends are actually paid on the common stock. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as defined in the Certificate of
Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders of Series A preferred stock
are entitled to be paid from assets of the Company available for distribution to its stockholders, before any payment is made to the
holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the original issue price
($5.75 on an as-converted-to-common stock basis), plus all accrued and unpaid dividends and (ii) the amount that the holder would have
been entitled to receive at such time if the Series A preferred stock were converted into common stock. The Company may not, without
the consent of holders of a majority of the outstanding shares of Series A preferred stock, amend its charter in a manner that adversely
affects the powers, preferences or rights of the Series A preferred stock or issue or obligate itself to issue shares of any additional
class or series of capital stock unless the same ranks junior to the Series A preferred stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company and the payment of dividends.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock converted basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$5.75 on an as-converted-to-common stock basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock', window );">Conversion of preferred to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred to common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELC_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELC_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELC_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_LeerinkPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_LeerinkPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CELC_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CELC_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Activity (Details) - Equity Option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">4,306,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price at beginning of year</a></td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 13,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">2,186,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 35.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(393,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 8.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(257,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise, Forfeited</a></td>
<td class="nump">$ 14.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">5,842,485<span></span>
</td>
<td class="nump">4,306,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price at end of year</a></td>
<td class="nump">$ 19.62<span></span>
</td>
<td class="nump">$ 11.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 468,191<span></span>
</td>
<td class="nump">$ 13,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, options exercisable</a></td>
<td class="nump">2,740,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 241,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.40%<span></span>
</td>
<td class="nump">71.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">82.10%<span></span>
</td>
<td class="nump">76.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding shares | shares</a></td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, outstanding | $ / shares</a></td>
<td class="nump">$ 14.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted shares | shares</a></td>
<td class="nump">34,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, granted | $ / shares</a></td>
<td class="nump">$ 89.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested shares | shares</a></td>
<td class="num">(1,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, vested | $ / shares</a></td>
<td class="nump">$ 14.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited shares | shares</a></td>
<td class="num">(6,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, forfeited | $ / shares</a></td>
<td class="nump">$ 98.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding shares | shares</a></td>
<td class="nump">27,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share, outstanding | $ / shares</a></td>
<td class="nump">$ 87.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockBasedCompensationExpensesLineItem', window );"><strong>StockBasedCompensationExpensesLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 6,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StatementOfIncomeLocationBalanceAxis=CELC_ResearchAndDevelopmentExpensesMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockBasedCompensationExpensesLineItem', window );"><strong>StockBasedCompensationExpensesLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,409<span></span>
</td>
<td class="nump">4,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StatementOfIncomeLocationBalanceAxis=CELC_GeneralAndAdministrativeExpensesMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockBasedCompensationExpensesLineItem', window );"><strong>StockBasedCompensationExpensesLineItem [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,974<span></span>
</td>
<td class="nump">$ 2,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockBasedCompensationExpensesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockBasedCompensationExpensesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StatementOfIncomeLocationBalanceAxis=CELC_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StatementOfIncomeLocationBalanceAxis=CELC_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StatementOfIncomeLocationBalanceAxis=CELC_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StatementOfIncomeLocationBalanceAxis=CELC_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,383<span></span>
</td>
<td class="nump">$ 6,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Option vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandTwelveEquityIncentivePlanMember', window );">2012 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Number of shares reserved for issuance description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provided for options, restricted
stock awards, performance stock awards and stock bonuses. The exercise price of each option granted under the 2012 Plan is not less than
100% of the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Plan is
ten years. The Company&#8217;s board of directors administers the 2012 Plan and determines the provisions of incentive awards, including
eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. In September 2017, the 2012 Plan was frozen and no further awards may be
made under the 2012 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember', window );">2017 Amended And Restated Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Number of shares reserved for issuance description</a></td>
<td class="text">the Company adopted the 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan provides
for the grant of options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock bonuses.
The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on the date
of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered by
the compensation committee of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other
determinations necessary for the administration of the 2017 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Number of shares reserved for issuance description</a></td>
<td class="text">The
number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1 of each year from 2026 to 2027 by
the number of shares equal to 1.0% of the aggregate number of outstanding shares of common stock as of the immediately preceding December
31.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInCommonStockSharesReservedForIssuance', window );">Change in common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,432<span></span>
</td>
<td class="nump">255,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Number of shares reserved for issuance, additional increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,591,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Number of shares reserved for issuance description</a></td>
<td class="text">The
number of shares reserved for issuance under the ESPP automatically increases on January 1 of each year from 2023 to 2027 by the number
of shares equal to 0.5% of the aggregate number of outstanding shares of common stock as of the immediately preceding December 31.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ChangeInCommonStockSharesReservedForIssuance', window );">Change in common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,716<span></span>
</td>
<td class="nump">127,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Employee stock purchase plan description</a></td>
<td class="text">the Company adopted the 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides participating employees
with an opportunity to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions. The ESPP is available
to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value
of the Company&#8217;s common stock. The ESPP is administered using overlapping 24 month offering periods (the &#8220;Offering Periods&#8221;).
Each Offering Period has four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and
November 1 of each year. Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of
the fair market value of a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase
date has a lower price, the employee will automatically be placed in the Offering Period beginning immediately after the purchase date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ChangeInCommonStockSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in common stock, shares reserved for issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ChangeInCommonStockSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining stock based compensation expense related to modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_RemainingStockBasedCompensationExpenseRelatedToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-20<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandTwelveEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandTwelveEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Note payable</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Add: Final fee</a></td>
<td class="nump">5,850<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentInKindInterestDebt', window );">Add: PIK interest (added to principal)</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(2,619)<span></span>
</td>
<td class="num">(1,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt discount</a></td>
<td class="num">(8,401)<span></span>
</td>
<td class="num">(5,752)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term debt</a></td>
<td class="nump">$ 126,527<span></span>
</td>
<td class="nump">$ 97,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentInKindInterestDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment in kind interest debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentInKindInterestDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long Term Debt Future Principal Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">$ 43,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">93,648<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 137,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2026</div></th>
<th class="th">
<div>Sep. 09, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2025 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>May 13, 2025</div></th>
<th class="th">
<div>May 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,324,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,401,000<span></span>
</td>
<td class="nump">$ 5,752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,422,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Final fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,850,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair value of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AmendmentFee', window );">Amendment fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherBorrowings', window );">Costs associated with new borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFeePercentage', window );">Final fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFee', window );">Final fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_WarrantOrRightToPurchasePercentage', window );">Warrant or right, reason for issuance, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term D Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DisbursementLoanAmount', window );">Disbursement loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DebtFinalFeePercentage', window );">Debt final fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Two Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Two Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term G Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Contingent loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term A Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term B Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term C Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Funded loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember', window );">Prior Loan Agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an ATM offering, net of issuance costs, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_NoteUnderwritingAgreementMember', window );">Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.4932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Redemption description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company&#8217;s option at any
time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately
before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid
interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds
130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days
ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading
day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes
unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company
sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with
respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances
if it is converted after it is called for redemption.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">First Amendment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">beneficially own in excess of 4.99% of the number of shares of the Company&#8217;s
common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes;
provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that
such limitation in no event can exceed 19.99%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Fair value of the Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 436,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_NoteUnderwritingAgreementMember', window );">Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Accrue interest payable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_NoteUnderwritingAgreementMember', window );">Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember', window );">Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember', window );">Second Amendment To Amended And Restated Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AmendmentFee', window );">Amendment fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Amount of indebtedness eligible to incur under Term D Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">First Amendment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment,
(ii) extend to March 9, 2026 the expiration date of Innovatus&#8217; right to convert up to 20% of the outstanding principal of the Term
A Loan into shares of the Company&#8217;s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D
Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&R Loan Agreement),
(iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company
had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the
Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders
from any and all claims arising out of or related to the A&R Loan Agreement, the First Amendment and related documentation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember', window );">Amended and Restated Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months
if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DebtFinalFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt final fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DebtFinalFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DisbursementLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursement loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DisbursementLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_WarrantOrRightToPurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant or right, reason for issuance, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_WarrantOrRightToPurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_AmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermETwoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermETwoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermFLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermFLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermFTwoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermFTwoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermGLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermGLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_PriorLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_NoteUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_NoteUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_AmendedAndRestatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_PfizerLicenseAgreementMember', window );">Pfizer License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for upfront fees</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_PfizerLicenseAgreementMember', window );">Pfizer License Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement</a></td>
<td class="nump">349,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentOnMilestoneEventOne', window );">Payment on milestone event one</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ResearchAndDevelopmentExpenseMilestone', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AggregateValueOfMilestoneEvents', window );">Aggregate value of milestone events</a></td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AggregateValueOfMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of milestone events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AggregateValueOfMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentOnMilestoneEventOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on milestone event one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentOnMilestoneEventOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ResearchAndDevelopmentExpenseMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ResearchAndDevelopmentExpenseMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_PfizerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_PfizerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at statutory rate</a></td>
<td class="num">$ (37,179)<span></span>
</td>
<td class="num">$ (23,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at statutory rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Federal change in valuation allowance on deferred tax assets</a></td>
<td class="nump">$ 38,249<span></span>
</td>
<td class="nump">$ 23,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Federal change in valuation allowance on deferred tax assets, percentage</a></td>
<td class="num">(21.60%)<span></span>
</td>
<td class="num">(21.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="num">$ (1,358)<span></span>
</td>
<td class="num">$ (982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits, percentage</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year adjustments</a></td>
<td class="num">$ (343)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year adjustments, percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items, percentage</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (benefit), percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,056<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsRightofuseAssets', window );">Right-of-use assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures', window );">Section 174 expenditures</a></td>
<td class="nump">48,070<span></span>
</td>
<td class="nump">30,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures', window );">Start-up expenditures</a></td>
<td class="nump">21,955<span></span>
</td>
<td class="nump">12,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses and tax credits</a></td>
<td class="nump">23,483<span></span>
</td>
<td class="nump">13,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">100,281<span></span>
</td>
<td class="nump">60,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(100,281)<span></span>
</td>
<td class="num">(60,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Start-up expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">83,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 09, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AggregateOfferingAmount', window );">Aggregate offering amount</a></td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AggregateOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AggregateOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OrganizationAndLiquidity</Role>
      <ShortName>Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Other Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OtherAccruedExpenses</Role>
      <ShortName>Other Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Investments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Other Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OtherAccruedExpensesTables</Role>
      <ShortName>Other Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/OtherAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Commitments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Debt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Organization and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative</Role>
      <ShortName>Organization and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/OrganizationAndLiquidity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails</Role>
      <ShortName>Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Net Loss Per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfInvestmentDetails</Role>
      <ShortName>Schedule of Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Other Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails</Role>
      <ShortName>Schedule of Other Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Other Accrued Expenses (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative</Role>
      <ShortName>Other Accrued Expenses (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/OtherAccruedExpensesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails</Role>
      <ShortName>Schedule of Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLeaseCostsDetails</Role>
      <ShortName>Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails</Role>
      <ShortName>Schedule of Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails</Role>
      <ShortName>Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLong-termDebtDetails</Role>
      <ShortName>Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Schedule of Long Term Debt Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/DebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - License Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/LicenseAgreementDetailsNarrative</Role>
      <ShortName>License Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/LicenseAgreement</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>celc-20251231.xsd</File>
    <File>celc-20251231_cal.xml</File>
    <File>celc-20251231_def.xml</File>
    <File>celc-20251231_lab.xml</File>
    <File>celc-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="673">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "CELC",
   "nsuri": "http://celcuity.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "celc-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "celc-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celc-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "celc-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celc-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 343,
   "keyCustom": 52,
   "axisStandard": 16,
   "axisCustom": 1,
   "memberStandard": 18,
   "memberCustom": 48,
   "hidden": {
    "total": 92,
    "http://fasb.org/us-gaap/2025": 66,
    "http://celcuity.com/20251231": 23,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 171,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 673,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 673,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/ecd/2025": 9,
    "http://xbrl.sec.gov/cyd/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://celcuity.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://celcuity.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://celcuity.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://celcuity.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://celcuity.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://celcuity.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Statements of Cash Flows (Parenthetical)",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-10-012025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-012025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://celcuity.com/role/OrganizationAndLiquidity",
     "longName": "999015 - Disclosure - Organization and Liquidity",
     "shortName": "Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://celcuity.com/role/NetLossPerCommonShare",
     "longName": "999017 - Disclosure - Net Loss Per Common Share",
     "shortName": "Net Loss Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://celcuity.com/role/Investments",
     "longName": "999018 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://celcuity.com/role/PropertyAndEquipment",
     "longName": "999019 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://celcuity.com/role/OtherAccruedExpenses",
     "longName": "999020 - Disclosure - Other Accrued Expenses",
     "shortName": "Other Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://celcuity.com/role/Commitments",
     "longName": "999021 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://celcuity.com/role/StockholdersEquity",
     "longName": "999022 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://celcuity.com/role/Stock-basedCompensation",
     "longName": "999023 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://celcuity.com/role/Debt",
     "longName": "999024 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://celcuity.com/role/LicenseAgreement",
     "longName": "999025 - Disclosure - License Agreement",
     "shortName": "License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CELC:LicenseAgreementTestBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CELC:LicenseAgreementTestBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://celcuity.com/role/IncomeTaxes",
     "longName": "999026 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://celcuity.com/role/SubsequentEvents",
     "longName": "999027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999028 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "999029 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://celcuity.com/role/NetLossPerCommonShareTables",
     "longName": "999030 - Disclosure - Net Loss Per Common Share (Tables)",
     "shortName": "Net Loss Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://celcuity.com/role/InvestmentsTables",
     "longName": "999031 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://celcuity.com/role/PropertyAndEquipmentTables",
     "longName": "999032 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://celcuity.com/role/OtherAccruedExpensesTables",
     "longName": "999033 - Disclosure - Other Accrued Expenses (Tables)",
     "shortName": "Other Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://celcuity.com/role/CommitmentsTables",
     "longName": "999034 - Disclosure - Commitments (Tables)",
     "shortName": "Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://celcuity.com/role/StockholdersEquityTables",
     "longName": "999035 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://celcuity.com/role/Stock-basedCompensationTables",
     "longName": "999036 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://celcuity.com/role/DebtTables",
     "longName": "999037 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://celcuity.com/role/IncomeTaxesTables",
     "longName": "999038 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative",
     "longName": "999039 - Disclosure - Organization and Liquidity (Details Narrative)",
     "shortName": "Organization and Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "999040 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999041 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CapitalizationAndAmortizationOfFuelCostsPolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
     "longName": "999042 - Disclosure - Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)",
     "shortName": "Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
     "longName": "999043 - Disclosure - Net Loss Per Common Share (Details Narrative)",
     "shortName": "Net Loss Per Common Share (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://celcuity.com/role/ScheduleOfInvestmentDetails",
     "longName": "999044 - Disclosure - Schedule of Investment (Details)",
     "shortName": "Schedule of Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails",
     "longName": "999045 - Disclosure - Summary of Property and Equipment (Details)",
     "shortName": "Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999046 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails",
     "longName": "999047 - Disclosure - Schedule of Other Accrued Expenses (Details)",
     "shortName": "Schedule of Other Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative",
     "longName": "999048 - Disclosure - Other Accrued Expenses (Details Narrative)",
     "shortName": "Other Accrued Expenses (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails",
     "longName": "999049 - Disclosure - Schedule of Minimum Lease Payments (Details)",
     "shortName": "Schedule of Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://celcuity.com/role/ScheduleOfLeaseCostsDetails",
     "longName": "999050 - Disclosure - Schedule of Lease Costs (Details)",
     "shortName": "Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://celcuity.com/role/CommitmentsDetailsNarrative",
     "longName": "999051 - Disclosure - Commitments (Details Narrative)",
     "shortName": "Commitments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-30",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-30",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails",
     "longName": "999052 - Disclosure - Schedule of Common Stock Warrants (Details)",
     "shortName": "Schedule of Common Stock Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_WarrantOneMember",
      "name": "CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails",
     "longName": "999053 - Disclosure - Schedule of Common Stock Warrants Outstanding (Details)",
     "shortName": "Schedule of Common Stock Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_PrefundedWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_PrefundedWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999054 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_PrefundedWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
     "longName": "999055 - Disclosure - Schedule of Stock Options Activity (Details)",
     "shortName": "Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
     "longName": "999056 - Disclosure - Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)",
     "shortName": "Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
     "longName": "999057 - Disclosure - Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)",
     "shortName": "Schedule of Restricted Stock Award And Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails",
     "longName": "999058 - Disclosure - Schedule of Stock-based Compensation Expenses (Details)",
     "shortName": "Schedule of Stock-based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999059 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://celcuity.com/role/ScheduleOfLong-termDebtDetails",
     "longName": "999060 - Disclosure - Schedule of Long-term Debt (Details)",
     "shortName": "Schedule of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails",
     "longName": "999061 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)",
     "shortName": "Schedule of Long Term Debt Future Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://celcuity.com/role/DebtDetailsNarrative",
     "longName": "999062 - Disclosure - Debt (Details Narrative)",
     "shortName": "Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ConvertibleDebtNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
     "longName": "999063 - Disclosure - License Agreement (Details Narrative)",
     "shortName": "License Agreement (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CELC:LicenseAgreementTestBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CELC:LicenseAgreementTestBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "999064 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999065 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://celcuity.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999066 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://celcuity.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999067 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember",
      "name": "CELC:AggregateOfferingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember",
      "name": "CELC:AggregateOfferingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://celcuity.com/role/OtherAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/OtherAccruedExpensesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable included accrued interest",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r727"
     ]
    },
    "CELC_AccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AccruedClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical trial costs",
        "documentation": "Accrued clinical trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r126",
      "r555"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r448",
      "r449",
      "r450",
      "r451",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r448",
      "r449",
      "r450",
      "r451",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r727",
      "r999"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r893",
      "r894",
      "r895",
      "r896",
      "r963",
      "r1002"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrants, note payable",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r28",
      "r80"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash and cash equivalents used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_AggregateOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AggregateOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering amount",
        "documentation": "Aggregate offering amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_AggregateValueOfMilestoneEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AggregateValueOfMilestoneEvents",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate value of milestone events",
        "documentation": "Aggregate value of milestone events"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r783",
      "r797",
      "r824"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r800",
      "r827"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r819",
      "r828",
      "r832",
      "r840"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r381",
      "r390"
     ]
    },
    "CELC_AllowanceForCreditLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AllowanceForCreditLossesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for Credit Losses",
        "documentation": "Allowance For Credit Losses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_AmendedAndRestatedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AmendedAndRestatedLoanAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended and Restated Loan Agreement [Member]",
        "documentation": "Amended and Restated Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_AmendmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "AmendmentFee",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment fee payable",
        "documentation": "Amendment fee."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Discount amount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r62",
      "r298",
      "r979"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs and discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r699",
      "r700",
      "r882",
      "r979"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Square feet",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r102",
      "r128",
      "r150",
      "r153",
      "r154",
      "r189",
      "r197",
      "r208",
      "r209",
      "r243",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r437",
      "r439",
      "r468",
      "r538",
      "r539",
      "r546",
      "r621",
      "r690",
      "r691",
      "r701",
      "r727",
      "r730",
      "r731",
      "r742",
      "r919",
      "r920",
      "r985"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r134",
      "r150",
      "r153",
      "r154",
      "r243",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r437",
      "r439",
      "r468",
      "r727",
      "r919",
      "r920",
      "r985"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_CapitalizationAndAmortizationOfFuelCostsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizationAndAmortizationOfFuelCostsPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Software Development Costs",
        "documentation": "Disclosure of accounting policy for fuel costs amortized and recorded and recovered through rates, such as under a fuel adjustment clause or other tracking arrangement."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized software development costs",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r672"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r124",
      "r673"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r65",
      "r149"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r65"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r997"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_CashPaidForOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "CashPaidForOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for operating leases",
        "documentation": "Cash paid for operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ChangeInAccruedInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ChangeInAccruedInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in accrued interest income",
        "documentation": "Change in accrued interest income.",
        "label": "ChangeInAccruedInterestIncome"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ChangeInCommonStockSharesReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ChangeInCommonStockSharesReservedForIssuance",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in common stock, shares reserved for issuance",
        "documentation": "Change in common stock, shares reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r130",
      "r131",
      "r132",
      "r150",
      "r154",
      "r179",
      "r180",
      "r182",
      "r184",
      "r191",
      "r192",
      "r243",
      "r267",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r468",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r609",
      "r629",
      "r646",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r861",
      "r887",
      "r889",
      "r897"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r191",
      "r312",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r441",
      "r580",
      "r581",
      "r582",
      "r583",
      "r702",
      "r861",
      "r885",
      "r887"
     ]
    },
    "CELC_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date",
        "documentation": "Class of warrant or righst date from which warrants or rights issue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Class of warrant exercise price",
        "terseLabel": "Warrants exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r156",
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional warrants exercised",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Outstanding",
        "verboseLabel": "Prefunded warrant shares",
        "terseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering",
        "documentation": "Description of reason for issuing warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r93",
      "r548",
      "r608"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r669"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock converted basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r893",
      "r894",
      "r896",
      "r963",
      "r998",
      "r1002"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r609",
      "r627",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r310",
      "r317",
      "r550",
      "r727"
     ]
    },
    "CELC_CommonStockWarrantsIssuedWithNotePayableTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "CommonStockWarrantsIssuedWithNotePayableTransaction",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants issued with the note payable transaction",
        "documentation": "Common stock warrants issued with note payable transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cancelable contractual commitment",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r892",
      "r994"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r92",
      "r996"
     ]
    },
    "CELC_ConvertibleNotesToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ConvertibleNotesToCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes to common stock [Member]",
        "documentation": "Convertible Notes to Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r851"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r851"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r855"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r846"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r847"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r847"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r845"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r848"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r850"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r850"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r851"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r854"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r852"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r849"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion percentage",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion, number of shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r150",
      "r152",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r266",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r292",
      "r299",
      "r300",
      "r302",
      "r441",
      "r479"
     ]
    },
    "CELC_DebtFinalFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DebtFinalFeePercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt final fee percentage",
        "documentation": "Debt final fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r41",
      "r42",
      "r90",
      "r92",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r725",
      "r885",
      "r886",
      "r888",
      "r892",
      "r915",
      "r916",
      "r917",
      "r978",
      "r980",
      "r994"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funded loan amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r92",
      "r303"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r279"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion rate",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r45",
      "r78",
      "r79",
      "r279"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consecutive trading days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of indebtedness eligible to incur under Term D Loan",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r888"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Amendment description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r39",
      "r41",
      "r90",
      "r92",
      "r479"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r479",
      "r480",
      "r697",
      "r698",
      "r725"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrue interest payable rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r295",
      "r978"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r278"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate description",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r696",
      "r967",
      "r968"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r725",
      "r885",
      "r886",
      "r888",
      "r892",
      "r915",
      "r916",
      "r917",
      "r978",
      "r980",
      "r994"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption description",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt discount",
        "label": "Discount amount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r977",
      "r978",
      "r980"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r304",
      "r478",
      "r479",
      "r480",
      "r697",
      "r698",
      "r725"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuance costs and discount",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r977",
      "r978",
      "r980"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Transaction Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred transaction costs",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible note payable, net of debt issuance cost and discount",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r980"
     ]
    },
    "CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing, offering and registration statement costs included in accounts payable",
        "documentation": "Deferred financing costs and offering and registration statement costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "CELC_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liabilities",
        "documentation": "Deferred tax assets lease liability.",
        "label": "DeferredTaxAssetsLeaseLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses and tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "CELC_DeferredTaxAssetsRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DeferredTaxAssetsRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "documentation": "Deferred tax assets right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 expenditures",
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "CELC_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Start-up expenditures",
        "documentation": "Start-up expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r142",
      "r674",
      "r675",
      "r677",
      "r679"
     ]
    },
    "CELC_DisbursementLoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DisbursementLoanAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement loan amount",
        "documentation": "Disbursement loan amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_DisclosureLicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "DisclosureLicenseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r345",
      "r376",
      "r377",
      "r379",
      "r707"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779",
      "r820"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r141",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r179",
      "r182",
      "r183",
      "r184",
      "r188",
      "r308",
      "r380",
      "r432",
      "r435",
      "r455",
      "r456",
      "r537",
      "r561",
      "r683"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r141",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r179",
      "r182",
      "r183",
      "r184",
      "r188",
      "r308",
      "r380",
      "r432",
      "r435",
      "r455",
      "r456",
      "r537",
      "r561",
      "r683"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r185",
      "r186",
      "r187"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense (benefit), percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit at statutory rate, percentage",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r155",
      "r401",
      "r423",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal change in valuation allowance on deferred tax assets, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r712",
      "r885",
      "r891",
      "r955"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible items, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r885",
      "r891",
      "r955"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year adjustments, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r891",
      "r955",
      "r956"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax benefit, net of federal tax effect, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r712",
      "r885",
      "r891",
      "r955"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r712"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal research and development credits, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r885",
      "r891",
      "r955",
      "r957"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDescription",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchase plan description",
        "documentation": "Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r709",
      "r710"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails",
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r115",
      "r116",
      "r117",
      "r138",
      "r139",
      "r140",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r190",
      "r244",
      "r245",
      "r255",
      "r307",
      "r337",
      "r380",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r481",
      "r482",
      "r497",
      "r559",
      "r566",
      "r567",
      "r568",
      "r586",
      "r646"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r783",
      "r797",
      "r824"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r794",
      "r821"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "CELC_FinalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "FinalFee",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: Final fee",
        "verboseLabel": "Final fee",
        "documentation": "Final fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_FinalFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "FinalFeePercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final fee percentage",
        "documentation": "Final fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r301",
      "r333",
      "r441",
      "r452",
      "r460",
      "r467",
      "r469",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r544",
      "r560",
      "r695",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r728",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r906",
      "r907",
      "r908",
      "r909",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r972",
      "r973"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r828"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r828"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r631"
     ]
    },
    "CELC_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Member]",
        "documentation": "General and Administrative Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost, as Adjusted",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r226",
      "r248",
      "r461",
      "r911"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Holding Gains",
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r236"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Holding Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r237"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r235",
      "r457",
      "r459",
      "r462",
      "r463",
      "r466",
      "r536",
      "r545"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r756",
      "r779"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Costs",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r97",
      "r101",
      "r538",
      "r540",
      "r557",
      "r676",
      "r678",
      "r680",
      "r686",
      "r690",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r401",
      "r402",
      "r411",
      "r419",
      "r712",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r401",
      "r402",
      "r411",
      "r419",
      "r712",
      "r960"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r155",
      "r396",
      "r401",
      "r408",
      "r409",
      "r410",
      "r413",
      "r418",
      "r424",
      "r426",
      "r427",
      "r428",
      "r543",
      "r572",
      "r585",
      "r712"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest or penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "totalLabel": "Income tax expense (benefit)",
        "verboseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r113",
      "r150",
      "r174",
      "r175",
      "r189",
      "r200",
      "r209",
      "r400",
      "r401",
      "r425",
      "r563",
      "r676",
      "r678",
      "r680",
      "r712"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r398",
      "r399",
      "r413",
      "r414",
      "r417",
      "r420",
      "r579"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal change in valuation allowance on deferred tax assets",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r712",
      "r955"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r712"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r955"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax benefit, net of federal tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r712",
      "r955"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r955",
      "r957"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "CELC_IncreaseDecreaseInAccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "IncreaseDecreaseInAccruedClinicalTrialCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical trial costs",
        "documentation": "Increase decrease in accrued clinical trial costs.",
        "label": "IncreaseDecreaseInAccruedClinicalTrialCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued expenses",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current and non-current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid clinical trial costs",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r801",
      "r819",
      "r828",
      "r832",
      "r840"
     ]
    },
    "CELC_InnovatusLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "InnovatusLifeSciencesMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innovatus Life Sciences [Member]",
        "documentation": "Innovatus Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r844"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r844"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r844"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r296",
      "r306",
      "r699",
      "r700",
      "r1001"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r676",
      "r680",
      "r878"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r147"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r198",
      "r209",
      "r690",
      "r877"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r575",
      "r576",
      "r577",
      "r578",
      "r653",
      "r654"
     ]
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r905"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://celcuity.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r905"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2025 Convertible Notes Offering [Member]",
        "documentation": "July 2025 Convertible Notes Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_JulyTwoThousandAndTwentyFiveEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "JulyTwoThousandAndTwentyFiveEquityOfferingMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2025 Equity Offering [Member]",
        "documentation": "July 2025 Equity Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r726"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r496"
     ]
    },
    "CELC_LeerinkPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LeerinkPartnersLLCMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leerink Partners LLC [Member]",
        "documentation": "Leerink Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r886",
      "r892",
      "r994"
     ]
    },
    "CELC_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Lessee operating lease liability payments due after year one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r886",
      "r892",
      "r994"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Amount representing interest",
        "label": "Undiscounted future minimum lease",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r41",
      "r42",
      "r43",
      "r47",
      "r48",
      "r49",
      "r50",
      "r150",
      "r153",
      "r154",
      "r243",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r438",
      "r439",
      "r440",
      "r468",
      "r607",
      "r685",
      "r701",
      "r742",
      "r919",
      "r985",
      "r986"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r94",
      "r552",
      "r727",
      "r730",
      "r731",
      "r885",
      "r890",
      "r910",
      "r976"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r123",
      "r150",
      "r153",
      "r154",
      "r243",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r438",
      "r439",
      "r440",
      "r468",
      "r727",
      "r919",
      "r985",
      "r986"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "CELC_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LicenseAgreementAbstract",
     "auth_ref": []
    },
    "CELC_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_LicenseAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LicenseAgreementTable",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicenseAgreementTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_LicenseAgreementTestBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LicenseAgreementTestBlock",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "License Agreement",
        "documentation": "License Agreement [Test Block]",
        "label": "License Agreement [Test Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_LicensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LicensesPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses",
        "documentation": "Licenses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r92",
      "r151",
      "r159",
      "r289",
      "r305",
      "r541",
      "r697",
      "r698",
      "r725",
      "r996"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r151",
      "r159",
      "r294",
      "r541"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r151",
      "r159",
      "r294",
      "r541"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, non-current",
        "totalLabel": "Total long-term debt",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r792"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r793"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r793"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r793"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r793"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r261",
      "r262",
      "r263",
      "r264",
      "r341",
      "r371",
      "r372",
      "r373",
      "r392",
      "r458",
      "r534",
      "r564",
      "r565",
      "r571",
      "r599",
      "r600",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r694",
      "r702",
      "r706",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r723",
      "r724",
      "r729",
      "r921",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r261",
      "r262",
      "r263",
      "r264",
      "r341",
      "r371",
      "r372",
      "r373",
      "r392",
      "r458",
      "r534",
      "r564",
      "r565",
      "r571",
      "r599",
      "r600",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r694",
      "r702",
      "r706",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r723",
      "r729",
      "r921",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r68",
      "r98",
      "r117",
      "r121",
      "r135",
      "r136",
      "r140",
      "r150",
      "r153",
      "r154",
      "r158",
      "r163",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r181",
      "r243",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r308",
      "r311",
      "r314",
      "r319",
      "r380",
      "r432",
      "r435",
      "r456",
      "r468",
      "r558",
      "r628",
      "r644",
      "r645",
      "r676",
      "r678",
      "r680",
      "r740",
      "r919"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Rule 10b51 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "CELC_NoncashOperatingLeaseExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "NoncashOperatingLeaseExpenseNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating lease expense",
        "documentation": "Noncash operating lease expense net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income:"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_NoteUnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "NoteUnderwritingAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Underwriting Agreement [Member]",
        "documentation": "Note Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of note payable",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r41",
      "r42",
      "r965",
      "r969",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_NotesReceivableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesReceivableFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the Notes",
        "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r900"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r693",
      "r900"
     ]
    },
    "CELC_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sale Agreement [Member]",
        "documentation": "Open Market Sale Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r676",
      "r680",
      "r686",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current",
        "negatedLabel": "Less: operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial annual lease payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r492"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r726"
     ]
    },
    "CELC_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options To Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/OrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r118",
      "r119",
      "r120",
      "r573",
      "r574"
     ]
    },
    "CELC_OtherAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "OtherAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Other accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "CELC_OtherAccruedLicenseMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "OtherAccruedLicenseMilestone",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfOtherAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License milestone",
        "documentation": "Other accrued license milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r727"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs associated with new borrowings",
        "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued expenses",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r727"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical trial costs",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r913"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r785",
      "r799",
      "r826"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r802",
      "r829"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r802",
      "r829"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment-in-kind interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "CELC_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs",
        "documentation": "Patent Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PaymentInKindInterestDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PaymentInKindInterestDebt",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: PIK interest (added to principal)",
        "documentation": "Payment in kind interest debt"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PaymentOnMilestoneEventOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PaymentOnMilestoneEventOne",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment on milestone event one",
        "documentation": "Payment on milestone event one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for upfront fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "CELC_PaymentsForSecondaryRegistrationStatementCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PaymentsForSecondaryRegistrationStatementCosts",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for secondary registration statement costs",
        "documentation": "Payments for secondary registration statement costs.",
        "label": "PaymentsForSecondaryRegistrationStatementCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions and other offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "CELC_PfizerLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PfizerLicenseAgreementMember",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pfizer License Agreement [Member]",
        "documentation": "Pfizer License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r998",
      "r1002"
     ]
    },
    "CELC_PreferredStockOnAnAsIfConvertedToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PreferredStockOnAnAsIfConvertedToCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock On An As If Converted To Common Stock [Member]",
        "documentation": "Preferred Stock On An As If Converted To Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r609"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r609",
      "r627",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r310",
      "r316",
      "r549",
      "r727"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r51"
     ]
    },
    "CELC_PrefundedWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PrefundedWarrantShares",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant shares",
        "documentation": "Prefunded warrant, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_PriorLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PriorLoanAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Loan Agreement [Member]",
        "documentation": "Prior Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ProceedsFromAtmOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ProceedsFromAtmOfferingNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from an ATM offering, net of issuance costs",
        "documentation": "Proceeds from atm offering net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The cash inflow associated with the amount received from entity's offering of stock to the public",
        "verboseLabel": "Net proceeds from offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from public offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "CELC_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from public offering",
        "documentation": "Proceeds from issuance of common stock net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from loan",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r580"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent loan",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from equity offering, net of underwriting discounts and offering costs",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from maturities of investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from employee stock purchases",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock warrants",
        "verboseLabel": "Proceeds from warant exercise",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "CELC_PropertyAndEquipmentIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "PropertyAndEquipmentIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in accounts payable",
        "documentation": "Property and equipment included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r125",
      "r556"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r496",
      "r542",
      "r556",
      "r727"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r110",
      "r111",
      "r554"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://celcuity.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r261",
      "r262",
      "r263",
      "r264",
      "r338",
      "r341",
      "r371",
      "r372",
      "r373",
      "r379",
      "r392",
      "r458",
      "r509",
      "r518",
      "r534",
      "r564",
      "r565",
      "r571",
      "r599",
      "r600",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r694",
      "r702",
      "r706",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r723",
      "r724",
      "r729",
      "r734",
      "r918",
      "r921",
      "r967",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r196",
      "r261",
      "r262",
      "r263",
      "r264",
      "r338",
      "r341",
      "r371",
      "r372",
      "r373",
      "r379",
      "r392",
      "r458",
      "r509",
      "r518",
      "r534",
      "r564",
      "r565",
      "r571",
      "r599",
      "r600",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r694",
      "r702",
      "r706",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r723",
      "r724",
      "r729",
      "r734",
      "r918",
      "r921",
      "r967",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "CELC_RecentAccountingPrononcementAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "RecentAccountingPrononcementAdoptedPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Recent Accounting Prononcement Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r769",
      "r780",
      "r794",
      "r821"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegistrationPaymentArrangementTerm",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration rights",
        "documentation": "Describes the term of the registration payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r157",
      "r158",
      "r212",
      "r339",
      "r340",
      "r498",
      "r499",
      "r547",
      "r553",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r651",
      "r1000"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r157",
      "r158",
      "r212",
      "r339",
      "r340",
      "r498",
      "r499",
      "r547",
      "r553",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r651",
      "r984",
      "r1000"
     ]
    },
    "CELC_RemainingStockBasedCompensationExpenseRelatedToModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "RemainingStockBasedCompensationExpenseRelatedToModification",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation expense related to modification",
        "documentation": "Remaining stock based compensation expense related to modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r672",
      "r676",
      "r677",
      "r690",
      "r993"
     ]
    },
    "CELC_ResearchAndDevelopmentExpenseMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseMilestone",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "documentation": "Research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "CELC_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Member]",
        "documentation": "Research and Development Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r781",
      "r795",
      "r822"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r782",
      "r796",
      "r823"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r803",
      "r830"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r80",
      "r551",
      "r569",
      "r570",
      "r584",
      "r610",
      "r727"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r244",
      "r245",
      "r255",
      "r307",
      "r380",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r442",
      "r444",
      "r445",
      "r447",
      "r454",
      "r481",
      "r482",
      "r566",
      "r568",
      "r586",
      "r1002"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Rule 10b51 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant exercisable description",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r88"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Common stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/OtherAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r34",
      "r38",
      "r77",
      "r79",
      "r697",
      "r699",
      "r886",
      "r892",
      "r978",
      "r994"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r182",
      "r184"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r712",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "CELC_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives of Property and Equipment",
        "documentation": "Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long Term Debt Future Principal Payments",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://celcuity.com/role/SummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r496"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r379"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Award And Restricted Stock Unit Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r77",
      "r79",
      "r80",
      "r130",
      "r131",
      "r132",
      "r191",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r441",
      "r580",
      "r581",
      "r582",
      "r583",
      "r702",
      "r861",
      "r885",
      "r887"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Warrants Outstanding",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "CELC_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amendment To Amended And Restated Loan And Security Agreement [Member]",
        "documentation": "Second Amendment To Amended And Restated Loan And Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Data",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r688",
      "r689",
      "r692"
     ]
    },
    "CELC_SeniorNotesDueTwoThousandAndThirtyOneNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "SeniorNotesDueTwoThousandAndThirtyOneNotesMember",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Due 2031 Notes [Member]",
        "documentation": "Senior Notes Due 2031 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873",
      "r923",
      "r924"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails",
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issuance description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average exercise price per share, exercised",
        "documentation": "Weighted- average exercise price per share, exercised."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average exercise price per share, expired",
        "documentation": "Weighted- average exercise price per share, expired."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average exercise price per share, issued",
        "documentation": "Weighted- average exercise price per share, issued."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average exercise price per share, surrendered upon cashless exercise",
        "documentation": "Weighted- average exercise price per share, surrendered upon cashless exercise."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- average exercise price per share, outstanding",
        "periodEndLabel": "Weighted- average exercise price per share, outstanding",
        "documentation": "Weighted- average exercise price per share, outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value per share, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted shares",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value per share, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding shares",
        "periodEndLabel": "Outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant date fair value per share, outstanding",
        "periodEndLabel": "Weighted-average grant date fair value per share, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average period",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total fair value of restricted stock vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value per share, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails",
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock warrants, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants, expired",
        "verboseLabel": "Common stock warrants expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock warrants, issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock warrants, surrendered upon cashless exercise",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other",
        "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Common stock warrants, outstanding shares",
        "periodEndLabel": "Common stock warrants, outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares available for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The number of additional common stock shares the Underwriters can purchase",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares, options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issuance, additional increases",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, aggregate intrinsic value",
        "periodEndLabel": "Options outstanding, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding at beginning of year",
        "periodEndLabel": "Options outstanding at end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, weighted average exercise price at beginning of year",
        "periodEndLabel": "Options outstanding, weighted average exercise price at end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense related to modification",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfRestrictedStockAwardAndRestrictedStockUnitActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant purchase price",
        "verboseLabel": "Common stock price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEmployeeAndNon-employeeStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "verboseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r875"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r130",
      "r131",
      "r132",
      "r150",
      "r154",
      "r179",
      "r180",
      "r182",
      "r184",
      "r191",
      "r192",
      "r243",
      "r267",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r468",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r609",
      "r629",
      "r646",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r861",
      "r887",
      "r889",
      "r897"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsOutstandingDetails",
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r55",
      "r56",
      "r115",
      "r116",
      "r117",
      "r138",
      "r139",
      "r140",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r190",
      "r244",
      "r245",
      "r255",
      "r307",
      "r337",
      "r380",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r481",
      "r482",
      "r497",
      "r559",
      "r566",
      "r567",
      "r568",
      "r586",
      "r646"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r190",
      "r309",
      "r310",
      "r312",
      "r315",
      "r482",
      "r535",
      "r575",
      "r587",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r678",
      "r680",
      "r735",
      "r1000"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location Balance [Axis]",
        "documentation": "Statement of Income Location Balance [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StatementOfIncomeLocationBalanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r190",
      "r212",
      "r309",
      "r310",
      "r312",
      "r315",
      "r482",
      "r535",
      "r575",
      "r587",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r678",
      "r680",
      "r735",
      "r1000"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r784",
      "r798",
      "r825"
     ]
    },
    "CELC_StockBasedCompensationExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockBasedCompensationExpensesAbstract",
     "auth_ref": []
    },
    "CELC_StockBasedCompensationExpensesLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockBasedCompensationExpensesLineItem",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockBasedCompensationExpensesLineItem [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockBasedCompensationExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockBasedCompensationExpensesTable",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockBasedCompensationExpensesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock to common stock, shares",
        "documentation": "Conversion of preferred stock to common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred to common stock, shares",
        "documentation": "Conversion of preferred to common stock, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchases, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r80"
     ]
    },
    "CELC_StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares",
        "documentation": "Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in an ATM offering, net of issuance costs, shares",
        "verboseLabel": "Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement",
        "terseLabel": "Pre-funded warrants sold to investors",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r80",
      "r580",
      "r646",
      "r660"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, net of shares withheld for exercise price, shares",
        "negatedLabel": "Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r80",
      "r355"
     ]
    },
    "CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, net of shares withheld for exercise price, shares",
        "documentation": "Exercise of common stock warrants, net of shares withheld for exercise price, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock to common stock",
        "documentation": "Conversion of preferred stock to common stock value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock purchases",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r80"
     ]
    },
    "CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrants in connection with note agreement",
        "documentation": "Stock issued during period value issuance of common stock warrants in connection with note agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs",
        "documentation": "Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in an ATM offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r80",
      "r586",
      "r646",
      "r660",
      "r741"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock options, net of shares withheld for exercise price",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r55",
      "r56",
      "r80"
     ]
    },
    "CELC_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, net of shares withheld for exercise price",
        "documentation": "Exercise of common stock warrants, net of shares withheld for exercise price, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r962"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r611",
      "r627",
      "r647",
      "r648",
      "r727",
      "r742",
      "r885",
      "r889",
      "r890",
      "r910",
      "r976",
      "r1002"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r441",
      "r453",
      "r649",
      "r650",
      "r664"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r501"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r501"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r501"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r501"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r501"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://celcuity.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r502"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "CELC_TermALoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermALoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term A Loan [Member]",
        "documentation": "Term A Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermBLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermBLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term B Loan [Member]",
        "documentation": "Term B Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermCLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermCLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term C Loan [Member]",
        "documentation": "Term C Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermDLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermDLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term D Loan [Member]",
        "documentation": "Term D Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermELoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermELoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term E Loan [Member]",
        "documentation": "Term E Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermETwoLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermETwoLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term E Two Loan [Member]",
        "documentation": "Term E Two Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermFLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermFLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term F Loan [Member]",
        "documentation": "Term F Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermFTwoLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermFTwoLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term F Two Loan [Member]",
        "documentation": "Term F Two Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TermGLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TermGLoanMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term G Loan [Member]",
        "documentation": "Term G Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Amendment to Amended and Restated Loan and Security Agreement [Member]",
        "documentation": "Third Amendment to Amended and Restated Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r301",
      "r333",
      "r441",
      "r452",
      "r460",
      "r467",
      "r469",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r544",
      "r560",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r728",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r906",
      "r907",
      "r908",
      "r909",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r972",
      "r973"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "CELC_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Amended And Restated Stock Incentive Plan [Member]",
        "documentation": "2017 Amended And Restated Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TwoThousandSeventeenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TwoThousandSeventeenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Employee Stock Purchase Plan [Member]",
        "documentation": "2017 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Plan [Member]",
        "documentation": "2017 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_TwoThousandTwelveEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "TwoThousandTwelveEquityIncentivePlanMember",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2012 Equity Incentive Plan [Member]",
        "documentation": "2012 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r682",
      "r703",
      "r704",
      "r705",
      "r716",
      "r995"
     ]
    },
    "CELC_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://celcuity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r412",
      "r711"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r193",
      "r194",
      "r195",
      "r196",
      "r538",
      "r540",
      "r684"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r726"
     ]
    },
    "CELC_WarrantEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantEightMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Eight [Member]",
        "documentation": "Warrant Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantElevenMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Eleven [Member]",
        "documentation": "Warrant Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantFiveMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Five [Member]",
        "documentation": "Warrant Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Four [Member]",
        "documentation": "Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "CELC_WarrantNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantNineMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Nine [Member]",
        "documentation": "Warrant Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantOrRightToPurchasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantOrRightToPurchasePercentage",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant or right, reason for issuance, description",
        "documentation": "Warrant or right, reason for issuance, description."
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantSevenMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Seven [Member]",
        "documentation": "Warrant Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantSixMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Six [Member]",
        "documentation": "Warrant Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantTenMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Ten [Member]",
        "documentation": "Warrant Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELC_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfCommonStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration Date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r968"
     ]
    },
    "CELC_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celcuity.com/20251231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfPotentially-dilutiveSharesExcludedFromDilutedWeighted-averageSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Common Stock [Member]",
        "documentation": "Warrants To Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r184"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r184"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478742/980-340-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-20"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-9"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001493152-26-012801-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-012801-xbrl.zip
M4$L#!!0    ( -,[>EQH:]3+<A(  "'8   1    8V5L8RTR,#(U,3(S,2YX
M<V3M7=USV[@1?^],_P?6G6FO#XIL)W$NOJ0=6;(SOBJ6QE8NUWOI0"0DH:$
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MJ5,W/M<Q8].0NRMU*#8][957T(C2!I6&C-[+(1OD4/:>L4J=S$AM4"HY$6<
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M^? .D^7^X?OW!_O_?7EQ%S["%9BAA)DMA'LE%>.BHCOX\N7+/O]MV51J^?I
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M<X0UUS[N9"0?:W>UUQ#>RJ,N;0@HAYA[T 7]=TUJ^)K!)()1*3?KH/W\J^"
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M\@ELC?;%]OAN*[A*'LZ*"8401GQ'ZP[$K,CU)<CXP[WB30:K.G0=V7BZ FS
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MXR[0K\[O*$+$33#YN_,O-TS9O^#+($3$.<.+IQ EB/Z0#?RK\_&7#ZYS=*1
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M*GT-Q;>L:^- /,HR]RA3L":GCSJ4VV$P#;5E??8?4(RO2Y;%4YP#2*FSN4Q
M3;':SM>@K!F+'CS#HM)!9>EIE#J;R2+4! U%'*L:L2FS4-= VIQUJ%.P+<U$
M=)D2JGFZ2Z)<7P:O[$_27!YP'T.YB9I\:[B!*,.99HO=\DRP85+H;"H?2^N-
MD:I,$)+VS;-KQL]1[)& /_$9SUBQC]KDVSOAK3;$/EI% \D59H$^@X'TEENM
M'IXK7EH][O,:=X*YU#R5Q!:E5/Q?E^LF>2T=7EU X;BM@[;IX[A4AA@20OF\
MOO,0UASH]1D3>.#7A(?U'H%5!0_QV7^KF06G?%T 89&<UNU$VTN]EBSRV0)]
MXRZD!\MN1C/C4JA'MB;%6D?:M<G;,'PKLMF?8<K2NG%U0.\L4!1@PF+XX_,4
M35[P9([3F.Y.*5N3>4!/ >,(\9]!MP9_3="0C*F\LIW.#'A'?8 3C+%EBCT;
MH!RS_[!#X+,;,A6-DC-Z"EG2 PI_+0+/&$K=IY\L-86VFT]UJ:USJ]S/,4G8
M<;XF/+MN0:BVWCLT02&MVU.R,(^K**:G$,;D%5WL"&6852\M/_""X53KOW<
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M]E@*+.; ]6A363*R5N3VV!3:ZP.R%&-EUNI$804[F8,@2@A52#.SV.S[D]E
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M>O+I[TY&SJ*R'%G<&V>U8BQ@'.!V<].%,C@_7Y><.^6*%S6=K EK$L("UJ
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MJ6HK/(-Z?=^!7D=*>BVUFIX.1*\5GL$-<Q=Z_:JDUZ]E'C\,0Z\5GD&]?NA
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MX#^A^8D4 1J@,=<.E^M!+OI#$]&9W@6;S>[&')"Y=2@_:&7&@G$Z^<#.@^?
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M903W%.5=U:+BT.A[VSHA+JN]75;4>EN7,\/^C]6SI/_R_P%02P,$%     @
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M'N5Q&F57.>TV-XR)FKDSI;3725T]Y,&,KEPT.%WL\ ESN:TTVHE#62+X?/]
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M-SDVGLKIR?@^@B/ &Y^WZ02"UZ\.E:I)4SE/]?SP6ACKN2?CNYX%>.-Z[@1
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MDD&U9PI.(*6C=77,0+H_IVX/5F!E@FG7U\%();^+#2]IO=6'G#?4KILN$/R
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M<;*C*/WEU]N7]8,D4!D^\D$J&1C&EO[?@]-  D:R#Q2]E.@6$SX;SRIY-_F
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M))WMQYBZ6<"^V"-H)).V$=B6>>S-9<\-!C9M!F2GPFX-)U5:#GK1_5N.0[$
M6H[S1[!H.=9E0F\YKH:XM9RN]%$(!K7E2,9?.]1S]#Y[O@#2:-_]P[B,[>U+
MA]G"YC!I\KB]U]*.K<<R]>1W>%V0ZJ'@4Q/SCXDDQ0/HP29_E!EB0*%LF.UM
M?X/FCPGK-[%UU7HB+<BXJEW2'9ASE<<IVT6E.<QFJ>>K=3B9T=+>2@D$GUV0
M*K/T#AG;:H<[:*8UZE-4;8@V>')3!T%$A5%6?!SIPJ>E'+ K.^M20D8C6B/O
MXV(]G:5C;1 DE9MDQ=&A*GR*2O&Z,I07 I:@]>6,DQDJJ(.@J,(H*XZ.=.&3
M5 [8E:7-=:]0:=H^O%JM:20B;GH</I],Y\FO 4'[/3^25?.8^ [XS6@_PUR;
M6_>\+DZ^HW8L!+5QUC-'_#@-2^W2)D*[(>P2HO9N\<EMTK5T$$UQVB>Q:H%N
M1<-O>)/L<6UOO9?4R8+:U["6UW_1X1K9,BH?^??:E*=/4;1N$EUE5=G^9=?D
MFC_\>D.>HCS]!\?-;LTNLC3AORSRY);6$#6-_WJSO$Q96ACZ!>[I7^I;FA2S
M,S.7[:.Y'>1SL,8V:\'!F]HAK!DWM'[9)VA0>I.4:U<^6[7KWH!VKSC4E)+W
M%K:[#UK5NQWN-4?3[C0?:;8F*'G'VVB-:L-T#9.WQ.OT[YLTH;U@\#:VB.-B
MDU>]!*B&KDFGX)/W9N!]!JNEP7#1"%'(;]PI['(O O+>'Z(R+6^6_69$6]5]
M^I3S _YY)1IL\M3[%>F3G7,8W^?O/N6!8?@,1HS; "^2Q3*#V(:YV/O-:A61
M+7O6>P.2-)K@+>4B(CD%5-YB<O\<$54>4K.X3X:;0/?9JY(%PTP#0.'FB48<
M47G$%2 YWK$Q)J^JD0])**T_5 J#I93)DWW"%;HNRII3;-<)]6-<,3B?KO(7
M7%;U #3+;JIG3/I_TCLK6V6?3',SJ$\[.TTP''2"*^;W[B1/$%5'7!_U_@S)
MZ>U@F=R=5#(,_;0N3B(&Y6(W,T0-F8)3Y984;.OZ]C9C(6>>7-"Q^'JEWC+G
MH.>31M9F]$EE5 +CNVR1CIG6ZIT@KLG' ITN)(^E--!^YM*M"!#DM)QQ=-&'
M3UG[F<*VB"%MPW,UVK(%N9(:10?09!-EIKA/J^&5B6;H ^*IQ>'PS(A1H%6C
MP6G5ZD!RALVT3-D Y1!Q<IU&CVE67_>6)SS^[/UIUZK.-H181'YSOR3 =/?,
M'T@R13[3&\ TEH.8)2SP\*%14S8_&IF7 "86Z\,K]6 O3\X*/N^)\WA@HL&1
M.Y;ALTU,,J]/>:<"P#!Z"FKA!-2N#-XG#$I!NV(@]1$]S/8ALDDI$%\MPV"]
M!D1&VH>Z/:7@U&*1=K4UK;N,A+Q.CDL!#F;$!Q)@J"&%):RG<"%(ON:^HL1]
M+K($D[)&]ZFHL+W;<=#W22-GL_H,LU8&0SY7Q&->]O7_QS_]R_MW?_U75)<3
MG* [(VZ6U).R@).O?=_AC%V2<U:45<F7CQZC$B<T^+59K-FW4)]4GN<#]/F]
M7XE@2#^+&4)+8 JG'Y@&:E30@A J@J'-JUK;_Z%OO\FA[UTJR+:A_P23&H>\
MR.-K'5H[I!U%TSSZI89O#/BQLA[JJX2]4E<+>,!(J20<HNG@C?G#A(&.NH=V
M&-VD2CH<A_1N32X*E$4F-\2D]R5,C+.8L^#=^^_><2:<75R?]?SF=1JSV<W%
M$\%8LVINK>6#&8XF,(98J@1GBAO.,6,:<=3)'X@^8U@/N)3Z$9.P-[(8 7<<
M44I"V:UCA?+@Q)AAAU=<K/!#],4ZGM%J^-WQ980^W/FE% _N;NPQBEO F :B
M*D C'8E)YKV$.I7 %#/L+E3+0R:9>:-ARS( ZZ_WF\<2_WU#O>?%B\7TFUK<
MZQRQ ?1@2E@A"X9!!H#".+X31[4\)/\TML6X!J&6#\DG_1J#2A@LHXQ30V-*
M!>=1<PQO=-AN6__7\@BF43G 84M+@R3'*@V:8+CG!-?JJ&1P,GYFZ>DORBI=
M114N%7:/A7R22PZP3Z*A!!BR2&%ISI!WHL$Y<1:5SVQG$_V'K;:^1!GSFW;^
MR5+7Z[8?%W,&NW]L%,'PS06ML!>(*M7[T-@//?7@7-P=7++CGT8^S!DS"YXI
MA:',8-D"A7SJ[#)*R4]1ML&]7#)7.1U;;%:[=J*PVU+7)\&<S.F3S4H1C%-S
M03MF']-%7'F8;*NG'YR59ZRF<SK Y6O@:?G;&<%)6K&?5&Y>I^%W-ZT1^G K
MK5(<#-O,&,5-M#T-1K-:@]]I<:"EG$66%:^4RNQ>VOIM+&T!-L1G;JK>EGD<
MC>D6?2SU@C-K EAAB-!J\YN(&G[5!01W7\H3EW;!FKTZB+.S%J&<K2ZTR,X1
M]Y$<F[W&M)7@:QP9W:.5AD\26D#O\TXC'MP'VF,4%L&Y;' :G47KM(JR)H$D
M._6[*DC5_$H#TPW.^+Y%[1C"M1"_,R13#!Q.E;B4 (:2DV"+DR=-(3A!]\6R
M>F7YR,[Q"\Z*.ND%+R(XBUFB_)34=R2>I^6Z**/L9GE=Y$_7Z0M.%K1QVD[R
M32O*Z_S+'L8.IF8FE .&W7N %SPQ53KE6JA6"T[G<[S$A ;#9\\1>;+MWDU*
M?G?)VA@PW"RKTP!#.RN8XM;96@D]D"@OHYB/IV$X3K:KUY9>$DG?.Z^MB"2(
M 6*/"IMTT_Y566[XX!@&5]CA$X*?<5Y27UGOA7)9W;=7]WQNWLFHT0EZ*UTP
M_',$+#E5OU/GTS00.*G*5V'-2NL"@.0?L6.FI38D;KI!=DH[$IRHNW-__3-\
M-^MF;';%I]IILV*35/K!]J22O&[*FV[J8+N>>S'09AZGFW TAT#O<(GI1V:[
M,WK3 DV6*BV/K31]\M;!E#Y/+=3 .%E[K&,"MIK<M?9T@Q/P*K\E18S+4FZ;
MEH*6NGXWUSB8,]QH8Z$(AH@N:(6.GA:8QE%&A]/\YK\Y!D?ZHX4VZ\]*4=_'
M"HWKRPJYX-RP *<X27BHZK^-*DK&WBRYE@$Z:6\D,$/N>* 6A4$%(SXQ$VT%
M:$FB/5]FN[=3)1[DI)_5SDZY++0@W( 3]B$__,2ZPSN\9DMW;J=I+'6]C@Q=
MS!F,!6T4@WNM*6B%@5ZMB\ZC*CI0KW:'V;"S=]"'%#FK.Y[2(2G6%4XL>KLI
MI7CK!:>;V/6.[D4$Y]]^N,41'RLHVZ)&:W"]'2MTTY0:WDU^PJ\C@SML+A[3
MO1B?SG.JD7T_ZEI&<$KO"5S.:363^1WQ?\-5R_D#>>#[^!DGFZQWAB[Y7.+E
M)F.[$/@MEO66P_YFQ0>685[KD><HU9N'GN\3=!Y[_R*#TWU>.X38HBF8[>7O
MBD9UV8@77A_A!;G?=?=5%K3E)FFV83/G]SC>$'ZOPL67.-LD.+FD'&,SY)OV
M=FW7*RL/\2*O0?;!/M0@(I_]+<$;W\%-T[7'VX+-7:11EFU/SYM7UG=TEJA]
M(6(5C?A3^LO/.'UZIC^<+N@@.'KJI&\V55G1MDN1!&^TO4O\=-V763S0'8K*
M#L<D"X;,!H Z2NY4@_-(>81C\BD<:.=OIIV\@<<W:ZAB+ION3G7X$8APT9.5
M>W,I(%#$8&F8(A(P:(,AJ3-DG9L$>C]7?2+IAC:DB UT^7&CULSMQZABP<S6
MBK:32O)_GFR2J>(Y,Z=BP#!Z.G8=M3^F>;K:K! OKKV; 0*U*1RVRF=)7X6T
M7XIJ(0]I*!4%1#4=/AV=:AK!6)[==0'RBWQ^CM@-)%5Y0^[8,,N<$'%Z>6&Z
M^HEFRWM^Q\+ <'E?"W1L9_N1BQSQ@E%;$&C>.P:QY@*@,-LEB#5I'P5WG5VS
ME*R@II)ZYDIW57/H]=;J<A%7Z<L$0D\N.!#1]_P0B@8PL52(#6,_4W0-IFXI
M32FH+09D*VGB]L5K1)*^[2Q]6)T;H"PWJ_IODUO,/B\)W7KV_T"FEC3]#:!;
MU=YFZ5I83Y=GAQJFO+M8K;-BBS%:Y GZ5.2GW1_Z+1-:>WP<^Z([7%8DC2M<
M?S]JS.@OG_.TVJL_F_F5 =OJ03Z>IN7.^CZH[?@01NI:]:ZPIJ%RY\%;L?"(
MO0EBU]JZFGM,7M(8RZ,,EMHN;A:&[W!</.4LB<XM)FE1WP1IWXYG?U^81GR@
MSR9OP3._#&#S/8R%QICW]%$XA IGT6/W=5@"C5XR7/O&IE8,TVI,ALCIK]("
MR&,#5.V$,LO<5&&R0G/<3CDC^YH5EY1MUV,@'RA&!M$Q@+,M)@PSW8R4\]2N
M#("L=0)NXC!Z:#F,+C<5N[KNEJ1YG*ZC#,ZJ6Z_G62XQB\IP=[3J+JHPZUXH
MYBSE?8(CTZ<4&2B*F6R\(E!Q+@]@:YALA':+<ELHZEWOR,I%PX(!M8PVTQM%
M6J<2I..:Z;N$'$L+%9],,%D5M#@4!; 53,&O:P"[O(&4^'6)?$M<KTP=]P]8
M_7>XBM(<)^V.YT4<;U:;C)TGH*#3.)7>Z&C6^O6]GVK]OJ[6'#^QEU]K:M<!
ML^3^JU84);5L<%<UND%I49U%A&RI87QB5?$-3$J^+[PR&S"^Z4JM >VTNA5:
MY157,?L! [KB:N<<U1N#F5LT^E:3>IC.S\XH>6^GUP78O5D!5MV><(*XVG!+
M-_J%JX:__E9IVC7U_5<57JENC[11!'&^0##$ZGQ!IP6&CM90'8G(U!'7!\S&
M]ACH4N4OK31!\%$TQ8J0.S7XC!2PCBFY.X.[J<_@9NP,[C'0[QR7,4G7];H"
MF[RZ^%*QM,#4F5_DFQ6N[PR;_L%LRP=&9;?/XDAXN\*/J5DX663PYR=#AWZR
M.]:^Q"=\?O4$]=Z'?MF]"_5>%M[YFW:O+=C>S*<Z7<6'K7POCEU(O7?YH?=M
M[?597#8_6A<.IO7-;9%V69AI2W(3H_Y+T.-V(-B\J-G^ 64<8/Q8JF]E&B?,
M47#X'-Y3/H0YI;=+J7 :V%RF""W+HC49&I/E6.:@]"E(Q3K=WBW9<D*(<K[F
M@%W2N&M0BO5'A>M-"2F@*\*'NRRN<@J08F.K:><;PG)J\2U!B@]@J^S[.B![
M@\8W!)DUP7@:)[B2-0BRP92)M19:1UO6TR(:[>+@G.Q=+ECGT<&DO6/P1U*4
MJK[4K!;D?DF#$=(;)14Z8+AG"51W:V39WAJ9]&Z-C$&< >XN<V-HSC;TQ[Q2
M-D*9:) K]21@I1?I]>3 \$D#3GEI7M6[-,_(FX.N>6ONSI O=VL4X$4Y=G"U
M]X+TFSBN%8,W\D^;U2,F-\LN-T:385G5NVCDO69[-<$>I'55"8-I^":$8UK5
M\FQVH6@U4%FK@&%4G=^;A5.6E)(IA."4&KB,5*(T.%8I(:II13H5,+R:+^^D
MU?3O/"\YSLRFYHG@.=X IIT<Q"QAJ-DK&C5E;T]VR4LO;N_1693%;$<<7X$!
M,N>[YR<QS?S.5[S/IC;W1^DWLKG*!M.\9C;(IF&E0EK@WBOXYOGF)8B^I9XK
MAK7'9<]OMEBQ!/Z'J8^V["-J;\//,6-CJPM^*RUM8,VXF3T4590%;Q>],S4C
M\!^B,HT_;.M,36=95)9V<9YU.8'.4[F9J3A$95<(&!Y/12[L(!.\_ GB)9RP
M)<(FJ1<OY80=HJ*MA VD'UZ+4_Y']!%7SP6<Y7>VU'%6Y"^8E+3]UC]5.-FM
M?M0I[J_*<H.3=YKU$I="?"]:N1LX7KRR+P$,X2?!%J>$']G205O*"<J[X7Q9
MWWV0<OU#W09*'VYRVL\T^?%JR".#M9+^;@'50MW= "H5"TX:,S9Q,R ^K:71
M:RW>, *$2]M%*O^!L^2A:/,QL^0<KQ&MR<N"G!&<I-5UH>_5)Y?FV\GM8?+8
MVTTH*CB#Y\$O]7^[XDX0*_"T*D[;(D]05RA/F587BUBYH/KXX2>IBI7VDYAF
M6/8J,6S#<#9=WSBLBP/<0%QMF+>10)HB&;J+G4F*3ZD6]\EQ$^@^@56R8-AI
M "A,U*W8?;__X!LW2W8BH42+Y+\WY0P721Z,3+U#ZI]STF4(^X\B8T/%'Z-4
M=8IGGP(A$-+><!O*FDL#3VIK$\:TYSO!$--IMGPU*HCIA(_ I]E[K=Y_N$^!
M\)E_K=BS.+VT(V?^M7J?HY+Y3 ? X%-E,$NEK$OX8:$'@<B"&39\[93 TW*,
M5'U\>)<:.SCEE,<^=3NZ34H@CODJ=W/K-<#0S JF=%$,K?L7,N+=&=LGIAF<
M<H.43&OJO^NT</3G#/-#67G21.;\[\KOH%ISG*UXKPO*,W^4P9KR3&5#R_4U
MLUWCML3NZ/L!#;."[=X2:%>[THA/6%KW.GG/>]HKYIMT]6F%U<WCY5B[3_2@
MDX<[KLAG W?/X1TND*(3I^YV0F#.#S07N[;9UC_@'"]3TW$ADY+GGL#"@)%_
MUVB "6BL8 I!<WM-3-P_6\U:^6.C?Z#58WY-<'?=<,RX_3'-<%D5^7@89B'O
M;279!G:WGJP3#DX;6X1"MUV+H54KYX$@[2E?DPD[N2"$&,.4$J$5@D> $;)Q
MQ;>/H71!-)Q9TA"2^JLHN\38K@M2*@7H@@P&2+H@A49P*CG!%$Y'%WFYR?B1
M-M;OK'O*:(D!3!L.G627:[JQB@;2GVB5:\GG5()/)DXPK4]+!W4P''7'/"8L
M+P$X*R<9#XE[[G2#-=BVP@ISSSU%S<X%E+=U<A0VS>-(,Z<2//>\KJ:-NF%;
M=3#^SAVS)&D.+Z'+EI/FS4FKJ"ZIRZ<3G+IL3A'C[E3]-8Y*W-JY;:\..M_@
M3_A+]?"*LQ?\L<BK9]5"S/3B?))Z7Z/[#)]:%ABZ[VG F/N487\YT #7%NEB
M21O7WW!$;N0S(]/*\39 WL?,;@ ]I9#@E-P7N1 =T(@"1TSN:/SLGHT4IA_=
MQV_""E(=4<O7AE9IGJXV*Y0Q;18CP,CPJ+7M<YZD)8]J<'+Q)::BVA/4$\L"
M0UZ3N=9,5A4$;>EZ'R,4Z]1<A.7)H9 IP=ET%9BP5V&H:FBJDO8Z^M=#'@S[
MY:+!^W<[?)*S>8P_Z(7M3QMF]*H]:!;\.CN%0;J9&:T&O&OL+/'*78&FPDY0
M,W4(S"7\C-.G9_I-%B_TKT_X#J^B-&\?LE3.JM/C[L6$<R+V1JJI:RX#J-NQ
M!C[F=*MX&M6:M(MK5!MZL]S=L.E\WG3G+ GT+::?6#W_[5P,&#IKC+2FLZ2,
MXZ"S&KB1SFVL!R/']]!*=B[.ZG/4@N&XV >J9AN3 LJG'C1A.6_4G;.DRL%Y
M\E-$4C;7;J*)1,XG2Y0P^R01A,!P1(5L3)%6#A)#3,P(Q @M$\(PP&(:3%_]
M]3P7H+K?Y<LZ*S(*HV .[ 7W+YAJ-C(H'C_LDLA;IDV;[T5A\JK-_:'DB=?F
M>@L8#WDPT\1=8#W]P>5.;%-8_W>^LP)5SU&.ADI04KK,\*6N#3E>YGV%U_MA
M#O!Q!G?)S%@^F%9X *,.T?ZN 66+61 <W2RO*7C5OIB>@-<M2 *PP0ZC[BD8
M\@F0A"O>_KYA^9276'\8+-BJWPV_XO:AX%?<JNA@HQAZ/4]NB&GQ;J@%AE;6
M4,5)>!:'%_6]Q56!,!<&R;S>#<L.7V&@%9IS$A-,A.NI@&:;B%-.M60G%YQE
M0PO:+1I64V [X7#SB&/ ZKG$5A(,@[3PQ+-2:95&&8V=\DTW==!LC0FTJ!MX
M@XC?(]BNKL >_[BF^PIHN:DV! ]W1 5W&3)[V8(@&]+G%:'C X</-58,W3W)
M#3'1=:@%FIE2J/)^"L1";8N4NKV;QRQ]BC3!CT+6[W2$!NYP7D$B"(8Y.G3"
MI6]%?AJS=*\97]*(=ZHL"< JK0)V4O=5$?]69[WOW^9<)SO_A%_Y(_G5Z5::
M\#*!..(6 @WZF*?N+9:\]NB0J&0EMC< T/'1[3+]!R9HO2%,M&)_BG+$DK]4
M6_0C3PZ_>"(8@[CT[PX_I65%ZH1"=;S4G]"B'D[Q'6T4?3H6>T.&=^2:M,"X
M'&NHXA6Y.T5$V&Z-\)O%^?4O-\OF;H4;<L=@Z1;&= I>^R\C\$$GII0&0RLC
M1&'BFM_<0]U?HX(*@K@2G/4@F4G7IA4>@U)PD@D&&(EV#6]=Q0:F ^&NYUL
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M'8[@?G<^Q5_,\63.^'7D_NDG'L4%BS?&KW\;WD7^4?TXC^&[WTQZF6EVCSU
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MGD99OZ2SHJSF_N1.KSZ*EC?A8\[2(AW>>_PMU=U8Z6P]4L_6TT%CQC8XHJI
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M%3D"FM*_E3C>5.D+[MGFW)F;RX-%7X/9;E16%'9$M-9;( D&6FE4P:6[:R@
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MXS'JZ51F)2%>E);/L+?S?0=M?=H$5+-'JMD:%=RY.(RDSRGVLDKC_<?DNY*
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M8,CJ=1YCQ-O@6T66\GE-NH7^8G#GVDESZ=K7@&C!K_?BS]JK;B^^8!*GY3
MG5C$452^&;^PR-@\%R[5:V\ [M)_-[?LO:;5\S/.$GXI(VZUUR1E5U/SJ](@
M<:)N#?N10E?&4;#"PH##T@*HKV@OE/R\+O*SK"A9(HSE9<&VT#&_67=_GW!U
ML_R<)YB\DI0M![#KC5F'R 9[K1 [>BP>,?#X[J/@X0$-EQ[X1BF'@!*.@64I
MH2":ZQS3]C+1#<6!XAH(O^6@@;*+?QJB;WIP4-+BX;O*.]&808+$\]VUJ@&(
M?I"7'P73#VFY ]4;W_P[X?K O=PL>[%NV^M=Y32\S>OC?3_3#HM=7]_=!SS)
M?;N_YBCX.X^-TYVR*NI@&?WC[KT\Z$ Y?3.*VE<'(>0G^CPJGW<[#]B1ZF;7
MV&BCN(T\+(K8@96D'61:_5T4_)QYFSV,.IH@5=7>,=%,P+>S]?6LOE!16FE8
MU60#51CL=]=D1./UB/H>J"!51"$3QI5S7/_;V71&)=,XRAY(&F7R2,1!%U;U
MN0.7;#_EFBAIBNC7:]R4@BI63,"^N[DMN[PLR#W;Q9Q$9'N'G]*RJA,0\OU7
M3$)>OV[JL*IX$G;%;>,E'V>7;3&(],KA-W3B^H:$</5,BACCI+RD?UI4JT&T
MVP86BBJVU016NXZP)>F?N#YB'Q%%U4H(RKOH*%RMMAO3+M.<(FD')KV!"OU1
M36GJH;)-POHFZMOXB(*R>;Q<>\CWP&+,88U4GF!>MJ^K>30<U+%?=+Z$Q07\
MM4WG4H\+U_6;0SD:GC:MGV'-GFA.VK#H,P6Z7<XY>)4L&X#R860[]&S,?*"/
MRBCN?[)=+.]>!JP*GVZ N,@G'5O7 _/=H+JI<1HS=@4&J7W[\/](@GW7T'X!
M+8H_HT/[VRA-:"@[G!<0JT0M"JM.C#B%1L2F-]94@X?BHWF.,-72Y8F@1M3G
M!:YYZIO;(DOC[0/^4GW(9/LB+/5@59@;:*%)=;>!4G54ZZ.Z /1+701B92!>
MB.]CM?7<;/R,DTV&;Y87996N6/J0SR5>;K+K] 67;%^'& #PK8#JBMZ_2%@<
MF,T>8:JZ*9B-N[JB45TVXH6S)X/PJ7M!LR$S-'VNTY@GF#<U?H4<K(K6@Q12
MFC;24%KR+65/,VPSU89:%%:%&'&*$U=, 7$-*/5RA]FU)<U0B2U^D2)G*LSR
M15*L:9LWU9=[$;#J<3)^(?\T+PCM2D+]HE!3%I2:9WLBV2)WTHRDZ@5[R?2
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M6;1:A7R72D&BAW]7Z6;^*Y\_Y%7!IWY\=CG_Q3%M+OC$$*:!Y49OX3CH&EL
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MKE&43%BXN,FS6[$C4/Q-(?+E!GRB++JGE["C(-*$1@D3ZT&&1P5!@<L10YK
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M.Q00*)UZ0;GL W?'&7VB:;X&K.J(D:M+^BCA(G $8C,3NE051^Q:RD1K!^V
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M;(O8<-:C9@]1N/+D-\F4%<#W;# 15Z@Z]OT]<>6'/SI*UT*.*_9#-^R2HE#
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ML7DCS%1%.Z]9S)?AGX0VC4_];IBR"G;NP)XVN/>V&  32_MU(R(.I,":TWX
M"NR"?TKS/.B"0)G<^<,IN?,IN?-^ IKU.HF%VUFW#.@HBIV7U"3'LU13.^-7
M2K,:_NQ?.^S9/WZ[XR.P9'QB?Z_]^5C&H7VI:[/:R*!*S;@2T)%5ZCY>W5@.
MM-KL!>8G[S5<YVL5G(TB:"N=)EPM,#MU05^WE(&<Z55"KXCJK+-5$#N;N]37
MTKQ2W:TA.O+%>6IQSJI8(.Z5PMY*@4'O4LY6AH85FQ)63"[A[9XM/X4123,V
M%U\^D^Z#&I'[0%<+>UFAAQJDAE7HRZXUB_<_.XME_F=5!>P]*@QPO<J6L+YC
M:+!&']GV^8(\DRAY$HO_(LO35A@)[M#*Z,G%01R80>' :=?NG:3+Y9+X_%SJ
M.F9_)0OOE0>[W1$_B?TP"KTB+;,XP^HZ ON^>016M3Q)EI-MVY.B\0EK?<*;
MG^RWOSTEZW<V-D!&ME+UG2:*@[2REK(25F:YBL(]>+>_+@WRC,1D&6;3[(JP
MSN-%W,9S)LUFSP0 F@_S&>1E&X#\5D(["S"CK_X@ T%ODQFD<>RUIKFE#(@I
MNGU(K%Y,D&S>NV$?C;9E5/LVXX:P%[Z#C1 ZK- YAMBK.>&'M8J]"K?3ZYTW
M!8D)GS]RE](U6Q(60:RLP#1-29;R[5[!210E+SQ+G/$(8-0V]L9@L$&A!Z+H
MQ@&Q\$$L9? /8;]S9&<T.48;DG0']HMSID&8I=6FVG@<Z6H"^WFDP88+.3[F
M=PP^%LZ 6/CK M2+3Q K-S&-ONUAO[MD9WQXHT8CZ2)S&B;T7TS-0[8CW8U@
MO](TV#"BP@A]:H"8M!G)_5O$?MK)SH#@-/T2D[U-N(,[]\7;2*6/S;A;=S>"
M_D348/U:!1(ZL1#+-&.Y?XOHKTS9Z=A.\R_QD ,Z<;,"^F-3!W38;N7[IQ9.
M,B]R<.U^GL19&.=AO)H]$2J8,9Z@N]M ?Z%JJ*ZK@FA0>\ [7FYY)+C/,_0>
M>%K2D*2*D^4?5"?+5;/B1+EH>.+%P:36].E0>:C,0 T&N73E[\JAC&\JZ3/A
MW$Y]G^9>E(K_DCK5<J6'^\+1'24/#2[Z% ]0:"^99QR4\V#:G>WS/$F5.>IM
M?.WXSIEMHG[4^91:P,QIPJ;:;#./O#AC./"[$B)8R\#(%&T<WU&U.4+6WGMJ
M""+RL23+/"7%OR61A(!Z1W2$#-1H7"9N>-;(:K;90'EHUCJB$UN0/O@.="A_
MX-G@^N[\_4_?BS)!F#& P)WNH$\<T:'L\,J/VY7A"X/,HUG^9-46.K]Q1">U
M%K1W=1E?.BCBU4V2IN+MNV5">:Y]DWV=JI'C.WCM@9%[O/Y,$W5&[.[RQW<.
MJM;\B+VO!\57#1DSY= 1:+\XJ.,+@&BO47<NH5MBLJ=M5CS"$U$@&$?M6*\=
MUT,2%/[8]*'O[F'5'.2'YB8\N<J-@MBZDR$:17.YD"/1<L":(PD4(<+>Z',K
M&C;C!K7&YMR#Z!N7$C5NY9SFV6/"'Y)2Y\J2E7\;],FT0T_AV!9,ES=+7L,-
MJM2&I^7%E;193 Z29J%_SE]8IAM=ZBQ)<6?\Q!+S:BX[54JC;_CW[IG]5T[#
M- A%8D,=.=J*SCAM830!@4 G;/08.6M9Z/JLG$:*F7/R:%KN/JR&F$%<K;O&
ML.,<AK"0 U!$[^H&LN^-7H.80:-%[,"%D6VA$T_W#&)[;VM/>/WM-^.&L",D
MK- /0P^=]6U(P55"/\<^H1E;Q3#9YTD:BI#@\YQ29802O 7LM?40/)OBA4[P
MYY@R!5=Q^*<PSNK\5\ZGM +VFGL(^C1HH+-56W-ZZS NKLN1V(OX.0*;,JHW
M0<L@7-#"'-80=N3#P"MV$_1<2(F7/Z3DCYSG[1.9*B'G*S^U[BAL&YD4K;AS
MR-+43W_"(J^!Y,O8ET=SDM)=V@U_GXZ+IN^B4Q7\PY&&7*VQ04O*C6M''BH3
M4Y-RX])!QIMX<<J<DM.;4Z<WITS)E03.SIY(_,FCOY.,OS<.>^M(4P?;W3;
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MQRN:U%82S6ABV8-1E"315#];G.(J)]2R.JVA[7RIU^QN:_L7FMC;G=T/]=K
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MMR!*(Q;TX0TJA-*!U7N7JNHNT=';ZK,>ST.,R$,XP/F$PI_A+ HAT6$M",6
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M13.L$<$[R"B$CT:8':C,RKO6H3&6Q4&,KW,D>$M\%6Z:J!2L.)8"9L=I /D
MS1\C;\AF5()5K(0K$7S7-(O%/H1I4SD4@K8C4# @H8%<=(-4^M=*ZF,_Q%LR
M<$Q/N&;(.-^3X26.GT0H./C0ID*3*)9L0V=.^?$,&/AF$DT+#2:TG1] +DJY
MF=[?B4N%$SC!34C+$'W&_L ;235V3!79R+_H3K$_/2:P4@-LC-%*K.G:&"28
M6!/W)/+EG"NJJ9O-;43#R!R7B<J)*WN*Y32^42A+6GX-0;F2J%&OE0R7>Q5&
M-W3N7)?Z+5:39,>YJ8K(IVW-.$HO%5"!Y5,J4<^+7LP9\:R$C%XL5WV72AZS
MPZ\")YES1>BRGD)%5:G(RREN'LEBE9O:O8RS*N6%,EWH:LJOR-'KK<U8K^#R
MD(:I-,]JM1GP-H[ [B$4D/"O5-RC*_]\=4@>%Z[:JX5HDP>%0F"!Z_R/U(_U
MC1TCM=D[@8A.30R4RU/5A(;'>8&>BTYCB:P0;INJ&P*J ,Y""?62[3;E*NBH
M_RRI*B:RU$^*^_"*$KJ@(P.N])Q4=2J>4$^!]MV=T?[6[H:[N;&[N>%O(G:=
MJ['UU57'X9INHJ^BU9B0WB)'40F1?$/WV^Q.Z_$,S>*O%Z Y6"%<5,-Q&A.V
MF7OQ,$+RRNJK4% W.SAY6XP'"\3W**WCGA=C(34& JXJU\?H;147I#S%-9\_
M>END2M_7_V+/%5X<]K# #SCTPE[:0<7BK,\=>!7342*KU4-=Z_[^ZNUW*]:*
M69G_$06D3?TAA0)#U^Z^O@(:M.I>?DHH593J@1EV-PCY/5[57.?[85VO\WV$
MJP,?JM,573B\M]+[AN^R2S]*X?ZZ*L_SN''R9'[_-=6K7_%[.;B^CDQY.-$M
MC4\6+_5<!W>WD4'BFP_B\YXP^'"P,/;N2V]7I?./[IY?XIDGBV=F>*59>)EU
MM5O>VEOOU.8^)[!D<M^S"IXLN;E/O&LSK_5-?)Z)"F]<Q+[Y^P&X_[_YR&[\
MV:0=#TM]4X%OJ_OK)\\#&7D>PGE9(VM!_6UKY!>U^X_Q!W*6_,6/M4Z\GW(>
M#ZO<WS6S%]?P-.IG_F*F!M]#=_MY+)O=]^]V]A5][]XG$]:\%F$J6'<;FL!\
M<$=XYWG,A$X/\!ED(;*AR#SOLOW]O;WW3_C'7I[B#W^OA32J--Y1R[U7N JD
MPV7R4M#]! 7=>P]7T/W@Y=4/J;=O3GKM+V@@WIPYYYWC_P%02P,$%     @
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MSF;15.._]#*+TY7&Z< C*8R>![G.<EW UBL\E 4\'9SH>%I%Y0JF,!T'>XX
M\\&U5)ZDRTPE-3*'@ZM%"ANS"A;J4@=J.M5%@8NU!/Z61RH.DC0YR*H)S"^(
M$J ?/HC2)%"3M"II?!D57Q>513"%C4R7-*FBRK(X@G\&*@EE4I.JP*4H@DSE
M90*?C7?T]&V/,7(/D_L%-A-.LX9K D>D +Z91V4$0\3JBG?;G(J,KU]F[EZ9
MJZ104SQ#!1PH^]Q[-X8J Q640$!PM=!)L$HK.J 3C<]G:5' \<$C"/?!G-+A
MX/JS62Y@T(4JX#27,!",RD<Z7L%U+*9Q6NAPO'Y3/*K\B[74, =__._S C^
M"SY-ETN@ *[ ] -<Y8SG"?<IJ_(I$*"#QA-Y0'>'[D:YRC3.REM/(MR?":Y$
M5!25'L%J3..*&=@$YHM3BZ-E!'K)<%"FR('T3.<YJ"GRLFF:7.J\C":Q#D(]
M <Y2Y9JWZTKEL#$E;#DLTI6.8_P;=C>Z).:S1I+*-;V02 F#R<HG$F_^= $C
M# ?Z(\PZF>L#V'?4GS(@%.8\5? &LSKP<W&EL@(87@QO@_G >K6LKK<;/=/X
M"B?W1UH-!WAP"CBEL<ICQQ;@9,SR= G2887[CR<"SB#^TSMX*/_D%K0*&2LX
MUV2,8R0DY4#^:CC4X0CNR2)/J_D"/\M%"(.F7_I".":F4BRB++B*RD7]H-],
M3-)UV$2SH78XL"(QN%B X+>K0[=$Q44:*/@>Z3)+O9S0]V=,^B*M"KU(X]"_
MOW3)<!:X ,#BZLQ7>*HJRSP"_J&0*Y3I< #CC8/C9)4FR(#3X#)*80GHXJ\1
M-55),%-3Y _ 68"Y19=13 QEFL,F)[ PF8;_]W?V:YV<%8F_M8E:7RI&!8DR
M__2SJ( [I(HT@0.&%[X*\7Y%((G@.N3!55K!H07)Q#HW'&V4\\LLS4M%S\&,
M/R C4"".IA$)?GRH6@T'PB;@(^$2JW%P!K<M@P=!L8;COQ(AJ3?0QF]7LQEH
MY'2QY0K#*G_0)5 +ZGDP$T6Z*8Y8D@\')%W'P6E$# ,4E(A$)GPKT7,6G_Z+
MY=X9SC$.WB;P$F5>K9(DK> WQ(9092%U90G2$R\[TF%YCC?JB.YM4"QH0E<*
M-"V87@P+7P9'CY$] !.8I7&<7I& A6%J+YIH&$H'.IFK.3X Z\[:!JT#"6^?
M_]*4@ST]GH]'M8& P9=P=)X^>A2H\7(<P'Q_2Y-0 :OD0=0,B&\\<5'I AYY
M5B<)!CK"IS)YZE4>K8U3>X!?M(\J3%$!\YD3,3A54B9E]3P>2!(A3$F1(<'
M++]M?5LT2-H2WK2>M7V%DW/:Y'"PR6PAH6MM%S$50&GV;8]-HA]47PTK@TH
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MSV%/]R8='2-]M9KGD1?5<5>% FR.I9CZZ"L$%>0L+MM7"!,D%#7VD?0)XXU
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M([-SWO$DS?/T2DZJ0L"RHN2U]V^(H5 JUN)4)5R*[[H>*X& NTWN!J@ B!.
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M_2(S:4V\*5.1(9&R8:_L:2'OCLD$/4NFXQ$7[L%7E6M&2-$#T$20W5&X(,M
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M,TS]*#:%!E<9)^K[M1PFW#DBH,.1M :P$<=1,(]F&)TKI^-]=C8E%7J@*'9
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M(4*A8(.,K@.));%#]1%XD>H O73S3?<,#W+-L80;X.K5<-O'P5O;XT"^+^C
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M+<]Z?:==TBZ?S^?W=/GL_@)02P,$%     @ TSMZ7#"Z3GBF!P  :RT   H
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M;)_W'S\?W_WFH%4VY=3MK<^RFN5!Z[F@?N!&O#IP;UI)5^[8AMX0#]N+>%K
MURQ@=\(ELHK YAS=B10>ZS\))Z&#,7:;%3,O1/C5&)]&[B(6TWZ3F%WFA*P\
M_\GCBQT77?Y1++(K*91;9W>0O0;F]BU!&DAS:K#;R!8@=7;-45X5B_E*]P:_
M;0R5V_Y$VK(1.3KKD0.C+Q5D53$V%64]#FU+P89D; >(O?G1.AJ4\&R/K:K!
MUAV;V5>^7<TR5B)?E)6E+--:INOUY[:E3!]+IU]/TT?6_P502P,$%     @
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M.5""<,0$2#%0THYH. T+(0XD$'3M2^LI;5/,(]DP6F5 C8WVA(_;EIT"E[X
MT#/P=;][(QX-!6LC(S^F"B/.+WCY_/)4?'!3SR_]["J[E-231!E!R#ZCM+W
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MSJEP\9CZ\MHORC.C87[9PZ@^U]+Z*G/H^P6\&[PZ?P &4 S*^KK(@[ZM>EE
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M=B1@SX#'Y'U( @]FG= $^85M$O3S&>9/IX"WV8&A#9W7!I%9\2T6L49?&#3
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M-,<F[,BCI_>$Q-R\RJ#9!0?;F#4Q06' !.$8O3DAS!T%S0CG^S5@O<CY;/>
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M/#_,EP/^S^'?;A2%OSO;CY8#/<\?FN&O6_9]^+[C>0XSW="/6$9 [.8)"'6
MN+_[NZV=#S-E16@]>@6+)$58_/;Y^=?V9QK,U<GEQ=6-<?GUZOIK^_S&N+DP
M0#NX 17 J#>-BRNCOOW&>FM<G!HWOYT8B>*0* WMHQO\N;[?;*5D(DP7_N5S
MZX)H_6!]>',5QXE'I^>7P@$S>G8 S&F,F>D;E%9G9/EI)\-/E^2 .>'>F7R&
M^O1[S[]S3[?_^*L0?K(PRP/N&UCF& ?*W Q;[>6Q56J<6Q-BHBFF=13Y\,#P
ME-;A;WCZS)E='G5.;MK=_;O!XU6&:5.;F-:^.JUIX]PZ.&9=[I-%WUFNU"A/
M;.IV9E.3QY["-T'^Y&_^[+#A;_O__O=?K4+TI48M;]\R0]DBU^!4<:@UJI53
MT&,9X_EK:?QI->LQ:A;E1=L8>YRE:IW>W(<_Q^W/T6BO2%6K9SI!1M=JU'.-
ML<PHA;[56A=]Z^:J?7Y]ADK5FNA<&RY%EZ25A3&9&CS>9?2 (8SO^?\ L^?]
MI$_!ES]&,/78#C!.7CJUX?  \0*:VOL)?>Q02-,3"KCBI?S*?"EZY-Y^^OWP
M_O0WJUF,(M90965V#!@RKE>:>XW:[E0IN8Y[L\YTE1[U/!$HP:/H47MOF%'H
MQ6SKV_U!_)TX^!O;#\:IXKA3-D[U''&H52&8TB-#F<L_3-:,K&=HFL<IV7C%
M^G: YV.(98'Y\O&;^^VZ=^YW[LY9,?*Q.2D?T^, 2<^<+A:AE,[<;G69=NF+
MD/Z;DWM8BQ(N@N'U##^>O&$&1C!B74P?L@P;]BT,C.[ ]&$ 3_>FKZCVL4Z&
M(%^6I]B"^4^,A]O:_^49? FSA0+FR?I@SYFH,E-2K,B$/O*L*3+BG_'_?+YV
MVG\W]Q[OS%(LT4K NN^I&GGD>[?()UEW7J,U*41FCAL]>XYY9V+RT,/B),=&
MS>,>>;[_,IU2),4_P>I=4:*IIXCFQKP_$YF/7=J 62KW7XW>\+]/O^X/;HJ)
M%3>V)ZEARH"V#O8:E<;>3G-[9V=.2HA-]Q=W)<%BK<T91PRH9"\^_(_G&Q=@
MK_N&FGL/!Z1Z7-#"K<L:I 1224[1[YNN_2]]IY[I*1%1A-A8)V(YJUY5KZL+
M4<O)<.1X8\S47%?J2$DG&ONY5YT@B=61/L]L$1;/#DL<::&[M#PM<_H&3D8S
M^3':MBR?!8'XSV?;9?7\,SWZZ\(^K5GU_GYOJS"5HP#58&=2-<B9T]9!?:=9
MVZ85;^Y\#*+103B #8Y&.6'11#WH'$PX'QL/+%\C?_DN?OP[''X[ZUT<=0I:
MO@+6;G>>M6ML';1OF1LQ(<)\7+CIBE6G0#Z<#,7O/[#ZS2DY%HV_S)V;\[-H
M7) />&^>E8-W74>VT)+ 4'W((5SPZGWL^.^$C)F2]9D:^!%\O/!OO#LW?PV=
M\5^7?_Q]]5?DF\6LX?[4-4R&LG7PQ79=9HX\QPZ>>?W*N6NWF[=VI Q?^)=@
MS=IN=XH1??'SKO8YV/E\]<^/0A:P69NZ@)GQP"J>S[%X\YK%+V(+/[O]>YBW
MT9=>$)K._]BCZ;Z2=KM^6*_UKD_&W6*VN3YUFU.CV3K8WFZUUL_H7;KQ(1:+
M&V@]8^0#2]@CTS'8/>M&H7V+7EK0TUGP=EG*Z=+G"#1 8T-">)N[SSHOX<4L
MP23Z\9__L=>H[WX(2B%SV&C@N<QPR6U5-H HG0C=X8;I,Q,DA<4F(]_R\,$#
ML@V739="M5ZC<?AST/S9J1<CA5)1;_7]0'V[.\VW4^3.Q!3VQ!0(A>$2EV"6
M)_'L\BX\^_8_?_K_/#X%*C6-5' J.X:M@^9^HU+;W5F%V/U2ZC"GD+J.C.M4
MBGGU)-$AW&9!B4<VF<\L8Q3Y080ASM"#F[EKM]YXTWF+1RYF:;6[X?OU#>F^
M3& S+F+N>HYCC@(8CORT_)CG[/KIZ8KZPC-M[BT]O'5CAPZ3"B SNP.CZYA!
ML&@\4.QKO"949_ZT(.&SK7(=5UE.0,CJ)HY??L=%.GVUY,WP37PAK<3U>-CQ
MG#?YFO>F;D6KMBI;@=DX*;9@]]T!XB(9(+[O!C9\D\CX@LS'IUB**[%H68WV
M1&BTXF <UQL=DC?Y&NV_]>VC"^?PTT]G4(Q&F\J4R(Z!)]6*\!.!^I:-_UVK
MUFIU6#??N#6=B&'6M$$X,P]IO85;Q2NYG[*&3\@I+J+R-W-T_:<[OOA]_[>S
MW6(V,Y7HD!H 1RA[G3MT,V"YOMC##.>=".DU/=G1W_WQ\UMT>_;?_N.3';.)
M3"@S\W*8FCMYG*F.$05P8)D_I]G.Q+ &!Z0S/N/N/T>1K[9_BK-_^AMB_YQ[
M+EM>+K=V@&@'R%+&_D\4A'9O7&S2EX4I/:S4&1O= 8,-A''\,&S.Y4JNMQT8
MIG'''*?RP_7NX.7,#("++/@AB-#C:P:&Q7JVRU/!<3/!,MB6\B(1,R@ZJH:
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M(.E! R)CG*$1#]J=YUHET13K9\1AC W*1D"#@TM^6#"#5SD81^;(#N%24="
M0\0<!6SK5*:,)7,$EOJ]#=S#X$W_.\O0IRF&OB1SZ-3QS/"[?2;8>:=9^_[O
MER^#X/AB?&5>)DQ\2GD$\,HLSRF/V4JQ>#NXZ'$6WZD@U$Z*>7?3;.Y&0\L+
M+=:%L3M;AO@04*P2>SW3 ZFW>FM[M]S:VR[O[,88 W)HDK.K:\H::\W7;3+R
M@3*!(.N[Q"H[Q&R@%]WAOV;#X_(J.ZK7X0WH+Z*0_$_ II(Z=VK-^N[W?P=?
M>L/]K_O?K#^W'Z;.6<_-)=>=2JU9P=:)*7+=FY-<S\Y/%8+E;P2:W2LWFSM
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M%PG)3_(\[@R\R_NUK6#&VI1DP><<:N; [N0I4(^;2J:14JT*V_ ,G([G88&
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M>&Z^<4(E/66XPJ%D4265U/B"\ .84>I:!@<^-RXCOSLP YXLS^\U$G#@M5<
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M+:3'#:QR&PV@<#Q"A<+Q7+*;X H86,?F(H0/7*CW/C-#X2I!Q_)"PXA\+IG
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MP1,Y^F:WRT9A4E(K\[.BD!25)R3BEA%-:O!0\KZ6"%HB:(E0I$2@]FT12ZD
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M7L$%D* #Q*V3\+TJ0":6^'(<@;'1,0.;=LND3@@?2N1#GYAKOBD26XQ!".)
M7$J_B"&3I9(9"WZ73G,(/@AS![:'W6/2(64JVH@%"E1"EJO%AB!>0K%J5.]K
M]EC(05>"""\EO+VAV7?!"K,H"" *J7D7)L(BSEVQ#'YHO+<EB7<LVP:(67U
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MY_"RGGGK4;>54MR'14@5OM>=>*4RG/&0MC(!"$ZN*TQ%D-V$J#0A3<@EAL=
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M1N[3)A'\1K+P,6CBPP[L'6?C.W3X!-RLYOJ:/)]D4W"A8I:QLX-;@=UF8(
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M_5'X7&1_#:34!<*_ N.*A:%M7%<-%E9-!PP]=_2/P<]+XTBD9& 9GMZUEYW
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M,&=$E_'R:[GW(7"!J.Z-97=6BF7:N1HVA8+8+?D9Y*[B20-"OFI<1'ZIHZX
M!?RZ(G!G8LQKQ)WQ2+5)L]SIJAL_R23J51@W02^+8G*U-XZ\4SIO,GZ>W$#B
M+#_* S'8NP'6G<LHE1)FLS@"5WS4EM*^>1EYHZ0UV&!8 %@(%;M5'P\K/:/4
MD^A=%NMZ/&OR/6\LC2A!6P=$U*5FAF[B#)8;;IPD[9_?&O$R;<YJ;=[^G[DE
MKA7<L3AT92E=O,NQ/ -[PALQMP+'!G,0L\"UO*&-@%99,>?%IJ>10H&F#GPD
M\;)N8-LM34@S57H)X ,)JY"2=.BQMLAR?E"N#;BG6\HVJ;TDJ10E*<]R\S3R
MY1M/@" \WPKW/):Y?N]*#80OR\ ,E#(PYJ).+8V7W>T6GN__4/*"&99<RJ(#
M?:V6+&Y@HUY@$GJW<0X'S\!H#V%7NV;9.(D0PJ)L?$9W??(U+G@[L,W*I4G0
M UR!X;W7954VGF26+%"(Z]^0)K3D7ND9H3\IPWF8B,,0Y(WR])7X34);71#N
M<=8BI1*ET=XPQSU:&FS;KL9M>VG<-@W;MH:P;=>"?VF F TW9"Q,V3>)_8(H
M0KS)%IF-V%[ ]L$(-J; .AIO["JKEHUO-V]Y73$_V3GR$$P([GQ3?P__]Y9G
M_5.=+0T$&W?U8>#D#&(V^:)32!W*,5V>L$C>M/VAT7Z;]D?D7G3XEII#3'Q_
M]+9*XSB.),@,89G!P?@S,GT\VV%<"+1*VHT <[+(NZT<OWW/I$JIYG8]D9.X
MQF@)IM?LVTW5^,;B)"SD252.:1!D -+BLQ!L:V8E#GUR5Y*3PXM&,8K]P):]
M/%)C#L2@M\DAEW'M5U5J72+RWFK)Z=F91G6=:51@IE%=9QII-4.K&5K-F$/-
M(/WB :WBRPRMHOF^F=8J4AH%#>)Q6L7QVRP V\0E)URG>$CWH$&<OJT:)RE[
M'8YQ&'5SNS:I,20M0.Q (KV0UH#!#$PMYCJ#<!BG50-X9D<MN!&J0L P!$%#
M22LV.Z]3']@\PWWDVT.,#"51&M[Y*(FK];! /*D;%T7TEZ?7LHJ^N/&5Q6(;
M(R"TJY.CL^L;HUZMQ[Q/BFD<QNB,C8YCNSQW-"FRY-TK'!F>D0,^/#N*Z_ZK
MI9L[+V?J=X@$V5';7]GN%,V\^4>LF9<%KCZ;>.+L!Y;R'_CEAC 5YW@M%5B<
M7D^Z-!<*T)2$.10/5K06HP"_*I6&GNO%M9W<"DK F' <\.*'QI%C8=%[2XN]
M=YX5^O+H%2I-$>VY*Y1(^W2]1X[<UV[-E9Y1&\@PH2G<:JD<).D^62]FHE/P
MS'43-AJA@\"NIP?92NF@?:O <T0N1I)'7$&7X-EE#AQ4+HF @^6;=]Q%T,4&
M9FXHJL2Q(%!689%/O6I(!0IIFWB$SX 4)9X0)*L$XTFE\IBD]J.DXY=(+J"N
M0HS*05)\T[(Q8CX:B%!_XN7)QG I;^$ZM: =]),XCG<G<JG20*YE&:,!'00#
M@9A@@3@S6/Q5$A4%)/QIQ"#^Q1%Q"V=$&144F=R(B11"*F=P3S0+KO2,9,I0
M8T^"(*+[S'6]B-!PTAJL3/&([0 #Y?ZW&R#) 2:9B9+A)**8#1?R8]NXZ(8>
M1I[J\4O-D&KA>6P+D]/A8!"QPR\B ^_"[7J.UT]Z&YQ<?[F(NQL 4Q +E&-H
M9-Z;<R(:F4J]%76[-'BT7$IQ TH>/OO!QKD/F;(<0D^03T1X?&:]WZ",V;7W
M;F1:VL@Y%N=C>*WN!#1T<&RI>F<?N]Z",I8RZ54UC7*X$C7P;1H/Q:0()57U
M3^2XJ8E3#O4/Q/P]>#:-0LV9@^,9%5(3'MR/\Z+*27-! C2R ^QNDG>@4O\2
MU!'P^-O=^66JTOR&8S11FY6!^:_I<RN>TFN,__O;U?_#%P"1M,K&_O8O_!27
M$!M@:Z&I]W^/SOX?7%+?!=NZN?W!&/VG$WZH56NU6OTM%T@"7 PF-&&9H;E5
MIA#_?K6)*CSB(5)[:FK_,V"Y>R-:%#>J-?46=6)E 7?FTW)F$Q)[QF[\MJJ1
MZZ(HG)F+8%O-IPDM6%[4R?)IUF9]RW%GGLZ?*OEP7BV0/W=V9_#G;U>< YM-
MSH%'9\2.P&NMO0\TE$?RVVZUE6*>+*_)]9V#UWBL=2:_;<=OR_<(:G9;079+
M;-.X+7JJ7>[%5=(O5VC1>=(:J:U93],X_#GA_I ^(D&^5L23//E0>LD8Y.N/
M+]+M>NN[U>U8J",?P/CRQB4I&^]I[%6;OV3?# _F#TR(GL?Q;R:OP30&B6Q*
M>F8ODPC0850A3HG(C&ZA]B"4$3^QOIHYUH8Y\BB=I[8(ZF(I4,I,2S:98Y%T
MD$$$,>S'YMU5^M0?)G:Z5/+[V= H)"_<7+5/@MAOS0E5 <^5'6?HLK@\+6<*
MY3Q.F0QB430HD.457&=T612B(>S:IO%FNP%\539JO_![:]6]5#N<= N?MQ]@
M9S!O%4S@P'A3WZ\V?L$. _0(NGW6S=2<S'C3JN[\PD\B.&OFN>\##Q&FVN^\
MX>^<\\U\G:4WGZ]QBZ\Q#63&.M/#\X226%G>RD]=T3H<\;_$BYD9"6(]1C_D
MI;3:G,*FDBJ]A^.$C> ]0"1\\>6]4\>&LR8J<E@,K9II^T?5CN3G3*HRA-*$
M*YLJUQ2,,'6(9:-9K?^2=UEJ5/%NB0LGB/69 I':PU><E)W,4T/?E7!3U<O3
M/%AEQ/2&;;6# ?K;&;EV"0H?AH+X7QR.F\AD8 ?D/D8M'6O9U)*O5#%AJ7UX
M])P^L1<A&>THT\DXC]"$N-^(^XQF*A<I_8C*&+$L4T!.. (%B4)1%+FB#KAQ
M*FL'?=GCN)TAUYRH#E\<)3PG:*+"YID$_XMFF#9TAFF!&:8-G6&JCY;G.%IR
MSWT=F%&.EMUJLT*G!MAT%>%^G.)E))TN\7P^RO@BY($)SV:ZVRR>6]@I7;8;
M?O1YE5<-RI,NT(&,S<,)/8MJX&@</,O2H- V=VL1?,7ZN(RT]J2,5<%*X\9Q
M(" ?L?9506:G=BPY8/($Q*.@ HT\:K/ 8HJ35M-T8(5W*0N*1@%6U$RT!1ZZ
M$ B5<5;0-#AD39IK29I2^BJN;MZB)!&\Z%I70SSDHJ1T,8_C7WO.0I8 -\9!
MJ@8)A#@A4HG0TD3;$-%<2.:CH6OI\XLH_AH$;N$9G;DEM8Y_&QNK66:J(</T
MW*=$P"D96R*Q*\EB(O]IG!>%IRG>B2\SKF$6;3?T7-LKI1 JC>OQ$*5H-!2.
M;3N)[6(6<8770)BNZ8P#EJ0ARB]$8@B_/B9B+PJ['JX/L@-& < LH 8?\.;(
M+PZ%?0$<W$W*NYIM/RZHQT\Q+5]*-Y\]G&*[/BIZ*2\]5AJ"5J^K9>01TS++
MQC<0T<QW):)'24)X& +"HZPJX11%W:GNS,PT4,^$W6I]D:R$>G5?7%[*QEW?
M_';U:ZU:;WT0:1.X;;4]K/_9R^0H39X3<U/50O2S&+6EKN;#6M*H-H>,#[U,
M!PVA'F"9NF..,6 %?W+-N4=@0M3-#(N&!*)421!6*B]!3>9?6+X+5#\1*05J
MY86*<'HPAW<6@N,OB!(D->KQ.3)M]QV%U88]BFEP_+)[S"]^9[&XS^@;2D#^
M[\KV<67[LP&7^RR=!/30A'D61+.Z*]F.\TUSG_BFQ/FF\?^S]Z[-;5O)NO!W
M_ I4SO9;=FV(T<V2G<RD2I;MQ#NQK6,[DSKGRRF07)0P!@$.0$A6?OW;3W>O
M&PC)<D:V+L,/>X]#D<"Z]O7IIQ_3O=G;IWN3_CWE:[/S*/9EHU;OEUUPX"70
M1.8DH$D=A'7),/:C80#VM+<7#T,W;-?CDWJ2(&S'#@?>OE4\+>W@?CXIC;2_
MM$Z-5 79"2K%:5A8("YX$6VZ]%HUTZ05Y1>:Q?+EX '"ZT1_H2\WRXC$;J47
MS("0<J;L_;(:[K9I"]<IT']*5GD9.BKTA"Y" 9XQ,U>%[DE27<046V226K3
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MLWYMNB_H>9D7);+W4N.R*,]7Z+;8F@PIL-A4L?N8:ZW6N;2Z"4"688GR*;/
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M(!MU^S-[OM-%O5"@:"88#2Q/!.'*HLHSV\C*8:Z"E@E!FZX!B$S12O\H7;L
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M#,4Z@C;=V=O]<7LS)25=%E+WLOO WBN%]Q^S*G8M5&@, IITCUQ:5U15$%0
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MF?:!C\B_=(X^)Y%G8J._O<-&8]]>Z,Z786\$BYW=#:?YNI/G"PSZZ)N!Q3^
MM9 Z9(;K$A\7(PY>*M"!4WL'F8^DQA[MM,6BTI8(.PH0Y4V+QV3:1S2?,%5B
MK[THT*(%Y^")MP7Z",DLYG]J#Z_ CO/?347DDD,J$H@Y^%LI+&\O&_^R23\7
MED(TTZC%0NX.Q5W4XUB2<<A_*J&#N!O:QE[_KW)X_+"^;MLZ?5X:6&(NGOT^
M,1;9V%@DEB1:#$S)F6F5-[)R.[2?#OXYNNHP[%SSV^=-N3GU?F79=IX^_TAZ
M5]PF6YWRO[4W8)_I/Z9C#<*84.KJ7KF-8+6]M=[ZL] OFN\<K/:?JST-B[I<
M<*1HE(A9?!%># ;V5=4*,6,DTS"?SKYV2H[QG;2D?&TP&-22>MN.N$V8^586
M#Z$X@!IG5HU$CP7<:\>>\1&*P.*9I(;7<A#12=PB7L3<;8<^J^MJ#\2%/\+8
M.?$SY0(1A+@J6//\/ Q*-W!Z?I-NDR?SL&40M;^Y>7I_R+1$*+(6!AAB/](-
M[]]M+/.&;<R8$_8L(K%/NE!&T!:1T3@M)\1[/2)_0G!>07(*_ESX1ZMR@C@>
M^ 28A&18C/]U]-X1@(_>9[EF^V,L]>?1W8X,M;4K-Z(]&Q>VI7"%B[6/ZS,Q
M^/B=E7D1U1723&*1<#PZ]H;NPR+_*VPCAF8/M9;Z#VOU/_M#)=TK0?42U#[J
M%H^\]KU1K C>^M//<7N>"Q;#\OO^W)6+O$>[9EV>Z*!XY;R5;>O0;;,Y8N=)
MZX@RC05-#FZ*8-BH_]F?6S_@5W7UCU>0DO'?@AS72SI7/^/[S(X;&_JY@%#_
MY@:R5#K>9(HCSF<2^H !3V*5W\OHG]UGPD-(E)^9X?FXB$Z-K)?XPK %$X5X
MI.-D<<$Z= 69R9H-<,SR$1FQEE0WXD#(G]>#LW>-_W06E[1RTO1T*%;[MOF:
MM<A[&5_L6SVSEZ[LO<!5^/,@\FVI\??[H"9NL)WCJ#23J#2>)>2H,_MP7]'[
MK0A!J$\0'UN:<'M1I7!H*<:^+,QG2F_FO7\!>*-#J"@-H @Y9<Q%")G]$;/M
MRMA919<]]9!B8O,07),R_PK.Q\8!-(AQ\83P5\ 5>FPB<=+?6F(5:7+2JAK[
M6]&7\TOKQ7?/A9 ,!Z"3P.Z3Q]DO],72+_0&^X6^6/J%EGZA^XR!+U9M_M_?
M])O_[Y-//@V,6"]__.:OV=/G5_GW5?\J_Y9UF3\T:.D'Z1[CA65;$=)FJ6SN
ML04_4!Y(6$EY@102C# RHV;!Y&<B4W.-AG0CP,QM&>^20YIY/XCV5V\"/'\J
M=R*ZQ@A"2>V8 L>Z=QQIDU/DX]'G3-_X/0EE7.7/C7:&'V,O"E3"BD&.@[3Z
M]IQ7?=6 +8ET3[@]5TB.8BL!BVX3]%\9!JVL Y0L;+MO(+&PG!+IA')6!7.%
M[$+R]2([,U'Y[$2-53%XS-3H8(>\88VR,)5"HU*^=K(R?G)0DZZ)I3%YUOEG
MTI[OR2A"L[@V\]>26AL)A;C-5?XK\S<\:(/QALT];$.?<7\7:WV@#^(K>>D/
M^"A[Z"_&V^V?7$8,1K!))S>DDGZ(0D;T0\)64V@+$RG6$W/MA*>4R;NWU7#%
M>V\YQ=_O$?FE0'I40:;C"071LTJ3)SV?M5YAZ(^0\RK]&=J=I&ZAW+WGUEAV
MUQH3<EMMW@NGXJ&6VA^?IF"I=CU9^A\JS@2(F'JDRT1K8M,F/+KX>::<PLDI
M+,</V+M:EIC78?!))'W&YI0Z=)5_FQ5$SZX[:E)4EF;_K&M#-:U"H[@$O""H
MC"G[%!B'P+7)1/N4!CLV+&*RT:YI4DGRPQ8V+331=-2GI(0N=8OB@W8;@FCF
M#(VP:'RQV[07EB]FJ'(T;ZID&RO]]2G4;\1QH[+H;E9K53+=A1)!&W:90)SE
M0SW6:TC51'=NXS]85WVU KU7?S2N45VM0>=L&BHIH_/=UG^1"5B(:YQ9V9!Y
MB:])V'*B-Y$F9#(:ZX%$H,VJL[IJQ)DF]&<-]H?I;XVD:"++4M?LKIE.5%%U
MEB5>;3,EHU]J ._UB+QYC(<=[0?.I"9"B2D+7 'ME4;T]#9M\9H#DTPJ,4(A
MXUF)?EZYOJ8F8=V9E(Z^RGYR=[&?)Z8LL)^3/1W9-2U_D:Y0[QP3+A'Q9E0C
M;/R"EH_?"@<[B=%O:VP;C"'--%-8]T]_! RLDRU_O2+';UM6M= H1?N33^R/
M$*1O'&L"<)\S":S': ?A8-5E(Y8]OT%[<# =_(5JD#GZT(,DCBG,U$/E;+>Y
MVZ+'LR_LAV.$0JW>,MOI ;"02;PS+Q;4;]ZBCY> "4=E-0"?! ++ R\QOR;W
MH6@FNI_8H,1!,B9OE#42>4\2Y6LRZX'#L<C,^;7XOP]B1&+@11ED;O$PGSF+
M@00SFEA7_23]T'^?B&S3]44"F,)504:0^2C8V-)1D>E/S!H*>A=JD5*_I9CW
M5C3/\SI:#2M\063<?G.0*T2.IYV*K>! "70)[Q"833G6E).>&%:1R_$N#A.1
MLW R7%QO@FM2+87[V%"0R,R^9QXR4P%2?!+^E()0(X&K=SN'BA*$7-35IYT\
M%]5O&:1'5(4-R4\ECY%RP-)-^48)65]4\[7RM'5[*V2*"OR3\XJ\ P!@PEC$
MCWT'X(\';0+>_,'!#..:(DU$T>2M;KRS,O J]ML*=1_X_.UM(P -63']T*Y?
M@0E3Z[\V_1T^H.S3X+^L:_8E\#%.>T(M+MJ5($)L"9F7H^1!C$B.$I)&NLL;
MT42!1/TA&P!&[-60AV79%X:A7(D_.0JF16N$F&W%(E-K34$'Y4GR\L:[W^S\
M<(EBZA Q*SKBYUH/!AX!+D>"S%7?'^GLFV8KJH&)2P-S>T8[2)0)E6;6;A?_
MQ#Z$FER*;@*NW<CA'5EH2?>JA\ZK(ST+HE_M*.%2 8O="P(E@ ^17]'MJ:D6
MS5S$>[((AN2#1//+O#8LF)6/X9F%E6T]GE+EP90J?3J6\3:/2F?;ZF?HSY<G
MIH$=B9V)\#EI_A$\Q45S<..(=,HO$<R$ZLJ3ZZJ+I!G[L!RZQ2%EM,[ <XO)
MMF/E,12ON9XV5K0Q*0/X([%?'3F5!YCF*;RP* D0+9TU<)FI^[U.[QV%H..(
M')<\ #J#B>]=>/YS*M<S@>!]-U(VC21O@YB7.(DLD4C;)S\V)"P3M]%RK+_+
MJ@85?!V\<-I7TY4[B!0D><BT;0$Q9.F:QM7+2?L@1C0B?2^[I!@<%\#Q()U)
MP%M6:Q=. 27IHH6 %6#2N1$12/U[EN.D,+#?T+"5A=8/PM93NP:.AMA7$K\T
MZA;!E37%'O5!2F4F3P !5/I@=G <#!JPVM%1.4'4,AH<.J46'XR)CVO=<):7
MK)9R:H_!>-*MX#J(US"S=>CTX>L1,7N<Q SO7M^"2D>1R(I],G5V;[V]G0M&
M[6VMT'+0/>M?^8?LHUV&DY#"('#(T74A&3]9"JZBV4HZR_PW0LN--?['1A\I
M*8N$MS9]6X\27?GI)PNZ\LVA*S_]9$%7OGUTI?<==*"_^NG_YH<B?5R9H=*N
MRVK/D#(6U)!2R.$H9PVK,VW1@W7LZ/"BXB22F*K05TBMRUQK@CI;O*<',2+)
M4ZP<BYM$D7&@]ZAC3CH!)RM(:Y55<\UZDI+D'D$Y8O?1\W/7HD+B_&)<G2@"
M@P/FK5TO+AXQZ9HL;>B&%0F<&#?/EG%"45Z^GN:,L^E3QJV@I=(S@R3Q;BKJ
MPAW@ND#%J6>*2-&P,B!!XC\7TS"::/F14*C>"_.O(VM:=L3HMN?\, %54(Y:
M2ISDA\4'GJMV;06KJ0,%#W4GN#S.=5_E0:76"J+-S4C0X=,,DR9IPB_HZ4ZL
MHIT6MH,<'=)0^E3X3UW'H@K"<RH\9^)_X1IPEY\;YTL64@FB[7[ Y4*'CQ3(
MCPT]LY$5J/CBR-;\3*UC[79N7(JJO6'R"(XL,LE,H%1,>8EF5"2^#'+[0,^8
M#R=/P&4U)7 >ZW\9T-*Z/,35,U%R1#\=NL"BM"!J66C KE:< ;7?YR#1B%@5
MNL1) 9$25D#)5VO_.\'5$>)(GY/;VM(:E+];=SP,4V3"<AJ__R.*JY';&6E-
M&1R/]#&JW-R1Q!>FL@6"V8DUUV0M%%3ZQ**B/DFY6(EL-/&U=,>=K746"69O
MNRVKK@\2G@'69K(4$SG+1 ^.6Q&Y)#$6X"PF&R@;;R!",@KLCIHUPAX0R%\"
MA KQN.Q4.++TC'P%6/+B#F2@]&46&3L4\<)^$-VQ&E3DM&IL4L6[R+5_8<CI
MQ_3*U_S%+4K5+FD=]6?+$>Q.W@3X)UMC^+?Q-(V'?<9'#7?!A!D0T]6;^4_%
MX::/:LY@7D']J,@Q.X ?[:VRZ:VJGC3HI/^"P@NTH YFNL.;")D1:VC#^+D:
ME(!Y9+BAC9=A8;5W&WD&*/MV)D]&LW#6*C[(H^L#.'=?L!@B2BQ^56Y@(^IJ
M?;(9U\;=LG^FA;*A]%?<]E'IB; ?)!&LV!C\U2@H%O/>6YYZ;]G$>[NH">E=
MG*T?4-+C5RD0O.;5%J]O,)MVE"$XC9UM)R- 1IX:,0?1^C5D,)E9[%5:8)#5
M77CSVPXEP\PW!N'>1VU3^56BTXU](.PZ09D\?'Z'8*81=,"W;9>YGTN<C855
M,>^)=H<8F#:AD"T#*@+G%>JY=",+9M /P9=(!BA9 BE<,Y!XUQ)8BT63$)%:
M_=7)F*G"OE?R"%+PK78T!V(-0$U'-J#GZJZ.R%::X_@3?55^DT2G0O==N>&6
M^DBF\O5!<OR*5IXU1?*!T9NW5DWP9UVUVZ'GHPA'9((+S.0#!954?)3*'I>\
MWY59>.%A9-VV/I#>-?8MR]7E=6H(CGI+A?80GE L.GK*OFR"VGM&3P^5*?!1
M")F'D,SPJ'.4B;#P^4XT-FJ_8;4<4<!*/N/?FHKZ^<-Z?Y!-!^[ /NX_[VM!
MS<\/^@#0E/>[>+,RQ"]QA,V^6YHFWNL122(IDV,<[](:3=([DZSCR#3ZC?VM
M6W721D8"<[\S!NN'XP'"[/D+?W3[;7TD\D_)_X0/'91[CW,VWM0@EJ#M'Y*&
MA,_;ABT=%;%?)C1>WQ"W2^-W\S<*[OP.>,\^?^Z#G8_P!5SRV2=?OOSFF^^>
MT]^??OGQ5?XG_ZD;;&O_$1]8K6G)YY@-4-V=F0QPED%<NJ0$5J_-V/J0AG93
ME.8"/QP].9Z -Q753\&'Q-_,=&-N%'J&7"ITY%B,C]OK]1SQ3OW,7.L8+-"L
M)M=-*75"QG/Z[<R_*:JFSKZC/'U'X50KR1N\;;MZ<XODHEBB$!)1]O#IYY_D
MF_+4<_-)7#N?\=JA&"9+SQ*N8_AK%Y.+PR@!J(TB>\])7PUCZ6Y;7MC!*$8[
M?9_5%W7*BR@LB$R0M7(<$.$YK;UCA%HZC,EQ-/40,)S,#L?UZ[(>G;P^3CH0
M R-EIGP8MFEO&R@*!@S[KFY7 (?1'CCET4+CM@XSKT[WN9;\;$;1_-*$J82C
M@T:4FV-7FG=Z;D*RQ&72/(DY981<HM$L?@1RAZ>2BZ8A T$5PDL2"#LP#_B@
M[&4EQXA(/>,+]?/.Q]R1+X],^XSG)?50..K?\3N/QVU.;I]WQ.C$9<=,\O*[
MK@0IHN0CN2[!L3<G/EBRLZS%'/KM)J$Z?HQFR7HYA=_O$3UO3JGE*VQH[?]2
M1']Z#G5NO>R6C=W-3!7,^^T;2BQ])$?A\^]>ZD%(6[SJK]TFLPVP\7YJ+_K\
M(ZFRH3NB;=2#9%L=/O6Q=@#J(/@;/1.5TA;S=X]WS4=WS<9WI<4O.-MX1<+K
M]_&:YO.A@+=I]ZA-KIG5!/6JM9R(Q*2B"7I84&]*1\^=<1](S\J2>.;0]3[[
MZ(03N^:1ZC7ZUYA<"Y^=-:C9N=Q&_N-X6<S$GM0PY\J-:40=^WFX_DV+XT;J
MA]'&R8D2[D[/<L[NHLFIW> 2G",FH#PUGA,'8M,?]PQYV^+@!6>F/5"K9LLG
M7B&5F;W.<,(^Y-]#%KMX3F'&PY/<G56*I\CE627=HH\3+_9TP8N]0;S8TP4O
MMN#%?DD;M>EQ@76R@ D+JZ$#M^RO\RUQJ87C4)&W-K_*Z"( ,U ^(V:PU_1Y
M9+\P-M!:7UEU$^"/_T2_/4F-?Y4TV[P7%?+%CWV='TNX]J_=VE'I^].G%-I_
M+@P_&^BN_.'J#T&SI-QYCW1')>C.^TK5 :?T'H$2@WW,0L>B91H==)QYK].[
M;?XS[+G]V]-//[F*@BZW/I)61I[D(I1@Y98R"41_=-T^_TN+,N1')0J>6R(-
M]_[/WUK_6$\_T4Y@4W4&@R_G325Q?IZD,&.2PH\!89./:CW__-#]M__MV2=/
MKSX- YJ;G7-=;P:O(H/,M&M1!_V"NYI#ANW9U>\__^3?_4NEACP,O"?V[F>?
M?/HTR9S1KV+F["<G>>RT92U]'I2'G1LR::Z/C;SH3>=R1Q[*'4H$5285^W_S
M][Y*]'K(L:;^B]J^0C99!-#S/GEYVYB<VW-BR_X^PR?SYX&7Z&V\=:&F_#CV
MM A%#/<>A#;$S" W_."\R^[7-1M(C8,B\XQ_I6B/[)FB9;2L@[MKO6EEY:1E
M+]Y%'ZR_]#Z>,ML3_:]P/:[\CO3+$\N, Q&(?_3_\2&9MSF#?9'[>O]1)]YL
MXC9-G:;$N[W_+6;\X-_\,?M%LGKRM#+CO_WC+[K(V 4?7_:-OL@O?O?[+Q)-
MP7_YD=^"TQ>+,N2<W_</$3$=:V1(33NE8BHT<B<_3('1,7A.)X54"I?5]4&N
M+HH2?LG:,JM*$.Z6?R8<\'/8]L!;L"RSQ[+,N./STG5&"C*DIZ)UHY+4$=&-
MRHFXSD(*8YS+A.717:&&$FHC%5:FZ#@5%ST1AQI"G1&(DZ)#3H\PBK+)$3H<
M.P37BV5]-$O^%UO6;>U^KJ)UI3YRHE^EFF%)K3*%Q3)9AWU97X]E?3%ASR^P
MJ*JI.T.QD]!CI3D$)1/JK\LN\C)0J:?A+U[T(!05,U.RXN+Q;)1<^!)NZ;*.
M'\DZ!NWVI<OX2 )E)2IQ/?%LHPKMADJ4'GL?YY1, 4<MAOK;H'H")$B-K$GM
MN(-PPT)_Q_XR:]TILG) 'UBY5G4[X2*ZFBSBH/3^@*H.'UZ&VJ+-0Q=/('HV
MO3=$I9:H* 3^DY1BQ+3VAB^3+PC06'=#D* 6_&'B*W)NE37%)QYI9-3'%2A%
MJCE6A8(82/*(3=.D.?-1FA-E?V OBX <DWRLO7NF?<PQJSMEWI4K%:,FJ1$F
MQ5*?\;Z;;?5F/]V-B& 24B\&1[]RRL"F"%"J8-%-[1"4F@84U@QWV!_J4V"A
MZ>UC,?G<F6NG938B4_6OC>:XH59O;3P@-=MMB:-2D\T$J;<OU32 %@HST?0J
M3W$YA#<_'51&+-P,@(/&I)\Q4"<)T;9_=EJ*_CJ@N5F07N^+\0P=S!-6(E[@
MO+% V-@XG!X PU+SH@I.1[>(HDF.<0G$S\+)^'(I51"."61-D[%I3A*2LM7)
MR.K ]=J7 V7^BSN6W'F2[=G'.W_;/-S6?[KJ,KWY0^_*^O!.1KQ)"0"P8@&#
M7?U#V!E*TQ\25%N4UDQ  \FZJ+JP<.]<K^3*R6D9OL\<O(&H(P.K3:V0];E:
M:%R(+-86K^7M[:&&R[A>=^ J9;FS0UEM0BP488"(K5='R#%(TU<1]J@\=B:/
M;1X6'=17^7_;C94\4FQ]QO;@J9F,@?5HSSXB;#LF"5(S-1_4[F0Z>Y)V U*@
MP< [M\'IO^'D09B14+>%YT/7< UQW,;<%;T0%-PG5":&AWD@#-[@%Y5RP5G.
MS7-FXAXV(LSCR+T137@\4%W>VK[WK#P.UVT761^XPJY=:M)YI;0,9ZR=^B[_
MHL'+S@YF)*UAKGNA$8T+C?R2,.V4FT2QE]O*LG+BF;"_US A_8::69A5X/EQ
MAR4:\!H6[2YP 9I80H5^53:O\A\[?.&%REK_K93\__.^;]<,FJ>6A@&?<R[!
M$7R%0;_4)XD(9 AB ZY.KRTV2VZKSM\J_D8@!O3EY+H_V(^$ZQ=R@TQ71GK[
ML[<]<[7<MA*-QP#:F^FDAX_E@ER=L835T+MZ:_F$%;([?HT7+&QU/65]&W<S
MF]D%LV[FR+W,RRW%N\W)[D=O2BC!#LZ3<DU$[!5U*(Y-S3C R@SL"VU0DQ!I
MDK1_G,C;9POR]@TB;Y\MR-L%>7LQ4Z,T0V>2$XE&W1">,,<]4YN#H-:DC!H'
MRP='MGSE8+>I<?"= %N70.BN$;T0=-XAO')-@[&?IF[$> %0)JD$[JW;/ &'
MTPF,R.COLT3\/A@A(9O '":J9TQ%.,)#0GPPKI?HVO6ST11GIY+ ;1*V^7&;
M0(]=1J8_(%+)W;4P_\V'=ED:VG%.8N2F(YHZ]\R8HB>W_N9S+E!,KLUP^"OY
M@'^CV:BE+!22.)5H8B]Z,B&.]D\J>GE5HRV9:,UBRF\KZQ#]MCO?]_@QI MS
M+6@'41>/%@#BYOY6L.RR2')>)(18&'^O<_OVAID5UF"!:@;#TF1X26"-2C1]
M-3VW.',R<:2D86MU-+LWE=\.WN\-B@A+VO">(WI[TMN\T!$E"BUP_@.ZT=WN
ME/_JYT-T41[2612;9!I7=D\ .0L(:F_-A:LA=GX3"Q^3E.I.8:VR>B0":[4"
M#?G]&9YYE=_-@N*N)5*CYM[7J.VV5E+9#W"D-!>8\@,3H6/W@TZJ34O%^M9:
M">X"AZ$E]+R?&?"M\7F0-,HKA>W95E5EH'@O&G(>DN%X=_5.J=[I2J?W&?-;
M8Y5;.L&9$:7J[U1H21;]/92D,^80'HMS6B%I0LT9N3\LU0:]%D=5^$[2"9P=
MTCIDH"A,%'='>R^3LE_K';!3Q+_ ZXH21& S&<D0\;[$62H*6<0Q0A,[8=3L
MI]L3"1.2<.)R:#:)%N9L@?  3%25SEN&L./?4M\%6N#NLY"?+,T7"SCI88.3
M  *X!!&4,*)NO/O>$)E0X%KB-*<XZ1*E?/OU<SGK?2B@L&$BBS/%C4L>PA9"
M*!"PQK5B!GXFXU1JI@4U^E@6M/8#7HIS\V=*VQ QT8V2,0F'%QV'ZN,.3+NB
MW##C'PL/$J<-B,3ZDL<(>K]]Y0=?=M*@Z4>+*HF((Y2!^HPC:,H>[$7,0+4(
MK;Q6Y_0Q+WJ8?O!'+!?L9D9?KOS^0N^+J@DO.^RQ[#!9I4^$*/ RRZW]>3=4
MV8NN(]4C):47,/\SZPZJKT9X[4A<CMAH%P-;L4_+ U:XV6WF(%D6]*-9T&U[
MF1,4W(I&<BK6_U!/I^$T)189<9.AW$NIS]&J7M;98UEGC**_L)VE;(06C)40
MO%^Q#SK/_@9=6^<EB64KGR/:#=RJA4[!\9#"<@/8XE=QDI:%_5@6-LC0+UI*
MFZX]/ 'G;T=Y)"+PE*.?5M.RDA[I2HKRCI?%*ISX]Q:*9&,8G&J+&X8Z,G)G
M1D"Z*NH%*?=M8M N,]DQ0FSIP2 '8K.9E&I=EO1C6=([XEC_!<=^D+4"\W)B
M$+E;J#DBSR8^):A;ES7U6-;4L0F0AHO6U303:PLRDE4ES0YXG)'AD( 4Q$XQ
M6HA]-2RYU4>S[ 37?UG4P$>IQ8M1W,(T]!Q4W("X>E=R^W+:SFC6ITEU$H_\
M14\1 $J@Z9,& WT.]-U8:!2#C?Q4L,9=XQBKL%#Z/*[5SEB3R]*;J?K6F<5;
MJ"(3$8\?*W\CP%(2':ZQNL:%6=:0_3>/T!*"$-C'LFN/C74J',,#HFJT7^YC
M[>)+*X4QO^IG(HI]+OOGL>R?!(!UV=)A7E*-ZK9W:RB,X[HO_<^61?9(%MF-
M#]\O)5>AA7F OIW(BJ31/EH&2VV/@\<L8*[SX 4+2%@H4=[YPP=* A(3 XS.
MNYAM?1-YJ1V)3J>8N:3V)T)2;<=TS8#!)AC!B&S' 7==$HB]7*^A  6W4>&&
MFR(+TFA%7'C2 -T1@S(L&E8<9SY%O,E4[7G]39$&%JZ[P%0?PHC\D@0_?-/J
M@J2E1XY6VX5R#G64<!<SH[3/KH7S"YA I'>OVDQ6K>0\B2$*41$(?<H.M232
M#XMWJ(CIM.TV5']2LAG;(.O/Y*'UZUT4&]P.RN;63/J?]M07"_;N'#27F[+;
M]%]FTQT4]D841V/5ISJ=$(6IS&V2.+2Q,TO%,NM'$"5;G)+.WV%(= VYIR;N
M7Z+N#-N667?XMH^S=_?3I7?W#?;N?KKT[BZ]NQ?[.]0M '_GY(;Y9AUF18,P
MHVJ HC$Q-9L)'5S"Z+3QAK/-N;_AQ.;3= /P-S(Y,A:7Y$&,"%XRFJ% PC?I
M=A%!#S#Y[%$F#0O%NQ2'MF*9D->N)H#Y.FHVC4SJ)#TNC(+B1'#SS 60\10&
MWHH6'^LJ)5*%+\J.@L0<B(.9Q].D&^",W9,>M)K9:P>%1E_:52#O=J1ELB9J
MON<]]<1WN[*16F]4?,'>3&B,[K$K,_$JT.4;YI%V(ETW= "!%.I8U>RIN)\/
M@6-QSEODZ"/,Y+H\!'6M0EN!T9C4DTP6-_/,603O)G7'BJ_G']V_32K ;RM&
M*_5MT[B:G5&0O3"2*6E<HHL@RS,.J@R:.:G%A^E0,<[T:WYF,,NI]<,"H+<_
M3?QOCCQHJ@L$I-7&E1M*RNHJG-8CLC2E>QN;MJ:$4O-M3Y,&2%H&TSXKOX)5
MVV: H.?X1623?<NM#TQ!4Z/_RZV/@PN)#*PY@WX8N\U4_[@E'B]06OJI8(+Y
MXVI?];VR5-$HBF0K(Q&3C&^R%:6U33OOJ?L-E19QKT'&*?5R42.E2K@T=P>*
M6[[G*;YHCNQYLO$09^8[G%H!%:)<H'IHY=]&ZBIZ-0T3_NBL42$H-*%RJQSX
MRYM)C;Y'Y _,G;:^'14I)Q? #\!X9A: 4APES_AK]JP_Z+/RS;M4D&J/&VL<
M;M.[UX7D+250<'ZS!<'9Q0-Z$"-*N)(Y7=*/VN;/O?Q4>5K70E!:GBX)-G.C
M?N,&:L&)-/L>ABKH_B&-LW*G5L]S3A-=!?X$XX(SQ>[AX$I:FMY<,[F&27H>
MP'!"F10[(EA381/.(,' J1WQJ$AVFGC$44\L>ZZ1!_;(J1Q:(1IU*59$DSBX
M5W_=W@K1Y7008+?,B+T\ .U'0&@&UY%+Y8_ *+_35QLG7Q($WL_^$,0!_Z6>
MFLJ9[#T75TES=3P*9PZ./I-FD7#JEF+ Z6#'58B)@.#7^ITOM4/,_]M[SVZ@
MBZ/X:IO$Q-&JPNG6F*.)?NG6UTU;MSODZW!W/4R,[;%31P?,RG$.RS@6FX7X
MY+T>$0Z:VC4[)(*W[! E;,G!:1N[:K1(Q#4C+B[)QA)J8$LP06QARJT:[@T0
M*U4-Q0322K@ZD1C&A&OTE-^4'3=)!<W%6MA\0&&0U&*E![CQD\4"BOJI-?@.
M>2C)!V1#198H4(-V$$0B7Y%#4W8+K>;CV10U,TPYD#PB7LQ?-<S*>WOMR#PE
M1W9)'$>Z2VK0!<&(%.')I,<Q&YG^,D<:F3+8]!88'#3=C@4AAKPEI_?)LTZ3
MR?!DL:3*M$*/OC'L#J2(:MS4C+A8:G\Q3I##^9U]?();541Q27JRRG?IK[:M
MV$YJ;&AZN1F%%6FCHF?#_O>A.A!,)0N<\&.]Y,7*O.<C>MED"8%9<N55N7ZU
M(UP0,NAM]Q_P/@;WFS^:JI),AIZ=_3GKHB(\@=,DQ%E8PX=C1TH[!3(*RN8;
M<QC.,KO977_P >&3<!\+;#("VL356U=)B:IW"?P*#AB"RYJYX3/2B4C"/NDE
M$/)8YC/A*MTX.!L]U'DA\?RU0N+9K!#M5/R"TS)E?8L8E/GL)$/C)[A(K'B$
M](J-LH1L>X*"51NJQIU,6BH[-K";9'Z\L=C+V*.%2\8<&\]&O;W@?6PLAIU<
M2.K-Z/S)P"6-TQ+=OK/H]N46&]"_!!S.?J&'4QC'O6M\C%'3L>$7HBA"YQ*7
MS#3[%7?D&N'!<Y9VK6<'.=#LR =H;C9[H' (_>$9XP]O1'!B!34M_JIPP,SE
M%Z=  E(,4/R Q.'SP>64HXM7*XEG:MHS:T H2?2S807?7B/NVS,['-E.CDS]
M^O=!83408H#:6]LFY"HM^YS=(81JI0O+[14D,9.M/NO]+5Q6"Y?5@@5]0X_I
M-_1E=#NZ??T3J1XI%\_$!N1K[Z\ 5 QM@JJ)^$$U5 N8?5E;\W_P7>4_TW5V
M: ]PS(G$64F?&4Q1UJ>^ZO7SZ7D)T8VGO_^RURK\94PE6JA?5NJR4L]8P:[]
M&?SII\150B \;?5<EM&RC,[\V3CD:N9-V+)J'LNJN;1),%$@8RC1R.RDW<$6
M=4Z5-5"/<O',1VB* X\A6W%Q^R9=7)ZJ58C1I$4YI,WH=AQ]]D?)KJL179;]
M8UGV?KF)\LBEO?',F;M%5H#J,[6; TXM2^G1+*5_P8+.@6LU]H!"#=DD_'I9
M3(]D,5WJQ,524@@$^'#CU,<XD4O%.W"Y$;96K)G\3BKP,1/\[AICEUS^Q2/Z
MFKDOYG/<J<ZF"D1M!+%+H)-0^A3U7!&?\,O$+PAWMH9DN2H5ZA174!;\,8-^
MF2VV&J/H?T]E!NK7.PO@M&CK1]F^]]G2OO<&V_<^6]KWEO:]"ZOQF,9J7V1^
M!H&S(N/F;2"T#1O  &.S<6(ZM?\Y(&R:ICU*U\+AN*JK_EI:E/U3$  /_X6%
M5G%ZE6HDU@M']CF(I).:=-DEF)S2WY#A>\!S;!5M2 U0FV.GS\)6/)X3RL]B
M"9)4V8@Y-Q; _(,8T;=^-65V-86.)%IO:S!K5/VZ;GN7+&"B>J-%_IJU; #T
M*W(L1&<B7DHK)N(1-$_"@J5+AQ:V@#GG?C>6']Q"0*#9"65 */CWXW4N^V/K
MCR%&D9:\4>"0=.Z:I4R%'%'[%FE@7=0YY/*/<E_1 $^Q'8ZU5/O^N%>5.F29
M]J7\PT_)6@I&,P_;TX75C^$9<30C<0IN1TIB MPCW V8*/!X+3'4'AOQEV('
MV=K/!__+W7C7 )DVD"_03J4N1YG=0DJB]DUG^J;U!:AY8EH'>BJ@*5S'RT T
MQ@P$CA,C?I&%1=%V\A6)9\-4,'<&L/\J8X;+<R/B*2-X6K@PJ91%>C1Z7S0U
M*^>:.#^$7D[&OD'#Q?G%3.]3L"5SMC*[TU:.E>NM510\OY$JC+.@W!/3@^+6
MV493.0C\(++DQ=VU/?MK!6MA@2N'QKH\T@@8,C-Z4FR@L!/]&A% H#[OFH#9
MPZV?Z>RN.]/DQZOR09+BS]%Y0^L>JKW,XR1Y#P6DNJWWG'[=[KGE++G\+#EV
M@'85&7?$V&[L:U?6P_6Z9.G!FXJ5?KU34YZD28H-&[?_$+YUUSD7@;ISAM6-
MS&IA#4G61CNJ86R@?"%*1%?MK@,W8S>H$ ,MT[ KJ477!+*L)4I?@RTQL(!P
M+HB&$EE2[:#5&D3:(UQ:8;7T"FD<RZJ+_,/0"DZZ)-2X)%2/4WBQ_R5I3%#
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M.,8%I::Z0G[LOS..]"AJ)L $TUM')V<F_!-\NUI)JU.13#)I?ZR/7,:6X&[
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M:RC% (>NNBG7)XE!Y*NMCSP5U&"I<;CK/.+M2BO!II?56DYF'NZ>X?CY4O-
M50W,G;<V/G#BYII7#O0!(\[>T*5O8OHB.]-/'VH-0[M^%2Z&"JR,9FXZX709
MXQN8C7.U'[7[F0'3Y+"2MR%>#_$J%X'9:36GQ #'I$FQ)=QJZN#4@I\?)DC:
M.O0AY&J,B(["$))""^1\)TYAP]/,Y*UR/,66FR)6C3SGJV!<E_L(IXTY%$[3
M(^'CI*(V7Y C8F5A"]L$?C#;+#7SQ:##0?[<#JTD3%'D&NJ*XJ7)"9O\HR1
M3 $[!2-SB@C+\6\&2@9R)/C]=)#$S\=?6B*H6!M/YM!_Y[<X7BEDWET/ .\
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ME=%0M@F]4*6D(G5HA?;9N3V(ZX2*AOU'/ZU^.-6:R*_281C2@2+0Y;U^DTU
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M=?OZR]1MXX+JU;B_B'^U![I5&+^U 3<C77"'PO"=F]VO?+"D*J8V[ON#=U2
M0P/J-^2I(I)8<)>F%5ZW,@GK1D.1V<9/'_B#3H#MD ]Y8JP=FJ2((,N,2^^=
M=I/'#JE"A![3#M-H[H0I(&M7?AJ 47;4DFS9A\TF9]MBN_I?_]*D XZ>EEY<
MCY>].U8; HO;$SJCR>5.-2KC)_:%LQ,%M7CT/9_;/7T.HX9 4-5SEN+:U0?Z
M6!T@B3B\![\^QUUS8[NB#D0F#H1?<T%(?>U_X==*2:4Q;\2EL=J:VC4E2 [>
MN(O@YKAG=\:EV$Y4S &TP?D 0ERN+ILCZYXK-RS7Q2J^UR/"(9[Q(8[U\;K]
MU">GHO;4TA%*S;;:ZH6=E"NI^*KL_0HZ'+O^6++@Z"3_Y_WI+.XP6JBPRM3Y
M/VF7ZAP96,DIPCOHW*@QGBT%_ <T'U-O 0#[+7K?S&@T\"=/'"="%MCZBA2N
M2O1_Z&,V#5XT4A'AI8Y!*")J>,!:4J]K_C+=-&0H[<-E;.AI4J+ZE47GSX0-
M$A44<Q$#L]A(O4/K[(KG%V\T?)@4)O%;R.MR00/3*9>EVVP@TL%3T]"AH #>
M9(J)BO.69+=(=-<O3S#/0\\BWBTV>U_E+YL\'M0V>$)HWF4;!S6KZ<G6M+D_
MC7>DO8E^=OR.6JQ# CG8I#Z@P_W3>#.WF4X^:VGQW <1#Q/%"2F*"^M 1C".
M .?[]C!529O?DAAX9XF!ORO\-.-%P<)ML#S4>6;J) :?8E@]M;;QWU<_7.6;
MUO^ 1>K*)J#K58$Y0N=3W.M,>T5VY_W8G?S'L:OZC91HECS @QC1VUEMNR,I
M&#@W67(CAC,*XD6:<(;AB8Z5YC2SOHB6&;04_M!AEARE>TZ7<C(*^ZQ!,[X,
MO3[B_:LDT\PNT./LW)HG6C3W<XDFE+0EDE.^),<T _.F+,MD<OU1EMV/Z8T)
MRW)J"-2#@&DMFB-8>JA'K[!WYJ-\WUH_9?( /&%M[S+*&'>_NK[QLITO+3VH
MN8X.$73 _$KQ(?8N7:W<=<G!5EO?N 3=(:)>25>H^EH(LS8]J?:XCF@H_$IB
MOVM'$1?)VS=%QCU=9M=9B*Y!MAR\=SWBVJ(4P[AMVSNU8Q",-*!)YX9W^NP0
M;2=U<)17IW/XA'.;^F7#/%7I[+7'H6?'3\<VLX5Y7ZZ<NF<;X;"J]BL??G!J
M0QJ.*U:;'M,H]F4M4^@-J7T">JZ^W:/#ME?2H4,''5<UNAPD"[K5>WR4XTQ0
MK6C'AM&PB*'(KO?A[(L/;Z?'@WON7(A-L43> BXD2B\Q$^3T"\G69X&_&-C9
M3!H7&HM4LHM8L]I>>$6/>E=<A8]D"EYP''*(Y->EL&CSX9,N21\8B3IV/'6D
M_11GO33?'K23EULV@^N0C 1JM\CD-R&/1"<@/>!O:2-RKA5%!#\^G++3TQGQ
MEG] B9F$357]&:G$!B%AH[GL32%Z@QEH=*SUYB;;=MZKTLN+=O ;6K@/"EW^
MV2<+NOS-H<L_^V1!E[]](O%W*;W\YH?RC3?8&;?<JZ'T)XYP<D[/FB)-+02'
M0F65S7?:52VY?3TKP+5R=#,% ='?R20[-G,D&4<2M8:FEZJ&\!VD#^-_7XK.
MY-D3Y=RYV'99A'6!@< _]+HZ4#K5SX'?.7LI%L];]24E\B!&!&A$,R8IMH<S
MM8*)CTYN]^F>RSY93<R1GL3GVD,)0N3UJW*'OV:]_ZHWC44"8"Z8VWRH>OZX
MAO*%CQ?@[.&'?L_Z\^O)*^<.]&\CH#*"]VO,10)K"9) N"K@X$G)./UFU0!"
M+< DVWX)-].!>XJIE)F?;^R;A62,X?Z5K;:]F^,^,W';*$,_;X2BA1E[PY.7
M@I<_Z;507A*90YJ&)5)Z$"/Z:]AD3FBF]_8G2B?G?P#7O9(-GK+<Q,/!/ZO4
M[)4([KXI.KO0KK+G:^Q.OUGJ$ZW90"DG1\CM=;NGM=QVKSB+H$N8$$4XZ#92
MPM^WC3LIW15P0\B:HB(*25ML)?,X<?6;_9J-[- A1F>6&!@/T+7+<G^_1_2\
M.<WS8ZD-4U]NE RR)]S4;S)TS,KZ&-)4*:T:79=]MC'09Z7A-9-,!*[&4 95
M6)P0J="*X]+ R$:'&)HXGY1O::9EK<C&G/V?S0J)]\?NQOEC@\X%B*:T#3'Q
MLNB''H*1B/Q<ROPJ?R')BT!^"' ?)%ZNVP-=6B% 4ML(TZC7"DP*E)G3.ON^
M?$4Y0F+9IO)P]!;B$+U=J*&F2DYV!\D$/[F6BC$CJ*&"H(0?Y$GG@#<D% &Q
M8*)<2*7QB%L0_<M66#H9CK3N'*=JM;7+U%JV,R?M?)9&' 0\Z(92DCQ>+@OQ
M4JFVT<,FWD'A>+;OH'-,&LB%#ZR#J_POE(T&) , LA,+N/FXHCWV]2D[-J^:
M]K:YE_.>IJY%5^9&G94T&.B!H"#NT0 I!=&XS!-GDZXK[YM!]^*4)<=1/G8+
MM>;DN.Z_C:(0]XA9BCR-FS#V7I$F=A-GD;^#L+DD[2,+/W7R]DQLQO[A&4=R
MFKRGRQ(UJ;TRLZ%JCU^E%.MW,H0H#ZCY*6-#RJ1M[RK_NSBLFFVC9<MIC\!$
M7TAA1+G7P1;R'V_G-%BXUY:^]T?2_/:OM.I&ZTV-4&-C.)$.TI-GVCH<H+1\
MN4NUHV_:^NA/(#Y(]SB=R+K&TP8PXZ4+_M$LZBT4NXM?PDSE)Y!U9,%-W-:L
M9C4Z'Y=U]%C64>>VQ_Y".@ZC/31$A ]2 %*HC%(WU RD%)6]^?@F_1RA@R]]
MB&,?J1MZ80CW+F4K@%9O@/T-D(&/8>>RL!_+PI:3\3)>!%?];P#O#8SLYD5%
MFT28<(#D)]P *2[EA+$[B$K*?+3VY65,AHMV_:-9I57SCV/S2US3+BS!&/ZN
MJYN*2)?6'76_U;&^N# V/* 1J<P(ARUU0 @Z@]:UY3E3?)M":0.2*3#M'NH2
M&*$DNKE2(>Z0;>6+D%J4=#3/95E#S1SI0ZHAQ 2;1#^:XI%X*%R!GM\R^?=U
M2QTYD4R_W)0'2X>958;A:%0,]Q]N_8>1SAG_AF1"*LE81=)^8AN0.\W OI/B
MA%3O:Z"/D2:=04U;50."<JO<@RW_,\,!*<Z([T)W]9?85BI(NW2[O">:]2^,
MJ 9>]=^A-";;Y '#:1[Z>S)8H)035_85;?^^,@UTO> BL ,58J.?YC[@7>>H
M[4Q D0S/9KVL4WZX/O7>@)3H[U0MP"+)F1_*4]OUMFHJ> )EDH ^"Q$[> .%
M]#D2.5LJ*>D2T_:G!9;S($8DL!SU]6]#,[D6-.<Z:U1/C1I"_?*H48#0!;G#
M09"H:=]W*69F*>;W7XKC_B ]6$752CD-Q!\ ^LT1,S^1!8!A@0Y/Y3IP9>\G
M,K.DU-1W81N%Z;2?+53V=@8W;7).@KEDX_<T,#LU/D*%V3 M12J!QD)'5D3<
M)$E)_*@?'\@K1U5&/81KIRPMYZT"\0*<IN,@4:!0Q1KO\!+S3' @%I+G1O#F
M2-*@_I)(+/N79XI[2_5GJ?XL$?:_\IB*D;@T!6-*M4:ZS)($^,B:>SF\L5_X
M]_//GBX=$F^P0^+ITB&Q\.\O)]$'=!*AB_^B0RC*>Q))X AJ8!S-(O;FEL%-
MQ4*F!MREZ/5HEA@3$EU.]$Q@4J+2VR9M]D0+%#T>P:4I/]VRL![-PKK4=B'(
M]:=E@P2':JASQ_)4!)!)\TZ4NH]I!TI@;$W"@WFY7+_NJ@OI[HF!$IV"3/M'
MPKYRFV4%+RMX_H\W@*[9 1^]M9D\T-99/+"0XR[K:%E'\W^L%\<L4R;':Q.W
MU!- K94FW=@K]8WD/Q.NE@56LBS2-[-(T87BHP<D&*C])72,<)J;F(6$C'A!
MDCR@$;W<9DF)])=65K >0FTEO[RVDIG:R@,M/'\ 57._&JAI/*(:W'P5JS_7
MMQ[:X[6U>(=#JQ']><'.,"8H\B ?NNH&RX8JDP&,P]S9W,F@3&'2TBN<V4F+
MIX8-D5\\6=@H9/987U5_+5D/_Y6*^-7B,^9(Z _2$J;\M1,:LBL">JR.?=7H
M^8M?;X]HB9/N-:6E C\:M]_5I[PD"\FD;D; E]H;S=PL%?X',2+#-Z,+Q/MI
M#2KJA%8[PU8[5_6?HCST9!VWVPK7%O7:2HVX:K(:H3/=/G0[WY15K:ZEOU8%
M30^J3*L;>8??J+U(8]" ;2HUFX9_F6F7+F[_/\^+_*^$)^CX1OR/*C)R%_FG
MGWWR52%4THU_(+ [$K9Z5S;5_\K.MK0;5"P'Q9IW. YN3;H!B7U)O@HLH%HA
MP\SVG_&Y&0II;$^?=ZV/VAKL59"S,_ /SY;[']=RY4 !Y"T1=7/WA8K)@!<Q
M<H+C-,L.1V]SULPV&6_=KSO<B#M\P9I6KMV1?&8R3GZ"K_)OB!VAA[$@/I(^
M2-8H58FY(!&X,0A4S1M,6'G";\F"36X3\L3AG4+AI>T!XE@'?G?AF2#9%]+?
M(5![R=VU9(-':P?=]^VMZT94=A]55^ZJR/9^OOPU;UID#/F7'P,^#V;.M3YZ
MH0A-O\3=@?NACXW.L_XN[4.F"6!U65I1K_S%>.KYZ/"C!+\$SV(&(LJ!]CL!
M4#?@U;WU'NW@&K$?RGK.<C7KZ_%E"C'P8^M.AB"<#<C!-P2*J?;2Y/+KRI@M
M=OWB$3TWIC,C.A*[O 7M9(_R (PBQX>]@&M7UL/UFJE92+=5.0J$)U\U],#'
M*+P2/76(Q&]:RA-\XF6SE83H]TX)3YZO!Z$<TWW1CS8&</_"\8 -W+/"TPY&
MC8#%6-6-V[5(?T;]*#7>TD'O(.*W@A'*N'L]&/?O<.A\96R\_NSKP%\&-W*\
M"<FY\\;V4-*/96"ZP0F!SB>)7"N<6KLR&@35O.!'+BE!K+\3>\:]]3\ OB5&
ME*#79C<6%@I7=BZ8;R*,TL\)S57B8ZY9!@A"/1F=36"].0YT:YXE#&!\\O']
MB EW?+>P1!@JSO:%!,/\5*ZZML0U>[<+I%,L1APSY>(T*WA=;_V$=7* 6_MA
MX%AN5_7^*W0S\B5H5B+K% Q_NSZ29RW29P'Y)T<>1WM@-%F=],7RI/LWG?EY
M:7K4A9KU*7CKX1*CU;"$?.^+[?MQ!K.,Y:$<NWSR'GOA**.HT! :"J%&XE/,
M4VYT$44?C!\GD"KO5JL#K%X*T6 9!3KZ )W,Z@=.JT9 8+<B87*:\EBKU0QA
MFO#R< (?&4S1)NW]?];,Z9OM4N>1RYW&U,N4219%78M[>=QCJNN6<FVA?C]!
MF&;"Y36.&VYU/$+UZ_U(X?4/CU$%KX?Y &.0D3Y3N8<A-9F:_+K:7?O#@^2-
MHO!?)BXKFRV-?TEBQZ2R.^?-34,*:#ROKNP0,)#.3U3@82DMDBO[D#;6AV<J
M?G)$+PIV07G]*+[R^44Q:B" V]7M"@?%U07IH?LG?[*WFOR9;DPV&-XQ*$?.
M?I&]\4R0;4Y;#LEWEA?U2QU&,"A1IW3R>&\^HA:',_+$%TDF=4;1)-:)P123
M8K?"^>FO[L]D^4KFC:BDD4I5YP*!5UD[6JEKM^0.'\2(7C8909&%%VV4;Y_1
M&$BX9V=D/[@40^H=QZK>F)5H5EW!*Z60I!:87+)XO:9MG@QN?<T\+^ORP#&P
M]L522J7L.A@K#D"DB==[C)1ZQ%Y@ @2*=QE(T[ONAE,ZD[J/R9 B5[<A^N&^
MI=X:4'+ %61[K(4&YLLF!01A$WV"\.FXUQU%'U0O-2'='@); \^M^]GY4 V7
M:K&5.8.4\;S0$W0<GC'E&Z>42#Y44GZJ0D.-S>%PT8T,EC[>E/Q-W?7II)H2
M"'.UPK8@V"?2Q%\\U8]3?N'9TESP!IL+GBW-!>^@N>#!GVEDF[Q?5'9%+(>P
M;#35E0]NJ$)6?>R_>&O6MTWCZE!1K1H#CKJNF'B'7: $FA ;).E*WDM"*(*@
M@GJOQ 'G8H51O4EX'9BE1^^<%'<U3\57O\J_/788'+I:S3";=J0CF$7VC+RE
M0)D;O#%VT_,:M0;[],BBEE<)L5I1$R?X?IVP8D0VC'B>$LVP\2JRL^Y$8"@=
M>1,)$0:I(O%1IZ=TXJ+./(NVZN+&X?PC9X-?=N,&4(7W<B-\;+P*-(LBAYR?
M#YX,9"WF<2?PG01GDD_>I/;V+W'4N].*/799B);]GG"=5@<I)^"W>T.Y+ C]
M]M93].Y;6?':$H'*R;ZJW$RL3G7XO=\PHO$7=]15]O=C*%'6:3K*%KY!R[T/
M)..,C5H?L=J(=F=;$_#EK@>R6WUH-RPO)EN0$P57V1*T/801@79I:(>@RS9Z
MV<KO ]8E@.?$8/LEN"I[)[W\-V57.0%.]CYR.42&I+#4K&TE0G?$A<J.Q,48
MAA9,<MZ4=(WB<&.;3H9>D"&UDW(@+\5>5S#Q1IRHG*5P8\L5/LJA(R<1A1QG
MA'-9R7&R,Z<B*%2  FF$,D\9\ G5\36IKUNU8!+\DQ3TI:ZPI<T5",!MG0&,
M?=W>@G#2%VBG'?%6>QQ,GK%(+BLHF^AXV/>R1GZ^"_0;8E- 1<_4'[@!UD%[
MI.?=<RE/FZ:*I!ILN#9.DJSGK#P5IOFHT_-OP[@=N70V>!>_G[]&2X ]%DGM
M#R :SSLR<NFG:5+2<6[\4UY[CZH\]I*]Y,$J-$6/Z'S7M;?#-0)[^81]"D;0
MS5O?:'%)$75FH]%263G7 &C.'B25(!D/1? :KMD4_O1'I>:$\JP_!33X'^V\
MWW)^V-AYD21NL9+]HFB[#F:>"D[P..B1RYZ6HZ*>_/$D!X/@4-BU,6N&?,+)
M2B\,CT!8,9R 1H6FZ^4,I!2'7Q^ZL8[].&N8!Z2*7H:PM51TU7PE"3I@BKR]
MY*(:N8R"Y)E4@,;;MICD^O,-*[R,\6:&^T#L#$D5I2X]@^+(@$36HUDQ$#P(
MJON&58Y\8,J6W?5NS8OEEQK?4\(+PQY&EN3S7^>A+)[D>\+#]M(;DAJ>F(\H
M0<#F7YM?8 L#VSNNF40.H\J^H(.^("%?EF/KNZV_1A=,3NW*J#%C->9QT- Y
M+B?Q%NQ6?6!R'JL!P[C4+>,);'C=5;MK(N0G% !7S37%*S" 6*Z;J?8MA98'
M,2*_##F#H:X!5XN#7P9%G2?7[6W!(H":O,>OYI;G5?YG=PH7(!>9P- QQN-3
MM:$$S$H7:>Q:GAS;8Z7&V4UQ\"?RL61P+1;T?YJ8\B^R\)^#C(QP$SDTM=(]
MDI"J_;*MP@46^@IY?[$@HOI" !AK[=T(2Z?UK;-:HP_2UGUX&^;KJC\<@?.$
M9T38+Q].]/"WAUNXW"*7+@O3.VME)W7J.1-O6H->NVX75KN%2VAI\'U7; 9K
MR/TAJ<#&?D>%C(W!,0>I#-VO!HI D?P!E1F<-T\TZ5+Y6&RAT'@\B^[V&J2U
MW<7,0IPX&J1[B#WR<RX2T]>SPB#2*_"_W-D8XS(:F*U9Z,1G7PZJ[S@ZR":;
M85GDCV61^X5YT:HB@\KEV94N&PX@C $5JTNKRX)\V/P2D&0%H51*IT6T]&4/
MX@15>ET=%J.\K-<S?S8^<-L1VJ?UZW57FJ8P% N,$3PR'UR(6"&8RO "76H:
M#?[2)9OV.&C_[5D9)0Y1J0,J@@=[_Z5^>Y(*3!C=92=#G(DO%YZ<1[1Y+G6C
MVUOT_WL#RSWW-PPZ35--DG%!T!PT/_]!TMN &:FDF&PNZ]5<R-@C(?CJQ/E4
M\6KX68Z1MD))"Q;>G@<THI?;;".)FAQ)R#/I%X4D4,DQV.D#%8X'$;(NJ^X\
M*,[_?'WL.GR:OTYE2(-,1O>-X9-%UK$/A;75672:PL/&!IY;H4-WS+M-%"[K
M\I>FVV-O,&403? DE5J"M91[Q=>/O0O_W@>G?32O6=O>Y J4GO+G#  Q1G/R
M!=D'BJ'4>E.PCT$ 2."E]4F?)Z=*T^SC%.,]E.(O1]UCIM"$#DG7/4[,_J<+
M9O\-8O8_73#[;QFSSY5M'>BO7OY]6X1O:O!(S_#$QI@*H2;^XT0$^XM#= =$
MR9&K073N"]8>L99^1),;2DTA%$*<[5MJZ@]N1'+(ESG#,W%4SE0'S,)(ZM<"
MN  2ZXE^ZY4IJH\PTVC&,_ .9:-1D&.(YXO<#\;U0]LXI;TJ\JX]E34.YTA_
M%G-N=GFW*&RJ1S"W'Q@B:[Y2Z-B\HYN1?PV?)B3[M/SN;+H8SR'C9P\<@%G:
M+XIS'W=/:/.$K=\+[H!1CP3X4\\^FW5-0L,*[\^RD9LI*Q#M2W*[8])$N#WX
M'KJ[X5D-P-&Y#:'UB!'N%NTOTJ-!+2)9E$457IX(2*[+VUXH?I(>=^G;5"""
M812Y\6N;!5)=0PW.+%MA$!RQ C7-_K/E6< %[[IS?M+PFU(BTC+GD!/_-%C0
MD!:/ >-)Z15F\G\SP>ARICR($:$U:%U7W'L^(#:RNSNP<4@RHCXI<>0I;:4I
MM"_;VI"9A2),-=PH'G/9L'$9*5=2_AO@;*(<<H-9C=>N)K.85&JN\N>D;NW7
M;RT@>T; :[8Z]*$Q%(W2Y$K8.0H=RS4]5Y&9$U(R@GP,31_J*O]I)N4B%V(@
M>KB4@--4&!YT &ZX;C>$^SKBE(H%5C\=HNEB^C'FXW&9G4@=&CO5)?!6X#FB
M];C'.0LU[Q!&!'9_E<D(]706LGSA2^")D2'VU"8I&'T.!ZF=HLNI(R3\5+)5
M(&FDMLJ4$XK@;(E[FJLY<XP[7E-7J&1JN6LC3BM9-9G8\8%]W]F,JUQO*;2D
M6;"'!F=/</ER?:U3+@V4MDA.=[_S_?$,,-W)@*DV&XF9#T:,31EUA_I'=<(S
M!:>&Z!-&S@QW2AA-Q,+<3$Z(+4CDB*CNFWBUTEQ,W[IQJ8BA*ELY(K!P/Z_K
M(R@BI#,7##_<<4.Y3&E!IC1XX H*R2ABOVCK=H=5&]*EU&Q!#4LTJ^2YV12G
MF!%\D!B1T.-JT)-#M7?B\TA;RLC#"V$2TQXRB:H^R:\J]KZ<6Q>/"#V!)C-.
M'36L+AZ M_<TG#[(*6./_ TM^[+0#+E_WF!*9=VQJK)2CWCOWZ\E"D1V*".Y
MSBXXZ7W=M'F =:X<AV7,RH>&F)W0BI@S1T^0>X]"FYQP&Z6V3(U].?B;<?,9
MM=W/LN"<00GG?QV-V4P-[DC#3V8Q"]JL7"<Y]MJQQ-R9>)>%OT5_;::+R)IE
M$H-38DGJYNO2EMU%.63\P_N9SIJ6&I,X!-7S<-PK.>[?/]1N<&PV$X)6*N#5
M [4U(<6^CFZ,Q9&X,T&1?XRN/3:AO?0>GI*\4.7$ECLN<=4[3MPISZLN("WL
M@0.W;JD]3[Q/O^4V8 A:=VX8.=;!DS2]BNS WB W/R&C"FQVYI"K3]FF(E7
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M-W,9))3E*B/.:4I!*X=0QHG1[;D/FVU\!ZI;W>,(=PR,UJH,Q[:"O)6K_'G
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M!C >L,,LFB7K;NU)%'$(6Z[.TO2J=F1_*$9T2.F&X1Y82#=)RMV%9]JD9%F
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MW@[\G%,8.*0,DPN&5^R59 T$C<D1E2_?EY2:J>"+"(R'I(E(!@Y"J%:<.E_
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M)_[C_Y@58US:PSW<&O!O9PL<YR0J<IA0(+:)UX 'QD<*.,($_,16UZ Z+<-
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M^>7OI(,!$AUKA?Z208V//]>?KT849#;T1GB4A4%<#7((JH3BH(C[$M/SGE!
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MY;V33!C-L3,$-_\_H18,,\S[_K25[GD@Z%G_)X2L;?2:FEA7,O.>.*#P",%
MR'4DC=&( 2P^?%2)+X/*WR.N3JYD3G2'( _!K*D!<'28]\ P[4,;S7]_%)R7
MJ5(N^5X,(EO^)U9*@8P45"=P:BL@J3:FQR=(1^^FQW!9D<G$QYYJTYR68M6'
M\JL/FWMC#&^3@HLI&KF HK%A ;:9<V[6IGQU9+TU<@-%&W%#1:$Q*LU54*9"
M+ZY\(78\F78-5L@3R!3#L5SA@"RAK^K *TF0V#0E_=[E^0O9UA#X!J9^Y C;
M"BY,ID<CTPT(,\;-O?P9-AR3A)X"([/)\&T4N6PVK6;H]Y3Y::K4536:-(:"
MRQN>R>RAG#4 <""+1^:H:?A??SZX:C.0^-R:)MRX(Z'@E<0_!U<UM#8YYFF[
M>-Z:AD*%?)8A/]2L%RKDPTR^1(2W\^!C+N#<7'JW+#+US\=4+YGE^>'79GJ1
MM7*EYM]D. D]W9;78"JV=.)Z3?H_+TI"^!CJ<RQYQ#(TF1-Y[%Y8*%>Y]D R
MF6I^;2J'IT27YKX33F:3B?0CD'TD<<T986+J,ILHYO-\/I\'+8PL AP*N8FA
MTPP4?#.JF;8;86I2GGJ'VN(S:JW 6>KAU%-\[,;U(1'KP5IJ1XQ)>DLH)C$"
MW'0:50_KQ*C/U82CLJ?NOK,4J@USU2.NC:<8 #SA+:1LJO)AJ<W0\P8&A'M5
M#*]+PUD1[9Y*X_Y7=^YA#S-T2@.CON-T86 TPB;U$'JIS40A?]AD]+%?R!^!
M9M.U]\C[AI"7954N@S.A@:T\L[$-$_3C%\RN0C=&B1>K(&LJ]#F!KXH5OE"J
M<,],QI!V-XAL3$H@GP<%75YJ'Z@SNTLBE:"'/VR\T^1(FH^&^N__BN)48@=F
M808+2.A@^:6V$5PR5E;L^?_;(Z$E^?^ITC4=R22:FD@D0,C8A$U=C11,H2$1
MJ;8$+'Y*(?JL$+>E0DTWZ9ZD KF*U5)[@?4HC3QC@N&8^D.IR@@&#$]=L[8Z
MI E!*O:I<EU]@4WXJAYQSA%U;ZEM4-40#&^6=1UT@5('+:5O7()HI.@7#1:<
MT4,P^8@10LOI6B1MPM;&2PI$-\$35P%E-NCWU+G/DD[NKD;L^O(1U_*3G0C<
MZK!1C7%&+$-!S5LHUOA*/K_4/@A_K9;XBE"<HTK/>"IM CK@")B<@?<7@AOF
M.I5*F%2[W-7@VKS+0XG=/ZTO5()J2Q]0F0-S@A72$$\"R9(-IGN[M[K43KS<
M81HX+B36SUT; ]>GBDP!GO,09#GU_0F=(GOV_>>R;S^U,<+&+O#5BI#4_(7]
M.P&S=SGV$)8(YPK2TR-W+9DV$*K%G9\WX. G<&@W%L2]NVO7_\8/R';; $8%
M./REVC,TR;$XDB;*-6BR^G(:$*;UF".#Z%AQEG6IO 3E9F]91Q,<?GVV1^["
MIK9K)9/YBWOX#W(GPXBNFQN;XWR[-*25D(3:@6J"@ .LDPGFO<,_XDV)^0]3
MGY&_"A_^]I*0AS1E"#'O!JP%HHV3W%R"BQ1)45#[FD[P[='IS^XB'T(9PM%[
MAR4,/;CYJ.SHP/(?W-1J1NYS7GNJFF#*+WPK%\BY;NEA]C']/MS!G$QO5\/Q
MX6@R.*(%QJFVA6]33<4>TZ3K&>@&WR:3"Z"Z2I6H,@+JDK ^6X'GNHK]K( >
MZE#!W=)UXTFR':ISDMQ:FU;YW'N9Z&19_#HP(!U>1/YB*K"]X&5>FRH8;M,
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M KL0'\ZT;MG )@,N;O0=+*$GO6<02^GP:.\+V'M&Q:%(I+\+'M%4,16-)'W
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M:M\V;YHGW/7=\7FKP072E$Y;-Q?KTV&S/_L.>H!N#>+29'F1?5!#P6XF*1%
M53MUDG:@!S^&:AN*UB,>YI;>6[]W,2CLMA]6P&JO1F"M8U!;G\J;]1EKUAST
M=;/9D26]R"^=6K7:461%/3RL.S(F,C%(W,+>CC7 H4X/RZ? @A,Z'?Q)$ M"
M9]*Z>'D<6[7AU_-BZC[@"Z&@OKS7#?W2&<(W>B3]"QZ[4?K_'6!6-&[D,"_
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MRH=W!H;1!)>%4B\*:R&XDVBS\M+0>YYB&"2TECQ4/OTZ_B3>:NN38@NM2 #
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M4"[62AVTU?)"7NAT_!R7\=E .:\.+RL]>5I%F*N$Q#3<=Y$,%TGD<9AYW^:
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MGM>V0ZB4^&WNPK[Y^8;I[R*+!I>O+%TW-<5Z70$'63RK]*IC\5=UC8.L7W%
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M7\.Q 3>TKM%3827\+J**2GHRD><&<'FX/5/I*2/ _\,1XCI>T+M/-_\_(/7
M >;"*2,5>/H0]GEO&L^X($#<,'/NUSCQ4%<01.2+S1OQ\&_O!N$]_Y _>=@J
MR4_8OTOFT-"SL)\*_&;ZY'#<\!X%,#'\Q-M2=!,,8\(>J#<7^!;R$5FQ)553
M\"\6\ S*3GH&',[F )#A(_^K?KQN?2DTZNCA@#]I\J$-)JVW_'>/&"G' ;+
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MALI9?_8Y75%H]2:<CYC=^&[,G:".MT!5#KHV>P,DH1SNX]X RN:!EL$T1P6
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M&9FJ@2KL1*%ZHZJ/')K8XCOQ26<*];<#CY!V%/ A UC@M%1U\M]^KSZQ5PY
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M3 H6!,A[0&'R_RFYJ4F.VWPBX\'OB"(T5?H"(O51W"Z$SB<,3>9(6$-&G>L
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M-T//D[_($1H50JFWA>)8(>"U4R+N*%\N=G,/XW3&!X/Z'J0-W@E#K+9*R"E
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M8H(83@3MP(UN=D.02.!^)G^A]U)@9;($2*/#(<.)AYQ9[LL'_=N'[Q6][1>
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M2X+,4W[7VQ!N8%#9;)[%3M5B9_(Z.##3JX5NWHSO,NET9@-\]Z87A1 .181
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MI(_PMU3G!@Z^-V<N(6TXU31Z-HTXN@4,+4^=$$")(M/=HZN@\$$:8()2(#Y
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ML'7-T8;ZAF*:+@/9(J^T$92!L-*>UK$!4T="V%?O7@E@H14$F%+A*^SVJ3,
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M#S1Z!CS7P,NYE58&9+GZ";*<(\AR]1-D>2U!EB.F[Z?E^YI=@68>6(8*Z5&
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M$O8<*H\BPCP'?F=<2%Z[X4+K"$W@XPGP^#B(HD2=6];5J:KL?DC[&K?^$<,
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MDZ=;>:"-S9I\FBR->\$+4 Z&B9P@:]-KQ6$88T2&DN>B"9UAJ7/1_+N-216
M=[%U 'PC0B7REV^2[SF(I^@A,WJW;.BV1T P'"W_0N@WAH:PF5A\9["%+>_[
MZRASTV+WHK;_XMX<GS:%<O,X@@6)E29/(=J\6Z"K4LPC'E!.!U;_#%*_P^+/
MA1J465G5[$:M",L&"L\1)],PF8Z1[I2"E&RL/7W9/A[W.Y.]VZJ:V+$<! *<
MLV"%2=R"LA<2K/+L$I8();_\&W!\:*IJ; CM['QO&SA4V OVTD&H.E%LY/!?
MV##Y B35:6T)8.1.-NBP4/I'21=L0N%B(?I]J(V%:9[8($]<),7V"8ME)$A=
M;Z01+-QQ$5'DJT+K.PAI(->%O]+IKXB/1APMV*]87R&EM R0;6#A36.S4?NK
M0&,G7SO?Y/)F$W^V+0"V4>E0U!*;\XI7G+?B9Z*" %B9]_GR4$MG(M/27W*E
M2BR&X^T)'U':3*O+85]C1!C#91S_08ZPB7XE'@,Y0PKIS.&;,;U-ZT :2;4+
MLQ*?.F B=UU(%L#6R*;)):6-P]5!X"US@%'LPH"%(F -@CM;-DZ^Y6BA(]<>
M60YU$4"/@"41:\+W-1-SFQW7T;':GO5;(Y.&>\TMLV_!OWGWB="0$M>(0C]6
MZORG+$,?\L;^1KE8DL*?Y-4GD8>60P^=F3X&O4 $PQ&,+UL;$4;B924,'I5B
M\.@:A:3P7*-"H,/?M]\4^TG; -:@ZZ3D(&2-\:[$8AB_D@F^1:U"_RM#37'(
M>3LL ,+U?+0Q62C1 4,3JI2PB0B40@%$&G/C!HNSP*L(5^L&+^%J>564X<*U
M\-51SG1U(#:^&COBS&]I70\3<<'4T\55>:\_Z78GV_Z@,V3$OSB!>30*B_?F
M\\]FD7K5,E*58M8 9JXMM=+26VIC Q0EL:66[.2L=PD/P 94<D;8U2DVV'YH
M&>C=GKF#[>M>4<^GE3>!GJO'\5FCA8NV_0KJ'FT?V+]NNAK<#Q@8\'0_*!AO
M$@.PL/:D6ZY#3!.(VAF6XT\R(B:=8K);21\+A0NQ.2YQ(LQ,>&$XK@,<:[+C
M$I'LTR)3ND_BZ>"?G+ \9)8,7-L;QPQL^^FD>/7KMEINQ?-UMBDNV2@3V\F9
MZ,<DDF/NL$'6$%O\R)9RO5"LEM-'MDB+:=GJ4K3L>_"2>79KUP^<N_[O!%YZ
M0QV9&_.4Y@+12!I,54T.SW*'2BC9K)0^(U#OL'CB9TEI?I8P);G 6J4@^I$T
M+[GL VS%S$I.\B+6QI::7NF5,_WW:&)]%Z9[SCO].&WR<2X!K_D%/R>4WRS#
MCHF_/P87F8^]8K]6_#)Q\,(=674UKP\,VY<<#)=BV:48T/+ KP DJH AJ#&=
MHD+<9M8EQ3#NO- 9:Y7I?F/U0N$*(C_&AA$)&^#RJ(.N,)L-ZL0ELLT-%]#]
MI_0UP <TZ,<>L<L?LN?-21E3.&%_?'$4[3=C<06-P(36(&'<S<%H2!BL6'@#
M7-"F)1L6V0BAY@@)]:0)$4;V07)Y88P.:S'@2(!P/%X7.AXAIBA!>IBPNHC*
M%M>QA!'$N%/4^1^RG",TF84.4H<$G&5H4LR)'@0<QYC^JUVA_XJ^X!OVCCE>
M$0J6EKN&6&$6.G1"+)N?-S8'[HH[9X\5GVM:H./)JKQFA#9K1ACCIL<0I*6M
M_92):$^=@N'%GD6$XEG3'F$$WIC9_V'/.%1\$+?=0I)7#3%;LD^RR#EH0-8>
MYD^4$>1HF-5+.%P2N7/W54PG)S'=;B:FDW)CNC@UTO:.I=3<P#"S. N0?V.7
M=[Q*5 Y$/J54\=Q$:\0+$.D*(*Y<D#LN/22_L19_'5F0K*A/$/96.;@FKQF)
MU+U+D09J/[+O+PY[?>D?B&]+B$K8!5FZB[&R,%?S>8U>9-/?1GB=L!>%Z'Z'
ML*[I![%59>+XS9&8%/!/HN#+UP@^1S[!]\?8A_?-1K[(V0S\;QBDR%"0H>:S
M"U.\@&@4UE3'@# R,;0HG]L6Y% 4&4WA@NR5<,2G8]K?,!&0#B9'R1 H3:5A
M8 # E+Q<"C8GX>;\D9,":ZI4K6Y]8YV:GEWW=9LG@;S/XN]I/F>'K1+#V^):
MSSK$-&51=U!"$MPH(5$5<@L%E'GH*L4""?QB@9\);\'>I:CX#HO#^VDM6!_O
M/L8TE:A L)W7A+0;81)< 5(=1&XL)S>T"</N Q2)]5MC3-NUK)K8WK4>?]RH
M/V_Z_:@)F\EN?;^"B%(>];0S#%2O=B@PI"_KJ'EIM4?-KPQD5.,3,BI'R*C&
M)V346D)&?8:AV.(/3"G.TQ5B VB$B?;0MM\3'O)JG1 XI@?E@W']P!!Q8:J%
M],R']HBI$72LXH9NIZ8<$^-CN[X1$9P ?V6=L]=^B,3[M/7C2-MVBQ>_'VJ>
ME<'GCP.B"*UM !05\ ?);_@L@D)L75B<.9).P'<T5.;*(L[(FV<(IL6UNJ$#
M.QH9Y((B>E_RG @V/,[S^(*#WGF$]UEQ"A'[.B1\A:!+8UC/P8*R)\MPB>?^
MC*5MX*^0^Y(<B01Y2^;H=+5,PL2C:3WB86W >"ZTMXA1/Z)A%(WI">K4&0HX
M0L*G].%04W5:$DV<(>+N0H4!VWQP9D!2E[?MAPM"RY_GG7+XG5+R.XGC@IXF
M^9HQ*43;RX/5B)"&C*B:FI!GVR8K)-P?E)@SWY5;YZJ&2PXML_O;U<<3H(IE
M0ED;?9CW.;9Y#R#A]O"Y8__:*;64L()R,B:!TZCZIK4-;%'W@6V&E-+K\L*E
M8J70;-03?2?O#D7-H9@AY9):<A-+SEWV#$R(>G]TV%^=TA_(N<='9^=%=W!Z
M]EN-<FZ(YIESSPL1?]48O)Q+[KJ9W"_AD9/.E\3D"L3]>HINRT_@T_*KQ!<&
M""7,[LL1*_K],:$JF-I (I_PT6#3G\/UE>I0UZ?E]O4/G^OW F3G)$]C]9DD
M?I],;";FS@-WH;297-CCS4S;LR(X[,RM"FD7X&T<H>P90F %2H(5&/H"-^6>
M@Q=M8*9@V,D3K:\$HS)LE06 %M_.J(QD6)D+NRG-[( /.JS8 :]X!?J"[RKZ
MJ'%.;%+*N!=$PQ*3; $'FK9'TO2O]ZXAV6S'/T>5MDC ,#G,+M$>"0R(VMZG
M:.Y$R$% VC"0ZI(B+HKG[D.2@JXASO..G"%U6#! P$LA=2>P$+Y'H2>0[T:B
M_ )+CYG\1W3V" *X& )6/%T!W84P>P];=W"D'N:/V-L_4$!W?19_)<"J:G ?
MT)('<-<&T-2&&@'G.-+,9OMR6ZXVBALUXD_]5_\7V]10393^D4\L5>\1GO1Z
M+79?H-3#U9W!$/$K]7_C76.0:BDDU=%>#YIGBF*DSG _V>Q)C)L&=N5-IU1U
M%1.^9$FN,8:F+8>0&K?A?Y^!S6(S"W[?:]J'15I#O8N0M&,^$!(SI$ 9NCS7
M88^GJ+O0)B40*OQYLAH)/0"1=N*G/I*<9,':+I'_&UOX[U)YHT),9XW<T2/(
M"MBN%KKIJ^'NQ,ON0%-=J X-UO [5^1-6P;M01EY)F6S)>+)I7_Y?GJQWSC<
MONR,?FJ#+^MR%# _5/+2S%!C0E&KL7J17$O J1P!TBN]^HH=C9;K$"YUOOW]
M(;@PX$XTM_;NI^6=CG:R?UG[]5CUCE/5G9&AD)<12L'L<<850*)CR^QO()@'
M<$B0)G/EU>:EVP;DR/Z6%7=L_2.G)^5:D)-CW\0(,OWJ%T@Z"9FYP$[_D<.)
M.IHW_,(R57YZ+O2U:+;.ISODU1*_B*=%351XF:'^(S/2>2G+DGB(Y&'>4LB6
M@?C_[TOYBW>BU58+YPB4RI72_=1Z.JDWU(M.?ZL93F<F)DS3%QBW67AGRE9C
M]A7S^'>C6P7]8TJWHED\?NK=W9Z6^\NG6W4)=(,\KC0C_YS$UMGY.)<#J&>F
M;D9RMATZ>*"+/C$,+ BO>V%J!K3&BM*SG#<]X\3Z=7*\LON,B.$K.<73+ $H
MG6V_)1A'FI]3DX06AU7,ROU0.;XZ/9_N;!GWT];3Z(=^?J%:U[[ZCN>\.,QZ
MN]_Y6BY6"^5*LU"NU;Y%N9/=E'6X*6.-$%@B+\X+DX=]N?Q7_%D%/U7Z*Z[<
MY7\2GEFJASZ.]W=J5#J>M G38)EA'3"E,V._5;R@6242-*L4"\78CL[XK<82
M)EYTUIKBU5B*-_*@>#%GBL<*\6Y216=$:']89[7:SP=7&2P@M#_IH(E9]TC\
MF%YJZ[=5]6_9*]#D%)C%+EF9+S-SI%=_Q@M?*P=6J!6:M71&2-ORBI$K5G(J
MF=&^9I"K6JAED)L%A$4H?SZG->('YA'A5 YG 9YCO/2<'1GZHWI9[4YJ2[GR
MYA*D\X,COZS\*S$':(3=JZ'Y]GX<DTC6[!)7R9PCFJ5\"_56'.#PJDO<?/2+
M%\%*'AJK55F& %82P7NN3:_2?(=5H)_;VE!WAVU3Q8^RVCH$1SS5B)R><D%5
M]?NAX\OJC^;^S77GYG;PO?'V-]VQYC@P4LJOF\=X,J\,)*=(EK]D_OHZ#Y3/
MW(2?0Y)K.7!BN5 OM1;@Q64KP7<@<KRXY^(=$"+'58QD)'*LK%?GD?5D:?ZI
M.];V4^=A=/Z&-V^LCYU=VGD/30;7?:;/E!9%R,J^\SPG)_:>0TMD!E.>P<#-
M0K582F7@Y&.-5QV?YS9+\>3C&35J<=4\KSFW5,L#4D50+1*,=%UY=O_8USZ#
MR>7/JC;:<:^J2[8EPGLL;]:P+, "C$S#2VZIF-R:31[VU7D9%+\FJY9+R)$I
M2#/G4S+%;N+.)KLNJ9;RN S+]4*MG.X]Q)(]NW#_D:<6JTFJ>7A\K4:AL:Q#
MXQJ%=2!*4@0[5ZA;:)?NIY/BJ5/^7GXL_336IA1AK:NGVHX42K!Q/-E!7&6S
M*200>,.0JO=Z *R (Z4!$Z'+AE#0KQ80RT>CT!S$T',=7BT9KM$D'CN62:N>
M'8AHU@6H_%0 081A[=JZ\[C1LS6-_9DN0[$U"6L_5)Q3>ZP]:89<D75SY"(6
M0"23F'FC6)(Y<VJC*+Y>A?$.Q6ET[1!4 ,OEGW6V!R_%RF/%>$BH:1;7D*9(
M4E8PQTV01Y<]$8@LM<;Q9U*E8Z&"7!1[+D)IO1,^QZ]!!OB<Q?M>M9DQ81R4
M8D_&.0B\[PM"U3,/TVH4$\1'44!KCG$#<GVP"EWC #K!@0/24!L/+#51#^"2
M_/:ZA*>@)L@^OC4CL+:@%&JG1]6CK9/)W5[)4PH'X@J6##<=KQ)RZF<ME9-G
MV?V%!Q F[78>I&4U0-:Q<?@RFFQ_O]+>A;3Q%MQ<77DS21L7=Z:D+0@H1<9D
M4][Q@<DF,$""#F7G(B'Y5V-$"$. <NF7I#@)DU.,H?Q@SDBX%8NE8NE>J'7[
MOM_H-7[=5;>F,:+ %I1V9#&OC.WQB:W1%<^IELMPWFKZ-!YQ',-,]-PVU998
M@4V+>T,!TEFTO3F_>KPIWEX-?O@8]_SK&>>.I;Y_04+G,F VP\Q,@9558>?>
MGKB82 EBXELK.8A).;.85+VC9&IMK_)0.BI9^MZ%LG0QJ=+32U)FM5Q,QV*R
M)LLD)%L+"DF$LK>_K^V3\8\M][3ZMD*21N;,B8N9O8"I5(X3$2D@(FMJE;Y%
M&T>MF=S&P5 G=8T8!CP !+QQ!0HBJ:FC%=O4D>U1]]/^Y5B[MJVG4:>_-G&5
MQ-!$SR6;%J%/^,"M\"PC\A,TA:C!P@\P- 7\0V@ 5!S6)>+\"3TBC?OI8:NI
MEO9_/71>_$K4E!X1UMP*WMP>/8!S[P!8]86SNMTC]6S=(UGKP.=-5,46&M^"
M5;%+.U_G+'&?IQ&B)!A^E>:/R>#[N-(=*U_BLBJS:]K3%A*?0=J.R2 !&_FZ
MZX(CCQ(MYC'5@0GTN1K8X<+,G6G5V;^?#O8']=.JU3:413),F8NIF_'UI82D
MS;>LYZTM4L^[&+6S!P;JN10M5@KD=EMRM6_]-3RX9[EV+ M>_#RRC<[^N']5
MSB_)F3%G2\ZDM<;I]IP9%XYH#K[-)6]6*=2KS;Q2\ MS<"C_SCCSN;;U?5K;
M'3^8#TM1CIFS@3G&DB&A[QD8'S\E/%_Q;SVS[SVSUZ51J%57(A?<O)_^*#[N
ME9Z.MG\?/JR-S[+6V9J9N6 .L0'Q*]VD<Q^ZY'>&CGD="OM&?A<W-94C+%+
MI"34PS6EVJO0L)N?:-@YHF$W/]&P<T3#[I!E=M85%)NLGA]'> _A:R?OT%^]
M_D7L3#G6NQ!4]_3<E>;$!?B*>WZ/5>)7[J</[M:H^7Q2K5ZL#U8+.8M2:5,*
MA:'*N_?3_NG/R=-WM_C4KW_YE^W:OQ%X/'J-V7"M[8$S4Q+F-)9+04, M3;B
M0<'\%=E@I^>/<4.3X+Q''FC+!V9W4_X*E5[EXC_T=_A#Z9]OD%Z &>Z*W1T
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MN(1F01N$'C(]W0'&%E$LZ,_P*5AIUP4US\Q '-L](O=D3R>_[&+Q*6JJ3?G
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M]RO [>6E<7OD/KZ9MO=^O5R];#]I*\7NS=>Q^Z*7V_8 "O$/S!VMIP$Z(_E
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MIPT1N:R=R1@1\4(%X1C(+\E)(\/\_-NW?O%3LS8\A#3BX-B=3*HE().\_YW
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M%Z$G_-H DC$F&^W?&2EXU*YX5'$/>I>O=H5XTF9 3+&JE6D0[I;_R O\1RT
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MG(J*QY%6Z%&1*LF*5)0VDT7+G2R>U_=X!:Y7U*YF6M^;WTH>BHF+\G$DJ\]
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M_Y;6H"5\,1]UT6Y*E0GDQG@<_Y >T;8<)1W3RI2^2Z-^PVD8$#>>ZECG"B
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M#"$N\4S1O56Z+=N>*KOL07A\F=2337F$TL(>3.3]T:2^VA+8%D-D7*8$((4
M7.W?@6U_,IOSQ0CM67ICB)/X+F*RSV=NGRLCZP>[2A( =C5S E!53P!.95V7
MOP<U_'0]U$<-P4,51W>@<[ +[CJT#:*.K*Y3V!:@[<D&J->19EYH1$]]):NT
MN3K;>M*?W6?(I,K11X[>ZBTO.3>3GN3R3AG=QU!FE&IYW,JO;4KP"R>R3U,J
MMET^@?1./C$,(@KZN&SWBY8]#(2J?%Z;NM86$_PQX%&69$+^2X_7)I<P5D.A
M:GSKS'IZBGB^J>K@%7']1^B^G%7J?/V]G/N:,8M.FZ9B.U*#QCREI\AJ1*(R
MT,Z)ML^8J!286&-?,ZA]E^+M+O+P*9SDY=F;C8972J:YE6M@.I?(;O83:XG/
MHO95BPLZ7IYN#V,6)DZ>J/$M=@4R2S'(B#.)FD)7@75*(9Y7DWM!\._(@G-?
M#&78:K#W_;;1C89&FB(!LPARX3/T=_J5-REQWM8N\CR3HG.&^_9>7O]T24O&
MAUVK<8^]Z#S?LS3&>7>=[[H0@*[F]BRO_'L!;NXV9O&"-;_M@8<5+XL%EE^<
MKGXBZN5<YEK_V6;)8KO>HF%89<S]K:92B(&>GN1X&\P*8Q/1ZKGLR1#M*VH%
M>CI:]VP:;:7W6R8MJ.MYH^;$:^- A[)O!?IW$*.8)1:('U'4Z<9T4ME7][HK
MMN1C5/.L24D#\MM/7V_FLQS=:.]JPV@DEIKCPGI&7=*$[JL*-3A.WJB_5>FY
MCLA@'&3Y(9F0>_R3CQ_3$7H#YPBS^S1K+MX[M- O6-BWGDJCU<PU2J'T&>"<
MORT]76/.KP'Q4YG[F[0]OX]-;B+R/F),7JG]3=A1[2]B6NK7WZ2[W3Q-Z>0[
M:AK1=HZ:AXN^Z@%MT!, '\<XN$NP@8\B 6"$"F.H(IXB'^-_A-HW<-PG*;T_
MH2R47T8ID'A?--$HFZ?^THA1?V'02!^,R6E1)K?_#-R#XIAQDYF1%E&[UNKZ
M(36B1U#!T&MRM7P>:HC^65H&X?O]F/2A$",#T]/"YCTCZF?%)!JO'KZBLC3(
MK6"@G[^TDOC3V9_!]'PXF,D30]4-GEL4]O8ON-?R,'E\?#],N^'5H3A-=M^=
M+V$)860\F3_0AXGGHK[+'^#FF:/6LI6_7.IO3%(CJK(9:@8^6'V\I:*A0B?.
MS+[[$V*J,O+3J;\EQ"&#490[@N?-,%C&BO6$ENA$XSPE0BJ4 1["WKKOV.\#
M%-5O<N'QAH(YCVQHH6J""7 ?;-*<^.EA;>C.-G_N,A_)PXPPI@/1#YG2GLKO
MFD0%W!ZG"X722UI78QS-1D-N[/KQ"=8@]VMG.FI6&N!Z.0(<=T8X^9E*KCSA
M6[I=.:?/AM-#+D]-OY,M=VWS<+U44!]CH?NE^U7- :J"Y=#]0&M8__&26G?%
M_GI':^@T64:Q%\_S.2<Q/06A&+]\NSNI,)74 6HOL@_9_ <&W27D/$R'-F;G
M&AB&2*CTFNL0K\NF?JA1J3.2W73)GFS/ZU)7SDSXUEJ#@NQO_Y[R%II#$"YT
M4R>-^F@NMC]M4<=>Y"WU0.=5N^V8Y]7#:\0DUHZXB(@\UX$Z+G&PSXS(7\R9
M#7(A*L#/\P@ \Q)WT+P%;*N^\"71+V)M:L_!U.>.$I$OT).H&DU/MGZ4(<:6
M*F3OUGAQT<1BXR'.P]7SE/D6&&T+/U</&-D/(@""]8?XKNF.,\-6ZP\@,UBW
MMP5L-,F+ (2Q$H!58?!*LW@- ;BNWH^G-2( 48CWS9G'H% 8S7-<E.^+UKK&
MY[*UGYT;+EV*OS7E7_I*D7[)G,(;2;4_XN:52&Z9?=3W,9L K+V'=?M8.(+0
MX9:PY5XP+F:EG08JBSZ):16FFV[+CZYCP] &6A86^*@:"0^^8R!G=!UH??Z<
M,G5UV&5P3-M\;F&(]::^2,P\[4G!0N:C<BNYF=,G^/GI'B8"<$FWDP TQL P
M;'0C^PVN_JYB('2$97%FH1S,J9B+<V3^!)$Z+!)\?)KX\Z:G1MK&A-8/Y3G+
MF=BO$9>2)?TXK[\=2=^2W-4C .'.'9N[?[_)_HT.!'W-@CL@WD-.MV>E3]F5
M!=_+%VUWG%,3@(P(J R1%1_#SQPUS_G=D?N6L*"ARDZ-@,W<U$U%ANBZC/9;
MN([N+XO!98/C7U&KT\))FND"+5^H'Z=9ONFUE(1$+RW6);B<2R0;K.N%G61:
MM"V-#.PD1EC2>[P,5FYW^A\8Z["EYCX<%"^B:]>#S;W6GFCVN;[Q0?4D^_S=
M<4G+P2Q-\FLBTE8(O7[TIR??'\B]0\]+I-@*G^D_FVBQZ/A]>R0B"Q\"^\7K
ML@5CL+%R3O6EB!P$SL?8?\! +G#YO:DI'/ SZ$!1A "8'[UJ57^D)\5:=BZ&
MEL^/_+77<+,RIOOK>'QE>?#C\!#Z1\0JQQ+5@>8A !ACV-><K&)LCPV.'H8K
M.VJO&X0:X]XP=#.0NEA?3P/5?O.PBUE<DF>Q?+B3=$WE?0TM_!%RZTO7\X]-
M!8F;Q]$]VM!2HBN<"W_KV))D5X+7W*'"JYCY$("(YOH,VK&GN$\6-QT'TN3)
M>K[0VHF1>2= 9);"\&*3RC;%D% ZC8"1J-I@]:,+C6D??9%I7X.[4<6+<>N,
M^D*% >HG?0A.R WDJDE57<F587W=]HGE\?S6"=/IARM-&;92;\DCXYCG @12
M-ROMQ>YP2ZS,%UHP8AT+$\.2]T>PK5?MP)B];@+@4 BFN@'ZS1E+ $A&" ";
MM>]J8NSB[8D*7QU1B_*L$A\&EH6M$^2T@>:-0B]7UNL/TN2C4-\+VZ$,S:)S
MJE=<?^&*.[DIJU46ZLZ1T]$RZ7?"F%K\K\+ @=?"N_57HK3;(!X_[/"L\_UD
M9[82YU3@<Q.?3,^]8=6\YW0#& &F:+.7^M62_7@5*\W HQ$Z C! VH]O(IY1
M#$Z147O QXOMQ9*TLA&>RV4-'Q$$.R?QQ-]*QW/9;B+.!;#K@;$WU@@ " %=
M;=7'%F.*X_ \.#M-C$2$[U.9-L4?>(9]#>YG+>%S&50?D/1ZMF^-O 9)7P5T
MLG6)L)JI51NG2"?NU2C&$8"OCST3-O=T"4#O& &@K2.F 37U#L1Y@!R1%_42
MR^05_(U%*'A,YB94Y45F<114)X W(IXUCEU!*D(CQ=LK/N;AB+7HX&&(U*[<
MJ43GOG_WXHW)@B\84(Q>;+F%"SOZY^-ZPZTY3=JXK'M& VQ\@ZG['J7!&\*Z
M>\-C9^*6H#\9R_T7$&(;R:%Y+C7<?T&+)0#ZU7^%6YQ82V(H<\[,G=N9\<AD
M&*V+*G?3%'V6P./]",BZL6%B_,S57.H=5^2?3B$R?F7_\K?<AC'O S/.G!<7
MS<Y&<NK@LV7!_%JM[:H"$8_=F=[WU;L58N:4< @9&UI)("N5"S2/0"@[@%>3
MICMVQ_4W;&XCYD':V-M/:%4@"KI\?D(<YEF6%5VJG,\)@(0:_F)466SOY2TS
MU2SPZ7$'LK1_+0:S])98F5OO(2!8=P:K%E*_B-7GKALW&S+8=:ME\TN&XH+W
MCF07?YW3.N0-=60,\3B(&'CKVXV.O/VAT&P9U&\F(>:KJX&ZXEKIL7IPB811
MW5NT6;T?'3K#8Y:#ZU[]GNF?8*%EECOT8.+ 7>R8]_ZHJ'8#RZ_HNJ;9-Z$:
M^K(Y]IAIA;JYK'W-?79STKDE_>**:^9*&W7RZ=_Q5V=YZ+.12E_MMRU2+S8U
M&_I4]+6(F>9)8HO/G2-02]=Y"7%$U&MSBYAX?H:P07Z>]3:G%3M7<+G+0L3=
M#Z_H#LI(WI,ZB,^W7\_MX5MMX^ [GJ)MH! <YL0+B54WEFB/.Y;B![BE__ZP
M 5$@34TR8>75 .JKP^I"4\Z$XZ":K03@,['4;+G:F",''8R=1WODC5 #)VA9
M1_-$F1/E1&Q>C2+\JXKY)#B-^PDUU!'42E4(-84R$G/M>4>XX[GK/@% 27B>
MBUP8I,3IT,,.JVT$7DO&;;9!$^183%--.*6/#SB^O7R:0._K9?P'+FW1OE@L
MILS:#]H>(@ A([AQ$,5M^;-7F^!Y\)JYZJW,U;FOJ$FLO[Z=OZ>[0)(^WT2$
ML=!5.5[-P-\TX%C%I7-1$$GS UD;=DC"[#K=KX\T/.YB5922+;;+]!G*2#%)
M^8Q*P>G^,>2 E*5,I:*B^5F'!%BZ@VC$:]7P^L0S+*P_ABKTR3N*7]E'?QC
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M>'8=]R1U"79E'<@SF$-X$EM@KA'@*&$8MN01^VT[>HFE[#J/]TWH-9*/GL8
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M<P&4'4)-:=](C^ @4A7#JJ/=$LB!^^*'%*_ 5/I5$@$ZKU[]M\_ -K:D.%O
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MVENZ*8^:ZG?4'ZD]/[RXJ/21CZK#?*= X<&3N[)#Q\YZ?[ "P]%#KH<E6^/
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M%:]VEDN5W"Y(+;="IS Q$7#+\/UM\:P22^78JIFBHHGG&U)3=>_&T:ZH]V0
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MK %J29%/ZK9Z$C-3=O>G< @^FU*V$"<M]TK+Y4,"Y>Z8Y^RC* B-1D9D$O/
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MLEAP(8K]"_,GTZT?UTP> &0/ $N3W7*G"ZG#7%5M[9FT@*X_"\<3Q$\LU!\
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MJ9VZ.E,KTFSRL A9.Q(X"_ONO<[LK\V[,B3)60Z0";/(S<9%F5^3Q#NU&CP
M\/3+*Y1*#$U,*BM.RQ5OP JM &*W1K)Q.CFW3K !3D'U2E&A'><\:>6,@$ C
MMFU/<-V+N'A( S-8>;_WFNK[.W672KLYI&8+W,>Q0"\IX'W*P+5!'PTTL<=$
M""IQD6"!87N-76Y[H<\"%:BT4,?HZ?CD[Z-(%6;EN)_P L2*D(@XDC4I#QR[
MH+YG1HS'6#T PAW\V/X@W0^9<FBB3S?XL]8E&=VYD^>OSQ\ ;&T*H%=G[4[4
MMIXG78S-8SF4Z?@@?+DI#/;L<$79L$4J\0(XD9"*+?4#0*>NVF[12MU-NL_*
M26E)66NJ0^H!8 <BN6*ANV?MMT/LJR =JE(0?9V93@I6OJ*?C$(:P>]:<CX,
MHJDETX#L=]MEO!4ZY7E0!(CMKOJ(>3A-;Q 9RG-<8T)LOVE(%2L?MOHN*?83
M[_13M\L?,)]^DL('0%7'!O5]^_&IP@NW]ZQ(XE2/$KFOTEF_Y@>SYJK'XOG6
MJ]XSQG2B7&!TK4]R=_^HP@G:7-BG*QW04F?S1K0QA;FQ73>L-N/]\=;&OYJS
MHD#K';0DA-[R#&8&6JA"@;,<,N8K]N2AE2=)OQM>XXQ\JPEM"3P>5X$VG#=S
M7YO>T30BQ1/M+ 4.KBN_BSLWQ:A'"Y)9JN!@J5,$*Q[XE*:;3&?(&-!<] H^
M -:7OPY'-XX/N)VZ[%J0W3(A?IN+H$36R[U;Q6 @FCV$O\K\5O6TOY'[1[#E
M]C,O /92)_./=:F!?7,)6+R!?CV*!4%/@EZPQRPX>6M1:=0%+'TC/R8T1<<P
M%/W]VT3I!XIL%U4@*I#+Y%Q!S6,UFID:,=H+;B\&&2XLF8XY?(S>PEIYA\8+
MV';&9/2;-6P70 D[<.C/&O0T>UTXIK!&7!^,8>H?F=CJ6W;*-%[/CR@ VJEV
M[V50=@A0[SWN#-;L?5: 7Q!<9<Z1*^)D6_<'NYE/G^RWG1UER,DAOK2!&5QA
MX55/("]B-?K,^U;7 =8F>**<KCE9 0<N2B[U\_UDU$K3Z7NWJ!O.GS2N?$8^
M<VEX_\1;V4SYOLO_U0>GIYP)#"6ML!_F*N^5G%Z.# '.V2ML@TA;Q>!FVF?+
M_"8U'>WJ06!:UN\B/C(C@1^8YGUK-ER28A =E/?#&9>Q)N8UZ>;U4V=F[Z#@
M$7'AM\PGMD=L:>KUF(<1.M4U(31T7[)3(^Y99N09[Z># *(+V^ <[71(\UBL
MC\!7\_=>U']P?X?$7+#^2IIVD2QH.)\P(ZE &Q5@/RO,_:A$^0[M_^/$84*R
MK#T PN0%%TR,O?LA:?*L$;,CCUP"3!0B8,93H;4>]V<&YLQU?&8)#V2;=G>0
MO^F$ODW+D%4FP(5']6XH:\*#\S!+I3C)%3FSP7NB[W"(RFY)$8(-S(5,EQ&B
M-S_.!:29V ^9Y;EKH[9X<7&.2G?X5?I9"/T%D/P0.]@#@-(VK7DE+B%9(&LJ
M.6;PTO #0LGC<5E9.PJUVY .PE<VQ*DP=0+>@[6F^@:R\L ]F6#,/6%?20RQ
M\J);3D1$PCTS4 ![;+E5X?.U9RI887UJ88:_)_B1U/!SPW;- BB#3X/P[L<L
MB/R)2O9HH#AA9\N">_=T E7TF Z5E#D!5*K0F.7N8'Y?A?!VBDC8'HI:#G]4
MEK6^XQ.]=!$K:="XK*^!GM(S*=M &I3Q:L^%.7OBJUH-UV&M^Z&&#K+["WZM
M*WCQ#3BEU!\3Y5>!(A[O\EHAFSIJ%;#J/70?9!OQ/#"LWQG7D_HLA<FLX77V
M#@</%A22C8[0&(MUR?,VT)S:GDQV_Y.\(E )R&3V)/81"DEVU92>6QX/KB,8
MIUM U00(KEB0+4#;4NOS]W]^#!\0C/$%O*'K=7_<(PSD.$RIHP\4(=WQ=;O5
M0=P$)&AB<J9Q"'2AC.740>MS'A(6&>"N;=6]D?"714670:J\(=T9CBUPH=I^
M3&A<4HUL)@X3K<NO-4^05GZPY'YBV#U12SU2K/6>N2:#A(*=NYJA/\F_+)-2
M=3\<WFS&H@J><"_7$.\C<[*VPU?$Y/^E0E^BIYW=">#;I$0;AZ(P('/&?6UE
M7;\7E4KV!Y+VO/ [Q*#YW]_=-^HHN62L'K0@RGLR F.M2U$<;UO DP[QV5D,
M_"2U+TU<XM]\<,D&SNSD$JN\06G B+!/U%N(T,=6MC0$Y<@VWP\":4]K,%*&
MB$;[VUSIBP]2$&'&#=,?VA#4*2[4F;9/G\ZF/@!<'.E^O/XM@4_PO+_-]Y 2
M+0MV3+*[0CEQX![ /B5#)-S'%0J%"K60HP47R(6_1XR'NBM@QZO?4&B$:=Q/
MM?K==+"Y;)O*2PRL;*,W\.:2B,\%V;!$9+--_)X$L^#8-4A_R?@*S0LN$!0L
MDDI[UQE!>(?PJ50G"6/&G:IHE;"QA,5+#\U#4ABRV&G9<.M=ORFZ8Z"B>#BW
MI:KF8@#;MT)K+"0HP6/#IHFS<@=!AT\[J_9$7UJ41C8^#$"*UA/>[)MA4;Y#
M]P!)-Z/4Q%@2YBS(G#Q(9.V:^7>E/7^Q=X9LIOA/IX]SI>H]3P" E/.#20GQ
MC7EST6/^SY)$"%6X'F_1G<T^Y5!7^JD)F"6C_<.N77F7.UNR 1(Q3O=!><EM
MWU1OOE>(OHL+41MR3@MKQ/OT /C\ $C<9[<F-T-(/3],# EVFSBB.N/&8GTG
M%R0-V+@E*-_+Z(@H:OJ9#%=TXS->?MN"-8+_-T$'L.Y\QGRW7S1]I+$9WWJ0
M1V\X.Q3V#8^N],='DUT]48LKC+\/@'G,!\"$$L#L/S<OP.:^N)&797')F@!*
MP!Y?803(L@Q;W.";6?A-'YY>]YVS)M\R@%);Z?_W9 /A(BWZA&A7_76;$#9?
M<[KG1%[#>3?GIBX^9_7X_0W<I99$#=!]2ZE#0MM6VOWNRLX#@"I-"+G$R"./
M6)I9CR=SF_XR7)652XL""Q&"@M@]?5),AE88O8)Y3?L6)$>WUG)92^8BTV=^
M)G]_H].=F?SDBH#A#CK4\-H.R#I(7<\;F'IU"]4'=3=-/LI>W>3+(7G@OL2S
MI>64IHXY59*CO^N,(-I>3]&>K.X8939%SC7BK7+N8CNAU)HMFE-5LL-O3!L>
MB^.2%[G6D3?Q9V490K<A!T'[H4$[[,4Q6_R-/W-3N;53EQFPZ9A4J+!C'P"L
M?BS7:SG7N+D$=?]A(ZA^PDU&7T(4.QJG<NL;9]C#?T?P#QI+&@6/T:4:AAQ1
MWO%KE@(M3G#:'W41>= .=_!S?XR*_>OM< $QID"(5FU'4YSF-[MT82W2^._"
MFRNB,DW;F_UMV@B<&(]Q>L5*%3@)85>^DH.,49G R7)LJ##G /XS:8_]%!-S
MG = $C_D 7!!TO  F 0:F9.U)FI-WVIY/&?G]5!O8@SY^R%G\P5E.Z6W[BM$
M-?*UKV!LL2URL'R(R?WFS1I)^%LK5KH^+0OC8^#@/9J_VA]4HA/<+Y;!+]:Y
M.7-$WX/%8\9A@]%F4XJI+.A1IC<C$J/ <H);HUQ^AH\:.V7PY3CWKR3JU.[M
M8SQ*E>R?29J2HFA[H@;?E)#E.LQ<=1'[K_WDQ(&\UBX<0C]  E.="<4*PO[K
M$XB5A7*6_M*J6V:Q<C^Y:NB*T:*9:./*O4W:R9<XYDQ. ./=6@#OHK-<4<R6
M/]HZ#W(LHCG%SDO:U/6+MU*7[E8?LB)F/VP')7547$_D/@/05J+\KZ=1(.]\
M$(P.<7=??L%?^=KXM;5XO1J]'6"/DAQ-<AMD7[DV3M$1>R8I)CX%.O/X82W@
M0?D^W>DSFV$<:8 MAN>_>./T 1!OW)#@+H37'[ F@3C9>[[45YM(UBO[[<>/
M@RO,I[_%MW0'^]".8P[.M$N(F'OL#[] 2T+DY^;4NC'$)UO[:-/P6B0'>6A'
M_T<U_N\2C43MJO^BIVT9)^0,].?OR@/ UEZ$<!P&.KSY4?_"Q%W\=\@BX<*5
M(O/YF<NN.1VRI3-;"-E7:]N!B-Y9>3+YE(M&VD\%SM#&? W5"6>L5?XMR9K4
MQ<B<^M3V*!#'.%8H/) E6/D3'AH#<8)HLKSG R!=\;[X;K6_S<NC\Y9QTE\;
M=DR824)FM.OK_NZ9"8.<]/76%3PQV7\_^MZ.MEIV#2"YU;+74,K;A\Q.5(CR
M9ZNT\ZQ1HAH]_#Z'')1.4[)YF?L'DUQJ&[O=9ZK#>IS4Q&YKR$R_6^Q7GLG$
ML<#*SQI+010G;LC*VT/+>GG &KP])__;^'.4"J)YO_-:LYJX\$(RXZIR?,&]
MWB-<MMP]TEM2M_D5\\5Z:9])Z1D1H</D%YR[9UIWF'K]_Z&,8U>=!2?_W>-W
MSB9J0[IGBR&)TII*=@U\K?-[Y@:M/R.&9$=[G#XGA732KA&>Y^*/PD(#1>-?
M (TG$F]D#A465AV=JIV6-VT&=Z=S0'+VE[W\^\.5Z.L0*!.$)^K\C3&_+MVC
MR>KHY<^!O1 6V7M!)S:.BH6+YQ3YFTG+A57EP9^(=CD017&B\<LCVYIY\4Z9
M48RN2E[,-(C^"WHM-P^%17!L-_/161P-1W[)/:5Y2% I=[!D8D0.<2L0EH-C
MO-L,BMN0>.ZH]\9A_:>E9DS>LA<C":*,A2 0<P5E?>X&7[9KU6(:G<_!:DU^
M\Q&'QSWA*^QGX]H&H4&-]@LJT4/N_C?1^7]J&FKB,_VX6M5I>6:"<<0X_IJH
MNEQ$-D07GXR8 UD%_OQ*'3>E@!;G!XNL(>[3@>0JQ)DVA"[!)4F=99382P"
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MV7OZA>#/K96K@MI)&P_D@B)P0AH<MTHN!!+SG";[/?VA^4V1Q8_;<(-<#$(
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M@]G<16\.&$[$K32T/;/,'/KB]?0NX@J//XTSB4&$5-G91S;LK$H+'A%?9/<
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M3)>_>]Y_*$O^O]E@?.^C"/G\_D/3<2>/,:WTOT&!V1^-<*053K'4<S[ZS9=
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M]N4#(-2(.VFXZ^FLZW514PBLB-?3+>EYD5I+0"BU*M4-#1M;OR17(]R]KT7
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MYV@^.LK FW]O4O!_<SXL_@]02P,$%     @ TSMZ7.2J@8*,<   +($  !
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M <@M>A(PG0E2VQ[REQ?(E7]02B^Q$_DTH/A?X 6&TLM_S(#1/ 8O/S6'Q),
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M)8=^6V'SIH9IQ40WI.IA#LPKXZJ4@[]A4]KENZ[UO"&P:\$1_#$'@3>:PGL
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MX*VF2#4H6'+S@[J">] YX,JJ;--2>+Z\AO4Y"Q]3$O#<O'*T YITCZ@<%;Q
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MC=/'I]%GG3]Q/DF@Z%@WQ.PR^>O!&4A < .UWUA /T1F:7.X<.QBI&R0.NU
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MQO1$Q-O)2=/Z;/L\QY@W7<X>V=IYHS_DVKF:2]MR,<<SULX^ 3XLP?7^.G0
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MCB4XV?V@A4Y82VH-P\7C>>6\QO"S;AG\3-HO=O7\*MD/78X0H+RI31G0KQ^
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M'A$9A(*,A(2,CXF%!B(F("4A)B B(J-BHB&C8* D(J+E^LC S,+.SDY*PR/
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M3BKH>J:S9.+HT<<P)K;<O-8A;QF*+SYA<E)I(KN!%\Q\X;F.P7^Y*:L+Q<K
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M-/?>^M3)6JO4(9FWDI%?SQ89B P*FS7TP$#3\1J;7L(-0C,?6#Y*S[UL;S%
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MWO_>MF__+FP70\LI^*/H^NM-U9UCFB?V^5N05$0<CGB30F7P0IXQMP"[4TZ
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M0D)?OPD+CXF-BT](_)"4G)F5G9.;]RF_H+2LO**RJKJFMKFEM:V]XUMG5__
MX-#PR*_1L=FY^87%I>65U;7=O?V#PZ-CY GJ7"\<$"[.WY__J!<%H-<E/#Q<
M/,)SO7 N^9QWH,##ORE(0'E7F_"Q^S46H>>7J>Y%9Y0T$;$*Z^Q06WKT$=.P
MB<RR[YZK=J'9_YEB+_Z?-/NCV#]ZC8%(<7& S<.E $% 1]T,).(#FZ/PQ[:"
M^6SM0KZ%X-%AB_UEPK-38S,(YF[E]&$G--XH=[QQ08&7&EKV&;K\@_STB OS
MHP0+@DE MG\5ZFG[3 1^*CQ+M<*"9)] ITN4CKRBT"=-6%!PFW'FV\;9KG#$
MZ##D8DXJJ-U#+*CW(_AX0[^ JVZ+$1@'^V=<T#_CXJ>?+"I8;*P+G.R_Q)S!
M_Y%JMY@I4&.7__F\C+S:EX0^EW3N+](,45S9^S!=TVTT/Y0.F-\)C"; @M9'
MK)_$6\<^&-5R,46!3R6[,8$S6!#",NK/K(&[6! )K!VR/]:!!>$@4 ?0YN7=
M*/01H-M7-TR#X6"A#WAH] !RY)7X6[#A_V6L3.#I[YL-CEC0H+ULGCRJI?GR
M'6098WSUB:*2OVR>8760&4P."[(S@I[KO6F/^5'Z>^G&1GHA.S5H0'V9SX@=
M!BRHV( /P^>[M&IKC_^Y\))?3%PYIR4JS9>J,<^PAC\B*OB?D7UGJ3:_5ZVB
M&#:/;)A7T5%A=5)4_FK',A)"WR$]5(%,VB5:N@W_;"MGR'O$NK=U6K/\KN]0
ML@$+HC3C95[_9WS6GX5Q,B>>ID:[1O>POM57MNB.CRB^//4ZK?ZZBBP?\@=?
MVN,R;9;M!^->%N;E&$ @Z3?'B(UU\,5BA$/^-@S>IIO(JGG>, ,NXWX5.G1!
MY2CG83:83MH4NEB1B,'%@@Y7SQ2K/"RXMV%_[2@*L(G?2[-A^(+\+88/"TJK
MM$"28T$C.5A02,/<],DZ(.LS+.C,'ZI5I!:GZ?_'^/[+.A "O>OF>D\V_^Z]
M6H^_2VBQ2QX^.U!!6"FV?:V$HJ5\X<J=G@<[7AFTG#]5G[AVY$/M1G_?7/O/
M5"4&GXH8&I<^GMNTS7^RZ=2_;/,?Y1$7RO,,49D=7]'3_V>?!AW<R!JSTQX(
M=M32_&C#E8:;%\"QH)L2B/6W6)!HAA@9FX)HO?":*D<8VR7&9UU7[N1#_YZL
M'/I="SH"7C?X5$>I_#])\K9Q_K]) OUODOSMIL V=_QE_W!MA?\_!7I+_PR3
M_=MMX/H!J\8D)&'O(W9;O]<<XHIPG+[F8?@C6(;2/U[2Z .^+FVI!Y;\RZT0
M?YLY],+,S1 Z\(GIM8U_.:73OT?[ CO9.P\^V03&/)L^\X?,>B([, %&T!EQ
M+,@\*M]@"VQH]Q,+^H,)?Q2HV#] T$I[X9?34K[5"PW\D.UT#^_#^LLT1S#2
M%",(6-:P!9+LW+( 3V@[] XB_\]^0/AXU["C-J=C=,.JLB;%P27:>$OB</T^
M@KK>#__XEVWDE!2\*3"A[.:>/ZEM5(%^0Y& 9<#R'P7:_@&KG9)=SKF;+^A#
MDNERV:T>6RI[2,[#K![$SD5%L92+Z[2Y,5[2Y T8HV9HD#R]+IMOB)A3RPU
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MZZ7O:/"I#8I,@2-]-)X_?:L64)?E"89==KM=KDSOGM#^<,=W6T=A1ET03R7
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M)$.Q[)EF^3VD[Z]+D$FV]V)IAV1%=<7R?.]KJ@+&?=U%#,J:]FYKMSP1DBM
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M:A3*Q!RIG^[[VJ1FR(VMGI:60>W-8O-.1I!,(01#]3H$"UHNRL""H C4T/I
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M#B)-6!!M9K F.K ;V(QDGQ @J?T"T'Z3\VN])WR 5"/?$2BB3 LJQ%<)M"!
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M-IG+9=LR1D6OE*?J%J'% I2G @L2^%V_ Z5<G$G*ME04U-ORDI)BO5%3$RG
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M>213%$:C90!-EO]_$P!02P$"% ,4    " #3.WI<:&O4RW(2   AV   $0
M            @ $     8V5L8RTR,#(U,3(S,2YX<V102P$"% ,4    " #3
M.WI<U4&TB0@6  !U&0$ %0              @ &A$@  8V5L8RTR,#(U,3(S
M,5]C86PN>&UL4$L! A0#%     @ TSMZ7$M 2CQK-   WGX# !4
M     ( !W"@  &-E;&,M,C R-3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( -,[
M>ER*>#-82X@    <"  5              "  7I=  !C96QC+3(P,C4Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " #3.WI<;3%O*79<  ")*08 %0
M    @ 'XY0  8V5L8RTR,#(U,3(S,5]P<F4N>&UL4$L! A0#%     @ TSMZ
M7)K"<O!:%0  LH$   L              ( !H4(! &5X,3 M-# N:'1M4$L!
M A0#%     @ TSMZ7$8!K*CV-P  9ZH!  @              ( !)%@! &5X
M,3DN:'1M4$L! A0#%     @ TSMZ7(6I6)@4 P  ?0L   H
M ( !0) ! &5X,C,M,2YH=&U02P$"% ,4    " #3.WI<,+I.>*8'  !K+0
M"@              @ %\DP$ 97@S,2TQ+FAT;5!+ 0(4 Q0    ( -,[>EQZ
M&[>ZH <  /LM   *              "  4J; 0!E>#,Q+3(N:'1M4$L! A0#
M%     @ TSMZ7!L!'Y]!!   R!(   H              ( !$J,! &5X,S(M
M,2YH=&U02P$"% ,4    " #3.WI<'1S+HRX$  "L$@  "@
M@ %[IP$ 97@S,BTR+FAT;5!+ 0(4 Q0    ( -,[>ES[%P3"1QP  )&]   )
M              "  =&K 0!E>#0M,BYH=&U02P$"% ,4    " #3.WI<$[,\
MY^$R P#[/AL #               @ $_R $ 9F]R;3$P+6LN:'1M4$L! A0#
M%     @ TSMZ7)%V4FQE<   \'0  !               ( !2OL$ &9O<FTQ
M,"UK7S P,2YJ<&=02P$"% ,4    " #3.WI<Q:#WB+9T   %>0  $
M        @ '=:P4 9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0    ( -,[>ESD
MJH&"C'   "R!   0              "  <'@!0!F;W)M,3 M:U\P,#,N:G!G
M4$L! A0#%     @ TSMZ7,/F.$6&.P  $#X  !               ( !>U$&
M &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " #3.WI<Q4HVQ.$=   T'P
M$               @ $OC08 9F]R;3$P+6M?,# U+FIP9U!+ 0(4 Q0    (
M -,[>ESK+N40Q4@  -E4   0              "  3ZK!@!F;W)M,3 M:U\P
<,#8N:G!G4$L%!@     4 !0 MP0  #'T!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CELC="http://celcuity.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="celc-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2026-03-17</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:SeniorNotesDueTwoThousandAndThirtyOneNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:SeniorNotesDueTwoThousandAndThirtyOneNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ConvertibleNotesToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:ConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertibleNotesToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:ConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CELC:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PreferredStockOnAnAsIfConvertedToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="From2025-11-012025-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="From2025-07-302025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveEquityOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:LeerinkPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-08</instant>
        </period>
    </context>
    <context id="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="From2024-05-012024-05-31_custom_OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_OpenMarketSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELC:WarrantElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELC:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2012-08-012012-08-31_custom_TwoThousandTwelveEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2012-08-31</endDate>
        </period>
    </context>
    <context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1427656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CELC:StatementOfIncomeLocationBalanceAxis">CELC:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-30</instant>
        </period>
    </context>
    <context id="AsOf2025-08-01_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-01_us-gaap_SubsequentEventMember_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-01</endDate>
        </period>
    </context>
    <context id="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-30</startDate>
            <endDate>2025-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:NoteUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-09</instant>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermETwoLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermETwoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFTwoLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFTwoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermGLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermGLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-09</instant>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-09</instant>
        </period>
    </context>
    <context id="AsOf2025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-09</instant>
        </period>
    </context>
    <context id="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-09</startDate>
            <endDate>2025-09-09</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="From2025-05-132025-05-13_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-13</startDate>
            <endDate>2025-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermFLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:PriorLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedAndRestatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-08_custom_PfizerLicenseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PfizerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="From2021-04-082021-04-08_custom_LicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-08_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-09</startDate>
            <endDate>2026-01-09</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>CELC:Integer</measure>
    </unit>
    <unit id="Segment">
        <measure>CELC:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001603454</dei:EntityCentralIndexKey>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0134"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="Shares"
      xsi:nil="true"/>
    <CELC:NoncashOperatingLeaseExpenseNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="AsOf2025-12-31" id="xdx2ixbrl0597">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_ConvertibleNotesToCommonStockMember"
      id="xdx2ixbrl0655"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember"
      id="xdx2ixbrl0663"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:OtherAccruedLicenseMilestone
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:OtherAccruedInterest
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0999"
      unitRef="Shares"
      xsi:nil="true"/>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl1001"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1396"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1398"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1419"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1431"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1433"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1468"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000016">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000017">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000018">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000019">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000020">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000021">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000022">001-38207</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000023">Celcuity Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000024">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000025">82-2863566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000026">16305     36th</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000027">Avenue     North</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2025-01-01to2025-12-31" id="Fact000028">Suite     100</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000029">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000030">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000031">55446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000032">(763)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000033">392-0767</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000034">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000035">CELC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000037">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000040">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000043">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000045">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">457485677</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-17"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">48336675</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000049">Portions
of the registrant&#x2019;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders are incorporated by reference
into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000052">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="sp_002"&gt;&lt;/span&gt;ITEM
1C. Cybersecurity&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk
Management &amp;amp; Strategy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cybersecurity risk management process is a component of our overall approach to managing material risks that could impact our operations,
including cybersecurity threats. In general, we seek to manage material internal and third-party cybersecurity risks through an approach
that focuses on: (i) protecting information systems and the information residing therein; (ii) identifying, preventing, and mitigating
cybersecurity threats; and (iii) assessing and responding to cybersecurity incidents when they occur. Maintaining, monitoring, and updating
our information security program&#x2014;in an effort to ensure that it remains reasonable and appropriate in light of changes in the security
threat landscape, available technology, and applicable legal and contractual requirements&#x2014;is an ongoing effort.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;/div&gt;
    &lt;div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="text-align: center; width: 100%"&gt;51&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt"&gt;&lt;p style="margin: 0pt"&gt;&#160;&lt;/p&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zPE2J48wJxKe"&gt;We
have implemented and maintain various processes, procedures, and measures to support our overall risk management strategy and to manage
and mitigate the material risks posed by cybersecurity threats to our systems and data.&lt;/span&gt; With respect to cybersecurity, these measures
include conducting risk assessments of our operations and using a risk register to assess identified risks; developing business continuity,
disaster recovery and incident response plans; implementing technical safeguards and tools; conducting ongoing cybersecurity awareness
training; and using contractual protections where appropriate. Our incident response plan outlines the procedures for reporting, investigating,
and remediating cybersecurity incidents, including a framework to facilitate the escalation to our management team and board of cybersecurity
incidents, so that our management team is alerted in a timely manner to material information that would be required to be disclosed or
reported.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
IT department maintains policies and procedures regarding network security, data protection and incident response. Pursuant to those
policies, IT engages with the Chief Financial Officer, General Counsel and other experts when assessing cybersecurity threats, incident
response, and making disclosure determinations following a data or network breach. The Vice President, IT is accountable at the management
level for our overall IT risk management program. Additionally, our Chief Executive Officer and Audit Committee receive regular updates
from the Chief Financial Officer, General Counsel and the Vice President, IT about significant threats and incidents involving cybersecurity
and data protection, as well as security enhancements made to our IT infrastructure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
use &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zipBTX3fdTAb"&gt;third-party&lt;/span&gt; service providers for a variety of services throughout our business, ranging from infrastructure support and maintenance,
cybersecurity incident response, data protection and privacy compliance. In addition, we engage with contract research organizations,
contract manufacturing organizations, distributors, and other supply chain resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
believe that the use of external service providers improves our operational capabilities, and we have implemented a vendor qualification
and management program that applies to our service providers, including those that handle health information, personal information,
or other information subject to protection under applicable privacy and data protection regulations. This program is designed to identify,
address and seek to mitigate potential cybersecurity and data protection risks that arise from our use of external service providers.
While we do not have full visibility into the cybersecurity risk management processes of our vendors, we require new service providers
to complete a vendor questionnaire that identifies the vendor&#x2019;s network and user protections, such as the use of multi-factor authentication,
and other cybersecurity risk management processes. Vendors that store or access our confidential information are required to certify
that their information systems comply with applicable industry guidelines for cybersecurity, backup, and system recovery. We rely on
our third-party service providers to provide notification of, and remediate, significant cybersecurity threats and cybersecurity incidents
that jeopardize the confidentiality, integrity, or availability of our information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
periodically evaluate, test, and update our policies, standards, and processes to mitigate cybersecurity threats and manage incidents
effectively. These efforts include risk assessments, vulnerability assessments and remediations, phishing tests and employee education,
and external scans. Additionally, to enhance our capabilities, we periodically engage third-party service providers, including cybersecurity
consultants, to incorporate threat intelligence into our processes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this Form 10-K, we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zZdq1dpZU2wi"&gt;no&lt;/span&gt;t aware of any risks from cybersecurity threats, including those resulting from any previous
cybersecurity incidents experienced by us or, to our knowledge, by any of our third-party service providers, that have materially affected,
or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. For further discussion
of cybersecurity and data privacy risks that may materially affect the Company and how they may do so, see &#x201c;Risk Factors&#x2014;If
our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could face clinical
trial delays; regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational
harm; and other adverse consequences,&#x201d; included in Item 1A of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000053">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2025-01-01to2025-12-31" id="Fact000055">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000059">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zyNLlmbEho35"&gt;Our
Audit Committee oversees Celcuity&#x2019;s management of risks arising from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zPSgImT98hWj"&gt;Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations&lt;/span&gt;. Additionally, we have
processes to promptly notify the Audit Committee and Board of a significant cybersecurity incident and to inform the Audit Committee
and Board of remediation progress, as appropriate&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Vice President, IT has overall responsibility for our information security program, with support from our management team and specialized
partners in cybersecurity incident response and privacy. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zbgtjC9IF8O3"&gt;The process includes managing our incident response strategy. If a cybersecurity
incident meets certain criteria, however, our CEO, CFO and General Counsel will become involved with the response strategy, including
decisions about public disclosure and reporting. Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine
strategic cybersecurity priorities and to establish compliance procedures&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
believe our business leaders have the appropriate expertise, background and depth of experience to manage risks arising from cybersecurity
threats. Our Vice President, IT has served in various roles in information technology and information security for over three decades,
which includes experience in the biotech, pharmaceutical and healthcare industries and experience in cybersecurity risk management and
data privacy compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of our business, we, and the third parties upon which we rely, collect, process, receive, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, share and store  proprietary,
confidential, and sensitive information, including health information, personal information, credit card and other financial
information, or other sensitive information owned or controlled by ourselves or our customers, payors, and other parties.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000060">Our
Audit Committee oversees Celcuity&#x2019;s management of risks arising from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zPSgImT98hWj"&gt;Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations&lt;/span&gt;. Additionally, we have
processes to promptly notify the Audit Committee and Board of a significant cybersecurity incident and to inform the Audit Committee
and Board of remediation progress, as appropriate</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000061">Our CEO delivers periodic briefings
to the Board and Audit Committee on material cybersecurity risks that are pertinent to our business operations</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000062">The process includes managing our incident response strategy. If a cybersecurity
incident meets certain criteria, however, our CEO, CFO and General Counsel will become involved with the response strategy, including
decisions about public disclosure and reporting. Our Vice President, IT also coordinates with our CEO, CFO and General Counsel to determine
strategic cybersecurity priorities and to establish compliance procedures</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorOpinionTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000063">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2025 and 2024, and the related statements
of operations, changes in stockholders&#x2019; equity, and cash flows for each of the years in the two-year period ended December 31,
2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally
accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000064">Boulay LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000065">Minneapolis, Minnesota</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000066">542</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">165703000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">22515000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">275794000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">212589000</us-gaap:ShortTermInvestments>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">18896000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">6769000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">5266000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">2698000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">465659000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">244571000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">336000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">51000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">216000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">466558000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">245123000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">6407000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">9366000</us-gaap:AccountsPayableCurrent>
    <CELC:AccruedClinicalTrialCosts
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000110"
      unitRef="USD">16826000</CELC:AccruedClinicalTrialCosts>
    <CELC:AccruedClinicalTrialCosts
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">16708000</CELC:AccruedClinicalTrialCosts>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">20865000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">5477000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">54000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">172000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">44152000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">31723000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">54000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">195324000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">126527000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">97727000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">366003000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">129504000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">317577</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">317577</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">48244960</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">48244960</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">37143242</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">37143242</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">48000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">37000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">549404000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">387437000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">-448897000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">-271855000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">100555000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">115619000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000187"
      unitRef="USD">466558000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">245123000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">144995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">104203000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">27197000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">9064000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">172192000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">113267000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-172192000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-113267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">17148000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">10280000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">12298000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">11768000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">-4850000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">1488000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">-177042000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">-111779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">-177042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">-111779000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000226"
      unitRef="USDPShares">-3.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000228"
      unitRef="USDPShares">-3.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000230"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="USDPShares">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">46757691</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">46757691</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">39449393</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">39449393</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">25506012</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">26000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">854134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">299818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">-160076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">139769000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">1429</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">6988000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">6988000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">5365570</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">5000</CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">-536557</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">-1000</CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">-4000</CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">33215</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">276000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">276000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">103245</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">1827357</CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">2000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">14734000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">14736000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">435414</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">7378000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">7378000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">3871000</CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">4000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">56248000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">56252000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">1229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">1229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">-111779000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">-111779000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000328"
      unitRef="Shares">37143242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">317577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">387437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">-271855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">115619000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">37143242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">317577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">387437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">-271855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">115619000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">1029</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">21383000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">21383000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">3175770</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">3000</CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000358"
      unitRef="Shares">-317577</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStockShares>
    <CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">-3000</CELC:StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">77090</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">711000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">711000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">393086</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">3485000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">3485000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000382"
      unitRef="Shares">5282375</CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">6000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">42055000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">42061000</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">2786000</CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">2786000</CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrantsInConnectionWithNoteAgreement>
    <CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="Shares">2172368</CELC:StockIssuedDuringPeriodSharesIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">2000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">91550000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">91552000</CELC:StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">-177042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">-177042000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">48244960</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">549404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000407"
      unitRef="USD">-448897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">100555000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000420"
      unitRef="Shares">48244960</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">549404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">-448897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">100555000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000427"
      unitRef="USD">-177042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">-111779000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">167000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000434"
      unitRef="USD">130000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">21383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">6988000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">3137000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">1331000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">1104000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">1364000</us-gaap:PaidInKindInterest>
    <CELC:NoncashOperatingLeaseExpenseNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">-7000</CELC:NoncashOperatingLeaseExpenseNet>
    <CELC:ChangeInAccruedInterestIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">-630000</CELC:ChangeInAccruedInterestIncome>
    <CELC:ChangeInAccruedInterestIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">-150000</CELC:ChangeInAccruedInterestIncome>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">12127000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">1994000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">2991000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-2770000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">-3040000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">4316000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <CELC:IncreaseDecreaseInAccruedClinicalTrialCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">118000</CELC:IncreaseDecreaseInAccruedClinicalTrialCosts>
    <CELC:IncreaseDecreaseInAccruedClinicalTrialCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">10244000</CELC:IncreaseDecreaseInAccruedClinicalTrialCosts>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">15388000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">3013000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">-153280000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">-83467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">332507000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">642346000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">396342000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">705165000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">249000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000482"
      unitRef="USD">250000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">-64084000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">-63069000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">711000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">276000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">3485000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">770000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">42061000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">14736000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">6246000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">0</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">195004000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">2255000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">2438000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">27745000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">59226000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">91592000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">56252000</us-gaap:ProceedsFromOtherEquity>
    <CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">7356000</CELC:ProceedsFromAtmOfferingNetOfIssuanceCosts>
    <CELC:PaymentsForSecondaryRegistrationStatementCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">46000</CELC:PaymentsForSecondaryRegistrationStatementCosts>
    <CELC:PaymentsForSecondaryRegistrationStatementCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000520"
      unitRef="USD">228000</CELC:PaymentsForSecondaryRegistrationStatementCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">360552000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">138388000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">143188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">-8148000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">22515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">30663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">165703000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">22515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">10348000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">7586000</us-gaap:InterestPaidNet>
    <CELC:CashPaidForOperatingLeases
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">220000</CELC:CashPaidForOperatingLeases>
    <CELC:CashPaidForOperatingLeases
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">325000</CELC:CashPaidForOperatingLeases>
    <CELC:CommonStockWarrantsIssuedWithNotePayableTransaction
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">2786000</CELC:CommonStockWarrantsIssuedWithNotePayableTransaction>
    <CELC:CommonStockWarrantsIssuedWithNotePayableTransaction
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">1229000</CELC:CommonStockWarrantsIssuedWithNotePayableTransaction>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">82000</CELC:PropertyAndEquipmentIncludedInAccountsPayable>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000553"
      unitRef="USD">1000</CELC:PropertyAndEquipmentIncludedInAccountsPayable>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">42000</CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000558">&lt;p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zcuHu0fZI2Cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_822_zYNqMeQ8y7j3"&gt;Organization and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Organization&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Celcuity
Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company focused on the development of targeted
therapies for the treatment of multiple solid tumor indications. The Company&#x2019;s lead therapeutic candidate is gedatolisib, a kinase
inhibitor of the phosphatidylinositol 3-kinase (&#x201c;PI3K&#x201d;), serine/threonine-protein kinase protein kinase B (&#x201c;AKT&#x201d;),
mechanistic target of rapamycin (&#x201c;mTOR&#x201d;) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and
mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PI3K/AKT/mTOR (&#x201c;PAM&#x201d;)
pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational
therapies that target PI3K&#x3b1;, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in
combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor
receptor 2-negative (HER2-) (&#x201c;HR+/HER2-&#x201d;) advanced breast cancer (&#x201c;ABC&#x201d;) has completed enrollment and reported
detailed results for cohort 1, patients with &lt;i&gt;PIK3CA&lt;/i&gt; wild-type (&#x201c;WT&#x201d;) tumors, and has completed enrollment of cohort
2, patients with &lt;i&gt;PIK3CA&lt;/i&gt; mutant-type (&#x201c;MT&#x201d;) tumors. Our Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib
in combination with a cyclin-dependent kinase (&#x201c;CDK&#x201d;) 4/6 inhibitor and fulvestrant as first-line treatment for patients
with endocrine treatment resistant HR+/HER2- ABC is ongoing. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib
in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. The Company was co-founded
in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenue to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
inception, the Company has not generated any revenue from product sales or other sources and has incurred operating losses and negative
cash flows from operations. The Company&#x2019;s primary uses of cash, cash equivalents, and investments to date have been funding clinical
trials and research and development activities, the scaling of commercial launch related activities such as marketing, supply chain,
distribution, market access and other commercial operations, business planning, establishing and maintaining the Company&#x2019;s intellectual
property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and
administrative support for these operations. As of December 31, 2025, the Company had an accumulated deficit of $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zlytoKkGzHY4" title="Accumulated deficit"&gt;448.9&lt;/span&gt; million. To date,
the Company has funded operations primarily through private placements, registered offerings of its equity securities, convertible notes,
and borrowings under loan agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had $&lt;span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zcJP1Uc9YhH4" title="Cash and cash equivalents"&gt;441.5&lt;/span&gt; million in cash, cash equivalents and short-term investments. The Company believes its existing
cash, cash equivalents and short-term investments will be sufficient to fund planned operations for at least one year from the issuance
of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to companies in the development stage including, but not limited to, the clinical and commercial success
of its initial drug product, gedatolisib, the regulatory approval of gedatolisib, the need for substantial additional financing to achieve
its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000560"
      unitRef="USD">-448900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000562"
      unitRef="USD">441500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000564">&lt;p id="xdx_80C_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_za1GI9lDVlY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_821_zMV7gxTrM3X"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZyqntnbGC3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zSEcArUGpUL7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
Operating results during the year ended December 31, 2025, are not necessarily indicative of results to be expected for any future year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_z4wX2KuNTQh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zq0Rkpzqv5Hd"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such
estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyuqO5zJgMfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zX3Kco5Tshj5"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains its accounts at two financial institutions. As of December 31, 2025 and 2024, the Company had $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_z9RHZLhNlC2g" title="Cash and cash equivalents"&gt;165.7&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zzkYYFbsgxCl" title="Cash and cash equivalents"&gt;22.5&lt;/span&gt;
million, respectively, in business checking accounts and money market funds that are considered cash equivalents. Cash and cash equivalents
are classified as Level 1 assets under the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--InvestmentPolicyTextBlock_zHhi3kTKMJhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zNunFUOvHYNb"&gt;Investments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains its investments in U.S. treasury securities and has classified them as held-to-maturity at the time of purchase. Held-to-maturity
purchases are those investments which the Company has the ability and intent to hold until maturity. Held-to-maturity investments are
recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity investment using the straight-line method. The difference between the carrying
value, which is based on cost, and the aggregate fair value of the held-to-maturity investments, was immaterial as of December 31, 2025.
As of December 31, 2025 and 2024, the Company had $&lt;span id="xdx_907_eus-gaap--ShortTermInvestments_iI_pn5n6_c20251231_zZD871QV3Pu1" title="Short-term investments"&gt;275.8&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_ziLL23bT0Wa9" title="Short-term investments"&gt;212.6&lt;/span&gt; million, respectively, of short-term investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zW2gzexcYwa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zmywVMpiYPyj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The accounting guidance establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs that are significant to the fair value measurement and supported by little or no market activity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
level in the fair value hierarchy within which a fair value measurement in its entirety falls, is based on the lowest level input that
is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of cash equivalents, accounts payable, accrued expenses and other financial working capital items approximate fair value
as of each of December 31, 2025 and 2024, due to the short maturity nature of these items. Refer to Note 10 for disclosures around the
Company&#x2019;s &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z13StAFalI86" title="Accrue interest payable rate"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z2cFbGR9qQUa" title="Accrue interest payable rate"&gt;2.750&lt;/span&gt;&lt;/span&gt;% Senior Notes due 2031 (the &#x201c;Notes&#x201d;) and note payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZKo6AbqVvxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zT1PkDBaxKtc"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Financial
instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents, and
investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company
has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--AllowanceForCreditLossesPolicyTextBlock_zPDb6xwx063k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zCVZbl4QFzhc"&gt;Allowance
for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
investments in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that
it will be required to sell, the investment before recovery of its amortized cost basis. If either of the criteria regarding intent or
requirement to sell is met, the investment&#x2019;s amortized cost basis is written down to fair value through earnings. For investments
that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses
or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes
in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates
that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost
basis of the investment. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit
loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost
basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQGdqKZJAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zaLp4t9hew6c"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and
repairs are expensed as incurred; major improvements and betterments are capitalized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
useful lives of property and equipment are as follows for the major classes of assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_ztk6McHWACA7" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify"&gt;Asset description&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center"&gt;Estimated useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives"&gt;4&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zi5mSi50J9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zx6fJWTV2tY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_z8XMZLoRvvog"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies
leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use
asset and current and non-current lease liabilities, as applicable, on the balance sheets. The Company has elected not to recognize on
the balance sheets leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease
term. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s leases may include options to extend or terminate the leases. Periods covered by an option to extend the lease are included
in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate
the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. The Company monitors
its plans to renew or terminate its material leases each reporting period. If a lease includes provisions for leasehold improvements
for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets.
If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding
right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Lease
liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease
term. The present value of future lease payments is discounted using the interest rate implicit in the lease contracts if that rate
is readily determinable; otherwise, the Company utilizes information available at the commencement of the lease to calculate the incremental
borrowing rate, which reflects the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar
term and in a similar economic environment. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Lease
cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the
period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities,
real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company.
The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CapitalizationAndAmortizationOfFuelCostsPolicy_zZyNUMrJAi27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zX4lzNpaEKzi"&gt;Capitalized
Software Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company capitalizes qualifying costs incurred during the application development stage related to software developed for internal use.
Capitalized software development costs are classified as other non-current assets on the balance sheets. As of December 31, 2025 and
2024, the Company had $&lt;span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn5n6_c20251231_zM6b5cWY6VC" title="Capitalized software development costs"&gt;0.1&lt;/span&gt; million and &lt;span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0_do_c20241231_zlMEzTHKCPo1" title="Capitalized software development costs"&gt;no&lt;/span&gt; capitalized software development costs, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software,
beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general
and administrative expenses. The Company did not record any amortization expense during the years ended December 31, 2025 and 2024. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlOi0Upf1PA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zhM3A0omLsCd"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment,
the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--DeferredChargesPolicyTextBlock_zD1nPD22SC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zqNNtcbHJsu7"&gt;Deferred
Transaction Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
transaction costs primarily consist of legal fees that are capitalized as incurred and will be offset against the proceeds from future
equity financing arrangements. The deferred transaction costs will be reviewed periodically to assess the probability that future securities
will be offered. In the event that no future offering will occur, any deferred transaction costs will be expensed. Total costs incurred,
but not accounted for as a reduction in equity, were $&lt;span id="xdx_904_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20251231_z8r3RBeFpgX6" title="Deferred transaction costs"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20241231_zUpNBA8nvcm2" title="Deferred transaction costs"&gt;0.2&lt;/span&gt; million as of December 31, 2025 and 2024, respectively. D&lt;span style="background-color: white"&gt;eferred
transaction costs are classified as other assets on the balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--DebtPolicyTextBlock_zcAx6RA6yAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zgV1CyFnZHhk"&gt;Debt
Issuance Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes debt issuance costs as deferred costs, which are capitalized and amortized over the term of the related debt
using the effective interest method. These costs primarily consist of fees, commissions, and legal and other costs directly
attributable to securing debt financing. Debt issuance costs are reported as a direct reduction of the carrying amount of the
related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements of operations over
the life of the debt instrument. In the event of early extinguishment of debt, any related unamortized debt issuance costs are
written off and recognized as a component of the gain or loss on extinguishment of debt in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zV1w1M8nL3P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zCXXW4tYrEEk"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other
than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zviD542vWEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zp6BOAhm9hV1"&gt;Commitments
and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other
amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount,
the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z1nUe2xca6V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zMG8KiOHKv49"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation consists of stock options, restricted stock awards and restricted stock units issued
to certain employees and non-employees of the Company under the 2017 Amended and Restated Stock Incentive Plan, and shares issued under
the 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to account for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation expense based on the estimated grant date fair value using the Black-Scholes
option-pricing model and the expense is recognized on a straight-line basis over the requisite service period. Compensation expense
for awards with performance-based conditions is recognized when the achievement of the performance condition is deemed
probable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes the Monte Carlo simulation model for awards with market-based vesting conditions. If the factors change and different
assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
inputs for the Black-Scholes valuation model and the Monte Carlo simulation model require management&#x2019;s significant assumptions,
including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected
dividends. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available
in combination with the Company&#x2019;s calculated volatility since being publicly traded. The expected term of the award is based on
the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free interest rate is based on the
rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected term of the award at the
grant date. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay
any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with such agreements would also be cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records compensation expense based on the quoted fair value of the shares on the grant date over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;ESPP&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
expense for ESPP rights is recorded in line with each respective offering period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIunJ3n2ufXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z0eJafjg7AM5"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development costs were $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn6n6_c20250101__20251231_z12fj9fPToT6" title="Research and development expense"&gt;145.0&lt;/span&gt; million and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_z3gNzyhfz9ni" title="Research and development expense"&gt;104.2&lt;/span&gt; million during the years
ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--InProcessResearchAndDevelopmentPolicy_zvxAfo7Fc65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z4e7z51IdGNc"&gt;Clinical
Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on third-party service providers to conduct certain aspects of clinical studies and to formulate and manufacture its drug
product. While there are alternative vendors that can perform these functions, any disruption or delay by the Company&#x2019;s current
third-party service providers in carrying out their contractual duties could delay its clinical trials and/or the commercial launch of
 gedatolisib, if approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). The Company records prepaid or accrued
clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials. These costs can be a
significant component of the Company&#x2019;s research and development expenses. The Company uses progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, the Company&#x2019;s estimated expenses in future periods and actual services performed
may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes
to the Company&#x2019;s prepaid or accrued clinical trial costs could materially affect the Company&#x2019;s results of operations and
financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--LicensesPolicyTextBlock_zc84EiKOSzja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zdYLlh0qBtz4"&gt;Licenses&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upfront
payments and other consideration under license agreements are expensed as research and development expense upon receipt of the license,
and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
license agreements include milestone payments which are recognized when it becomes probable that the achievement of those milestones
will be met. The Company records this expense as research and development expense in its statements of operations. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--PatentCostsPolicyTextBlock_zawpsPqfjNCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_z3zaSHAgoOal"&gt;Patent
Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zMp5hH9dGpD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zJiPQCUlSyMg"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss
and tax credit carryforwards. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized
in results of operations in the period that includes the enactment date. The effects of any future changes in tax laws or rates have
not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that
the deferred tax assets will be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the impact of an uncertain tax position in its financial statements if, in management&#x2019;s judgment, the position
is more-likely-than-not sustainable upon audit based on the position&#x2019;s technical merits. This involves the identification of potential
uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position
is necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgrcRyEGF68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zxYl1G2LUNR6"&gt;Segment
Data&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has &lt;span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20251231_zyV0gJPysRfb" title="Number of operating segment"&gt;&lt;span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zBXIOtyInZfa" title="Number of reportable segment"&gt;one&lt;/span&gt;&lt;/span&gt; reportable operating segment, which is the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#x2019;s chief operating decision makers (&#x201c;CODMs&#x201d;) are its chief executive officer, chief science
officer and chief financial officer, who, together manage the Company&#x2019;s operations as one operating segment for the purpose of
evaluating financial performance and allocating resources. The CODMs assess the performance and allocate resources for the reportable
segment based on net loss and total assets, which are the same amounts in all material respects as those reported in the statements of
operations and balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--RecentAccountingPrononcementAdoptedPolicyTextBlock_zykMCmeNJmPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z9oy2onAva6a"&gt;Recently Adopted
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09,
&lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which enhances the annual income
tax disclosures for the effective tax rate reconciliation, income taxes paid, and continuing operations. ASU 2023-09 also eliminates
certain disclosure requirements related to unrecognized tax benefits. ASU 2023-09 is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 on January 1, 2025 on a retrospective basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zI0ml4PUQfTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zw21V0E5gg1h"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03&lt;i&gt;, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; (&#x201c;ASU 2024-03&#x201d;), which requires public entities to provide
disaggregated disclosure of income statement expense. In January 2025, the FASB issued ASU 2025-01, &lt;i&gt;Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt;, to clarify the effective
date of ASU 2024-03. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025&lt;i&gt;, &lt;/i&gt;the FASB issued ASU 2025-05&lt;i&gt;, Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt; (&#x201c;ASU
2025-05&#x201d;), which provides certain entities with an additional practical expedient for estimating expected credit losses on current
accounts receivable and current contract assets arising from revenue transactions under Accounting Standards Codification (&#x201c;ASC&#x201d;)
606. ASU 2025-05 is effective for all entities for annual and interim periods in fiscal years beginning after December 15, 2025. Early
adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2025-05 on its financial statements and
related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-06, &lt;i&gt;Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software &lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which modernizes the accounting for
internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs
when management has committed to the software project, and it is probable the software will be completed and perform to its intended
use. In evaluating whether it is probable the project will be completed, management is required to consider whether there is significant
uncertainty associated with the development activities of the software. ASU 2025-06 is effective for annual and interim periods beginning
after December 15, 2027. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective
basis. The Company is currently evaluating the timing, method of its adoption, and effect of ASU 2025-06 on its financial statements
and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zCWzM4W03Ghd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000566">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZyqntnbGC3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zSEcArUGpUL7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
Operating results during the year ended December 31, 2025, are not necessarily indicative of results to be expected for any future year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000568">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_z4wX2KuNTQh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zq0Rkpzqv5Hd"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenue
and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such
estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000570">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyuqO5zJgMfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zX3Kco5Tshj5"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains its accounts at two financial institutions. As of December 31, 2025 and 2024, the Company had $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_z9RHZLhNlC2g" title="Cash and cash equivalents"&gt;165.7&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zzkYYFbsgxCl" title="Cash and cash equivalents"&gt;22.5&lt;/span&gt;
million, respectively, in business checking accounts and money market funds that are considered cash equivalents. Cash and cash equivalents
are classified as Level 1 assets under the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000572"
      unitRef="USD">165700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000574"
      unitRef="USD">22500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000576">&lt;p id="xdx_841_eus-gaap--InvestmentPolicyTextBlock_zHhi3kTKMJhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zNunFUOvHYNb"&gt;Investments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains its investments in U.S. treasury securities and has classified them as held-to-maturity at the time of purchase. Held-to-maturity
purchases are those investments which the Company has the ability and intent to hold until maturity. Held-to-maturity investments are
recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity investment using the straight-line method. The difference between the carrying
value, which is based on cost, and the aggregate fair value of the held-to-maturity investments, was immaterial as of December 31, 2025.
As of December 31, 2025 and 2024, the Company had $&lt;span id="xdx_907_eus-gaap--ShortTermInvestments_iI_pn5n6_c20251231_zZD871QV3Pu1" title="Short-term investments"&gt;275.8&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_ziLL23bT0Wa9" title="Short-term investments"&gt;212.6&lt;/span&gt; million, respectively, of short-term investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000578"
      unitRef="USD">275800000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000580"
      unitRef="USD">212600000</us-gaap:ShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000582">&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zW2gzexcYwa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zmywVMpiYPyj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The accounting guidance establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Unobservable inputs that are significant to the fair value measurement and supported by little or no market activity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
level in the fair value hierarchy within which a fair value measurement in its entirety falls, is based on the lowest level input that
is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of cash equivalents, accounts payable, accrued expenses and other financial working capital items approximate fair value
as of each of December 31, 2025 and 2024, due to the short maturity nature of these items. Refer to Note 10 for disclosures around the
Company&#x2019;s &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z13StAFalI86" title="Accrue interest payable rate"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeniorNotesDueTwoThousandAndThirtyOneNotesMember_z2cFbGR9qQUa" title="Accrue interest payable rate"&gt;2.750&lt;/span&gt;&lt;/span&gt;% Senior Notes due 2031 (the &#x201c;Notes&#x201d;) and note payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-01-012024-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Pure">0.02750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-01-012025-12-31_custom_SeniorNotesDueTwoThousandAndThirtyOneNotesMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Pure">0.02750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-12-31" id="Fact000588">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZKo6AbqVvxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zT1PkDBaxKtc"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Financial
instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents, and
investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company
has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due
to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <CELC:AllowanceForCreditLossesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000590">&lt;p id="xdx_849_ecustom--AllowanceForCreditLossesPolicyTextBlock_zPDb6xwx063k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zCVZbl4QFzhc"&gt;Allowance
for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
investments in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that
it will be required to sell, the investment before recovery of its amortized cost basis. If either of the criteria regarding intent or
requirement to sell is met, the investment&#x2019;s amortized cost basis is written down to fair value through earnings. For investments
that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses
or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes
in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates
that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost
basis of the investment. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit
loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost
basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CELC:AllowanceForCreditLossesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000592">&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQGdqKZJAib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zaLp4t9hew6c"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and
repairs are expensed as incurred; major improvements and betterments are capitalized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
useful lives of property and equipment are as follows for the major classes of assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_ztk6McHWACA7" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify"&gt;Asset description&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center"&gt;Estimated useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives"&gt;4&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zi5mSi50J9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000594">&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_z4JmSv0EuJ48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
useful lives of property and equipment are as follows for the major classes of assets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_ztk6McHWACA7" style="display: none"&gt;Schedule of Estimated Useful Lives of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: justify"&gt;Asset description&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 49%; font-weight: bold; text-align: center"&gt;Estimated useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zfddJVWMFIw8" title="Estimated useful lives"&gt;4&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231_zzUFMy3TC2H7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELC:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000596">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000599">&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zx6fJWTV2tY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_z8XMZLoRvvog"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies
leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use
asset and current and non-current lease liabilities, as applicable, on the balance sheets. The Company has elected not to recognize on
the balance sheets leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease
term. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s leases may include options to extend or terminate the leases. Periods covered by an option to extend the lease are included
in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate
the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. The Company monitors
its plans to renew or terminate its material leases each reporting period. If a lease includes provisions for leasehold improvements
for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets.
If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding
right-of-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Lease
liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease
term. The present value of future lease payments is discounted using the interest rate implicit in the lease contracts if that rate
is readily determinable; otherwise, the Company utilizes information available at the commencement of the lease to calculate the incremental
borrowing rate, which reflects the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar
term and in a similar economic environment. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Lease
cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the
period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities,
real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company.
The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CapitalizationAndAmortizationOfFuelCostsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000601">&lt;p id="xdx_84B_eus-gaap--CapitalizationAndAmortizationOfFuelCostsPolicy_zZyNUMrJAi27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zX4lzNpaEKzi"&gt;Capitalized
Software Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company capitalizes qualifying costs incurred during the application development stage related to software developed for internal use.
Capitalized software development costs are classified as other non-current assets on the balance sheets. As of December 31, 2025 and
2024, the Company had $&lt;span id="xdx_907_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn5n6_c20251231_zM6b5cWY6VC" title="Capitalized software development costs"&gt;0.1&lt;/span&gt; million and &lt;span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareGross_iI_pp0p0_do_c20241231_zlMEzTHKCPo1" title="Capitalized software development costs"&gt;no&lt;/span&gt; capitalized software development costs, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company amortizes the capitalized software development costs on a straight-line basis over the estimated useful life of the software,
beginning when the asset is substantially ready for use. The amortization of capitalized software development costs is reflected in general
and administrative expenses. The Company did not record any amortization expense during the years ended December 31, 2025 and 2024. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CapitalizationAndAmortizationOfFuelCostsPolicy>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000603"
      unitRef="USD">100000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">0</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000607">&lt;p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlOi0Upf1PA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zhM3A0omLsCd"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment,
the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000609">&lt;p id="xdx_847_eus-gaap--DeferredChargesPolicyTextBlock_zD1nPD22SC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zqNNtcbHJsu7"&gt;Deferred
Transaction Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
transaction costs primarily consist of legal fees that are capitalized as incurred and will be offset against the proceeds from future
equity financing arrangements. The deferred transaction costs will be reviewed periodically to assess the probability that future securities
will be offered. In the event that no future offering will occur, any deferred transaction costs will be expensed. Total costs incurred,
but not accounted for as a reduction in equity, were $&lt;span id="xdx_904_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20251231_z8r3RBeFpgX6" title="Deferred transaction costs"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--DeferredCostsCurrent_iI_pn5n6_c20241231_zUpNBA8nvcm2" title="Deferred transaction costs"&gt;0.2&lt;/span&gt; million as of December 31, 2025 and 2024, respectively. D&lt;span style="background-color: white"&gt;eferred
transaction costs are classified as other assets on the balance sheets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000611"
      unitRef="USD">200000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000613"
      unitRef="USD">200000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000615">&lt;p id="xdx_84A_eus-gaap--DebtPolicyTextBlock_zcAx6RA6yAp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zgV1CyFnZHhk"&gt;Debt
Issuance Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes debt issuance costs as deferred costs, which are capitalized and amortized over the term of the related debt
using the effective interest method. These costs primarily consist of fees, commissions, and legal and other costs directly
attributable to securing debt financing. Debt issuance costs are reported as a direct reduction of the carrying amount of the
related debt on the balance sheets. Amortization of these costs is recorded as interest expense in the statements of operations over
the life of the debt instrument. In the event of early extinguishment of debt, any related unamortized debt issuance costs are
written off and recognized as a component of the gain or loss on extinguishment of debt in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000617">&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zV1w1M8nL3P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zCXXW4tYrEEk"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other
than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000619">&lt;p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zviD542vWEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zp6BOAhm9hV1"&gt;Commitments
and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the
amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other
amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount,
the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000621">&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z1nUe2xca6V8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zMG8KiOHKv49"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation consists of stock options, restricted stock awards and restricted stock units issued
to certain employees and non-employees of the Company under the 2017 Amended and Restated Stock Incentive Plan, and shares issued under
the 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to account for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes stock-based compensation expense based on the estimated grant date fair value using the Black-Scholes
option-pricing model and the expense is recognized on a straight-line basis over the requisite service period. Compensation expense
for awards with performance-based conditions is recognized when the achievement of the performance condition is deemed
probable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes the Monte Carlo simulation model for awards with market-based vesting conditions. If the factors change and different
assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
inputs for the Black-Scholes valuation model and the Monte Carlo simulation model require management&#x2019;s significant assumptions,
including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected
dividends. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available
in combination with the Company&#x2019;s calculated volatility since being publicly traded. The expected term of the award is based on
the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110. The risk-free interest rate is based on the
rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected term of the award at the
grant date. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay
any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with such agreements would also be cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records compensation expense based on the quoted fair value of the shares on the grant date over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;ESPP&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
expense for ESPP rights is recorded in line with each respective offering period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000623">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIunJ3n2ufXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z0eJafjg7AM5"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development costs were $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn6n6_c20250101__20251231_z12fj9fPToT6" title="Research and development expense"&gt;145.0&lt;/span&gt; million and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_z3gNzyhfz9ni" title="Research and development expense"&gt;104.2&lt;/span&gt; million during the years
ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-6"
      id="Fact000625"
      unitRef="USD">145000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact000627"
      unitRef="USD">104200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000629">&lt;p id="xdx_840_eus-gaap--InProcessResearchAndDevelopmentPolicy_zvxAfo7Fc65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z4e7z51IdGNc"&gt;Clinical
Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on third-party service providers to conduct certain aspects of clinical studies and to formulate and manufacture its drug
product. While there are alternative vendors that can perform these functions, any disruption or delay by the Company&#x2019;s current
third-party service providers in carrying out their contractual duties could delay its clinical trials and/or the commercial launch of
 gedatolisib, if approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). The Company records prepaid or accrued
clinical trial costs conducted by third-party service providers, which includes the conduct of clinical trials. These costs can be a
significant component of the Company&#x2019;s research and development expenses. The Company uses progress reports from third-party service
providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid or accrued clinical
trial costs. With the ongoing clinical trials, the Company&#x2019;s estimated expenses in future periods and actual services performed
may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes
to the Company&#x2019;s prepaid or accrued clinical trial costs could materially affect the Company&#x2019;s results of operations and
financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <CELC:LicensesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000631">&lt;p id="xdx_840_ecustom--LicensesPolicyTextBlock_zc84EiKOSzja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zdYLlh0qBtz4"&gt;Licenses&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upfront
payments and other consideration under license agreements are expensed as research and development expense upon receipt of the license,
and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
license agreements include milestone payments which are recognized when it becomes probable that the achievement of those milestones
will be met. The Company records this expense as research and development expense in its statements of operations. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CELC:LicensesPolicyTextBlock>
    <CELC:PatentCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000633">&lt;p id="xdx_84B_ecustom--PatentCostsPolicyTextBlock_zawpsPqfjNCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_z3zaSHAgoOal"&gt;Patent
Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CELC:PatentCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000635">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zMp5hH9dGpD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zJiPQCUlSyMg"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under
this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss
and tax credit carryforwards. Deferred taxes are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized
in results of operations in the period that includes the enactment date. The effects of any future changes in tax laws or rates have
not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that
the deferred tax assets will be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the impact of an uncertain tax position in its financial statements if, in management&#x2019;s judgment, the position
is more-likely-than-not sustainable upon audit based on the position&#x2019;s technical merits. This involves the identification of potential
uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position
is necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000637">&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgrcRyEGF68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zxYl1G2LUNR6"&gt;Segment
Data&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has &lt;span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20251231_zyV0gJPysRfb" title="Number of operating segment"&gt;&lt;span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zBXIOtyInZfa" title="Number of reportable segment"&gt;one&lt;/span&gt;&lt;/span&gt; reportable operating segment, which is the development of targeted therapies for the treatment of multiple solid tumor
indications. The Company&#x2019;s chief operating decision makers (&#x201c;CODMs&#x201d;) are its chief executive officer, chief science
officer and chief financial officer, who, together manage the Company&#x2019;s operations as one operating segment for the purpose of
evaluating financial performance and allocating resources. The CODMs assess the performance and allocate resources for the reportable
segment based on net loss and total assets, which are the same amounts in all material respects as those reported in the statements of
operations and balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000639"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000641"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <CELC:RecentAccountingPrononcementAdoptedPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000643">&lt;p id="xdx_84C_ecustom--RecentAccountingPrononcementAdoptedPolicyTextBlock_zykMCmeNJmPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z9oy2onAva6a"&gt;Recently Adopted
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09,
&lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which enhances the annual income
tax disclosures for the effective tax rate reconciliation, income taxes paid, and continuing operations. ASU 2023-09 also eliminates
certain disclosure requirements related to unrecognized tax benefits. ASU 2023-09 is effective for annual reporting periods beginning
after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 on January 1, 2025 on a retrospective basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</CELC:RecentAccountingPrononcementAdoptedPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000645">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zI0ml4PUQfTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zw21V0E5gg1h"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03&lt;i&gt;, Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt; (&#x201c;ASU 2024-03&#x201d;), which requires public entities to provide
disaggregated disclosure of income statement expense. In January 2025, the FASB issued ASU 2025-01, &lt;i&gt;Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt;, to clarify the effective
date of ASU 2024-03. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods
beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025&lt;i&gt;, &lt;/i&gt;the FASB issued ASU 2025-05&lt;i&gt;, Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/i&gt; (&#x201c;ASU
2025-05&#x201d;), which provides certain entities with an additional practical expedient for estimating expected credit losses on current
accounts receivable and current contract assets arising from revenue transactions under Accounting Standards Codification (&#x201c;ASC&#x201d;)
606. ASU 2025-05 is effective for all entities for annual and interim periods in fiscal years beginning after December 15, 2025. Early
adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2025-05 on its financial statements and
related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-06, &lt;i&gt;Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software (Subtopic 350-40):
Targeted Improvements to the Accounting for Internal-Use Software &lt;/i&gt;(&#x201c;ASU 2025-06&#x201d;), which modernizes the accounting for
internal-use software. ASU 2025-06 removes all references to software development stages and requires capitalization of software costs
when management has committed to the software project, and it is probable the software will be completed and perform to its intended
use. In evaluating whether it is probable the project will be completed, management is required to consider whether there is significant
uncertainty associated with the development activities of the software. ASU 2025-06 is effective for annual and interim periods beginning
after December 15, 2027. The guidance may be applied on a prospective basis, a modified basis for in-process projects, or a retrospective
basis. The Company is currently evaluating the timing, method of its adoption, and effect of ASU 2025-06 on its financial statements
and related disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000647">&lt;p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zRMsbBidY5v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span&gt;&lt;span id="xdx_82C_zRnbgNmfQRfk"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options, convertible note, warrants,
restricted stock and preferred stock have been excluded from the calculation because their effect would be anti-dilutive.
Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zORYutVOwcoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the potentially-dilutive shares that have been excluded from the calculation of diluted weighted-average shares
outstanding because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z5QGd34saOD3" style="display: none"&gt;Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zmiwONDliCC2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_ziB8ERXgONb3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zMZiJmSvch96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,842,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesToCommonStockMember_zCYOYBvJ442f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note as-if-converted-to-common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,296,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z0n4IUGxwnmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;274,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,521,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zSts8C0b8t1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zhapCbcSARVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Preferred stock as-if-converted-to-common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,175,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zXTfV9N7vzj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,440,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zpfn2jNhLOWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
maximum number of shares of common stock issuable upon conversion of the Notes is &lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_zZwOhTZ0Xqdf" title="Debt conversion, number of shares issued"&gt;5,296,053&lt;/span&gt;. As of December 31, 2025, the number of shares
issuable based on the Company&#x2019;s closing common stock price would be &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20250101__20251231_zsPa8XWSvsY9" title="Debt conversion, number of shares issued"&gt;3,923,002&lt;/span&gt; if the Notes were converted in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, pre-funded warrant shares of &lt;span id="xdx_90A_ecustom--PrefundedWarrantShares_iI_c20251231_zYYCzTTEV7g1" title="Pre-funded warrant shares"&gt;6,147,787&lt;/span&gt; and &lt;span id="xdx_907_ecustom--PrefundedWarrantShares_iI_c20241231_zckerqX3QTgl" title="Pre-funded warrant shares"&gt;5,747,787&lt;/span&gt;, respectively, were included in the
computation of basic and diluted net loss per share, as the pre-funded warrants are exercisable for nominal consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000649">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zORYutVOwcoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the potentially-dilutive shares that have been excluded from the calculation of diluted weighted-average shares
outstanding because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z5QGd34saOD3" style="display: none"&gt;Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zmiwONDliCC2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_ziB8ERXgONb3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseCommonStockMember_zMZiJmSvch96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,842,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesToCommonStockMember_zCYOYBvJ442f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note as-if-converted-to-common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,296,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_z0n4IUGxwnmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;274,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,521,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zSts8C0b8t1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementEquityComponentsAxis__custom--PreferredStockOnAnAsIfConvertedToCommonStockMember_zhapCbcSARVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Preferred stock as-if-converted-to-common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0663"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,175,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zXTfV9N7vzj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,440,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,004,978&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">5842485</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_OptionsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000652"
      unitRef="Shares">4306977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_ConvertibleNotesToCommonStockMember"
      decimals="INF"
      id="Fact000654"
      unitRef="Shares">5296053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">274773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact000658"
      unitRef="Shares">5521152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000660"
      unitRef="Shares">27439</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000661"
      unitRef="Shares">1079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_PreferredStockOnAnAsIfConvertedToCommonStockMember"
      decimals="INF"
      id="Fact000664"
      unitRef="Shares">3175770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000666"
      unitRef="Shares">11440750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">13004978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2025-01-012025-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">5296053</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">3923002</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <CELC:PrefundedWarrantShares
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">6147787</CELC:PrefundedWarrantShares>
    <CELC:PrefundedWarrantShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">5747787</CELC:PrefundedWarrantShares>
    <us-gaap:InvestmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000677">&lt;p id="xdx_80E_eus-gaap--InvestmentTextBlock_zaEzdAeDtini" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82A_zZTKmvcocLb8"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
investments for which the Company has the positive intent and ability to hold to maturity are classified as held-to-maturity and reported
at historical cost adjusted for amortization of premiums and accretion of discounts. Expected credit losses, if any, are recorded through
the establishment of an allowance for credit losses. All of the Company&#x2019;s held-to-maturity investments are U.S. treasury securities
that are guaranteed or otherwise supported by the United States government and have no history of credit losses. Accordingly, the Company
does not expect to incur any credit losses on held-to-maturity investments and has no allowance for credit losses recorded for these
investments. As of December 31, 2025, all of the Company&#x2019;s held-to-maturity investments had maturities of one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--InvestmentTableTextBlock_zIw6y3x3FzVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the Company&#x2019;s held-to-maturity investments (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z9VkKqNddUAc" style="display: none"&gt;Schedule of Investment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zS2HjqxEFScd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zdHHY3oytKqk"&gt;Amortized Cost, as Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zw5EFQuv06ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_zMPPl2Q5vWpl"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_480_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zhlS1jzeWiT8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zIHFZOjFXl3l"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_zOZiMPCK5oF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zYTQN66rSKi1"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20251231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zyZAFzIPQay2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;275,794&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0686"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;276,019&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20251231_z9wbGKXfl9vi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;275,794&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zDJAenC5wlUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zWQvLHjoRvda"&gt;Amortized Cost, as Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zJ8u1D7HdVg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_z5SmvX2XEiy6"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zzXxS7N8w3Li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zbYZEkUByjd9"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_z8NLpWxhuCX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zBwpQIjZEqnk"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQJNT1vkE24g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;212,589&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;82&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;212,671&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20241231_zfqjcTaUByIg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zP75axjGoJB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s U.S. treasury securities are classified as Level 2 investments within the fair value hierarchy. These assets have been
valued based on quoted prices in active markets for similar assets or other inputs that are observable or can be corroborated by observable
market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no changes in valuation techniques or transfers within the fair value hierarchy during the years presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000679">&lt;p id="xdx_897_eus-gaap--InvestmentTableTextBlock_zIw6y3x3FzVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the Company&#x2019;s held-to-maturity investments (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z9VkKqNddUAc" style="display: none"&gt;Schedule of Investment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zS2HjqxEFScd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zdHHY3oytKqk"&gt;Amortized Cost, as Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zw5EFQuv06ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_zMPPl2Q5vWpl"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_480_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zhlS1jzeWiT8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zIHFZOjFXl3l"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_zOZiMPCK5oF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zYTQN66rSKi1"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20251231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zyZAFzIPQay2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;275,794&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0686"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;276,019&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20251231_z9wbGKXfl9vi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;275,794&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--HeldToMaturitySecurities_iI_pn3n3_zDJAenC5wlUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_912_eus-gaap--HeldToMaturitySecurities_zWQvLHjoRvda"&gt;Amortized Cost, as Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_iI_pn3n3_zJ8u1D7HdVg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_917_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_z5SmvX2XEiy6"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_iI_pn3n3_zzXxS7N8w3Li" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_919_eus-gaap--HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_zbYZEkUByjd9"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_pn3n3_z8NLpWxhuCX7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_918_eus-gaap--HeldToMaturitySecuritiesFairValue_zBwpQIjZEqnk"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amortized Cost, as Adjusted&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gross Unrealized Holding Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Estimated Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zQJNT1vkE24g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;U.S. treasury securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;212,589&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;82&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;212,671&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20241231_zfqjcTaUByIg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;212,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">275794000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">225000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2025-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">276019000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000688"
      unitRef="USD">275794000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">225000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">276019000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000696"
      unitRef="USD">212589000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000697"
      unitRef="USD">82000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">212671000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">212589000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000701"
      unitRef="USD">82000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">212671000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000705">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z1IzjeLSsmm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_825_zc93a7nIJAsl"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxBgPwA6mhB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zHgvA72Kgd55" style="display: none"&gt;Summary of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zyTdLKSsDgNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zIuzqQovFCHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOVBm9dvY31" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhWT1ENzaIH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zvOutspI9J44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 9pt"&gt;Total property and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zP8QBER7Dw9c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zdsQLanmJtpf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zNh4YhIfYeKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_900_eus-gaap--Depreciation_pn5n6_c20250101__20251231_zIYKdD9wMTPd" title="Depreciation expense"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--Depreciation_pn5n6_c20240101__20241231_zXUT31eu0ygb" title="Depreciation expense"&gt;0.1&lt;/span&gt; million during the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000707">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxBgPwA6mhB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zHgvA72Kgd55" style="display: none"&gt;Summary of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zyTdLKSsDgNf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zIuzqQovFCHa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOVBm9dvY31" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Furniture and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhWT1ENzaIH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;304&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzGp4_zvOutspI9J44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 9pt"&gt;Total property and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzGp4_zP8QBER7Dw9c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,992&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzGp4_zdsQLanmJtpf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">2354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact000710"
      unitRef="USD">2025000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">304000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000715"
      unitRef="USD">2658000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000716"
      unitRef="USD">2328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">2159000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000719"
      unitRef="USD">1992000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">336000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000724"
      unitRef="USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact000726"
      unitRef="USD">100000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000728">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zLvZ8fMuJURf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82D_z06hjorMYkc8"&gt;Other Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZbWWTgPirOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zj2tIjtimwig" style="display: none"&gt;Schedule
of Other Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_z52ERfs6jbuc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zyb99emckFoh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maOALCzJtq_z9f7AjR0Usy1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Employee compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,338&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OtherAccruedLicenseMilestone_iI_maOALCzJtq_zu2RMw5Kvkhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;License milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OtherAccruedInterest_iI_maOALCzJtq_zLzTDb4eKmr1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzJtq_zXrs85If1x79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Consulting and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maOALCzJtq_zl5AKWtjUVw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzJtq_zZpg8DjEfTd3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zdpC3meloNO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, and 2024, accounts payable included $&lt;span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20251231_zUkwZTmiRyB6" title="Accounts payable included accrued interest"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zaC7jz3tevm1" title="Accounts payable included accrued interest"&gt;820&lt;/span&gt; of accrued interest, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000730">&lt;p id="xdx_896_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zZbWWTgPirOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zj2tIjtimwig" style="display: none"&gt;Schedule
of Other Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_z52ERfs6jbuc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zyb99emckFoh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maOALCzJtq_z9f7AjR0Usy1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Employee compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,338&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OtherAccruedLicenseMilestone_iI_maOALCzJtq_zu2RMw5Kvkhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;License milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OtherAccruedInterest_iI_maOALCzJtq_zLzTDb4eKmr1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOALCzJtq_zXrs85If1x79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Consulting and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maOALCzJtq_zl5AKWtjUVw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_mtOALCzJtq_zZpg8DjEfTd3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">8338000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000733"
      unitRef="USD">4092000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <CELC:OtherAccruedLicenseMilestone
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000735"
      unitRef="USD">5000000</CELC:OtherAccruedLicenseMilestone>
    <CELC:OtherAccruedInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000738"
      unitRef="USD">3379000</CELC:OtherAccruedInterest>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000741"
      unitRef="USD">2335000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">511000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">1813000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">874000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">20865000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">5477000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">820000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000754">&lt;p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zn6L9igRsxCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_820_z65XpHziTd96"&gt;Commitments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: justify; text-indent: -19.8pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.8pt; text-align: left; text-indent: -19.8pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Operating
and Finance Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases its corporate space in Minneapolis, Minnesota, with an operating lease in place through April 30, 2026 (the &#x201c;Existing
Lease&#x201d;). The Existing Lease provides for monthly rent, real estate taxes, and operating expenses. Rent expense is recorded on a
straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2025, the Company entered into a lease for clinical laboratory and office space in Minnesota for &lt;span id="xdx_905_eus-gaap--AreaOfLand_iI_usqft_c20251130_zpCiYYXsrGC6" title="Square feet"&gt;19,594&lt;/span&gt; square feet. &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20251101__20251130_zCdOoCCDTyM" title="Lease option to extend"&gt;The lease
term will commence on April 1, 2026 and is 62 months with two options to extend the lease term for five years each. The Company also
has a one-time option to terminate the lease at the end of the third year, provided certain conditions are met. &lt;/span&gt;To exercise this option,
the Company must pay a termination fee equal to eight months&#x2019; rent plus the landlord&#x2019;s unamortized transaction costs, which
include abated rent, tenant improvement allowances and broker fees. &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20251101__20251130_z2XeypAftfRh" title="Lease description"&gt;The initial annual lease payment is $&lt;span id="xdx_903_eus-gaap--OperatingLeasePayments_pn5n6_c20251101__20251130_zXrdOaQbJ496" title="Initial annual lease payment"&gt;0.3&lt;/span&gt; million and increases by
3.5% on an annual basis, resulting in total undiscounted future minimum lease payments of $&lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn5n6_c20251130_z99u4GodQlVl" title="Undiscounted future minimum lease"&gt;1.5&lt;/span&gt; million over the initial &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20251130_zYh1W81o6era" title="Lease term"&gt;62&lt;/span&gt;-month term.
&lt;/span&gt;As of December 31, 2025, the lease has not commenced and is therefore excluded from the tables below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5OAgmDvZCz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under the Company&#x2019;s Existing Lease consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zFNpIZgwWV3j" style="display: none"&gt;Schedule
of Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zd68EMBIexzj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zUJ1rqmQQXC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; text-indent: 9pt"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_iI_maLOLLPzXrd_zrTeJp5gO3S3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zfuLN0O1hiyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNAOuArXgvM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zPYqHNQA0Eo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zpbBBzqH2pJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: operating lease liabilities, current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxd97nAkHF13" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and discount rate under the Company&#x2019;s Existing Lease were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zkpNCPmDa5ze" title="Weighted-average remaining lease term"&gt;0.3&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zdzuwqCIGnn4" title="Weighted-average remaining lease term"&gt;1.3&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFzrBzzk5Oac" title="Weighted-average discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zCm9fm80LA4b" title="Weighted-average discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zukE4zy9Kwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_ze1GqYxJdhzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents components of lease costs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zR5QI8yk12aj" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20250101__20251231_zGGU5Xhnmcgg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240101__20241231_zlqgEUsFD1D4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zCqkWBzh8CP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--VariableLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zrB0DEKtwVbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;110&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LeaseCost_iT_pn3n3_mtLCzphc_z2BpqhRDFbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zFs5wNnq9OL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Clinical
Research Studies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third-party
service providers that include, among others, arrangements with vendors, consultants, contract manufacturing organizations, and contract
research organizations. Contracts related to the Company&#x2019;s ongoing clinical trials are generally cancelable with advance notice
and the Company&#x2019;s obligations under these contracts are primarily based on services performed through termination dates plus certain
cancelation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be
subject to amendments as a result of any change orders executed. As of December 31, 2025, the Company had $&lt;span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20251231_zWDYx32IGm87" title="Non-cancelable contractual commitment"&gt;5.5 &lt;/span&gt;million of non-cancelable
purchase commitments with respect to these arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Registration
Rights Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with a securities purchase agreement with certain investors pursuant to which the Company agreed to sell to the investors
in a private placement pre-funded warrants to purchase up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdLgI1OmU4Yc" title="Pre-funded warrants sold to investors"&gt;5,747,787&lt;/span&gt; shares of the Company&#x2019;s common stock in October 2023 (the &#x201c;Securities Purchase Agreement&#x201d;),
the Company entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the investors. Under
the Registration Rights Agreement, the Company agreed to file a registration statement and to use commercially reasonable efforts to cause such registration statement to become effective and to keep such
registration statement effective until such time as there are no longer registrable securities held by the Investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company fails to meet the specified filing deadlines, effectiveness deadlines, or maintain the effectiveness of the registration
statement, &lt;span id="xdx_906_eus-gaap--RegistrationPaymentArrangementTerm_c20250101__20251231_zcNLKNPkrlXk" title="Registration rights"&gt;the
Company is required to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0% of the aggregate
amount paid pursuant to the Securities Purchase Agreement by such investor&#160;for each 30-day period or pro rata for any portion
thereof during which such event continues, provided that the maximum liquidated damages shall not exceed 6.0% of the aggregate
amount invested by each such holder in the registrable securities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for these arrangements in accordance with ASC 825-20, &lt;i&gt;Registration Payment Arrangements&lt;/i&gt;. As of December 31,
2025, the required registration statement has been timely filed and declared effective by the SEC, and the Company remains in
compliance with the maintenance requirements. Management has determined that it is not probable that the Company will be obligated
to pay any liquidated damages; accordingly, no liability has been recorded for these arrangements.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2025-11-30"
      decimals="INF"
      id="Fact000756"
      unitRef="sqft">19594</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2025-11-012025-11-30" id="Fact000758">The lease
term will commence on April 1, 2026 and is 62 months with two options to extend the lease term for five years each. The Company also
has a one-time option to terminate the lease at the end of the third year, provided certain conditions are met.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2025-11-012025-11-30" id="Fact000760">The initial annual lease payment is $0.3 million and increases by
3.5% on an annual basis, resulting in total undiscounted future minimum lease payments of $1.5 million over the initial 62-month term.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-11-012025-11-30"
      decimals="-5"
      id="Fact000762"
      unitRef="USD">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-11-30"
      decimals="-5"
      id="Fact000764"
      unitRef="USD">1500000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2025-11-30" id="Fact000766">P62M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000768">&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5OAgmDvZCz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under the Company&#x2019;s Existing Lease consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zFNpIZgwWV3j" style="display: none"&gt;Schedule
of Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zd68EMBIexzj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzXrd_zUJ1rqmQQXC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; text-indent: 9pt"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne_iI_maLOLLPzXrd_zrTeJp5gO3S3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzXrd_zfuLN0O1hiyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNAOuArXgvM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: Amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zPYqHNQA0Eo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zpbBBzqH2pJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: operating lease liabilities, current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxd97nAkHF13" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and discount rate under the Company&#x2019;s Existing Lease were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zkpNCPmDa5ze" title="Weighted-average remaining lease term"&gt;0.3&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zdzuwqCIGnn4" title="Weighted-average remaining lease term"&gt;1.3&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zFzrBzzk5Oac" title="Weighted-average discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zCm9fm80LA4b" title="Weighted-average discount rate"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000770"
      unitRef="USD">74000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000774"
      unitRef="USD">74000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000776"
      unitRef="USD">20000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">54000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000780"
      unitRef="USD">54000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact000784">P0Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact000786">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000788"
      unitRef="Pure">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000790"
      unitRef="Pure">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000792">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_ze1GqYxJdhzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents components of lease costs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zR5QI8yk12aj" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20250101__20251231_zGGU5Xhnmcgg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240101__20241231_zlqgEUsFD1D4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zCqkWBzh8CP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--VariableLeaseCost_pn3n3_maLCzXSJ_maLCzphc_zrB0DEKtwVbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;110&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LeaseCost_iT_pn3n3_mtLCzphc_z2BpqhRDFbC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">213000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000795"
      unitRef="USD">213000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">110000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000798"
      unitRef="USD">111000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000800"
      unitRef="USD">323000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000801"
      unitRef="USD">324000</us-gaap:LeaseCost>
    <us-gaap:ContractualObligation
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000803"
      unitRef="USD">5500000</us-gaap:ContractualObligation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">5747787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RegistrationPaymentArrangementTerm contextRef="From2025-01-01to2025-12-31" id="Fact000807">the
Company is required to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0% of the aggregate
amount paid pursuant to the Securities Purchase Agreement by such investor&#160;for each 30-day period or pro rata for any portion
thereof during which such event continues, provided that the maximum liquidated damages shall not exceed 6.0% of the aggregate
amount invested by each such holder in the registrable securities.</us-gaap:RegistrationPaymentArrangementTerm>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000809">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTf2Ux3D7zNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_820_z98N5HmjSZs4"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Capital
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company&#x2019;s authorized capital stock consisted of &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zJjYdsfUBFIg" title="Common stock, shares authorized"&gt;95,000,000&lt;/span&gt; shares of common stock, of which &lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zcP87RyHEJz3" title="Common stock, shares outstanding"&gt;48,244,960&lt;/span&gt;
shares were outstanding, and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zCkkfZr0wOF3" title="Preferred stock, shares authorized"&gt;2,500,000&lt;/span&gt; shares of preferred stock, including &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zX8m2jQ78vI7" title="Preferred stock, shares authorized"&gt;1,850,000&lt;/span&gt; shares designated as Series A Preferred Stock,
of which &lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20251231_z2QTmNQHBmb4" title="Preferred stock, shares outstanding"&gt;none&lt;/span&gt; were outstanding. As of December 31, 2025, no dividends have been declared on the Company&#x2019;s capital stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;July
2025 Equity Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 30, 2025, the Company entered into an underwriting agreement (the &#x201c;Equity Underwriting Agreement&#x201d;) with Jefferies
LLC (&#x201c;Jefferies&#x201d;), TD Securities (USA) LLC, and Leerink Partners LLC as representatives (the
&#x201c;Representatives&#x201d;) of the several underwriters named therein (collectively, the &#x201c;Underwriters&#x201d;) agreeing,
subject to customary conditions, to issue and sell in a public offering (i) &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zOwi6t22itnl" title="Number of share sold"&gt;1,836,842&lt;/span&gt;
shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, at a price to the public of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z0PXs6UPLt8l" title="Sale of stock perice per share"&gt;38.00&lt;/span&gt;
per Share and (ii) in lieu of Shares to certain investors, pre-funded warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_z1DuOVzIo6W9" title="Prefunded warrant shares"&gt;400,000&lt;/span&gt;
shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;), at a price to the public of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zell8W0EWesj" title="Share price"&gt;37.999&lt;/span&gt;
per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zuS9JyWijuC5" title="Exercise price per warrants"&gt;0.001&lt;/span&gt;
per share exercise price for each such Pre-Funded Warrant (the &#x201c;Equity Offering&#x201d;). In addition, pursuant to the Equity
Underwriting Agreement, the Company granted the Underwriters an option to purchase up to an additional &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zcrlcf88qlEc" title="The number of additional common stock shares the Underwriters can purchase"&gt;335,526&lt;/span&gt;
shares of common stock (the &#x201c;Option Shares&#x201d;), less underwriting discounts and commissions. The Underwriters exercised
their option to purchase the Option Shares in full on July 30, 2025. The Equity Offering was completed on July 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net proceeds from the Equity Offering, after deducting underwriting discounts and commissions and offering expenses, were $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_ziW0um8Cddp3" title="The cash inflow associated with the amount received from entity's offering of stock to the public"&gt;91.6&lt;/span&gt; million,
including the proceeds from the Underwriters&#x2019; exercise of their option in full to purchase the Option Shares. The Company may also
receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zNeqmJXLgNVa" title="Warrant exercise price"&gt;0.001&lt;/span&gt; per share, or alternatively, at the election
of each holder, shares of common stock may be issued through a cashless exercise, with the net number of shares of common stock determined
according to the formula set forth in each Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at any time after the date of
issuance until all of the Pre-Funded Warrants are exercised. &lt;span id="xdx_904_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250730__20250730__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveEquityOfferingMember_zp7XYY1Vzzhg" title="Pre-funded warrant exercisable description"&gt;A holder (together with its &#x201c;attribution parties,&#x201d; as defined
in the Pre-Funded Warrant) may not exercise any portion of the Pre-Funded Warrants if immediately after exercise, the holder (together
with its attribution parties), would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise. However, a holder may increase or decrease such percentage to any other percentage not in excess
of 19.99%, which increase or decrease shall not become effective until 61 days after notice from the holder to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Sale
and Issuance of Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Stifel, Nicolaus
&amp;amp; Company, Incorporated as representatives of the several underwriters relating to the issuance and sale of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zPV5ZuHbjmpf" title="Sale of stock number of shares issued in transaction"&gt;3,871,000&lt;/span&gt; shares of common
stock, at a price to the public of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zYsnbmQKlUw4" title="Issuance of public offering price per share"&gt;15.50&lt;/span&gt; per share, generating gross proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zE486h3Wy01k" title="Gross proceeds from public offering"&gt;60.0&lt;/span&gt; million. The offering closed on May 31, 2024
and resulted in net proceeds to the Company of $&lt;span id="xdx_903_ecustom--ProceedsFromIssuanceOfCommonStockNet_pn5n6_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LeerinkPartnersLLCMember_zzWgaqRf9m09" title="Net proceeds from public offering"&gt;56.3&lt;/span&gt; million after deducting underwriting discounts and other offering expenses payable
by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 8, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zg8Xyijxdon4" title="Sale of stock number of shares issued in transaction"&gt;149,700&lt;/span&gt; shares of common stock
in a single transaction at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5mE2J82qjF1" title="Issuance of public offering price per share"&gt;17.65&lt;/span&gt; per share, generating gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240508__20240508__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zNDCQgTXQCwi" title="Gross proceeds from public offering"&gt;2.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 22, 2024, pursuant to an Open Market Sale Agreement with Jefferies, as agent, the Company sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z2jzKsB4saOb" title="Sale of stock"&gt;285,714&lt;/span&gt; shares of common stock
in a single transaction at a price of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z6ckh86vykJa" title="Share price"&gt;17.50&lt;/span&gt; per share, generating gross proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240422__20240422__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zY9EdIUhP4h5" title="Gross proceeds"&gt;5.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commissions
and other offering expenses related to the Open Market Sale Agreement transactions in May and April 2024 were $&lt;span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_z1RjZoIh99ab" title="Commissions and other offering expenses"&gt;&lt;span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember_zgwXXxxewzT4" title="Commissions and other offering expenses"&gt;0.3&lt;/span&gt;&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuWHMhzGo9Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had the following common stock warrants outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zY1ytPWLNUyc" style="display: none"&gt;Schedule
of Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration &lt;br/&gt; Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Offering&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_znF7acZVjZ4" title="Issue Date"&gt;1/21/2016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zhnZppxtvQ45" title="Expiration Date"&gt;1/14/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zk2Mw9EYW8H3" style="width: 11%; text-align: right" title="Number of Warrants Outstanding"&gt;28,716&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zHyXpIYLRYi" style="width: 9%; text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zI8hpZN5OdBc" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zWoep6ko0o6h" title="Issue Date"&gt;5/2/2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zkl24SZw7vEh" title="Expiration Date"&gt;5/2/2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zKwhd0DvrB12" style="text-align: right" title="Number of Warrants Outstanding"&gt;18,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zFAO4x8AVNQ9" style="text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zS7k8CSa0a3j" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zAFRJnIXM30b" title="Issue Date"&gt;4/28/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zRKSHCpIQnwa" title="Expiration Date"&gt;4/28/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zcDmLPUyp4Td" style="text-align: right" title="Number of Warrants Outstanding"&gt;32,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zReh2tr8pRm4" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zuNGbngV4fBj" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zclugJRqklN7" title="Issue Date"&gt;5/17/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zxiXJsqAg9i8" title="Expiration Date"&gt;5/17/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEziq4xBRE57" style="text-align: right" title="Number of Warrants Outstanding"&gt;14,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_znoRCtWmvgCd" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_z9xKaE7Arcq7" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z7MA7HnPVIpj" title="Issue Date"&gt;4/8/2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBOiBldDJvNf" title="Expiration Date"&gt;4/8/2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_znqkO7Jpk9Bk" style="text-align: right" title="Number of Warrants Outstanding"&gt;26,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zqMM6I1aTAfj" style="text-align: right" title="Exercise Price"&gt;14.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zAZdpAqgLUl1" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zEFvxS7ie88g" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zy1eUogQej5g" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdrW9Y4jmDmk" style="text-align: right" title="Number of Warrants Outstanding"&gt;84,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zWim2INAWGub" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdm4KenlCym1" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zq1Rclq2cx44" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z3WLQeqny3Ff" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_za2mYVkOjUc1" style="text-align: right" title="Number of Warrants Outstanding"&gt;19,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zgKKOcOQfO69" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zMnEPRfw0b0e" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zHdsHyxT9PQ6" title="Issue Date"&gt;9/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zjCg9xYcyDT2" title="Expiration Date"&gt;9/9/2035&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zLLSV398LSSk" style="text-align: right" title="Number of Warrants Outstanding"&gt;25,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zSFbo8yOcaUf" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zfYJFO2roqVg" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_z6sgr6CaXIYd" title="Issue Date"&gt;9/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zSnWlrTdJqsl" title="Expiration Date"&gt;9/9/2035&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zn6CZLd8Raq6" style="text-align: right" title="Number of Warrants Outstanding"&gt;25,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zQHkfNELAb9b" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zuuO2eabQgW6" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zdHCDyqWLa44" title="Issue Date"&gt;10/18/2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;N/A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zNiCWbmI4cC8" style="text-align: right" title="Number of Warrants Outstanding"&gt;5,747,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z4SdBJHrOnq8" style="text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zzANf3ZPrRMk" title="Offering"&gt;Private placement offering &#x2013; issued to investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_z7PfKVLsdvxj" title="Issue Date"&gt;7/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;N/A&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zcGfIow7zqk8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding"&gt;400,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zjLdLiLLDsK9" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zUiYBUZj5gQ7" title="Offering"&gt;Equity offering &#x2013; issued to underwriters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total warrants outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_z6Yy2e5tTo0k" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Warrants Outstanding"&gt;6,422,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zCWBFAhATkal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pre-Funded
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 18, 2023, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain
investors (the &#x201c;Investors&#x201d;) pursuant to which the Company agreed to sell to the Investors in a private placement pre-funded
warrants to purchase up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231018__20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRwbdsTUGT5k" title="Pre-funded warrants sold to investors"&gt;5,747,787&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAmCPPU4Z3Zb" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share. Each warrant to purchase
one share had a purchase price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV8BpTWG9ife" title="Warrant purchase price"&gt;8.699&lt;/span&gt; per share, and an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231018__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsXVpykm0fA3" title="Exercise price of common stock warrants"&gt;0.001&lt;/span&gt; per share for the common stock issuable upon exercise
of the warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
warrant is immediately exercisable and will not expire. Under the terms of the warrants, the Company may not effect the exercise of any
such warrant, and a holder will not be entitled to exercise any portion of any warrant, if, upon giving effect to such exercise, the
aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who
could be deemed to be acting as a group together with the holder or any of the holder&#x2019;s affiliates, and any other persons whose
beneficial ownership of common stock would or could be aggregated with the holder&#x2019;s or any of the holder&#x2019;s affiliates for
purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) would exceed
4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC (the &#x201c;Maximum Percentage&#x201d;).
A holder may reset the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the
Company, or a lower percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only
to that holder and not to any other holder of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Securities Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company, other obligations of the parties and termination provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zKyuRQPGnTud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all common stock warrants outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zHKDaQ9sDNLe" style="display: none"&gt;Schedule
of Common Stock Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted- average exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdZ94uhfSK5f" style="width: 16%; text-align: right" title="Common stock warrants, outstanding shares"&gt;11,268,939&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbbqAq7Di5ck" style="width: 16%; text-align: right" title="Weighted- average exercise price per share, outstanding"&gt;4.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zr3btbfI5lV1" style="text-align: right" title="Common stock warrants, issued"&gt;450,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdOFkWbiJAm3" style="text-align: right" title="Weighted- average exercise price per share, issued"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKlIT7Yuuu7" style="text-align: right" title="Common stock warrants, exercised"&gt;(5,282,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zf8zruGCcwn4" style="text-align: right" title="Weighted- average exercise price per share, exercised"&gt;8.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Surrendered upon cashless exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z5YU7llqoyJ4" style="text-align: right" title="Common stock warrants, surrendered upon cashless exercise"&gt;(14,541&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zLYOpxidlSx6" style="text-align: right" title="Weighted- average exercise price per share, surrendered upon cashless exercise"&gt;10.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMizbNcfmHx5" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock warrants, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zJd6gzxtBn0k" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- average exercise price per share, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zY4JevYww3J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock warrants, outstanding shares"&gt;6,422,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z59zeD648rui" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- average exercise price per share, outstanding"&gt;0.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zFC0BNDh0IQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, several of the Company&#x2019;s investors exercised &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znxFSsD9p9wk" title="Additional warrants exercised"&gt;1,827,357&lt;/span&gt;
common stock warrants, net of shares withheld for the exercise price, at exercise prices ranging between $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zN7fSoNfBU3e" title="Class of warrant exercise price"&gt;8.05&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zEClnvNV3hh4" title="Class of warrant exercise price"&gt;9.50&lt;/span&gt;
per share, which generated $&lt;span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zHF5cxuCjVg3" title="Proceeds from warant exercise"&gt;14.7&lt;/span&gt;
million in cash. During the year ended December 31, 2024, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z3MvDscA8A62" title="Common stock warrants expired"&gt;3,544&lt;/span&gt;
common stock warrants expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A preferred stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockVotingRights_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHbB9vIAvTy2" title="Preferred stock voting rights"&gt;The
Series A preferred stock is non-voting, and each share is convertible at the option of the holder, subject to certain limitations, into
10 shares of common stock. Holders of Series A preferred stock are entitled to receive dividends, on an as-if-converted-to-common stock
basis, when, as and if, and in the same form as, dividends are actually paid on the common stock. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as defined in the Certificate of
Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders of Series A preferred stock
are entitled to be paid from assets of the Company available for distribution to its stockholders, before any payment is made to the
holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the original issue price
(&lt;span id="xdx_908_eus-gaap--CommonStockConversionBasis_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKsgAAOuvQx6" title="Common stock converted basis"&gt;$5.75 on an as-converted-to-common stock basis&lt;/span&gt;), plus all accrued and unpaid dividends and (ii) the amount that the holder would have
been entitled to receive at such time if the Series A preferred stock were converted into common stock. The Company may not, without
the consent of holders of a majority of the outstanding shares of Series A preferred stock, amend its charter in a manner that adversely
affects the powers, preferences or rights of the Series A preferred stock or issue or obligate itself to issue shares of any additional
class or series of capital stock unless the same ranks junior to the Series A preferred stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company and the payment of dividends.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, &lt;span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0vPzVwClfH4" title="Conversion of preferred to common stock, shares"&gt;317,577&lt;/span&gt; shares of Series A preferred stock were converted into &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QZQQZKgs7i" title="Conversion of preferred to common stock, shares"&gt;3,175,770&lt;/span&gt; shares of common stock. As
of December 31, 2025, &lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5i1gdO0ybFd" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt; shares of Series A preferred stock were outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">48244960</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">1850000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Shares">1836842</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000823"
      unitRef="USDPShares">38.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000827"
      unitRef="USDPShares">37.999</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000829"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-07-30_custom_UnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000831"
      unitRef="Shares">335526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-302025-07-30_custom_UnderwritingAgreementMember_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="-5"
      id="Fact000833"
      unitRef="USD">91600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      decimals="INF"
      id="Fact000835"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2025-07-302025-07-30_custom_PrefundedWarrantsMember_custom_JulyTwoThousandAndTwentyFiveEquityOfferingMember"
      id="Fact000837">A holder (together with its &#x201c;attribution parties,&#x201d; as defined
in the Pre-Funded Warrant) may not exercise any portion of the Pre-Funded Warrants if immediately after exercise, the holder (together
with its attribution parties), would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately
after giving effect to the exercise. However, a holder may increase or decrease such percentage to any other percentage not in excess
of 19.99%, which increase or decrease shall not become effective until 61 days after notice from the holder to the Company.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Shares">3871000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="INF"
      id="Fact000841"
      unitRef="USDPShares">15.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-05-302024-05-30_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="-5"
      id="Fact000843"
      unitRef="USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CELC:ProceedsFromIssuanceOfCommonStockNet
      contextRef="From2024-05-312024-05-31_custom_UnderwritingAgreementMember_custom_LeerinkPartnersLLCMember"
      decimals="-5"
      id="Fact000845"
      unitRef="USD">56300000</CELC:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">149700</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">17.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-05-082024-05-08_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="-5"
      id="Fact000851"
      unitRef="USD">2600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">285714</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">17.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-04-222024-04-22_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="-5"
      id="Fact000857"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-05-012024-05-31_custom_OpenMarketSaleAgreementMember"
      decimals="-5"
      id="Fact000859"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-04-012024-04-30_custom_OpenMarketSaleAgreementMember"
      decimals="-5"
      id="Fact000861"
      unitRef="USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000863">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuWHMhzGo9Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had the following common stock warrants outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zY1ytPWLNUyc" style="display: none"&gt;Schedule
of Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration &lt;br/&gt; Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Offering&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_znF7acZVjZ4" title="Issue Date"&gt;1/21/2016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zhnZppxtvQ45" title="Expiration Date"&gt;1/14/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zk2Mw9EYW8H3" style="width: 11%; text-align: right" title="Number of Warrants Outstanding"&gt;28,716&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zHyXpIYLRYi" style="width: 9%; text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 46%; text-align: justify"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zI8hpZN5OdBc" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zWoep6ko0o6h" title="Issue Date"&gt;5/2/2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zkl24SZw7vEh" title="Expiration Date"&gt;5/2/2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zKwhd0DvrB12" style="text-align: right" title="Number of Warrants Outstanding"&gt;18,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zFAO4x8AVNQ9" style="text-align: right" title="Exercise Price"&gt;7.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_zS7k8CSa0a3j" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zAFRJnIXM30b" title="Issue Date"&gt;4/28/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zRKSHCpIQnwa" title="Expiration Date"&gt;4/28/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zcDmLPUyp4Td" style="text-align: right" title="Number of Warrants Outstanding"&gt;32,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zReh2tr8pRm4" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zuNGbngV4fBj" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zclugJRqklN7" title="Issue Date"&gt;5/17/2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zxiXJsqAg9i8" title="Expiration Date"&gt;5/17/2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_zEziq4xBRE57" style="text-align: right" title="Number of Warrants Outstanding"&gt;14,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_znoRCtWmvgCd" style="text-align: right" title="Exercise Price"&gt;8.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFourMember_z9xKaE7Arcq7" title="Offering"&gt;Private placement offering &#x2013; issued to placement agent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_z7MA7HnPVIpj" title="Issue Date"&gt;4/8/2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zBOiBldDJvNf" title="Expiration Date"&gt;4/8/2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_znqkO7Jpk9Bk" style="text-align: right" title="Number of Warrants Outstanding"&gt;26,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zqMM6I1aTAfj" style="text-align: right" title="Exercise Price"&gt;14.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantFiveMember_zAZdpAqgLUl1" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zEFvxS7ie88g" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zy1eUogQej5g" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdrW9Y4jmDmk" style="text-align: right" title="Number of Warrants Outstanding"&gt;84,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zWim2INAWGub" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSixMember_zdm4KenlCym1" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zq1Rclq2cx44" title="Issue Date"&gt;5/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_z3WLQeqny3Ff" title="Expiration Date"&gt;5/30/2034&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_za2mYVkOjUc1" style="text-align: right" title="Number of Warrants Outstanding"&gt;19,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zgKKOcOQfO69" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantSevenMember_zMnEPRfw0b0e" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zHdsHyxT9PQ6" title="Issue Date"&gt;9/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zjCg9xYcyDT2" title="Expiration Date"&gt;9/9/2035&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zLLSV398LSSk" style="text-align: right" title="Number of Warrants Outstanding"&gt;25,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zSFbo8yOcaUf" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantEightMember_zfYJFO2roqVg" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_z6sgr6CaXIYd" title="Issue Date"&gt;9/9/2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zSnWlrTdJqsl" title="Expiration Date"&gt;9/9/2035&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zn6CZLd8Raq6" style="text-align: right" title="Number of Warrants Outstanding"&gt;25,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zQHkfNELAb9b" style="text-align: right" title="Exercise Price"&gt;14.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantNineMember_zuuO2eabQgW6" title="Offering"&gt;Debt financing &#x2013; issued to lender&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zdHCDyqWLa44" title="Issue Date"&gt;10/18/2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;N/A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zNiCWbmI4cC8" style="text-align: right" title="Number of Warrants Outstanding"&gt;5,747,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_z4SdBJHrOnq8" style="text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTenMember_zzANf3ZPrRMk" title="Offering"&gt;Private placement offering &#x2013; issued to investors&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_z7PfKVLsdvxj" title="Issue Date"&gt;7/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;N/A&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zcGfIow7zqk8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Outstanding"&gt;400,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zjLdLiLLDsK9" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;0.001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantElevenMember_zUiYBUZj5gQ7" title="Offering"&gt;Equity offering &#x2013; issued to underwriters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total warrants outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231_z6Yy2e5tTo0k" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of Warrants Outstanding"&gt;6,422,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantOneMember"
      id="Fact000865">2016-01-21</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantOneMember"
      id="Fact000867">2026-01-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantOneMember"
      decimals="-3"
      id="Fact000869"
      unitRef="Shares">28716000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000871"
      unitRef="USDPShares">7.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantOneMember"
      id="Fact000873">Private placement offering &#x2013; issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantTwoMember"
      id="Fact000875">2016-05-02</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantTwoMember"
      id="Fact000877">2026-05-02</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantTwoMember"
      decimals="-3"
      id="Fact000879"
      unitRef="Shares">18175000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000881"
      unitRef="USDPShares">7.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantTwoMember"
      id="Fact000883">Private placement offering &#x2013; issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantThreeMember"
      id="Fact000885">2017-04-28</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantThreeMember"
      id="Fact000887">2027-04-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantThreeMember"
      decimals="-3"
      id="Fact000889"
      unitRef="Shares">32458000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000891"
      unitRef="USDPShares">8.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantThreeMember"
      id="Fact000893">Private placement offering &#x2013; issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantFourMember"
      id="Fact000895">2017-05-17</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantFourMember"
      id="Fact000897">2027-05-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantFourMember"
      decimals="-3"
      id="Fact000899"
      unitRef="Shares">14969000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantFourMember"
      decimals="INF"
      id="Fact000901"
      unitRef="USDPShares">8.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantFourMember"
      id="Fact000903">Private placement offering &#x2013; issued to placement agent</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantFiveMember"
      id="Fact000905">2021-04-08</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantFiveMember"
      id="Fact000907">2031-04-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantFiveMember"
      decimals="-3"
      id="Fact000909"
      unitRef="Shares">26042000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantFiveMember"
      decimals="INF"
      id="Fact000911"
      unitRef="USDPShares">14.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantFiveMember"
      id="Fact000913">Debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantSixMember"
      id="Fact000915">2024-05-30</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantSixMember"
      id="Fact000917">2034-05-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantSixMember"
      decimals="-3"
      id="Fact000919"
      unitRef="Shares">84227000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantSixMember"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantSixMember"
      id="Fact000923">Debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantSevenMember"
      id="Fact000925">2024-05-30</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantSevenMember"
      id="Fact000927">2034-05-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantSevenMember"
      decimals="-3"
      id="Fact000929"
      unitRef="Shares">19649000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantSevenMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantSevenMember"
      id="Fact000933">Debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantEightMember"
      id="Fact000935">2025-09-09</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantEightMember"
      id="Fact000937">2035-09-09</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantEightMember"
      decimals="-3"
      id="Fact000939"
      unitRef="Shares">25269000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantEightMember"
      decimals="INF"
      id="Fact000941"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantEightMember"
      id="Fact000943">Debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantNineMember"
      id="Fact000945">2025-09-09</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantNineMember"
      id="Fact000947">2035-09-09</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantNineMember"
      decimals="-3"
      id="Fact000949"
      unitRef="Shares">25268000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantNineMember"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantNineMember"
      id="Fact000953">Debt financing &#x2013; issued to lender</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantTenMember"
      id="Fact000955">2023-10-18</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantTenMember"
      decimals="-3"
      id="Fact000957"
      unitRef="Shares">5747787000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantTenMember"
      decimals="INF"
      id="Fact000959"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantTenMember"
      id="Fact000961">Private placement offering &#x2013; issued to investors</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue
      contextRef="From2025-01-012025-12-31_custom_WarrantElevenMember"
      id="Fact000963">2025-07-31</CELC:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_WarrantElevenMember"
      decimals="-3"
      id="Fact000965"
      unitRef="Shares">400000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantElevenMember"
      decimals="INF"
      id="Fact000967"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2025-01-012025-12-31_custom_WarrantElevenMember"
      id="Fact000969">Equity offering &#x2013; issued to underwriters</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000971"
      unitRef="Shares">6422560000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-182023-10-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">5747787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000975"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000977"
      unitRef="USDPShares">8.699</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000979"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000981">&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zKyuRQPGnTud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all common stock warrants outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zHKDaQ9sDNLe" style="display: none"&gt;Schedule
of Common Stock Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted- average exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdZ94uhfSK5f" style="width: 16%; text-align: right" title="Common stock warrants, outstanding shares"&gt;11,268,939&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbbqAq7Di5ck" style="width: 16%; text-align: right" title="Weighted- average exercise price per share, outstanding"&gt;4.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zr3btbfI5lV1" style="text-align: right" title="Common stock warrants, issued"&gt;450,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdOFkWbiJAm3" style="text-align: right" title="Weighted- average exercise price per share, issued"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKlIT7Yuuu7" style="text-align: right" title="Common stock warrants, exercised"&gt;(5,282,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zf8zruGCcwn4" style="text-align: right" title="Weighted- average exercise price per share, exercised"&gt;8.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Surrendered upon cashless exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z5YU7llqoyJ4" style="text-align: right" title="Common stock warrants, surrendered upon cashless exercise"&gt;(14,541&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue_iI_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zLYOpxidlSx6" style="text-align: right" title="Weighted- average exercise price per share, surrendered upon cashless exercise"&gt;10.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMizbNcfmHx5" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock warrants, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExpiredDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zJd6gzxtBn0k" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- average exercise price per share, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zY4JevYww3J1" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock warrants, outstanding shares"&gt;6,422,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z59zeD648rui" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- average exercise price per share, outstanding"&gt;0.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000983"
      unitRef="Shares">11268939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">4.04</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">450537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">1.67</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000991"
      unitRef="Shares">5282375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000993"
      unitRef="USDPShares">8.07</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageExercisedDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Shares">14541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue
      contextRef="From2025-01-012025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000997"
      unitRef="USDPShares">10.43</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsGrantsInPeriodWeightedAverageSurrenderedUponCashlessExerciseDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001003"
      unitRef="Shares">6422560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001005"
      unitRef="USDPShares">0.53</CELC:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001007"
      unitRef="Shares">1827357</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_srt_MinimumMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001009"
      unitRef="USDPShares">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_srt_MaximumMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001011"
      unitRef="USDPShares">9.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember"
      decimals="-5"
      id="Fact001013"
      unitRef="USD">14700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001015"
      unitRef="Shares">3544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001017">The
Series A preferred stock is non-voting, and each share is convertible at the option of the holder, subject to certain limitations, into
10 shares of common stock. Holders of Series A preferred stock are entitled to receive dividends, on an as-if-converted-to-common stock
basis, when, as and if, and in the same form as, dividends are actually paid on the common stock. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or in the event of a Deemed Liquidation Event (as defined in the Certificate of
Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock), the holders of Series A preferred stock
are entitled to be paid from assets of the Company available for distribution to its stockholders, before any payment is made to the
holders of common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the original issue price
($5.75 on an as-converted-to-common stock basis), plus all accrued and unpaid dividends and (ii) the amount that the holder would have
been entitled to receive at such time if the Series A preferred stock were converted into common stock. The Company may not, without
the consent of holders of a majority of the outstanding shares of Series A preferred stock, amend its charter in a manner that adversely
affects the powers, preferences or rights of the Series A preferred stock or issue or obligate itself to issue shares of any additional
class or series of capital stock unless the same ranks junior to the Series A preferred stock with respect to the distribution of assets
on the liquidation, dissolution or winding up of the Company and the payment of dividends.</us-gaap:PreferredStockVotingRights>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001019">$5.75 on an as-converted-to-common stock basis</us-gaap:CommonStockConversionBasis>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Shares">317577</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001023"
      unitRef="Shares">3175770</CELC:StockIssuedDuringPeriodSharesConversionOfPreferredToCommonStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001027">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLuItsdnxrU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_823_zeXtXG7mKgqh"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2012
Equity Incentive Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2012, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20120801__20120831__us-gaap--PlanNameAxis__custom--TwoThousandTwelveEquityIncentivePlanMember_zM6gtsJD1vKf" title="Stock based compensation description"&gt;the Company adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provided for options, restricted
stock awards, performance stock awards and stock bonuses. The exercise price of each option granted under the 2012 Plan is not less than
100% of the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Plan is
ten years. The Company&#x2019;s board of directors administers the 2012 Plan and determines the provisions of incentive awards, including
eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. In September 2017, the 2012 Plan was frozen and no further awards may be
made under the 2012 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2017
Amended and Restated Stock Incentive Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2017, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember_z0n5vRNzsOMc" title="Stock based compensation description"&gt;the Company adopted the 2017 Amended and Restated Stock Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2017 Plan provides
for the grant of options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock bonuses.
The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on the date
of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered by
the compensation committee of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other
determinations necessary for the administration of the 2017 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zZ5bHPexIIrf" title="Number of shares reserved for issuance description"&gt;The
number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1 of each year from 2026 to 2027 by
the number of shares equal to 1.0% of the aggregate number of outstanding shares of common stock as of the immediately preceding December
31.&lt;/span&gt; However, the Company&#x2019;s board of directors may reduce the amount of the increase in any particular year. The number of shares
reserved for issuance under the 2017 Plan was automatically increased by &lt;span id="xdx_909_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zu1vQ7ho5Bi9" title="Number of shares reserved for issuance"&gt;371,432&lt;/span&gt; and &lt;span id="xdx_901_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zpnVLhuVPXL9" title="Number of shares reserved for issuance"&gt;255,060&lt;/span&gt; shares on January 1, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the board of directors and the stockholders approved additional increases of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z6nNPwSBcZyi" title="Number of shares reserved for issuance, additional increases"&gt;3,000,000&lt;/span&gt; and
&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z9FyvHfjAABg" title="Number of shares reserved for issuance, additional increases"&gt;1,500,000&lt;/span&gt;, respectively, to the number of shares reserved for issuance under the 2017 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the number of shares available for issuance under the 2017 Plan is &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_z7kIUC3NquR8" title="Number of shares available for issuance"&gt;2,591,634&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted under the 2017 Plan are exercisable at various dates as determined upon grant and will expire no more than 10 years from their
date of grant. The exercise price of each option shall be determined by the board of directors based on the estimated fair value of the
Company&#x2019;s common stock on the grant date. The exercise price shall not be less than 100% of the fair market value of the Company&#x2019;s
common stock on the grant date. Most option grants generally vest &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9dTr5QzcwU9" title="Option vested percentage"&gt;25&lt;/span&gt;% on the first anniversary of the original vesting commencement date,
with the balance vesting monthly over the remaining &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSJ1D3SGXX3c" title="Option vested period"&gt;three years&lt;/span&gt;. The 2017 Plan is generally administered by the compensation committee
of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other determinations necessary
for the administration of the 2017 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTcIIS7MgWOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all stock options outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zlfIIvSxZYSd" style="display: none"&gt;Schedule of Stock Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted- average exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-average remaining contractual term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Options outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCkkFqEa3hA7" style="width: 11%; text-align: right" title="Options outstanding at beginning of year"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMrXPEQNQhsk" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z827ybDJ6FT8" title="Options outstanding, weighted average remaining contractual term"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfVKMidhnWxf" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;13,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvNkbSZkP4f" style="text-align: right" title="Shares, Granted"&gt;2,186,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx8BY35J20T3" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;35.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBgTugSTIG62" style="text-align: right" title="Shares, Exercised"&gt;(393,301&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJRL0p6hVJzi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBGFofiqjod7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(257,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFvDeYHk0Gxd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;14.29&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPMAvV2Ci8Ae" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at end of year"&gt;5,842,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJUeAh6Ohkm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;19.62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRpxRljttXc" title="Options outstanding, weighted average remaining contractual term"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRoCp1nQzBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;468,191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z22A603GPpa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;2,740,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUxQ8RT8mgid" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;11.61&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zafuMNCGgrKd" title="Options exercisable, weighted average remaining contractual term"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgWXNQtrKRHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;241,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zRmzYZgIWFY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company modified previously granted stock option awards to 44 employees by reducing the exercise price of these options
to the Company&#x2019;s closing common stock price on the modification date. During the year ended December 31, 2025, the incremental
compensation expense recognized as a result of these modifications was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEbOxAGEBFGf" title="Stock based compensation expense related to modification"&gt;0.2&lt;/span&gt; million. The effect of these modifications on stock-based
compensation over the remaining service periods will be $&lt;span id="xdx_90A_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHyW3d1nUdie" title="Remaining stock based compensation expense related to modification"&gt;0.3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, the market conditions associated with options previously granted to an employee were satisfied following
the achievement of the specified stock price threshold. As a result, the options vested and the Company recognized $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsghp4TFUmGc" title="Stock-based compensation expense"&gt;8.4&lt;/span&gt; million in stock-based
compensation expense related to these awards during the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the weighted-average grant date fair value of options granted was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQyUcCSuSM28" title="Weighted-average grant date fair value of options granted"&gt;25.01&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKLtiLHbux2l" title="Weighted-average grant date fair value of options granted"&gt;11.22&lt;/span&gt; per share,
respectively. The total intrinsic value of options exercised during the years ended December 31, 2025 and 2024, was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zK2IC7BfVC3b" title="Total intrinsic value of options exercised"&gt;35.7&lt;/span&gt; million and
$&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zS9xHGJyemp2" title="Total intrinsic value of options exercised"&gt;0.6&lt;/span&gt; million, respectively. Upon the exercise of stock options, the Company will issue new shares of its common stock. As of December
31, 2025, the unrecognized compensation cost related to outstanding employee and non-employee options was $&lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHBwHWyZ9IKi" title="Unrecognized compensation cost"&gt;52.7&lt;/span&gt; million and is expected
to be recognized as expense over a weighted-average period of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkbUGsQ1ZG5" title="Weighted-average period"&gt;1.7&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z3FcRz9Z6IZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assumptions used in the Black-Scholes option pricing model and Monte Carlo simulation model to determine the fair value of the employee
and non-employee stock option grants issued, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zHooiLxHocnc" style="display: none"&gt;Schedule of Assumptions for Fair Value of Employee
And Non-Employee Stock Option&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zftQrWlbl5I1" title="Risk-free interest rate, minimum"&gt;3.6&lt;/span&gt;% &#x2212; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zEwoFc6JrAyd" title="Risk-free interest rate, maximum"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zRFq2DnHJSQ" title="Risk-free interest rate, minimum"&gt;3.5&lt;/span&gt;% &#x2212; &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjePQYYY2x43" title="Risk-free interest rate, maximum"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_z6dJPR4OaN51" title="Expected volatility, minimum"&gt;74.4&lt;/span&gt;% &#x2212; &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zuWx75cDXpV5" title="Expected volatility, maximum"&gt;82.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zFtSAyO9ecTi" title="Expected volatility, minimum"&gt;71.2&lt;/span&gt;% &#x2212; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zK42ZgMSlxQj" title="Expected volatility, maximum"&gt;76.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_zoqo3A5HeYL1" title="Expected life (years)"&gt;5.0&lt;/span&gt; &#x2212; &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0dMAcFxpFdb" title="Expected life (years)"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zj9pmRcLPN8a" title="Expected life (years)"&gt;5.3 &lt;/span&gt;&#x2212; &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zf3CXz8mmseb" title="Expected life (years)"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_z034pBWCJwz8" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zBjl1WuZGpo8" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zqcRHHL9OmT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for stock options of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrexFWYFtkaj" title="Stock-based compensation expense"&gt;20.0&lt;/span&gt; million
and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX4wc6vHjIMg" title="Stock-based compensation expense"&gt;6.6&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zpkKKu1o9ZB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock award and restricted stock unit activity during the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zVDyisgCqHH4" style="display: none"&gt;Schedule of Restricted Stock Award And Restricted Stock Unit Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-average grant date fair value per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR764yhxFZ0i" style="width: 16%; text-align: right" title="Outstanding shares"&gt;1,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2IAvpjTNKMh" style="width: 16%; text-align: right" title="Weighted-average grant date fair value per share, outstanding"&gt;14.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkTXxhRztcic" style="text-align: right" title="Granted shares"&gt;34,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQAA84K3GOj" style="text-align: right" title="Weighted-average grant date fair value per share, granted"&gt;89.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxngmZhrjeBi" style="text-align: right" title="Vested shares"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcxsEPykwxok" style="text-align: right" title="Weighted-average grant date fair value per share, vested"&gt;14.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvp5duBIU3uj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited shares"&gt;(6,600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zre61j4B5Omk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, forfeited"&gt;98.49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg7btdZuLY7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares"&gt;27,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOZtNknRa617" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value per share, outstanding"&gt;87.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zr7g9kI8in6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the unrecognized compensation cost related to outstanding restricted stock was $&lt;span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zD73JRzblUKj" title="Unrecognized compensation cost"&gt;2.3&lt;/span&gt; million and is expected to
be recognized over a weighted-average period of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgRlh61bIB7h" title="Weighted-average period"&gt;1.9&lt;/span&gt; years. The total fair value of restricted stock vested during the year ended December
31, 2025 was less than $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFrzVNnCDBg6" title="Total fair value of restricted stock vested"&gt;0.1 &lt;/span&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense for restricted stock of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkXhTy2tOvI6" title="Stock-based compensation expense"&gt;0.1&lt;/span&gt; million
and less than $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjJuhnagOZbd" title="Stock-based compensation expense"&gt;0.1&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2017
Employee Stock Purchase Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2017, &lt;span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_pid_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zNL7eWWSrptc" title="Employee stock purchase plan description"&gt;the Company adopted the 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP provides participating employees
with an opportunity to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions. The ESPP is available
to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value
of the Company&#x2019;s common stock. The ESPP is administered using overlapping 24 month offering periods (the &#x201c;Offering Periods&#x201d;).
Each Offering Period has four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and
November 1 of each year. Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of
the fair market value of a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase
date has a lower price, the employee will automatically be placed in the Offering Period beginning immediately after the purchase date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170901__20170930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z6YMVZmEWkWg" title="Number of shares reserved for issuance description"&gt;The
number of shares reserved for issuance under the ESPP automatically increases on January 1 of each year from 2023 to 2027 by the number
of shares equal to 0.5% of the aggregate number of outstanding shares of common stock as of the immediately preceding December 31.&lt;/span&gt; However,
the Company&#x2019;s board of directors may reduce the amount of the increase in any particular year. The number of shares reserved for
issuance under the ESPP was automatically increased by &lt;span id="xdx_90C_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_ztkc3zKI8Ibc" title="Change in common stock, shares reserved for issuance"&gt;185,716&lt;/span&gt; and &lt;span id="xdx_90A_ecustom--ChangeInCommonStockSharesReservedForIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zMuviZlBUBC" title="Change in common stock, shares reserved for issuance"&gt;127,530&lt;/span&gt; shares on January 1, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the number of shares available for issuance under the ESPP is &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_z9uPhR5KjFYk" title="Number of shares available for issuance"&gt;469,576&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense related to the ESPP of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zjwrZ56LwCk8" title="Stock-based compensation expense"&gt;1.3&lt;/span&gt; million
and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEmployeeStockPurchasePlanMember_zVbGnKbKX70l" title="Stock-based compensation expense"&gt;0.3&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziI9tdsa1ugl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized the following stock-based compensation expense in its statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zwdJtQjabLL6" style="display: none"&gt;Schedule
of Stock-based Compensation Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zQtol8iQV0Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zXTRHnhdGiub" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zckkQtDacQ07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zoucFZd5Trn4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_z2oJyb8fyoXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zMXa4m9dn6C9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A8_za1T61RK1uU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2012-08-012012-08-31_custom_TwoThousandTwelveEquityIncentivePlanMember"
      id="Fact001029">the Company adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provided for options, restricted
stock awards, performance stock awards and stock bonuses. The exercise price of each option granted under the 2012 Plan is not less than
100% of the fair market value of one share on the date of grant. The maximum permitted term of options granted under the 2012 Plan is
ten years. The Company&#x2019;s board of directors administers the 2012 Plan and determines the provisions of incentive awards, including
eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. In September 2017, the 2012 Plan was frozen and no further awards may be
made under the 2012 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenAmendedAndRestatedStockIncentivePlanMember"
      id="Fact001031">the Company adopted the 2017 Amended and Restated Stock Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2017 Plan provides
for the grant of options, restricted stock awards, stock appreciation rights, restricted stock units, performance awards and stock bonuses.
The exercise price of each option granted under the 2017 Plan is not less than 100% of the fair market value of one share on the date
of grant. The maximum permitted term of options granted under the 2017 Plan is ten years. The 2017 Plan is generally administered by
the compensation committee of the board of directors, which has the authority to interpret the 2017 Plan, grant awards and make all other
determinations necessary for the administration of the 2017 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenPlanMember"
      id="Fact001033">The
number of shares reserved for issuance under the 2017 Plan will automatically increase on January 1 of each year from 2026 to 2027 by
the number of shares equal to 1.0% of the aggregate number of outstanding shares of common stock as of the immediately preceding December
31.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2025-01-01_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">371432</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2024-01-01_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Shares">255060</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="From2025-01-012025-12-31_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-12-31_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Shares">2591634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      id="Fact001047">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001049">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTcIIS7MgWOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all stock options outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zlfIIvSxZYSd" style="display: none"&gt;Schedule of Stock Options Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted- average exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-average remaining contractual term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Options outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCkkFqEa3hA7" style="width: 11%; text-align: right" title="Options outstanding at beginning of year"&gt;4,306,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMrXPEQNQhsk" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price at beginning of year"&gt;11.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z827ybDJ6FT8" title="Options outstanding, weighted average remaining contractual term"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfVKMidhnWxf" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;13,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvNkbSZkP4f" style="text-align: right" title="Shares, Granted"&gt;2,186,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx8BY35J20T3" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;35.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBgTugSTIG62" style="text-align: right" title="Shares, Exercised"&gt;(393,301&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJRL0p6hVJzi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBGFofiqjod7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Forfeited"&gt;(257,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFvDeYHk0Gxd" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise, Forfeited"&gt;14.29&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPMAvV2Ci8Ae" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at end of year"&gt;5,842,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJUeAh6Ohkm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, weighted average exercise price at end of year"&gt;19.62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRpxRljttXc" title="Options outstanding, weighted average remaining contractual term"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcRoCp1nQzBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;468,191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z22A603GPpa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, options exercisable"&gt;2,740,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUxQ8RT8mgid" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options exercisable"&gt;11.61&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zafuMNCGgrKd" title="Options exercisable, weighted average remaining contractual term"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgWXNQtrKRHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;241,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">4306977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001053"
      unitRef="USDPShares">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      id="Fact001055">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001057"
      unitRef="USD">13914000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Shares">2186593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001061"
      unitRef="USDPShares">35.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">393301</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">8.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">257784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001069"
      unitRef="USDPShares">14.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Shares">5842485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001073"
      unitRef="USDPShares">19.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      id="Fact001075">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">468191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">2740854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001081"
      unitRef="USDPShares">11.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      id="Fact001083">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-12-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001085"
      unitRef="USD">241560000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001087"
      unitRef="USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001089"
      unitRef="USD">300000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001091"
      unitRef="USD">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001093"
      unitRef="USDPShares">25.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001095"
      unitRef="USDPShares">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001097"
      unitRef="USD">35700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001099"
      unitRef="USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="-5"
      id="Fact001101"
      unitRef="USD">52700000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      id="Fact001103">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001105">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z3FcRz9Z6IZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assumptions used in the Black-Scholes option pricing model and Monte Carlo simulation model to determine the fair value of the employee
and non-employee stock option grants issued, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zHooiLxHocnc" style="display: none"&gt;Schedule of Assumptions for Fair Value of Employee
And Non-Employee Stock Option&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20251231_zftQrWlbl5I1" title="Risk-free interest rate, minimum"&gt;3.6&lt;/span&gt;% &#x2212; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20251231_zEwoFc6JrAyd" title="Risk-free interest rate, maximum"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231_zRFq2DnHJSQ" title="Risk-free interest rate, minimum"&gt;3.5&lt;/span&gt;% &#x2212; &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231_zjePQYYY2x43" title="Risk-free interest rate, maximum"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20251231_z6dJPR4OaN51" title="Expected volatility, minimum"&gt;74.4&lt;/span&gt;% &#x2212; &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20251231_zuWx75cDXpV5" title="Expected volatility, maximum"&gt;82.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231_zFtSAyO9ecTi" title="Expected volatility, minimum"&gt;71.2&lt;/span&gt;% &#x2212; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231_zK42ZgMSlxQj" title="Expected volatility, maximum"&gt;76.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MinimumMember_zoqo3A5HeYL1" title="Expected life (years)"&gt;5.0&lt;/span&gt; &#x2212; &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__srt--RangeAxis__srt--MaximumMember_z0dMAcFxpFdb" title="Expected life (years)"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zj9pmRcLPN8a" title="Expected life (years)"&gt;5.3 &lt;/span&gt;&#x2212; &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zf3CXz8mmseb" title="Expected life (years)"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_z034pBWCJwz8" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zBjl1WuZGpo8" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001107"
      unitRef="Pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001109"
      unitRef="Pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001111"
      unitRef="Pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001113"
      unitRef="Pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001115"
      unitRef="Pure">0.744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001117"
      unitRef="Pure">0.821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001119"
      unitRef="Pure">0.712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001121"
      unitRef="Pure">0.762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_srt_MinimumMember"
      id="Fact001123">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_srt_MaximumMember"
      id="Fact001125">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact001127">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact001129">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001131"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001133"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001135"
      unitRef="USD">20000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001137"
      unitRef="USD">6600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001139">&lt;p id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zpkKKu1o9ZB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock award and restricted stock unit activity during the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zVDyisgCqHH4" style="display: none"&gt;Schedule of Restricted Stock Award And Restricted Stock Unit Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-average grant date fair value per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR764yhxFZ0i" style="width: 16%; text-align: right" title="Outstanding shares"&gt;1,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2IAvpjTNKMh" style="width: 16%; text-align: right" title="Weighted-average grant date fair value per share, outstanding"&gt;14.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkTXxhRztcic" style="text-align: right" title="Granted shares"&gt;34,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQAA84K3GOj" style="text-align: right" title="Weighted-average grant date fair value per share, granted"&gt;89.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxngmZhrjeBi" style="text-align: right" title="Vested shares"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcxsEPykwxok" style="text-align: right" title="Weighted-average grant date fair value per share, vested"&gt;14.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvp5duBIU3uj" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited shares"&gt;(6,600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zre61j4B5Omk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, forfeited"&gt;98.49&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg7btdZuLY7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares"&gt;27,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOZtNknRa617" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant date fair value per share, outstanding"&gt;87.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">1079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">14.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">34039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001147"
      unitRef="USDPShares">89.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">1079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001151"
      unitRef="USDPShares">14.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001153"
      unitRef="Shares">6600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="INF"
      id="Fact001155"
      unitRef="USDPShares">98.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001157"
      unitRef="Shares">27439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001159"
      unitRef="USDPShares">87.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="-5"
      id="Fact001161"
      unitRef="USD">2300000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      id="Fact001163">P1Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="-5"
      id="Fact001165"
      unitRef="USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="-5"
      id="Fact001167"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember1427656"
      decimals="-5"
      id="Fact001169"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription
      contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      id="Fact001171">the Company adopted the 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP provides participating employees
with an opportunity to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions. The ESPP is available
to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value
of the Company&#x2019;s common stock. The ESPP is administered using overlapping 24 month offering periods (the &#x201c;Offering Periods&#x201d;).
Each Offering Period has four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and
November 1 of each year. Participating employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of
the fair market value of a share of common stock on either the offering date or the purchase date, whichever is lower. If the purchase
date has a lower price, the employee will automatically be placed in the Offering Period beginning immediately after the purchase date.</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2017-09-012017-09-30_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      id="Fact001173">The
number of shares reserved for issuance under the ESPP automatically increases on January 1 of each year from 2023 to 2027 by the number
of shares equal to 0.5% of the aggregate number of outstanding shares of common stock as of the immediately preceding December 31.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2025-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001175"
      unitRef="Shares">185716</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <CELC:ChangeInCommonStockSharesReservedForIssuance
      contextRef="AsOf2024-01-01_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001177"
      unitRef="Shares">127530</CELC:ChangeInCommonStockSharesReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001179"
      unitRef="Shares">469576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="Fact001181"
      unitRef="USD">1300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_TwoThousandSeventeenEmployeeStockPurchasePlanMember"
      decimals="-5"
      id="Fact001183"
      unitRef="USD">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001185">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziI9tdsa1ugl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized the following stock-based compensation expense in its statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zwdJtQjabLL6" style="display: none"&gt;Schedule
of Stock-based Compensation Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zQtol8iQV0Ck" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zXTRHnhdGiub" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zckkQtDacQ07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zoucFZd5Trn4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,583&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_z2oJyb8fyoXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zMXa4m9dn6C9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,988&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001187"
      unitRef="USD">8409000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001188"
      unitRef="USD">4405000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001190"
      unitRef="USD">12974000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001191"
      unitRef="USD">2583000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001193"
      unitRef="USD">21383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">6988000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">21383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">6988000</us-gaap:ShareBasedCompensation>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001199">&lt;p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zNJ9iwbJZHJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_827_zqTVI7TqyZG4"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;July
2025 Convertible Notes Offering&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 30, 2025, the Company entered into an underwriting agreement (the &#x201c;Note Underwriting Agreement&#x201d;) with the Underwriters,
subject to customary conditions, to issue and sell in a public offering $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zjW3xipiuuTd" title="Principal amount"&gt;175.0&lt;/span&gt; million aggregate principal amount of the Notes to the
Underwriters (the &#x201c;Note Offering&#x201d;). In addition, pursuant to the Note Underwriting Agreement, the Company granted the Underwriters
an option to purchase up to an additional $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zo5THxCavrV7" title="Principal amount"&gt;26.3&lt;/span&gt; million aggregate principal amount of Notes solely to cover over-allotments. On July
30, 2025, the Underwriters exercised such option to purchase an additional $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zJojX9ASBFD3" title="Principal amount"&gt;26.3&lt;/span&gt; million aggregate principal amount of the Notes. The
issuance of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250801__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z1rc3wJthAt9" title="Principal amount"&gt;201.3&lt;/span&gt; million aggregate principal amount of the Notes was completed on August 1, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notes were issued pursuant to, and are governed by, an indenture (the &#x201c;Base Indenture&#x201d;), dated as of August 1, 2025, between
the Company and U.S. Bank Trust Company, National Association, as trustee (the &#x201c;Trustee&#x201d;), as supplemented by a first supplemental
indenture (the &#x201c;Supplemental Indenture,&#x201d; and the Base Indenture, as supplemented by the Supplemental Indenture, the &#x201c;Indenture&#x201d;),
dated as of August 1, 2025, between the Company and the Trustee. The net proceeds from the Note Offering, after deducting underwriting
discounts and commissions and offering expenses, were $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBy8QJ7EBD1i" title="Net proceeds from offering"&gt;194.9&lt;/span&gt; million, including the proceeds from the Underwriters&#x2019; exercise of
their over-allotment option in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notes are general, unsecured, senior obligations of the Company. The Notes will accrue interest payable semi-annually in arrears on February
1 and August 1 of each year, beginning on February 1, 2026, at a rate equal to &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260201__20260201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5bZi4EXSiBl" title="Accrue interest payable rate"&gt;2.750&lt;/span&gt;% per year. In addition, special interest will accrue
on the Notes upon the occurrence of certain events relating to the Company&#x2019;s failure to file certain reports with the SEC as provided
in the Indenture and as described below. The Notes also have customary provisions relating to the occurrence of &#x201c;Events of Default&#x201d;
(as defined in the Indenture) with certain interest penalty provisions. The Notes will mature on August 1, 2031, unless earlier converted,
redeemed or repurchased by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Noteholders
may convert their Notes at their option at any time prior to the close of business on the scheduled trading day immediately preceding
the maturity date based on an initial conversion rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionRatio1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zBfkY00FdAh8" title="Conversion rate"&gt;19.4932&lt;/span&gt; shares of common stock, per $&lt;span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zEV3IefxYaF6" title="Principal amount"&gt;1,000&lt;/span&gt; principal amount of the Notes, which
is equivalent to an initial conversion price of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z5JxhvZoeKp" title="Conversion price"&gt;51.30&lt;/span&gt; per share of common stock. The conversion rate is subject to customary adjustments
upon the occurrence of certain events as described in the Indenture. In addition, if certain corporate events that constitute a &#x201c;Make-Whole
Fundamental Change&#x201d; (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased
for a specified period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentRedemptionDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zQKzqYDaaDDe" title="Redemption description"&gt;The
Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company&#x2019;s option at any
time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately
before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid
interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds
130% of the conversion price on (i) each of at least &lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zMDQkhaajZ09" title="Trading days"&gt;20&lt;/span&gt; trading days, whether or not consecutive, during the &lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_dtD_uInteger_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zfiS8p3T0LJg" title="Consecutive trading days"&gt;30&lt;/span&gt; consecutive trading days
ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading
day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes
unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company
sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with
respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances
if it is converted after it is called for redemption.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a &#x201c;Fundamental Change&#x201d; (as defined in the Indenture) occurs, then, subject to certain conditions and except as set forth
in the Indenture, noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount
of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The definition in the Indenture of a Fundamental Change includes certain business combination transactions involving the Company and
certain de-listing events with respect to the common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lastly,
the Notes contain a beneficial ownership limitation, and as a result of such limitation, noteholders do not have the right to convert
all or any portion of the Notes held by such noteholder, to the extent that immediately prior to, or immediately after giving effect
to such conversion by such noteholder, together with its affiliates and any other persons acting as a group together with such noteholder
or any of such noteholder&#x2019;s affiliates, would &lt;span id="xdx_905_eus-gaap--DebtInstrumentDescription_c20250730__20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zlp8C3osLE0c" title="Beneficial ownership description"&gt;beneficially own in excess of 4.99% of the number of shares of the Company&#x2019;s
common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes;
provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that
such limitation in no event can exceed 19.99%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Notes, which differs from their carrying value, is influenced by interest rates, stock price and stock price volatility
and is determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an
active market and therefore the fair value is determined using Level 2 inputs. As of December 31, 2025, the carrying value and fair value
of the Notes was $&lt;span id="xdx_909_eus-gaap--ConvertibleDebtNoncurrent_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z3dJUdAbK471" title="Convertible debt"&gt;195.3&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--NotesReceivableFairValueDisclosure_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_z4RYwsXowP81" title="Fair value of the Notes"&gt;436.5&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
issuance costs attributed to the Notes amounted to $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20250730__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zXdRWHalttef" title="Discount amount"&gt;6.4&lt;/span&gt;
million and were discounted from the Notes. The issuance cost discount is being amortized to interest expense over the term of the
Notes based on the effective interest rate method. As of December 31, 2025, the effective interest rate was &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zhYseCXMpbf" title="Interest rate"&gt;3.3&lt;/span&gt;%.
During the year ended December 31, 2025, interest expense related to the Notes was $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zeSe91SKnsrk" title="Interest expense"&gt;2.7&lt;/span&gt;
million, including $&lt;span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--NoteUnderwritingAgreementMember__us-gaap--AwardTypeAxis__custom--JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_zepFXfvQYXib" title="Discount amount"&gt;0.4&lt;/span&gt;
million related to discount amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Amended
and Restated Loan and Security Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Third
Amendment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 9, 2025, the Company entered into the Third Amendment (the &#x201c;Third Amendment&#x201d;) to the Amended and Restated Loan
and Security Agreement (the &#x201c;A&amp;amp;R Loan Agreement&#x201d;) with Oxford Finance LLC, a Delaware limited liability company
(&#x201c;Oxford&#x201d;), as collateral agent and a lender, Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership
(&#x201c;Innovatus&#x201d;), as a lender, and the other lenders party thereto (together with Oxford and Innovatus, the
&#x201c;Lenders&#x201d;), pursuant to which the A&amp;amp;R Loan Agreement was amended to (i) replace Innovatus with Oxford as collateral
agent; (ii) recognize the achievement of the Term D Milestone (as defined in the A&amp;amp;R Loan Agreement, as amended by the Third
Amendment (the &#x201c;Amended A&amp;amp;R Loan Agreement&#x201d;)) and provide for the immediate disbursement of the $&lt;span id="xdx_905_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zziupAojIKz1" title="Disbursement loan amount"&gt;30.0&lt;/span&gt;
million Term D Loan (as defined in the Amended A&amp;amp;R Loan Agreement); (iii) increase the size of the Term E Loan (as defined in
the Amended A&amp;amp;R Loan Agreement) from $&lt;span id="xdx_90E_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zZSyeJnlayA2" title="Contingent loans"&gt;50.0&lt;/span&gt;
million to up to $&lt;span id="xdx_901_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermETwoLoanMember_zP3U8a74fA2e" title="Contingent loans"&gt;100.0&lt;/span&gt;
million, which Term E Loan may only be drawn upon FDA approval of gedatolisib in second line wild-type ABC
patients post CDK4/6 inhibitor therapy; (iv) add three new up to $&lt;span id="xdx_909_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zthlCpxtehdg" title="Contingent loan"&gt;40.0&lt;/span&gt;
million Term F Loans (as defined in the Amended A&amp;amp;R Loan Agreement), for a total of $&lt;span id="xdx_908_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzUAsh4rGZsj" title="Contingent loan"&gt;120.0&lt;/span&gt;
million, which may only be drawn upon achievement of certain trailing three months&#x2019; product revenue thresholds; (v) replace
the prior $&lt;span id="xdx_904_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFTwoLoanMember_zOE6xVw3try4" title="Contingent loan"&gt;45.0&lt;/span&gt;
million Term F Loan (as defined in the A&amp;amp;R Loan Agreement) with a new $&lt;span id="xdx_90B_eus-gaap--ProceedsFromLoans_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermGLoanMember_zSQItI5irxzd" title="Contingent loan"&gt;150.0&lt;/span&gt;
million Term G Loan (as defined in the Amended A&amp;amp;R Loan Agreement), which continues to be available only in the Lenders&#x2019;
sole discretion upon the Company&#x2019;s request; (vi) require an amendment fee payable by the Company to the Lenders in the amount
of $&lt;span id="xdx_904_ecustom--AmendmentFee_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZZSPj30VzZ2" title="Amendment fee payable"&gt;0.1&lt;/span&gt;
million, which was paid at the closing of the Third Amendment; (vii) make certain revisions to the non-utilization fee for the Term
E Loan, and add a new non-utilization fee for the Term F Loans, in each case equal to 3.0% of the applicable unfunded commitment,
after taking into consideration any reductions to the applicable term loan commitment that the Company may make by notice to the
collateral agent before the date that is eight weeks after the achievement of any applicable milestones; and (viii) extend the
maturity date of the term loans to November 1, 2029. The Term E Loan and each Term F Loan also are subject to other customary
conditions and limits on when the Company can request funding. With the disbursement of the $&lt;span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwIEMMMhyagk" title="Disbursement loan amount"&gt;30.0&lt;/span&gt;
million Term D Loan, the Company received net proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20250909__20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z5LnX8pzav5g" title="Net proceeds from loan"&gt;27.7&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with the A&amp;amp;R Loan Agreement, a Final Fee equal to &lt;span id="xdx_901_ecustom--DebtFinalFeePercentage_iI_pid_dp_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zPjQPZxOgoNl" title="Debt final fee percentage"&gt;4.5&lt;/span&gt;% of the $&lt;span id="xdx_904_ecustom--DisbursementLoanAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zZi3lmIKEKve" title="Disbursement loan amount"&gt;30.0&lt;/span&gt; million Term D Loan was recognized and an additional
$&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zYAEUtwe9nwa" title="Funded loan amount"&gt;1.4&lt;/span&gt; million was added to debt principal and a corresponding debt discount to be amortized over the life of the loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Third Amendment, the Company issued warrants with an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdeJxjkvrBD4" title="Warrants exercise price per share"&gt;14.84&lt;/span&gt; per share to purchase an aggregate
of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250909__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3KOKwpAUOq8" title="Warrants issued"&gt;50,537&lt;/span&gt; shares of the Company&#x2019;s common stock to Innovatus, Oxford, and certain of its affiliates (the &#x201c;Third Amendment
Warrants&#x201d;). The Third Amendment Warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the funding date of the Term D Loan. The number of shares of common stock for which each Third Amendment Warrant is exercisable and
the associated exercise price are subject to certain proportional adjustments as set forth in such Third Amendment Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
portion of the proceeds from the Term D Loan in the amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zXIo47y5aDge"&gt;2.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million was allocated to the Third Amendment Warrants based
on their relative fair value to the underlying Term D Loan. The proceeds allocated to the Third Amendment Warrants were recorded as additional
paid in capital in the accompanying balance sheets and were discounted from the Term D Loan. The relative fair value of the Third Amendment
Warrants was based on the Black-Scholes model with the following assumptions: risk-free interest rate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zUk5W1e8peA9"&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%;
expected volatility of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zwGubhApG6Lh"&gt;74.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%;
expected life of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_zIyGBJcFhRsl"&gt;10.0&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years; and expected dividend yield of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250909__20250909__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z9GaAKrUnQU8"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
The underlying stock price used in the analysis was the traded market price. The discount related to the Third Amendment Warrants is
being amortized to interest expense ratably over the term of the Term D Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Second
Amendment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 28, 2025, the Company entered into the Second Amendment (the &#x201c;Second Amendment&#x201d;) to the A&amp;amp;R Loan Agreement with
Innovatus, as collateral agent, and the Lenders including Innovatus in its capacity as a Lender and Oxford, pursuant to which Innovatus
and Oxford, as Lenders, have agreed to make certain term loans (&#x201c;Term Loans&#x201d;) to the Company in the aggregate principal amount
of up to $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zGVu2FjAhbz1" title="Debt instrument principal amount"&gt;180&lt;/span&gt; million. The A&amp;amp;R Loan Agreement was amended to (i) subject to certain terms and conditions, permit the issuance of
the Notes discussed above and certain transactions in connection therewith, including the conversion thereof settled solely in common
stock (together with cash in lieu of the issuance of any fractional share of common stock), (ii) permit capped call transactions in connection
with the pricing of the Notes, (iii) require an amendment fee payable by the Company to Oxford in the amount of less than $&lt;span id="xdx_905_ecustom--AmendmentFee_iI_pn5n6_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_z0IuHxQczcg1" title="Amendment fee payable"&gt;0.1&lt;/span&gt; million,
which was paid upon execution of the Second Amendment, and (iv) extend to &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zrAGHknOGxb6" title="Maturity date"&gt;May 9, 2026&lt;/span&gt; the expiration date of Innovatus&#x2019; right to
convert up to &lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_ze5dx5i4Shk2" title="Conversion percentage"&gt;20&lt;/span&gt;% of the outstanding principal of the Term A Loan into shares of the Company&#x2019;s common stock at a price per share
of $&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zL1coVu8wIsf" title="Common stock price per share"&gt;10.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further,
in connection with the release of the topline data from the wild-type cohort of the VIKTORIA-1 Phase 3 clinical trial, the Company achieved
the Term D Milestone (as defined in the A&amp;amp;R Loan Agreement) and therefore became eligible to draw an additional $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20250728__20250728__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_zeNtBvfcXrtc" title="Amount of indebtedness eligible to incur under Term D Loan"&gt;30.0&lt;/span&gt; million of
indebtedness under the Term D Loan (as defined in the A&amp;amp;R Loan Agreement). As described above, the Term D Loan was disbursed to the
Company in connection with the Third Amendment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;First
Amendment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 13, 2025, the Company entered into the First Amendment (the &#x201c;First Amendment&#x201d;) to the A&amp;amp;R Loan Agreement, pursuant
to which the Company agreed to &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20250513__20250513__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zDgzxSboZEbf" title="First Amendment description"&gt;(i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment,
(ii) extend to March 9, 2026 the expiration date of Innovatus&#x2019; right to convert up to 20% of the outstanding principal of the Term
A Loan into shares of the Company&#x2019;s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D
Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&amp;amp;R Loan Agreement),
(iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company
had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the
Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders
from any and all claims arising out of or related to the A&amp;amp;R Loan Agreement, the First Amendment and related documentation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;May
30, 2024 Amendment and Restatement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30, 2024, the Company entered into the A&amp;amp;R Loan Agreement. The A&amp;amp;R Loan Agreement amended and restated, in its entirety,
that certain Loan and Security Agreement, dated April 8, 2021, as amended, between the Company and Innovatus, as collateral agent, and
the Lenders named therein (the &#x201c;Prior Loan Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Funding
of the first $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zVNBS9WrKuT6" title="Funded loan amount"&gt;100&lt;/span&gt; million under the A&amp;amp;R Loan Agreement occurred on May 30, 2024, including tranche payments of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zIt9owQwRmm2" title="Funded loan amount"&gt;16.8&lt;/span&gt; million (the
&#x201c;Term A Loan&#x201d;) and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_zBywFpf9mrre" title="Funded loan amount"&gt;21.5&lt;/span&gt; million (the &#x201c;Term B Loan&#x201d;) reflecting repayment of the principal amount of loans under
the Prior Loan Agreement plus accrued payment-in-kind interest, in addition to $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zabCoOTcteag" title="Funded loan amount"&gt;61.7&lt;/span&gt; million of new borrowings (the &#x201c;Term C Loan&#x201d;).
As described above, the Term D Loan was disbursed to the Company in connection with the Third Amendment. Prior to the Third Amendment,
the Company also would have become eligible to draw on a fifth tranche of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn6n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_z18iOBq3PGUh" title="Funded loan amount"&gt;50.0&lt;/span&gt; million (the &#x201c;Term E Loan&#x201d;), upon achievement
of certain clinical trial milestones and satisfaction of certain financial covenants. The Lenders also could have, in their sole discretion
upon the Company&#x2019;s request, made additional term loans to the Company of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermFLoanMember_zXOQ5LL7ndtg" title="Funded loan amount"&gt;45.0&lt;/span&gt; million (the &#x201c;Term F Loan&#x201d;). Funding
of these additional tranches was also subject to other customary conditions and limits on when the Company could have requested funding
for such tranches. Costs associated with the new borrowings were approximately $&lt;span id="xdx_908_eus-gaap--OtherBorrowings_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z0cR5GxuVLN8" title="Costs associated with new borrowings"&gt;2.4&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the A&amp;amp;R Loan Agreement, &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20240530__20240530__us-gaap--TypeOfArrangementAxis__custom--AmendedAndRestatedLoanAgreementMember_zxCLtgbyFY4d" title="Debt instrument interest rate description"&gt;the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months
if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.&lt;/span&gt; The A&amp;amp;R Loan Agreement is secured by all assets of the Company. Proceeds are being used for working capital purposes and
to fund the Company&#x2019;s general business requirements, including the ongoing Phase 3 VIKTORIA-1 clinical trial, the Phase 1b/2 CELC-G-201
clinical trial, and the Phase 3 VIKTORIA-2 clinical trial. The A&amp;amp;R Loan Agreement contains customary representations and warranties
and covenants, subject to customary carve-outs, and includes financial covenants related to liquidity and other financial measures. Prior
to the Second Amendment, Innovatus also had the right, at its election and until August 9, 2025, to convert up to &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zRT2FgyccyCl" title="Loan % convertible to stock"&gt;20&lt;/span&gt;% of the outstanding
principal of the Term A Loan into shares of the Company&#x2019;s common stock at a price per share of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermALoanMember_zfYOuhCUf0i" title="Common stock price per share"&gt;10.00&lt;/span&gt;. Innovatus will continue
to have the right to exercise a previously disclosed warrant granted to it under the Prior Loan Agreement to purchase &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240530__20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zrrvM0TXY429" title="Common stock issued"&gt;26,042&lt;/span&gt; shares of
common stock at a price per share of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--PriorLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_znOYr6IsZgq9" title="Common stock price per share"&gt;14.40&lt;/span&gt; through April 8, 2031.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
A&amp;amp;R Loan Agreement contains a Final Fee, which is equal to &lt;span id="xdx_902_ecustom--FinalFeePercentage_pid_dp_uPure_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zTi3OiqpyoHa" title="Final fee percentage"&gt;4.5&lt;/span&gt;% of the initial funding of the agreement and is due on the earliest
to occur of (a) the Maturity Date, (b) the acceleration of any Term Loan, and (c) the prepayment of the Term Loans. There is also a contingent
non-utilization fee for the Term E Loans. Following the disbursement of the Term D Loan in connection with the Third Amendment, the non-utilization
provisions related to the Term D Loan are no longer operative. The Term D Loan shall become due and payable on the earliest of (i) the
termination of the Term D Draw Period, (ii) the Maturity Date, (iii) the acceleration of any Term Loan, and (iv) the prepayment in whole
of the Term Loans. If the Company achieves the Term E Milestone and (i) fails to draw the full amount of the Term E Loan during the Term
E Draw Period and (ii) fails to notify Collateral Agent, at any time before the date that is four weeks after the Company&#x2019;s achievement
of the Term E Milestone, of the Company&#x2019;s intent not to draw the full amount of the Term E Loan, a non-utilization fee with respect
to the Term E Loan shall become due and payable on the earliest of (i) the termination of the Term E Draw Period, (ii) the Maturity Date,
(iii) the acceleration of any Term Loan, and (iv) the prepayment in whole of the Term Loans. After the 18-month anniversary of the Effective
Date, the Company shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under the A&amp;amp;R
Loan Agreement, provided the Company (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least
seven business days prior to such prepayment, and (ii) pays to Lenders on the date of such prepayment, payable to each Lender in accordance
with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid
interest thereon through the prepayment date, (B) the Final Fee, (C) the Prepayment Fee, plus (D) all other outstanding Obligations that
are due and payable, including, without limitation, Lenders&#x2019; Expenses and interest at the Default Rate with respect to any past
due amounts. At May 30, 2024, the Company recognized the Final Fee of $&lt;span id="xdx_902_ecustom--FinalFee_iI_pn5n6_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zCEokQVdWVgg" title="Final fee"&gt;4.5&lt;/span&gt; million as additional debt principal and a corresponding debt
discount to be amortized over the life of the loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the funding of each of the Term C Loan and the Term D Loans, the Company agreed to issue to Innovatus and Oxford
warrants to purchase that number of shares of the Company&#x2019;s common stock equal to &lt;span id="xdx_90E_ecustom--WarrantOrRightToPurchasePercentage_iI_pid_dp_uPure_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z9QKeCu0Rqj5" title="Warrant or right, reason for issuance, description"&gt;2.5&lt;/span&gt;% of the principal amount of the applicable
Term Loan divided by the exercise price, which was, with respect to the Term C Loan, equal to the lower of (i) the volume weighted average
closing price of the Company&#x2019;s common stock for the five-trading day period ending on the last trading day immediately preceding
the execution of the A&amp;amp;R Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of
the A&amp;amp;R Loan Agreement. Accordingly, on May 30, 2024, the Company issued &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYJwbrXD19a" title="Warrants issued"&gt;103,876&lt;/span&gt; warrants with an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLKOP0uhNOqd" title="Warrants exercise price per share"&gt;14.84&lt;/span&gt; per share.
The relative fair value of the warrants was approximately $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240530__20240530__us-gaap--PlanNameAxis__custom--AmendedAndRestatedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z34miiz2AUQd" title="Fair value of warrants"&gt;1.2&lt;/span&gt; million. For the Term D Loans, the exercise price was based on the lower
of (i) the exercise price for the warrants issued pursuant to the Term C Loan or (ii) the volume weighted average closing price of the
Company&#x2019;s common stock for the five-trading day period ending on the last trading day immediately preceding the Term D Loan funding.
Prior to the Third Amendment, the Company also was required to issue warrants to Innovatus and Oxford in connection with the funding
of the Term E Loan and the Term F Loan. The warrants may be exercised on a cashless basis and are exercisable through the tenth anniversary
of the applicable funding date. The number of shares of common stock for which each warrant is exercisable and the associated exercise
price are subject to certain proportional adjustments as set forth in such warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the change of terms under ASC 470-50, &lt;i&gt;Debt &#x2013; Modification and Extinguishment&lt;/i&gt; with respect to the Third
Amendment, the Second Amendment, the First Amendment and the A&amp;amp;R Loan Agreement and concluded the change in terms did not result
in significant and consequential changes to the economic substance of the debt and thus resulted in a modification of the debt and not
an extinguishment of the debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zRG7JCSbpWeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
payable, non-current consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z2DbeMGS5Xk4" style="display: none"&gt;Schedule of Long-term Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zovM67dRbgB8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z0n0LvfZYN2g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_maLTNPzDBl_z9vpQiPRdoU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Note payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FinalFee_iI_pn3n3_maLTNPzDBl_z9QoO55Wjuah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: Final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PaymentInKindInterestDebt_iI_pn3n3_maLTNPzDBl_zOKlikdS4cy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: PIK interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTNPzDBl_zQ8GVUbVYhH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,619&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,614&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msLTNPzDBl_zWisoCvbjpP5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,401&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermNotesPayable_iTI_pn3n3_mtLTNPzDBl_zhySW4epDuT4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;126,527&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97,727&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zy0Ns2H2k1Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the fair value of the note payable, which differs from its carrying value, is determined using the Company&#x2019;s estimated discount rate, volatility and risk-free rate, which are
considered Level 3 inputs. As of December 31, 2025, the fair value of the note payable was $&lt;span id="xdx_907_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20251231_zObChx03k3lj" title="Fair value of note payable"&gt;160.2&lt;/span&gt; million. As of December 31, 2024,
the carrying value of the note payable approximates the fair value (Level 3 inputs).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
debt issuance costs and discount will be amortized to interest expense over the term of the Notes based on the effective interest rate
method. As of December 31, 2025 and 2024, the effective interest rate was &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20251231_z5NK4KBMyZF1" title="Interest rate"&gt;12.7&lt;/span&gt;% and &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231_zoLlJxpyCHTe" title="Interest rate"&gt;12.3&lt;/span&gt;%, respectively. During the year ended December
31, 2025, interest expense related to the note payable was $&lt;span id="xdx_90E_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zHG7f7XZ4Bz1" title="Interest expense"&gt;14.4&lt;/span&gt; million, including $&lt;span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20250101__20251231_zVPTkV0YThQl" title="Discount amount"&gt;2.7&lt;/span&gt; million related to discount amortization. During
the year ended December 31, 2024, interest expense related to the note payable was $&lt;span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zF3j1K1oiFRa" title="Interest expense"&gt;10.3&lt;/span&gt; million, including $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231_zYqUrMtQBuN4" title="Discount amount"&gt;1.3&lt;/span&gt; million related to discount
amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgSteUrovpbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, future principal payments, including the incurred PIK interest and Final Fee, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zJ98d1GXjbx8" style="display: none"&gt;Schedule of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_z38QyhHt3cta" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz4sG_zhGh6N4oAla4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 81%; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;43,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz4sG_zRWKrlbGtgT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;93,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz4sG_zw5BHz5Etjnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;137,547&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zQ0kF1vKCqJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company was in full compliance with all financial covenants of the Amended A&amp;amp;R Loan Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001201"
      unitRef="USD">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact001203"
      unitRef="USD">26300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact001205"
      unitRef="USD">26300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-08-01_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001207"
      unitRef="USD">201300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact001209"
      unitRef="USD">194900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2026-02-012026-02-01_us-gaap_SubsequentEventMember_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Pure">0.02750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001213"
      unitRef="Pure">19.4932</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="0"
      id="Fact001215"
      unitRef="USD">1000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001217"
      unitRef="USDPShares">51.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionDescription
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      id="Fact001219">The
Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company&#x2019;s option at any
time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately
before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid
interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds
130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days
ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading
day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes
unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company
sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with
respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances
if it is converted after it is called for redemption.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001221"
      unitRef="Integer">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Integer">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2025-07-302025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      id="Fact001225">beneficially own in excess of 4.99% of the number of shares of the Company&#x2019;s
common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes;
provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that
such limitation in no event can exceed 19.99%.</us-gaap:DebtInstrumentDescription>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001227"
      unitRef="USD">195300000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:NotesReceivableFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001229"
      unitRef="USD">436500000</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-07-30_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001231"
      unitRef="USD">6400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="INF"
      id="Fact001233"
      unitRef="Pure">0.033</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001235"
      unitRef="USD">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-012025-12-31_custom_NoteUnderwritingAgreementMember_custom_JulyTwoThousandAndTwentyFiveConvertibleNotesOfferingMember"
      decimals="-5"
      id="Fact001237"
      unitRef="USD">400000</us-gaap:AmortizationOfDebtDiscountPremium>
    <CELC:DisbursementLoanAmount
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001239"
      unitRef="USD">30000000.0</CELC:DisbursementLoanAmount>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember"
      decimals="-5"
      id="Fact001241"
      unitRef="USD">50000000.0</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermETwoLoanMember"
      decimals="-5"
      id="Fact001243"
      unitRef="USD">100000000.0</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember"
      decimals="-5"
      id="Fact001245"
      unitRef="USD">40000000.0</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001247"
      unitRef="USD">120000000.0</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFTwoLoanMember"
      decimals="-5"
      id="Fact001249"
      unitRef="USD">45000000.0</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermGLoanMember"
      decimals="-5"
      id="Fact001251"
      unitRef="USD">150000000.0</us-gaap:ProceedsFromLoans>
    <CELC:AmendmentFee
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001253"
      unitRef="USD">100000</CELC:AmendmentFee>
    <CELC:DisbursementLoanAmount
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001255"
      unitRef="USD">30000000.0</CELC:DisbursementLoanAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-09-092025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001257"
      unitRef="USD">27700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <CELC:DebtFinalFeePercentage
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="INF"
      id="Fact001259"
      unitRef="Pure">0.045</CELC:DebtFinalFeePercentage>
    <CELC:DisbursementLoanAmount
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001261"
      unitRef="USD">30000000.0</CELC:DisbursementLoanAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001263"
      unitRef="USD">1400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001265"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-09_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">50537</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember"
      decimals="-5"
      id="Fact001268"
      unitRef="USD">2800000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember"
      decimals="INF"
      id="Fact001269"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember"
      decimals="INF"
      id="Fact001270"
      unitRef="Pure">0.744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember"
      id="Fact001271">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-09-092025-09-09_custom_ThirdAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_custom_TermDLoanMember"
      decimals="INF"
      id="Fact001272"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="-6"
      id="Fact001274"
      unitRef="USD">180000000</us-gaap:DebtInstrumentFaceAmount>
    <CELC:AmendmentFee
      contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001276"
      unitRef="USD">100000</CELC:AmendmentFee>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      id="Fact001278">2026-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001280"
      unitRef="Pure">0.20</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:SharePrice
      contextRef="AsOf2025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="INF"
      id="Fact001282"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2025-07-282025-07-28_custom_SecondAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"
      decimals="-5"
      id="Fact001284"
      unitRef="USD">30000000.0</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2025-05-132025-05-13_custom_LoanAgreementMember"
      id="Fact001286">(i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment,
(ii) extend to March 9, 2026 the expiration date of Innovatus&#x2019; right to convert up to 20% of the outstanding principal of the Term
A Loan into shares of the Company&#x2019;s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D
Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&amp;R Loan Agreement),
(iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company
had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the
Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders
from any and all claims arising out of or related to the A&amp;R Loan Agreement, the First Amendment and related documentation.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      id="Fact001288"
      unitRef="USD">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="-5"
      id="Fact001290"
      unitRef="USD">16800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember"
      decimals="-5"
      id="Fact001292"
      unitRef="USD">21500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember"
      decimals="-5"
      id="Fact001294"
      unitRef="USD">61700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember"
      decimals="-6"
      id="Fact001296"
      unitRef="USD">50000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermFLoanMember"
      decimals="-5"
      id="Fact001298"
      unitRef="USD">45000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:OtherBorrowings
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001300"
      unitRef="USD">2400000</us-gaap:OtherBorrowings>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember"
      id="Fact001302">the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months
if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined
in the A&amp;R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an
amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May
31, 2027.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermALoanMember"
      decimals="INF"
      id="Fact001306"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-302024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001308"
      unitRef="Shares">26042</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-05-30_custom_PriorLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001310"
      unitRef="USDPShares">14.40</us-gaap:SaleOfStockPricePerShare>
    <CELC:FinalFeePercentage
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001312"
      unitRef="Pure">0.045</CELC:FinalFeePercentage>
    <CELC:FinalFee
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      id="Fact001314"
      unitRef="USD">4500000</CELC:FinalFee>
    <CELC:WarrantOrRightToPurchasePercentage
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      id="Fact001316"
      unitRef="Pure">0.025</CELC:WarrantOrRightToPurchasePercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001318"
      unitRef="Shares">103876</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001320"
      unitRef="USDPShares">14.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-05-302024-05-30_custom_AmendedAndRestatedLoanAgreementMember_custom_InnovatusLifeSciencesMember_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001322"
      unitRef="USD">1200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001324">&lt;p id="xdx_897_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zRG7JCSbpWeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
payable, non-current consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z2DbeMGS5Xk4" style="display: none"&gt;Schedule of Long-term Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zovM67dRbgB8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z0n0LvfZYN2g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_maLTNPzDBl_z9vpQiPRdoU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Note payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FinalFee_iI_pn3n3_maLTNPzDBl_z9QoO55Wjuah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: Final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PaymentInKindInterestDebt_iI_pn3n3_maLTNPzDBl_zOKlikdS4cy5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Add: PIK interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pn3n3_di_msLTNPzDBl_zQ8GVUbVYhH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: 10pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,619&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,614&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_msLTNPzDBl_zWisoCvbjpP5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 10pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,401&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermNotesPayable_iTI_pn3n3_mtLTNPzDBl_zhySW4epDuT4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;126,527&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97,727&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">130000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001327"
      unitRef="USD">100000000</us-gaap:ConvertibleNotesPayable>
    <CELC:FinalFee
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001329"
      unitRef="USD">5850000</CELC:FinalFee>
    <CELC:FinalFee
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">4500000</CELC:FinalFee>
    <CELC:PaymentInKindInterestDebt
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001332"
      unitRef="USD">1697000</CELC:PaymentInKindInterestDebt>
    <CELC:PaymentInKindInterestDebt
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001333"
      unitRef="USD">593000</CELC:PaymentInKindInterestDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001335"
      unitRef="USD">2619000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001336"
      unitRef="USD">1614000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001338"
      unitRef="USD">8401000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001339"
      unitRef="USD">5752000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001341"
      unitRef="USD">126527000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001342"
      unitRef="USD">97727000</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001344"
      unitRef="USD">160200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001346"
      unitRef="Pure">0.127</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001348"
      unitRef="Pure">0.123</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001350"
      unitRef="USD">14400000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001352"
      unitRef="USD">2700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001354"
      unitRef="USD">10300000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001356"
      unitRef="USD">1300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001358">&lt;p id="xdx_899_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgSteUrovpbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, future principal payments, including the incurred PIK interest and Final Fee, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zJ98d1GXjbx8" style="display: none"&gt;Schedule of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_z38QyhHt3cta" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDz4sG_zhGh6N4oAla4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 81%; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;43,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDz4sG_zRWKrlbGtgT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;93,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz4sG_zw5BHz5Etjnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;137,547&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001360"
      unitRef="USD">43899000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001362"
      unitRef="USD">93648000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001364"
      unitRef="USD">137547000</us-gaap:LongTermDebt>
    <CELC:LicenseAgreementTestBlock contextRef="From2025-01-01to2025-12-31" id="Fact001366">&lt;p id="xdx_80F_ecustom--LicenseAgreementTestBlock_zjuBp8wM44Rh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_82E_zgNWyvHu0vg6"&gt;License Agreement&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 8, 2021, the Company entered into a license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) to research, develop, manufacture
and commercialize gedatolisib. During 2021, the Company paid $&lt;span id="xdx_909_eus-gaap--PaymentsForFees_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember_zbc509plt2Q9" title="Payment for upfront fees"&gt;5.0&lt;/span&gt; million in upfront fees and
issued &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--PfizerLicenseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqYm3BxcJfIc" title="Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement"&gt;349,406&lt;/span&gt; shares of the Company&#x2019;s common stock to Pfizer pursuant to an Equity Grant Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $&lt;span id="xdx_907_ecustom--AggregateValueOfMilestoneEvents_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z0tKV2Vzsji1" title="Aggregate value of milestone events"&gt;335.0&lt;/span&gt; million. One of these milestone events requires a $&lt;span id="xdx_90D_ecustom--PaymentOnMilestoneEventOne_pn5n6_c20210408__20210408__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zflpqQkHfooa" title="Payment on milestone event one"&gt;5.0&lt;/span&gt; million payment within 60 days following the FDA
regulatory filing of a New Drug Application (&#x201c;NDA&#x201d;) for gedatolisib. The FDA granted the Company&#x2019;s request to submit
its NDA via the FDA&#x2019;s Real-Time Oncology Review (&#x201c;RTOR&#x201d;) program, and the Company completed its final NDA submission
to the FDA in November 2025. The Company recorded the $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseMilestone_pn5n6_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z0l1FXNmv5Sf" title="Research and development expense"&gt;5.0&lt;/span&gt; million NDA filing milestone as research and development expense in June 2025.
As of December 31, 2025, this amount was included in other accrued expenses on the Company&#x2019;s balance sheets. Additionally, the
Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject
to deductions for expiration of valid patent claims, amounts due under third-party licenses and generic competition. Unless earlier terminated,
the license agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country
basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration
of all regulatory or data exclusivity in such country for such product, or (c) the date upon which the manufacture, use, sale, offer
for sale or importation of such product in such country would no longer infringe, but for the license granted in the license agreement,
a valid claim of a licensed patent right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the right to terminate the license agreement for convenience upon 90 days&#x2019; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</CELC:LicenseAgreementTestBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2021-04-082021-04-08_custom_PfizerLicenseAgreementMember"
      decimals="-5"
      id="Fact001368"
      unitRef="USD">5000000.0</us-gaap:PaymentsForFees>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-04-08_custom_PfizerLicenseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">349406</us-gaap:SharesIssued>
    <CELC:AggregateValueOfMilestoneEvents
      contextRef="From2021-04-082021-04-08_custom_LicenseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact001372"
      unitRef="USD">335000000.0</CELC:AggregateValueOfMilestoneEvents>
    <CELC:PaymentOnMilestoneEventOne
      contextRef="From2021-04-082021-04-08_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact001374"
      unitRef="USD">5000000.0</CELC:PaymentOnMilestoneEventOne>
    <CELC:ResearchAndDevelopmentExpenseMilestone
      contextRef="From2025-06-012025-06-30_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact001376"
      unitRef="USD">5000000.0</CELC:ResearchAndDevelopmentExpenseMilestone>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001378">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zB4ycJKhnbT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_82D_zaFnGuP0iiS1"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20250101__20251231_ztRlKSeyVz8i" title="Income tax benefit::XDX::-"&gt;&lt;span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20240101__20241231_zKRqlBujv4eh" title="Income tax benefit::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1382"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
income tax benefit was recorded during the years ended December 31, 2025 and 2024, due to net losses and recognition of a valuation allowance.
The following table, which reflects the Company&#x2019;s retrospective adoption of ASU 2023-09, presents a reconciliation of the
U.S. federal statutory rate to the Company&#x2019;s effective tax rate, including the amount (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB3xO0XQqI93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zXKuzL1MbR" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20251231_zUwDHxk8jng3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zoWNkiNcVURl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_ziebyqsOJc92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(37,179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20250101__20251231_zL63fZk0dl26" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(23,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20240101__20241231_z6cRILfVTY7" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_zgqX4NFo0xvc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20250101__20251231_zDpqV0uM4qG" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1396"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20240101__20241231_zVzAFXxTxCve" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1398"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zhml9Ekrhf68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal change in valuation allowance on deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20250101__20251231_zOmMd2nRCly4" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage"&gt;(21.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20240101__20241231_zdb0sY3vq3m6" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage"&gt;(21.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zax8rep7fNze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Federal research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,358&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20250101__20251231_zH4mnEAzRpyc" style="text-align: right" title="Federal research and development credits, percentage"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20240101__20241231_zTw96vKP64D2" style="text-align: right" title="Federal research and development credits, percentage"&gt;0.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzqmi_zrZMhgxG5O75" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior year adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20250101__20251231_znonAdPmj3L8" style="text-align: right" title="Prior year adjustments, percentage"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20240101__20241231_zsnyNadTXYgi" style="text-align: right" title="Prior year adjustments, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzqmi_zwRyp2LG002a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Non-deductible items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;645&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20250101__20251231_zpePl9cUOEnf" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage"&gt;(0.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20240101__20241231_zl13fGkZpJ7j" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage"&gt;(0.6&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zojvmUBQFXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20250101__20251231_zK8BpRcZ8NZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20240101__20241231_zfOpLpICZWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1433"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zj8MHAkAjtU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted, introducing a series of corporate tax changes in the
U.S., including 100% bonus depreciation on qualified property and full expensing of domestic research and development expenditures.
The impacts of OBBBA are reflected in our results of operations during the year ended December 31, 2025. OBBBA did not have a
material impact on the Company&#x2019;s effective income tax rate and its net deferred tax assets as the Company maintains a full
valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets (liabilities) reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred tax assets relate primarily to
its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, the
Company recorded a valuation allowance to fully offset the net deferred tax assets as of December 31, 2025 and 2024, because it is more
likely than not that the Company will not realize future benefits associated with these deferred tax assets. The tax effects of temporary
differences and carryforwards that give rise to significant portions of the deferred tax assets (liabilities) were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUFrOLm4Vzyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zre4SKsiI4lb" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zcIYmg432i63" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zkrhoV03I3be" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gross deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzhJd_zln8t7ZgwkH3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;459&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhJd_zoB2sDFjTEq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhJd_ze93AiysZFki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzhJd_zIUU6WviV2zl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsLeaseLiability_iNI_di_msDTAGzhJd_zHeeNCWYlM17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_maDTAGzhJd_zzn3WiI5NEjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Section 174 expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_maDTAGzhJd_zhY8OqeXuK6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Start-up expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzhJd_zEFoI7g1VCQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt"&gt;Net operating losses and tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,483&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhJd_maDTALNzwuF_zYguL3PnOq6d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzwuF_zgvG9dZHx7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(100,281&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,214&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzwuF_zSgkTYACRlLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zw4nMVGVelI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had federal and state net operating loss carryforwards of $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20251231_z5bfEfY9SMh2" title="Federal net operating loss carryforwards"&gt;83.3&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zbDIeqydPvd6" title="State net operating loss carryforwards"&gt;4.8&lt;/span&gt; million, respectively.
The federal and state net operating loss carryforwards for 2017 will begin to expire during the year ending December 31, 2037. The federal
net operating loss carryforwards starting in 2018 have no expiration. These deferred tax assets were subject to a full valuation allowance
as of December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the Company had federal and state research and development tax credit carryforwards resulting in deferred tax assets
of $&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwvpU8Y4FgWg" title="Tax credit carryforwards"&gt;4.3&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zpHnSKFDCzx4" title="Tax credit carryforwards"&gt;2.0&lt;/span&gt; million, respectively. The federal and state credit carryforwards will begin to expire during the years ending
December 31, 2038 and December 31, 2033, respectively. These deferred tax assets were subject to a full valuation allowance as of December
31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the provisions of Section 382 of the Internal Revenue Code of 1986, certain substantial changes in the Company&#x2019;s ownership, including
a sale of the Company, or significant changes in ownership due to sales of equity, may limit in the future the amount of net operating
loss carryforwards available to offset future taxable income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes uncertain tax positions in accordance with ASC 740 on the basis of evaluating whether it is more-likely-than not that
the tax positions will be sustained upon examination by tax authorities. For those tax positions that meet the more-likely-than not recognition
threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate
settlement. As of December 31, 2025 and 2024, the Company had &lt;span id="xdx_90A_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20251231_zddnx6RfG1X4" title="Uncertain tax positions"&gt;&lt;span id="xdx_902_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20241231_zwwzxLDpgCZd" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt; significant uncertain tax positions. There are &lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_zE7mnCpCYX09" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20241231_ztnBIQiKME3j" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits
included on the balance sheets that would, if recognized, impact the effective tax rate. The Company does not anticipate there will be
a significant change in unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is no longer subject to U.S. federal income
tax examinations for years before 2022, although carryforward attributes that were generated before 2022 may still be adjusted upon examination
if used in a future period. State income tax statutes vary by jurisdiction. In most states in which the Company operates, the statute
of limitations remains open for four years, and accordingly, the Company is generally no longer subject to state income tax examinations
for years before 2021.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax
positions as a component of general and administrative expenses. As of December 31, 2025, the Company had &lt;span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20251231_zWrCQwo0An2f" title="Accrued interest or penalties"&gt;no&lt;/span&gt; accrued interest or penalties
and no amounts were recognized in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2025 and 2024, the Company made state tax payments which were deemed immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001384">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zB3xO0XQqI93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zXKuzL1MbR" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20251231_zUwDHxk8jng3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zoWNkiNcVURl" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqmi_ziebyqsOJc92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(37,179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20250101__20251231_zL63fZk0dl26" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(23,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maABC_c20240101__20241231_z6cRILfVTY7" style="width: 11%; text-align: right" title="Tax benefit at statutory rate, percentage"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqmi_zgqX4NFo0xvc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20250101__20251231_zDpqV0uM4qG" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1396"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maABC_c20240101__20241231_zVzAFXxTxCve" style="text-align: right" title="State income tax benefit, net of federal tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1398"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqmi_zhml9Ekrhf68" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal change in valuation allowance on deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20250101__20251231_zOmMd2nRCly4" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage"&gt;(21.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maABC_c20240101__20241231_zdb0sY3vq3m6" style="text-align: right" title="Federal change in valuation allowance on deferred tax assets, percentage"&gt;(21.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzqmi_zax8rep7fNze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Federal research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,358&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20250101__20251231_zH4mnEAzRpyc" style="text-align: right" title="Federal research and development credits, percentage"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_msABC_c20240101__20241231_zTw96vKP64D2" style="text-align: right" title="Federal research and development credits, percentage"&gt;0.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzqmi_zrZMhgxG5O75" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior year adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20250101__20251231_znonAdPmj3L8" style="text-align: right" title="Prior year adjustments, percentage"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maABC_c20240101__20241231_zsnyNadTXYgi" style="text-align: right" title="Prior year adjustments, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzqmi_zwRyp2LG002a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Non-deductible items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;645&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20250101__20251231_zpePl9cUOEnf" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage"&gt;(0.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_maABC_c20240101__20241231_zl13fGkZpJ7j" style="border-bottom: Black 1pt solid; text-align: right" title="Non-deductible items, percentage"&gt;(0.6&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqmi_zojvmUBQFXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20250101__20251231_zK8BpRcZ8NZc" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtABC_c20240101__20241231_zfOpLpICZWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax expense (benefit), percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1433"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001386"
      unitRef="USD">-37179000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001389"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001387"
      unitRef="USD">-23474000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001391"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001393"
      unitRef="USD">-14000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001394"
      unitRef="USD">-3000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001400"
      unitRef="USD">38249000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001403"
      unitRef="Pure">-0.216</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001401"
      unitRef="USD">23797000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001405"
      unitRef="Pure">-0.213</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001407"
      unitRef="USD">1358000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001410"
      unitRef="Pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001408"
      unitRef="USD">982000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001412"
      unitRef="Pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001414"
      unitRef="USD">-343000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001417"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001415"
      unitRef="USD">-3000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001421"
      unitRef="USD">645000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001424"
      unitRef="Pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001422"
      unitRef="USD">665000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001426"
      unitRef="Pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001435">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUFrOLm4Vzyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zre4SKsiI4lb" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zcIYmg432i63" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zkrhoV03I3be" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gross deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzhJd_zln8t7ZgwkH3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;459&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzhJd_zoB2sDFjTEq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzhJd_ze93AiysZFki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzhJd_zIUU6WviV2zl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsLeaseLiability_iNI_di_msDTAGzhJd_zHeeNCWYlM17" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures_iI_maDTAGzhJd_zzn3WiI5NEjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Section 174 expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures_iI_maDTAGzhJd_zhY8OqeXuK6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Start-up expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzhJd_zEFoI7g1VCQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt"&gt;Net operating losses and tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,483&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzhJd_maDTALNzwuF_zYguL3PnOq6d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzwuF_zgvG9dZHx7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(100,281&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,214&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzwuF_zSgkTYACRlLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001437"
      unitRef="USD">253000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001438"
      unitRef="USD">459000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001440"
      unitRef="USD">6056000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001441"
      unitRef="USD">2861000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001443"
      unitRef="USD">463000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001444"
      unitRef="USD">420000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <CELC:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001446"
      unitRef="USD">-11000</CELC:DeferredTaxAssetsRightofuseAssets>
    <CELC:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001447"
      unitRef="USD">-45000</CELC:DeferredTaxAssetsRightofuseAssets>
    <CELC:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001449"
      unitRef="USD">-12000</CELC:DeferredTaxAssetsLeaseLiability>
    <CELC:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001450"
      unitRef="USD">-48000</CELC:DeferredTaxAssetsLeaseLiability>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001452"
      unitRef="USD">48070000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001453"
      unitRef="USD">30133000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001455"
      unitRef="USD">21955000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures>
    <CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001456"
      unitRef="USD">12998000</CELC:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001458"
      unitRef="USD">23483000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001459"
      unitRef="USD">13340000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001461"
      unitRef="USD">100281000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001462"
      unitRef="USD">60214000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001464"
      unitRef="USD">100281000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001465"
      unitRef="USD">60214000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001470"
      unitRef="USD">83300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001472"
      unitRef="USD">4800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001474"
      unitRef="USD">4300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001476"
      unitRef="USD">2000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001478"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001480"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001482"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001484"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001486"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001488">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zXsOXkjyedj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_824_zCWQNwrnbswh"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 9, 2026, the Company filed a new registration statement and accompanying prospectus supplement, which increased the aggregate
offering amount under the Open Market Sale Agreement to $&lt;span id="xdx_903_ecustom--AggregateOfferingAmount_pn5n6_c20260109__20260109__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRP6AY2JAHV" title="Aggregate offering amount"&gt;400.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <CELC:AggregateOfferingAmount
      contextRef="From2026-01-092026-01-09_custom_OpenMarketSaleAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001490"
      unitRef="USD">400000000.0</CELC:AggregateOfferingAmount>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="From2025-10-012025-12-31" id="Fact001491">On
&lt;span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_904_eecd--TrdArrAdoptionDate_c20251001__20251231_zDiVZPjSgOVk"&gt;December 8, 2025&lt;/span&gt;&lt;/span&gt;, Oncology Diagnostic &amp;amp; Drug Development Consulting LLC, an entity controlled by &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_901_eecd--TrdArrIndName_c20251001__20251231_zszfvE2Zlq3i"&gt;Richard E. Buller&lt;/span&gt;, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbT_c20251001__20251231_zIJLl0FNZMma" title="Rule 10b51 Arrangement Adopted"&gt;adopted&lt;/span&gt; a 10b5-1
plan for the sale of up to &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_901_eecd--TrdArrSecuritiesAggAvailAmt_iI_c20251231_zr5hNgUfzYic"&gt;12,000&lt;/span&gt; shares of Celcuity Inc. common stock beginning March 18, 2026 through &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_902_eecd--TrdArrExpirationDate_c20251001__20251231_zdPLoHFgwEAk"&gt;December 23, 2026&lt;/span&gt;.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="From2025-10-012025-12-31" id="Fact001492">December 8, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="From2025-10-012025-12-31" id="Fact001493">Richard E. Buller</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-10-012025-12-31" id="Fact001495">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001496"
      unitRef="Shares">12000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="From2025-10-012025-12-31" id="Fact001497">December 23, 2026</ecd:TrdArrExpirationDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-10-012025-12-31" id="Fact001499">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-10-012025-12-31" id="Fact001501">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-10-012025-12-31" id="Fact001503">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
